{"1e0a165313e080137556cb75b1af2bb0f6984d9f": [["Pulmonary complications occur frequently in immunocompromised patients who are treated for hematological malignancies, and they cover a wide range of etiologies, including infections of bacterial, fungal, parasitic, or viral origin; pulmonary edema; diffuse alveolar hemorrhage; drug-or radiation-induced toxicity; graft-versus-host disease; and bronchiolitis obliterans [1] .", [["Pulmonary", "ANATOMY", 0, 9], ["hematological malignancies", "ANATOMY", 91, 117], ["pulmonary", "ANATOMY", 233, 242], ["alveolar", "ANATOMY", 258, 266], ["graft", "ANATOMY", 315, 320], ["Pulmonary complications", "DISEASE", 0, 23], ["hematological malignancies", "DISEASE", 91, 117], ["infections", "DISEASE", 172, 182], ["pulmonary edema", "DISEASE", 233, 248], ["alveolar hemorrhage", "DISEASE", 258, 277], ["toxicity", "DISEASE", 305, 313], ["graft-versus-host disease", "DISEASE", 315, 340], ["bronchiolitis obliterans", "DISEASE", 346, 370], ["Pulmonary", "ORGAN", 0, 9], ["patients", "ORGANISM", 62, 70], ["malignancies", "CANCER", 105, 117], ["pulmonary", "ORGAN", 233, 242], ["alveolar", "MULTI-TISSUE_STRUCTURE", 258, 266], ["graft", "TISSUE", 315, 320], ["patients", "SPECIES", 62, 70], ["Pulmonary complications", "PROBLEM", 0, 23], ["hematological malignancies", "PROBLEM", 91, 117], ["infections", "PROBLEM", 172, 182], ["bacterial, fungal, parasitic", "PROBLEM", 186, 214], ["viral origin", "PROBLEM", 219, 231], ["pulmonary edema", "PROBLEM", 233, 248], ["diffuse alveolar hemorrhage", "PROBLEM", 250, 277], ["radiation-induced toxicity", "PROBLEM", 287, 313], ["graft-versus-host disease", "PROBLEM", 315, 340], ["bronchiolitis obliterans", "PROBLEM", 346, 370], ["complications", "OBSERVATION", 10, 23], ["malignancies", "OBSERVATION", 105, 117], ["bacterial", "OBSERVATION_MODIFIER", 186, 195], ["viral origin", "OBSERVATION", 219, 231], ["pulmonary", "ANATOMY", 233, 242], ["edema", "OBSERVATION", 243, 248], ["diffuse", "OBSERVATION_MODIFIER", 250, 257], ["alveolar", "ANATOMY_MODIFIER", 258, 266], ["hemorrhage", "OBSERVATION", 267, 277], ["graft", "OBSERVATION", 315, 320], ["host disease", "OBSERVATION", 328, 340], ["bronchiolitis obliterans", "OBSERVATION", 346, 370]]], ["In addition, an entity named \"idiopathic pneumonia syndrome,\" defined as diffuse lung injury for which the etiology is not identified, is frequently recognized after hematopoietic stem cell transplantation (HSCT).", [["lung", "ANATOMY", 81, 85], ["hematopoietic stem cell", "ANATOMY", 166, 189], ["idiopathic pneumonia syndrome", "DISEASE", 30, 59], ["lung injury", "DISEASE", 81, 92], ["lung", "ORGAN", 81, 85], ["hematopoietic stem cell", "CELL", 166, 189], ["idiopathic pneumonia syndrome", "PROBLEM", 30, 59], ["diffuse lung injury", "PROBLEM", 73, 92], ["hematopoietic stem cell transplantation", "TREATMENT", 166, 205], ["idiopathic", "OBSERVATION_MODIFIER", 30, 40], ["pneumonia", "OBSERVATION", 41, 50], ["diffuse", "OBSERVATION_MODIFIER", 73, 80], ["lung", "ANATOMY", 81, 85], ["injury", "OBSERVATION", 86, 92], ["hematopoietic stem cell transplantation", "OBSERVATION", 166, 205]]], ["A large number of these cases of pneumonia may be related to unrecognized viral infections, and, in the absence of routine screening or reliable diagnostic procedures, this number is probably an underestimate.", [["pneumonia", "DISEASE", 33, 42], ["viral infections", "DISEASE", 74, 90], ["pneumonia", "PROBLEM", 33, 42], ["unrecognized viral infections", "PROBLEM", 61, 90], ["routine screening", "TEST", 115, 132], ["reliable diagnostic procedures", "TEST", 136, 166], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["pneumonia", "OBSERVATION", 33, 42], ["may be related to", "UNCERTAINTY", 43, 60], ["viral", "OBSERVATION_MODIFIER", 74, 79], ["infections", "OBSERVATION", 80, 90], ["underestimate", "OBSERVATION", 195, 208]]]], "dcdac60c21863b1fa82d5c583d62b428ee5389ca": [["INTRODUCTION EV71 belongs to the human enterovirus A species of the Enterovirus genus within the family Picornaviridae.", [["EV71", "ORGANISM", 13, 17], ["human", "ORGANISM", 33, 38], ["enterovirus A species", "ORGANISM", 39, 60], ["Enterovirus genus", "ORGANISM", 68, 85], ["human", "SPECIES", 33, 38], ["human enterovirus A", "SPECIES", 33, 52], ["the human enterovirus", "PROBLEM", 29, 50], ["the Enterovirus genus", "PROBLEM", 64, 85], ["Picornaviridae", "TREATMENT", 104, 118]]]], "4ef71600d49057154d87551483d26579a03ac163": [["IntroductionBronchiolitis is the most common lower respiratory tract infection and a major cause of hospitalization in infants around the world.", [["lower respiratory tract", "ANATOMY", 45, 68], ["Bronchiolitis", "DISEASE", 12, 25], ["respiratory tract infection", "DISEASE", 51, 78], ["lower respiratory", "ORGANISM_SUBDIVISION", 45, 62], ["tract", "ORGANISM_SUBDIVISION", 63, 68], ["infants", "ORGANISM", 119, 126], ["infants", "SPECIES", 119, 126], ["IntroductionBronchiolitis", "PROBLEM", 0, 25], ["the most common lower respiratory tract infection", "PROBLEM", 29, 78], ["Bronchiolitis", "OBSERVATION", 12, 25], ["most common", "OBSERVATION_MODIFIER", 33, 44], ["lower", "ANATOMY_MODIFIER", 45, 50], ["respiratory tract", "ANATOMY", 51, 68], ["infection", "OBSERVATION", 69, 78], ["hospitalization", "OBSERVATION", 100, 115]]], ["It is characterized by acute inflammation, edema, and necrosis of epithelial cells lining small airways; increased mucus production; and bronchospasm.", [["edema", "ANATOMY", 43, 48], ["epithelial cells", "ANATOMY", 66, 82], ["airways", "ANATOMY", 96, 103], ["mucus", "ANATOMY", 115, 120], ["inflammation", "DISEASE", 29, 41], ["edema", "DISEASE", 43, 48], ["necrosis", "DISEASE", 54, 62], ["bronchospasm", "DISEASE", 137, 149], ["edema", "PATHOLOGICAL_FORMATION", 43, 48], ["epithelial cells", "CELL", 66, 82], ["airways", "MULTI-TISSUE_STRUCTURE", 96, 103], ["mucus", "MULTI-TISSUE_STRUCTURE", 115, 120], ["epithelial cells", "CELL_TYPE", 66, 82], ["acute inflammation", "PROBLEM", 23, 41], ["edema", "PROBLEM", 43, 48], ["necrosis", "PROBLEM", 54, 62], ["epithelial cells lining small airways", "PROBLEM", 66, 103], ["increased mucus production", "PROBLEM", 105, 131], ["bronchospasm", "PROBLEM", 137, 149], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["inflammation", "OBSERVATION", 29, 41], ["edema", "OBSERVATION", 43, 48], ["necrosis", "OBSERVATION", 54, 62], ["epithelial cells", "OBSERVATION", 66, 82], ["lining", "OBSERVATION_MODIFIER", 83, 89], ["small", "OBSERVATION_MODIFIER", 90, 95], ["airways", "ANATOMY", 96, 103], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["mucus production", "OBSERVATION", 115, 131], ["bronchospasm", "OBSERVATION", 137, 149]]], ["Clinical symptoms and signs of bronchiolitis typically include rhinitis, tachypnea, wheezing, cough, crackles, use of accessory muscles, and/or nasal flaring.", [["accessory muscles", "ANATOMY", 118, 135], ["nasal", "ANATOMY", 144, 149], ["bronchiolitis", "DISEASE", 31, 44], ["rhinitis", "DISEASE", 63, 71], ["tachypnea", "DISEASE", 73, 82], ["wheezing", "DISEASE", 84, 92], ["cough", "DISEASE", 94, 99], ["muscles", "ORGANISM_SUBDIVISION", 128, 135], ["nasal", "ORGANISM_SUBDIVISION", 144, 149], ["Clinical symptoms", "PROBLEM", 0, 17], ["bronchiolitis", "PROBLEM", 31, 44], ["rhinitis", "PROBLEM", 63, 71], ["tachypnea", "PROBLEM", 73, 82], ["wheezing", "PROBLEM", 84, 92], ["cough", "PROBLEM", 94, 99], ["crackles", "PROBLEM", 101, 109], ["accessory muscles", "PROBLEM", 118, 135], ["nasal flaring", "PROBLEM", 144, 157], ["bronchiolitis", "OBSERVATION", 31, 44], ["rhinitis", "OBSERVATION", 63, 71], ["tachypnea", "OBSERVATION", 73, 82], ["cough", "OBSERVATION", 94, 99], ["crackles", "OBSERVATION", 101, 109], ["accessory muscles", "ANATOMY", 118, 135], ["nasal", "ANATOMY", 144, 149], ["flaring", "OBSERVATION", 150, 157]]], ["1, 2 With the development of molecular techniques and the availability of monoclonal antibodies for numerous viral species, detection of viral respiratory agents has been markedly improved in the past decades.", [["monoclonal antibodies", "PROTEIN", 74, 95], ["molecular techniques", "TREATMENT", 29, 49], ["monoclonal antibodies", "TREATMENT", 74, 95], ["numerous viral species", "PROBLEM", 100, 122], ["viral respiratory agents", "TREATMENT", 137, 161], ["viral species", "OBSERVATION", 109, 122], ["viral", "OBSERVATION_MODIFIER", 137, 142], ["respiratory agents", "OBSERVATION", 143, 161], ["markedly", "OBSERVATION_MODIFIER", 171, 179], ["improved", "OBSERVATION_MODIFIER", 180, 188]]], ["These advances allowed re-evaluation of the role of various respiratory viruses in the pathogenesis of acute bronchiolitis.", [["respiratory viruses", "DISEASE", 60, 79], ["bronchiolitis", "DISEASE", 109, 122], ["various respiratory viruses", "PROBLEM", 52, 79], ["acute bronchiolitis", "PROBLEM", 103, 122], ["respiratory viruses", "OBSERVATION", 60, 79], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["bronchiolitis", "OBSERVATION", 109, 122]]], ["However, it is not infrequently seen that no causative agent can be identified in patients with bronchiolitis.IntroductionRespiratory syncytial virus (RSV) is the most frequently identified agent responsible for bronchiolitis worldwide.", [["bronchiolitis", "DISEASE", 96, 109], ["IntroductionRespiratory syncytial virus (RSV)", "DISEASE", 110, 155], ["bronchiolitis", "DISEASE", 212, 225], ["patients", "ORGANISM", 82, 90], ["IntroductionRespiratory syncytial virus", "ORGANISM", 110, 149], ["RSV", "ORGANISM", 151, 154], ["patients", "SPECIES", 82, 90], ["IntroductionRespiratory syncytial virus", "SPECIES", 110, 149], ["RSV", "SPECIES", 151, 154], ["causative agent", "PROBLEM", 45, 60], ["bronchiolitis", "PROBLEM", 96, 109], ["IntroductionRespiratory syncytial virus", "PROBLEM", 110, 149], ["bronchiolitis", "PROBLEM", 212, 225], ["not infrequently seen", "UNCERTAINTY", 15, 36], ["bronchiolitis", "OBSERVATION", 96, 109], ["syncytial virus", "OBSERVATION", 134, 149], ["bronchiolitis", "OBSERVATION", 212, 225]]], ["3, 4 However, many other respiratory viruses may also cause bronchiolitis.", [["respiratory viruses", "DISEASE", 25, 44], ["bronchiolitis", "DISEASE", 60, 73], ["many other respiratory viruses", "PROBLEM", 14, 44], ["bronchiolitis", "PROBLEM", 60, 73], ["respiratory viruses", "OBSERVATION", 25, 44], ["may also cause", "UNCERTAINTY", 45, 59], ["bronchiolitis", "OBSERVATION", 60, 73]]], ["Until now, viral etiology of bronchiolitis in children in Taiwan has been limited, particularly the newly identified viruses, including human metapneumovirus (hMPV), human bocavirus (hBoV), and human coronavirus (hCoV) NL-63.", [["bronchiolitis", "DISEASE", 29, 42], ["human metapneumovirus (hMPV)", "DISEASE", 136, 164], ["children", "ORGANISM", 46, 54], ["human metapneumovirus", "ORGANISM", 136, 157], ["hMPV", "ORGANISM", 159, 163], ["human", "ORGANISM", 166, 171], ["bocavirus", "GENE_OR_GENE_PRODUCT", 172, 181], ["hBoV", "ORGANISM", 183, 187], ["human coronavirus", "ORGANISM", 194, 211], ["NL-63", "CELL", 219, 224], ["children", "SPECIES", 46, 54], ["human", "SPECIES", 136, 141], ["metapneumovirus", "SPECIES", 142, 157], ["hMPV", "SPECIES", 159, 163], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 194, 199], ["coronavirus", "SPECIES", 200, 211], ["human metapneumovirus", "SPECIES", 136, 157], ["hMPV", "SPECIES", 159, 163], ["human", "SPECIES", 166, 171], ["hBoV", "SPECIES", 183, 187], ["human coronavirus", "SPECIES", 194, 211], ["bronchiolitis", "PROBLEM", 29, 42], ["the newly identified viruses", "PROBLEM", 96, 124], ["human metapneumovirus (hMPV", "PROBLEM", 136, 163], ["human bocavirus (hBoV", "PROBLEM", 166, 187], ["human coronavirus", "TEST", 194, 211], ["bronchiolitis", "OBSERVATION", 29, 42], ["viruses", "OBSERVATION", 117, 124], ["metapneumovirus", "OBSERVATION", 142, 157]]], ["5, 6 Therefore, we conducted a prospective study to figure out the viral epidemiology of bronchiolitis among pediatric inpatients in Taiwan.Patients and respiratory specimensThe study was approved by the Institutional Review Board of Chang Gung Memorial Hospital, and informed consent was obtained from parents or legal guardians of the children.", [["respiratory specimens", "ANATOMY", 153, 174], ["bronchiolitis", "DISEASE", 89, 102], ["Patients", "ORGANISM", 140, 148], ["children", "ORGANISM", 337, 345], ["Patients", "SPECIES", 140, 148], ["children", "SPECIES", 337, 345], ["a prospective study", "TEST", 29, 48], ["bronchiolitis", "PROBLEM", 89, 102], ["respiratory specimens", "TEST", 153, 174], ["The study", "TEST", 174, 183], ["bronchiolitis", "OBSERVATION", 89, 102], ["respiratory", "ANATOMY", 153, 164]]], ["From January 2009 to March 2011, children (aged <24 months) with the initial diagnosis of acute bronchiolitis, hospitalized in Chang Gung Children's Hospital situated in northern Taiwan, were eligible for this study, and up to three cases per week were randomly selected for viral etiology investigation.", [["bronchiolitis", "DISEASE", 96, 109], ["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["Children", "SPECIES", 138, 146], ["acute bronchiolitis", "PROBLEM", 90, 109], ["this study", "TEST", 205, 215], ["viral etiology investigation", "TEST", 275, 303], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["bronchiolitis", "OBSERVATION", 96, 109]]], ["Nasopharyngeal aspirates were collected prospectively from all patients within 1e3 days after hospital admission.Patients and respiratory specimensThe diagnosis of acute bronchiolitis was made by an acute onset of respiratory distress with cough, tachypnea, retraction, and expiratory wheezes, often accompanied by rales.", [["Nasopharyngeal aspirates", "ANATOMY", 0, 24], ["respiratory specimens", "ANATOMY", 126, 147], ["respiratory", "ANATOMY", 214, 225], ["bronchiolitis", "DISEASE", 170, 183], ["respiratory distress", "DISEASE", 214, 234], ["cough", "DISEASE", 240, 245], ["tachypnea", "DISEASE", 247, 256], ["expiratory wheezes", "DISEASE", 274, 292], ["Nasopharyngeal aspirates", "CANCER", 0, 24], ["patients", "ORGANISM", 63, 71], ["Patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 63, 71], ["Patients", "SPECIES", 113, 121], ["Nasopharyngeal aspirates", "TEST", 0, 24], ["respiratory specimens", "TEST", 126, 147], ["acute bronchiolitis", "PROBLEM", 164, 183], ["respiratory distress", "PROBLEM", 214, 234], ["cough", "PROBLEM", 240, 245], ["tachypnea", "PROBLEM", 247, 256], ["retraction", "PROBLEM", 258, 268], ["expiratory wheezes", "PROBLEM", 274, 292], ["rales", "PROBLEM", 315, 320], ["aspirates", "OBSERVATION", 15, 24], ["respiratory", "ANATOMY", 126, 137], ["acute", "OBSERVATION_MODIFIER", 164, 169], ["bronchiolitis", "OBSERVATION", 170, 183], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["respiratory", "ANATOMY", 214, 225], ["distress", "OBSERVATION", 226, 234], ["cough", "OBSERVATION", 240, 245], ["tachypnea", "OBSERVATION", 247, 256], ["retraction", "OBSERVATION_MODIFIER", 258, 268], ["expiratory", "OBSERVATION_MODIFIER", 274, 284], ["wheezes", "OBSERVATION", 285, 292], ["rales", "OBSERVATION", 315, 320]]], ["Patients with underlying chronic diseases, including cerebral palsy with bedridden status, tracheostomy, congenital heart disease, chronic pulmonary disease, and immunodeficiency, were excluded.Patients and respiratory specimensMedical records were reviewed for detailed demographic, clinical, and laboratory data; radiographic images; and underlying conditions of the patients.", [["cerebral", "ANATOMY", 53, 61], ["heart", "ANATOMY", 116, 121], ["pulmonary", "ANATOMY", 139, 148], ["respiratory specimens", "ANATOMY", 207, 228], ["chronic diseases", "DISEASE", 25, 41], ["cerebral palsy", "DISEASE", 53, 67], ["congenital heart disease", "DISEASE", 105, 129], ["chronic pulmonary disease", "DISEASE", 131, 156], ["immunodeficiency", "DISEASE", 162, 178], ["Patients", "ORGANISM", 0, 8], ["cerebral", "ORGAN", 53, 61], ["heart", "ORGAN", 116, 121], ["pulmonary", "ORGAN", 139, 148], ["Patients", "ORGANISM", 194, 202], ["patients", "ORGANISM", 369, 377], ["Patients", "SPECIES", 0, 8], ["Patients", "SPECIES", 194, 202], ["patients", "SPECIES", 369, 377], ["underlying chronic diseases", "PROBLEM", 14, 41], ["cerebral palsy", "PROBLEM", 53, 67], ["bedridden status", "PROBLEM", 73, 89], ["tracheostomy", "TREATMENT", 91, 103], ["congenital heart disease", "PROBLEM", 105, 129], ["chronic pulmonary disease", "PROBLEM", 131, 156], ["immunodeficiency", "PROBLEM", 162, 178], ["laboratory data", "TEST", 298, 313], ["radiographic images", "TEST", 315, 334], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["diseases", "OBSERVATION", 33, 41], ["cerebral", "ANATOMY", 53, 61], ["palsy", "OBSERVATION", 62, 67], ["tracheostomy", "OBSERVATION", 91, 103], ["congenital", "OBSERVATION_MODIFIER", 105, 115], ["heart", "ANATOMY", 116, 121], ["disease", "OBSERVATION", 122, 129], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["pulmonary", "ANATOMY", 139, 148], ["disease", "OBSERVATION", 149, 156], ["immunodeficiency", "OBSERVATION", 162, 178]]], ["All the clinical symptoms and signs were recorded on a standardized form while the patients were hospitalized.Virus detectionAll the specimens were processed, and then nucleic acids (including DNA and RNA) were extracted by commercial kits and kept in a refrigerator at e70 C for further analysis.", [["specimens", "ANATOMY", 133, 142], ["nucleic acids", "CHEMICAL", 168, 181], ["patients", "ORGANISM", 83, 91], ["Virus", "ORGANISM", 110, 115], ["specimens", "CANCER", 133, 142], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["patients", "SPECIES", 83, 91], ["All the clinical symptoms", "PROBLEM", 0, 25], ["Virus detection", "TEST", 110, 125], ["nucleic acids", "TEST", 168, 181], ["DNA and RNA", "TREATMENT", 193, 204], ["further analysis", "TEST", 280, 296]]], ["All specimens were sent for viral detection by conventional viral culture, immunofluorescent antigen detection for RSV, and multiplex reverse transcriptionpolymerase chain reaction (RT-PCR) for six viruses, including rhinovirus (RV), hMPV, hCoV-229E, hCoV-OC43, NL-63, and hBoV.Virus detectionSample preparation for virus culture and immunofluorescence Nasopharyngeal aspirates were mixed with sterilized phosphate-buffered saline (PBS) followed by vigorous vortex.", [["specimens", "ANATOMY", 4, 13], ["Nasopharyngeal aspirates", "ANATOMY", 353, 377], ["phosphate", "CHEMICAL", 405, 414], ["phosphate", "CHEMICAL", 405, 414], ["RSV", "ORGANISM", 115, 118], ["rhinovirus", "ORGANISM", 217, 227], ["hMPV", "ORGANISM", 234, 238], ["hCoV-229E", "GENE_OR_GENE_PRODUCT", 240, 249], ["hCoV-OC43", "GENE_OR_GENE_PRODUCT", 251, 260], ["NL-63", "GENE_OR_GENE_PRODUCT", 262, 267], ["hBoV", "GENE_OR_GENE_PRODUCT", 273, 277], ["Virus", "ORGANISM", 278, 283], ["Nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 353, 377], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 405, 430], ["hCoV", "PROTEIN", 251, 255], ["hBoV", "DNA", 273, 277], ["hMPV", "SPECIES", 234, 238], ["RSV", "SPECIES", 115, 118], ["RV", "SPECIES", 229, 231], ["hMPV", "SPECIES", 234, 238], ["All specimens", "TEST", 0, 13], ["viral detection", "TEST", 28, 43], ["conventional viral culture", "TEST", 47, 73], ["immunofluorescent antigen detection", "TEST", 75, 110], ["RSV", "PROBLEM", 115, 118], ["multiplex reverse transcriptionpolymerase chain reaction", "PROBLEM", 124, 180], ["RT-PCR", "TEST", 182, 188], ["six viruses", "PROBLEM", 194, 205], ["rhinovirus", "PROBLEM", 217, 227], ["RV", "TEST", 229, 231], ["hMPV", "TEST", 234, 238], ["hCoV", "TEST", 240, 244], ["hCoV", "TEST", 251, 255], ["OC43", "TEST", 256, 260], ["NL", "TEST", 262, 264], ["hBoV", "PROBLEM", 273, 277], ["Virus detectionSample preparation", "TREATMENT", 278, 311], ["virus culture", "TEST", 316, 329], ["immunofluorescence", "TEST", 334, 352], ["Nasopharyngeal aspirates", "TEST", 353, 377], ["sterilized phosphate", "TREATMENT", 394, 414], ["buffered saline (PBS)", "TREATMENT", 415, 436], ["hBoV", "OBSERVATION", 273, 277], ["vigorous vortex", "OBSERVATION", 449, 464]]], ["Then the cell suspension was centrifuged at 3000 rpm for 10 minutes to get the cell pellet.", [["cell", "ANATOMY", 9, 13], ["cell", "ANATOMY", 79, 83], ["cell", "CELL", 9, 13], ["cell", "CELL", 79, 83], ["the cell suspension", "TREATMENT", 5, 24], ["the cell pellet", "TREATMENT", 75, 90]]], ["Finally, the supernatant was discarded and PBS was added to resuspend the cells again.", [["supernatant", "ANATOMY", 13, 24], ["cells", "ANATOMY", 74, 79], ["PBS", "SIMPLE_CHEMICAL", 43, 46], ["cells", "CELL", 74, 79], ["the supernatant", "TREATMENT", 9, 24], ["PBS", "TREATMENT", 43, 46]]], ["After the third time wash, the cell pellet was resuspended in viral transport medium and treated with antibiotics for 30 minutes.Virus isolationSpecimens of cell suspension prepared as described above were inoculated into MK2, MRC-5, and MDCK cells and incubated at 35 C for 2 weeks.", [["cell pellet", "ANATOMY", 31, 42], ["cell", "ANATOMY", 157, 161], ["MRC-5", "ANATOMY", 227, 232], ["MDCK cells", "ANATOMY", 238, 248], ["cell", "CELL", 31, 35], ["Virus", "ORGANISM", 129, 134], ["cell", "CELL", 157, 161], ["MK2", "GENE_OR_GENE_PRODUCT", 222, 225], ["MRC-5", "CELL", 227, 232], ["MDCK cells", "CELL", 238, 248], ["MK2, MRC-5", "CELL_LINE", 222, 232], ["MDCK cells", "CELL_LINE", 238, 248], ["the third time wash", "TREATMENT", 6, 25], ["the cell pellet", "TREATMENT", 27, 42], ["viral transport medium", "TREATMENT", 62, 84], ["antibiotics", "TREATMENT", 102, 113], ["Virus isolationSpecimens of cell suspension", "TREATMENT", 129, 172], ["MRC", "TEST", 227, 230], ["MDCK cells", "TEST", 238, 248], ["cell pellet", "OBSERVATION", 31, 42], ["cell suspension", "OBSERVATION", 157, 172]]], ["Cytopathic effect (CPE) of all culture tubes was checked every 2 days.", [["culture tubes", "ANATOMY", 31, 44], ["Cytopathic effect (CPE", "PROBLEM", 0, 22], ["all culture tubes", "TEST", 27, 44]]], ["For CPEpositive tubes, a screening kit of immunofluorescence assay for respiratory virus (Chemicon Inc., Temecula, California, USA) was used for further examination of respiratory virus infection.", [["respiratory virus infection", "DISEASE", 168, 195], ["CPEpositive tubes", "TISSUE", 4, 21], ["respiratory virus", "ORGANISM", 71, 88], ["respiratory virus", "ORGANISM", 168, 185], ["respiratory virus", "SPECIES", 71, 88], ["respiratory virus", "SPECIES", 168, 185], ["CPEpositive tubes", "TREATMENT", 4, 21], ["a screening kit", "TEST", 23, 38], ["immunofluorescence assay", "TEST", 42, 66], ["respiratory virus", "PROBLEM", 71, 88], ["further examination", "TEST", 145, 164], ["respiratory virus infection", "PROBLEM", 168, 195], ["tubes", "OBSERVATION", 16, 21], ["respiratory virus", "OBSERVATION", 168, 185]]], ["Only the respiratory viruses identified, including RSV, parainfluenza (PIV)-1, PIV-2, PIV-3, adenovirus, influenza viruses A and B, were regarded as pathogens.Immunofluorescent assay for the detection of RSV antigenThe cell suspension (50 mL) was added to a slide and fixed in acetone for 10 minutes.", [["cell", "ANATOMY", 219, 223], ["respiratory viruses", "DISEASE", 9, 28], ["parainfluenza", "DISEASE", 56, 69], ["influenza viruses", "DISEASE", 105, 122], ["acetone", "CHEMICAL", 277, 284], ["acetone", "CHEMICAL", 277, 284], ["RSV", "ORGANISM", 51, 54], ["parainfluenza (PIV)-1", "ORGANISM", 56, 77], ["PIV-2", "ORGANISM", 79, 84], ["PIV-3", "ORGANISM", 86, 91], ["adenovirus", "ORGANISM", 93, 103], ["influenza viruses A", "ORGANISM", 105, 124], ["B", "CELL", 129, 130], ["RSV", "ORGANISM", 204, 207], ["cell", "CELL", 219, 223], ["acetone", "SIMPLE_CHEMICAL", 277, 284], ["RSV antigen", "PROTEIN", 204, 215], ["RSV", "SPECIES", 51, 54], ["parainfluenza", "SPECIES", 56, 69], ["influenza viruses", "SPECIES", 105, 122], ["RSV", "SPECIES", 51, 54], ["PIV", "SPECIES", 71, 74], ["PIV-3", "SPECIES", 86, 91], ["RSV", "SPECIES", 204, 207], ["the respiratory viruses", "PROBLEM", 5, 28], ["RSV", "TEST", 51, 54], ["parainfluenza", "TEST", 56, 69], ["PIV", "TEST", 71, 74], ["PIV", "TEST", 79, 82], ["PIV", "TEST", 86, 89], ["adenovirus", "PROBLEM", 93, 103], ["influenza viruses", "PROBLEM", 105, 122], ["pathogens", "PROBLEM", 149, 158], ["Immunofluorescent assay", "TEST", 159, 182], ["the detection", "TEST", 187, 200], ["RSV antigen", "PROBLEM", 204, 215], ["The cell suspension", "TREATMENT", 215, 234], ["a slide and fixed in acetone", "TREATMENT", 256, 284], ["respiratory viruses", "OBSERVATION", 9, 28], ["cell suspension", "OBSERVATION", 219, 234]]], ["Monoclonal antibody that conjugated Fluorescein isothiocyanate (FITC) to RSV was used to detect RSV antigen.RT-PCR assayIt is designed to amplify conserved region of each virus target.", [["Fluorescein isothiocyanate", "CHEMICAL", 36, 62], ["Fluorescein isothiocyanate", "CHEMICAL", 36, 62], ["FITC", "CHEMICAL", 64, 68], ["Fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 36, 62], ["FITC", "SIMPLE_CHEMICAL", 64, 68], ["RSV", "ORGANISM", 73, 76], ["RSV", "ORGANISM", 96, 99], ["Monoclonal antibody", "PROTEIN", 0, 19], ["RSV antigen", "PROTEIN", 96, 107], ["RT-PCR assayIt", "DNA", 108, 122], ["RSV", "SPECIES", 73, 76], ["RSV", "SPECIES", 96, 99], ["Monoclonal antibody", "TEST", 0, 19], ["conjugated Fluorescein isothiocyanate (FITC)", "TREATMENT", 25, 69], ["RSV", "PROBLEM", 73, 76], ["RSV antigen", "PROBLEM", 96, 107], ["RT-PCR assayIt", "TEST", 108, 122], ["each virus target", "PROBLEM", 166, 183]]], ["Sequence of primer for each virus target is given in Supplementary Table 1 .", [["Sequence of primer", "TREATMENT", 0, 18], ["each virus target", "TREATMENT", 23, 40]]], ["Viral RNAs were extracted from 200 mL respiratory specimens using QIAmp Viral RNA kit (Qiagen, Chatsworth, CA, USA), and reverse transcription reactions were performed for complementary DNA synthesis using SuperScriptTM III One-Step RT-PCR kit (Invitrogen, Carlsbad, CA, USA).", [["respiratory specimens", "ANATOMY", 38, 59], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["Viral RNAs", "RNA", 0, 10], ["Viral RNAs", "PROBLEM", 0, 10], ["respiratory specimens", "TEST", 38, 59], ["QIAmp", "TREATMENT", 66, 71], ["reverse transcription reactions", "PROBLEM", 121, 152], ["complementary DNA synthesis", "TREATMENT", 172, 199], ["SuperScriptTM III", "TREATMENT", 206, 223], ["PCR kit", "TEST", 236, 243], ["Invitrogen", "TEST", 245, 255], ["RNAs", "OBSERVATION", 6, 10]]], ["Each reaction included the following components: 0.2 M probe, 0.4 M primer, 12.5 l of 2\u00c2 ABI Mater mixture (containing 0.4 mmol/L deoxyribonucleotide triphosphate (dNTP) and 2.4 mmol/L MgSO 4 ), and 5mL of specimen RNA extract or control.", [["extract", "ANATOMY", 219, 226], ["deoxyribonucleotide triphosphate", "CHEMICAL", 130, 162], ["NTP", "CHEMICAL", 165, 168], ["deoxyribonucleotide triphosphate", "CHEMICAL", 130, 162], ["dNTP", "CHEMICAL", 164, 168], ["MgSO 4", "CHEMICAL", 185, 191], ["deoxyribonucleotide triphosphate", "SIMPLE_CHEMICAL", 130, 162], ["dNTP", "SIMPLE_CHEMICAL", 164, 168], ["Each reaction", "PROBLEM", 0, 13], ["2\u00c2 ABI Mater mixture", "TREATMENT", 86, 106], ["L deoxyribonucleotide triphosphate (dNTP)", "TREATMENT", 128, 169], ["mmol/L MgSO", "TREATMENT", 178, 189], ["specimen RNA extract", "TREATMENT", 206, 226]]], ["The final reaction volume was adjusted to 25 mL with PCRgrade water, and RT-PCR amplification was performed using the following conditions: an initial cDNA step at 50 C for 30 minutes, followed by at 95 C for 15 minutes, and 50 cycles at 95 C for 30 seconds, at 55 C for 30 seconds, and at 72 C for 30 seconds.", [["The final reaction volume", "TREATMENT", 0, 25], ["PCRgrade water", "TREATMENT", 53, 67], ["RT-PCR amplification", "TREATMENT", 73, 93]]], ["RT-PCR products of hCoV-NL63 and hBoV for positive control were kindly provided by Professor Patrick C.Y. Woo (Hong Kong University).Statistical analysisOne-way analysis of variance and Student t test were used for the comparison of continuous variables.", [["hCoV-NL63", "GENE_OR_GENE_PRODUCT", 19, 28], ["hBoV", "SIMPLE_CHEMICAL", 33, 37], ["hCoV", "PROTEIN", 19, 23], ["NL63", "PROTEIN", 24, 28], ["hBoV", "DNA", 33, 37], ["RT-PCR products", "TEST", 0, 15], ["hCoV", "TEST", 19, 23], ["NL63", "TREATMENT", 24, 28], ["hBoV", "PROBLEM", 33, 37], ["Statistical analysisOne", "TEST", 133, 156], ["Student t test", "TEST", 186, 200]]], ["The c 2 test was used to analyze categorical independent variables.", [["The c 2 test", "TEST", 0, 12]]], ["Results for continuous data were expressed as mean AE SD.", [["continuous data", "TEST", 12, 27]]], ["A p value of <0.05 was considered statistically significant.", [["A p value", "TEST", 0, 9]]], ["All analyses were performed using the SPSS version 17.0 for Windows.ResultsA total of 113 children were included in this study.", [["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["All analyses", "TEST", 0, 12], ["the SPSS version", "TEST", 34, 50], ["this study", "TEST", 116, 126]]], ["The median age of the children was 9 months, ranging from 1.5 to 24 months, and 77 (68%) were male.", [["children", "ORGANISM", 22, 30], ["children", "SPECIES", 22, 30]]], ["Clinical characteristics of the patients are described in Table 1 .", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["In our study, 24/113 (21.2%) children received antibiotic treatment during hospitalization mostly due to secondary bacterial infection such as acute sinusitis, acute otitis media, or pneumonia.ResultsA total of 132 viruses were detected from 113 children, but 12 viruses, including cytomegalovirus in seven and enterovirus in five, were regarded as nonpathogenic agents and excluded from analysis in this study.", [["bacterial infection", "DISEASE", 115, 134], ["sinusitis", "DISEASE", 149, 158], ["acute otitis media", "DISEASE", 160, 178], ["pneumonia", "DISEASE", 183, 192], ["children", "ORGANISM", 29, 37], ["children", "ORGANISM", 246, 254], ["cytomegalovirus", "ORGANISM", 282, 297], ["children", "SPECIES", 29, 37], ["children", "SPECIES", 246, 254], ["our study", "TEST", 3, 12], ["antibiotic treatment", "TREATMENT", 47, 67], ["secondary bacterial infection", "PROBLEM", 105, 134], ["acute sinusitis", "PROBLEM", 143, 158], ["acute otitis media", "PROBLEM", 160, 178], ["pneumonia", "PROBLEM", 183, 192], ["132 viruses", "PROBLEM", 211, 222], ["12 viruses", "PROBLEM", 260, 270], ["cytomegalovirus", "PROBLEM", 282, 297], ["enterovirus", "PROBLEM", 311, 322], ["this study", "TEST", 400, 410], ["secondary", "OBSERVATION_MODIFIER", 105, 114], ["bacterial", "OBSERVATION_MODIFIER", 115, 124], ["infection", "OBSERVATION", 125, 134], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["sinusitis", "OBSERVATION", 149, 158], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["otitis", "OBSERVATION", 166, 172], ["pneumonia", "OBSERVATION", 183, 192], ["cytomegalovirus", "OBSERVATION", 282, 297]]], ["At least one viral pathogen was identified in 86 children (76%), of whom single viral pathogen was detected in 58 (67%) and at least two viruses were detected in 28 (33%).", [["children", "ORGANISM", 49, 57], ["children", "SPECIES", 49, 57], ["one viral pathogen", "PROBLEM", 9, 27], ["single viral pathogen", "TEST", 73, 94], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["pathogen", "OBSERVATION", 19, 27], ["viruses", "OBSERVATION", 137, 144]]], ["RSV was the most common virus identified and accounted for 49 (43.4%) cases, followed by hBoV in 22 (19.5%), hMPV in 19 (16.8%), and RV in 14 (12.4%) (Fig. 1) .", [["hMPV", "DISEASE", 109, 113], ["RSV", "ORGANISM", 0, 3], ["hMPV", "ORGANISM", 109, 113], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["hBoV", "TEST", 89, 93], ["hMPV", "TEST", 109, 113], ["RV", "TEST", 133, 135], ["most common", "OBSERVATION_MODIFIER", 12, 23], ["virus", "OBSERVATION", 24, 29], ["RV", "ANATOMY", 133, 135]]], ["CPE was observed in one case, but the virus species could not be identified.", [["CPE", "CHEMICAL", 0, 3], ["CPE", "PROBLEM", 0, 3], ["the virus species", "PROBLEM", 34, 51], ["could not be", "UNCERTAINTY", 52, 64]]], ["All 113 specimens were negative for CoV-229E or influenza virus B. Of the 49 RSV-positive children, 18 (36.7%) had coinfection with other viruses.ResultsMonthly distribution of the viruses identified during the study period is illustrated in Fig. 2 .", [["specimens", "ANATOMY", 8, 17], ["coinfection", "DISEASE", 115, 126], ["specimens", "CANCER", 8, 17], ["CoV-229E", "ORGANISM", 36, 44], ["influenza virus B.", "ORGANISM", 48, 66], ["RSV", "ORGANISM", 77, 80], ["children", "ORGANISM", 90, 98], ["influenza virus B.", "SPECIES", 48, 66], ["RSV", "SPECIES", 77, 80], ["children", "SPECIES", 90, 98], ["CoV-229E", "SPECIES", 36, 44], ["RSV", "SPECIES", 77, 80], ["All 113 specimens", "TEST", 0, 17], ["CoV", "TEST", 36, 39], ["229E", "PROBLEM", 40, 44], ["influenza virus B.", "PROBLEM", 48, 66], ["coinfection", "PROBLEM", 115, 126], ["other viruses", "PROBLEM", 132, 145], ["the viruses", "PROBLEM", 177, 188], ["the study", "TEST", 207, 216], ["coinfection", "OBSERVATION", 115, 126], ["viruses", "OBSERVATION", 138, 145], ["viruses", "OBSERVATION", 181, 188]]], ["The incidence of RSV infection peaked in April 2009, March 2010, and November 2010.", [["RSV infection", "DISEASE", 17, 30], ["RSV", "ORGANISM", 17, 20], ["RSV", "SPECIES", 17, 20], ["RSV infection", "PROBLEM", 17, 30], ["RSV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30]]], ["The incidence of hMPV detection peaked in April 2009, while that of hBoV peaked in August 2010.", [["hMPV", "DISEASE", 17, 21], ["hMPV", "ORGANISM", 17, 21], ["hMPV", "SPECIES", 17, 21], ["hMPV detection", "TEST", 17, 31], ["hBoV", "PROBLEM", 68, 72], ["hMPV", "OBSERVATION", 17, 21]]], ["We could not evaluate the differences in incidence of other viruses due to the small case numbers.ResultsBronchiolitis due to single viral infection was identified in 58 patients, of whom RSV was detected in 31 (53%), hBoV in six (10%), hMPV in six (10%), and RV in seven (12%).", [["RV", "ANATOMY", 260, 262], ["Bronchiolitis", "DISEASE", 105, 118], ["viral infection", "DISEASE", 133, 148], ["hMPV", "DISEASE", 237, 241], ["patients", "ORGANISM", 170, 178], ["RSV", "ORGANISM", 188, 191], ["hMPV", "ORGANISM", 237, 241], ["patients", "SPECIES", 170, 178], ["RSV", "SPECIES", 188, 191], ["other viruses", "PROBLEM", 54, 67], ["Bronchiolitis", "PROBLEM", 105, 118], ["single viral infection", "PROBLEM", 126, 148], ["RSV", "TEST", 188, 191], ["hBoV", "TEST", 218, 222], ["hMPV", "TEST", 237, 241], ["RV", "TEST", 260, 262], ["viruses", "OBSERVATION", 60, 67], ["small", "OBSERVATION_MODIFIER", 79, 84], ["Bronchiolitis", "OBSERVATION", 105, 118], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["infection", "OBSERVATION", 139, 148], ["RV", "ANATOMY", 260, 262]]], ["Clinical characteristics of these patients are given in Table 2 .", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["No significant differences were observed in terms of sex, age, radiographic findings, duration of fever, length of hospital stay, antibiotic treatment, leukocyte count, and serum C-reactive protein level.ResultsMultiple viral infections were found in 28 cases (25%).", [["leukocyte", "ANATOMY", 152, 161], ["serum", "ANATOMY", 173, 178], ["fever", "DISEASE", 98, 103], ["viral infections", "DISEASE", 220, 236], ["leukocyte", "CELL", 152, 161], ["serum", "ORGANISM_SUBSTANCE", 173, 178], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 179, 197], ["serum C-reactive protein", "PROTEIN", 173, 197], ["fever", "PROBLEM", 98, 103], ["antibiotic treatment", "TREATMENT", 130, 150], ["leukocyte count", "TEST", 152, 167], ["serum C", "TEST", 173, 180], ["ResultsMultiple viral infections", "PROBLEM", 204, 236], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION", 15, 26], ["viral", "OBSERVATION_MODIFIER", 220, 225], ["infections", "OBSERVATION", 226, 236]]], ["RSV was the most common virus encountered in mixed infections, followed by hBoV, hMPV, and RV.", [["infections", "DISEASE", 51, 61], ["RSV", "ORGANISM", 0, 3], ["hMPV", "ORGANISM", 81, 85], ["RSV", "SPECIES", 0, 3], ["hBoV", "SPECIES", 75, 79], ["hMPV", "SPECIES", 81, 85], ["RV", "SPECIES", 91, 93], ["RSV", "PROBLEM", 0, 3], ["mixed infections", "PROBLEM", 45, 61], ["hBoV", "TEST", 75, 79], ["hMPV", "TEST", 81, 85], ["most common", "OBSERVATION_MODIFIER", 12, 23], ["mixed", "OBSERVATION_MODIFIER", 45, 50], ["infections", "OBSERVATION", 51, 61], ["RV", "ANATOMY", 91, 93]]], ["The detailed incidence rate of mixed viral infection is listed in Table 3 .", [["viral infection", "DISEASE", 37, 52], ["mixed viral infection", "PROBLEM", 31, 52], ["mixed", "OBSERVATION_MODIFIER", 31, 36], ["viral", "OBSERVATION_MODIFIER", 37, 42], ["infection", "OBSERVATION", 43, 52]]], ["In addition, clinical characteristics of the children with RSVmixed infection are described in Table 2 .", [["infection", "DISEASE", 68, 77], ["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["RSVmixed infection", "PROBLEM", 59, 77], ["infection", "OBSERVATION", 68, 77]]], ["Clinical manifestations of children with RSV-mixed infection were similar to those with single viral infection, and no significant differences were found among the different groups.DiscussionTo our knowledge, this is the first comprehensive viral etiology study of hospitalized pediatric patients with bronchiolitis, including newly identified respiratory viruses, in Taiwan.", [["RSV-mixed infection", "DISEASE", 41, 60], ["viral infection", "DISEASE", 95, 110], ["bronchiolitis", "DISEASE", 302, 315], ["respiratory viruses", "DISEASE", 344, 363], ["children", "ORGANISM", 27, 35], ["RSV", "ORGANISM", 41, 44], ["patients", "ORGANISM", 288, 296], ["children", "SPECIES", 27, 35], ["patients", "SPECIES", 288, 296], ["RSV", "SPECIES", 41, 44], ["RSV", "PROBLEM", 41, 44], ["mixed infection", "PROBLEM", 45, 60], ["single viral infection", "PROBLEM", 88, 110], ["significant differences", "PROBLEM", 119, 142], ["bronchiolitis", "PROBLEM", 302, 315], ["newly identified respiratory viruses", "PROBLEM", 327, 363], ["mixed", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60], ["viral", "OBSERVATION_MODIFIER", 95, 100], ["infection", "OBSERVATION", 101, 110], ["no", "UNCERTAINTY", 116, 118], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["bronchiolitis", "OBSERVATION", 302, 315], ["respiratory viruses", "OBSERVATION", 344, 363]]], ["Results from the present study showed that RSV, hMPV, and hBoV were the most common viral pathogens for acute lower respiratory tract infection among hospitalized children, less than 2 years of age, in northern Taiwan.We demonstrated again that RSV remained the major pathogen in infants with bronchiolitis.", [["lower respiratory tract", "ANATOMY", 110, 133], ["lower respiratory tract infection", "DISEASE", 110, 143], ["bronchiolitis", "DISEASE", 293, 306], ["RSV", "ORGANISM", 43, 46], ["hMPV", "ORGANISM", 48, 52], ["hBoV", "GENE_OR_GENE_PRODUCT", 58, 62], ["tract", "ORGANISM_SUBDIVISION", 128, 133], ["children", "ORGANISM", 163, 171], ["RSV", "ORGANISM", 245, 248], ["infants", "ORGANISM", 280, 287], ["children", "SPECIES", 163, 171], ["infants", "SPECIES", 280, 287], ["RSV", "SPECIES", 43, 46], ["hMPV", "SPECIES", 48, 52], ["hBoV", "SPECIES", 58, 62], ["RSV", "SPECIES", 245, 248], ["the present study", "TEST", 13, 30], ["RSV", "PROBLEM", 43, 46], ["hMPV", "PROBLEM", 48, 52], ["hBoV", "PROBLEM", 58, 62], ["acute lower respiratory tract infection", "PROBLEM", 104, 143], ["RSV", "PROBLEM", 245, 248], ["bronchiolitis", "PROBLEM", 293, 306], ["RSV", "OBSERVATION", 43, 46], ["hMPV", "OBSERVATION", 48, 52], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory tract", "ANATOMY", 116, 133], ["infection", "OBSERVATION", 134, 143], ["RSV", "OBSERVATION", 245, 248], ["major", "OBSERVATION_MODIFIER", 262, 267], ["pathogen", "OBSERVATION", 268, 276], ["bronchiolitis", "OBSERVATION", 293, 306]]], ["5,7 By thecombination of virus isolation and antigen test, RSV was detected in 43% of the patients in the current study.", [["5,7", "CHEMICAL", 0, 3], ["RSV", "ORGANISM", 59, 62], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["RSV", "SPECIES", 59, 62], ["virus isolation", "TREATMENT", 25, 40], ["antigen test", "TEST", 45, 57], ["RSV", "PROBLEM", 59, 62], ["the current study", "TEST", 102, 119], ["virus", "OBSERVATION", 25, 30]]], ["RSV bronchiolitis followed the biennial seasonal pattern of Taiwan, with peaks during the spring and the fall (April 2009, March 2010, and November 2010), which were consistent with those previously reported from Taiwan.", [["bronchiolitis", "DISEASE", 4, 17], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV bronchiolitis", "PROBLEM", 0, 17], ["bronchiolitis", "OBSERVATION", 4, 17]]], ["8 This this study was strengthened by the use of RT-PCR assays in combination with virus culture and immunofluorescent assay to detect respiratory viruses, including the newly identified viruses (hMPV, hBoV, and hCoV-NL63) and other viruses (RV, hCoV-OC43, and hCoV-229E), which may be responsible for bronchiolitis but not identified by routine virus tissue culture.", [["tissue", "ANATOMY", 352, 358], ["respiratory viruses", "DISEASE", 135, 154], ["bronchiolitis", "DISEASE", 302, 315], ["hMPV", "ORGANISM", 196, 200], ["hBoV", "GENE_OR_GENE_PRODUCT", 202, 206], ["hCoV", "GENE_OR_GENE_PRODUCT", 212, 216], ["NL63", "GENE_OR_GENE_PRODUCT", 217, 221], ["hCoV-OC43", "GENE_OR_GENE_PRODUCT", 246, 255], ["hCoV-229E", "GENE_OR_GENE_PRODUCT", 261, 270], ["hCoV", "PROTEIN", 212, 216], ["hMPV", "SPECIES", 196, 200], ["hBoV", "SPECIES", 202, 206], ["hCoV-229E", "SPECIES", 261, 270], ["This this study", "TEST", 2, 17], ["RT-PCR assays", "TEST", 49, 62], ["virus culture", "TEST", 83, 96], ["immunofluorescent assay", "TEST", 101, 124], ["respiratory viruses", "PROBLEM", 135, 154], ["the newly identified viruses", "PROBLEM", 166, 194], ["hMPV", "TEST", 196, 200], ["hBoV", "TEST", 202, 206], ["hCoV", "TEST", 212, 216], ["other viruses", "PROBLEM", 227, 240], ["RV", "TEST", 242, 244], ["hCoV", "TEST", 246, 250], ["OC43", "TEST", 251, 255], ["hCoV", "TEST", 261, 265], ["bronchiolitis", "PROBLEM", 302, 315], ["routine virus tissue culture", "TEST", 338, 366], ["respiratory viruses", "OBSERVATION", 135, 154], ["viruses", "OBSERVATION", 187, 194], ["RV", "ANATOMY", 242, 244], ["may be responsible for", "UNCERTAINTY", 279, 301], ["bronchiolitis", "OBSERVATION", 302, 315]]], ["With these technologies, we were allowed to detect up to 15 different viruses (groups) and could also explain a higher viral detection rate (79%) in the present study.", [["a higher viral detection rate", "PROBLEM", 110, 139], ["the present study", "TEST", 149, 166]]], ["In 57% of the patients, viruses other than RSV were identified; after RSV, the most frequently detected viruses included hBoV, hMPV, and RV.", [["patients", "ORGANISM", 14, 22], ["RSV", "ORGANISM", 43, 46], ["RSV", "ORGANISM", 70, 73], ["hBoV", "GENE_OR_GENE_PRODUCT", 121, 125], ["hMPV", "ORGANISM", 127, 131], ["patients", "SPECIES", 14, 22], ["RSV", "SPECIES", 43, 46], ["RSV", "SPECIES", 70, 73], ["hBoV", "SPECIES", 121, 125], ["hMPV", "SPECIES", 127, 131], ["RV", "SPECIES", 137, 139], ["viruses", "PROBLEM", 24, 31], ["RSV", "PROBLEM", 43, 46], ["RSV", "PROBLEM", 70, 73], ["hBoV", "PROBLEM", 121, 125], ["hMPV", "PROBLEM", 127, 131], ["viruses", "OBSERVATION", 104, 111], ["hMPV", "OBSERVATION", 127, 131], ["RV", "ANATOMY", 137, 139]]], ["The prevalence rate for hBoV (16.7%) was the highest so far reported among infants hospitalized for bronchiolitis.", [["bronchiolitis", "DISEASE", 100, 113], ["infants", "ORGANISM", 75, 82], ["infants", "SPECIES", 75, 82], ["The prevalence rate", "TEST", 0, 19], ["hBoV", "TEST", 24, 28], ["bronchiolitis", "PROBLEM", 100, 113], ["bronchiolitis", "OBSERVATION", 100, 113]]], ["6, 9, 10 Calvo et alreported an incidence rate of 11.4% for hBoV detection and Midulla et al a rate of 12.2%.", [["an incidence rate", "TEST", 29, 46], ["hBoV detection", "TEST", 60, 74], ["Midulla et al a rate", "TEST", 79, 99]]], ["The role of these respiratory agents in causing single or multiple viral infections in bronchiolitis has not yet been thoroughly studied.", [["respiratory", "ANATOMY", 18, 29], ["viral infections", "DISEASE", 67, 83], ["bronchiolitis", "DISEASE", 87, 100], ["these respiratory agents", "TREATMENT", 12, 36], ["multiple viral infections", "PROBLEM", 58, 83], ["bronchiolitis", "PROBLEM", 87, 100], ["respiratory agents", "OBSERVATION", 18, 36], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["infections", "OBSERVATION", 73, 83], ["bronchiolitis", "OBSERVATION", 87, 100]]], ["These findings suggest that many other respiratory viruses, in addition to RSV, may also cause acute bronchiolitis.DiscussionIn the present study, clinical characteristics of children with bronchiolitis due to different viral etiologies seemed similar, regardless of whether the infection was caused by single or multiple viruses.", [["respiratory viruses", "DISEASE", 39, 58], ["RSV", "DISEASE", 75, 78], ["bronchiolitis", "DISEASE", 101, 114], ["bronchiolitis", "DISEASE", 189, 202], ["infection", "DISEASE", 279, 288], ["RSV", "ORGANISM", 75, 78], ["children", "ORGANISM", 175, 183], ["children", "SPECIES", 175, 183], ["RSV", "SPECIES", 75, 78], ["many other respiratory viruses", "PROBLEM", 28, 58], ["RSV", "PROBLEM", 75, 78], ["acute bronchiolitis", "PROBLEM", 95, 114], ["the present study", "TEST", 128, 145], ["bronchiolitis", "PROBLEM", 189, 202], ["different viral etiologies", "PROBLEM", 210, 236], ["the infection", "PROBLEM", 275, 288], ["single or multiple viruses", "PROBLEM", 303, 329], ["respiratory viruses", "OBSERVATION", 39, 58], ["RSV", "OBSERVATION", 75, 78], ["may also cause", "UNCERTAINTY", 80, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["bronchiolitis", "OBSERVATION", 101, 114], ["bronchiolitis", "OBSERVATION", 189, 202], ["infection", "OBSERVATION", 279, 288], ["multiple", "OBSERVATION_MODIFIER", 313, 321], ["viruses", "OBSERVATION", 322, 329]]], ["In our study, we also observed no statistical significance in clinical characteristics between children with bronchiolitis caused by different single viral infection.", [["bronchiolitis", "DISEASE", 109, 122], ["viral infection", "DISEASE", 150, 165], ["children", "ORGANISM", 95, 103], ["children", "SPECIES", 95, 103], ["our study", "TEST", 3, 12], ["bronchiolitis", "PROBLEM", 109, 122], ["different single viral infection", "PROBLEM", 133, 165], ["bronchiolitis", "OBSERVATION", 109, 122], ["viral", "OBSERVATION_MODIFIER", 150, 155], ["infection", "OBSERVATION", 156, 165]]], ["However, a trend related to older age in hBoVinfected children than in RSV-infected was observed in previous studies.", [["RSV-infected", "DISEASE", 71, 83], ["children", "ORGANISM", 54, 62], ["RSV", "ORGANISM", 71, 74], ["children", "SPECIES", 54, 62], ["RSV", "SPECIES", 71, 74], ["RSV", "PROBLEM", 71, 74], ["previous studies", "TEST", 100, 116], ["infected", "OBSERVATION", 75, 83]]], ["6, 10, 11 The proportion of RV infections (12.4%) in Taiwan is slightly lower than that reported from the USA (16%) and Spain (17.4%), 6,12 but higher than that from Italy (8.8%).", [["RV", "ANATOMY", 28, 30], ["RV infections", "DISEASE", 28, 41], ["6, 10, 11", "CHEMICAL", 0, 9], ["RV", "ORGAN", 28, 30], ["RV infections", "PROBLEM", 28, 41], ["the USA", "TEST", 102, 109], ["Spain", "TEST", 120, 125], ["RV", "ANATOMY", 28, 30], ["infections", "OBSERVATION", 31, 41], ["slightly", "OBSERVATION_MODIFIER", 63, 71], ["lower", "OBSERVATION_MODIFIER", 72, 77], ["higher", "OBSERVATION_MODIFIER", 144, 150]]], ["10 The prevalence rate of hMPV (14.4%) in this study was higher than in most previous reports (1.7e9%), 6,10,12 except in the report byXepapadaki et al 13 (16%) .DiscussionMultiple viral infections were present in one-fourth of the patients with positive respiratory viral detection.", [["hMPV", "DISEASE", 26, 30], ["viral infections", "DISEASE", 181, 197], ["hMPV", "ORGANISM", 26, 30], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["hMPV", "SPECIES", 26, 30], ["hMPV", "TEST", 26, 30], ["this study", "TEST", 42, 52], ["DiscussionMultiple viral infections", "PROBLEM", 162, 197], ["positive respiratory viral detection", "PROBLEM", 246, 282], ["higher", "OBSERVATION_MODIFIER", 57, 63], ["viral", "OBSERVATION_MODIFIER", 181, 186], ["infections", "OBSERVATION", 187, 197], ["respiratory viral detection", "OBSERVATION", 255, 282]]], ["In agreement with previous studies, coinfection of hBoV and hMPV with other viruses was very common.", [["hBoV", "GENE_OR_GENE_PRODUCT", 51, 55], ["hMPV", "ORGANISM", 60, 64], ["hBoV", "SPECIES", 51, 55], ["hMPV", "SPECIES", 60, 64], ["previous studies", "TEST", 18, 34], ["coinfection", "PROBLEM", 36, 47], ["hBoV", "PROBLEM", 51, 55], ["hMPV", "PROBLEM", 60, 64], ["other viruses", "PROBLEM", 70, 83], ["hBoV", "OBSERVATION", 51, 55]]], ["6, 9, 10, 14 The role of viral coinfection is still unclear, and the controversies regarding their severities were found in the literature.", [["viral coinfection", "DISEASE", 25, 42], ["viral coinfection", "PROBLEM", 25, 42], ["their severities", "PROBLEM", 93, 109], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["coinfection", "OBSERVATION", 31, 42]]], ["15e19 In this study, clinical manifestations of children with RSVmixed infection were similar to those with single viral infections.DiscussionAlthough the combination of PCR method with other technologies was used, the causative viral agents remained undetected for one-fifth of the patients, which was in agreement with previous studies.", [["RSVmixed infection", "DISEASE", 62, 80], ["viral infections", "DISEASE", 115, 131], ["children", "ORGANISM", 48, 56], ["patients", "ORGANISM", 283, 291], ["children", "SPECIES", 48, 56], ["patients", "SPECIES", 283, 291], ["this study", "TEST", 9, 19], ["RSVmixed infection", "PROBLEM", 62, 80], ["single viral infections", "PROBLEM", 108, 131], ["PCR method", "TEST", 170, 180], ["the causative viral agents", "PROBLEM", 215, 241], ["previous studies", "TEST", 321, 337], ["infection", "OBSERVATION", 71, 80], ["infections", "OBSERVATION", 121, 131]]], ["5, 8, 9 The negative results may be due to technical problems related to sample collection, processing, and storage, or due to that bronchiolitis may be caused by unidentified viruses.", [["sample", "ANATOMY", 73, 79], ["bronchiolitis", "DISEASE", 132, 145], ["technical problems", "PROBLEM", 43, 61], ["sample collection", "PROBLEM", 73, 90], ["bronchiolitis", "PROBLEM", 132, 145], ["unidentified viruses", "PROBLEM", 163, 183], ["may be due to", "UNCERTAINTY", 29, 42], ["bronchiolitis", "OBSERVATION", 132, 145], ["viruses", "OBSERVATION", 176, 183]]], ["In this study, we did find a specimen with CPE in the virus culture, but the viral pathogen could not be identified.DiscussionThere were several limitations in the present study.", [["specimen", "ANATOMY", 29, 37], ["CPE", "CHEMICAL", 43, 46], ["this study", "TEST", 3, 13], ["a specimen", "TEST", 27, 37], ["CPE", "PROBLEM", 43, 46], ["the virus culture", "TEST", 50, 67], ["the viral pathogen", "PROBLEM", 73, 91], ["the present study", "TEST", 160, 177]]], ["First, a relatively small sample size made it difficult to compare among children with different viral etiologies.", [["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["a relatively small sample size", "PROBLEM", 7, 37], ["different viral etiologies", "PROBLEM", 87, 113], ["small", "OBSERVATION_MODIFIER", 20, 25], ["size", "OBSERVATION_MODIFIER", 33, 37], ["viral etiologies", "OBSERVATION", 97, 113]]], ["Second,the severity score of bronchiolitis could not be calculated to evaluate the disease severity of patients because oxygen saturation data were not detected for most patients and oxygen supplement such as O 2 hood was routinely provided for children hospitalized with bronchiolitis in our hospital.", [["bronchiolitis", "DISEASE", 29, 42], ["oxygen", "CHEMICAL", 120, 126], ["oxygen", "CHEMICAL", 183, 189], ["bronchiolitis", "DISEASE", 272, 285], ["oxygen", "CHEMICAL", 120, 126], ["oxygen", "CHEMICAL", 183, 189], ["patients", "ORGANISM", 103, 111], ["oxygen", "SIMPLE_CHEMICAL", 120, 126], ["patients", "ORGANISM", 170, 178], ["oxygen", "SIMPLE_CHEMICAL", 183, 189], ["children", "ORGANISM", 245, 253], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 170, 178], ["children", "SPECIES", 245, 253], ["bronchiolitis", "PROBLEM", 29, 42], ["the disease severity", "PROBLEM", 79, 99], ["oxygen saturation data", "TEST", 120, 142], ["oxygen supplement", "TREATMENT", 183, 200], ["bronchiolitis", "PROBLEM", 272, 285], ["bronchiolitis", "OBSERVATION", 29, 42], ["bronchiolitis", "OBSERVATION", 272, 285]]], ["Third, we included only those inpatients who may affect the true prevalence rate of the viral etiology of bronchiolitis, since not all patients with bronchiolitis needed hospitalization.DiscussionIn conclusion, although RSV remains the major viral pathogen for bronchiolitis, more than half of bronchiolitis are associated with other respiratory viruses, including newly identified viruses such as hMPV and hBoV.", [["bronchiolitis", "DISEASE", 106, 119], ["bronchiolitis", "DISEASE", 149, 162], ["bronchiolitis", "DISEASE", 261, 274], ["bronchiolitis", "DISEASE", 294, 307], ["respiratory viruses", "DISEASE", 334, 353], ["inpatients", "ORGANISM", 30, 40], ["patients", "ORGANISM", 135, 143], ["RSV", "ORGANISM", 220, 223], ["hMPV", "ORGANISM", 398, 402], ["hBoV", "GENE_OR_GENE_PRODUCT", 407, 411], ["patients", "SPECIES", 135, 143], ["RSV", "SPECIES", 220, 223], ["hMPV", "SPECIES", 398, 402], ["bronchiolitis", "PROBLEM", 106, 119], ["bronchiolitis", "PROBLEM", 149, 162], ["RSV", "PROBLEM", 220, 223], ["the major viral pathogen", "PROBLEM", 232, 256], ["bronchiolitis", "PROBLEM", 261, 274], ["bronchiolitis", "PROBLEM", 294, 307], ["other respiratory viruses", "PROBLEM", 328, 353], ["newly identified viruses", "PROBLEM", 365, 389], ["hMPV", "PROBLEM", 398, 402], ["hBoV", "PROBLEM", 407, 411], ["viral", "OBSERVATION_MODIFIER", 88, 93], ["bronchiolitis", "OBSERVATION", 106, 119], ["bronchiolitis", "OBSERVATION", 149, 162], ["RSV", "OBSERVATION", 220, 223], ["bronchiolitis", "OBSERVATION", 261, 274], ["bronchiolitis", "OBSERVATION", 294, 307], ["respiratory viruses", "OBSERVATION", 334, 353], ["viruses", "OBSERVATION", 382, 389], ["hBoV", "OBSERVATION", 407, 411]]], ["Molecular diagnostic methods such as RT-PCR provide a rapid, sensitive, and specific approach to improve the etiological diagnosis for bronchiolitis, which enables to prompt a more appropriate and rapid management.", [["bronchiolitis", "DISEASE", 135, 148], ["RT-PCR", "TEST", 37, 43], ["bronchiolitis", "PROBLEM", 135, 148], ["rapid management", "TREATMENT", 197, 213], ["bronchiolitis", "OBSERVATION", 135, 148]]], ["Further studies are needed to identify new viruses implicated in childhood bronchiolitis.Conflicts of interestAll authors declare that they have no conflicts of interest related to the material discussed in this article.", [["bronchiolitis", "DISEASE", 75, 88], ["Further studies", "TEST", 0, 15], ["new viruses", "PROBLEM", 39, 50], ["childhood bronchiolitis", "PROBLEM", 65, 88], ["viruses", "OBSERVATION", 43, 50], ["childhood", "OBSERVATION_MODIFIER", 65, 74], ["bronchiolitis", "OBSERVATION", 75, 88]]]], "557958d9134c47ff5cf61d192fef2c426b7f9a52": [["Information is given only where it has been derived from study with animal adenoviruses, particularly with respect to the basic properties of adenoviruses.I. INTRODUCTIONThe first adenovirus isolated was the virus of infectious canine hepatitis (ICH) (Rubarth, 1947) , although Cowdrey and Scott (1930) predicted that the intranuclear inclusions they saw in the hepatic and epithelial cells of two dogs with ICH would eventually be found to be due to a filterable agent.", [["hepatic", "ANATOMY", 362, 369], ["epithelial cells", "ANATOMY", 374, 390], ["infectious canine hepatitis", "DISEASE", 217, 244], ["ICH", "DISEASE", 246, 249], ["ICH", "DISEASE", 408, 411], ["adenoviruses", "ORGANISM", 75, 87], ["adenoviruses", "ORGANISM", 142, 154], ["adenovirus", "ORGANISM", 180, 190], ["infectious canine hepatitis", "ORGANISM", 217, 244], ["hepatic", "CELL", 362, 369], ["epithelial cells", "CELL", 374, 390], ["dogs", "ORGANISM", 398, 402], ["hepatic and epithelial cells", "CELL_TYPE", 362, 390], ["canine", "SPECIES", 228, 234], ["dogs", "SPECIES", 398, 402], ["canine hepatitis (ICH)", "SPECIES", 228, 250], ["animal adenoviruses", "PROBLEM", 68, 87], ["adenoviruses", "PROBLEM", 142, 154], ["The first adenovirus", "PROBLEM", 170, 190], ["infectious canine hepatitis", "PROBLEM", 217, 244], ["the intranuclear inclusions", "PROBLEM", 318, 345], ["ICH", "PROBLEM", 408, 411], ["a filterable agent", "TREATMENT", 451, 469], ["adenoviruses", "OBSERVATION", 142, 154], ["infectious", "OBSERVATION_MODIFIER", 217, 227], ["hepatitis", "OBSERVATION", 235, 244], ["intranuclear inclusions", "OBSERVATION", 322, 345], ["hepatic", "ANATOMY", 362, 369], ["epithelial cells", "OBSERVATION", 374, 390]]], ["Green and Stillinger (1934) noted similar inclusions when they experimentally infected dogs with material from fox encephalitis.", [["encephalitis", "DISEASE", 115, 127], ["dogs", "ORGANISM", 87, 91], ["fox encephalitis", "ORGANISM", 111, 127], ["dogs", "SPECIES", 87, 91], ["fox encephalitis", "SPECIES", 111, 127], ["similar inclusions", "PROBLEM", 34, 52], ["fox encephalitis", "PROBLEM", 111, 127], ["infected", "OBSERVATION", 78, 86], ["fox encephalitis", "OBSERVATION", 111, 127]]], ["The first avian adenovirus was isolated when material from bovine lumpy skin disease was inoculated into latently infected embryonated eggs and a virus was isolated (Van den Ende et al., 1949) .I. INTRODUCTIONHuman adenoviruses were isolated during investigations into respiratory disease (Rowe et al. 1953) ; (Hilleman and Werner, 1954) .", [["skin", "ANATOMY", 72, 76], ["eggs", "ANATOMY", 135, 139], ["respiratory", "ANATOMY", 269, 280], ["skin disease", "DISEASE", 72, 84], ["respiratory disease", "DISEASE", 269, 288], ["avian", "ORGANISM", 10, 15], ["adenovirus", "ORGANISM", 16, 26], ["bovine", "ORGANISM", 59, 65], ["skin", "ORGAN", 72, 76], ["embryonated", "ORGANISM", 123, 134], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 135, 139], ["adenoviruses", "ORGANISM", 215, 227], ["bovine", "SPECIES", 59, 65], ["adenovirus", "SPECIES", 16, 26], ["bovine", "SPECIES", 59, 65], ["The first avian adenovirus", "PROBLEM", 0, 26], ["material from bovine lumpy skin disease", "PROBLEM", 45, 84], ["latently infected embryonated eggs", "PROBLEM", 105, 139], ["a virus", "PROBLEM", 144, 151], ["INTRODUCTIONHuman adenoviruses", "TREATMENT", 197, 227], ["respiratory disease", "PROBLEM", 269, 288], ["adenovirus", "OBSERVATION", 16, 26], ["lumpy", "OBSERVATION_MODIFIER", 66, 71], ["skin", "ANATOMY", 72, 76], ["disease", "OBSERVATION", 77, 84], ["latently", "OBSERVATION_MODIFIER", 105, 113], ["infected", "OBSERVATION_MODIFIER", 114, 122], ["embryonated eggs", "OBSERVATION", 123, 139], ["respiratory disease", "OBSERVATION", 269, 288]]], ["Huebner et al. (1954) rec ognized that these agents constituted a new virus group, and Rowe et al. (1955) suggested the name \"adenoidal-pharyngeal-conjunctival (APC) viruses.\"", [["pharyngeal", "ANATOMY", 136, 146], ["conjunctival", "ANATOMY", 147, 159], ["adenoidal-pharyngeal-conjunctival", "CANCER", 126, 159], ["APC", "GENE_OR_GENE_PRODUCT", 161, 164], ["pharyngeal", "ANATOMY", 136, 146], ["conjunctival", "ANATOMY", 147, 159]]], ["How ever, the name \"adenoviruses\" was subsequently accepted as the generic name (Enders et al., 1956) .I. INTRODUCTIONThe general properties required for classifying an isolate as an adenovirus were established by an international committee (Pereira et al., 1963) .", [["adenoviruses", "ORGANISM", 20, 32], ["adenovirus", "ORGANISM", 183, 193], ["an adenovirus", "PROBLEM", 180, 193]]], ["The Inter national Committee on Taxonomy of Viruses recognized the genus Adenovirus (Wildy, 1971) , and a second report suggested the establishment of the family Adenoviridae with two genera, Mast adenovirus and Aviadenovirus, with human adenovirus type 2 and Celo virus as the type species (Norrby et al., 1976) .A. MorphologyThe adenovirus virion is considered to be an icosahedral structure 70-90 nm in diameter, composed of 252 capsomers.", [["Adenovirus", "ORGANISM", 73, 83], ["Mast adenovirus", "ORGANISM", 192, 207], ["Aviadenovirus", "GENE_OR_GENE_PRODUCT", 212, 225], ["human adenovirus type 2", "ORGANISM", 232, 255], ["Celo virus", "ORGANISM", 260, 270], ["adenovirus", "ORGANISM", 331, 341], ["human", "SPECIES", 232, 237], ["Mast adenovirus", "SPECIES", 192, 207], ["human adenovirus type 2", "SPECIES", 232, 255], ["Celo virus", "SPECIES", 260, 270], ["the family Adenoviridae", "TREATMENT", 151, 174], ["two genera", "TREATMENT", 180, 190], ["Mast adenovirus", "TREATMENT", 192, 207], ["Aviadenovirus", "TREATMENT", 212, 225], ["human adenovirus type 2", "TREATMENT", 232, 255], ["Celo virus", "PROBLEM", 260, 270], ["The adenovirus virion", "PROBLEM", 327, 348], ["Mast adenovirus", "OBSERVATION", 192, 207], ["adenovirus virion", "OBSERVATION", 331, 348], ["considered to be", "UNCERTAINTY", 352, 368], ["icosahedral", "OBSERVATION_MODIFIER", 372, 383], ["90 nm", "OBSERVATION_MODIFIER", 397, 402]]], ["There are 240 nonvertex capsomers (hexons) of diameter 8-9.5 nm and 12 vertex capsomers (penton base) of diame ter 7-9 nm.", [["diameter", "TEST", 46, 54]]], ["The vertex capsomers carry projections called \"fibers\" (Norrby et al., 1976) .", [["fibers", "ANATOMY", 47, 53], ["fibers", "CELLULAR_COMPONENT", 47, 53], ["vertex", "ANATOMY_MODIFIER", 4, 10]]], ["The virion has no envelope but does possess a core of 60-65 nm (Home et al., 1959) .A. MorphologyAll the accepted animal adenovirus species have been shown to possess at least most of these properties.", [["virion", "CELLULAR_COMPONENT", 4, 10], ["adenovirus", "ORGANISM", 121, 131], ["animal adenovirus species", "PROBLEM", 114, 139], ["virion", "OBSERVATION", 4, 10], ["no", "UNCERTAINTY", 15, 17], ["envelope", "OBSERVATION_MODIFIER", 18, 26], ["adenovirus species", "OBSERVATION", 121, 139]]], ["Most isolates made at Stormont have fallen into the size range 74-80 nm (McFerran, unpublished observations) .", [["size", "OBSERVATION_MODIFIER", 52, 56]]], ["One exception has been the hemagglutinating virus (127) isolated from a depressed egg production syn-drome.", [["egg", "ANATOMY", 82, 85], ["depressed", "DISEASE", 72, 81], ["hemagglutinating virus", "ORGANISM", 27, 49], ["egg", "ORGANISM_SUBSTANCE", 82, 85], ["the hemagglutinating virus", "PROBLEM", 23, 49], ["a depressed egg production syn-drome", "PROBLEM", 70, 106], ["hemagglutinating", "OBSERVATION_MODIFIER", 27, 43], ["virus", "OBSERVATION", 44, 49], ["depressed egg", "OBSERVATION", 72, 85], ["production syn-drome", "OBSERVATION", 86, 106]]], ["Although it has most of the properties of adenoviruses including size, the typical adenovirus structure of 20 triangular faces and 12 vertices is not resolved (Fig. 1) .A. MorphologyThere are few records of fiber lengths for animal adenoviruses.", [["fiber", "ANATOMY", 207, 212], ["adenoviruses", "ORGANISM", 42, 54], ["adenovirus", "ORGANISM", 83, 93], ["adenoviruses", "ORGANISM", 232, 244], ["adenoviruses", "PROBLEM", 42, 54], ["the typical adenovirus structure", "PROBLEM", 71, 103], ["animal adenoviruses", "PROBLEM", 225, 244], ["adenoviruses", "OBSERVATION", 42, 54], ["size", "OBSERVATION_MODIFIER", 65, 69], ["typical", "OBSERVATION_MODIFIER", 75, 82], ["adenovirus structure", "OBSERVATION", 83, 103], ["20 triangular", "OBSERVATION_MODIFIER", 107, 120], ["12 vertices", "OBSERVATION_MODIFIER", 131, 142], ["not", "UNCERTAINTY", 146, 149], ["resolved", "OBSERVATION_MODIFIER", 150, 158], ["few", "OBSERVATION_MODIFIER", 192, 195], ["fiber lengths", "OBSERVATION_MODIFIER", 207, 220], ["adenoviruses", "OBSERVATION", 232, 244]]], ["The fibers of the canine adenovirus, which causes infectious canine hepatitis (CI), are 25-27 nm long, while a second canine adenovirus associated with respiratory disease (A26/61) has fibers of 35-37 nm (Marusyk et al., 1970) .", [["fibers", "ANATOMY", 4, 10], ["respiratory", "ANATOMY", 152, 163], ["fibers", "ANATOMY", 185, 191], ["infectious canine hepatitis", "DISEASE", 50, 77], ["canine adenovirus", "DISEASE", 118, 135], ["respiratory disease", "DISEASE", 152, 171], ["fibers", "CELLULAR_COMPONENT", 4, 10], ["canine adenovirus", "ORGANISM", 18, 35], ["canine hepatitis", "ORGANISM", 61, 77], ["canine adenovirus", "ORGANISM", 118, 135], ["fibers", "CELLULAR_COMPONENT", 185, 191], ["canine", "SPECIES", 18, 24], ["canine", "SPECIES", 61, 67], ["canine", "SPECIES", 118, 124], ["canine adenovirus", "SPECIES", 18, 35], ["canine", "SPECIES", 118, 124], ["the canine adenovirus", "PROBLEM", 14, 35], ["infectious canine hepatitis", "PROBLEM", 50, 77], ["a second canine adenovirus", "PROBLEM", 109, 135], ["respiratory disease", "PROBLEM", 152, 171], ["fibers", "TEST", 185, 191], ["canine adenovirus", "OBSERVATION", 18, 35], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["canine", "OBSERVATION_MODIFIER", 61, 67], ["hepatitis", "OBSERVATION", 68, 77], ["respiratory disease", "OBSERVATION", 152, 171]]], ["The mouse 1 (AL) strain has a fiber length of 29 nm (Wigand et al., 1977) .", [["fiber", "ANATOMY", 30, 35], ["mouse", "ORGANISM", 4, 9], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["a fiber length", "TEST", 28, 42]]], ["Laver et al. (1971) reported two fibers on FI (Celo), one of which was 42.5 nm and the other 8.5 nm.", [["fibers", "ANATOMY", 33, 39], ["fibers", "CELLULAR_COMPONENT", 33, 39], ["8.5 nm", "OBSERVATION_MODIFIER", 93, 99]]], ["However, Norrby (1971) found that the fiber length of Fl was 14 nm, and El Mishad et al. (1975) demonstrated fibers of 17.5 nm on Fl particles.", [["fiber", "ANATOMY", 38, 43], ["the fiber length of Fl", "TEST", 34, 56], ["fibers", "TEST", 109, 115], ["17.5 nm", "OBSERVATION_MODIFIER", 119, 126]]], ["An F8 isolate has fibers approximately 27 nm long, an untyped isolate has fibers about 14 nm long, and the structures associated with a turkey adenovirus are 27-30 nm in length (Fig. 1) .", [["fibers", "ANATOMY", 18, 24], ["fibers", "ANATOMY", 74, 80], ["fibers", "CELLULAR_COMPONENT", 18, 24], ["fibers", "CELLULAR_COMPONENT", 74, 80], ["turkey adenovirus", "ORGANISM", 136, 153], ["turkey", "SPECIES", 136, 142], ["turkey adenovirus", "SPECIES", 136, 153], ["An F8 isolate", "TEST", 0, 13], ["an untyped isolate", "TEST", 51, 69], ["a turkey adenovirus", "TEST", 134, 153], ["27 nm", "OBSERVATION_MODIFIER", 39, 44], ["14 nm", "OBSERVATION_MODIFIER", 87, 92]]], ["A hemagglutinating virus (127) has fibers 25-30 nm in length (ToddandMcNulty, 1978) .B. Physicochemical PropertiesThe estimated molecular weight of the human and avian adenovirus virion is 173 x 10 6 (Schlesinger, 1969; Laver et al., 1971) .", [["hemagglutinating virus", "ORGANISM", 2, 24], ["human", "ORGANISM", 152, 157], ["avian adenovirus virion", "ORGANISM", 162, 185], ["human", "SPECIES", 152, 157], ["avian adenovirus", "SPECIES", 162, 178], ["human", "SPECIES", 152, 157], ["A hemagglutinating virus", "TEST", 0, 24], ["fibers", "TEST", 35, 41], ["avian adenovirus virion", "TREATMENT", 162, 185], ["hemagglutinating", "OBSERVATION_MODIFIER", 2, 18], ["virus", "OBSERVATION", 19, 24]]], ["Although it is generally accepted that mature mammalian virion has a density of 1.33-1.34 gm/cm 3 and the avian virion that of 1.35 gm/ml in CsCl (Norrby et al., 1976) , there is little evidence that there are differences between mammalian and avaian viruses.", [["CsCl", "CHEMICAL", 141, 145], ["mammalian virion", "ORGANISM", 46, 62], ["avaian viruses", "ORGANISM", 244, 258], ["the avian virion", "TREATMENT", 102, 118], ["mammalian and avaian viruses", "PROBLEM", 230, 258], ["mammalian virion", "OBSERVATION", 46, 62], ["density", "OBSERVATION_MODIFIER", 69, 76], ["little evidence that", "UNCERTAINTY", 179, 199], ["avaian viruses", "OBSERVATION", 244, 258]]], ["Values for bovine adenoviruses are 1.25 gm/ml in sucrose density gradients for B5 and 1.34 gm/ml in CsCl for complete B3 virus (Niiyama et al, 1975) .", [["sucrose", "CHEMICAL", 49, 56], ["CsCl", "CHEMICAL", 100, 104], ["sucrose", "CHEMICAL", 49, 56], ["bovine", "ORGANISM", 11, 17], ["adenoviruses", "ORGANISM", 18, 30], ["sucrose", "SIMPLE_CHEMICAL", 49, 56], ["B3 virus", "ORGANISM", 118, 126], ["bovine", "SPECIES", 11, 17], ["bovine", "SPECIES", 11, 17], ["B3 virus", "SPECIES", 118, 126], ["Values", "TEST", 0, 6], ["bovine adenoviruses", "TREATMENT", 11, 30], ["sucrose density gradients", "TEST", 49, 74], ["B5", "TEST", 79, 81], ["CsCl", "TEST", 100, 104], ["complete B3 virus", "PROBLEM", 109, 126]]], ["Density values in CsCl of 1.29 (Konishi et al, 1977) , 1.31 (Ardans et al., 1973) , and 1.33 (Harden, 1974) to 1.34 (Dutta, 1975) have been recorded for the equine adenovirus.", [["CsCl", "CHEMICAL", 18, 22], ["CsCl", "CHEMICAL", 18, 22], ["equine", "ORGANISM", 157, 163], ["adenovirus", "ORGANISM", 164, 174], ["equine adenovirus", "SPECIES", 157, 174], ["Density values", "TEST", 0, 14], ["CsCl", "TEST", 18, 22], ["the equine adenovirus", "PROBLEM", 153, 174]]], ["The dog adenovirus (Cl) has a density of 1.35 gm/ml in CsCl (Carmichael, 1964) , and a murine adenovirus has a density of 1.34 gm/ml (Wigand er al., 1977) .", [["Cl", "CHEMICAL", 20, 22], ["CsCl", "CHEMICAL", 55, 59], ["dog adenovirus", "ORGANISM", 4, 18], ["murine", "ORGANISM", 87, 93], ["adenovirus", "ORGANISM", 94, 104], ["dog", "SPECIES", 4, 7], ["murine", "SPECIES", 87, 93], ["dog adenovirus", "SPECIES", 4, 18], ["adenovirus", "SPECIES", 94, 104], ["a murine adenovirus", "TEST", 85, 104], ["density", "OBSERVATION_MODIFIER", 30, 37], ["1.35 gm/ml", "OBSERVATION_MODIFIER", 41, 51]]], ["Densities between 1.32 and 1.37 gm/ml in CsCl have been estimated for fowl isolates (Laver et al., 1971; Potter et al., 1971; Yasue and Ishibashi, 1977; Todd and McNulty, 1978) .", [["CsCl", "CHEMICAL", 41, 45], ["CsCl", "CHEMICAL", 41, 45], ["CsCl", "SIMPLE_CHEMICAL", 41, 45], ["fowl", "SPECIES", 70, 74], ["Densities", "TEST", 0, 9]]], ["A value of 1.32 gm/ml was obtained for a hemagglutinating adenovirus, 127, probably of duck origin (Todd and McNulty, 1978) , and values of 1.32-1.34 gm/ml for the turkey hemorrhagic enteritis/marble spleen disease viruses (Carlson et al., 1974; Iltis et al., 1975) .", [["spleen", "ANATOMY", 200, 206], ["hemorrhagic enteritis", "DISEASE", 171, 192], ["spleen disease", "DISEASE", 200, 214], ["adenovirus", "ORGANISM", 58, 68], ["duck", "ORGANISM", 87, 91], ["turkey", "ORGANISM", 164, 170], ["spleen", "ORGAN", 200, 206], ["turkey hemorrhagic enteritis", "SPECIES", 164, 192], ["turkey hemorrhagic enteritis/marble spleen disease viruses", "SPECIES", 164, 222], ["A value", "TEST", 0, 7], ["a hemagglutinating adenovirus", "TEST", 39, 68], ["values", "TEST", 130, 136], ["the turkey hemorrhagic enteritis", "PROBLEM", 160, 192], ["marble spleen disease viruses", "PROBLEM", 193, 222], ["hemorrhagic", "OBSERVATION_MODIFIER", 171, 182], ["enteritis", "OBSERVATION", 183, 192], ["marble spleen disease", "OBSERVATION", 193, 214]]], ["Differences in the buoyant densities of human adenoviruses have been demonstrated, and these have been attributed to differences in DNA content and base composition (Green and Pina, 1964) .B. Physicochemical PropertiesThe virions consist of 11.3 to 13.5% DNA, with the remainder protein (Schlesinger, 1969) .", [["human", "ORGANISM", 40, 45], ["adenoviruses", "ORGANISM", 46, 58], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["the buoyant densities of human adenoviruses", "PROBLEM", 15, 58], ["The virions consist", "TEST", 218, 237], ["buoyant", "OBSERVATION_MODIFIER", 19, 26], ["densities", "OBSERVATION_MODIFIER", 27, 36], ["human", "ANATOMY", 40, 45], ["adenoviruses", "OBSERVATION", 46, 58], ["DNA content", "OBSERVATION", 132, 143], ["base", "OBSERVATION_MODIFIER", 148, 152], ["composition", "OBSERVATION_MODIFIER", 153, 164]]], ["However, one report suggests that one avian virus (Fl) has 17.3% DNA ( L a v e r \u00e0 / . , 1971).i.", [["avian virus", "ORGANISM", 38, 49], ["DNA", "CELLULAR_COMPONENT", 65, 68]]], ["Viral ProteinsBetween 10 and 13 polypeptides have been described for human adenoviruses (MaizeUfa/., 1968; Anderson et al., 1973; Evenite al., 1973) , and at least 10 polypeptides have been resolved for B3 (Niiyama et al., 1975) .", [["human", "ORGANISM", 69, 74], ["adenoviruses", "ORGANISM", 75, 87], ["human", "SPECIES", 69, 74], ["human adenoviruses (MaizeUfa/., 1968; Anderson et al., 1973; Evenite al., 1973)", "SPECIES", 69, 148], ["Viral ProteinsBetween", "TEST", 0, 21]]], ["A study of six human, a simian, a canine, and an equine adenovirus demonstrated that there are major differences between the polypeptides of adenoviruses isolated from pri-mates and nonprimates.", [["pri-mates", "ANATOMY", 168, 177], ["human", "ORGANISM", 15, 20], ["simian", "ORGANISM", 24, 30], ["canine", "ORGANISM", 34, 40], ["adenovirus", "ORGANISM", 56, 66], ["adenoviruses", "ORGANISM", 141, 153], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["canine", "SPECIES", 34, 40], ["equine adenovirus", "SPECIES", 49, 66], ["A study", "TEST", 0, 7], ["an equine adenovirus", "TEST", 46, 66], ["the polypeptides of adenoviruses", "PROBLEM", 121, 153], ["major", "OBSERVATION_MODIFIER", 95, 100], ["adenoviruses", "OBSERVATION", 141, 153]]], ["However, there are also significant differences between the human strains at the molecular level (Marusyk and Cummings, 1978) .i.", [["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["the human strains", "PROBLEM", 56, 73], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["differences", "OBSERVATION_MODIFIER", 36, 47]]], ["Viral ProteinsWhile one study of a fowl adenovirus (Fl) demonstrated 5-6 polypeptides (Laver et al., 1971) , other workers resolved 11-14 polypeptides in Fl (Yasue and Ishibashi, 1977) .", [["fowl adenovirus", "ORGANISM", 35, 50], ["fowl", "SPECIES", 35, 39], ["fowl adenovirus", "SPECIES", 35, 50], ["a fowl adenovirus", "TEST", 33, 50]]], ["Another avian adenovirus, 127, has 13 polypeptides, and 7 of these have counterparts in the 13 resolved polypeptides of Fl (Todd and McNulty, 1978) .Viral DNAThe DNA of FI has been calculated at 30 X 10 6 daltons, compared to 23 -10 6 daltons for a human adenovirus (Green et al., 1967; Laver\u00e0 al., 1971; Robinson et al., 1973) .", [["adenovirus", "ORGANISM", 14, 24], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["human", "ORGANISM", 249, 254], ["adenovirus", "ORGANISM", 255, 265], ["Viral DNAThe DNA", "DNA", 149, 165], ["FI", "DNA", 169, 171], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["Another avian adenovirus", "TEST", 0, 24], ["polypeptides", "TEST", 38, 50], ["Viral DNAThe DNA of FI", "PROBLEM", 149, 171], ["adenovirus", "OBSERVATION", 14, 24]]], ["The DNA of the B3 virion is a linear duplex, with a buoyant density in CsCl of 1.72 gm/ml (Niiyama et al., 1975) .", [["CsCl", "CHEMICAL", 71, 75], ["CsCl", "CHEMICAL", 71, 75], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["B3 virion", "PROTEIN", 15, 24], ["a linear duplex", "TEST", 28, 43], ["CsCl", "TEST", 71, 75], ["B3 virion", "OBSERVATION", 15, 24], ["buoyant", "OBSERVATION_MODIFIER", 52, 59], ["density", "OBSERVATION", 60, 67]]], ["Panigraphy et al. (1977) recorded buoyant densities of Bl to B3 as ranging from 1.71 to 1.72.", [["buoyant densities of Bl to B3", "PROBLEM", 34, 63], ["densities", "OBSERVATION_MODIFIER", 42, 51]]], ["There appears to be an identical structure for the DNA of FI and mammalian adeno viruses.", [["DNA", "CELLULAR_COMPONENT", 51, 54], ["FI", "GENE_OR_GENE_PRODUCT", 58, 60], ["mammalian adeno viruses", "ORGANISM", 65, 88], ["an identical structure", "PROBLEM", 20, 42], ["the DNA of FI", "PROBLEM", 47, 60], ["mammalian adeno viruses", "PROBLEM", 65, 88], ["appears to be", "UNCERTAINTY", 6, 19], ["structure", "OBSERVATION", 33, 42], ["adeno viruses", "OBSERVATION", 75, 88]]], ["Thus the DNA was isolated as a circular DNA protein complex and visualized as a linear molecule with the ends joined by a protein (Robinson et al., 1973) .", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["circular DNA protein complex", "PROTEIN", 31, 59], ["the DNA", "TEST", 5, 12], ["a circular DNA protein complex", "PROBLEM", 29, 59]]], ["There was about 25% homology between the DNAs of B3 and H5 by filter hybridization (Niiyama et al., 1975) .", [["DNAs", "CELLULAR_COMPONENT", 41, 45], ["DNAs", "DNA", 41, 45], ["B3", "DNA", 49, 51], ["H5", "DNA", 56, 58], ["filter hybridization", "TEST", 62, 82]]], ["Burnett et al. (1972) divided simian adenoviruses into three groups on the basis of DNA homology and into two groups on the basis of base composition.", [["simian", "ORGANISM", 30, 36], ["adenoviruses", "ORGANISM", 37, 49], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["simian adenoviruses", "SPECIES", 30, 49], ["simian adenoviruses", "TREATMENT", 30, 49], ["DNA homology", "TREATMENT", 84, 96], ["base", "ANATOMY_MODIFIER", 133, 137]]], ["The DNA of a mouse adenovirus has been described as a linear duplex of molecular weight 20 x 10 6 .", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["mouse", "ORGANISM", 13, 18], ["adenovirus", "ORGANISM", 19, 29], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["a mouse adenovirus", "PROBLEM", 11, 29], ["mouse adenovirus", "OBSERVATION", 13, 29]]], ["There was less than 10% nucleotide sequence homology between the mouse and human adenoviruses (Larsen and Nathans, 1977) .Viral DNAIt has been possible to establish a correlation between the base composition, the guanine x cytosine (G-C), of the DNA, and the ability of human adenovirus serotypes to produce tumors in newborn hamsters (Pina and Green, 1965; Green, 1970) .", [["tumors", "ANATOMY", 308, 314], ["nucleotide", "CHEMICAL", 24, 34], ["guanine", "CHEMICAL", 213, 220], ["cytosine", "CHEMICAL", 223, 231], ["tumors", "DISEASE", 308, 314], ["nucleotide", "CHEMICAL", 24, 34], ["guanine", "CHEMICAL", 213, 220], ["cytosine", "CHEMICAL", 223, 231], ["mouse", "ORGANISM", 65, 70], ["human", "ORGANISM", 75, 80], ["adenoviruses", "ORGANISM", 81, 93], ["guanine x cytosine", "SIMPLE_CHEMICAL", 213, 231], ["G-C", "SIMPLE_CHEMICAL", 233, 236], ["DNA", "CELLULAR_COMPONENT", 246, 249], ["human", "ORGANISM", 270, 275], ["adenovirus", "ORGANISM", 276, 286], ["tumors", "CANCER", 308, 314], ["hamsters", "ORGANISM", 326, 334], ["Viral DNAIt", "PROTEIN", 122, 133], ["mouse", "SPECIES", 65, 70], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 270, 275], ["hamsters", "SPECIES", 326, 334], ["mouse", "SPECIES", 65, 70], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 270, 275], ["hamsters", "SPECIES", 326, 334], ["10% nucleotide sequence homology", "TREATMENT", 20, 52], ["the base composition", "TREATMENT", 187, 207], ["the guanine x cytosine (G-C)", "TREATMENT", 209, 237], ["the DNA", "PROBLEM", 242, 249], ["human adenovirus serotypes", "TREATMENT", 270, 296], ["tumors", "PROBLEM", 308, 314], ["tumors", "OBSERVATION", 308, 314]]], ["Thus highly oncogenic human adenoviruses (HI2, HI8, H31) have a G-C content of 48-49%, weakly oncogenic strains (e.g., H3, H7) 50-52%, and nononcogenic strains (e.g., H8, H9, H10) 57-61%.", [["human", "ORGANISM", 22, 27], ["adenoviruses", "ORGANISM", 28, 40], ["H31", "GENE_OR_GENE_PRODUCT", 52, 55], ["G-C", "GENE_OR_GENE_PRODUCT", 64, 67], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["highly oncogenic human adenoviruses", "PROBLEM", 5, 40], ["HI2", "TEST", 42, 45], ["a G-C content", "TEST", 62, 75], ["weakly oncogenic strains", "PROBLEM", 87, 111], ["H3", "TEST", 119, 121], ["nononcogenic strains", "PROBLEM", 139, 159], ["H8", "TEST", 167, 169], ["oncogenic strains", "OBSERVATION", 94, 111]]], ["However, this pattern does not apply to the simian adenoviruses, in which oncogenic viruses have a G-C content of 55.1-61.6% (Table V) .", [["simian adenoviruses", "ORGANISM", 44, 63], ["G-C", "SIMPLE_CHEMICAL", 99, 102], ["simian adenoviruses", "SPECIES", 44, 63], ["the simian adenoviruses", "PROBLEM", 40, 63], ["a G-C content", "TEST", 97, 110], ["adenoviruses", "OBSERVATION", 51, 63]]], ["Thus the highly oncogenic strains SA7 and SV20 (Hull et al., 1965) have a G-C content of 58-62% (Pina and Green, 1968; Burnett et al., 1972) .", [["G-C", "SIMPLE_CHEMICAL", 74, 77], ["a G", "TEST", 72, 75]]], ["The highly oncogenic B3 (Darbyshire, 1966 ) from cattle has been described as having a G-C content of 58% (Niiyama et al., 1975) and would therefore resemble the oncogenic simian viruses.", [["simian viruses", "DISEASE", 172, 186], ["cattle", "ORGANISM", 49, 55], ["G-C", "SIMPLE_CHEMICAL", 87, 90], ["simian viruses", "ORGANISM", 172, 186], ["cattle", "SPECIES", 49, 55], ["cattle", "SPECIES", 49, 55], ["simian viruses", "SPECIES", 172, 186], ["a G-C content", "TEST", 85, 98], ["the oncogenic simian viruses", "PROBLEM", 158, 186], ["highly", "OBSERVATION_MODIFIER", 4, 10], ["oncogenic B3", "OBSERVATION", 11, 23], ["oncogenic simian viruses", "OBSERVATION", 162, 186]]], ["However, Panigrahy et al. (1977) established the G-C content of B3 at 48% and that of the non oncogenic Bl and B2 at 61-62%, which would fit into the classification of human adenoviruses. agglutinated cells from seven mammalian species, and bovine cells were used in a hemagglutination (HI) test for Bl, B2, and B7 ).", [["cells", "ANATOMY", 201, 206], ["cells", "ANATOMY", 248, 253], ["G-C", "SIMPLE_CHEMICAL", 49, 52], ["Bl", "GENE_OR_GENE_PRODUCT", 104, 106], ["human", "ORGANISM", 168, 173], ["adenoviruses", "ORGANISM", 174, 186], ["cells", "CELL", 201, 206], ["bovine", "ORGANISM", 241, 247], ["cells", "CELL", 248, 253], ["Bl", "GENE_OR_GENE_PRODUCT", 300, 302], ["B2", "GENE_OR_GENE_PRODUCT", 304, 306], ["B7", "GENE_OR_GENE_PRODUCT", 312, 314], ["B2", "PROTEIN", 111, 113], ["agglutinated cells", "CELL_TYPE", 188, 206], ["bovine cells", "CELL_TYPE", 241, 253], ["Bl", "PROTEIN", 300, 302], ["B2", "PROTEIN", 304, 306], ["B7", "PROTEIN", 312, 314], ["human", "SPECIES", 168, 173], ["bovine", "SPECIES", 241, 247], ["human", "SPECIES", 168, 173], ["bovine", "SPECIES", 241, 247], ["the G", "TEST", 45, 50], ["B2", "TEST", 111, 113], ["human adenoviruses", "PROBLEM", 168, 186], ["agglutinated cells", "PROBLEM", 188, 206], ["seven mammalian species", "PROBLEM", 212, 235], ["bovine cells", "PROBLEM", 241, 253], ["a hemagglutination", "TEST", 267, 285], ["Bl", "TEST", 300, 302], ["B2", "TEST", 304, 306], ["mammalian species", "OBSERVATION", 218, 235], ["bovine cells", "OBSERVATION", 241, 253]]], ["There appears to be no information on B8 and B9.Viral DNAc.", [["Viral", "ORGANISM", 48, 53], ["B8", "DNA", 38, 40], ["B9", "PROTEIN", 45, 47], ["Viral DNAc", "PROTEIN", 48, 58], ["Viral DNAc", "PROBLEM", 48, 58], ["appears to be", "UNCERTAINTY", 6, 19], ["DNAc", "OBSERVATION", 54, 58]]], ["Ovine Adenoviruses.", [["Ovine", "ORGANISM", 0, 5], ["Ovine Adenoviruses", "PROBLEM", 0, 18], ["Adenoviruses", "OBSERVATION", 6, 18]]], ["Of the seven potential ovine serotypes and one caprine serotype examined, only 01, which agglutinated some batches of rat cells poorly (McFerran et al., 1969) , and 07, which agglutinated fowl erythrocytes (Davies and Humphreys, 1977b) , were found to have activity.Viral DNAd.", [["cells", "ANATOMY", 122, 127], ["erythrocytes", "ANATOMY", 193, 205], ["ovine", "ORGANISM", 23, 28], ["caprine", "ORGANISM", 47, 54], ["rat", "ORGANISM", 118, 121], ["cells", "CELL", 122, 127], ["fowl", "ORGANISM", 188, 192], ["erythrocytes", "CELL", 193, 205], ["Viral", "ORGANISM", 266, 271], ["rat cells", "CELL_TYPE", 118, 127], ["agglutinated fowl erythrocytes", "CELL_TYPE", 175, 205], ["Viral DNAd", "PROTEIN", 266, 276], ["caprine", "SPECIES", 47, 54], ["rat", "SPECIES", 118, 121], ["fowl", "SPECIES", 188, 192], ["caprine", "SPECIES", 47, 54], ["rat", "SPECIES", 118, 121], ["fowl", "SPECIES", 188, 192], ["ovine serotypes", "TREATMENT", 23, 38], ["one caprine serotype", "TREATMENT", 43, 63], ["ovine serotypes", "OBSERVATION", 23, 38]]], ["Porcine Adenoviruses.", [["Porcine", "ORGANISM", 0, 7], ["Porcine", "SPECIES", 0, 7], ["Porcine Adenoviruses", "TREATMENT", 0, 20], ["Adenoviruses", "OBSERVATION", 8, 20]]], ["Of the five proposed pig adenovirus species, P5 does not appear to have been tested for hemagglutinin, and P2 and P3 did not agglutinate cells from a number of species (Clarke et al., 1967) .", [["cells", "ANATOMY", 137, 142], ["pig", "ORGANISM", 21, 24], ["adenovirus", "ORGANISM", 25, 35], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 88, 101], ["cells", "CELL", 137, 142], ["hemagglutinin", "PROTEIN", 88, 101], ["P2", "PROTEIN", 107, 109], ["P3", "PROTEIN", 114, 116], ["agglutinate cells", "CELL_TYPE", 125, 142], ["pig", "SPECIES", 21, 24], ["pig", "SPECIES", 21, 24], ["the five proposed pig adenovirus species", "PROBLEM", 3, 43], ["hemagglutinin", "TEST", 88, 101], ["P2", "TEST", 107, 109], ["agglutinate cells", "PROBLEM", 125, 142], ["pig adenovirus species", "OBSERVATION", 21, 43], ["agglutinate cells", "OBSERVATION", 125, 142]]], ["Kasza (1966) described the agglutination of rat and fowl erythrocytes by P4, and PI aggluti nated guinea pig, human, rat, monkey, and mouse cells (Haig et al., 1964) .", [["erythrocytes", "ANATOMY", 57, 69], ["cells", "ANATOMY", 140, 145], ["rat", "ORGANISM", 44, 47], ["fowl", "ORGANISM", 52, 56], ["erythrocytes", "CELL", 57, 69], ["P4", "SIMPLE_CHEMICAL", 73, 75], ["PI aggluti", "ORGANISM", 81, 91], ["guinea pig", "ORGANISM", 98, 108], ["human", "ORGANISM", 110, 115], ["rat", "ORGANISM", 117, 120], ["monkey", "ORGANISM", 122, 128], ["mouse", "ORGANISM", 134, 139], ["cells", "CELL", 140, 145], ["rat and fowl erythrocytes", "CELL_TYPE", 44, 69], ["human, rat, monkey, and mouse cells", "CELL_TYPE", 110, 145], ["rat", "SPECIES", 44, 47], ["fowl", "SPECIES", 52, 56], ["guinea pig", "SPECIES", 98, 108], ["human", "SPECIES", 110, 115], ["rat", "SPECIES", 117, 120], ["monkey", "SPECIES", 122, 128], ["mouse", "SPECIES", 134, 139], ["rat", "SPECIES", 44, 47], ["fowl", "SPECIES", 52, 56], ["pig", "SPECIES", 105, 108], ["human", "SPECIES", 110, 115], ["rat", "SPECIES", 117, 120], ["mouse", "SPECIES", 134, 139], ["the agglutination of rat", "PROBLEM", 23, 47], ["fowl erythrocytes", "PROBLEM", 52, 69]]], ["However, as PI was subsequently shown to be contaminated by a hemagglutinat ing pig parvovirus (Derbyshire et al., 1975) , its agglutinating activity has still to be determined.", [["PI", "SIMPLE_CHEMICAL", 12, 14], ["hemagglutinat ing pig parvovirus", "ORGANISM", 62, 94], ["pig parvovirus", "SPECIES", 80, 94], ["hemagglutinat ing pig parvovirus", "SPECIES", 62, 94], ["a hemagglutinat ing pig parvovirus", "TREATMENT", 60, 94]]], ["Of four unclassified Danish strains, three did not agglutinate the cells tested, while the remaining one agglutinated fowl and guinea pig erythro cytes (Rasmussan, 1969) .", [["cells", "ANATOMY", 67, 72], ["cells", "CELL", 67, 72], ["fowl", "ORGANISM", 118, 122], ["guinea pig", "ORGANISM", 127, 137], ["erythro cytes", "ORGANISM", 138, 151], ["fowl", "SPECIES", 118, 122], ["guinea pig", "SPECIES", 127, 137], ["fowl", "SPECIES", 118, 122], ["guinea pig erythro cytes", "SPECIES", 127, 151], ["four unclassified Danish strains", "PROBLEM", 3, 35]]], ["A French strain was tested against a very wide range of erythrocytes and agglutinated, to very low titers, only patas and vervet mon key cells (Chappuis and Tektoff, 1975) .Viral DNAe.", [["erythrocytes", "ANATOMY", 56, 68], ["cells", "ANATOMY", 137, 142], ["erythrocytes", "CELL", 56, 68], ["vervet", "ORGANISM", 122, 128], ["cells", "CELL", 137, 142], ["erythrocytes", "CELL_TYPE", 56, 68], ["vervet mon key cells", "CELL_TYPE", 122, 142], ["vervet", "SPECIES", 122, 128], ["A French strain", "TREATMENT", 0, 15], ["a very wide range of erythrocytes", "PROBLEM", 35, 68], ["agglutinated", "PROBLEM", 73, 85], ["very low titers", "PROBLEM", 90, 105], ["Viral DNAe", "PROBLEM", 173, 183], ["erythrocytes", "ANATOMY", 56, 68], ["DNAe", "OBSERVATION", 179, 183]]], ["Equine Adenoviruses.", [["Equine", "ORGANISM", 0, 6], ["Equine", "SPECIES", 0, 6], ["Equine Adenoviruses", "PROBLEM", 0, 19], ["Adenoviruses", "OBSERVATION", 7, 19]]], ["Although only one equine serotype is recognized, considerable differences have been recorded in the activity of strains of this virus.", [["equine", "ORGANISM", 18, 24], ["equine", "SPECIES", 18, 24], ["this virus", "PROBLEM", 123, 133], ["one equine", "OBSERVATION_MODIFIER", 14, 24], ["serotype", "OBSERVATION", 25, 33]]], ["Thus some workers found that horse erythrocytes agglutinated Wilks and Studdard, 1973; Harden, 1974; Konishi^\u03b1/., 1977) , while others did not (Petzoldt and Schmidt, 1971; Dutta, 1975) .", [["erythrocytes", "ANATOMY", 35, 47], ["horse", "ORGANISM", 29, 34], ["erythrocytes", "CELL", 35, 47], ["horse erythrocytes", "CELL_TYPE", 29, 47], ["horse", "SPECIES", 29, 34], ["horse erythrocytes agglutinated", "PROBLEM", 29, 60]]], ["England et al. (1973) observed hemagglutination of mouse cells, whereas others did not (Dutta, 1975; Konishi et al., 1977) .", [["cells", "ANATOMY", 57, 62], ["mouse", "ORGANISM", 51, 56], ["cells", "CELL", 57, 62], ["mouse cells", "CELL_TYPE", 51, 62], ["mouse", "SPECIES", 51, 56], ["mouse", "SPECIES", 51, 56], ["hemagglutination of mouse cells", "PROBLEM", 31, 62], ["mouse cells", "OBSERVATION", 51, 62]]], ["Rat erythrocytes are agglutinated to varying degrees (Todd, 1969; England et al., 973; Harden, 1974; Konishi et al., 1977; Moorthy and Spradbrow, 1978) .", [["Rat erythrocytes", "ANATOMY", 0, 16], ["Rat erythrocytes", "CELL", 0, 16], ["Rat erythrocytes", "CELL_TYPE", 0, 16], ["Rat", "SPECIES", 0, 3], ["Rat", "SPECIES", 0, 3], ["Rat erythrocytes", "TEST", 0, 16], ["agglutinated", "OBSERVATION", 21, 33], ["varying degrees", "OBSERVATION_MODIFIER", 37, 52]]], ["Human erythrocytes also appear to have different sensi tivities in different laboratories (Todd, 1969; England et al., 1973; Dutta, 1975; Konishi et al., 1977) .Viral DNAf.", [["erythrocytes", "ANATOMY", 6, 18], ["Human", "ORGANISM", 0, 5], ["erythrocytes", "CELL", 6, 18], ["Viral", "ORGANISM", 161, 166], ["Human erythrocytes", "CELL_TYPE", 0, 18], ["Viral DNAf", "PROTEIN", 161, 171], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human erythrocytes", "PROBLEM", 0, 18], ["Viral DNAf", "PROBLEM", 161, 171], ["DNAf", "OBSERVATION", 167, 171]]], ["Canine Adenoviruses.", [["Canine", "ORGANISM", 0, 6], ["Canine", "SPECIES", 0, 6], ["Canine", "SPECIES", 0, 6], ["Canine Adenoviruses", "TREATMENT", 0, 19], ["Adenoviruses", "OBSERVATION", 7, 19]]], ["ICH was reported by Fastier (1957) to agglutinate fowl but not human or rat erythrocytes, whereas Italian workers reported positive results with erythrocytes from a large number of species (Mantovani and Gramenzi, 1956) .", [["erythrocytes", "ANATOMY", 76, 88], ["erythrocytes", "ANATOMY", 145, 157], ["ICH", "DISEASE", 0, 3], ["fowl", "ORGANISM", 50, 54], ["human", "ORGANISM", 63, 68], ["rat", "ORGANISM", 72, 75], ["erythrocytes", "CELL", 76, 88], ["erythrocytes", "CELL", 145, 157], ["human or rat erythrocytes", "CELL_TYPE", 63, 88], ["erythrocytes", "CELL_TYPE", 145, 157], ["fowl", "SPECIES", 50, 54], ["human", "SPECIES", 63, 68], ["rat", "SPECIES", 72, 75], ["fowl", "SPECIES", 50, 54], ["human", "SPECIES", 63, 68], ["rat", "SPECIES", 72, 75], ["ICH", "PROBLEM", 0, 3], ["human or rat erythrocytes", "PROBLEM", 63, 88], ["erythrocytes", "PROBLEM", 145, 157], ["large", "OBSERVATION_MODIFIER", 165, 170]]], ["Epsmark and Salenstedt (1961) , on the other hand, obtained agglutination only with human and rat cells and not with fowl.", [["cells", "ANATOMY", 98, 103], ["human", "ORGANISM", 84, 89], ["rat", "ORGANISM", 94, 97], ["cells", "CELL", 98, 103], ["human and rat cells", "CELL_TYPE", 84, 103], ["human", "SPECIES", 84, 89], ["rat", "SPECIES", 94, 97], ["human", "SPECIES", 84, 89], ["rat", "SPECIES", 94, 97], ["fowl", "SPECIES", 117, 121], ["agglutination", "TEST", 60, 73], ["human and rat cells", "TREATMENT", 84, 103]]], ["Infectious canine laryngotracheitis (ICL) virus hemagglutinates human and rat cells to similar titers (Marusyk and Yamamoto, 1971) .Viral DNAThe canine adenoviruses differ from the majority of human serotypes in that 80% of the hemagglutinating activity is associated with the intact or \"empty\" virus particles and the remainder with the soluble penton dimer structure (Marusyk and Yamamoto, 1971) .", [["cells", "ANATOMY", 78, 83], ["Infectious canine laryngotracheitis", "DISEASE", 0, 35], ["canine laryngotracheitis", "ORGANISM", 11, 35], ["human", "ORGANISM", 64, 69], ["rat", "ORGANISM", 74, 77], ["cells", "CELL", 78, 83], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["canine adenoviruses", "ORGANISM", 145, 164], ["human", "ORGANISM", 193, 198], ["human and rat cells", "CELL_TYPE", 64, 83], ["soluble penton dimer structure", "PROTEIN", 338, 368], ["canine", "SPECIES", 11, 17], ["human", "SPECIES", 64, 69], ["rat", "SPECIES", 74, 77], ["canine", "SPECIES", 145, 151], ["human", "SPECIES", 193, 198], ["Infectious canine laryngotracheitis", "SPECIES", 0, 35], ["human", "SPECIES", 64, 69], ["rat", "SPECIES", 74, 77], ["canine", "SPECIES", 145, 151], ["human", "SPECIES", 193, 198], ["Infectious canine laryngotracheitis (ICL) virus hemagglutinates human and rat cells", "PROBLEM", 0, 83], ["Viral DNA", "PROBLEM", 132, 141], ["The canine adenoviruses", "TREATMENT", 141, 164], ["human serotypes", "TREATMENT", 193, 208], ["the hemagglutinating activity", "PROBLEM", 224, 253], ["the intact or \"empty\" virus particles", "PROBLEM", 273, 310], ["laryngotracheitis", "OBSERVATION", 18, 35], ["canine", "OBSERVATION_MODIFIER", 145, 151], ["adenoviruses", "OBSERVATION", 152, 164], ["hemagglutinating activity", "OBSERVATION", 228, 253], ["intact", "OBSERVATION", 277, 283]]], ["These workers showed that fluorocarbon and ultrasonication quickly inactivated the hemagglutinating activity.", [["fluorocarbon", "CHEMICAL", 26, 38], ["fluorocarbon", "CHEMICAL", 26, 38], ["fluorocarbon", "SIMPLE_CHEMICAL", 26, 38], ["fluorocarbon and ultrasonication", "TREATMENT", 26, 58]]], ["This contrasts to many of the human adenoviruses, with which fluorocarbon can be used for virus purifica tion (Green and Pina, 1963) , although H19 and H26 are inactivated by fluorocar bon (Wigand et al., 1966) .", [["fluorocarbon", "CHEMICAL", 61, 73], ["fluorocarbon", "CHEMICAL", 61, 73], ["human", "ORGANISM", 30, 35], ["adenoviruses", "ORGANISM", 36, 48], ["fluorocarbon", "SIMPLE_CHEMICAL", 61, 73], ["H19", "GENE_OR_GENE_PRODUCT", 144, 147], ["H26", "GENE_OR_GENE_PRODUCT", 152, 155], ["H19", "DNA", 144, 147], ["H26", "DNA", 152, 155], ["human", "SPECIES", 30, 35], ["virus purifica", "SPECIES", 90, 104], ["human", "SPECIES", 30, 35], ["virus purifica", "SPECIES", 90, 104], ["the human adenoviruses", "PROBLEM", 26, 48], ["fluorocarbon", "TREATMENT", 61, 73], ["adenoviruses", "OBSERVATION", 36, 48]]], ["The ICH hemagglutinin-erythrocyte receptor complex appears to be more stable than human strains, since it is not dissociated either by lowering of the temperature or by the use of receptor-destroying enzyme (Simon, 1962; Norrby\u00e9>itf/., 1967; Marusyk and Yamamoto, 1971) .Viral DNAg.", [["ICH", "DISEASE", 4, 7], ["ICH hemagglutinin-erythrocyte receptor", "GENE_OR_GENE_PRODUCT", 4, 42], ["human", "ORGANISM", 82, 87], ["Viral", "ORGANISM", 271, 276], ["ICH hemagglutinin-erythrocyte receptor complex", "PROTEIN", 4, 50], ["Viral DNAg", "PROTEIN", 271, 281], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["The ICH hemagglutinin", "TREATMENT", 0, 21], ["erythrocyte receptor complex", "PROBLEM", 22, 50], ["human strains", "PROBLEM", 82, 95], ["Norrby\u00e9", "TEST", 221, 228], ["Viral DNAg", "PROBLEM", 271, 281], ["ICH", "OBSERVATION", 4, 7], ["stable", "OBSERVATION_MODIFIER", 70, 76], ["DNAg", "OBSERVATION", 277, 281]]], ["Simian Adenoviruses.", [["Simian", "ORGANISM", 0, 6], ["Simian", "SPECIES", 0, 6], ["Simian Adenoviruses", "SPECIES", 0, 19], ["Simian Adenoviruses", "PROBLEM", 0, 19], ["Adenoviruses", "OBSERVATION", 7, 19]]], ["It is possible to group monkey adenoviruses in a similar fashion to human adenoviruses on the basis of their power to agglutinate erythrocytes from three species (Table V) .", [["erythrocytes", "ANATOMY", 130, 142], ["monkey", "ORGANISM", 24, 30], ["adenoviruses", "ORGANISM", 31, 43], ["human", "ORGANISM", 68, 73], ["adenoviruses", "ORGANISM", 74, 86], ["erythrocytes", "CELL", 130, 142], ["agglutinate erythrocytes", "CELL_TYPE", 118, 142], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["human adenoviruses", "TREATMENT", 68, 86], ["agglutinate erythrocytes", "PROBLEM", 118, 142]]], ["The main differences are that most strains of monkey adenoviruses agglutinate guinea pig and rhesus erythrocytes at 4\u00b0C but not at 37\u00b0C, (Rapoza, 1967) .", [["erythrocytes", "ANATOMY", 100, 112], ["monkey", "ORGANISM", 46, 52], ["adenoviruses", "ORGANISM", 53, 65], ["guinea pig", "ORGANISM", 78, 88], ["rhesus", "ORGANISM", 93, 99], ["erythrocytes", "CELL", 100, 112], ["guinea pig and rhesus erythrocytes", "CELL_TYPE", 78, 112], ["monkey", "SPECIES", 46, 52], ["guinea pig", "SPECIES", 78, 88], ["rhesus", "SPECIES", 93, 99], ["pig", "SPECIES", 85, 88], ["monkey adenoviruses agglutinate guinea pig and rhesus erythrocytes", "PROBLEM", 46, 112], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This can be contrasted to the human strains, of which only H8, H9, H10, and H19 hemagglutinate guinea pig cells, and with which rat and rhesus monkey cells are agglutinated at 37'C (Hierholzer, 1973) .", [["cells", "ANATOMY", 106, 111], ["cells", "ANATOMY", 150, 155], ["human", "ORGANISM", 30, 35], ["H9, H10", "CELL", 63, 70], ["H19", "GENE_OR_GENE_PRODUCT", 76, 79], ["guinea pig cells", "CELL", 95, 111], ["rat", "ORGANISM", 128, 131], ["rhesus", "ORGANISM", 136, 142], ["monkey", "ORGANISM", 143, 149], ["cells", "CELL", 150, 155], ["guinea pig cells", "CELL_TYPE", 95, 111], ["rat and rhesus monkey cells", "CELL_TYPE", 128, 155], ["human", "SPECIES", 30, 35], ["guinea pig", "SPECIES", 95, 105], ["rat", "SPECIES", 128, 131], ["rhesus monkey", "SPECIES", 136, 149], ["human", "SPECIES", 30, 35], ["guinea pig", "SPECIES", 95, 105], ["rat", "SPECIES", 128, 131], ["rhesus monkey", "SPECIES", 136, 149], ["the human strains", "TEST", 26, 43], ["H10", "TEST", 67, 70], ["H19 hemagglutinate guinea pig cells", "TREATMENT", 76, 111], ["H10", "ANATOMY", 67, 70], ["pig cells", "OBSERVATION", 102, 111]]], ["S4 will also agglutinate human, bovine, and ovine erythrocytes (Tyrrell et al., 1960) .", [["erythrocytes", "ANATOMY", 50, 62], ["S4", "GENE_OR_GENE_PRODUCT", 0, 2], ["human", "ORGANISM", 25, 30], ["bovine", "ORGANISM", 32, 38], ["ovine", "ORGANISM", 44, 49], ["erythrocytes", "CELL", 50, 62], ["human, bovine, and ovine erythrocytes", "CELL_TYPE", 25, 62], ["human", "SPECIES", 25, 30], ["bovine", "SPECIES", 32, 38], ["ovine", "SPECIES", 44, 49], ["human", "SPECIES", 25, 30], ["bovine", "SPECIES", 32, 38], ["ovine", "SPECIES", 44, 49]]], ["Hillis and Goodman (1969) divided the adenoviruses isolated from chimpan zees into three subgroups.", [["adenoviruses", "ORGANISM", 38, 50], ["chimpan zees", "CANCER", 65, 77], ["the adenoviruses", "TREATMENT", 34, 50]]], ["Subgroup 1 agglutinated rhesus or vervet monkey erythrocytes; subgroup 2 hemagglutinated rat cells in the presence of heterotypic immune serum; and subgroup 3 did not agglutinate monkey, rat, guinea pig, or human cells.", [["erythrocytes", "ANATOMY", 48, 60], ["cells", "ANATOMY", 93, 98], ["immune serum", "ANATOMY", 130, 142], ["cells", "ANATOMY", 213, 218], ["rhesus", "ORGANISM", 24, 30], ["vervet", "ORGANISM", 34, 40], ["monkey", "ORGANISM", 41, 47], ["erythrocytes", "CELL", 48, 60], ["rat", "ORGANISM", 89, 92], ["cells", "CELL", 93, 98], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["monkey", "ORGANISM", 179, 185], ["rat", "ORGANISM", 187, 190], ["guinea pig", "ORGANISM", 192, 202], ["human", "ORGANISM", 207, 212], ["cells", "CELL", 213, 218], ["vervet monkey erythrocytes", "CELL_TYPE", 34, 60], ["hemagglutinated rat cells", "CELL_TYPE", 73, 98], ["rat, guinea pig, or human cells", "CELL_TYPE", 187, 218], ["vervet monkey", "SPECIES", 34, 47], ["rat", "SPECIES", 89, 92], ["rat", "SPECIES", 187, 190], ["guinea pig", "SPECIES", 192, 202], ["human", "SPECIES", 207, 212], ["vervet monkey", "SPECIES", 34, 47], ["rat", "SPECIES", 89, 92], ["rat", "SPECIES", 187, 190], ["pig", "SPECIES", 199, 202], ["human", "SPECIES", 207, 212], ["vervet monkey erythrocytes", "TEST", 34, 60], ["subgroup 2 hemagglutinated rat cells", "TREATMENT", 62, 98], ["heterotypic immune serum", "PROBLEM", 118, 142]]], ["The subgroup 1 viruses include the Cl isolate.", [["Cl", "CHEMICAL", 35, 37], ["Cl", "CHEMICAL", 35, 37], ["the Cl isolate", "TREATMENT", 31, 45]]], ["These isolates may have some relationship to human 16, but full cross His were not undertaken.", [["human", "ORGANISM", 45, 50], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50]]], ["The Cl isolate has been shown to be related by serum neutralization to H14 (Rowe et al., 1956) .", [["serum", "ANATOMY", 47, 52], ["Cl", "CHEMICAL", 4, 6], ["Cl", "CHEMICAL", 4, 6], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["The Cl isolate", "PROBLEM", 0, 14], ["serum neutralization", "PROBLEM", 47, 67], ["Cl isolate", "OBSERVATION", 4, 14], ["serum", "OBSERVATION_MODIFIER", 47, 52], ["neutralization", "OBSERVATION", 53, 67]]], ["The subgroup 2 viruses were divided into four strains: Y25, Y141, those viruses apparently identical to H5, and those, including C2, related to H2.", [["H2", "CHEMICAL", 144, 146], ["H5", "PROTEIN", 104, 106], ["C2", "PROTEIN", 129, 131], ["H2", "PROTEIN", 144, 146], ["The subgroup 2 viruses", "PROBLEM", 0, 22], ["those viruses", "PROBLEM", 66, 79], ["viruses", "OBSERVATION", 72, 79], ["C2", "ANATOMY", 129, 131], ["H2", "OBSERVATION_MODIFIER", 144, 146]]], ["Four serologically distinct viruses, PAN5, 6, 7, and 9, were isolated from lymph nodes of chimpanzees.PAN6 hemagglutinated rhesus monkey cells, and they were not related to human or other simian viruses (Basnight et al., 1971) .Viral DNAh.", [["lymph nodes", "ANATOMY", 75, 86], ["cells", "ANATOMY", 137, 142], ["PAN5", "GENE_OR_GENE_PRODUCT", 37, 41], ["7", "GENE_OR_GENE_PRODUCT", 46, 47], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 75, 86], ["chimpanzees", "ORGANISM", 90, 101], ["PAN6", "GENE_OR_GENE_PRODUCT", 102, 106], ["rhesus", "ORGANISM", 123, 129], ["monkey", "ORGANISM", 130, 136], ["cells", "CELL", 137, 142], ["human", "ORGANISM", 173, 178], ["simian viruses", "ORGANISM", 188, 202], ["Viral", "ORGANISM", 228, 233], ["PAN6 hemagglutinated rhesus monkey cells", "CELL_LINE", 102, 142], ["Viral DNAh", "PROTEIN", 228, 238], ["rhesus monkey", "SPECIES", 123, 136], ["human", "SPECIES", 173, 178], ["rhesus monkey", "SPECIES", 123, 136], ["human", "SPECIES", 173, 178], ["simian viruses", "SPECIES", 188, 202], ["Four serologically distinct viruses", "PROBLEM", 0, 35], ["PAN5", "TEST", 37, 41], ["serologically", "OBSERVATION_MODIFIER", 5, 18], ["distinct", "OBSERVATION_MODIFIER", 19, 27], ["viruses", "OBSERVATION", 28, 35], ["lymph nodes", "OBSERVATION", 75, 86], ["monkey cells", "OBSERVATION", 130, 142]]], ["Murine Adenoviruses.", [["Murine", "ORGANISM", 0, 6], ["Murine", "SPECIES", 0, 6], ["Murine Adenoviruses", "TREATMENT", 0, 19], ["Adenoviruses", "OBSERVATION", 7, 19]]], ["No complete or partial hemagglutination has been recorded (Hartley and Rowe, 1960; Missal, 1969; Wigand^al., 1977) .Viral DNAi.", [["Viral", "ORGANISM", 116, 121], ["complete or partial hemagglutination", "PROBLEM", 3, 39], ["Viral DNAi", "PROBLEM", 116, 126], ["complete", "OBSERVATION_MODIFIER", 3, 11], ["partial", "OBSERVATION_MODIFIER", 15, 22], ["hemagglutination", "OBSERVATION", 23, 39]]], ["Avian Adenoviruses.", [["Avian", "ORGANISM", 0, 5], ["Avian", "SPECIES", 0, 5], ["Avian Adenoviruses", "TREATMENT", 0, 18], ["Adenoviruses", "OBSERVATION", 6, 18]]], ["Fl has been shown to hemagglutinate rat cells (Clemmer, 1964; Burke et al., 1968) .", [["cells", "ANATOMY", 40, 45], ["rat", "ORGANISM", 36, 39], ["cells", "CELL", 40, 45], ["Fl", "PROTEIN", 0, 2], ["hemagglutinate rat cells", "CELL_TYPE", 21, 45], ["rat", "SPECIES", 36, 39]]], ["Anderson et al. (1971) demonstrated that peaks of hemagglutinating activity were recorded at densities of 1.32 and 1.34 gm/ml in association with bands of complete and incomplete particles.", [["hemagglutinating activity", "PROBLEM", 50, 75], ["bands of complete and incomplete particles", "PROBLEM", 146, 188], ["peaks", "OBSERVATION_MODIFIER", 41, 46], ["hemagglutinating activity", "OBSERVATION", 50, 75], ["particles", "OBSERVATION", 179, 188]]], ["El Mishad et al. (1975) demonstrated that while rat erythrocytes were agglutinated at 4\u00b0C and 37\u00b0C, maximum titers were achieved between pH 6 and pH 9, with tempera tures between 20\u00b0C and 45\u00b0C. The hemagglutinin was stable to trypsin, RNase, DNase, and neuraminidase.", [["erythrocytes", "ANATOMY", 52, 64], ["rat", "ORGANISM", 48, 51], ["erythrocytes", "CELL", 52, 64], ["trypsin", "GENE_OR_GENE_PRODUCT", 226, 233], ["RNase", "GENE_OR_GENE_PRODUCT", 235, 240], ["DNase", "GENE_OR_GENE_PRODUCT", 242, 247], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 253, 266], ["rat erythrocytes", "CELL_TYPE", 48, 64], ["hemagglutinin", "PROTEIN", 198, 211], ["trypsin", "PROTEIN", 226, 233], ["RNase", "PROTEIN", 235, 240], ["DNase", "PROTEIN", 242, 247], ["neuraminidase", "PROTEIN", 253, 266], ["rat", "SPECIES", 48, 51], ["rat", "SPECIES", 48, 51], ["rat erythrocytes", "TEST", 48, 64], ["maximum titers", "TEST", 100, 114], ["pH", "TEST", 137, 139], ["pH", "TEST", 146, 148], ["tempera tures", "TEST", 157, 170], ["The hemagglutinin", "TREATMENT", 194, 211], ["trypsin", "TREATMENT", 226, 233], ["RNase", "TREATMENT", 235, 240], ["DNase", "TREATMENT", 242, 247], ["neuraminidase", "TREATMENT", 253, 266], ["stable", "OBSERVATION_MODIFIER", 216, 222]]], ["It was, however, inactivated after 15 minutes at 56\u00b0C, and 0.2% formaldehyde reduced its titer by eightfold.", [["formaldehyde", "CHEMICAL", 64, 76], ["formaldehyde", "CHEMICAL", 64, 76], ["formaldehyde", "SIMPLE_CHEMICAL", 64, 76]]], ["By agglutinating rat cells, the virus resembled the viruses of Rosen's human adenovirus group 2, but the fiber length of 17 nm would classify it in the human subgroup 3.Viral DNAWhile strains of Fl, including Phelps, EV89, and GAL3, did not agglutinate sheep cells (Clemmer, 1964; Burke et al., 1968) , Fl (Indiana C) did (Fadly and Winterfield, 1975) .", [["cells", "ANATOMY", 21, 26], ["fiber", "ANATOMY", 105, 110], ["cells", "ANATOMY", 259, 264], ["rat", "ORGANISM", 17, 20], ["cells", "CELL", 21, 26], ["human", "ORGANISM", 71, 76], ["adenovirus", "ORGANISM", 77, 87], ["human", "ORGANISM", 152, 157], ["Fl", "GENE_OR_GENE_PRODUCT", 195, 197], ["Phelps", "GENE_OR_GENE_PRODUCT", 209, 215], ["EV89", "GENE_OR_GENE_PRODUCT", 217, 221], ["GAL3", "GENE_OR_GENE_PRODUCT", 227, 231], ["sheep cells", "CELL", 253, 264], ["agglutinating rat cells", "CELL_TYPE", 3, 26], ["agglutinate sheep cells", "CELL_TYPE", 241, 264], ["rat", "SPECIES", 17, 20], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 152, 157], ["sheep", "SPECIES", 253, 258], ["rat", "SPECIES", 17, 20], ["human adenovirus", "SPECIES", 71, 87], ["human", "SPECIES", 152, 157], ["sheep", "SPECIES", 253, 258], ["the virus", "PROBLEM", 28, 37], ["Phelps", "TEST", 209, 215], ["EV89", "TEST", 217, 221], ["GAL3", "TEST", 227, 231], ["rat cells", "OBSERVATION", 17, 26], ["GAL3", "ANATOMY", 227, 231]]], ["Fl did not hemagglutinate a wide range of cells, including rhesus monkey erythrocytes (Kraus, 1965; El Mishad et al., 1975) .Viral DNAThere has been little work reported for other avian serotypes, except the failure of eight Japanese serotypes to agglutinate fowl erythrocytes .", [["cells", "ANATOMY", 42, 47], ["erythrocytes", "ANATOMY", 73, 85], ["erythrocytes", "ANATOMY", 264, 276], ["cells", "CELL", 42, 47], ["rhesus", "ORGANISM", 59, 65], ["monkey", "ORGANISM", 66, 72], ["erythrocytes", "CELL", 73, 85], ["fowl", "ORGANISM", 259, 263], ["erythrocytes", "CELL", 264, 276], ["rhesus monkey erythrocytes", "CELL_TYPE", 59, 85], ["agglutinate fowl erythrocytes", "CELL_TYPE", 247, 276], ["rhesus monkey", "SPECIES", 59, 72], ["fowl", "SPECIES", 259, 263], ["rhesus monkey", "SPECIES", 59, 72], ["fowl", "SPECIES", 259, 263], ["other avian serotypes", "PROBLEM", 174, 195], ["the failure", "PROBLEM", 204, 215], ["eight Japanese serotypes", "TREATMENT", 219, 243], ["agglutinate fowl erythrocytes", "PROBLEM", 247, 276], ["wide", "OBSERVATION_MODIFIER", 28, 32]]], ["The turkey isolate (TA-1) failed to agglutinate a variety of cells (Scott and McFerran, 1972 ).Viral DNAAn adenovirus, 127, probably of duck origin, agglutinates fowl, duck, and turkey but not mammalian erythrocytes to high titers (McFerran et al., 1978a; Adair et al., 1979c) .", [["cells", "ANATOMY", 61, 66], ["erythrocytes", "ANATOMY", 203, 215], ["turkey", "ORGANISM", 4, 10], ["TA-1", "CELL", 20, 24], ["cells", "CELL", 61, 66], ["Viral DNAAn adenovirus", "ORGANISM", 95, 117], ["duck", "ORGANISM", 136, 140], ["fowl", "ORGANISM", 162, 166], ["duck", "ORGANISM", 168, 172], ["turkey", "ORGANISM", 178, 184], ["mammalian erythrocytes", "CELL", 193, 215], ["mammalian erythrocytes", "CELL_TYPE", 193, 215], ["turkey", "SPECIES", 4, 10], ["duck", "SPECIES", 136, 140], ["fowl", "SPECIES", 162, 166], ["duck", "SPECIES", 168, 172], ["turkey", "SPECIES", 178, 184], ["turkey", "SPECIES", 4, 10], ["fowl", "SPECIES", 162, 166], ["duck", "SPECIES", 168, 172], ["turkey", "SPECIES", 178, 184], ["Viral DNAAn adenovirus", "TEST", 95, 117], ["duck origin", "PROBLEM", 136, 147], ["mammalian erythrocytes", "PROBLEM", 193, 215], ["duck", "ANATOMY", 136, 140], ["origin", "ANATOMY_MODIFIER", 141, 147]]], ["The soluble hemagglutinin banded at a density of 1.24 gm/ml in CsCl gradients and had one major and one minor polypeptide.", [["CsCl", "CHEMICAL", 63, 67], ["CsCl", "CHEMICAL", 63, 67], ["soluble hemagglutinin", "PROTEIN", 4, 25], ["The soluble hemagglutinin banded", "TREATMENT", 0, 32], ["CsCl gradients", "TREATMENT", 63, 77], ["hemagglutinin banded", "OBSERVATION_MODIFIER", 12, 32]]], ["These corresponded to virus polypeptides P2 and P3, respectively, and the molecular weights of these polypeptides (67,000 and 65,000) are in the range given for the fiber and penton base of human adenovirus (Wadell and Norrby, 1969) .", [["fiber", "ANATOMY", 165, 170], ["fiber", "CELLULAR_COMPONENT", 165, 170], ["human", "ORGANISM", 190, 195], ["adenovirus", "ORGANISM", 196, 206], ["human", "SPECIES", 190, 195], ["human adenovirus", "SPECIES", 190, 206], ["virus polypeptides P2", "PROBLEM", 22, 43], ["these polypeptides", "TEST", 95, 113], ["human adenovirus", "TREATMENT", 190, 206], ["virus", "OBSERVATION", 22, 27], ["human adenovirus", "ANATOMY", 190, 206]]], ["The purified soluble hemagglutinin was not inactivated by 30 minutes at 70\u00b0C or by 24 hours at 56\u00b0C but was totally destroyed by 30 minutes at 80\u00b0C. It was inactivated by trypsin, urea, and pyridine (Todd and McNulty, 1978) .2, Group AntigenThe mammalian adenoviruses have a soluble group antigen (Enders et al., 1956) .", [["urea", "CHEMICAL", 180, 184], ["pyridine", "CHEMICAL", 190, 198], ["urea", "CHEMICAL", 180, 184], ["pyridine", "CHEMICAL", 190, 198], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 21, 34], ["C", "SIMPLE_CHEMICAL", 98, 99], ["trypsin", "SIMPLE_CHEMICAL", 171, 178], ["urea", "SIMPLE_CHEMICAL", 180, 184], ["pyridine", "SIMPLE_CHEMICAL", 190, 198], ["Todd", "SIMPLE_CHEMICAL", 200, 204], ["adenoviruses", "ORGANISM", 255, 267], ["trypsin", "PROTEIN", 171, 178], ["soluble group antigen", "PROTEIN", 275, 296], ["The purified soluble hemagglutinin", "TREATMENT", 0, 34]]], ["Thus hexon preparations of six human, three simian, and two canine adenoviruses showed cross reactivity in the complement fixation (CF) test .", [["human", "ORGANISM", 31, 36], ["simian", "ORGANISM", 44, 50], ["canine", "ORGANISM", 60, 66], ["adenoviruses", "ORGANISM", 67, 79], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["canine", "SPECIES", 60, 66], ["hexon preparations", "TREATMENT", 5, 23], ["two canine adenoviruses", "TEST", 56, 79], ["cross reactivity", "PROBLEM", 87, 103], ["the complement fixation", "TREATMENT", 107, 130]]], ["Exceptions to this have been the subgroup 2 bovine adenoviruses Table II ).", [["bovine", "ORGANISM", 44, 50], ["bovine", "SPECIES", 44, 50], ["the subgroup 2 bovine adenoviruses", "TREATMENT", 29, 63]]], ["While the subgroup 1 viruses fully share a common antigen with human adenoviruses, the subgroup 2 viruses have only a weak relationship.", [["human", "ORGANISM", 63, 68], ["adenoviruses", "ORGANISM", 69, 81], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["human adenoviruses", "TREATMENT", 63, 81]]], ["The reaction is stronger when human antigen is reacted against bovine subtype 2 sera than with the reverse reaction (Bartha, 1969) .", [["sera", "ANATOMY", 80, 84], ["human", "ORGANISM", 30, 35], ["bovine", "ORGANISM", 63, 69], ["sera", "ORGANISM_SUBSTANCE", 80, 84], ["human antigen", "PROTEIN", 30, 43], ["human", "SPECIES", 30, 35], ["bovine", "SPECIES", 63, 69], ["human", "SPECIES", 30, 35], ["The reaction", "PROBLEM", 0, 12], ["human antigen", "TEST", 30, 43], ["the reverse reaction", "PROBLEM", 95, 115]]], ["However, Inaba et al. (1968) showed that there was as much sharing of antigens between human strains and B4 and B7 as there was between B4 and B7.", [["human", "ORGANISM", 87, 92], ["B4", "CELL", 105, 107], ["B7", "GENE_OR_GENE_PRODUCT", 112, 114], ["B7", "GENE_OR_GENE_PRODUCT", 143, 145], ["antigens", "PROTEIN", 70, 78], ["B7", "PROTEIN", 112, 114], ["B4", "PROTEIN", 136, 138], ["B7", "PROTEIN", 143, 145], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["human strains", "TEST", 87, 100], ["B7", "ANATOMY", 143, 145]]], ["B6 shared a common CF antigen with B1-B4 and P4 adenoviruses (Mayr et al., 1970) .", [["B1-B4", "GENE_OR_GENE_PRODUCT", 35, 40], ["adenoviruses", "ORGANISM", 48, 60], ["B1", "PROTEIN", 35, 37], ["a common CF antigen", "TEST", 10, 29], ["B1", "TEST", 35, 37], ["B4", "ANATOMY", 38, 40]]], ["B4 had a common line of identity with H2 in the immunodiffusion test (Cole, 1970) , and a B5 isolate had the adenovirus group antigen (Coda et al., 1975) .", [["H2", "CHEMICAL", 38, 40], ["B4", "GENE_OR_GENE_PRODUCT", 0, 2], ["adenovirus", "ORGANISM", 109, 119], ["H2", "PROTEIN", 38, 40], ["adenovirus group antigen", "PROTEIN", 109, 133], ["the immunodiffusion test", "TEST", 44, 68], ["a B5 isolate", "TEST", 88, 100], ["common line", "OBSERVATION_MODIFIER", 9, 20], ["H2", "OBSERVATION_MODIFIER", 38, 40]]], ["Baczynski et al. (1974) used purified hexon antigens of B5 and B8 in the CF and fluorescent antibody CF tests against antisera to B4, 3, and 4 -8 and demonstrated that both subgroups shared an antigen, but titers were two-to fourfold higher with the homologous system.2, Group AntigenAlthough the ovine (McFerran et al., 1971b; Sharp et al., 1974; Bauer et al., 1975) , caprine (Gibbs et al., 1977) , porcine (Clarke et al., 1967) , and equine (Todd, 1969) strains have been reported to share the common group antigen, this is usually based on a nonquantitative immunodiffusion test.", [["ovine", "ORGANISM", 297, 302], ["caprine", "ORGANISM", 370, 377], ["porcine", "ORGANISM", 401, 408], ["equine", "ORGANISM", 437, 443], ["purified hexon antigens", "PROTEIN", 29, 52], ["B5", "PROTEIN", 56, 58], ["B8", "PROTEIN", 63, 65], ["porcine", "SPECIES", 401, 408], ["purified hexon antigens of B5", "TREATMENT", 29, 58], ["fluorescent antibody CF tests", "TEST", 80, 109], ["antisera", "TEST", 118, 126], ["B4", "TEST", 130, 132], ["an antigen", "TEST", 190, 200], ["titers", "TEST", 206, 212], ["a nonquantitative immunodiffusion test", "TEST", 544, 582]]], ["There were indica-tions that not all ovine adenoviruses shared the group antigen to the same degree (McFerran et al., 1971b) .", [["ovine", "ORGANISM", 37, 42], ["adenoviruses", "ORGANISM", 43, 55], ["group antigen", "PROTEIN", 67, 80], ["all ovine adenoviruses", "PROBLEM", 33, 55]]], ["The canine adenoviruses have a one-way cross with human adenoviruses.", [["canine", "ORGANISM", 4, 10], ["adenoviruses", "ORGANISM", 11, 23], ["human", "ORGANISM", 50, 55], ["adenoviruses", "ORGANISM", 56, 68], ["canine", "SPECIES", 4, 10], ["human", "SPECIES", 50, 55], ["canine", "SPECIES", 4, 10], ["human", "SPECIES", 50, 55], ["The canine adenoviruses", "TREATMENT", 0, 23], ["human adenoviruses", "TREATMENT", 50, 68], ["adenoviruses", "OBSERVATION", 56, 68]]], ["Thus Cl antigen will detect CF antibody in human serum as efficiently as human adenovirus antigen, but human adenovirus antigens do not detect antibody in dog sera (Kapsenberg, 1959; Heller and Salenstedt, 1960; Carmichael and Barnes, 1961) .", [["serum", "ANATOMY", 49, 54], ["sera", "ANATOMY", 159, 163], ["Cl", "CHEMICAL", 5, 7], ["Cl antigen", "GENE_OR_GENE_PRODUCT", 5, 15], ["human", "ORGANISM", 43, 48], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["human", "ORGANISM", 73, 78], ["adenovirus", "ORGANISM", 79, 89], ["human", "ORGANISM", 103, 108], ["adenovirus antigens", "ORGANISM", 109, 128], ["dog", "ORGANISM", 155, 158], ["sera", "ORGANISM_SUBSTANCE", 159, 163], ["Cl antigen", "PROTEIN", 5, 15], ["CF antibody", "PROTEIN", 28, 39], ["human adenovirus antigen", "PROTEIN", 73, 97], ["human adenovirus antigens", "PROTEIN", 103, 128], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 103, 108], ["dog", "SPECIES", 155, 158], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 103, 108], ["adenovirus", "SPECIES", 109, 119], ["dog", "SPECIES", 155, 158], ["Cl antigen", "TEST", 5, 15], ["CF antibody", "TEST", 28, 39], ["human serum", "TEST", 43, 54], ["human adenovirus antigen", "TEST", 73, 97], ["human adenovirus antigens", "TEST", 103, 128]]], ["The horse and canine adenoviruses have a cross relationship (Konishi et al., 1977) .", [["horse", "ORGANISM", 4, 9], ["canine", "ORGANISM", 14, 20], ["adenoviruses", "ORGANISM", 21, 33], ["horse", "SPECIES", 4, 9], ["canine", "SPECIES", 14, 20], ["canine", "SPECIES", 14, 20]]], ["The murine strains share a group antigen with human adenoviruses, but this is basically a one-way cross, with only antiserum to human adenovirus reacting with the mouse adenovirus (Hasimoto et al., 1966; Wigm\u00e0etal., 1977) .2, Group AntigenThe avian adenoviruses have a common group antigen, but this antigen is distinct from the mammalian group antigen McFerran et al., 1975) .", [["murine", "ORGANISM", 4, 10], ["human", "ORGANISM", 46, 51], ["adenoviruses", "ORGANISM", 52, 64], ["antiserum", "ORGANISM_SUBSTANCE", 115, 124], ["human", "ORGANISM", 128, 133], ["adenovirus", "ORGANISM", 134, 144], ["mouse", "ORGANISM", 163, 168], ["adenovirus", "ORGANISM", 169, 179], ["avian", "ORGANISM", 243, 248], ["adenoviruses", "ORGANISM", 249, 261], ["common group antigen", "PROTEIN", 269, 289], ["murine", "SPECIES", 4, 10], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 128, 133], ["mouse", "SPECIES", 163, 168], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 128, 133], ["mouse", "SPECIES", 163, 168], ["human adenoviruses", "PROBLEM", 46, 64], ["human adenovirus", "PROBLEM", 128, 144], ["the mouse adenovirus", "PROBLEM", 159, 179], ["Group Antigen", "TEST", 226, 239]]], ["The viruses of turkey hemorrhagic enteritis and pheasant marble spleen disease share a common antigen (Domermuth and Gross, 1975; Domermuth et al., 1975; Iltis et al., 1975) .", [["spleen", "ANATOMY", 64, 70], ["turkey hemorrhagic enteritis", "DISEASE", 15, 43], ["spleen disease", "DISEASE", 64, 78], ["turkey hemorrhagic enteritis", "ORGANISM", 15, 43], ["spleen", "ORGAN", 64, 70], ["turkey hemorrhagic enteritis", "SPECIES", 15, 43], ["pheasant marble spleen", "SPECIES", 48, 70], ["turkey hemorrhagic enteritis", "SPECIES", 15, 43], ["turkey hemorrhagic enteritis", "PROBLEM", 15, 43], ["pheasant marble spleen disease", "PROBLEM", 48, 78], ["viruses", "OBSERVATION_MODIFIER", 4, 11], ["turkey", "OBSERVATION_MODIFIER", 15, 21], ["hemorrhagic", "OBSERVATION_MODIFIER", 22, 33], ["enteritis", "OBSERVATION", 34, 43], ["pheasant marble spleen disease", "OBSERVATION", 48, 78]]], ["The hemagglutinating adenovirus (127) asso ciated with depressed egg production partially shares an antigen with other fowl adenoviruses (McFerran et al., 1978b) .A. Effect of Physical and Chemical AgentsIt is generally recognized that the adenoviruses are resistant to lipid solvents and are rapidly inactivated by 56\u00b0C (Norrby et al., 1976) .", [["egg", "ANATOMY", 65, 68], ["depressed", "DISEASE", 55, 64], ["hemagglutinating adenovirus", "ORGANISM", 4, 31], ["egg", "ORGANISM_SUBSTANCE", 65, 68], ["fowl adenoviruses", "ORGANISM", 119, 136], ["adenoviruses", "ORGANISM", 240, 252], ["lipid solvents", "SIMPLE_CHEMICAL", 270, 284], ["The hemagglutinating adenovirus", "TEST", 0, 31], ["depressed egg production", "PROBLEM", 55, 79], ["Physical and Chemical Agents", "TREATMENT", 176, 204], ["the adenoviruses", "PROBLEM", 236, 252], ["lipid solvents", "TREATMENT", 270, 284], ["hemagglutinating", "OBSERVATION_MODIFIER", 4, 20], ["adenovirus", "OBSERVATION", 21, 31], ["depressed", "OBSERVATION_MODIFIER", 55, 64], ["egg production", "OBSERVATION", 65, 79]]], ["They are acid stable (Andrewes et al., 1978) , and their heat stability is reduced by divalent ions (Wallis et al., 1962) .", [["acid", "OBSERVATION_MODIFIER", 9, 13], ["stable", "OBSERVATION_MODIFIER", 14, 20]]], ["While the animal adenoviruses have all been shown to be resistant to lipid solvents, there are differences in response to the other agents.A. Effect of Physical and Chemical AgentsThe equine adenoviruses vary in their stability to pH 3.", [["adenoviruses", "ORGANISM", 17, 29], ["lipid", "SIMPLE_CHEMICAL", 69, 74], ["equine", "ORGANISM", 184, 190], ["adenoviruses", "ORGANISM", 191, 203], ["the animal adenoviruses", "PROBLEM", 6, 29], ["lipid solvents", "TREATMENT", 69, 83], ["the other agents", "TREATMENT", 122, 138], ["Physical and Chemical Agents", "TREATMENT", 152, 180], ["The equine adenoviruses", "TREATMENT", 180, 203], ["lipid solvents", "OBSERVATION", 69, 83]]], ["Some workers have found them stable (Ardans et al., 1973; Dutta, 1975) , while others have found that pH 3 caused either complete inactivation or a marked fall in titer (Harden, 1974; Moorthy and Spradbrow, 1978) .", [["pH 3", "PROBLEM", 102, 106], ["complete inactivation", "PROBLEM", 121, 142], ["a marked fall in titer", "PROBLEM", 146, 168], ["stable", "OBSERVATION_MODIFIER", 29, 35], ["marked", "OBSERVATION_MODIFIER", 148, 154], ["fall", "OBSERVATION", 155, 159]]], ["Harden (1974) found that pH 5 caused a 99% reduction in titer.", [["pH", "TEST", 25, 27]]], ["The bovine and ovine strains tested were resistant to pH 3.", [["bovine", "ORGANISM", 4, 10], ["ovine", "ORGANISM", 15, 20], ["bovine", "SPECIES", 4, 10], ["bovine", "SPECIES", 4, 10], ["ovine", "SPECIES", 15, 20], ["The bovine and ovine strains", "TREATMENT", 0, 28], ["pH", "TEST", 54, 56]]], ["Variation on pH sensitivity has been found in the same laboratory between two porcine strains (Chappuis and Tektoff, 1975) .A. Effect of Physical and Chemical AgentsThe activity of equine adenoviruses was not removed by 30 minutes at 56\u00b0C, although the titer was reduced Harden, 1974) .", [["porcine", "ORGANISM", 78, 85], ["equine", "ORGANISM", 181, 187], ["adenoviruses", "ORGANISM", 188, 200], ["equine", "SPECIES", 181, 187], ["equine", "SPECIES", 181, 187], ["pH sensitivity", "TEST", 13, 27], ["Physical and Chemical Agents", "TREATMENT", 137, 165], ["equine adenoviruses", "TREATMENT", 181, 200]]], ["When divalent cations at 50\u00b0C were examined, one strain was unaffected (Dutta, 1975) and another destabilized (Harden, 1974) .", [["cations", "SIMPLE_CHEMICAL", 14, 21], ["50\u00b0C", "SIMPLE_CHEMICAL", 25, 29], ["divalent cations", "TREATMENT", 5, 21]]], ["The bovine adenoviruses show consid-\u00e9rable variation in their response to heat, and this property is discussed under their classification.", [["bovine", "ORGANISM", 4, 10], ["adenoviruses", "ORGANISM", 11, 23], ["bovine", "SPECIES", 4, 10], ["The bovine adenoviruses", "TREATMENT", 0, 23], ["\u00e9rable variation", "PROBLEM", 36, 52], ["bovine adenoviruses", "OBSERVATION", 4, 23], ["\u00e9rable variation", "OBSERVATION", 36, 52]]], ["The ovine adenoviruses resist 56\u00b0C, and divalent ions in crease their inactivation (McFerran et al., 1971b; Bauer et al., 1975) .", [["ovine", "ORGANISM", 4, 9], ["adenoviruses", "ORGANISM", 10, 22], ["The ovine adenoviruses", "TREATMENT", 0, 22], ["divalent ions", "TREATMENT", 40, 53]]], ["The ICL (A26/61) canine adenovirus is inactivated by 40 minutes at 56\u00b0C (Yamamoto, 1966) .", [["canine", "ORGANISM", 17, 23], ["adenovirus", "ORGANISM", 24, 34], ["canine", "SPECIES", 17, 23], ["canine", "SPECIES", 17, 23], ["The ICL (A26/61) canine adenovirus", "TREATMENT", 0, 34], ["ICL", "OBSERVATION", 4, 7]]], ["The fowl adenoviruses are apparently the most variable.", [["fowl adenoviruses", "ORGANISM", 4, 21], ["fowl adenoviruses", "SPECIES", 4, 21], ["The fowl adenoviruses", "PROBLEM", 0, 21], ["adenoviruses", "OBSERVATION", 9, 21], ["most variable", "OBSERVATION_MODIFIER", 41, 54]]], ["FI (EV-89) was still infective after 22 hours (Burke et al., 1959) .", [["EV-89", "CHEMICAL", 4, 9]]], ["The infectivity of Fl (93) was reduced by 30 minutes at 70\u00b0C but not removed until 80\u00b0C was reached (Clemmer, 1964) , and F2 (65) was not completely inactivated by 40 minutes at 60\u00b0C (Cho, 1971) .", [["Fl (93)", "CHEMICAL", 19, 26], ["Fl (93)", "CHEMICAL", 19, 26], ["Fl (93)", "GENE_OR_GENE_PRODUCT", 19, 26], ["infectivity", "OBSERVATION_MODIFIER", 4, 15]]], ["Strains tested in the same laboratory have shown variations in thermostability, suggesting that these variations cannot be ascribed just to differences in technique (Rosenberger et al., 1974; Mustaffa-Babjee and Spradbrow, 1975) .", [["Strains", "PROBLEM", 0, 7], ["variations in thermostability", "PROBLEM", 49, 78], ["thermostability", "OBSERVATION", 63, 78]]], ["Fowl adenoviruses have been found to be destabilized by divalent cations (Petek et al., 1963; Burke et al., 1965; McFerran et al., 1972) , although other workers could not confirm this .", [["Fowl adenoviruses", "ORGANISM", 0, 17], ["cations", "SIMPLE_CHEMICAL", 65, 72], ["Fowl adenoviruses", "PROBLEM", 0, 17]]], ["Some other variations could be due to technique, however.", [["could be due to", "UNCERTAINTY", 22, 37], ["technique", "OBSERVATION", 38, 47]]], ["Thus 3-30 minutes at 56\u00b0C inactivated both mouse adenovirus types, and divalent ions had no effect (Hartley and Rowe, 1960; Hasimoto et al., 1966; Missal, 1969) .", [["C", "GENE_OR_GENE_PRODUCT", 24, 25], ["mouse", "ORGANISM", 43, 48], ["adenovirus", "ORGANISM", 49, 59], ["mouse", "SPECIES", 43, 48], ["mouse", "SPECIES", 43, 48], ["C inactivated both mouse adenovirus types", "PROBLEM", 24, 65], ["both mouse", "OBSERVATION", 38, 48], ["adenovirus types", "OBSERVATION", 49, 65]]], ["But Wigand et al. (1977) found that if cell culture supernatant was used, 30 minutes at 56\u00b0C inactivated the virus, whereas if the supernatant was diluted 1:20 in distilled water, the virus was thermostable.", [["cell", "ANATOMY", 39, 43], ["supernatant", "ANATOMY", 52, 63], ["supernatant", "ANATOMY", 131, 142], ["cell", "CELL", 39, 43], ["C", "GENE_OR_GENE_PRODUCT", 91, 92], ["cell culture", "TEST", 39, 51], ["C inactivated the virus", "PROBLEM", 91, 114], ["the virus", "PROBLEM", 180, 189], ["virus", "OBSERVATION", 109, 114]]], ["Yamamoto (1967) drew attention to the importance of pH when testing for the effects of cations on thermal stability.B. Growth in Cell CultureThe human adenoviruses have been divided into two subgroups on the basis of their growth in cell culture (Boyer et al., 1957 (Boyer et al., , 1959 .", [["Cell Culture", "ANATOMY", 129, 141], ["cell", "ANATOMY", 233, 237], ["cations", "SIMPLE_CHEMICAL", 87, 94], ["Cell Culture", "CELL", 129, 141], ["human", "ORGANISM", 145, 150], ["adenoviruses", "ORGANISM", 151, 163], ["cell", "CELL", 233, 237], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["pH when testing", "TEST", 52, 67], ["cations on thermal stability", "TREATMENT", 87, 115], ["Cell Culture", "TEST", 129, 141], ["The human adenoviruses", "TREATMENT", 141, 163], ["Growth", "OBSERVATION_MODIFIER", 119, 125], ["Cell Culture", "OBSERVATION", 129, 141]]], ["The members of subgroup A of human adenoviruses tend to cause sporadic outbreaks of disease and exist in occult form in the tonsils, while the members of subgroup B tend to cause epidemics and do not normally persist in the tonsils (Parker et al., 1961) .", [["tonsils", "ANATOMY", 124, 131], ["tonsils", "ANATOMY", 224, 231], ["human", "ORGANISM", 29, 34], ["adenoviruses", "ORGANISM", 35, 47], ["tonsils", "ORGAN", 124, 131], ["tonsils", "ORGAN", 224, 231], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["subgroup A of human adenoviruses", "TREATMENT", 15, 47], ["sporadic outbreaks of disease", "PROBLEM", 62, 91], ["epidemics", "PROBLEM", 179, 188], ["disease", "OBSERVATION", 84, 91], ["tonsils", "ANATOMY", 124, 131], ["tonsils", "ANATOMY", 224, 231]]], ["In addition, there appears to be a correlation between cytopathology subgroup and virus multiplication cycle (Ginsberg, 1958) , neutralization reaction (Denny and Ginsberg, 1964) , G-C content (Philipson and Pettersson, 1973) , and hemagglutinating characteristics (Rosen, 1960) .", [["G-C", "GENE_OR_GENE_PRODUCT", 181, 184], ["cytopathology subgroup", "TEST", 55, 77], ["neutralization reaction", "PROBLEM", 128, 151], ["appears to be", "UNCERTAINTY", 19, 32]]], ["It has been possible to classify the animal adenoviruses studied into these human adenovirus subgroups (see Table I ).B. Growth in Cell CultureElectron microscopic studies on the development of human adenoviruses in cell cultures have been described (Martinez-Palomo et al., 1967; Weber and Stich, 1969) .", [["Cell", "ANATOMY", 131, 135], ["cell cultures", "ANATOMY", 216, 229], ["adenoviruses", "ORGANISM", 44, 56], ["human", "ORGANISM", 76, 81], ["adenovirus", "ORGANISM", 82, 92], ["Cell", "CELL", 131, 135], ["human", "ORGANISM", 194, 199], ["adenoviruses", "ORGANISM", 200, 212], ["cell cultures", "CELL", 216, 229], ["cell cultures", "CELL_LINE", 216, 229], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 194, 199], ["the animal adenoviruses", "TREATMENT", 33, 56], ["microscopic studies", "TEST", 152, 171], ["human adenoviruses", "PROBLEM", 194, 212], ["cell cultures", "TEST", 216, 229]]], ["Viral multiplication occurred in the nucleus of infected cells.", [["nucleus", "ANATOMY", 37, 44], ["cells", "ANATOMY", 57, 62], ["nucleus", "CELLULAR_COMPONENT", 37, 44], ["cells", "CELL", 57, 62], ["infected cells", "CELL_TYPE", 48, 62], ["Viral multiplication", "PROBLEM", 0, 20], ["infected cells", "PROBLEM", 48, 62], ["multiplication", "OBSERVATION", 6, 20], ["nucleus", "ANATOMY_MODIFIER", 37, 44], ["infected cells", "OBSERVATION", 48, 62]]], ["Virus particles, some with electron-dense and some with electron-lucent cores, accu- a Based on the classification suggested for human adenoviruses of Boyer^f al. (1957 ( , b Boyer et al. (1957 . c Curran (1978-1979) d Adair et al. (1979b) . '", [["Virus", "ORGANISM", 0, 5], ["human", "ORGANISM", 129, 134], ["adenoviruses", "ORGANISM", 135, 147], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["Virus particles", "PROBLEM", 0, 15], ["lucent cores", "PROBLEM", 65, 77], ["dense", "OBSERVATION_MODIFIER", 36, 41], ["lucent", "OBSERVATION_MODIFIER", 65, 71], ["cores", "OBSERVATION_MODIFIER", 72, 77]]], ["'Adair (1976) . f Adair (1979) . * Adair (1978) . h Adair et al. (1979c) .1959).112 mulated in the nucleus, sometimes forming crystalline lattices.", [["nucleus", "ANATOMY", 99, 106], ["nucleus", "CELLULAR_COMPONENT", 99, 106], ["nucleus", "ANATOMY", 99, 106], ["crystalline lattices", "OBSERVATION", 126, 146]]], ["Four types of inclusion, differing in density and morphology, were shown to be composed of viral proteins, some in association with viral DNA.", [["DNA", "CELLULAR_COMPONENT", 138, 141], ["viral proteins", "PROTEIN", 91, 105], ["viral DNA", "DNA", 132, 141], ["viral proteins", "PROBLEM", 91, 105], ["viral DNA", "PROBLEM", 132, 141], ["inclusion", "OBSERVATION", 14, 23], ["differing", "OBSERVATION_MODIFIER", 25, 34], ["density", "OBSERVATION", 38, 45], ["viral proteins", "OBSERVATION", 91, 105], ["viral DNA", "OBSERVATION", 132, 141]]], ["Large protein paracrystals with a well-defined structure were described.", [["protein paracrystals", "PROTEIN", 6, 26], ["Large protein paracrystals", "PROBLEM", 0, 26], ["a well-defined structure", "PROBLEM", 32, 56], ["protein paracrystals", "OBSERVATION", 6, 26], ["well-defined", "OBSERVATION_MODIFIER", 34, 46], ["structure", "OBSERVATION", 47, 56]]], ["The morphogenesis, structure of virus particles, and virus-associated inclu sions are similar in all the animal adenoviruses (Figs.", [["adenoviruses", "ORGANISM", 112, 124], ["virus particles", "PROBLEM", 32, 47], ["virus", "PROBLEM", 53, 58], ["inclu sions", "PROBLEM", 70, 81], ["virus particles", "OBSERVATION", 32, 47], ["adenoviruses", "OBSERVATION", 112, 124]]], ["2 and 3) studied to those described for human adenoviruses.", [["human", "ORGANISM", 40, 45], ["adenoviruses", "ORGANISM", 46, 58], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["human adenoviruses", "PROBLEM", 40, 58], ["adenoviruses", "OBSERVATION", 46, 58]]], ["For further information, see for bovine Curran (1978-1979) , for ovine Adair (1979b) , for porcine Chandler (1965) , for equine Shahrabadi et al. (1977) , for canine Givan and Jezequel (1969) and Yamamoto (1969) , for simian Fong et al. (1965 Fong et al. ( , 1968 , for murine Blailock et al. (1968) , and for avian adenoviruses Maeda et al. (1967) and Adair et al. (1979a) .1959).The cell growth of each species is considered in Section IV.", [["cell", "ANATOMY", 385, 389], ["bovine", "ORGANISM", 33, 39], ["canine", "ORGANISM", 159, 165], ["simian", "ORGANISM", 218, 224], ["murine", "ORGANISM", 270, 276], ["adenoviruses", "ORGANISM", 316, 328], ["cell", "CELL", 385, 389], ["bovine", "SPECIES", 33, 39], ["canine", "SPECIES", 159, 165], ["murine", "SPECIES", 270, 276], ["Section IV", "TREATMENT", 430, 440], ["cell", "OBSERVATION", 385, 389], ["growth", "OBSERVATION_MODIFIER", 390, 396]]], ["In general, they grow best in cells from the homologous species, and some have a very limited range of cells in which they will grow.", [["cells", "ANATOMY", 30, 35], ["cells", "ANATOMY", 103, 108], ["cells", "CELL", 30, 35], ["cells", "CELL", 103, 108], ["the homologous species", "PROBLEM", 41, 63]]], ["The turkey hemorrhagic enteritis marble spleen disease viruses are unique in that they have not so far been propagated in cell cultures, although a wide range has been tried (Carlson et al., 1974; Iltis et al., 1975; Domermuth and Gross, 1978) ./ .", [["spleen", "ANATOMY", 40, 46], ["cell cultures", "ANATOMY", 122, 135], ["hemorrhagic enteritis", "DISEASE", 11, 32], ["spleen disease", "DISEASE", 40, 54], ["turkey hemorrhagic enteritis", "ORGANISM", 4, 32], ["spleen", "ORGAN", 40, 46], ["cell cultures", "CELL", 122, 135], ["cell cultures", "CELL_LINE", 122, 135], ["turkey", "SPECIES", 4, 10], ["turkey hemorrhagic enteritis marble spleen disease viruses", "SPECIES", 4, 62], ["The turkey hemorrhagic enteritis marble spleen disease viruses", "PROBLEM", 0, 62], ["cell cultures", "TEST", 122, 135], ["turkey", "OBSERVATION_MODIFIER", 4, 10], ["hemorrhagic", "OBSERVATION_MODIFIER", 11, 22], ["enteritis", "OBSERVATION_MODIFIER", 23, 32], ["marble spleen disease", "OBSERVATION", 33, 54]]], ["Bovine AdenovirusesBoth B3 (Darbyshire, 1966; Gilden et al., 1967; Nishibe et al., 1970) and B8 (Rondhuis, 1973) produce tumors when inoculated into newborn Syrian hamsters (Mesocricetus auratius).", [["tumors", "ANATOMY", 121, 127], ["tumors", "DISEASE", 121, 127], ["Bovine", "ORGANISM", 0, 6], ["AdenovirusesBoth B3", "ORGANISM", 7, 26], ["tumors", "CANCER", 121, 127], ["Syrian hamsters", "ORGANISM", 157, 172], ["Mesocricetus auratius", "ORGANISM", 174, 195], ["Bovine", "SPECIES", 0, 6], ["Syrian hamsters", "SPECIES", 157, 172], ["Mesocricetus auratius", "SPECIES", 174, 195], ["Bovine AdenovirusesBoth B3 (Darbyshire, 1966; Gilden et al., 1967; Nishibe et al., 1970)", "SPECIES", 0, 88], ["Syrian hamsters", "SPECIES", 157, 172], ["Mesocricetus auratius", "SPECIES", 174, 195], ["tumors", "PROBLEM", 121, 127], ["tumors", "OBSERVATION", 121, 127]]], ["No oncogenicity has been shown for Bl, B2, or B6 (Rondhuis, 1973; Panigraphy et al., 1977) .", [["Bl", "GENE_OR_GENE_PRODUCT", 35, 37], ["B2", "GENE_OR_GENE_PRODUCT", 39, 41], ["B2", "PROTEIN", 39, 41]]], ["Mohanty (1971) could find no onco genicity for serotypes 1-8, omitting B3.", [["B3", "PROTEIN", 71, 73], ["serotypes", "TEST", 47, 56]]], ["The conflicting results in these studies may be due to the use of different strains of B8./ .", [["these studies", "TEST", 27, 40], ["different strains of B8", "TREATMENT", 66, 89]]], ["Bovine AdenovirusesLow doses of B3 produced a solid tumor arising from the mesenchymatous tissue.", [["solid tumor", "ANATOMY", 46, 57], ["mesenchymatous tissue", "ANATOMY", 75, 96], ["tumor", "DISEASE", 52, 57], ["Bovine", "ORGANISM", 0, 6], ["solid tumor", "CANCER", 46, 57], ["mesenchymatous tissue", "TISSUE", 75, 96], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine AdenovirusesLow doses of B3", "TREATMENT", 0, 34], ["a solid tumor", "PROBLEM", 44, 57], ["Low doses", "OBSERVATION_MODIFIER", 19, 28], ["solid", "OBSERVATION_MODIFIER", 46, 51], ["tumor", "OBSERVATION", 52, 57], ["mesenchymatous tissue", "OBSERVATION", 75, 96]]], ["These tumors had a latent period of at least 1 month and occasionally produced m\u00e9tastases.", [["tumors", "ANATOMY", 6, 12], ["tumors", "DISEASE", 6, 12], ["tumors", "CANCER", 6, 12], ["These tumors", "PROBLEM", 0, 12], ["occasionally produced m\u00e9tastases", "PROBLEM", 57, 89], ["tumors", "OBSERVATION", 6, 12], ["latent", "OBSERVATION_MODIFIER", 19, 25], ["period", "OBSERVATION_MODIFIER", 26, 32], ["m\u00e9tastases", "OBSERVATION", 79, 89]]], ["High doses produced hemorrhagic cystic lesions with a latent period of less than 1 month (Darbyshire et al., 1968) ./ .", [["cystic lesions", "ANATOMY", 32, 46], ["hemorrhagic", "DISEASE", 20, 31], ["cystic lesions", "PATHOLOGICAL_FORMATION", 32, 46], ["hemorrhagic cystic lesions", "PROBLEM", 20, 46], ["hemorrhagic", "OBSERVATION_MODIFIER", 20, 31], ["cystic", "OBSERVATION_MODIFIER", 32, 38], ["lesions", "OBSERVATION", 39, 46], ["latent", "OBSERVATION_MODIFIER", 54, 60], ["period", "OBSERVATION_MODIFIER", 61, 67], ["less", "OBSERVATION_MODIFIER", 71, 75]]], ["Bovine AdenovirusesB3 transformed a variety of hamster cells but not rat or mouse cells in vitro (Panigrahy et al., 1976) .", [["hamster cells", "ANATOMY", 47, 60], ["cells", "ANATOMY", 82, 87], ["AdenovirusesB3", "CHEMICAL", 7, 21], ["Bovine", "ORGANISM", 0, 6], ["AdenovirusesB3", "GENE_OR_GENE_PRODUCT", 7, 21], ["hamster cells", "CELL", 47, 60], ["rat", "ORGANISM", 69, 72], ["mouse", "ORGANISM", 76, 81], ["cells", "CELL", 82, 87], ["Bovine AdenovirusesB3", "PROTEIN", 0, 21], ["hamster cells", "CELL_TYPE", 47, 60], ["rat or mouse cells", "CELL_TYPE", 69, 87], ["Bovine", "SPECIES", 0, 6], ["hamster", "SPECIES", 47, 54], ["rat", "SPECIES", 69, 72], ["mouse", "SPECIES", 76, 81], ["Bovine", "SPECIES", 0, 6], ["hamster", "SPECIES", 47, 54], ["rat", "SPECIES", 69, 72], ["mouse", "SPECIES", 76, 81], ["Bovine AdenovirusesB3", "TREATMENT", 0, 21], ["variety", "OBSERVATION_MODIFIER", 36, 43], ["hamster cells", "OBSERVATION", 47, 60]]], ["B3 was nononcogenic in mice, despite the use of antilymphocytic serum (Darbyshire et al., 1968; Panigrahy et al., 1976) .", [["antilymphocytic serum", "ANATOMY", 48, 69], ["B3", "GENE_OR_GENE_PRODUCT", 0, 2], ["mice", "ORGANISM", 23, 27], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["B3", "PROBLEM", 0, 2], ["nononcogenic", "PROBLEM", 7, 19], ["nononcogenic", "OBSERVATION_MODIFIER", 7, 19]]], ["Rondhuis (1973) found that B8 had a low oncogenic potential for hamsters.", [["hamsters", "ORGANISM", 64, 72], ["hamsters", "SPECIES", 64, 72], ["hamsters", "SPECIES", 64, 72]]], ["Thus although some tumors arose within a month, most developed 5 to 15 months after inoculation.", [["tumors", "ANATOMY", 19, 25], ["tumors", "DISEASE", 19, 25], ["tumors", "CANCER", 19, 25], ["some tumors", "PROBLEM", 14, 25], ["inoculation", "PROBLEM", 84, 95], ["some", "OBSERVATION_MODIFIER", 14, 18], ["tumors", "OBSERVATION", 19, 25]]], ["These were of the fibrosarcoma type, and about 10% showed m\u00e9tastases.Ovine, Porcine, Equine, and Murine AdenovirusesSerotypes of these species do not appear to have been tested for oncogenicity.Caprine AdenovirusesThe isolate 435 did not produce tumors after 15 months (Gibbs et al., 1977) .Canine AdenovirusesThe viruses ICH and ICL both produced tumors in hamsters (Sarma et al., 1967; Dulac et al., 1970) .", [["fibrosarcoma type", "ANATOMY", 18, 35], ["tumors", "ANATOMY", 246, 252], ["tumors", "ANATOMY", 348, 354], ["fibrosarcoma", "DISEASE", 18, 30], ["Caprine", "CHEMICAL", 194, 201], ["tumors", "DISEASE", 246, 252], ["ICH", "DISEASE", 322, 325], ["tumors", "DISEASE", 348, 354], ["fibrosarcoma type", "CANCER", 18, 35], ["Ovine", "ORGANISM", 69, 74], ["Porcine", "ORGANISM", 76, 83], ["Equine", "ORGANISM", 85, 91], ["Murine", "ORGANISM", 97, 103], ["tumors", "CANCER", 246, 252], ["Canine", "ORGANISM", 291, 297], ["tumors", "CANCER", 348, 354], ["hamsters", "ORGANISM", 358, 366], ["Porcine", "SPECIES", 76, 83], ["Murine", "SPECIES", 97, 103], ["Canine", "SPECIES", 291, 297], ["hamsters", "SPECIES", 358, 366], ["Canine Adenoviruses", "SPECIES", 291, 310], ["hamsters", "SPECIES", 358, 366], ["the fibrosarcoma type", "PROBLEM", 14, 35], ["m\u00e9tastases", "PROBLEM", 58, 68], ["Porcine, Equine", "TREATMENT", 76, 91], ["Murine AdenovirusesSerotypes", "TREATMENT", 97, 125], ["these species", "PROBLEM", 129, 142], ["Caprine Adenoviruses", "TREATMENT", 194, 214], ["tumors", "PROBLEM", 246, 252], ["Canine Adenoviruses", "TREATMENT", 291, 310], ["The viruses ICH", "PROBLEM", 310, 325], ["tumors in hamsters", "PROBLEM", 348, 366], ["fibrosarcoma", "OBSERVATION", 18, 30], ["tumors", "OBSERVATION", 246, 252], ["Adenoviruses", "OBSERVATION", 298, 310], ["viruses", "OBSERVATION_MODIFIER", 314, 321], ["ICH", "OBSERVATION", 322, 325], ["ICL", "OBSERVATION_MODIFIER", 330, 333], ["both", "OBSERVATION_MODIFIER", 334, 338], ["produced", "OBSERVATION_MODIFIER", 339, 347], ["tumors", "OBSERVATION", 348, 354]]], ["Both ICH and ICL have low oncogenicity (Sarma et al., 1967; Kinjo et al., 1968) .", [["ICH", "DISEASE", 5, 8], ["ICL", "CHEMICAL", 13, 16], ["Both ICH", "PROBLEM", 0, 8], ["low oncogenicity", "PROBLEM", 22, 38], ["ICH", "OBSERVATION", 5, 8], ["ICL", "OBSERVATION", 13, 16], ["low oncogenicity", "OBSERVATION_MODIFIER", 22, 38]]], ["Virus was not recovered from primary and transplanted tumors, but antibody to tumor antigen and to the cell culture T antigen of ICH was demonstrated in the sera of tumor-bearing hamsters (Sarma et al.y 1967; Kinjo et al., 1968) .", [["primary", "ANATOMY", 29, 36], ["tumors", "ANATOMY", 54, 60], ["tumor", "ANATOMY", 78, 83], ["cell", "ANATOMY", 103, 107], ["sera", "ANATOMY", 157, 161], ["tumor", "ANATOMY", 165, 170], ["primary and transplanted tumors", "DISEASE", 29, 60], ["tumor", "DISEASE", 78, 83], ["ICH", "DISEASE", 129, 132], ["tumor", "DISEASE", 165, 170], ["Virus", "ORGANISM", 0, 5], ["tumors", "CANCER", 54, 60], ["antibody to tumor antigen", "GENE_OR_GENE_PRODUCT", 66, 91], ["cell", "CELL", 103, 107], ["T antigen", "GENE_OR_GENE_PRODUCT", 116, 125], ["sera", "ORGANISM_SUBSTANCE", 157, 161], ["tumor", "CANCER", 165, 170], ["hamsters", "ORGANISM", 179, 187], ["tumor antigen", "PROTEIN", 78, 91], ["cell culture T antigen", "PROTEIN", 103, 125], ["hamsters", "SPECIES", 179, 187], ["Virus", "PROBLEM", 0, 5], ["primary and transplanted tumors", "PROBLEM", 29, 60], ["antibody", "TEST", 66, 74], ["tumor antigen", "TEST", 78, 91], ["the cell culture", "TEST", 99, 115], ["ICH", "PROBLEM", 129, 132], ["transplanted", "OBSERVATION_MODIFIER", 41, 53], ["tumors", "OBSERVATION", 54, 60], ["tumor", "OBSERVATION", 165, 170]]], ["The ICL virus produced undifferentiated sar comas following 187 to 273 days of incubation.", [["sar comas", "ANATOMY", 40, 49], ["sar comas", "CANCER", 40, 49], ["The ICL virus", "PROBLEM", 0, 13], ["undifferentiated sar comas", "PROBLEM", 23, 49], ["ICL virus", "OBSERVATION", 4, 13]]], ["These tumors were also transplantable, and the hamsters developed antibody to T antigen.", [["tumors", "ANATOMY", 6, 12], ["tumors", "DISEASE", 6, 12], ["tumors", "CANCER", 6, 12], ["hamsters", "ORGANISM", 47, 55], ["antibody to T antigen", "GENE_OR_GENE_PRODUCT", 66, 87], ["T antigen", "PROTEIN", 78, 87], ["hamsters", "SPECIES", 47, 55], ["These tumors", "PROBLEM", 0, 12], ["tumors", "OBSERVATION", 6, 12]]], ["Sera from hamsters with tumors due to virus generally had two to four times higher titers to ICL than to ICH T antigens (Dulac et al., 1970) .Simian AdenovirusesOncogenicity in hamsters has been established for the following monkey serotypes: SI (Huebner et al., 1962) , S5, SII, S12, S14, S15, S16 (Hull et al., 1965) , S2, S6, S7 (Gilden et al., 1968) , and S8 (Slifkin et al., 1968) .", [["Sera", "ANATOMY", 0, 4], ["tumors", "ANATOMY", 24, 30], ["tumors", "DISEASE", 24, 30], ["ICH", "DISEASE", 105, 108], ["AdenovirusesOncogenicity", "CHEMICAL", 149, 173], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["hamsters", "ORGANISM", 10, 18], ["tumors", "CANCER", 24, 30], ["ICH T antigens", "GENE_OR_GENE_PRODUCT", 105, 119], ["Simian", "ORGANISM", 142, 148], ["hamsters", "ORGANISM", 177, 185], ["monkey", "ORGANISM", 225, 231], ["ICH T antigens", "PROTEIN", 105, 119], ["Simian", "SPECIES", 142, 148], ["hamsters", "SPECIES", 177, 185], ["hamsters", "SPECIES", 10, 18], ["hamsters", "SPECIES", 177, 185], ["tumors", "PROBLEM", 24, 30], ["virus", "PROBLEM", 38, 43], ["tumors", "OBSERVATION", 24, 30], ["S2", "ANATOMY", 321, 323], ["S6", "ANATOMY", 325, 327], ["S8", "ANATOMY", 360, 362]]], ["These strains have differing degrees of oncogenicity.", [["These strains", "PROBLEM", 0, 13], ["differing degrees of oncogenicity", "PROBLEM", 19, 52], ["differing degrees", "OBSERVATION_MODIFIER", 19, 36], ["oncogenicity", "OBSERVATION", 40, 52]]], ["Thus S16 produced tumors in all animals inoculated after 41 days, whereas SII produced only one tumor after 229 days.", [["tumors", "ANATOMY", 18, 24], ["tumor", "ANATOMY", 96, 101], ["tumors", "DISEASE", 18, 24], ["tumor", "DISEASE", 96, 101], ["S16", "GENE_OR_GENE_PRODUCT", 5, 8], ["tumors", "CANCER", 18, 24], ["tumor", "CANCER", 96, 101], ["S16", "PROTEIN", 5, 8], ["SII", "PROTEIN", 74, 77], ["S16 produced tumors", "PROBLEM", 5, 24], ["one tumor", "PROBLEM", 92, 101], ["tumors", "OBSERVATION", 18, 24], ["one", "OBSERVATION_MODIFIER", 92, 95], ["tumor", "OBSERVATION", 96, 101]]], ["In a comparative study, Burnett et al. (1972) found S5 and S16 the most oncogenic and were unable to confirm the oncogenicity of S6 or S14.", [["S16", "GENE_OR_GENE_PRODUCT", 59, 62], ["S6", "GENE_OR_GENE_PRODUCT", 129, 131], ["S14", "GENE_OR_GENE_PRODUCT", 135, 138], ["S5", "PROTEIN", 52, 54], ["S16", "PROTEIN", 59, 62], ["S6", "PROTEIN", 129, 131], ["S14", "PROTEIN", 135, 138], ["a comparative study", "TEST", 3, 22]]], ["Strain S16 will also produce tumors in suckling rats (Hull et al., 1965) .", [["tumors", "ANATOMY", 29, 35], ["tumors", "DISEASE", 29, 35], ["tumors", "CANCER", 29, 35], ["rats", "ORGANISM", 48, 52], ["rats", "SPECIES", 48, 52], ["tumors", "PROBLEM", 29, 35], ["tumors", "OBSERVATION", 29, 35]]], ["Monkey adenovirus-induced tumors rarely metastasize unless virus is inoculated intraperitoneally.", [["tumors", "ANATOMY", 26, 32], ["intraperitoneally", "ANATOMY", 79, 96], ["tumors", "DISEASE", 26, 32], ["Monkey adenovirus", "ORGANISM", 0, 17], ["tumors", "CANCER", 26, 32], ["Monkey adenovirus", "PROBLEM", 0, 17], ["induced tumors", "PROBLEM", 18, 32], ["virus", "PROBLEM", 59, 64], ["tumors", "OBSERVATION", 26, 32]]], ["The tumors are usually invasive and poorly differentiated.", [["tumors", "ANATOMY", 4, 10], ["tumors", "DISEASE", 4, 10], ["tumors", "CANCER", 4, 10], ["The tumors", "PROBLEM", 0, 10], ["tumors", "OBSERVATION", 4, 10], ["invasive", "OBSERVATION_MODIFIER", 23, 31], ["poorly differentiated", "OBSERVATION_MODIFIER", 36, 57]]], ["Types S5, S8, and S16 induced tumors resembling lymphomas, while the other strains produce palisading, pseudoaciner, and spindle cell patterns (Merkow and Slifkin, 1973) .Avian AdenovirusesFl will produce fibrosarcomas (Sarma et al., 1965) , hepatomas (Anderson et al., 1971) , ependymonas (Mancini et al., 1969) , and adenocarcinomas (Stenback et al., 1973) .", [["tumors", "ANATOMY", 30, 36], ["lymphomas", "ANATOMY", 48, 57], ["spindle cell", "ANATOMY", 121, 133], ["fibrosarcomas", "ANATOMY", 205, 218], ["hepatomas", "ANATOMY", 242, 251], ["adenocarcinomas", "ANATOMY", 319, 334], ["tumors", "DISEASE", 30, 36], ["lymphomas", "DISEASE", 48, 57], ["fibrosarcomas", "DISEASE", 205, 218], ["hepatomas", "DISEASE", 242, 251], ["adenocarcinomas", "DISEASE", 319, 334], ["S8", "GENE_OR_GENE_PRODUCT", 10, 12], ["S16", "GENE_OR_GENE_PRODUCT", 18, 21], ["tumors", "CANCER", 30, 36], ["lymphomas", "CANCER", 48, 57], ["pseudoaciner", "GENE_OR_GENE_PRODUCT", 103, 115], ["spindle cell", "CELL", 121, 133], ["Avian", "ORGANISM", 171, 176], ["AdenovirusesFl", "GENE_OR_GENE_PRODUCT", 177, 191], ["fibrosarcomas", "CANCER", 205, 218], ["hepatomas", "CANCER", 242, 251], ["adenocarcinomas", "CANCER", 319, 334], ["S8", "PROTEIN", 10, 12], ["S16", "PROTEIN", 18, 21], ["Avian", "SPECIES", 171, 176], ["S16 induced tumors", "PROBLEM", 18, 36], ["lymphomas", "PROBLEM", 48, 57], ["palisading, pseudoaciner", "PROBLEM", 91, 115], ["spindle cell patterns", "PROBLEM", 121, 142], ["fibrosarcomas", "PROBLEM", 205, 218], ["hepatomas", "PROBLEM", 242, 251], ["adenocarcinomas", "PROBLEM", 319, 334], ["S8", "ANATOMY", 10, 12], ["tumors", "OBSERVATION", 30, 36], ["lymphomas", "OBSERVATION", 48, 57], ["palisading", "OBSERVATION", 91, 101], ["spindle cell patterns", "OBSERVATION", 121, 142], ["fibrosarcomas", "OBSERVATION", 205, 218], ["hepatomas", "ANATOMY", 242, 251], ["adenocarcinomas", "OBSERVATION", 319, 334]]], ["In vitro transformations of human and hamster cells have been reported (Andersons#/., 1969a,b) .Avian AdenovirusesAttempts to demonstrate oncogenicity with other avian serotypes have been unsuccessful (Sarma et al., 1965; Fadly \u00e9tal., 1976) .D. Adenovirus-associated VirusesThere are four adenovirus-associated viruses (AAV) which have been asso ciated with primates.", [["hamster cells", "ANATOMY", 38, 51], ["Adenovirus-associated Viruses", "DISEASE", 245, 274], ["human", "ORGANISM", 28, 33], ["hamster cells", "CELL", 38, 51], ["Avian", "ORGANISM", 96, 101], [".D. Adenovirus", "ORGANISM", 241, 255], ["adenovirus-associated viruses", "ORGANISM", 289, 318], ["AAV", "ORGANISM", 320, 323], ["primates", "ORGANISM", 358, 366], ["human and hamster cells", "CELL_TYPE", 28, 51], ["human", "SPECIES", 28, 33], ["hamster", "SPECIES", 38, 45], ["Avian", "SPECIES", 96, 101], ["human", "SPECIES", 28, 33], ["hamster", "SPECIES", 38, 45], ["AAV", "SPECIES", 320, 323], ["human and hamster cells", "TREATMENT", 28, 51], ["Avian AdenovirusesAttempts", "TREATMENT", 96, 122], ["oncogenicity with other avian serotypes", "PROBLEM", 138, 177], ["Adenovirus", "PROBLEM", 245, 255], ["associated Viruses", "PROBLEM", 256, 274], ["four adenovirus-associated viruses", "PROBLEM", 284, 318], ["hamster cells", "OBSERVATION", 38, 51], ["Viruses", "OBSERVATION", 267, 274], ["viruses", "OBSERVATION", 311, 318]]], ["Of these two, AAV1 and AAV4, are possibly of simian origin (Rapoza and Atchinson, 1967; Parks et al., 1970) .D. Adenovirus-associated VirusesAAV have been recognized in bovine ( Fig. 4a ) (Luchsinger et al., 1970) , ovine (Clarke et al., 1979) , equine (Dutta, 1975) , canine (Sugimura and Yanagawa, 1968 ), fowl (Dutta and Pomeroy, 1967; McFerran et al., 1971a) , and turkey (Scott and McFerran, 1972) adenovirus strains.", [["AAV1", "GENE_OR_GENE_PRODUCT", 14, 18], ["AAV4", "GENE_OR_GENE_PRODUCT", 23, 27], ["simian", "ORGANISM", 45, 51], [".D. Adenovirus", "ORGANISM", 108, 122], ["VirusesAAV", "GENE_OR_GENE_PRODUCT", 134, 144], ["bovine", "ORGANISM", 169, 175], ["ovine", "ORGANISM", 216, 221], ["equine", "ORGANISM", 246, 252], ["canine", "ORGANISM", 269, 275], ["fowl", "ORGANISM", 308, 312], ["adenovirus", "ORGANISM", 403, 413], ["AAV1", "DNA", 14, 18], ["AAV4", "DNA", 23, 27], ["bovine", "SPECIES", 169, 175], ["equine", "SPECIES", 246, 252], ["canine", "SPECIES", 269, 275], ["fowl", "SPECIES", 308, 312], ["turkey", "SPECIES", 369, 375], ["turkey", "SPECIES", 369, 375], ["Adenovirus", "PROBLEM", 112, 122], ["VirusesAAV", "PROBLEM", 134, 144], ["adenovirus strains", "PROBLEM", 403, 421], ["two", "OBSERVATION_MODIFIER", 9, 12], ["AAV4", "ANATOMY", 23, 27], ["possibly of", "UNCERTAINTY", 33, 44], ["simian origin", "OBSERVATION", 45, 58]]], ["AAV4 agglutinates human erythrocytes at 4\u00b0C (Ito and Mayor, 1968) .", [["erythrocytes", "ANATOMY", 24, 36], ["AAV4", "SIMPLE_CHEMICAL", 0, 4], ["human", "ORGANISM", 18, 23], ["erythrocytes", "CELL", 24, 36], ["AAV4", "PROTEIN", 0, 4], ["human erythrocytes", "CELL_TYPE", 18, 36], ["human", "SPECIES", 18, 23], ["AAV4", "SPECIES", 0, 4], ["human", "SPECIES", 18, 23]]], ["The bovine AAV agglutinates sheep, human, guinea pig, and mouse cells at 4\u00b0C and 22\u00b0C, and horse cells only at 4\u00b0C (Luchsinger et al., 1970) .", [["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 97, 102], ["bovine", "ORGANISM", 4, 10], ["AAV", "ORGANISM", 11, 14], ["sheep", "ORGANISM", 28, 33], ["human", "ORGANISM", 35, 40], ["guinea pig", "ORGANISM", 42, 52], ["mouse", "ORGANISM", 58, 63], ["cells", "CELL", 64, 69], ["horse cells", "CELL", 91, 102], ["human, guinea pig, and mouse cells", "CELL_TYPE", 35, 69], ["horse cells", "CELL_TYPE", 91, 102], ["bovine", "SPECIES", 4, 10], ["sheep", "SPECIES", 28, 33], ["human", "SPECIES", 35, 40], ["guinea pig", "SPECIES", 42, 52], ["mouse", "SPECIES", 58, 63], ["horse", "SPECIES", 91, 96], ["AAV", "SPECIES", 11, 14], ["sheep", "SPECIES", 28, 33], ["human", "SPECIES", 35, 40], ["guinea pig", "SPECIES", 42, 52], ["mouse", "SPECIES", 58, 63], ["The bovine AAV agglutinates sheep", "TREATMENT", 0, 33], ["human, guinea pig", "TREATMENT", 35, 52], ["mouse cells", "TREATMENT", 58, 69], ["bovine AAV", "OBSERVATION", 4, 14]]], ["The ovine strain agglutinates guinea pig and human erythrocytes at 4\u00b0C and guinea pig cells at 22\u00b0C (Clarke et al., 1979) .", [["erythrocytes", "ANATOMY", 51, 63], ["cells", "ANATOMY", 86, 91], ["ovine", "ORGANISM", 4, 9], ["guinea pig", "ORGANISM", 30, 40], ["human", "ORGANISM", 45, 50], ["erythrocytes", "CELL", 51, 63], ["C", "CELL", 69, 70], ["guinea pig cells", "CELL", 75, 91], ["guinea pig and human erythrocytes", "CELL_TYPE", 30, 63], ["guinea pig cells", "CELL_TYPE", 75, 91], ["guinea pig", "SPECIES", 30, 40], ["human", "SPECIES", 45, 50], ["guinea pig", "SPECIES", 75, 85], ["pig", "SPECIES", 37, 40], ["human", "SPECIES", 45, 50], ["guinea pig", "SPECIES", 75, 85], ["The ovine strain agglutinates guinea pig and human erythrocytes", "TREATMENT", 0, 63], ["C and guinea pig cells", "TREATMENT", 69, 91], ["pig cells", "OBSERVATION", 82, 91]]], ["Avian adenoviruses are distinct from mammalian AAV types (Yates et al., 1973; El Mishad et al., 1975) .", [["Avian adenoviruses", "ORGANISM", 0, 18], ["AAV", "ORGANISM", 47, 50], ["Avian", "SPECIES", 0, 5], ["Avian adenoviruses", "PROBLEM", 0, 18], ["adenoviruses", "OBSERVATION", 6, 18], ["mammalian AAV", "OBSERVATION", 37, 50]]], ["Although many stock cultures of fowl adenoviruses have AAV present (El Mishad et al., 1975) , this may be due to AAV infection in the parent flock supplying the eggs for cell culture.", [["eggs", "ANATOMY", 161, 165], ["cell", "ANATOMY", 170, 174], ["infection", "DISEASE", 117, 126], ["fowl adenoviruses", "ORGANISM", 32, 49], ["AAV", "ORGANISM", 55, 58], ["AAV", "ORGANISM", 113, 116], ["cell", "CELL", 170, 174], ["fowl", "SPECIES", 32, 36], ["fowl", "SPECIES", 32, 36], ["AAV", "SPECIES", 113, 116], ["many stock cultures", "TEST", 9, 28], ["fowl adenoviruses", "PROBLEM", 32, 49], ["AAV infection", "PROBLEM", 113, 126], ["cell culture", "TEST", 170, 182], ["may be due to", "UNCERTAINTY", 99, 112], ["AAV infection", "OBSERVATION", 113, 126]]], ["Immuno-electron microscopy examination of both field isolates and stock pools has shown relatively low levels of infection with AAV (McFerran, unpublished observations), and Yates et al. (1976) found that only 2 of 38 adenovirus isolates were infected with AAV.D. Adenovirus-associated VirusesAAV can reduce both pathogenicity (Pronovost et al., 1978) and oncogenicity (Kirschstein et al., 1968) , as well as reducing the replication of adenoviruses in cell cultures (Hoggan et al., 1966) .A. Infection in Cattle/.", [["cell cultures", "ANATOMY", 453, 466], ["infection", "DISEASE", 113, 122], ["AAV", "ORGANISM", 128, 131], ["adenovirus", "ORGANISM", 218, 228], ["AAV", "ORGANISM", 257, 260], ["D. Adenovirus", "ORGANISM", 261, 274], ["VirusesAAV", "GENE_OR_GENE_PRODUCT", 286, 296], ["adenoviruses", "ORGANISM", 437, 449], ["cell cultures", "CELL", 453, 466], ["D. Adenovirus", "SPECIES", 261, 274], ["AAV", "SPECIES", 128, 131], ["adenovirus", "SPECIES", 218, 228], ["AAV", "SPECIES", 257, 260], ["Immuno", "TEST", 0, 6], ["electron microscopy examination", "TEST", 7, 38], ["both field isolates", "TEST", 42, 61], ["stock pools", "TEST", 66, 77], ["relatively low levels of infection", "PROBLEM", 88, 122], ["AAV (McFerran", "TREATMENT", 128, 141], ["38 adenovirus isolates", "PROBLEM", 215, 237], ["AAV", "PROBLEM", 257, 260], ["D. Adenovirus", "PROBLEM", 261, 274], ["VirusesAAV", "PROBLEM", 286, 296], ["adenoviruses", "PROBLEM", 437, 449], ["cell cultures", "TEST", 453, 466], ["Infection", "PROBLEM", 493, 502], ["relatively", "OBSERVATION_MODIFIER", 88, 98], ["low levels", "OBSERVATION_MODIFIER", 99, 109], ["infection", "OBSERVATION", 113, 122], ["AAV", "OBSERVATION", 257, 260], ["Infection", "OBSERVATION", 493, 502]]], ["Nine bovine adenovirus serotypes are recognized on the basis of cross neutralization tests Guenov et al., 1971; Mohanty, 1971; Adair and McFerran, 1976) (Table II) .", [["bovine", "ORGANISM", 5, 11], ["adenovirus", "ORGANISM", 12, 22], ["bovine", "SPECIES", 5, 11], ["Nine bovine adenovirus serotypes", "TREATMENT", 0, 32]]], ["A tenth serotype has been proposed but not yet accepted (Kretzschmar, 1973) .A. Infection in Cattleb.", [["A tenth serotype", "TREATMENT", 0, 16], ["Infection in Cattleb", "PROBLEM", 80, 100], ["Infection", "OBSERVATION", 80, 89]]], ["Bartha (1969) suggested that the bovine adenoviruses could be divided into two groups.", [["bovine", "ORGANISM", 33, 39], ["adenoviruses", "ORGANISM", 40, 52], ["bovine", "SPECIES", 33, 39], ["bovine", "SPECIES", 33, 39], ["the bovine adenoviruses", "TREATMENT", 29, 52]]], ["Subgroup 1 viruses are inactivated by 56\u00b0C for 30 minutes, replicate in bovine testicular and kidney cells, are readily isolated on first passage in cell culture, have single, irregularly shaped inclusion bodies, and share an antigen with human adenoviruses.", [["testicular", "ANATOMY", 79, 89], ["kidney cells", "ANATOMY", 94, 106], ["cell culture", "ANATOMY", 149, 161], ["bodies", "ANATOMY", 205, 211], ["bovine", "ORGANISM", 72, 78], ["testicular", "CELL", 79, 89], ["kidney cells", "CELL", 94, 106], ["cell", "CELL", 149, 153], ["human", "ORGANISM", 239, 244], ["adenoviruses", "ORGANISM", 245, 257], ["bovine testicular and kidney cells", "CELL_TYPE", 72, 106], ["bovine", "SPECIES", 72, 78], ["human", "SPECIES", 239, 244], ["bovine", "SPECIES", 72, 78], ["human", "SPECIES", 239, 244], ["Subgroup 1 viruses", "TREATMENT", 0, 18], ["cell culture", "TEST", 149, 161], ["single, irregularly shaped inclusion bodies", "PROBLEM", 168, 211], ["human adenoviruses", "PROBLEM", 239, 257], ["viruses", "OBSERVATION", 11, 18], ["testicular", "ANATOMY", 79, 89], ["kidney cells", "ANATOMY", 94, 106], ["irregularly", "OBSERVATION_MODIFIER", 176, 187], ["shaped", "OBSERVATION_MODIFIER", 188, 194], ["inclusion bodies", "OBSERVATION", 195, 211], ["human adenoviruses", "OBSERVATION", 239, 257]]], ["Subgroup 2 viruses are reduced in titer but not inactivated by 56\u00b0C for 30 minutes, replicate only in bovine testes cells, form multiple regular inclusion bodies, and are difficult to adapt to cell culture.", [["testes cells", "ANATOMY", 109, 121], ["cell", "ANATOMY", 193, 197], ["bovine", "ORGANISM", 102, 108], ["testes cells", "CELL", 109, 121], ["cell", "CELL", 193, 197], ["bovine testes cells", "CELL_TYPE", 102, 121], ["bovine", "SPECIES", 102, 108], ["bovine", "SPECIES", 102, 108], ["Subgroup 2 viruses", "TREATMENT", 0, 18], ["bovine testes cells", "TREATMENT", 102, 121], ["cell culture", "TEST", 193, 205], ["viruses", "OBSERVATION", 11, 18], ["reduced", "OBSERVATION_MODIFIER", 23, 30], ["bovine testes", "ANATOMY", 102, 115], ["multiple", "OBSERVATION_MODIFIER", 128, 136], ["inclusion bodies", "OBSERVATION", 145, 161]]], ["There is only a partial sharing of an antigen with human adenoviruses.", [["human", "ORGANISM", 51, 56], ["adenoviruses", "ORGANISM", 57, 69], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["human adenoviruses", "TREATMENT", 51, 69], ["partial", "OBSERVATION_MODIFIER", 16, 23]]], ["Bartha and Kisary (1970) modified this classification, as they found that resistance at 56\u00b0C could be modified by passage.", [["C", "GENE_OR_GENE_PRODUCT", 91, 92], ["passage", "OBSERVATION_MODIFIER", 114, 121]]], ["Thus the prototype strains of Bl and B2 were still themolabile after 10 passages but thermolabile after 60 passages.", [["Bl", "GENE_OR_GENE_PRODUCT", 30, 32], ["B2", "GENE_OR_GENE_PRODUCT", 37, 39], ["B2", "PROTEIN", 37, 39], ["Bl and B2", "TEST", 30, 39], ["thermolabile", "PROBLEM", 85, 97]]], ["One B3 strain was reduced in titer but not inactivated by 56\u00b0C (Mattson, 1973) , while another B3 isolate was virtually inactivated (Lehmkuhl et al., 1975) .", [["One B3 strain", "PROBLEM", 0, 13], ["B3 strain", "OBSERVATION_MODIFIER", 4, 13], ["reduced", "OBSERVATION_MODIFIER", 18, 25]]], ["B4 and B6 strains were either inactivated or markedly reduce in titer by 30 minutes at 56\u00b0C (Tanaka et al., 1968; Cole, 1970; Coria et al., 1975) , whereas although B7 had a 99% fall in titer after 30 minutes at 56\u00b0C, 2000 TOD.\u2122 was still present after 120 minutes.", [["B4", "GENE_OR_GENE_PRODUCT", 0, 2], ["B6 strains", "ORGANISM", 7, 17], ["B7", "GENE_OR_GENE_PRODUCT", 165, 167], ["B7", "PROTEIN", 165, 167], ["B4", "TEST", 0, 2], ["B6 strains", "PROBLEM", 7, 17], ["B7", "TEST", 165, 167]]], ["Clearly, more work is required to establish if this is a reasonable parameter for classification.A. Infection in CattleThe serological relationship between the proposed subgroups 1 and 2 and human adenoviruses is discussed in Section IV.", [["human", "ORGANISM", 191, 196], ["adenoviruses", "ORGANISM", 197, 209], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["A. Infection", "PROBLEM", 97, 109], ["human adenoviruses", "TREATMENT", 191, 209], ["Infection", "OBSERVATION", 100, 109]]], ["It is clear that although differences Curran (1978-1979) . c Based on Bartha (1969) . d N.I., no information available.A. Infection in Cattledo exist between bovine subgroups 1 and 2, they may also exist between species within these subgroups and between adenoviruses of different species.", [["bovine", "ORGANISM", 158, 164], ["adenoviruses", "ORGANISM", 255, 267], ["bovine", "SPECIES", 158, 164], ["A. Infection", "PROBLEM", 119, 131], ["different species", "PROBLEM", 271, 288], ["clear", "OBSERVATION", 6, 11], ["Infection", "OBSERVATION", 122, 131], ["different species", "OBSERVATION", 271, 288]]], ["Phillip and Sands (1972) showed that B4 and B7 had inclusions which were numerous single irregular and multiple round types corresponding to both of Bartha's subgroups.", [["B7", "GENE_OR_GENE_PRODUCT", 44, 46], ["B7", "PROTEIN", 44, 46], ["Phillip and Sands", "TEST", 0, 17], ["B4", "TEST", 37, 39], ["inclusions", "PROBLEM", 51, 61], ["numerous single irregular and multiple round types", "PROBLEM", 73, 123], ["B4", "ANATOMY", 37, 39], ["numerous", "OBSERVATION_MODIFIER", 73, 81], ["single", "OBSERVATION_MODIFIER", 82, 88], ["irregular", "OBSERVATION_MODIFIER", 89, 98], ["multiple", "OBSERVATION_MODIFIER", 103, 111], ["round types", "OBSERVATION_MODIFIER", 112, 123]]], ["However, Curran (1978-1979) have shown that there is reasonable agreement between the pattern of growth in cell culture and Bartha's subgroups.", [["cell", "ANATOMY", 107, 111], ["cell", "CELL", 107, 111], ["cell culture", "TEST", 107, 119], ["Bartha's subgroups", "TREATMENT", 124, 142], ["growth", "OBSERVATION_MODIFIER", 97, 103]]], ["Thus B l -3 and B9 fell into group B, and B4-6 and B8 fell into group A. B7, however, is in Bartha's subgroup 2 but falls into cytopathology group B. A number of workers have confirmed that subgroup 2 viruses do not replicate in bovine kidney (BK) cells (Bartha and Aldasy, 1966; Tanaka et al., 1968; Cole, 1970; Phillip and Sands, 1972 ).", [["kidney (BK) cells", "ANATOMY", 236, 253], ["B l -3", "GENE_OR_GENE_PRODUCT", 5, 11], ["B9", "CELL", 16, 18], ["B4-6", "GENE_OR_GENE_PRODUCT", 42, 46], ["B8", "GENE_OR_GENE_PRODUCT", 51, 53], ["B7", "GENE_OR_GENE_PRODUCT", 73, 75], ["bovine", "ORGANISM", 229, 235], ["kidney (BK) cells", "CELL", 236, 253], ["B9", "PROTEIN", 16, 18], ["B4", "PROTEIN", 42, 44], ["B8", "PROTEIN", 51, 53], ["B7", "PROTEIN", 73, 75], ["bovine kidney (BK) cells", "CELL_TYPE", 229, 253], ["bovine", "SPECIES", 229, 235], ["bovine", "SPECIES", 229, 235], ["B4", "TEST", 42, 44], ["subgroup 2 viruses", "PROBLEM", 190, 208], ["B4", "ANATOMY", 42, 44], ["kidney", "ANATOMY", 236, 242]]], ["It appears that these viruses grow in the epithelial cells of bovine testes (BT) cultures but not in the epithelial cells of BK (Aldasy et al, 1965; Mattson et al., 1977; Sibalin et al., 1978) .", [["epithelial cells", "ANATOMY", 42, 58], ["testes", "ANATOMY", 69, 75], ["BT) cultures", "ANATOMY", 77, 89], ["epithelial cells", "ANATOMY", 105, 121], ["BK", "ANATOMY", 125, 127], ["epithelial cells", "CELL", 42, 58], ["bovine", "ORGANISM", 62, 68], ["testes", "DEVELOPING_ANATOMICAL_STRUCTURE", 69, 75], ["(BT) cultures", "CELL", 76, 89], ["epithelial cells", "CELL", 105, 121], ["BK", "CELL", 125, 127], ["epithelial cells", "CELL_TYPE", 42, 58], ["bovine testes (BT) cultures", "CELL_LINE", 62, 89], ["epithelial cells", "CELL_TYPE", 105, 121], ["bovine", "SPECIES", 62, 68], ["these viruses", "PROBLEM", 16, 29], ["bovine testes (BT) cultures", "TEST", 62, 89], ["viruses", "OBSERVATION", 22, 29], ["epithelial cells", "OBSERVATION", 42, 58], ["testes", "ANATOMY", 69, 75], ["epithelial cells", "ANATOMY", 105, 121]]], ["However, other workers have found that B4 (THT), B5 (B4/65), B6 (671130), B6 (KC-2), B7 (Fukuroi), and B8 (Misk/67) all grow as well in (BK) as in (BT) cells.", [["BT) cells", "ANATOMY", 148, 157], ["B4", "GENE_OR_GENE_PRODUCT", 39, 41], ["THT", "GENE_OR_GENE_PRODUCT", 43, 46], ["B5", "GENE_OR_GENE_PRODUCT", 49, 51], ["KC-2", "GENE_OR_GENE_PRODUCT", 78, 82], ["B7", "GENE_OR_GENE_PRODUCT", 85, 87], ["(BT) cells", "CELL", 147, 157], ["KC", "PROTEIN", 78, 80], ["B7", "PROTEIN", 85, 87], ["Fukuroi", "PROTEIN", 89, 96], ["B8", "PROTEIN", 103, 105], ["Misk", "PROTEIN", 107, 111], ["B4 (THT)", "TEST", 39, 47], ["B5", "TEST", 49, 51], ["B4", "TEST", 53, 55], ["B6", "TEST", 61, 63], ["B6", "TEST", 74, 76], ["KC", "TEST", 78, 80], ["B7", "TEST", 85, 87], ["Fukuroi", "TEST", 89, 96], ["B8", "TEST", 103, 105], ["Misk", "TEST", 107, 111]]], ["Other strains of species B4 (KC-6), B5 (BIL), and B6 (RG) all required one to two blind passages in bovine embryonic corneal (BEC) cells before pro ducing a cytopathic effect (CPE), and B4 (Negano) could not be adapted to BK cells (Mohanty, 1971) .", [["embryonic corneal (BEC) cells", "ANATOMY", 107, 136], ["BK cells", "ANATOMY", 222, 230], ["KC-6", "ORGANISM", 29, 33], ["B5 (BIL", "ORGANISM", 36, 43], ["B6 (RG)", "ORGANISM", 50, 57], ["bovine", "ORGANISM", 100, 106], ["embryonic corneal (BEC) cells", "CELL", 107, 136], ["BK cells", "CELL", 222, 230], ["KC", "PROTEIN", 29, 31], ["B5", "PROTEIN", 36, 38], ["BIL", "PROTEIN", 40, 43], ["RG", "PROTEIN", 54, 56], ["bovine embryonic corneal (BEC) cells", "CELL_TYPE", 100, 136], ["BK cells", "CELL_LINE", 222, 230], ["bovine", "SPECIES", 100, 106], ["bovine", "SPECIES", 100, 106], ["species B4", "TEST", 17, 27], ["KC", "TEST", 29, 31], ["B5 (BIL)", "TEST", 36, 44], ["a cytopathic effect", "PROBLEM", 155, 174], ["CPE", "TEST", 176, 179], ["B4 (Negano", "TEST", 186, 196], ["species", "OBSERVATION_MODIFIER", 17, 24], ["B4", "OBSERVATION_MODIFIER", 25, 27], ["BIL", "ANATOMY_MODIFIER", 40, 43], ["bovine embryonic corneal", "OBSERVATION", 100, 124]]], ["Although in general the subgroup 2 viruses conform to Bartha's classification in that they are difficult to isolate in cell cultures and grow to low titers (Cole, 1970; Mohanty, 1971) , others have recorded high titers (Tanaka et al., 1968; Stauber et al., 1976) .", [["cell cultures", "ANATOMY", 119, 132], ["cell cultures", "CELL", 119, 132], ["cell cultures", "CELL_LINE", 119, 132], ["cell cultures", "TEST", 119, 132]]], ["Furthermore, the subgroup 1 viruses can also be difficult to isolate and can grow to very low titers (Klein, 1962; Darby shire et al., 1965 Darby shire et al., , 1969 Lehmkuhl^a/., 1975) .A. Infection in CattleIt would appear, therefore, that the two subgroups proposed for bovine adenoviruses are, at best, only a guide to classification.DistributionBovine adeno viruses are widespread.", [["Bovine adeno viruses", "DISEASE", 351, 371], ["bovine", "ORGANISM", 274, 280], ["adenoviruses", "ORGANISM", 281, 293], ["Bovine adeno viruses", "ORGANISM", 351, 371], ["bovine", "SPECIES", 274, 280], ["Bovine", "SPECIES", 351, 357], ["Cattle", "SPECIES", 204, 210], ["bovine", "SPECIES", 274, 280], ["Bovine adeno viruses", "SPECIES", 351, 371], ["the subgroup 1 viruses", "PROBLEM", 13, 35], ["Infection", "PROBLEM", 191, 200], ["bovine adenoviruses", "TREATMENT", 274, 293], ["DistributionBovine adeno viruses", "PROBLEM", 339, 371], ["Infection", "OBSERVATION", 191, 200], ["adeno viruses", "OBSERVATION", 358, 371], ["widespread", "OBSERVATION_MODIFIER", 376, 386]]], ["Antibody studies have shown that be tween 25 and 87% of sera examined possess antibody to one or more types (Klein et al., 1959; Tanaka et al., 1968; Rondhuis, 1970; Phillip and Sands, 1972; Rossina/., 1973; Mattson et al., 1977) .Epizootiology and Pathog\u00e8ne sisA number of authors have shown that at least some strains are found more often in the oronasal secretions and in conjunctival swabs than in feces.", [["sera", "ANATOMY", 56, 60], ["oronasal secretions", "ANATOMY", 348, 367], ["conjunctival swabs", "ANATOMY", 375, 393], ["feces", "ANATOMY", 402, 407], ["sera", "ORGANISM_SUBSTANCE", 56, 60], ["oronasal secretions", "ORGAN", 348, 367], ["conjunctival swabs", "MULTI-TISSUE_STRUCTURE", 375, 393], ["feces", "ORGANISM_SUBSTANCE", 402, 407], ["Antibody studies", "TEST", 0, 16], ["tween", "TEST", 36, 41], ["sera", "TEST", 56, 60], ["antibody", "TEST", 78, 86], ["some strains", "PROBLEM", 307, 319], ["the oronasal secretions", "PROBLEM", 344, 367], ["conjunctival swabs", "PROBLEM", 375, 393], ["strains", "OBSERVATION", 312, 319], ["oronasal secretions", "ANATOMY", 348, 367], ["conjunctival swabs", "ANATOMY", 375, 393]]], ["Virus has not been detected in the feces in B3-infected animals (Mattson, 1973; Mattson et al., 1977) , while other isolates were made from the feces (Klein et al., 1959 (Klein et al., , 1960 .", [["feces", "ANATOMY", 35, 40], ["Virus", "ORGANISM", 0, 5], ["feces", "ORGANISM_SUBDIVISION", 35, 40], ["B3", "ORGANISM", 44, 46], ["animals", "ORGANISM", 56, 63], ["feces", "ORGANISM_SUBSTANCE", 144, 149], ["Virus", "PROBLEM", 0, 5], ["infected", "OBSERVATION_MODIFIER", 47, 55], ["feces", "ANATOMY", 144, 149]]], ["Following intratracheal inoculation of B3, there were more isolates from the nose (40) and conjunctiva (25) than from the feces (14) .", [["nose", "ANATOMY", 77, 81], ["conjunctiva", "ANATOMY", 91, 102], ["feces", "ANATOMY", 122, 127], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["nose", "ORGANISM_SUBDIVISION", 77, 81], ["conjunctiva", "ORGAN", 91, 102], ["feces", "ORGANISM_SUBDIVISION", 122, 127], ["intratracheal inoculation of B3", "TREATMENT", 10, 41], ["intratracheal", "ANATOMY", 10, 23], ["inoculation", "OBSERVATION", 24, 35], ["nose", "ANATOMY", 77, 81], ["conjunctiva", "ANATOMY", 91, 102], ["feces", "ANATOMY", 122, 127]]], ["Using B4, Aldasy et al. (1965) made more isolations from the feces than nasal swabs, but with a high recovery from the conjunctiva.", [["feces", "ANATOMY", 61, 66], ["nasal swabs", "ANATOMY", 72, 83], ["conjunctiva", "ANATOMY", 119, 130], ["feces", "ORGANISM_SUBDIVISION", 61, 66], ["nasal swabs", "ORGANISM_SUBSTANCE", 72, 83], ["conjunctiva", "ORGAN", 119, 130], ["nasal swabs", "TEST", 72, 83], ["conjunctiva", "ANATOMY", 119, 130]]], ["Cole (1971) found that following intratracheal inoculation, B4 was excreted in nasal secretions and in the feces from the fifth to the eleventh day after infection.", [["nasal secretions", "ANATOMY", 79, 95], ["feces", "ANATOMY", 107, 112], ["infection", "DISEASE", 154, 163], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["nasal secretions", "ORGANISM_SUBSTANCE", 79, 95], ["feces", "ORGANISM_SUBDIVISION", 107, 112], ["intratracheal inoculation", "TREATMENT", 33, 58], ["nasal secretions", "PROBLEM", 79, 95], ["infection", "PROBLEM", 154, 163], ["intratracheal", "ANATOMY", 33, 46], ["inoculation", "OBSERVATION", 47, 58], ["nasal", "ANATOMY", 79, 84], ["secretions", "OBSERVATION", 85, 95], ["infection", "OBSERVATION", 154, 163]]], ["The urine may well be a source of infection (Belak et al., 1977) and thus may be an important factor in intensive-production units, where food can be contaminated with urine or urine drinking occurs.Epizootiology and Pathog\u00e8ne sisIt is evident from the large number of adenoviruses isolated from all cultures derived from fetuses that transplacental infection occurs.", [["urine", "ANATOMY", 4, 9], ["urine", "ANATOMY", 168, 173], ["urine", "ANATOMY", 177, 182], ["fetuses", "ANATOMY", 322, 329], ["infection", "DISEASE", 34, 43], ["transplacental infection", "DISEASE", 335, 359], ["urine", "ORGANISM_SUBSTANCE", 4, 9], ["urine", "ORGANISM_SUBSTANCE", 168, 173], ["urine", "ORGANISM_SUBSTANCE", 177, 182], ["adenoviruses", "ORGANISM", 269, 281], ["fetuses", "ORGANISM", 322, 329], ["infection", "PROBLEM", 34, 43], ["intensive-production units", "TREATMENT", 104, 130], ["adenoviruses", "PROBLEM", 269, 281], ["all cultures", "TEST", 296, 308], ["fetuses", "PROBLEM", 322, 329], ["transplacental infection", "PROBLEM", 335, 359], ["urine", "OBSERVATION", 4, 9], ["infection", "OBSERVATION", 34, 43], ["may be", "UNCERTAINTY", 74, 80], ["large", "OBSERVATION_MODIFIER", 253, 258], ["number", "OBSERVATION_MODIFIER", 259, 265], ["adenoviruses", "OBSERVATION", 269, 281], ["infection", "OBSERVATION", 350, 359]]], ["Mattson (1973) suggested that latent infection was reactivated in the dam at calving and showed that calves should be infected in spite of maternally derived antibody.", [["infection", "DISEASE", 37, 46], ["calves", "ORGANISM", 101, 107], ["maternally derived antibody", "PROTEIN", 139, 166], ["calves", "SPECIES", 101, 107], ["calves", "SPECIES", 101, 107], ["latent infection", "PROBLEM", 30, 46], ["calves", "PROBLEM", 101, 107], ["maternally derived antibody", "PROBLEM", 139, 166], ["latent", "OBSERVATION_MODIFIER", 30, 36], ["infection", "OBSERVATION", 37, 46], ["calves", "ANATOMY", 101, 107], ["infected", "OBSERVATION", 118, 126]]], ["Cole (1971) studied the distribution of B4 (BIL) and found virus in the respira tory tract and drainage lymph nodes from days 1-12 postinfection (PI), with maximum dissemination in visceral organs from days 5-7 PI, when virus was found in the liver.", [["respira tory tract", "ANATOMY", 72, 90], ["lymph nodes", "ANATOMY", 104, 115], ["visceral organs", "ANATOMY", 181, 196], ["liver", "ANATOMY", 243, 248], ["B4", "GENE_OR_GENE_PRODUCT", 40, 42], ["BIL", "GENE_OR_GENE_PRODUCT", 44, 47], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 104, 115], ["visceral organs", "ORGAN", 181, 196], ["liver", "ORGAN", 243, 248], ["B4 (BIL)", "TEST", 40, 48], ["virus", "PROBLEM", 59, 64], ["drainage lymph nodes", "PROBLEM", 95, 115], ["maximum dissemination in visceral organs", "PROBLEM", 156, 196], ["virus", "PROBLEM", 220, 225], ["B4", "ANATOMY", 40, 42], ["virus", "OBSERVATION", 59, 64], ["drainage", "OBSERVATION_MODIFIER", 95, 103], ["lymph nodes", "OBSERVATION", 104, 115], ["maximum", "OBSERVATION_MODIFIER", 156, 163], ["dissemination", "OBSERVATION", 164, 177], ["visceral", "ANATOMY_MODIFIER", 181, 189], ["organs", "ANATOMY", 190, 196], ["liver", "ANATOMY", 243, 248]]], ["But as neither histological nor fluorescent antibody (FA) examination showed evidence of virus growth, the virus in the liver may be in macrophages.Association with Diseasea.", [["liver", "ANATOMY", 120, 125], ["macrophages", "ANATOMY", 136, 147], ["FA", "SIMPLE_CHEMICAL", 54, 56], ["liver", "ORGAN", 120, 125], ["macrophages", "CELL", 136, 147], ["fluorescent antibody", "PROTEIN", 32, 52], ["FA", "PROTEIN", 54, 56], ["macrophages", "CELL_TYPE", 136, 147], ["fluorescent antibody (FA) examination", "TEST", 32, 69], ["virus growth", "PROBLEM", 89, 101], ["the virus in the liver", "PROBLEM", 103, 125], ["Diseasea", "PROBLEM", 165, 173], ["evidence of", "UNCERTAINTY", 77, 88], ["virus growth", "OBSERVATION", 89, 101], ["virus", "OBSERVATION", 107, 112], ["liver", "ANATOMY", 120, 125], ["may be in", "UNCERTAINTY", 126, 135], ["macrophages", "OBSERVATION", 136, 147], ["Diseasea", "OBSERVATION", 165, 173]]], ["Normal Animals.", [["Animals", "OBSERVATION_MODIFIER", 7, 14]]], ["Many bovine adenoviruses have been isolated from apparently normal animals.", [["bovine", "ORGANISM", 5, 11], ["adenoviruses", "ORGANISM", 12, 24], ["bovine", "SPECIES", 5, 11], ["bovine", "SPECIES", 5, 11], ["Many bovine adenoviruses", "PROBLEM", 0, 24], ["bovine adenoviruses", "OBSERVATION", 5, 24]]], ["Among these were prototypes 1 and 2, isolated from feces (Klein et al., 1959 (Klein et al., , 1960 , and type 3 from the conjunctiva (Darbyshire et al., 1965) .", [["conjunctiva", "ANATOMY", 121, 132], ["feces", "ORGANISM_SUBSTANCE", 51, 56], ["conjunctiva", "ORGAN", 121, 132], ["conjunctiva", "ANATOMY", 121, 132]]], ["Isolations have also been made under conditions not associated with adenoviruses, such as the isolation of a type 6 virus from the lymph node of a leukotic cow (Mayr et al., 1970) .", [["lymph node", "ANATOMY", 131, 141], ["adenoviruses", "ORGANISM", 68, 80], ["lymph node", "MULTI-TISSUE_STRUCTURE", 131, 141], ["cow", "SPECIES", 156, 159], ["type 6 virus", "SPECIES", 109, 121], ["cow", "SPECIES", 156, 159], ["Isolations", "TREATMENT", 0, 10], ["adenoviruses", "PROBLEM", 68, 80], ["a type 6 virus", "PROBLEM", 107, 121], ["lymph node", "OBSERVATION", 131, 141]]], ["Some isolations have been made from organs taken for cell culture from normal animals.", [["organs", "ANATOMY", 36, 42], ["cell", "ANATOMY", 53, 57], ["organs", "ORGAN", 36, 42], ["cell", "CELL", 53, 57], ["Some isolations", "PROBLEM", 0, 15], ["cell culture", "TEST", 53, 65], ["isolations", "OBSERVATION", 5, 15]]], ["Thus the prototype 9 and a B2 virus were isolated from primary bovine kidney cells (Mohanty and Lillie, 1970; Guenov et al., 1971) ) and an untyped isolate also from kidney .", [["kidney cells", "ANATOMY", 70, 82], ["kidney", "ANATOMY", 166, 172], ["B2 virus", "ORGANISM", 27, 35], ["bovine", "ORGANISM", 63, 69], ["kidney cells", "CELL", 70, 82], ["kidney", "ORGAN", 166, 172], ["primary bovine kidney cells", "CELL_TYPE", 55, 82], ["bovine", "SPECIES", 63, 69], ["B2 virus", "SPECIES", 27, 35], ["the prototype", "TEST", 5, 18], ["a B2 virus", "PROBLEM", 25, 35], ["bovine kidney cells", "OBSERVATION", 63, 82], ["kidney", "ANATOMY", 166, 172]]], ["The B6 prototype strain came from a calf testes cell culture (Rondhuis, 1968) , as did B4 strains (Bartha and Csontos, 1969) and B4 and B6 (Phillip and Sands, 1972) strains.", [["testes cell culture", "ANATOMY", 41, 60], ["B6", "ORGANISM", 4, 6], ["calf", "ORGANISM", 36, 40], ["testes cell culture", "CELL", 41, 60], ["B4", "CELL", 129, 131], ["calf", "SPECIES", 36, 40], ["The B6 prototype strain", "TEST", 0, 23], ["a calf testes cell culture", "TEST", 34, 60], ["B4 strains", "TEST", 87, 97], ["Bartha", "TEST", 99, 105], ["Csontos", "TEST", 110, 117], ["B4", "TEST", 129, 131], ["B6", "TEST", 136, 138], ["Phillip", "TEST", 140, 147], ["strains", "PROBLEM", 165, 172], ["calf testes", "ANATOMY", 36, 47]]], ["Burki et al. (1978) made 14 isolations from the testicles of normal slaughterhouse calves.Association with Diseaseb.", [["testicles", "ANATOMY", 48, 57], ["testicles", "ORGAN", 48, 57], ["calves", "ORGANISM", 83, 89], ["Diseaseb", "PROTEIN", 107, 115], ["calves", "SPECIES", 83, 89], ["testicles", "ANATOMY", 48, 57], ["normal", "OBSERVATION", 61, 67], ["slaughterhouse calves", "OBSERVATION", 68, 89]]], ["Conjunctivitis.", [["Conjunctivitis", "DISEASE", 0, 14], ["Conjunctivitis", "PROBLEM", 0, 14]]], ["A number of strains of adenovirus have been isolated from the conjunctiva of cattle with infectious keratoconjunctivitis in Australia (Wilcox, 1969) .", [["conjunctiva", "ANATOMY", 62, 73], ["infectious keratoconjunctivitis", "DISEASE", 89, 120], ["adenovirus", "ORGANISM", 23, 33], ["conjunctiva", "ORGAN", 62, 73], ["cattle", "ORGANISM", 77, 83], ["cattle", "SPECIES", 77, 83], ["adenovirus", "SPECIES", 23, 33], ["cattle", "SPECIES", 77, 83], ["adenovirus", "PROBLEM", 23, 33], ["infectious keratoconjunctivitis", "PROBLEM", 89, 120], ["adenovirus", "OBSERVATION", 23, 33], ["conjunctiva", "ANATOMY", 62, 73], ["infectious", "OBSERVATION_MODIFIER", 89, 99], ["keratoconjunctivitis", "OBSERVATION", 100, 120]]], ["Experimental infection of calves with these isolates produced a mild conjunctivitis after an incubation period of 7-14 days.", [["infection", "DISEASE", 13, 22], ["conjunctivitis", "DISEASE", 69, 83], ["calves", "ORGANISM", 26, 32], ["calves", "SPECIES", 26, 32], ["calves", "SPECIES", 26, 32], ["Experimental infection of calves", "PROBLEM", 0, 32], ["these isolates", "PROBLEM", 38, 52], ["a mild conjunctivitis", "PROBLEM", 62, 83], ["infection", "OBSERVATION", 13, 22], ["calves", "ANATOMY", 26, 32], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["conjunctivitis", "OBSERVATION", 69, 83]]], ["Neisseria catarrhalis and Moraxelia bovis may be associated as secondary invaders (Wilcox, 1970) .Association with Diseasec.", [["Neisseria catarrhalis", "ORGANISM", 0, 21], ["Moraxelia bovis", "ORGANISM", 26, 41], ["Neisseria catarrhalis", "SPECIES", 0, 21], ["Moraxelia bovis", "SPECIES", 26, 41], ["Neisseria catarrhalis", "SPECIES", 0, 21], ["Moraxelia bovis", "SPECIES", 26, 41], ["Neisseria catarrhalis", "PROBLEM", 0, 21], ["Moraxelia bovis", "PROBLEM", 26, 41], ["Diseasec", "PROBLEM", 115, 123], ["catarrhalis", "OBSERVATION", 10, 21]]], ["Respiratory Disease and Enteritis.", [["Respiratory Disease", "DISEASE", 0, 19], ["Enteritis", "DISEASE", 24, 33], ["Respiratory Disease", "PROBLEM", 0, 19], ["Enteritis", "PROBLEM", 24, 33], ["Disease", "OBSERVATION", 12, 19], ["Enteritis", "OBSERVATION", 24, 33]]], ["Adenoviruses have been associated with both upper and lower respiratory tract disease.", [["lower respiratory tract", "ANATOMY", 54, 77], ["upper and lower respiratory tract disease", "DISEASE", 44, 85], ["upper", "ORGANISM_SUBDIVISION", 44, 49], ["lower", "ORGANISM_SUBDIVISION", 54, 59], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["Adenoviruses", "PROBLEM", 0, 12], ["both upper and lower respiratory tract disease", "PROBLEM", 39, 85], ["upper", "ANATOMY_MODIFIER", 44, 49], ["lower", "ANATOMY_MODIFIER", 54, 59], ["respiratory tract", "ANATOMY", 60, 77]]], ["In some of these outbreaks, diarrhea has been a minor or major problem.", [["diarrhea", "DISEASE", 28, 36], ["diarrhea", "PROBLEM", 28, 36], ["outbreaks", "OBSERVATION", 17, 26], ["minor", "OBSERVATION_MODIFIER", 48, 53]]], ["The first associations of bovine adenoviruses with respiratory tract disease came from serological (Darbyshire and Pereira, 1964; Harbourne, 1966) and histological evidence (Omar, 1966) .Association with DiseaseBl and B2 have not often been recorded from field outbreaks of disease.", [["respiratory tract", "ANATOMY", 51, 68], ["respiratory tract disease", "DISEASE", 51, 76], ["bovine", "ORGANISM", 26, 32], ["adenoviruses", "ORGANISM", 33, 45], ["tract", "ORGANISM_SUBDIVISION", 63, 68], ["B2", "PROTEIN", 218, 220], ["bovine", "SPECIES", 26, 32], ["bovine adenoviruses", "TREATMENT", 26, 45], ["respiratory tract disease", "PROBLEM", 51, 76], ["DiseaseBl and B2", "PROBLEM", 204, 220], ["disease", "PROBLEM", 274, 281], ["bovine adenoviruses", "OBSERVATION", 26, 45], ["respiratory tract", "ANATOMY", 51, 68], ["disease", "OBSERVATION", 274, 281]]], ["Saxegaard and Bratberg (1971) isolated Bl from an outbreak of anorexia, nasal discharge, and diarrhea.", [["nasal", "ANATOMY", 72, 77], ["Bl", "CHEMICAL", 39, 41], ["anorexia", "DISEASE", 62, 70], ["nasal discharge", "DISEASE", 72, 87], ["diarrhea", "DISEASE", 93, 101], ["nasal", "ORGANISM_SUBDIVISION", 72, 77], ["anorexia", "PROBLEM", 62, 70], ["nasal discharge", "PROBLEM", 72, 87], ["diarrhea", "PROBLEM", 93, 101], ["anorexia", "OBSERVATION", 62, 70], ["nasal", "ANATOMY", 72, 77], ["diarrhea", "OBSERVATION", 93, 101]]], ["Attempts at experimental reproduction of disease using these serotypes have produced only mild illness (Mohanty and Lillie, 1965; Darbyshire et al., 1969) , while other workers were unable to reproduce disease (Klein et al., 1960; Ide et al., 1969) .", [["illness", "DISEASE", 95, 102], ["disease", "PROBLEM", 41, 48], ["mild", "OBSERVATION_MODIFIER", 90, 94], ["illness", "OBSERVATION", 95, 102]]], ["Tury et al. (1978) claim to have produced microscopic changes in the respiratory tract, kidney, liver, intestine, and lymph nodes with a B2 type virus isolated from sheep.", [["respiratory tract", "ANATOMY", 69, 86], ["kidney", "ANATOMY", 88, 94], ["liver", "ANATOMY", 96, 101], ["intestine", "ANATOMY", 103, 112], ["lymph nodes", "ANATOMY", 118, 129], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["kidney", "ORGAN", 88, 94], ["liver", "ORGAN", 96, 101], ["intestine", "ORGAN", 103, 112], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 118, 129], ["B2 type virus", "ORGANISM", 137, 150], ["sheep", "ORGANISM", 165, 170], ["sheep", "SPECIES", 165, 170], ["B2 type virus", "SPECIES", 137, 150], ["sheep", "SPECIES", 165, 170], ["microscopic changes in the respiratory tract, kidney, liver, intestine, and lymph nodes", "PROBLEM", 42, 129], ["a B2 type virus", "PROBLEM", 135, 150], ["microscopic", "OBSERVATION", 42, 53], ["respiratory tract", "ANATOMY", 69, 86], ["kidney", "ANATOMY", 88, 94], ["liver", "ANATOMY", 96, 101], ["intestine", "ANATOMY", 103, 112], ["lymph nodes", "OBSERVATION", 118, 129]]], ["B3 has been isolated from an outbreak of acute respiratory tract disease in feedlot cattle (Lehmkuhl et al., 1975) and has also been associated with a disease syndrome in a beef herd over a 4-year period (Mattson, 1973) .", [["respiratory tract", "ANATOMY", 47, 64], ["acute respiratory tract disease", "DISEASE", 41, 72], ["B3", "GENE_OR_GENE_PRODUCT", 0, 2], ["tract", "ORGANISM_SUBDIVISION", 59, 64], ["B3", "PROTEIN", 0, 2], ["cattle", "SPECIES", 84, 90], ["beef", "SPECIES", 173, 177], ["B3", "SPECIES", 0, 2], ["cattle", "SPECIES", 84, 90], ["beef", "SPECIES", 173, 177], ["acute respiratory tract disease", "PROBLEM", 41, 72], ["a disease syndrome", "PROBLEM", 149, 167], ["outbreak", "OBSERVATION_MODIFIER", 29, 37], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory tract disease", "OBSERVATION", 47, 72], ["disease", "OBSERVATION", 151, 158]]], ["This occurred in 1-to 4-week-old calves and was characterized by ocular and nasal discharge, tympanies, colic, and diarrhea.", [["ocular", "ANATOMY", 65, 71], ["nasal", "ANATOMY", 76, 81], ["colic", "DISEASE", 104, 109], ["diarrhea", "DISEASE", 115, 123], ["calves", "ORGANISM", 33, 39], ["ocular", "ORGAN", 65, 71], ["nasal", "ORGANISM_SUBDIVISION", 76, 81], ["calves", "SPECIES", 33, 39], ["ocular and nasal discharge", "PROBLEM", 65, 91], ["tympanies", "PROBLEM", 93, 102], ["colic", "PROBLEM", 104, 109], ["diarrhea", "PROBLEM", 115, 123], ["ocular", "ANATOMY", 65, 71], ["nasal", "ANATOMY", 76, 81], ["discharge", "OBSERVATION", 82, 91], ["colic", "ANATOMY", 104, 109], ["diarrhea", "OBSERVATION", 115, 123]]], ["Experimental infections of calves with B3 have ranged from no disease (Ide et al., 1969) to clinical disease.", [["infections", "DISEASE", 13, 23], ["calves", "ORGANISM", 27, 33], ["calves", "SPECIES", 27, 33], ["Experimental infections of calves", "PROBLEM", 0, 33], ["B3", "PROBLEM", 39, 41], ["disease", "PROBLEM", 62, 69], ["clinical disease", "PROBLEM", 92, 108], ["infections", "OBSERVATION", 13, 23], ["calves", "ANATOMY", 27, 33], ["no", "UNCERTAINTY", 59, 61], ["disease", "OBSERVATION", 62, 69]]], ["Only mild clinical signs were seen when day-old colostrum-deprived calves were infected with B3 (WBR-1), but areas of col lapse, emphysema, and consolidation were seen in the lungs .", [["calves", "ANATOMY", 67, 73], ["lungs", "ANATOMY", 175, 180], ["emphysema", "DISEASE", 129, 138], ["colostrum", "ORGANISM", 48, 57], ["calves", "ORGANISM", 67, 73], ["WBR-1", "CELL", 97, 102], ["emphysema", "PATHOLOGICAL_FORMATION", 129, 138], ["lungs", "ORGAN", 175, 180], ["calves", "SPECIES", 67, 73], ["B3", "SPECIES", 93, 95], ["mild clinical signs", "PROBLEM", 5, 24], ["WBR", "TEST", 97, 100], ["col lapse", "PROBLEM", 118, 127], ["emphysema", "PROBLEM", 129, 138], ["consolidation", "PROBLEM", 144, 157], ["mild", "OBSERVATION_MODIFIER", 5, 9], ["areas", "OBSERVATION_MODIFIER", 109, 114], ["col lapse", "OBSERVATION", 118, 127], ["emphysema", "OBSERVATION", 129, 138], ["consolidation", "OBSERVATION", 144, 157], ["lungs", "ANATOMY", 175, 180]]], ["Intratracheal inoculation of 3-month-old calves with B3 (FOS-213) pro duced hyperpnea, dyspnea, and anorexia (Lehmkuhl et al., 1975) .Association with DiseaseA number of serotypes have been associated with pneumonoenteritis in calves.", [["Intratracheal", "ANATOMY", 0, 13], ["FOS-213", "CHEMICAL", 57, 64], ["dyspnea", "DISEASE", 87, 94], ["anorexia", "DISEASE", 100, 108], ["pneumonoenteritis", "DISEASE", 206, 223], ["calves", "ORGANISM", 41, 47], ["calves", "ORGANISM", 227, 233], ["calves", "SPECIES", 41, 47], ["calves", "SPECIES", 227, 233], ["Intratracheal inoculation", "TEST", 0, 25], ["B3 (FOS", "TEST", 53, 60], ["pro duced hyperpnea", "PROBLEM", 66, 85], ["dyspnea", "PROBLEM", 87, 94], ["anorexia", "PROBLEM", 100, 108], ["DiseaseA number of serotypes", "PROBLEM", 151, 179], ["pneumonoenteritis in calves", "PROBLEM", 206, 233], ["inoculation", "OBSERVATION", 14, 25], ["hyperpnea", "OBSERVATION", 76, 85], ["dyspnea", "OBSERVATION", 87, 94], ["anorexia", "OBSERVATION", 100, 108], ["serotypes", "OBSERVATION", 170, 179], ["associated with", "UNCERTAINTY", 190, 205], ["pneumonoenteritis", "OBSERVATION", 206, 223], ["calves", "ANATOMY", 227, 233]]], ["This condition occurs mainly in 2-week-old to 4-month-old calves.", [["calves", "ORGANISM", 58, 64], ["calves", "SPECIES", 58, 64], ["calves", "ANATOMY", 58, 64]]], ["Initially, upper respiratory tract signs are seen, quickly followed by increased salivation and diarrhea.", [["upper respiratory tract", "ANATOMY", 11, 34], ["respiratory tract signs", "DISEASE", 17, 40], ["diarrhea", "DISEASE", 96, 104], ["upper", "ORGANISM_SUBDIVISION", 11, 16], ["respiratory tract", "ORGANISM_SUBDIVISION", 17, 34], ["upper respiratory tract signs", "PROBLEM", 11, 40], ["increased salivation", "PROBLEM", 71, 91], ["diarrhea", "PROBLEM", 96, 104], ["upper", "ANATOMY_MODIFIER", 11, 16], ["respiratory tract", "ANATOMY", 17, 34], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["salivation", "OBSERVATION", 81, 91], ["diarrhea", "OBSERVATION", 96, 104]]], ["Following a 1-2-week course, most calves recover, although with a marked loss of condition; however, about 10% develop more severe respiratory signs, and many die.", [["respiratory", "ANATOMY", 131, 142], ["respiratory signs", "DISEASE", 131, 148], ["calves", "ORGANISM", 34, 40], ["calves", "SPECIES", 34, 40], ["a marked loss of condition", "PROBLEM", 64, 90], ["more severe respiratory signs", "PROBLEM", 119, 148], ["marked", "OBSERVATION_MODIFIER", 66, 72], ["loss", "OBSERVATION", 73, 77], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["respiratory signs", "OBSERVATION", 131, 148]]], ["At autopsy the main findings depend on the stage of the disease.", [["the disease", "PROBLEM", 52, 63], ["main", "OBSERVATION_MODIFIER", 15, 19], ["disease", "OBSERVATION", 56, 63]]], ["There is usually a hemorrhagic tracheitis, and lung changes vary from hyperemic through catarrhal pneumonia to a purulent pneumonia, often associ ated with pleurisy and endocarditis (Aldasy et al., 1965) .", [["lung", "ANATOMY", 47, 51], ["hemorrhagic tracheitis", "DISEASE", 19, 41], ["pneumonia", "DISEASE", 98, 107], ["pneumonia", "DISEASE", 122, 131], ["pleurisy", "DISEASE", 156, 164], ["endocarditis", "DISEASE", 169, 181], ["lung", "ORGAN", 47, 51], ["a hemorrhagic tracheitis", "PROBLEM", 17, 41], ["lung changes", "PROBLEM", 47, 59], ["hyperemic through catarrhal pneumonia", "PROBLEM", 70, 107], ["a purulent pneumonia", "PROBLEM", 111, 131], ["pleurisy", "PROBLEM", 156, 164], ["endocarditis", "PROBLEM", 169, 181], ["hemorrhagic", "OBSERVATION_MODIFIER", 19, 30], ["tracheitis", "OBSERVATION", 31, 41], ["lung", "ANATOMY", 47, 51], ["hyperemic", "OBSERVATION_MODIFIER", 70, 79], ["catarrhal", "OBSERVATION_MODIFIER", 88, 97], ["pneumonia", "OBSERVATION", 98, 107], ["purulent", "OBSERVATION_MODIFIER", 113, 121], ["pneumonia", "OBSERVATION", 122, 131], ["pleurisy", "OBSERVATION", 156, 164], ["endocarditis", "OBSERVATION", 169, 181]]], ["Experimental infection of calves with B4 reproduced the syndrome, albeit in a milder form.", [["infection", "DISEASE", 13, 22], ["calves", "ORGANISM", 26, 32], ["calves", "SPECIES", 26, 32], ["Experimental infection of calves", "PROBLEM", 0, 32], ["the syndrome", "PROBLEM", 52, 64], ["infection", "OBSERVATION", 13, 22], ["calves", "ANATOMY", 26, 32], ["syndrome", "OBSERVATION", 56, 64]]], ["Mohanty (1971) carried out experimental infections with B4, B5, and B8.", [["infections", "DISEASE", 40, 50], ["B5", "GENE_OR_GENE_PRODUCT", 60, 62], ["B8", "GENE_OR_GENE_PRODUCT", 68, 70], ["experimental infections with B4, B5, and B8", "PROBLEM", 27, 70], ["infections", "OBSERVATION", 40, 50], ["B8", "ANATOMY", 68, 70]]], ["Calves infected with B4 and B5 had clinical respiratory signs, while those given B8 did not.", [["respiratory", "ANATOMY", 44, 55], ["respiratory signs", "DISEASE", 44, 61], ["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6], ["clinical respiratory signs", "PROBLEM", 35, 61], ["infected", "OBSERVATION", 7, 15], ["B4", "OBSERVATION_MODIFIER", 21, 23], ["respiratory signs", "OBSERVATION", 44, 61]]], ["Some of the calves given B4 and B5 had macroscopic and micro scopic lung changes.", [["lung", "ANATOMY", 68, 72], ["calves", "ORGANISM", 12, 18], ["B5", "CELL", 32, 34], ["lung", "ORGAN", 68, 72], ["calves", "SPECIES", 12, 18], ["macroscopic and micro scopic lung changes", "PROBLEM", 39, 80], ["calves", "ANATOMY", 12, 18], ["micro scopic", "OBSERVATION_MODIFIER", 55, 67], ["lung", "ANATOMY", 68, 72], ["changes", "OBSERVATION", 73, 80]]], ["B4 appears to be the most important pathogenic bovine adenovirus in central Europe (Burki, 1973) .Association with DiseaseIn Australia, B4 (BIL) and B6 (RG) have been isolated from the lungs and noses or calves with pneumonia.", [["lungs", "ANATOMY", 185, 190], ["pneumonia", "DISEASE", 216, 225], ["B4", "GENE_OR_GENE_PRODUCT", 0, 2], ["bovine", "ORGANISM", 47, 53], ["adenovirus", "ORGANISM", 54, 64], ["B4 (BIL)", "GENE_OR_GENE_PRODUCT", 136, 144], ["B6 (RG)", "GENE_OR_GENE_PRODUCT", 149, 156], ["lungs", "ORGAN", 185, 190], ["noses", "ORGANISM_SUBDIVISION", 195, 200], ["calves", "ORGANISM", 204, 210], ["bovine", "SPECIES", 47, 53], ["calves", "SPECIES", 204, 210], ["B4 (BIL)", "TEST", 136, 144], ["B6 (RG)", "PROBLEM", 149, 156], ["pneumonia", "PROBLEM", 216, 225], ["appears to be", "UNCERTAINTY", 3, 16], ["bovine adenovirus", "OBSERVATION", 47, 64], ["central", "ANATOMY_MODIFIER", 68, 75], ["lungs", "ANATOMY", 185, 190], ["noses", "ANATOMY", 195, 200], ["calves", "ANATOMY", 204, 210], ["pneumonia", "OBSERVATION", 216, 225]]], ["The two BIL strains were from the lungs of calves with acute exudative pneumonia, while seven RG strains were from the lungs or noses of calves with varying degrees of penumonia or bronchitis and one RG strain was from a nasal swab of a normal calf.", [["lungs", "ANATOMY", 34, 39], ["lungs", "ANATOMY", 119, 124], ["penumonia", "ANATOMY", 168, 177], ["nasal swab", "ANATOMY", 221, 231], ["acute exudative pneumonia", "DISEASE", 55, 80], ["penumonia", "DISEASE", 168, 177], ["bronchitis", "DISEASE", 181, 191], ["BIL", "GENE_OR_GENE_PRODUCT", 8, 11], ["lungs", "ORGAN", 34, 39], ["calves", "ORGANISM", 43, 49], ["lungs", "ORGAN", 119, 124], ["noses", "ORGANISM_SUBDIVISION", 128, 133], ["calves", "ORGANISM", 137, 143], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 221, 231], ["calf", "ORGANISM_SUBDIVISION", 244, 248], ["calves", "SPECIES", 43, 49], ["calves", "SPECIES", 137, 143], ["calf", "SPECIES", 244, 248], ["The two BIL strains", "PROBLEM", 0, 19], ["acute exudative pneumonia", "PROBLEM", 55, 80], ["seven RG strains", "PROBLEM", 88, 104], ["varying degrees of penumonia", "PROBLEM", 149, 177], ["bronchitis", "PROBLEM", 181, 191], ["one RG strain", "PROBLEM", 196, 209], ["a nasal swab", "TEST", 219, 231], ["BIL", "ANATOMY_MODIFIER", 8, 11], ["strains", "OBSERVATION", 12, 19], ["lungs", "ANATOMY", 34, 39], ["calves", "ANATOMY", 43, 49], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["exudative", "OBSERVATION_MODIFIER", 61, 70], ["pneumonia", "OBSERVATION", 71, 80], ["RG strains", "OBSERVATION", 94, 104], ["lungs", "ANATOMY", 119, 124], ["noses", "ANATOMY", 128, 133], ["calves", "OBSERVATION", 137, 143], ["varying degrees", "OBSERVATION_MODIFIER", 149, 164], ["penumonia", "OBSERVATION", 168, 177], ["bronchitis", "OBSERVATION", 181, 191], ["one", "OBSERVATION_MODIFIER", 196, 199], ["RG strain", "OBSERVATION", 200, 209], ["nasal", "ANATOMY", 221, 226], ["swab", "OBSERVATION", 227, 231], ["normal", "OBSERVATION", 237, 243], ["calf", "ANATOMY", 244, 248]]], ["Following intratracheal inoculation of B4 (BIL) into calves, a mild interstitial pneumonia was induced (Cole, 1971) .Association with DiseaseA virus isolated from the blood of a cow with anorexia, pyrexia, diarrhea, and respiratory signs (Inabaet al., 1968) was designated \"prototype 7\" (Matumotoet al., 1970) .", [["intratracheal", "ANATOMY", 10, 23], ["interstitial", "ANATOMY", 68, 80], ["blood", "ANATOMY", 167, 172], ["respiratory", "ANATOMY", 220, 231], ["interstitial pneumonia", "DISEASE", 68, 90], ["anorexia", "DISEASE", 187, 195], ["pyrexia", "DISEASE", 197, 204], ["diarrhea", "DISEASE", 206, 214], ["respiratory signs", "DISEASE", 220, 237], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["BIL", "GENE_OR_GENE_PRODUCT", 43, 46], ["calves", "ORGANISM", 53, 59], ["DiseaseA virus", "ORGANISM", 134, 148], ["blood", "ORGANISM_SUBSTANCE", 167, 172], ["cow", "ORGANISM_SUBDIVISION", 178, 181], ["calves", "SPECIES", 53, 59], ["cow", "SPECIES", 178, 181], ["DiseaseA virus", "SPECIES", 134, 148], ["cow", "SPECIES", 178, 181], ["intratracheal inoculation of B4 (BIL) into calves", "TREATMENT", 10, 59], ["a mild interstitial pneumonia", "PROBLEM", 61, 90], ["DiseaseA virus", "PROBLEM", 134, 148], ["anorexia", "PROBLEM", 187, 195], ["pyrexia", "PROBLEM", 197, 204], ["diarrhea", "PROBLEM", 206, 214], ["respiratory signs", "PROBLEM", 220, 237], ["intratracheal", "ANATOMY", 10, 23], ["inoculation", "OBSERVATION", 24, 35], ["calves", "ANATOMY", 53, 59], ["mild", "OBSERVATION_MODIFIER", 63, 67], ["interstitial", "ANATOMY_MODIFIER", 68, 80], ["pneumonia", "OBSERVATION", 81, 90], ["anorexia", "OBSERVATION", 187, 195], ["pyrexia", "OBSERVATION", 197, 204], ["diarrhea", "OBSERVATION", 206, 214], ["respiratory", "ANATOMY", 220, 231]]], ["Adenoviruses have also been isolated from cases of enzootic pneu monia in calves.", [["Adenoviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["calves", "ORGANISM", 74, 80], ["calves", "SPECIES", 74, 80], ["enzootic pneu monia", "SPECIES", 51, 70], ["Adenoviruses", "TREATMENT", 0, 12], ["enzootic pneu monia in calves", "PROBLEM", 51, 80], ["enzootic", "OBSERVATION_MODIFIER", 51, 59], ["pneu monia", "OBSERVATION", 60, 70], ["calves", "ANATOMY", 74, 80]]], ["These include the proposed BIO virus (Kretzschmar, 1973) and untyped isolates (Lupini et al., 1970) . d.", [["BIO virus", "ORGANISM", 27, 36]]], ["Weak Calf Syndrome.", [["Calf", "GENE_OR_GENE_PRODUCT", 5, 9], ["Weak Calf Syndrome", "PROBLEM", 0, 18], ["Calf", "ANATOMY", 5, 9], ["Syndrome", "OBSERVATION", 10, 18]]], ["This syndrome has been described in the United States (Card et al., 1974; Cutlip and McClurkin, 1975) .", [["This syndrome", "PROBLEM", 0, 13]]], ["Calves are usually weak and listless at birth, with a locomotor disturbance due to a polyarthritis, and often have diarrhea.", [["locomotor disturbance", "DISEASE", 54, 75], ["polyarthritis", "DISEASE", 85, 98], ["diarrhea", "DISEASE", 115, 123], ["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6], ["a locomotor disturbance", "PROBLEM", 52, 75], ["a polyarthritis", "PROBLEM", 83, 98], ["diarrhea", "PROBLEM", 115, 123], ["weak", "OBSERVATION_MODIFIER", 19, 23], ["polyarthritis", "OBSERVATION", 85, 98], ["diarrhea", "OBSERVATION", 115, 123]]], ["At necropsy there is blood-tinged synovial fluid and subcutaneous hemorrhages in the hock, metacarpal, and metatarsal regions.", [["blood", "ANATOMY", 21, 26], ["synovial fluid", "ANATOMY", 34, 48], ["subcutaneous", "ANATOMY", 53, 65], ["hock", "ANATOMY", 85, 89], ["metacarpal", "ANATOMY", 91, 101], ["hemorrhages", "DISEASE", 66, 77], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["synovial fluid", "ORGANISM_SUBSTANCE", 34, 48], ["subcutaneous hemorrhages", "PATHOLOGICAL_FORMATION", 53, 77], ["metacarpal", "MULTI-TISSUE_STRUCTURE", 91, 101], ["metatarsal", "ORGAN", 107, 117], ["blood-tinged synovial fluid", "PROBLEM", 21, 48], ["subcutaneous hemorrhages in the hock, metacarpal, and metatarsal regions", "PROBLEM", 53, 125], ["blood", "ANATOMY", 21, 26], ["tinged", "OBSERVATION_MODIFIER", 27, 33], ["synovial fluid", "OBSERVATION", 34, 48], ["subcutaneous", "ANATOMY", 53, 65], ["hemorrhages", "OBSERVATION", 66, 77], ["hock", "ANATOMY", 85, 89], ["metacarpal", "ANATOMY", 91, 101], ["metatarsal", "ANATOMY", 107, 117], ["regions", "ANATOMY_MODIFIER", 118, 125]]], ["Mortality is 6-15% of calves in the herd.Association with DiseaseB5 viruses have been isolated from the synovial fluid ) and a B7 type virus from the buffy coat (Stauber et al., 1976) .", [["synovial fluid", "ANATOMY", 104, 118], ["buffy coat", "ANATOMY", 150, 160], ["calves", "ORGANISM", 22, 28], ["herd", "ORGANISM_SUBDIVISION", 36, 40], ["DiseaseB5", "GENE_OR_GENE_PRODUCT", 58, 67], ["synovial fluid", "ORGANISM_SUBSTANCE", 104, 118], ["calves", "SPECIES", 22, 28], ["B7 type virus", "SPECIES", 127, 140], ["Mortality", "TEST", 0, 9], ["DiseaseB5 viruses", "PROBLEM", 58, 75], ["the synovial fluid", "TEST", 100, 118], ["a B7 type virus", "PROBLEM", 125, 140], ["6-15", "OBSERVATION_MODIFIER", 13, 17], ["synovial", "ANATOMY", 104, 112], ["fluid", "OBSERVATION", 113, 118]]], ["Experimental inocula tions of calves with the B5 (Idaho) isolate resulted in a mild self-limiting illness, with pyrexia and mild diarrhea.", [["self-limiting illness", "DISEASE", 84, 105], ["pyrexia", "DISEASE", 112, 119], ["diarrhea", "DISEASE", 129, 137], ["calves", "ORGANISM", 30, 36], ["calves", "SPECIES", 30, 36], ["a mild self-limiting illness", "PROBLEM", 77, 105], ["pyrexia", "PROBLEM", 112, 119], ["mild diarrhea", "PROBLEM", 124, 137], ["inocula tions", "OBSERVATION", 13, 26], ["calves", "ANATOMY", 30, 36], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["self-limiting", "OBSERVATION_MODIFIER", 84, 97], ["mild", "OBSERVATION_MODIFIER", 124, 128], ["diarrhea", "OBSERVATION", 129, 137]]], ["Following intraveneous infection, lesions devel oped which closely resembled the natural disease seen in Idaho and Montana.", [["lesions", "ANATOMY", 34, 41], ["intraveneous infection", "DISEASE", 10, 32], ["lesions", "PATHOLOGICAL_FORMATION", 34, 41], ["intraveneous infection", "PROBLEM", 10, 32], ["lesions", "PROBLEM", 34, 41], ["the natural disease", "PROBLEM", 77, 96], ["infection", "OBSERVATION", 23, 32], ["lesions", "OBSERVATION", 34, 41], ["natural disease", "OBSERVATION", 81, 96]]], ["It has been suggested that this condition may be due to interaction of cold wet weather, bovine viral diarrhea, and adenovirus McClurkin and Coria, 1975) .DiagnosisMost isolations of bovine adenoviruses have been made in either calf kidney (CK) or calf testes (CT) cells.", [["kidney", "ANATOMY", 233, 239], ["CK", "ANATOMY", 241, 243], ["calf testes (CT) cells", "ANATOMY", 248, 270], ["viral diarrhea", "DISEASE", 96, 110], ["bovine", "ORGANISM", 89, 95], ["adenovirus", "ORGANISM", 116, 126], ["bovine", "ORGANISM", 183, 189], ["adenoviruses", "ORGANISM", 190, 202], ["calf", "ORGANISM", 228, 232], ["kidney", "ORGAN", 233, 239], ["CK", "GENE_OR_GENE_PRODUCT", 241, 243], ["calf testes (CT) cells", "CELL", 248, 270], ["calf kidney (CK) or calf testes (CT) cells", "CELL_TYPE", 228, 270], ["bovine", "SPECIES", 89, 95], ["bovine", "SPECIES", 183, 189], ["calf", "SPECIES", 228, 232], ["calf", "SPECIES", 248, 252], ["bovine", "SPECIES", 183, 189], ["cold wet weather", "PROBLEM", 71, 87], ["bovine viral diarrhea", "PROBLEM", 89, 110], ["bovine adenoviruses", "PROBLEM", 183, 202], ["CK) or calf testes (CT) cells", "TEST", 241, 270], ["bovine adenoviruses", "OBSERVATION", 183, 202], ["calf", "ANATOMY_MODIFIER", 228, 232], ["kidney", "ANATOMY", 233, 239], ["calf testes", "ANATOMY", 248, 259]]], ["However, these cells are not necessarily the most sensitive.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["not necessarily", "UNCERTAINTY", 25, 40]]], ["Thus Stauber et al. (1976) had the highest titers (10 7 ) for B7 in calf salivary gland cells, and Coria et al. (1975) found that B4 and B5 grew well in bovine turbinate cells.DiagnosisOne difficulty is that many bovine isolates (including subgroup A) required 20-50 days of incubation before a good CPE was observed.", [["salivary gland cells", "ANATOMY", 73, 93], ["turbinate cells", "ANATOMY", 160, 175], ["B7", "GENE_OR_GENE_PRODUCT", 62, 64], ["calf", "ORGANISM", 68, 72], ["salivary gland cells", "CELL", 73, 93], ["B4", "CELL", 130, 132], ["bovine", "ORGANISM", 153, 159], ["turbinate cells", "CELL", 160, 175], ["bovine", "ORGANISM", 213, 219], ["B7", "PROTEIN", 62, 64], ["calf salivary gland cells", "CELL_TYPE", 68, 93], ["bovine turbinate cells", "CELL_TYPE", 153, 175], ["calf", "SPECIES", 68, 72], ["bovine", "SPECIES", 153, 159], ["bovine", "SPECIES", 213, 219], ["bovine", "SPECIES", 213, 219], ["B7 in calf salivary gland cells", "PROBLEM", 62, 93], ["B4 and B5", "TEST", 130, 139], ["many bovine isolates", "PROBLEM", 208, 228], ["incubation", "TREATMENT", 275, 285], ["calf", "ANATOMY", 68, 72], ["salivary gland", "ANATOMY", 73, 87], ["B4", "ANATOMY", 130, 132], ["bovine turbinate cells", "OBSERVATION", 153, 175]]], ["Part of the difficulty may be that the CPE depends on the multiplicity of infections, as even with recognized isolates, tubes near the end point may take up to 17 days to produce a discernible CPE (Coriace//., 1975; Lehmkuhlef al., 1975) .", [["infections", "DISEASE", 74, 84], ["the CPE", "PROBLEM", 35, 42], ["infections", "PROBLEM", 74, 84], ["tubes", "TREATMENT", 120, 125], ["a discernible CPE", "PROBLEM", 179, 196], ["infections", "OBSERVATION", 74, 84], ["CPE", "OBSERVATION", 193, 196]]], ["Elazhary and Derbyshire (1978) found that higher titers of B3 were obtained if they were grown in suspension cultures of MDBK cells and suggested that the virus might have a preference for young, actively dividing cells.", [["MDBK cells", "ANATOMY", 121, 131], ["cells", "ANATOMY", 214, 219], ["B3", "GENE_OR_GENE_PRODUCT", 59, 61], ["MDBK cells", "CELL", 121, 131], ["cells", "CELL", 214, 219], ["B3", "PROTEIN", 59, 61], ["suspension cultures", "CELL_LINE", 98, 117], ["MDBK cells", "CELL_LINE", 121, 131], ["young, actively dividing cells", "CELL_TYPE", 189, 219], ["MDBK", "SPECIES", 121, 125], ["higher titers of B3", "PROBLEM", 42, 61], ["suspension cultures", "TEST", 98, 117], ["MDBK cells", "PROBLEM", 121, 131], ["the virus", "PROBLEM", 151, 160]]], ["This is of interest because a similar observation has been made for sheep adenoviruses (McFerran et al., 1971b) .", [["sheep", "ORGANISM", 68, 73], ["adenoviruses", "ORGANISM", 74, 86], ["sheep", "SPECIES", 68, 73], ["sheep", "SPECIES", 68, 73]]], ["It is therefore suggested that suspected specimens be passaged in freshly dispersed cells.DiagnosisThe observation that B3 grows in bovine trach\u00e9al organ culture is of interest (Bouffard and Derbyshire, 1978) , not only because the virus was shown to replicate only in cells of epithelial origin but also because of its potential use in diagnosis.", [["specimens", "ANATOMY", 41, 50], ["cells", "ANATOMY", 84, 89], ["trach\u00e9al organ culture", "ANATOMY", 139, 161], ["cells", "ANATOMY", 269, 274], ["epithelial", "ANATOMY", 278, 288], ["specimens", "CELL", 41, 50], ["cells", "CELL", 84, 89], ["bovine", "ORGANISM", 132, 138], ["cells", "CELL", 269, 274], ["epithelial", "TISSUE", 278, 288], ["freshly dispersed cells", "CELL_TYPE", 66, 89], ["bovine", "SPECIES", 132, 138], ["bovine", "SPECIES", 132, 138], ["B3", "PROBLEM", 120, 122], ["bovine trach\u00e9al organ culture", "TEST", 132, 161], ["the virus", "PROBLEM", 228, 237], ["dispersed cells", "OBSERVATION", 74, 89], ["epithelial origin", "OBSERVATION", 278, 295]]], ["It may well be that bovine trach\u00e9al organ culture will be most useful in isolating not only adenoviruses but also bovine respiratory syncytial virus and bovine coronavirus (Sioii et al., 1976) .ClassificationFive ovine serotypes are recognized (Adair and McFerran, 1976) (Table III) .", [["organ", "ANATOMY", 36, 41], ["respiratory syncytial virus", "DISEASE", 121, 148], ["bovine", "ORGANISM", 20, 26], ["adenoviruses", "ORGANISM", 92, 104], ["bovine", "ORGANISM", 114, 120], ["respiratory syncytial virus", "ORGANISM", 121, 148], ["bovine", "ORGANISM", 153, 159], ["coronavirus", "ORGANISM", 160, 171], ["ovine", "ORGANISM", 213, 218], ["bovine", "SPECIES", 20, 26], ["bovine", "SPECIES", 114, 120], ["respiratory syncytial virus", "SPECIES", 121, 148], ["bovine", "SPECIES", 153, 159], ["coronavirus", "SPECIES", 160, 171], ["bovine", "SPECIES", 20, 26], ["bovine respiratory syncytial virus", "SPECIES", 114, 148], ["bovine coronavirus", "SPECIES", 153, 171], ["bovine trach\u00e9al organ culture", "TEST", 20, 49], ["adenoviruses", "PROBLEM", 92, 104], ["bovine respiratory syncytial virus", "PROBLEM", 114, 148], ["bovine coronavirus", "PROBLEM", 153, 171], ["ClassificationFive ovine serotypes", "PROBLEM", 194, 228], ["respiratory syncytial virus", "OBSERVATION", 121, 148], ["serotypes", "OBSERVATION", 219, 228]]], ["Two isolates (WV419 and WV757) from New Zealand (Davies and Humphreys, 1977b ) may be new serotypes, but this has not yet been confirmed.", [["Two isolates", "TEST", 0, 12], ["new serotypes", "PROBLEM", 86, 99], ["new", "OBSERVATION_MODIFIER", 86, 89], ["serotypes", "OBSERVATION", 90, 99]]], ["They appar ently grow best in lamb testicular cells and may be counterparts of the subgroup 2 bovine adenoviruses.DistributionAdenoviruses have been isolated from sheep in Australia (Showdon, 1971), Hungary (Belak and Palfi, 1974) , New Zealand (Davies and Humphreys, 1977b) , Turkey (Bauer et al., 1975) , and the United Kingdom (McFerran et al., 1971b; Sharp et al., 1974) .", [["testicular cells", "ANATOMY", 35, 51], ["lamb testicular cells", "CELL", 30, 51], ["bovine", "ORGANISM", 94, 100], ["adenoviruses", "ORGANISM", 101, 113], ["Adenoviruses", "GENE_OR_GENE_PRODUCT", 126, 138], ["sheep", "ORGANISM", 163, 168], ["lamb testicular cells", "CELL_TYPE", 30, 51], ["bovine", "SPECIES", 94, 100], ["sheep", "SPECIES", 163, 168], ["sheep", "SPECIES", 163, 168], ["the subgroup 2 bovine adenoviruses", "TREATMENT", 79, 113], ["DistributionAdenoviruses", "PROBLEM", 114, 138], ["lamb testicular cells", "OBSERVATION", 30, 51]]], ["Little immunoprecipitin antibody is detectable (Darbyshire and Pereira, 1964; Timoney, 1971) , but virus-neutralizing antibody is wide spread.Epidemiology and PathogenesisThese viruses have been isolated from both nasal swabs and feces.", [["nasal swabs", "ANATOMY", 214, 225], ["feces", "ANATOMY", 230, 235], ["immunoprecipitin antibody", "GENE_OR_GENE_PRODUCT", 7, 32], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 214, 225], ["feces", "ORGANISM_SUBSTANCE", 230, 235], ["immunoprecipitin antibody", "PROTEIN", 7, 32], ["Little immunoprecipitin antibody", "TEST", 0, 32], ["Darbyshire", "TEST", 48, 58], ["Pereira", "TEST", 63, 70], ["Timoney", "TEST", 78, 85], ["virus", "TEST", 99, 104], ["neutralizing antibody", "TEST", 105, 126], ["These viruses", "PROBLEM", 171, 184], ["immunoprecipitin antibody", "OBSERVATION", 7, 32], ["wide", "OBSERVATION_MODIFIER", 130, 134], ["spread", "OBSERVATION_MODIFIER", 135, 141], ["viruses", "OBSERVATION", 177, 184], ["nasal swabs", "ANATOMY", 214, 225], ["feces", "OBSERVATION", 230, 235]]], ["Following experimental infection, one strain was isolated from the respiratory tract for 7 days, from the intestine for 10 days, and from the kidney for up to 14 days (Davies and Humphreys, 1977a ).", [["respiratory tract", "ANATOMY", 67, 84], ["intestine", "ANATOMY", 106, 115], ["kidney", "ANATOMY", 142, 148], ["infection", "DISEASE", 23, 32], ["respiratory tract", "ORGANISM_SUBDIVISION", 67, 84], ["intestine", "ORGAN", 106, 115], ["kidney", "ORGAN", 142, 148], ["experimental infection", "PROBLEM", 10, 32], ["one strain", "PROBLEM", 34, 44], ["infection", "OBSERVATION", 23, 32], ["respiratory tract", "ANATOMY", 67, 84], ["intestine", "ANATOMY", 106, 115], ["kidney", "ANATOMY", 142, 148]]], ["It appears that sheep can be infected not only with ovine adenoviruses but also with bovine strains (Belak and Palfi, 1974) .Association with DiseaseViruses have been isolated from clinically normal sheep (McFerran et ai, 1971b; Bauer et al., 1975; Davies and Humphreys, 1977b) , from sheep with diarrhea (McFerran et al., 1971b) , and from respiratory tract disease in inten sively reared lambs (Belak and Palfi, 1974; Sharper al., 1974) .", [["respiratory tract", "ANATOMY", 341, 358], ["diarrhea", "DISEASE", 296, 304], ["respiratory tract disease", "DISEASE", 341, 366], ["sheep", "ORGANISM", 16, 21], ["ovine adenoviruses", "ORGANISM", 52, 70], ["bovine", "ORGANISM", 85, 91], ["sheep", "ORGANISM", 199, 204], ["sheep", "ORGANISM", 285, 290], ["tract", "ORGANISM_SUBDIVISION", 353, 358], ["lambs", "ORGANISM", 390, 395], ["DiseaseViruses", "PROTEIN", 142, 156], ["sheep", "SPECIES", 16, 21], ["bovine", "SPECIES", 85, 91], ["sheep", "SPECIES", 199, 204], ["sheep", "SPECIES", 285, 290], ["lambs", "SPECIES", 390, 395], ["sheep", "SPECIES", 16, 21], ["ovine", "SPECIES", 52, 57], ["bovine", "SPECIES", 85, 91], ["sheep", "SPECIES", 199, 204], ["sheep", "SPECIES", 285, 290], ["ovine adenoviruses", "PROBLEM", 52, 70], ["bovine strains", "PROBLEM", 85, 99], ["DiseaseViruses", "TREATMENT", 142, 156], ["diarrhea", "PROBLEM", 296, 304], ["respiratory tract disease", "PROBLEM", 341, 366], ["infected", "OBSERVATION", 29, 37], ["diarrhea", "OBSERVATION", 296, 304], ["respiratory tract", "ANATOMY", 341, 358]]], ["Experimental infection has produced equivocal results.", [["infection", "DISEASE", 13, 22], ["Experimental infection", "PROBLEM", 0, 22], ["infection", "OBSERVATION", 13, 22]]], ["Inoculation of 04 into lambs did not produce clinical signs, although the virus replicated and stimulated an antibody response (Sharp et al., 1974) .", [["lambs", "ORGANISM", 23, 28], ["lambs", "SPECIES", 23, 28], ["clinical signs", "PROBLEM", 45, 59], ["the virus", "PROBLEM", 70, 79], ["an antibody response", "TEST", 106, 126]]], ["A similar failure to reproduce disease was recorded for 05 (Bauer et al., 1975) .", [["A similar failure", "PROBLEM", 0, 17], ["disease", "PROBLEM", 31, 38], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["failure", "OBSERVATION", 10, 17]]], ["A New Zealand isolate, WV757, produced a mild illness in 3-to 4-month-old lambs (Davies and Humphreys, 1977a ).Association with DiseaseAn isolate, serologically identical to B2, produced severe respiratory and intestinal signs in colostrum-deprived lambs following an incubation period of 3 days (Belak et al., 1975) .", [["respiratory", "ANATOMY", 194, 205], ["intestinal", "ANATOMY", 210, 220], ["WV757", "CHEMICAL", 23, 28], ["illness", "DISEASE", 46, 53], ["respiratory and intestinal signs", "DISEASE", 194, 226], ["lambs", "ORGANISM", 74, 79], ["intestinal", "ORGAN", 210, 220], ["colostrum", "ORGANISM", 230, 239], ["lambs", "ORGANISM", 249, 254], ["lambs", "SPECIES", 74, 79], ["a mild illness", "PROBLEM", 39, 53], ["DiseaseAn isolate", "PROBLEM", 128, 145], ["severe respiratory and intestinal signs in colostrum", "PROBLEM", 187, 239], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["illness", "OBSERVATION", 46, 53], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["respiratory", "ANATOMY", 194, 205], ["intestinal", "ANATOMY", 210, 220], ["signs", "OBSERVATION", 221, 226]]], ["Furthermore, in-contact lambs also became ill.", [["lambs", "ORGANISM", 24, 29], ["ill", "PROBLEM", 42, 45], ["ill", "OBSERVATION", 42, 45]]], ["The main pathological lesion was a catarrhal pneumonia./.", [["lesion", "ANATOMY", 22, 28], ["pneumonia", "DISEASE", 45, 54], ["The main pathological lesion", "PROBLEM", 0, 28], ["a catarrhal pneumonia", "PROBLEM", 33, 54], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pathological", "OBSERVATION_MODIFIER", 9, 21], ["lesion", "OBSERVATION", 22, 28], ["catarrhal", "OBSERVATION_MODIFIER", 35, 44], ["pneumonia", "OBSERVATION", 45, 54]]], ["ClassificationTwo adenoviruses, 1-435 and 2-480, which on the basis of the serum neutrali zation (SN) test are distinct serotypes, have been isolated from goats (Gibbs et al., 1977) .DistributionNeutralizing antibody to a caprine adenovirus (435) was found to be wide spread in goat, sheep, and cattle sera both in Nigeria and in England (Gibbs et al., 1977) .", [["serum", "ANATOMY", 75, 80], ["sera", "ANATOMY", 302, 306], ["1-435 and 2-480", "CHEMICAL", 32, 47], ["adenoviruses", "ORGANISM", 18, 30], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["goats", "ORGANISM", 155, 160], ["caprine adenovirus", "ORGANISM", 222, 240], ["goat", "ORGANISM", 278, 282], ["sheep", "ORGANISM", 284, 289], ["cattle", "ORGANISM", 295, 301], ["sera", "ORGANISM_SUBSTANCE", 302, 306], ["Neutralizing antibody", "PROTEIN", 195, 216], ["goats", "SPECIES", 155, 160], ["caprine", "SPECIES", 222, 229], ["goat", "SPECIES", 278, 282], ["sheep", "SPECIES", 284, 289], ["cattle", "SPECIES", 295, 301], ["goats", "SPECIES", 155, 160], ["caprine", "SPECIES", 222, 229], ["goat", "SPECIES", 278, 282], ["sheep", "SPECIES", 284, 289], ["cattle", "SPECIES", 295, 301], ["Two adenoviruses", "TEST", 14, 30], ["the serum neutrali zation", "TREATMENT", 71, 96], ["distinct serotypes", "PROBLEM", 111, 129], ["Neutralizing antibody", "TEST", 195, 216], ["a caprine adenovirus", "TEST", 220, 240], ["cattle sera", "TEST", 295, 306], ["adenoviruses", "OBSERVATION", 18, 30], ["distinct", "OBSERVATION_MODIFIER", 111, 119], ["serotypes", "OBSERVATION", 120, 129], ["Neutralizing antibody", "OBSERVATION", 195, 216], ["wide", "OBSERVATION_MODIFIER", 263, 267], ["spread", "OBSERVATION", 268, 274]]], ["It is not known if the antibody in sheep and cattle is due to infection with 435 virus or to the broad antigenicity of 435-detecting antibody to other adenoviruses.Epidemiology and Pathog\u00e8ne sisNo information is available.Association with DiseasesThese viruses were isolated in lamb kidney cells from the intestines of goats with peste des petit ruminants in Nigeria.", [["kidney cells", "ANATOMY", 283, 295], ["intestines", "ANATOMY", 305, 315], ["infection", "DISEASE", 62, 71], ["sheep", "ORGANISM", 35, 40], ["cattle", "ORGANISM", 45, 51], ["435 virus", "ORGANISM", 77, 86], ["adenoviruses", "ORGANISM", 151, 163], ["lamb kidney cells", "CELL", 278, 295], ["intestines", "ORGAN", 305, 315], ["goats", "ORGANISM", 319, 324], ["lamb kidney cells", "CELL_TYPE", 278, 295], ["sheep", "SPECIES", 35, 40], ["cattle", "SPECIES", 45, 51], ["lamb", "SPECIES", 278, 282], ["goats", "SPECIES", 319, 324], ["sheep", "SPECIES", 35, 40], ["cattle", "SPECIES", 45, 51], ["lamb", "SPECIES", 278, 282], ["goats", "SPECIES", 319, 324], ["peste des petit ruminants", "SPECIES", 330, 355], ["the antibody in sheep", "PROBLEM", 19, 40], ["infection", "PROBLEM", 62, 71], ["435 virus", "PROBLEM", 77, 86], ["the broad antigenicity", "TEST", 93, 115], ["other adenoviruses", "PROBLEM", 145, 163], ["Diseases", "PROBLEM", 239, 247], ["These viruses", "PROBLEM", 247, 260], ["lamb kidney cells", "TREATMENT", 278, 295], ["not known", "UNCERTAINTY", 6, 15], ["infection", "OBSERVATION", 62, 71], ["viruses", "OBSERVATION", 253, 260], ["lamb kidney cells", "OBSERVATION", 278, 295], ["intestines", "ANATOMY", 305, 315]]], ["They are not thought to have any part in the etiology of this condition (Gibbs et al., 1977) .Association with DiseasesIt is probable that goat cells are at least as sensitive to infection as lamb cells.", [["cells", "ANATOMY", 144, 149], ["lamb cells", "ANATOMY", 192, 202], ["infection", "DISEASE", 179, 188], ["goat", "ORGANISM", 139, 143], ["cells", "CELL", 144, 149], ["lamb cells", "CELL", 192, 202], ["goat cells", "CELL_TYPE", 139, 149], ["lamb cells", "CELL_TYPE", 192, 202], ["goat", "SPECIES", 139, 143], ["goat", "SPECIES", 139, 143], ["lamb", "SPECIES", 192, 196], ["Diseases", "PROBLEM", 111, 119], ["goat cells", "PROBLEM", 139, 149], ["infection as lamb cells", "PROBLEM", 179, 202], ["Diseases", "OBSERVATION", 111, 119], ["probable", "UNCERTAINTY", 125, 133], ["goat cells", "OBSERVATION", 139, 149], ["infection", "OBSERVATION", 179, 188], ["lamb cells", "OBSERVATION", 192, 202]]], ["Isolate 435 did not produce a CPE in bovine kidney, BHK21, or Vero cells (Gibbs et al., 1977) .ClassificationFour serotypes are recognized (Table IV) .", [["kidney", "ANATOMY", 44, 50], ["BHK21", "ANATOMY", 52, 57], ["Vero cells", "ANATOMY", 62, 72], ["bovine", "ORGANISM", 37, 43], ["kidney", "ORGAN", 44, 50], ["BHK21", "CELL", 52, 57], ["Vero cells", "CELL", 62, 72], ["BHK21", "CELL_LINE", 52, 57], ["Vero cells", "CELL_LINE", 62, 72], ["bovine", "SPECIES", 37, 43], ["bovine", "SPECIES", 37, 43], ["Isolate", "TEST", 0, 7], ["a CPE in bovine kidney", "PROBLEM", 28, 50], ["BHK21", "PROBLEM", 52, 57], ["Vero cells", "PROBLEM", 62, 72], ["CPE", "OBSERVATION", 30, 33], ["kidney", "ANATOMY", 44, 50], ["Vero cells", "OBSERVATION", 62, 72], ["serotypes", "OBSERVATION", 114, 123]]], ["The relationship between these strains is clear-cut (Derbyshire et al., 1975; Adair and McFerran, 1976) .", [["clear", "OBSERVATION", 42, 47]]], ["Derbyshire et al. (1975) suggested that strain 100 should be considered a new serotype.", [["a new serotype", "PROBLEM", 72, 86]]], ["They also described strains of broad antigenicity.", [["broad antigenicity", "PROBLEM", 31, 49], ["broad", "OBSERVATION_MODIFIER", 31, 36], ["antigenicity", "OBSERVATION_MODIFIER", 37, 49]]], ["A French isolate, not related to the four recognized serotypes, has also been described, but full cross neutralization tests were not undertaken (Chappuis and Tektoff, 1975) .DistributionPorcine adenoviruses are widely distributed.", [["adenoviruses", "ORGANISM", 195, 207], ["A French isolate", "TREATMENT", 0, 16], ["full cross neutralization tests", "TEST", 93, 124], ["DistributionPorcine adenoviruses", "PROBLEM", 175, 207], ["not related to", "UNCERTAINTY", 18, 32], ["serotypes", "OBSERVATION", 53, 62], ["adenoviruses", "OBSERVATION", 195, 207], ["widely", "OBSERVATION_MODIFIER", 212, 218], ["distributed", "OBSERVATION_MODIFIER", 219, 230]]], ["Thus 20% of sera examined from Bulgarian and Hungarian pigs had group antibody (Guenov and Bodon, 1976) , and 18% of Australian pig sera tested had type antibody to a local isolate (Kwon and Spradbrow, 1971 ).", [["sera", "ANATOMY", 12, 16], ["sera", "ANATOMY", 132, 136], ["sera", "ORGANISM_SUBSTANCE", 12, 16], ["pigs", "ORGANISM", 55, 59], ["pig", "ORGANISM", 128, 131], ["sera", "ORGANISM_SUBSTANCE", 132, 136], ["type antibody", "PROTEIN", 148, 161], ["pigs", "SPECIES", 55, 59], ["pig", "SPECIES", 128, 131], ["pig", "SPECIES", 128, 131], ["sera", "TEST", 12, 16], ["group antibody", "TEST", 64, 78], ["Australian pig sera", "TEST", 117, 136], ["type antibody", "PROBLEM", 148, 161]]], ["Antibody to types 1-3 was widespread in England (Clarke et al., 1967), and Bibrack (1970) demonstrated that antibody to type 4 was common in Bavarian pigs.PathogenesisSerotypes 1-3 and eight field isolates (including potential serotype 5) all appear to have a predilection for the alimentary tract (Derbyshire et al., 1975) .", [["alimentary tract", "ANATOMY", 281, 297], ["antibody to type 4", "GENE_OR_GENE_PRODUCT", 108, 126], ["pigs", "ORGANISM", 150, 154], ["alimentary tract", "ORGANISM_SUBDIVISION", 281, 297], ["pigs", "SPECIES", 150, 154], ["Bavarian pigs", "SPECIES", 141, 154], ["Antibody to types", "TEST", 0, 17], ["antibody", "TEST", 108, 116], ["PathogenesisSerotypes", "TEST", 155, 176], ["alimentary tract", "ANATOMY", 281, 297]]], ["Even following intranasal or aerosol exposure, the main site of replication was the alimentary tract, although virus was also recovered from the respiratory tract (Sharpe and Jesse\u00ab, 1967; Jericho^al., 1971 ).PathogenesisP4 appears able to grow in a wider variety of tissues, including the nervous, respiratory, and alimentary tracts.", [["alimentary tract", "ANATOMY", 84, 100], ["respiratory tract", "ANATOMY", 145, 162], ["tissues", "ANATOMY", 267, 274], ["nervous", "ANATOMY", 290, 297], ["respiratory", "ANATOMY", 299, 310], ["alimentary tracts", "ANATOMY", 316, 333], ["respiratory, and alimentary tracts", "DISEASE", 299, 333], ["alimentary tract", "ORGAN", 84, 100], ["respiratory tract", "ORGANISM_SUBDIVISION", 145, 162], ["tissues", "TISSUE", 267, 274], ["nervous", "ANATOMICAL_SYSTEM", 290, 297], ["alimentary tracts", "MULTI-TISSUE_STRUCTURE", 316, 333], ["PathogenesisP4", "PROTEIN", 209, 223], ["intranasal", "TREATMENT", 15, 25], ["aerosol exposure", "TREATMENT", 29, 45], ["virus", "PROBLEM", 111, 116], ["main", "OBSERVATION_MODIFIER", 51, 55], ["replication", "OBSERVATION", 64, 75], ["alimentary tract", "ANATOMY", 84, 100], ["virus", "OBSERVATION", 111, 116], ["respiratory tract", "ANATOMY", 145, 162], ["nervous", "ANATOMY", 290, 297], ["respiratory", "ANATOMY", 299, 310], ["alimentary tracts", "ANATOMY", 316, 333]]], ["Furthermore, it can be reisolated for up to 48 days following infection.", [["infection", "DISEASE", 62, 71], ["infection", "PROBLEM", 62, 71], ["infection", "OBSERVATION", 62, 71]]], ["As the virus was more widely distributed following intranasal than oral infection, it has been suggested that aerial transmission is important in* the spread of this virus (Shadduck<?f al., 1968) .", [["oral", "ANATOMY", 67, 71], ["oral infection", "DISEASE", 67, 81], ["oral", "ORGANISM_SUBDIVISION", 67, 71], ["the virus", "PROBLEM", 3, 12], ["intranasal than oral infection", "PROBLEM", 51, 81], ["this virus", "PROBLEM", 161, 171], ["virus", "OBSERVATION", 7, 12], ["more widely", "OBSERVATION_MODIFIER", 17, 28], ["infection", "OBSERVATION", 72, 81]]], ["Derbyshire et al. (1975) \" Based on Adair (1976) . h But the strain tested was later found contaminated with a hemagglutinating parvovirus.PathogenesisOne feature of pig adenoviruses has been the number of reported isolations made from cell cultures of apparently healthy pigs (K\u00f6hler and Apodaca, 1966; Mahnel and Bibrack, 1966; Rasmussen, 1969; Kwon and Spradbrow, 1971; Kawamura et al., 1972; Chappuis and Tektoff, 1975) .", [["cell cultures", "ANATOMY", 236, 249], ["hemagglutinating parvovirus", "DISEASE", 111, 138], ["hemagglutinating parvovirus", "ORGANISM", 111, 138], ["pig", "ORGANISM", 166, 169], ["adenoviruses", "ORGANISM", 170, 182], ["cell cultures", "CELL", 236, 249], ["pigs", "ORGANISM", 272, 276], ["cell cultures", "CELL_LINE", 236, 249], ["pig", "SPECIES", 166, 169], ["pigs", "SPECIES", 272, 276], ["hemagglutinating parvovirus", "SPECIES", 111, 138], ["pig", "SPECIES", 166, 169], ["the strain", "PROBLEM", 57, 67], ["a hemagglutinating parvovirus", "PROBLEM", 109, 138], ["pig adenoviruses", "PROBLEM", 166, 182], ["cell cultures", "TEST", 236, 249], ["hemagglutinating parvovirus", "OBSERVATION", 111, 138], ["pig adenoviruses", "OBSERVATION", 166, 182]]], ["Bibrack (1970) isolated adenoviruses from 35% of kidneys obtained from pigs at slaughter, and Guenov et al. (1968) found that up to 10% of pig kidneys contained latent adenoviruses.", [["kidneys", "ANATOMY", 49, 56], ["kidneys", "ANATOMY", 143, 150], ["adenoviruses", "ORGANISM", 24, 36], ["kidneys", "ORGAN", 49, 56], ["pigs", "ORGANISM", 71, 75], ["pig", "ORGANISM", 139, 142], ["kidneys", "ORGAN", 143, 150], ["adenoviruses", "ORGANISM", 168, 180], ["pigs", "SPECIES", 71, 75], ["pig", "SPECIES", 139, 142], ["pigs", "SPECIES", 71, 75], ["pig", "SPECIES", 139, 142], ["isolated adenoviruses", "PROBLEM", 15, 36], ["latent adenoviruses", "PROBLEM", 161, 180], ["kidneys", "ANATOMY", 49, 56], ["kidneys", "ANATOMY", 143, 150], ["latent", "OBSERVATION_MODIFIER", 161, 167], ["adenoviruses", "OBSERVATION", 168, 180]]], ["These viruses grew to very low titers.PathogenesisIt is possible that this high incidence of latent infection with adenovirus is responsible for the contamination of hog cholera strains.", [["infection", "DISEASE", 100, 109], ["adenovirus", "ORGANISM", 115, 125], ["hog", "ORGANISM", 166, 169], ["cholera strains", "ORGANISM", 170, 185], ["hog", "SPECIES", 166, 169], ["adenovirus", "SPECIES", 115, 125], ["hog", "SPECIES", 166, 169], ["These viruses", "PROBLEM", 0, 13], ["very low titers", "PROBLEM", 22, 37], ["Pathogenesis", "PROBLEM", 38, 50], ["latent infection", "PROBLEM", 93, 109], ["adenovirus", "PROBLEM", 115, 125], ["hog cholera strains", "PROBLEM", 166, 185], ["viruses", "OBSERVATION", 6, 13], ["very", "OBSERVATION_MODIFIER", 22, 26], ["low titers", "OBSERVATION_MODIFIER", 27, 37], ["is possible", "UNCERTAINTY", 53, 64], ["high", "OBSERVATION_MODIFIER", 75, 79], ["latent", "OBSERVATION_MODIFIER", 93, 99], ["infection", "OBSERVATION", 100, 109], ["adenovirus", "OBSERVATION", 115, 125]]], ["Thus Bodon (1966) found that seven supposedly cytopathic strains of hog cholera virus were in fact contaminated with adenovirus.PathogenesisAlthough transplacental passage of pig adenovirus has not been recorded, intrauterine infection of pig fetuses resulted in widespread dissemination of virus and abortion 9 days after infection (Sharpe, 1967) .Association with Diseasea.", [["intrauterine", "ANATOMY", 213, 225], ["fetuses", "ANATOMY", 243, 250], ["cholera virus", "DISEASE", 72, 85], ["intrauterine infection", "DISEASE", 213, 235], ["abortion", "DISEASE", 301, 309], ["infection", "DISEASE", 323, 332], ["hog cholera virus", "ORGANISM", 68, 85], ["adenovirus", "ORGANISM", 117, 127], ["pig", "ORGANISM", 175, 178], ["adenovirus", "ORGANISM", 179, 189], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 213, 225], ["pig", "ORGANISM", 239, 242], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 243, 250], ["hog cholera virus", "SPECIES", 68, 85], ["pig", "SPECIES", 175, 178], ["pig", "SPECIES", 239, 242], ["hog cholera virus", "SPECIES", 68, 85], ["adenovirus", "SPECIES", 117, 127], ["pig", "SPECIES", 175, 178], ["pig", "SPECIES", 239, 242], ["cytopathic strains", "PROBLEM", 46, 64], ["hog cholera virus", "PROBLEM", 68, 85], ["adenovirus", "PROBLEM", 117, 127], ["transplacental passage of pig adenovirus", "PROBLEM", 149, 189], ["intrauterine infection of pig fetuses", "PROBLEM", 213, 250], ["widespread dissemination of virus", "PROBLEM", 263, 296], ["infection", "PROBLEM", 323, 332], ["Diseasea", "PROBLEM", 366, 374], ["cytopathic", "OBSERVATION_MODIFIER", 46, 56], ["pig adenovirus", "OBSERVATION", 175, 189], ["infection", "OBSERVATION", 226, 235], ["pig fetuses", "OBSERVATION", 239, 250], ["widespread", "OBSERVATION_MODIFIER", 263, 273], ["dissemination", "OBSERVATION_MODIFIER", 274, 287], ["virus", "OBSERVATION", 291, 296], ["Diseasea", "OBSERVATION", 366, 374]]], ["Normal Animals.", [["Animals", "OBSERVATION_MODIFIER", 7, 14]]], ["Many adenoviruses have been isolated from normal swine (Derbyshire et al., 1966; Rasmussen, 1969) , in addition to the numerous isolations made from kidney cells grown from healthy pigs.Association with Diseaseb\u00b7 Encephalitis.", [["kidney cells", "ANATOMY", 149, 161], ["Diseaseb\u00b7 Encephalitis", "DISEASE", 203, 225], ["adenoviruses", "ORGANISM", 5, 17], ["kidney cells", "CELL", 149, 161], ["pigs", "ORGANISM", 181, 185], ["kidney cells", "CELL_TYPE", 149, 161], ["swine", "SPECIES", 49, 54], ["pigs", "SPECIES", 181, 185], ["swine", "SPECIES", 49, 54], ["Many adenoviruses", "PROBLEM", 0, 17], ["the numerous isolations", "TREATMENT", 115, 138], ["kidney cells", "PROBLEM", 149, 161], ["Diseaseb\u00b7 Encephalitis", "PROBLEM", 203, 225], ["adenoviruses", "OBSERVATION", 5, 17], ["numerous", "OBSERVATION_MODIFIER", 119, 127], ["isolations", "OBSERVATION", 128, 138], ["kidney", "ANATOMY", 149, 155], ["healthy pigs", "OBSERVATION", 173, 185], ["Diseaseb\u00b7 Encephalitis", "OBSERVATION", 203, 225]]], ["P4 virus was isolated from the brain of a pig with encepha litis (Kasza, 1966) , and encephalitis has been experimentally reproduced follow ing intracerebral inoculation (Shadduck et al., 1967) .", [["brain", "ANATOMY", 31, 36], ["intracerebral", "ANATOMY", 144, 157], ["encepha litis", "DISEASE", 51, 64], ["encephalitis", "DISEASE", 85, 97], ["P4 virus", "ORGANISM", 0, 8], ["brain", "ORGAN", 31, 36], ["pig", "ORGANISM", 42, 45], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 157], ["pig", "SPECIES", 42, 45], ["pig", "SPECIES", 42, 45], ["P4 virus", "PROBLEM", 0, 8], ["encephalitis", "PROBLEM", 85, 97], ["brain", "ANATOMY", 31, 36], ["encepha litis", "OBSERVATION", 51, 64], ["encephalitis", "OBSERVATION", 85, 97]]], ["Edington et al. (1972) , although producing no clinical signs, did obtain meningoencephalitis and a se vere peritubular mononuclear infiltration of the kidneys in pigs following oral or intranasal inoculation with P4.", [["peritubular mononuclear", "ANATOMY", 108, 131], ["kidneys", "ANATOMY", 152, 159], ["oral", "ANATOMY", 178, 182], ["meningoencephalitis", "DISEASE", 74, 93], ["peritubular mononuclear", "CELL", 108, 131], ["kidneys", "ORGAN", 152, 159], ["pigs", "ORGANISM", 163, 167], ["oral", "ORGANISM_SUBDIVISION", 178, 182], ["pigs", "SPECIES", 163, 167], ["pigs", "SPECIES", 163, 167], ["clinical signs", "PROBLEM", 47, 61], ["meningoencephalitis", "PROBLEM", 74, 93], ["a se vere peritubular mononuclear infiltration of the kidneys", "PROBLEM", 98, 159], ["oral or intranasal inoculation with P4", "TREATMENT", 178, 216], ["meningoencephalitis", "OBSERVATION", 74, 93], ["peritubular", "ANATOMY_MODIFIER", 108, 119], ["mononuclear infiltration", "OBSERVATION", 120, 144], ["kidneys", "ANATOMY", 152, 159]]], ["These lesions in the central nervous system (CNS) were not seen until 2 weeks after infection.Association with Diseasec.", [["lesions", "ANATOMY", 6, 13], ["central nervous system", "ANATOMY", 21, 43], ["CNS", "ANATOMY", 45, 48], ["lesions in the central nervous system", "DISEASE", 6, 43], ["infection", "DISEASE", 84, 93], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["central nervous system", "ANATOMICAL_SYSTEM", 21, 43], ["CNS", "ANATOMICAL_SYSTEM", 45, 48], ["These lesions", "PROBLEM", 0, 13], ["infection", "PROBLEM", 84, 93], ["Diseasec", "PROBLEM", 111, 119], ["lesions", "OBSERVATION", 6, 13], ["central", "ANATOMY_MODIFIER", 21, 28], ["nervous system", "ANATOMY", 29, 43], ["CNS", "ANATOMY", 45, 48], ["infection", "OBSERVATION", 84, 93]]], ["Following experimental infection with P4, an interstitial pneumonia was produced in addition to lesions in the kidneys, thyroid, and lymph nodes.", [["interstitial", "ANATOMY", 45, 57], ["lesions", "ANATOMY", 96, 103], ["kidneys", "ANATOMY", 111, 118], ["thyroid", "ANATOMY", 120, 127], ["lymph nodes", "ANATOMY", 133, 144], ["infection", "DISEASE", 23, 32], ["interstitial pneumonia", "DISEASE", 45, 67], ["lesions", "PATHOLOGICAL_FORMATION", 96, 103], ["kidneys", "ORGAN", 111, 118], ["thyroid", "ORGAN", 120, 127], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 133, 144], ["experimental infection", "PROBLEM", 10, 32], ["P4", "TREATMENT", 38, 40], ["an interstitial pneumonia", "PROBLEM", 42, 67], ["lesions in the kidneys, thyroid, and lymph nodes", "PROBLEM", 96, 144], ["infection", "OBSERVATION", 23, 32], ["interstitial", "OBSERVATION_MODIFIER", 45, 57], ["pneumonia", "OBSERVATION", 58, 67], ["lesions", "OBSERVATION", 96, 103], ["kidneys", "ANATOMY", 111, 118], ["thyroid", "ANATOMY", 120, 127], ["lymph nodes", "OBSERVATION", 133, 144]]], ["The cells affected were mostly members of the reticuloendothelial system (Shadduck et al., 1967) .", [["cells", "ANATOMY", 4, 9], ["reticuloendothelial system", "ANATOMY", 46, 72], ["cells", "CELL", 4, 9], ["reticuloendothelial system", "MULTI-TISSUE_STRUCTURE", 46, 72], ["reticuloendothelial system", "ANATOMY", 46, 72]]], ["Bibrack (1970) , in an investigation of natural cases of enzootic pneumonia, did not make many adenovirus isolations.", [["pneumonia", "DISEASE", 66, 75], ["adenovirus", "ORGANISM", 95, 105], ["enzootic pneumonia", "PROBLEM", 57, 75], ["many adenovirus isolations", "TREATMENT", 90, 116], ["enzootic", "OBSERVATION_MODIFIER", 57, 65], ["pneumonia", "OBSERVATION", 66, 75]]], ["Kasza et al. (1969) suggested a synergistic effect between P4 and Mycoplasma hypopneumoniae and drew attention to the difficulties of isolation of the virus even from experimental cases. d.", [["Mycoplasma hypopneumoniae", "DISEASE", 66, 91], ["P4", "SIMPLE_CHEMICAL", 59, 61], ["Mycoplasma hypopneumoniae", "ORGANISM", 66, 91], ["Mycoplasma hypopneumoniae", "SPECIES", 66, 91], ["Mycoplasma hypopneumoniae", "SPECIES", 66, 91], ["a synergistic effect between P4", "PROBLEM", 30, 61], ["Mycoplasma hypopneumoniae", "PROBLEM", 66, 91], ["the virus", "PROBLEM", 147, 156], ["Mycoplasma hypopneumoniae", "OBSERVATION", 66, 91]]], ["Enteritis.", [["Enteritis", "DISEASE", 0, 9], ["Enteritis", "PROBLEM", 0, 9]]], ["The prototype 1 virus was isolated from a case of diarrhea (Haig et al., 1964) , and pigs with diarrhea had intranuclear inclusions in the epitheliai cells of the villi of the ileum and jejunum (Fujiwara^f al., 1968) .", [["epitheliai cells", "ANATOMY", 139, 155], ["villi", "ANATOMY", 163, 168], ["ileum", "ANATOMY", 176, 181], ["jejunum", "ANATOMY", 186, 193], ["diarrhea", "DISEASE", 50, 58], ["diarrhea", "DISEASE", 95, 103], ["pigs", "ORGANISM", 85, 89], ["epitheliai cells", "CELL", 139, 155], ["villi", "MULTI-TISSUE_STRUCTURE", 163, 168], ["ileum", "MULTI-TISSUE_STRUCTURE", 176, 181], ["jejunum", "ORGAN", 186, 193], ["epitheliai cells", "CELL_TYPE", 139, 155], ["pigs", "SPECIES", 85, 89], ["pigs", "SPECIES", 85, 89], ["The prototype 1 virus", "TREATMENT", 0, 21], ["diarrhea", "PROBLEM", 50, 58], ["diarrhea", "PROBLEM", 95, 103], ["intranuclear inclusions", "PROBLEM", 108, 131], ["intranuclear", "OBSERVATION_MODIFIER", 108, 120], ["inclusions", "OBSERVATION", 121, 131], ["epitheliai cells", "OBSERVATION", 139, 155], ["villi", "ANATOMY_MODIFIER", 163, 168], ["ileum", "ANATOMY", 176, 181], ["jejunum", "ANATOMY", 186, 193]]], ["Some workers produced a mild diarrhea when isolates were given orally (Derbyshire et al., 1975) , while others were unsuccessful (Shadduck et al., 1967; Sharpe and Jessen, 1967) .Association with DiseaseFollowing aerosol exposure of P2 (6618), focally distributed intranuclear in clusions and subepithelial lymphoid accumulations were found in epithelial cells of the villi of the jejunum.", [["intranuclear", "ANATOMY", 264, 276], ["clusions", "ANATOMY", 280, 288], ["subepithelial lymphoid", "ANATOMY", 293, 315], ["epithelial cells", "ANATOMY", 344, 360], ["villi", "ANATOMY", 368, 373], ["jejunum", "ANATOMY", 381, 388], ["diarrhea", "DISEASE", 29, 37], ["subepithelial lymphoid", "CELL", 293, 315], ["epithelial cells", "CELL", 344, 360], ["villi", "MULTI-TISSUE_STRUCTURE", 368, 373], ["jejunum", "ORGAN", 381, 388], ["epithelial cells", "CELL_TYPE", 344, 360], ["a mild diarrhea", "PROBLEM", 22, 37], ["DiseaseFollowing aerosol exposure of P2", "TREATMENT", 196, 235], ["focally distributed intranuclear in clusions", "PROBLEM", 244, 288], ["subepithelial lymphoid accumulations", "PROBLEM", 293, 329], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["diarrhea", "OBSERVATION", 29, 37], ["focally", "OBSERVATION_MODIFIER", 244, 251], ["distributed", "OBSERVATION_MODIFIER", 252, 263], ["intranuclear", "OBSERVATION_MODIFIER", 264, 276], ["subepithelial lymphoid accumulations", "OBSERVATION", 293, 329], ["epithelial cells", "OBSERVATION", 344, 360], ["villi", "ANATOMY_MODIFIER", 368, 373], ["jejunum", "ANATOMY", 381, 388]]], ["In the lungs there was an increase of lymphoid tissue in connective tissue at all levels of the bronchial tree, and inclusion bodies were seen within these proliferations (Jericho et al., 1971 ) .DiagnosisPrimary pig kidney (PK) cells are probably the most sensitive, but the P4 strains required up to 42 days in cell cultures before the initial isolation (Shadduck et al., 1968; Kasza et al., 1969) .", [["lungs", "ANATOMY", 7, 12], ["lymphoid tissue", "ANATOMY", 38, 53], ["connective tissue", "ANATOMY", 57, 74], ["bronchial tree", "ANATOMY", 96, 110], ["bodies", "ANATOMY", 126, 132], ["proliferations", "ANATOMY", 156, 170], ["kidney (PK) cells", "ANATOMY", 217, 234], ["cell cultures", "ANATOMY", 313, 326], ["lungs", "ORGAN", 7, 12], ["lymphoid tissue", "TISSUE", 38, 53], ["connective tissue", "TISSUE", 57, 74], ["bronchial tree", "MULTI-TISSUE_STRUCTURE", 96, 110], ["pig", "ORGANISM", 213, 216], ["kidney", "ORGAN", 217, 223], ["PK) cells", "CELL", 225, 234], ["cell cultures", "CELL", 313, 326], ["DiagnosisPrimary pig kidney (PK) cells", "CELL_LINE", 196, 234], ["cell cultures", "CELL_LINE", 313, 326], ["pig", "SPECIES", 213, 216], ["pig", "SPECIES", 213, 216], ["lymphoid tissue in connective tissue", "PROBLEM", 38, 74], ["inclusion bodies", "PROBLEM", 116, 132], ["DiagnosisPrimary pig kidney (PK) cells", "TEST", 196, 234], ["the P4 strains", "PROBLEM", 272, 286], ["cell cultures", "TEST", 313, 326], ["lungs", "ANATOMY", 7, 12], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["lymphoid tissue", "OBSERVATION", 38, 53], ["connective tissue", "OBSERVATION", 57, 74], ["all levels", "ANATOMY_MODIFIER", 78, 88], ["bronchial", "ANATOMY", 96, 105], ["tree", "ANATOMY_MODIFIER", 106, 110], ["inclusion bodies", "OBSERVATION", 116, 132], ["proliferations", "OBSERVATION_MODIFIER", 156, 170], ["kidney", "ANATOMY", 217, 223], ["most sensitive", "OBSERVATION_MODIFIER", 252, 266]]], ["PI, P2, and P3 grew to IO 7 in PK cells (Sharp and Jessett, 1967) , whereas some of the isolates from latently infected cells reached 10 3 at maximum .", [["PK cells", "ANATOMY", 31, 39], ["cells", "ANATOMY", 120, 125], ["latently infected", "DISEASE", 102, 119], ["PI", "SIMPLE_CHEMICAL", 0, 2], ["PK cells", "CELL", 31, 39], ["cells", "CELL", 120, 125], ["P2", "DNA", 4, 6], ["P3", "DNA", 12, 14], ["PK cells", "CELL_LINE", 31, 39], ["latently infected cells", "CELL_TYPE", 102, 125], ["PI", "TEST", 0, 2], ["P2", "TEST", 4, 6], ["P3", "TEST", 12, 14], ["IO", "TEST", 23, 25], ["PK cells", "TEST", 31, 39], ["Sharp", "TEST", 41, 46], ["Jessett", "TEST", 51, 58], ["the isolates", "TEST", 84, 96], ["latently infected cells", "PROBLEM", 102, 125], ["latently", "OBSERVATION_MODIFIER", 102, 110], ["infected cells", "OBSERVATION", 111, 125]]], ["There have been reports that some strains grow in MDCK and in calf, human, and patas monkey kidneys (Kasza, 1966; Chappuis and Tektoff, 1975) .DiagnosisBoth the SN and double immunodiffusion (DID) techniques have been used for detecting antibody.", [["MDCK", "ANATOMY", 50, 54], ["calf", "ANATOMY", 62, 66], ["kidneys", "ANATOMY", 92, 99], ["MDCK", "CELL", 50, 54], ["calf", "ORGANISM_SUBDIVISION", 62, 66], ["human", "ORGANISM", 68, 73], ["monkey", "ORGANISM", 85, 91], ["kidneys", "ORGAN", 92, 99], ["MDCK", "CELL_LINE", 50, 54], ["calf", "SPECIES", 62, 66], ["human", "SPECIES", 68, 73], ["monkey", "SPECIES", 85, 91], ["human", "SPECIES", 68, 73], ["some strains", "PROBLEM", 29, 41], ["double immunodiffusion (DID) techniques", "TREATMENT", 168, 207], ["calf", "ANATOMY", 62, 66], ["kidneys", "ANATOMY", 92, 99]]], ["The SN test can be made more sensitive by adding the virus serum mixture to the cells in suspension and then allowing the monolayer to form (Kwon and Spradbrow, 1971 )./.", [["serum", "ANATOMY", 59, 64], ["cells", "ANATOMY", 80, 85], ["monolayer", "ANATOMY", 122, 131], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["cells", "CELL", 80, 85], ["monolayer", "CELL", 122, 131], ["The SN test", "TEST", 0, 11], ["the virus serum mixture", "TREATMENT", 49, 72]]], ["ClassificationOnly one serotype is recognized.", [["serotype", "OBSERVATION", 23, 31]]], ["However, 16 horses were found in Australia with adenovirus CF antibody but without antibody to El, suggesting that other adenoviruses infect horses (Studdert et al., 1974) .DistributionAntibody surveys indicate that between 10 and 25% of horses have precipitat ing antibody (Darbyshire and Pereira, 1964; Afshar, 1969; Timoney, 1971 ).", [["horses", "ORGANISM", 12, 18], ["adenovirus", "ORGANISM", 48, 58], ["adenoviruses", "ORGANISM", 121, 133], ["horses", "ORGANISM", 141, 147], ["horses", "ORGANISM", 238, 244], ["adenovirus CF antibody", "PROTEIN", 48, 70], ["horses", "SPECIES", 12, 18], ["adenovirus", "SPECIES", 48, 58], ["horses", "SPECIES", 238, 244], ["adenovirus CF antibody", "PROBLEM", 48, 70], ["antibody to El", "PROBLEM", 83, 97], ["other adenoviruses infect horses", "PROBLEM", 115, 147], ["DistributionAntibody surveys", "TEST", 173, 201]]], ["However, using the HI test, 73% of horse sera tested had antibody (Studdert et al., 191 A) .", [["sera", "ANATOMY", 41, 45], ["horse", "ORGANISM", 35, 40], ["sera", "ORGANISM_SUBSTANCE", 41, 45], ["horse", "SPECIES", 35, 40], ["horse", "SPECIES", 35, 40], ["the HI test", "TEST", 15, 26], ["horse sera", "TEST", 35, 45], ["antibody", "TEST", 57, 65]]], ["A comparative study revealed that 100% had SN antibody, 68% had CF antibody, and the immunodiffusion test indicated 19% affected (Harden et al., 1974) .Epidemiology and PathogenesisThere is no direct evidence of carriers or in utero infection, but indirect evidence suggests this possibility.", [["utero infection", "DISEASE", 227, 242], ["SN antibody", "PROTEIN", 43, 54], ["CF antibody", "PROTEIN", 64, 75], ["A comparative study", "TEST", 0, 19], ["SN antibody", "TEST", 43, 54], ["CF antibody", "TEST", 64, 75], ["the immunodiffusion test", "TEST", 81, 105], ["carriers", "PROBLEM", 212, 220], ["utero infection", "PROBLEM", 227, 242], ["no direct evidence of", "UNCERTAINTY", 190, 211], ["carriers", "OBSERVATION", 212, 220], ["utero", "OBSERVATION_MODIFIER", 227, 232], ["infection", "OBSERVATION", 233, 242], ["indirect evidence suggests this possibility", "UNCERTAINTY", 248, 291]]], ["Thus the virus has been recovered from the nasal mucus of a 3-day-old Clydesdale foal (Wilks and Studdert, 1973) .", [["nasal mucus", "ANATOMY", 43, 54], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 43, 54], ["Clydesdale", "ORGANISM", 70, 80], ["foal", "ORGANISM_SUBDIVISION", 81, 85], ["the virus", "PROBLEM", 5, 14], ["virus", "OBSERVATION", 9, 14], ["recovered", "OBSERVATION_MODIFIER", 24, 33], ["nasal mucus", "ANATOMY", 43, 54]]], ["Fur thermore, on four farms during a 4-year observation period, multiple incidences of disease occurred within groups of foals.", [["foals", "ORGANISM", 121, 126], ["disease", "PROBLEM", 87, 94], ["multiple", "OBSERVATION_MODIFIER", 64, 72], ["disease", "OBSERVATION", 87, 94]]], ["One mare gave birth in successive years to three foals that died of pneumonia, indicating not only a genetic defi ciency but also virus persistence .", [["pneumonia", "DISEASE", 68, 77], ["foals", "ORGANISM", 49, 54], ["pneumonia", "PROBLEM", 68, 77], ["a genetic defi ciency", "PROBLEM", 99, 120], ["virus persistence", "PROBLEM", 130, 147], ["pneumonia", "OBSERVATION", 68, 77]]], ["There is often a very high incidence of antibody on farms (Todd, 1969; Studdert et al., 1974) .", [["very", "OBSERVATION_MODIFIER", 17, 21], ["high", "OBSERVATION_MODIFIER", 22, 26]]], ["Foals before suckling had no antibody to adenovirus, which develops after ingestion of colostrum (Harden et al., 1974) .", [["adenovirus", "ORGANISM", 41, 51], ["colostrum", "ORGANISM_SUBSTANCE", 87, 96], ["adenovirus", "SPECIES", 41, 51], ["antibody to adenovirus", "PROBLEM", 29, 51]]], ["Serological studies indicate that reinfection is fre quent, and infection or reinfection can occur in the presence of high levels of circulating antibody.", [["infection", "DISEASE", 64, 73], ["reinfection", "DISEASE", 77, 88], ["circulating antibody", "PROTEIN", 133, 153], ["Serological studies", "TEST", 0, 19], ["reinfection", "PROBLEM", 34, 45], ["infection", "PROBLEM", 64, 73], ["reinfection", "PROBLEM", 77, 88], ["high levels of circulating antibody", "PROBLEM", 118, 153], ["reinfection", "OBSERVATION", 34, 45], ["infection", "OBSERVATION", 64, 73], ["reinfection", "OBSERVATION", 77, 88], ["circulating antibody", "OBSERVATION", 133, 153]]], ["However, subclinical infections appear to occur quite fre quently between 90 and 150 days, when maternal antibody levels have fallen (Harden^\u00ab/., 1974; Studdert^\u00f6/., 1974) .Association with Diseasea.", [["infections", "DISEASE", 21, 31], ["subclinical infections", "PROBLEM", 9, 31], ["maternal antibody levels", "TEST", 96, 120], ["Studdert", "TEST", 152, 160], ["Diseasea", "PROBLEM", 190, 198], ["subclinical", "OBSERVATION_MODIFIER", 9, 20], ["infections", "OBSERVATION", 21, 31], ["Diseasea", "OBSERVATION", 190, 198]]], ["Subclinical Infection in Horses.", [["Subclinical Infection", "DISEASE", 0, 21], ["Subclinical Infection in Horses", "PROBLEM", 0, 31], ["Infection", "OBSERVATION", 12, 21]]], ["In addition, antibody has been found in horses with no history of respiratory tract disease (Darbyshire and Pereira, 1964; Afshar, 1969; Timoney, 1971; Harden^\u00ab/., 1974) .b.", [["respiratory tract", "ANATOMY", 66, 83], ["respiratory tract disease", "DISEASE", 66, 91], ["tract", "ORGANISM_SUBDIVISION", 78, 83], ["Darbyshire and Pereira, 1964; Afshar, 1969; Timoney, 1971; Harden^\u00ab/., 1974) .b.", "SPECIES", 93, 173], ["respiratory tract disease", "PROBLEM", 66, 91], ["respiratory tract", "ANATOMY", 66, 83]]], ["Respiratory TractDisease.", [["Respiratory TractDisease", "DISEASE", 0, 24], ["Respiratory TractDisease", "PROBLEM", 0, 24], ["TractDisease", "OBSERVATION", 12, 24]]], ["An association is emerging between acute, nonfatal respiratory tract disease in horses and equine adenovirus infection.", [["respiratory tract", "ANATOMY", 51, 68], ["respiratory tract disease", "DISEASE", 51, 76], ["adenovirus infection", "DISEASE", 98, 118], ["respiratory tract", "ORGANISM_SUBDIVISION", 51, 68], ["horses", "ORGANISM", 80, 86], ["equine adenovirus", "ORGANISM", 91, 108], ["equine", "SPECIES", 91, 97], ["horses", "SPECIES", 80, 86], ["equine adenovirus", "SPECIES", 91, 108], ["acute, nonfatal respiratory tract disease in horses", "PROBLEM", 35, 86], ["equine adenovirus infection", "PROBLEM", 91, 118], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["nonfatal", "OBSERVATION_MODIFIER", 42, 50], ["respiratory tract disease", "OBSERVATION", 51, 76], ["adenovirus infection", "OBSERVATION", 98, 118]]], ["Virus has been isolated from nasal swabs taken from horses with rhinitis, mucopurulent discharge, and coughing (Todd, 1969; McChesney et al., 1973; Dutta, 1975; Moorthy and Spradbrow, 1978) .b.", [["nasal swabs", "ANATOMY", 29, 40], ["rhinitis", "DISEASE", 64, 72], ["coughing", "DISEASE", 102, 110], ["Virus", "ORGANISM", 0, 5], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 29, 40], ["horses", "ORGANISM_SUBDIVISION", 52, 58], ["Virus", "PROBLEM", 0, 5], ["nasal swabs", "TEST", 29, 40], ["rhinitis", "PROBLEM", 64, 72], ["mucopurulent discharge", "PROBLEM", 74, 96], ["coughing", "PROBLEM", 102, 110], ["nasal", "ANATOMY", 29, 34], ["swabs", "OBSERVATION", 35, 40], ["rhinitis", "OBSERVATION", 64, 72]]], ["Respiratory Tractc.", [["Respiratory Tractc", "TREATMENT", 0, 18], ["Tractc", "OBSERVATION", 12, 18]]], ["Fatal Pneumonia.", [["Pneumonia", "DISEASE", 6, 15], ["Fatal Pneumonia", "PROBLEM", 0, 15], ["Pneumonia", "OBSERVATION", 6, 15]]], ["Foals between 10 and 46 days were affected, and the disease lasted 10-56 days.", [["the disease", "PROBLEM", 48, 59], ["disease", "OBSERVATION", 52, 59]]], ["The foals were thin, depressed, and tired rapidly.", [["depressed", "DISEASE", 21, 30], ["foals", "ORGANISM", 4, 9], ["depressed", "PROBLEM", 21, 30]]], ["Persistent nasal and ocular discharge and occasional diarrhea were evident.", [["nasal", "ANATOMY", 11, 16], ["ocular", "ANATOMY", 21, 27], ["Persistent nasal and ocular discharge", "DISEASE", 0, 37], ["diarrhea", "DISEASE", 53, 61], ["nasal", "ORGAN", 11, 16], ["Persistent nasal and ocular discharge", "PROBLEM", 0, 37], ["occasional diarrhea", "PROBLEM", 42, 61], ["nasal", "ANATOMY", 11, 16], ["ocular", "ANATOMY", 21, 27], ["discharge", "OBSERVATION", 28, 37], ["occasional", "OBSERVATION_MODIFIER", 42, 52], ["diarrhea", "OBSERVATION", 53, 61]]], ["Dys pnea, polypnea, and a nonproductive cough were features Thompson et al., 1975) .", [["polypnea", "DISEASE", 10, 18], ["cough", "DISEASE", 40, 45], ["Dys pnea", "PROBLEM", 0, 8], ["polypnea", "PROBLEM", 10, 18], ["a nonproductive cough", "PROBLEM", 24, 45], ["nonproductive", "OBSERVATION_MODIFIER", 26, 39], ["cough", "OBSERVATION", 40, 45]]], ["Hematological examination revealed an absolute lymphopenia and neutropenia in the foals which died.", [["lymphopenia", "DISEASE", 47, 58], ["neutropenia", "DISEASE", 63, 74], ["foals", "ORGANISM", 82, 87], ["Hematological examination", "TEST", 0, 25], ["an absolute lymphopenia", "PROBLEM", 35, 58], ["neutropenia", "PROBLEM", 63, 74], ["absolute lymphopenia", "OBSERVATION", 38, 58], ["neutropenia", "OBSERVATION", 63, 74]]], ["No HI antobidy could be detected.", [["HI antobidy", "PROBLEM", 3, 14]]], ["In-contact foals were infected with equine adenovirus and developed respiratory signs and HI antibody, but did not show the severe lymphopenia .", [["respiratory", "ANATOMY", 68, 79], ["lymphopenia", "DISEASE", 131, 142], ["foals", "ORGANISM", 11, 16], ["equine", "ORGANISM", 36, 42], ["adenovirus", "ORGANISM", 43, 53], ["HI antibody", "PROTEIN", 90, 101], ["equine", "SPECIES", 36, 42], ["equine adenovirus", "SPECIES", 36, 53], ["equine adenovirus", "PROBLEM", 36, 53], ["respiratory signs", "PROBLEM", 68, 85], ["HI antibody", "TEST", 90, 101], ["the severe lymphopenia", "PROBLEM", 120, 142], ["respiratory", "ANATOMY", 68, 79], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["lymphopenia", "OBSERVATION", 131, 142]]], ["In the foals which died, rhinitis, tracheitis, pulmonary atelectasis, bronchopneumonia, and lymphoid atrophy were seen.", [["pulmonary", "ANATOMY", 47, 56], ["lymphoid", "ANATOMY", 92, 100], ["rhinitis", "DISEASE", 25, 33], ["tracheitis", "DISEASE", 35, 45], ["pulmonary atelectasis", "DISEASE", 47, 68], ["bronchopneumonia", "DISEASE", 70, 86], ["lymphoid atrophy", "DISEASE", 92, 108], ["pulmonary", "ORGAN", 47, 56], ["lymphoid", "ORGAN", 92, 100], ["rhinitis", "PROBLEM", 25, 33], ["tracheitis", "PROBLEM", 35, 45], ["pulmonary atelectasis", "PROBLEM", 47, 68], ["bronchopneumonia", "PROBLEM", 70, 86], ["lymphoid atrophy", "PROBLEM", 92, 108], ["rhinitis", "OBSERVATION", 25, 33], ["tracheitis", "OBSERVATION", 35, 45], ["pulmonary", "ANATOMY", 47, 56], ["atelectasis", "OBSERVATION", 57, 68], ["bronchopneumonia", "OBSERVATION", 70, 86], ["lymphoid atrophy", "OBSERVATION", 92, 108]]], ["Microscopi cally, there was necrosis of and large basophilic intranuclear inclusions in the epithelial cells of the respiratory tract, urinary tract, conjunctiva, pancreas, and focally in the intestine McGuire and Poppie, 1973) .", [["basophilic intranuclear inclusions", "ANATOMY", 50, 84], ["epithelial cells", "ANATOMY", 92, 108], ["respiratory tract", "ANATOMY", 116, 133], ["urinary tract", "ANATOMY", 135, 148], ["conjunctiva", "ANATOMY", 150, 161], ["pancreas", "ANATOMY", 163, 171], ["intestine", "ANATOMY", 192, 201], ["necrosis", "DISEASE", 28, 36], ["epithelial cells", "CELL", 92, 108], ["respiratory tract", "ORGANISM_SUBDIVISION", 116, 133], ["urinary tract", "ORGANISM_SUBDIVISION", 135, 148], ["conjunctiva", "ORGAN", 150, 161], ["pancreas", "ORGAN", 163, 171], ["intestine", "ORGAN", 192, 201], ["epithelial cells", "CELL_TYPE", 92, 108], ["Microscopi cally", "TEST", 0, 16], ["necrosis", "PROBLEM", 28, 36], ["large basophilic intranuclear inclusions", "PROBLEM", 44, 84], ["urinary tract, conjunctiva, pancreas", "PROBLEM", 135, 171], ["necrosis", "OBSERVATION", 28, 36], ["large", "OBSERVATION_MODIFIER", 44, 49], ["basophilic intranuclear inclusions", "OBSERVATION", 50, 84], ["epithelial cells", "OBSERVATION", 92, 108], ["respiratory tract", "ANATOMY", 116, 133], ["urinary tract", "ANATOMY", 135, 148], ["conjunctiva", "ANATOMY", 150, 161], ["pancreas", "ANATOMY", 163, 171], ["focally", "OBSERVATION_MODIFIER", 177, 184], ["intestine", "ANATOMY", 192, 201]]], ["These foals lacked bone marrow-derived (B) lymphocytes, as shown by the lymphopenia and hypogammaglobulinemia (IgM and IgA could not be detected) and by the absence of germinal centers in the lymph nodes and spleen.", [["bone marrow-derived (B) lymphocytes", "ANATOMY", 19, 54], ["germinal centers", "ANATOMY", 168, 184], ["lymph nodes", "ANATOMY", 192, 203], ["spleen", "ANATOMY", 208, 214], ["lymphopenia", "DISEASE", 72, 83], ["hypogammaglobulinemia", "DISEASE", 88, 109], ["foals", "ORGANISM", 6, 11], ["bone marrow-derived (B) lymphocytes", "CELL", 19, 54], ["IgM", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgA", "GENE_OR_GENE_PRODUCT", 119, 122], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 168, 184], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 192, 203], ["spleen", "ORGAN", 208, 214], ["bone marrow-derived (B) lymphocytes", "CELL_TYPE", 19, 54], ["IgM", "PROTEIN", 111, 114], ["IgA", "PROTEIN", 119, 122], ["bone marrow", "TEST", 19, 30], ["the lymphopenia", "PROBLEM", 68, 83], ["hypogammaglobulinemia", "PROBLEM", 88, 109], ["IgM", "TEST", 111, 114], ["IgA", "TEST", 119, 122], ["bone marrow", "OBSERVATION", 19, 30], ["lymphopenia", "OBSERVATION", 72, 83], ["hypogammaglobulinemia", "OBSERVATION", 88, 109], ["germinal centers", "OBSERVATION", 168, 184], ["lymph nodes", "OBSERVATION", 192, 203], ["spleen", "ANATOMY", 208, 214]]], ["They also lacked thymus-derived (T) lymphocytes, as indicated by thymic hypoplasia and the absence of thymic-dependent lymphoid tissue (periarteriolar lymphocytic sheaths) in the lymph nodes and spleen.", [["thymus-derived (T) lymphocytes", "ANATOMY", 17, 47], ["thymic", "ANATOMY", 65, 71], ["thymic", "ANATOMY", 102, 108], ["lymphoid tissue", "ANATOMY", 119, 134], ["periarteriolar lymphocytic sheaths", "ANATOMY", 136, 170], ["lymph nodes", "ANATOMY", 179, 190], ["spleen", "ANATOMY", 195, 201], ["thymic hypoplasia", "DISEASE", 65, 82], ["thymus-derived (T) lymphocytes", "CELL", 17, 47], ["thymic", "ORGAN", 65, 71], ["lymphoid tissue", "TISSUE", 119, 134], ["periarteriolar lymphocytic sheaths", "TISSUE", 136, 170], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 179, 190], ["spleen", "ORGAN", 195, 201], ["thymus-derived (T) lymphocytes", "CELL_TYPE", 17, 47], ["thymic hypoplasia", "PROBLEM", 65, 82], ["thymic-dependent lymphoid tissue", "PROBLEM", 102, 134], ["periarteriolar lymphocytic sheaths", "TREATMENT", 136, 170], ["thymus", "ANATOMY", 17, 23], ["thymic", "ANATOMY", 65, 71], ["hypoplasia", "OBSERVATION", 72, 82], ["thymic", "ANATOMY", 102, 108], ["dependent", "OBSERVATION_MODIFIER", 109, 118], ["lymphoid tissue", "OBSERVATION", 119, 134], ["periarteriolar", "OBSERVATION_MODIFIER", 136, 150], ["lymphocytic sheaths", "OBSERVATION", 151, 170], ["lymph nodes", "OBSERVATION", 179, 190], ["spleen", "ANATOMY", 195, 201]]], ["These immunological deficiencies sug gest that there might be a genetic component of this condition McGuire and Poppie, 1973) .", [["These immunological deficiencies sug", "PROBLEM", 0, 36]]], ["Following a study of the percentage of affected foals in Australia, Thompson et al. (1975) suggested that the immuno deficiency was due to a simple recessive autosomal gene.", [["immuno deficiency", "DISEASE", 110, 127], ["recessive autosomal gene", "DNA", 148, 172], ["a study", "TEST", 10, 17], ["the immuno deficiency", "PROBLEM", 106, 127], ["a simple recessive autosomal gene", "PROBLEM", 139, 172]]], ["These authors consider that the basic reason for the fatal pneumonia is the immunodeficiency and not the adenovirus.DiagnosisThe equine adenovirus differs from most of the other isolates in being able to grow in a range of cells.", [["cells", "ANATOMY", 223, 228], ["pneumonia", "DISEASE", 59, 68], ["immunodeficiency", "DISEASE", 76, 92], ["adenovirus", "ORGANISM", 105, 115], ["equine adenovirus", "ORGANISM", 129, 146], ["cells", "CELL", 223, 228], ["equine adenovirus", "SPECIES", 129, 146], ["the fatal pneumonia", "PROBLEM", 49, 68], ["the immunodeficiency", "PROBLEM", 72, 92], ["the adenovirus", "PROBLEM", 101, 115], ["The equine adenovirus", "TREATMENT", 125, 146], ["fatal", "OBSERVATION_MODIFIER", 53, 58], ["pneumonia", "OBSERVATION", 59, 68]]], ["Primary horse kidney (HK) cells appear the most sensitive.", [["Primary horse kidney (HK) cells", "ANATOMY", 0, 31], ["horse kidney (HK) cells", "CELL", 8, 31], ["Primary horse kidney (HK) cells", "CELL_TYPE", 0, 31], ["horse", "SPECIES", 8, 13], ["Primary horse kidney (HK) cells", "TEST", 0, 31], ["kidney", "ANATOMY", 14, 20], ["most sensitive", "OBSERVATION_MODIFIER", 43, 57]]], ["An equine dermis cell line has been reported equally sensitive (Konishi et al., 1977) and has been used for virus isolation (Ardans et al., 1973) , but other workers have found it less satisfactory Studdert et al., 1974 ).", [["dermis cell line", "ANATOMY", 10, 26], ["equine", "ORGANISM", 3, 9], ["dermis cell line", "CELL", 10, 26], ["equine dermis cell line", "CELL_LINE", 3, 26], ["An equine dermis cell line", "TREATMENT", 0, 26], ["virus isolation", "TREATMENT", 108, 123], ["dermis cell line", "OBSERVATION", 10, 26]]], ["An equine kidney (EK) cell line has also been used for isolation (Moorthy and Spradbrow, 1978) .", [["kidney (EK) cell line", "ANATOMY", 10, 31], ["equine", "ORGANISM", 3, 9], ["kidney", "ORGAN", 10, 16], ["EK) cell line", "CELL", 18, 31], ["equine kidney (EK) cell line", "CELL_LINE", 3, 31], ["An equine kidney (EK) cell line", "TREATMENT", 0, 31], ["kidney", "ANATOMY", 10, 16], ["cell line", "OBSERVATION", 22, 31]]], ["El causes a CPE in a range of cells, fetal PK cells have been shown to be as sensitive as HK cells (Konishi et al., 1977) , and bovine cells are virtually as sensitive as HK cells .DiagnosisSerological studies can be undertaken using the HI test, with human erythrocytes as the indicator system (Studdert et al., 1974) ./.", [["cells", "ANATOMY", 30, 35], ["fetal PK cells", "ANATOMY", 37, 51], ["HK cells", "ANATOMY", 90, 98], ["cells", "ANATOMY", 135, 140], ["HK cells", "ANATOMY", 171, 179], ["erythrocytes", "ANATOMY", 258, 270], ["cells", "CELL", 30, 35], ["fetal PK cells", "CELL", 37, 51], ["HK cells", "CELL", 90, 98], ["bovine", "ORGANISM", 128, 134], ["cells", "CELL", 135, 140], ["HK cells", "CELL", 171, 179], ["human", "ORGANISM", 252, 257], ["erythrocytes", "CELL", 258, 270], ["fetal PK cells", "CELL_TYPE", 37, 51], ["HK cells", "CELL_LINE", 90, 98], ["bovine cells", "CELL_TYPE", 128, 140], ["HK cells", "CELL_LINE", 171, 179], ["human erythrocytes", "CELL_TYPE", 252, 270], ["bovine", "SPECIES", 128, 134], ["human", "SPECIES", 252, 257], ["bovine", "SPECIES", 128, 134], ["human", "SPECIES", 252, 257], ["a CPE", "PROBLEM", 10, 15], ["fetal PK cells", "TEST", 37, 51], ["HK cells", "PROBLEM", 90, 98], ["Konishi et al.", "TEST", 100, 114], ["bovine cells", "PROBLEM", 128, 140], ["DiagnosisSerological studies", "TEST", 181, 209], ["the HI test", "TEST", 234, 245], ["CPE", "OBSERVATION", 12, 15], ["bovine cells", "OBSERVATION", 128, 140]]], ["ClassificationICH virus (Cl) and the virus associated with infectious laryngotracheitis (A26/61) (Ditchfield et al., 1962) can be distinguished using the HI test.", [["Cl", "CHEMICAL", 25, 27], ["infectious laryngotracheitis", "DISEASE", 59, 87], ["ClassificationICH virus", "ORGANISM", 0, 23], ["ClassificationICH virus (Cl", "PROBLEM", 0, 27], ["the virus", "PROBLEM", 33, 42], ["infectious laryngotracheitis", "PROBLEM", 59, 87], ["the HI test", "TEST", 150, 161], ["associated with", "UNCERTAINTY", 43, 58], ["infectious", "OBSERVATION_MODIFIER", 59, 69], ["laryngotracheitis", "OBSERVATION", 70, 87]]], ["But while antiserum to Cl neutralized only Cl, antiserum to A26/61 neutralized both viruses to the same titer (Ditchfield et al., 1962) .", [["Cl", "CHEMICAL", 23, 25], ["Cl", "CHEMICAL", 43, 45], ["A26/61", "CHEMICAL", 60, 66], ["Cl", "CHEMICAL", 23, 25], ["Cl", "CHEMICAL", 43, 45], ["antiserum", "ORGANISM_SUBSTANCE", 10, 19], ["Cl", "SIMPLE_CHEMICAL", 43, 45], ["antiserum", "ORGANISM_SUBSTANCE", 47, 56], ["A26/61", "GENE_OR_GENE_PRODUCT", 60, 66]]], ["However, it should be noted that the antiserum to A26/61 had apparently been prepared in dogs previously given Cl-attenuated vaccine.", [["A26/61", "CHEMICAL", 50, 56], ["Cl", "CHEMICAL", 111, 113], ["Cl", "CHEMICAL", 111, 113], ["antiserum", "ORGANISM_SUBSTANCE", 37, 46], ["A26/61", "SIMPLE_CHEMICAL", 50, 56], ["dogs", "ORGANISM", 89, 93], ["dogs", "SPECIES", 89, 93], ["the antiserum", "TEST", 33, 46], ["Cl-attenuated vaccine", "TREATMENT", 111, 132]]], ["Using both the HI and SN tests, it was possible to divide seven isolates into CI or A26/61 types (Swango et al., 1969) .", [["SN tests", "TEST", 22, 30]]], ["But using purified reagents, it was shown that antiserum to Cl hexons would neutralize both Cl and A26/61 viruses, whereas antiserum to A26/61 hexons would neutralize only A26/61 virus.", [["Cl", "CHEMICAL", 60, 62], ["Cl", "CHEMICAL", 92, 94], ["Cl", "CHEMICAL", 60, 62], ["antiserum", "ORGANISM_SUBSTANCE", 47, 56], ["Cl hexons", "SIMPLE_CHEMICAL", 60, 69], ["A26/61 viruses", "ORGANISM", 99, 113], ["antiserum", "ORGANISM_SUBSTANCE", 123, 132], ["A26/61", "GENE_OR_GENE_PRODUCT", 136, 142], ["A26/61 virus", "ORGANISM", 172, 184], ["A26/61 virus", "SPECIES", 172, 184], ["purified reagents", "TREATMENT", 10, 27], ["antiserum to Cl hexons", "TREATMENT", 47, 69], ["virus", "PROBLEM", 179, 184]]], ["Using antisera prepared to the fibers, the HI test indicated a similar one-way cross, but in the SN test these fiber antisera were type specific (Marusyk, 1972) .", [["fibers", "ANATOMY", 31, 37], ["fibers", "CELLULAR_COMPONENT", 31, 37], ["antisera", "TREATMENT", 6, 14], ["the HI test", "TEST", 39, 50]]], ["When antiserum to the virion was tested against complete soluble hemagglutinin as antigen, the two types of virus were readily differenti ated (Marusyk, 1972; Wright et al., 1972) ./.", [["antiserum", "ORGANISM_SUBSTANCE", 5, 14], ["virion", "CELLULAR_COMPONENT", 22, 28], ["soluble hemagglutinin", "PROTEIN", 57, 78], ["complete soluble hemagglutinin", "TREATMENT", 48, 78], ["virus", "PROBLEM", 108, 113]]], ["ClassificationThere are other reasons why A26/61 should be considered a separate serotype.", [["A26/61", "ORGANISM", 42, 48], ["a separate serotype", "PROBLEM", 70, 89]]], ["The viruses have different fiber lengths and the viral capsid components carry different ionic charges, as demonstrated by anion exchange chromatography (Marusyket al., 1970) .", [["fiber", "ANATOMY", 27, 32], ["anion", "SIMPLE_CHEMICAL", 123, 128], ["viral capsid components", "PROTEIN", 49, 72], ["the viral capsid components", "PROBLEM", 45, 72], ["different ionic charges", "PROBLEM", 79, 102], ["anion exchange chromatography", "TEST", 123, 152], ["viruses", "OBSERVATION", 4, 11], ["different", "OBSERVATION_MODIFIER", 17, 26], ["fiber", "OBSERVATION_MODIFIER", 27, 32], ["lengths", "OBSERVATION_MODIFIER", 33, 40], ["viral capsid components", "OBSERVATION", 49, 72], ["different", "OBSERVATION_MODIFIER", 79, 88], ["ionic charges", "OBSERVATION", 89, 102]]], ["The Cl and A26/61 viruses have different hemagglutinin receptors on erythrocytes (Marusyk and Yamamoto, 1971) , and DNA-DNA hybridization studies indicate a genetic relationship of 70% between these vi ruses (Marusyk and Hammarskjold, 1972) .", [["erythrocytes", "ANATOMY", 68, 80], ["Cl", "CHEMICAL", 4, 6], ["Cl", "GENE_OR_GENE_PRODUCT", 4, 6], ["A26/61 viruses", "ORGANISM", 11, 25], ["erythrocytes", "CELL", 68, 80], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["hemagglutinin receptors", "PROTEIN", 41, 64], ["erythrocytes", "CELL_TYPE", 68, 80], ["The Cl", "TEST", 0, 6], ["different hemagglutinin receptors", "PROBLEM", 31, 64], ["erythrocytes", "TEST", 68, 80], ["DNA", "TEST", 116, 119], ["DNA hybridization studies", "TEST", 120, 145], ["Cl", "OBSERVATION", 4, 6], ["viruses", "OBSERVATION", 18, 25], ["hemagglutinin receptors", "OBSERVATION", 41, 64]]], ["Also, the pattern of replication dif fers, with Cl behaving like cytopathology subgroup A and A26/61 resembling cytopathology subgroup B (Adair, 1979) ./.", [["replication", "OBSERVATION", 21, 32]]], ["ClassificationOne reason for considering Cl and A26/61 as the same serotype is that A26/61 protects dogs against infection with Cl (Fairchild^ a/., 1969).DistributionThese viruses are widely distributed.Epidemiology and Pathog\u00e8ne sisFollowing oral infection, Cl replicated in the tonsils and then traveled via the drainage lymph nodes and lymph to the blood.", [["oral", "ANATOMY", 243, 247], ["tonsils", "ANATOMY", 280, 287], ["lymph nodes", "ANATOMY", 323, 334], ["lymph", "ANATOMY", 339, 344], ["blood", "ANATOMY", 352, 357], ["Cl", "CHEMICAL", 41, 43], ["A26/61", "CHEMICAL", 84, 90], ["infection", "DISEASE", 113, 122], ["Cl", "CHEMICAL", 128, 130], ["oral infection", "DISEASE", 243, 257], ["Cl", "CHEMICAL", 259, 261], ["Cl", "CHEMICAL", 41, 43], ["Cl", "CHEMICAL", 259, 261], ["Cl", "SIMPLE_CHEMICAL", 41, 43], ["A26/61", "SIMPLE_CHEMICAL", 84, 90], ["dogs", "ORGANISM", 100, 104], ["oral", "ORGANISM_SUBDIVISION", 243, 247], ["tonsils", "ORGAN", 280, 287], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 323, 334], ["lymph", "MULTI-TISSUE_STRUCTURE", 339, 344], ["blood", "ORGANISM_SUBSTANCE", 352, 357], ["dogs", "SPECIES", 100, 104], ["Cl", "TEST", 41, 43], ["infection", "PROBLEM", 113, 122], ["Cl", "TEST", 128, 130], ["oral infection", "PROBLEM", 243, 257], ["the drainage lymph nodes", "TREATMENT", 310, 334], ["viruses", "OBSERVATION", 172, 179], ["widely", "OBSERVATION_MODIFIER", 184, 190], ["distributed", "OBSERVATION_MODIFIER", 191, 202], ["infection", "OBSERVATION", 248, 257], ["tonsils", "ANATOMY", 280, 287], ["drainage", "OBSERVATION_MODIFIER", 314, 322], ["lymph nodes", "OBSERVATION", 323, 334], ["lymph", "ANATOMY", 339, 344], ["blood", "ANATOMY", 352, 357]]], ["The viremia occurred 4 -6 days PI and lasted 1-3 days.", [["viremia", "DISEASE", 4, 11], ["The viremia", "PROBLEM", 0, 11], ["viremia", "OBSERVATION", 4, 11]]], ["Virus was in the kidney from day 5-7 to at least day 23, and there was irregular excretion in the urine for up to 161 days PI.", [["kidney", "ANATOMY", 17, 23], ["urine", "ANATOMY", 98, 103], ["Virus", "ORGANISM", 0, 5], ["kidney", "ORGAN", 17, 23], ["urine", "ORGANISM_SUBSTANCE", 98, 103], ["Virus", "PROBLEM", 0, 5], ["irregular excretion in the urine", "PROBLEM", 71, 103], ["kidney", "ANATOMY", 17, 23], ["irregular", "OBSERVATION_MODIFIER", 71, 80], ["excretion", "OBSERVATION", 81, 90]]], ["Virus was isolated from the tonsillar swabs from days 1-7, with peak titers on days 2 and 3.", [["tonsillar swabs", "ANATOMY", 28, 43], ["Virus", "ORGANISM", 0, 5], ["tonsillar swabs", "MULTI-TISSUE_STRUCTURE", 28, 43], ["Virus", "PROBLEM", 0, 5], ["the tonsillar swabs", "TEST", 24, 43], ["peak titers", "TEST", 64, 75], ["tonsillar", "ANATOMY", 28, 37], ["swabs", "OBSERVATION", 38, 43]]], ["Minimal quantities of virus were excreted in the feces (Poppensiek and Baker, 1951; Salenstedt, 1963; Hamilton et al., 1966) .", [["feces", "ANATOMY", 49, 54], ["feces", "ORGANISM_SUBSTANCE", 49, 54], ["virus", "PROBLEM", 22, 27], ["quantities", "OBSERVATION_MODIFIER", 8, 18], ["virus", "OBSERVATION", 22, 27], ["feces", "ANATOMY", 49, 54]]], ["Leukopenia accompanied the viremia and pyrexia and was followed by an intense leukocytosis (Hamilton et al., 1966) .", [["Leukopenia", "DISEASE", 0, 10], ["viremia", "DISEASE", 27, 34], ["pyrexia", "DISEASE", 39, 46], ["leukocytosis", "DISEASE", 78, 90], ["Leukopenia", "PROBLEM", 0, 10], ["the viremia", "PROBLEM", 23, 34], ["pyrexia", "PROBLEM", 39, 46], ["an intense leukocytosis", "PROBLEM", 67, 90], ["viremia", "OBSERVATION", 27, 34], ["pyrexia", "OBSERVATION", 39, 46], ["intense", "OBSERVATION_MODIFIER", 70, 77], ["leukocytosis", "OBSERVATION", 78, 90]]], ["The minimal dose required for oral infection was between 40 and 400 TCIDso (Salenstedt, 1963) .Epidemiology and Pathog\u00e8ne sisDamage to the vacular endothelium and to liver cells was widespread (Rubarth, 1947) .", [["oral", "ANATOMY", 30, 34], ["vacular endothelium", "ANATOMY", 139, 158], ["liver cells", "ANATOMY", 166, 177], ["infection", "DISEASE", 35, 44], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["vacular endothelium", "TISSUE", 139, 158], ["liver cells", "CELL", 166, 177], ["liver cells", "CELL_TYPE", 166, 177], ["oral infection", "PROBLEM", 30, 44], ["Pathog\u00e8ne sisDamage", "TREATMENT", 112, 131], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 35, 44], ["vacular endothelium", "ANATOMY", 139, 158], ["liver", "ANATOMY", 166, 171]]], ["Lesions occurred in the liver from day 7 to 11 and were maximal in the CNS at days 8 and 9, and nephritis was seen from day 11 (Hamilton et al., 1966) .", [["liver", "ANATOMY", 24, 29], ["CNS", "ANATOMY", 71, 74], ["nephritis", "DISEASE", 96, 105], ["liver", "ORGAN", 24, 29], ["CNS", "ANATOMICAL_SYSTEM", 71, 74], ["Lesions", "PROBLEM", 0, 7], ["nephritis", "PROBLEM", 96, 105], ["liver", "ANATOMY", 24, 29], ["CNS", "ANATOMY", 71, 74], ["nephritis", "OBSERVATION", 96, 105]]], ["Nephritis resulted from virus in the glomerular epithelial and mesengial cells in the larger renal vessels, causing marked cellular degenerative changes in both glomeruli and tubular epithelium.", [["glomerular epithelial", "ANATOMY", 37, 58], ["mesengial cells", "ANATOMY", 63, 78], ["renal vessels", "ANATOMY", 93, 106], ["cellular", "ANATOMY", 123, 131], ["glomeruli", "ANATOMY", 161, 170], ["tubular epithelium", "ANATOMY", 175, 193], ["Nephritis", "DISEASE", 0, 9], ["glomerular epithelial", "CELL", 37, 58], ["mesengial cells", "CELL", 63, 78], ["renal vessels", "MULTI-TISSUE_STRUCTURE", 93, 106], ["cellular", "CELL", 123, 131], ["glomeruli", "TISSUE", 161, 170], ["tubular epithelium", "TISSUE", 175, 193], ["glomerular epithelial and mesengial cells", "CELL_TYPE", 37, 78], ["Nephritis", "PROBLEM", 0, 9], ["virus", "PROBLEM", 24, 29], ["marked cellular degenerative changes in both glomeruli and tubular epithelium", "PROBLEM", 116, 193], ["virus", "OBSERVATION", 24, 29], ["glomerular", "ANATOMY_MODIFIER", 37, 47], ["epithelial", "ANATOMY_MODIFIER", 48, 58], ["mesengial cells", "OBSERVATION", 63, 78], ["larger", "ANATOMY_MODIFIER", 86, 92], ["renal vessels", "ANATOMY", 93, 106], ["marked", "OBSERVATION_MODIFIER", 116, 122], ["cellular", "OBSERVATION_MODIFIER", 123, 131], ["degenerative", "OBSERVATION", 132, 144], ["both", "ANATOMY_MODIFIER", 156, 160], ["glomeruli", "ANATOMY", 161, 170], ["tubular", "ANATOMY_MODIFIER", 175, 182], ["epithelium", "ANATOMY_MODIFIER", 183, 193]]], ["Swelling of the affected cells resulted in partial or complete occlusion of both capillaries and urinary spaces, leading to proteinuria and viruria.", [["cells", "ANATOMY", 25, 30], ["capillaries", "ANATOMY", 81, 92], ["urinary", "ANATOMY", 97, 104], ["proteinuria", "DISEASE", 124, 135], ["viruria", "DISEASE", 140, 147], ["cells", "CELL", 25, 30], ["capillaries", "TISSUE", 81, 92], ["urinary", "ORGANISM_SUBSTANCE", 97, 104], ["affected cells", "CELL_TYPE", 16, 30], ["Swelling of the affected cells", "PROBLEM", 0, 30], ["partial or complete occlusion of both capillaries and urinary spaces", "PROBLEM", 43, 111], ["proteinuria", "PROBLEM", 124, 135], ["viruria", "PROBLEM", 140, 147], ["affected cells", "OBSERVATION", 16, 30], ["partial", "OBSERVATION_MODIFIER", 43, 50], ["complete", "OBSERVATION_MODIFIER", 54, 62], ["occlusion", "OBSERVATION", 63, 72], ["both", "ANATOMY_MODIFIER", 76, 80], ["capillaries", "ANATOMY", 81, 92], ["urinary spaces", "ANATOMY", 97, 111], ["proteinuria", "OBSERVATION", 124, 135], ["viruria", "OBSERVATION", 140, 147]]], ["At this stage, there was no deposit of immune complexes (Poppensiek and Baker, 1951; Wright et al., 1973) .", [["immune complexes", "PROTEIN", 39, 55], ["deposit of immune complexes", "PROBLEM", 28, 55], ["no", "UNCERTAINTY", 25, 27], ["deposit", "OBSERVATION_MODIFIER", 28, 35], ["immune complexes", "OBSERVATION", 39, 55]]], ["These interstitial lesions appeared to be a type IV (cell-mediated) hypersensitivity reaction in which epithelial cells containing viral antigen were surrounded by macrophages and lymphocytes .Epidemiology and Pathog\u00e8ne sisAt the height of the disease, when antibody was developing but had not yet reached high levels, circulating immune complexes were formed .", [["interstitial lesions", "ANATOMY", 6, 26], ["cell", "ANATOMY", 53, 57], ["epithelial cells", "ANATOMY", 103, 119], ["macrophages", "ANATOMY", 164, 175], ["lymphocytes", "ANATOMY", 180, 191], ["interstitial lesions", "DISEASE", 6, 26], ["hypersensitivity", "DISEASE", 68, 84], ["interstitial lesions", "PATHOLOGICAL_FORMATION", 6, 26], ["cell", "CELL", 53, 57], ["epithelial cells", "CELL", 103, 119], ["viral antigen", "GENE_OR_GENE_PRODUCT", 131, 144], ["macrophages", "CELL", 164, 175], ["lymphocytes", "CELL", 180, 191], ["epithelial cells", "CELL_TYPE", 103, 119], ["viral antigen", "PROTEIN", 131, 144], ["macrophages", "CELL_TYPE", 164, 175], ["lymphocytes", "CELL_TYPE", 180, 191], ["circulating immune complexes", "PROTEIN", 319, 347], ["These interstitial lesions", "PROBLEM", 0, 26], ["a type IV (cell-mediated) hypersensitivity reaction", "PROBLEM", 42, 93], ["epithelial cells", "PROBLEM", 103, 119], ["viral antigen", "PROBLEM", 131, 144], ["lymphocytes", "PROBLEM", 180, 191], ["the disease", "PROBLEM", 240, 251], ["antibody", "TEST", 258, 266], ["interstitial", "ANATOMY_MODIFIER", 6, 18], ["lesions", "OBSERVATION", 19, 26], ["hypersensitivity reaction", "OBSERVATION", 68, 93], ["epithelial cells", "OBSERVATION", 103, 119], ["viral antigen", "OBSERVATION", 131, 144], ["macrophages", "OBSERVATION", 164, 175], ["lymphocytes", "ANATOMY", 180, 191], ["disease", "OBSERVATION", 244, 251], ["immune complexes", "OBSERVATION", 331, 347]]], ["It has been suggested that the glomerulonephritis associated with ICH is due to the deposition of these complexes (Kurtz et al., 1972) , and this has been confirmed by the identification of IgG and Cl antigen in the glomeruli of naturally occurring cases (Morrison et al., 1975) .", [["glomeruli", "ANATOMY", 216, 225], ["glomerulonephritis", "DISEASE", 31, 49], ["ICH", "DISEASE", 66, 69], ["Cl", "CHEMICAL", 198, 200], ["IgG", "GENE_OR_GENE_PRODUCT", 190, 193], ["Cl antigen", "GENE_OR_GENE_PRODUCT", 198, 208], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 216, 225], ["IgG", "PROTEIN", 190, 193], ["Cl antigen", "PROTEIN", 198, 208], ["the glomerulonephritis", "PROBLEM", 27, 49], ["ICH", "PROBLEM", 66, 69], ["IgG", "TEST", 190, 193], ["Cl antigen", "TEST", 198, 208], ["glomerulonephritis", "OBSERVATION", 31, 49], ["ICH", "OBSERVATION", 66, 69], ["glomeruli", "ANATOMY", 216, 225]]], ["These proliferative glomerulonephritic lesions are transient and do not lead to permanent damage.Epidemiology and Pathog\u00e8ne sisDuring the viremic phase, the virus enters the anterior chamber of the eye and infects the endothelial cells, producing a primary iridiocyclitis.", [["proliferative glomerulonephritic lesions", "ANATOMY", 6, 46], ["anterior chamber", "ANATOMY", 174, 190], ["eye", "ANATOMY", 198, 201], ["endothelial cells", "ANATOMY", 218, 235], ["primary iridiocyclitis", "DISEASE", 249, 271], ["proliferative glomerulonephritic lesions", "CANCER", 6, 46], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 174, 190], ["eye", "ORGAN", 198, 201], ["endothelial cells", "CELL", 218, 235], ["iridiocyclitis", "CANCER", 257, 271], ["endothelial cells", "CELL_TYPE", 218, 235], ["These proliferative glomerulonephritic lesions", "PROBLEM", 0, 46], ["permanent damage", "PROBLEM", 80, 96], ["the virus", "PROBLEM", 153, 162], ["a primary iridiocyclitis", "PROBLEM", 247, 271], ["proliferative", "OBSERVATION_MODIFIER", 6, 19], ["glomerulonephritic", "OBSERVATION_MODIFIER", 20, 38], ["lesions", "OBSERVATION", 39, 46], ["permanent", "OBSERVATION_MODIFIER", 80, 89], ["damage", "OBSERVATION", 90, 96], ["virus", "OBSERVATION", 157, 162], ["anterior", "ANATOMY_MODIFIER", 174, 182], ["chamber", "ANATOMY_MODIFIER", 183, 190], ["eye", "ANATOMY", 198, 201], ["infects", "OBSERVATION", 206, 213], ["endothelial cells", "OBSERVATION", 218, 235], ["primary", "OBSERVATION_MODIFIER", 249, 256], ["iridiocyclitis", "OBSERVATION", 257, 271]]], ["This may resolve without sequellae or the virus may persist.", [["sequellae", "PROBLEM", 25, 34], ["the virus", "PROBLEM", 38, 47], ["virus", "OBSERVATION", 42, 47]]], ["This results in a type III hypersensitiv ity reaction, with the formation of immune complexes in the aqueous fluid.", [["aqueous fluid", "ANATOMY", 101, 114], ["aqueous fluid", "ORGANISM_SUBSTANCE", 101, 114], ["immune complexes", "PROTEIN", 77, 93], ["a type III hypersensitiv ity reaction", "PROBLEM", 16, 53], ["immune complexes in the aqueous fluid", "PROBLEM", 77, 114], ["immune complexes", "OBSERVATION", 77, 93], ["aqueous", "OBSERVATION_MODIFIER", 101, 108], ["fluid", "OBSERVATION", 109, 114]]], ["These complexes are phagocytosed and the corneal epithelium is attacked, lead ing to corneal edema and the characteristic \"blue eye\" (Carmichael, 1964) .Epidemiology and Pathog\u00e8ne sisThe pathogenesis and pathological changes induced by Cl depend on the route of entry.", [["corneal epithelium", "ANATOMY", 41, 59], ["corneal edema", "ANATOMY", 85, 98], ["eye", "ANATOMY", 128, 131], ["corneal edema", "DISEASE", 85, 98], ["Cl", "CHEMICAL", 236, 238], ["Cl", "CHEMICAL", 236, 238], ["corneal epithelium", "TISSUE", 41, 59], ["eye", "ORGAN", 128, 131], ["Cl", "SIMPLE_CHEMICAL", 236, 238], ["phagocytosed", "PROBLEM", 20, 32], ["corneal edema", "PROBLEM", 85, 98], ["pathological changes", "PROBLEM", 204, 224], ["phagocytosed", "OBSERVATION", 20, 32], ["corneal epithelium", "ANATOMY", 41, 59], ["corneal", "ANATOMY", 85, 92], ["edema", "OBSERVATION", 93, 98]]], ["An isolate from a dog with acute hepatitis (Wright et al., 1970) pro-duced severe respiratory tract disease in dogs when given intratracheally or by aerosol (Wright et al., 1970 (Wright et al., , 1971 .", [["respiratory tract", "ANATOMY", 82, 99], ["acute hepatitis", "DISEASE", 27, 42], ["respiratory tract disease", "DISEASE", 82, 107], ["dog", "ORGANISM", 18, 21], ["respiratory tract", "ORGANISM_SUBDIVISION", 82, 99], ["dogs", "ORGANISM", 111, 115], ["dog", "SPECIES", 18, 21], ["dogs", "SPECIES", 111, 115], ["acute hepatitis", "PROBLEM", 27, 42], ["severe respiratory tract disease in dogs", "PROBLEM", 75, 115], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["hepatitis", "OBSERVATION", 33, 42], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["respiratory tract", "ANATOMY", 82, 99]]], ["The route of infection may well affect the pattern of excretion.", [["infection", "DISEASE", 13, 22], ["infection", "PROBLEM", 13, 22], ["infection", "OBSERVATION", 13, 22], ["excretion", "OBSERVATION", 54, 63]]], ["Thus although classical ICH virus was not airborne (Baker et al., 1950) when dogs were infected by the respiratory route, airborne infection occurred (Wright et al., 1971) .Epidemiology and Pathog\u00e8ne sisFollowing combined intranasal and intratracheal inoculation of an A26/61 type virus, a viremia occurred, and unlike Cl, virus was recovered from throat swabs for 8 days and rectal swabs for 10 days.", [["throat swabs", "ANATOMY", 348, 360], ["rectal swabs", "ANATOMY", 376, 388], ["ICH", "DISEASE", 24, 27], ["airborne infection", "DISEASE", 122, 140], ["viremia", "DISEASE", 290, 297], ["Cl", "CHEMICAL", 319, 321], ["ICH virus", "ORGANISM", 24, 33], ["dogs", "ORGANISM", 77, 81], ["A26/61 type virus", "ORGANISM", 269, 286], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 376, 388], ["dogs", "SPECIES", 77, 81], ["A26/61 type virus", "SPECIES", 269, 286], ["classical ICH virus", "PROBLEM", 14, 33], ["airborne infection", "PROBLEM", 122, 140], ["intranasal and intratracheal inoculation", "TREATMENT", 222, 262], ["an A26/61 type virus", "PROBLEM", 266, 286], ["a viremia", "PROBLEM", 288, 297], ["virus", "PROBLEM", 323, 328], ["throat swabs", "TEST", 348, 360], ["rectal swabs", "TEST", 376, 388], ["ICH", "OBSERVATION", 24, 27], ["infection", "OBSERVATION", 131, 140], ["intratracheal", "ANATOMY", 237, 250], ["viremia", "OBSERVATION", 290, 297]]], ["Only sporadic isolations were made from urine (Swangoef a/., 1970).Association with Diseasea.", [["urine", "ANATOMY", 40, 45], ["urine", "ORGANISM_SUBSTANCE", 40, 45], ["sporadic isolations", "PROBLEM", 5, 24], ["Diseasea", "PROBLEM", 84, 92], ["sporadic", "OBSERVATION_MODIFIER", 5, 13], ["isolations", "OBSERVATION", 14, 24], ["Diseasea", "OBSERVATION", 84, 92]]], ["Canine Adenovirus 1 (ICH) Virus 1.", [["ICH", "DISEASE", 21, 24], ["Canine Adenovirus 1", "ORGANISM", 0, 19], ["ICH) Virus 1", "ORGANISM", 21, 33], ["Canine", "SPECIES", 0, 6], ["Canine Adenovirus 1", "SPECIES", 0, 19], ["Canine Adenovirus 1 (ICH) Virus", "TREATMENT", 0, 31]]], ["Cl virus has been isolated from the respiratory tract of nor mal dogs (Campbell et al., 1968) and also from kidney cells grown from healthy dogs.Association with Disease2.", [["respiratory tract", "ANATOMY", 36, 53], ["kidney cells", "ANATOMY", 108, 120], ["Cl", "CHEMICAL", 0, 2], ["Cl virus", "ORGANISM", 0, 8], ["respiratory tract", "ORGANISM_SUBDIVISION", 36, 53], ["dogs", "ORGANISM", 65, 69], ["kidney cells", "CELL", 108, 120], ["dogs", "ORGANISM", 140, 144], ["kidney cells", "CELL_TYPE", 108, 120], ["dogs", "SPECIES", 65, 69], ["dogs", "SPECIES", 140, 144], ["Cl virus", "SPECIES", 0, 8], ["Cl virus", "PROBLEM", 0, 8], ["virus", "OBSERVATION", 3, 8], ["respiratory tract", "ANATOMY", 36, 53], ["kidney", "ANATOMY", 108, 114], ["healthy dogs", "OBSERVATION", 132, 144]]], ["Generalized Infection.", [["Infection", "DISEASE", 12, 21], ["Generalized Infection", "PROBLEM", 0, 21], ["Infection", "OBSERVATION", 12, 21]]], ["It varied in degree from fatal disease to mild illness.", [["fatal disease", "PROBLEM", 25, 38], ["mild illness", "PROBLEM", 42, 54], ["varied", "OBSERVATION_MODIFIER", 3, 9], ["degree", "OBSERVATION_MODIFIER", 13, 19], ["fatal disease", "OBSERVATION", 25, 38], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["illness", "OBSERVATION", 47, 54]]], ["Following an incubation period of 2-14 days, the signs seen were a biphasic pyrexia, anorex ia, ocular and nasal discharge, conjunctivitis, hyperemia of the oral mucus membranes, and vomiting.", [["ocular", "ANATOMY", 96, 102], ["nasal", "ANATOMY", 107, 112], ["oral mucus membranes", "ANATOMY", 157, 177], ["pyrexia", "DISEASE", 76, 83], ["ocular and nasal discharge", "DISEASE", 96, 122], ["conjunctivitis", "DISEASE", 124, 138], ["hyperemia", "DISEASE", 140, 149], ["vomiting", "DISEASE", 183, 191], ["nasal", "ORGANISM_SUBDIVISION", 107, 112], ["oral mucus membranes", "MULTI-TISSUE_STRUCTURE", 157, 177], ["the signs", "TEST", 45, 54], ["a biphasic pyrexia", "PROBLEM", 65, 83], ["anorex ia", "PROBLEM", 85, 94], ["ocular and nasal discharge", "PROBLEM", 96, 122], ["conjunctivitis", "PROBLEM", 124, 138], ["hyperemia", "PROBLEM", 140, 149], ["the oral mucus membranes", "PROBLEM", 153, 177], ["vomiting", "PROBLEM", 183, 191], ["biphasic", "OBSERVATION_MODIFIER", 67, 75], ["pyrexia", "OBSERVATION", 76, 83], ["ocular", "ANATOMY", 96, 102], ["nasal", "ANATOMY", 107, 112], ["discharge", "OBSERVATION", 113, 122], ["conjunctivitis", "OBSERVATION", 124, 138], ["hyperemia", "OBSERVATION", 140, 149], ["oral mucus", "ANATOMY", 157, 167]]], ["Hepatitis was rare, and there was subcutaneous edema of the head, neck, and body (Rubarth, 1947; Pay, 1950) .Association with DiseaseThe basic lesions were hepatitis, lymphadenitis, and vascular damage.", [["subcutaneous edema", "ANATOMY", 34, 52], ["head", "ANATOMY", 60, 64], ["neck", "ANATOMY", 66, 70], ["body", "ANATOMY", 76, 80], ["lesions", "ANATOMY", 143, 150], ["vascular", "ANATOMY", 186, 194], ["Hepatitis", "DISEASE", 0, 9], ["edema", "DISEASE", 47, 52], ["hepatitis", "DISEASE", 156, 165], ["lymphadenitis", "DISEASE", 167, 180], ["vascular damage", "DISEASE", 186, 201], ["edema", "PATHOLOGICAL_FORMATION", 47, 52], ["head", "ORGANISM_SUBDIVISION", 60, 64], ["neck", "ORGAN", 66, 70], ["body", "ORGANISM_SUBDIVISION", 76, 80], ["lesions", "CANCER", 143, 150], ["vascular", "MULTI-TISSUE_STRUCTURE", 186, 194], ["Hepatitis", "PROBLEM", 0, 9], ["subcutaneous edema of the head, neck, and body", "PROBLEM", 34, 80], ["DiseaseThe basic lesions", "PROBLEM", 126, 150], ["hepatitis", "PROBLEM", 156, 165], ["lymphadenitis", "PROBLEM", 167, 180], ["vascular damage", "PROBLEM", 186, 201], ["subcutaneous", "ANATOMY", 34, 46], ["edema", "OBSERVATION", 47, 52], ["head", "ANATOMY", 60, 64], ["neck", "ANATOMY", 66, 70], ["body", "ANATOMY", 76, 80], ["basic", "OBSERVATION_MODIFIER", 137, 142], ["lesions", "OBSERVATION", 143, 150], ["hepatitis", "OBSERVATION", 156, 165], ["lymphadenitis", "OBSERVATION", 167, 180], ["vascular", "ANATOMY", 186, 194], ["damage", "OBSERVATION", 195, 201]]], ["Histological examination revealed a severe hepatitis with focal parenchymal necrosis, with intranuclear inclusions (Fig. 5c) .", [["parenchymal", "ANATOMY", 64, 75], ["hepatitis", "DISEASE", 43, 52], ["parenchymal necrosis", "DISEASE", 64, 84], ["Histological examination", "TEST", 0, 24], ["a severe hepatitis", "PROBLEM", 34, 52], ["focal parenchymal necrosis", "PROBLEM", 58, 84], ["intranuclear inclusions", "PROBLEM", 91, 114], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["hepatitis", "OBSERVATION", 43, 52], ["focal", "OBSERVATION_MODIFIER", 58, 63], ["parenchymal", "ANATOMY_MODIFIER", 64, 75], ["necrosis", "OBSERVATION", 76, 84], ["intranuclear inclusions", "OBSERVATION", 91, 114]]], ["When examined using immunofluorescence, antigen was present in large amounts in the liver and also in the lymph nodes, spleen, and tonsils (Rubarth, 1947; Wrights al., 1972) .Association with DiseaseIt has also been suggested that Cl infection can give a chronic hepatitis (Gocke et al., 1970) , but this has not been confirmed.Association with Disease3.", [["liver", "ANATOMY", 84, 89], ["lymph nodes", "ANATOMY", 106, 117], ["spleen", "ANATOMY", 119, 125], ["tonsils", "ANATOMY", 131, 138], ["Disease", "DISEASE", 192, 199], ["Cl", "CHEMICAL", 231, 233], ["infection", "DISEASE", 234, 243], ["hepatitis", "DISEASE", 263, 272], ["Cl", "CHEMICAL", 231, 233], ["liver", "ORGAN", 84, 89], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 106, 117], ["spleen", "ORGAN", 119, 125], ["tonsils", "ORGAN", 131, 138], ["Cl", "SIMPLE_CHEMICAL", 231, 233], ["immunofluorescence", "TEST", 20, 38], ["antigen", "TEST", 40, 47], ["Disease", "PROBLEM", 192, 199], ["Cl infection", "PROBLEM", 231, 243], ["a chronic hepatitis", "PROBLEM", 253, 272], ["large", "OBSERVATION_MODIFIER", 63, 68], ["amounts", "OBSERVATION_MODIFIER", 69, 76], ["liver", "ANATOMY", 84, 89], ["lymph nodes", "OBSERVATION", 106, 117], ["spleen", "ANATOMY", 119, 125], ["tonsils", "ANATOMY", 131, 138], ["Disease", "OBSERVATION", 192, 199], ["infection", "OBSERVATION", 234, 243], ["chronic", "OBSERVATION_MODIFIER", 255, 262], ["hepatitis", "OBSERVATION", 263, 272], ["Disease3", "OBSERVATION", 345, 353]]], ["Respiratory Infection.", [["Respiratory Infection", "DISEASE", 0, 21], ["Respiratory Infection", "PROBLEM", 0, 21], ["Infection", "OBSERVATION", 12, 21]]], ["Cl has been isolated from the turbin\u00e2tes of dogs suffering from severe rhinitis .Association with DiseaseCl has also been isolated from dogs suffering from mild to severe respiratory tract disease, where there were lesions in both the upper and lower respiratory tracts (Binn et al., 1967; Studdert and Studdert, 1972; Wright et al., 1972) .", [["respiratory tract", "ANATOMY", 171, 188], ["lesions", "ANATOMY", 215, 222], ["upper", "ANATOMY", 235, 240], ["lower respiratory tracts", "ANATOMY", 245, 269], ["Cl", "CHEMICAL", 0, 2], ["rhinitis", "DISEASE", 71, 79], ["DiseaseCl", "CHEMICAL", 98, 107], ["respiratory tract disease", "DISEASE", 171, 196], ["Cl", "CHEMICAL", 0, 2], ["Cl", "SIMPLE_CHEMICAL", 0, 2], ["dogs", "ORGANISM", 44, 48], ["DiseaseCl", "GENE_OR_GENE_PRODUCT", 98, 107], ["dogs", "ORGANISM", 136, 140], ["tract", "ORGANISM_SUBDIVISION", 183, 188], ["lesions", "PATHOLOGICAL_FORMATION", 215, 222], ["upper", "ORGANISM_SUBDIVISION", 235, 240], ["dogs", "SPECIES", 44, 48], ["dogs", "SPECIES", 136, 140], ["severe rhinitis", "PROBLEM", 64, 79], ["mild to severe respiratory tract disease", "PROBLEM", 156, 196], ["lesions in both the upper and lower respiratory tracts", "PROBLEM", 215, 269], ["isolated", "OBSERVATION_MODIFIER", 12, 20], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["rhinitis", "OBSERVATION", 71, 79], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["respiratory tract disease", "OBSERVATION", 171, 196], ["lesions", "OBSERVATION", 215, 222], ["both", "ANATOMY_MODIFIER", 226, 230], ["upper", "ANATOMY_MODIFIER", 235, 240], ["lower", "ANATOMY_MODIFIER", 245, 250], ["respiratory tracts", "ANATOMY", 251, 269]]], ["It has been possible to reproduce respiratory tract disease in dogs using a Cl virus from a fatal case of ICH (Wright et al., 1971 ) and using a Cl virus isolated from a natural outbreak of respiratory disease .", [["respiratory tract", "ANATOMY", 34, 51], ["respiratory", "ANATOMY", 190, 201], ["respiratory tract disease", "DISEASE", 34, 59], ["Cl", "CHEMICAL", 76, 78], ["ICH", "DISEASE", 106, 109], ["Cl", "CHEMICAL", 145, 147], ["respiratory disease", "DISEASE", 190, 209], ["respiratory tract", "ORGANISM_SUBDIVISION", 34, 51], ["dogs", "ORGANISM", 63, 67], ["Cl virus", "ORGANISM", 145, 153], ["dogs", "SPECIES", 63, 67], ["Cl virus", "SPECIES", 76, 84], ["Cl virus", "SPECIES", 145, 153], ["respiratory tract disease in dogs", "PROBLEM", 34, 67], ["a Cl virus", "PROBLEM", 74, 84], ["ICH", "PROBLEM", 106, 109], ["a Cl virus", "PROBLEM", 143, 153], ["respiratory disease", "PROBLEM", 190, 209], ["respiratory tract", "ANATOMY", 34, 51], ["respiratory disease", "OBSERVATION", 190, 209]]], ["Following aerosol exposure, the dogs were dull and pyrexic and had respiratory signs.", [["respiratory", "ANATOMY", 67, 78], ["respiratory signs", "DISEASE", 67, 84], ["dogs", "ORGANISM", 32, 36], ["dogs", "SPECIES", 32, 36], ["aerosol exposure", "TREATMENT", 10, 26], ["dull", "PROBLEM", 42, 46], ["pyrexic", "PROBLEM", 51, 58], ["respiratory signs", "PROBLEM", 67, 84], ["respiratory signs", "OBSERVATION", 67, 84]]], ["At autopsy there was dull red consolidation of the lungs, with focal areas of pulmonary edema and a severe necrotizing bronchiolitis.", [["lungs", "ANATOMY", 51, 56], ["pulmonary", "ANATOMY", 78, 87], ["pulmonary edema", "DISEASE", 78, 93], ["bronchiolitis", "DISEASE", 119, 132], ["lungs", "ORGAN", 51, 56], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 78, 93], ["dull red consolidation of the lungs", "PROBLEM", 21, 56], ["pulmonary edema", "PROBLEM", 78, 93], ["a severe necrotizing bronchiolitis", "PROBLEM", 98, 132], ["dull", "OBSERVATION_MODIFIER", 21, 25], ["red", "OBSERVATION_MODIFIER", 26, 29], ["consolidation", "OBSERVATION", 30, 43], ["lungs", "ANATOMY", 51, 56], ["focal", "OBSERVATION_MODIFIER", 63, 68], ["areas", "OBSERVATION_MODIFIER", 69, 74], ["pulmonary", "ANATOMY", 78, 87], ["edema", "OBSERVATION", 88, 93], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["necrotizing", "OBSERVATION_MODIFIER", 107, 118], ["bronchiolitis", "OBSERVATION", 119, 132]]], ["There was also focal necrosis in the turbin\u00e2tes, nasal epithelium, and tonsils.", [["turbin\u00e2tes", "ANATOMY", 37, 47], ["nasal epithelium", "ANATOMY", 49, 65], ["tonsils", "ANATOMY", 71, 78], ["necrosis", "DISEASE", 21, 29], ["turbin\u00e2tes", "TISSUE", 37, 47], ["nasal epithelium", "TISSUE", 49, 65], ["tonsils", "ORGAN", 71, 78], ["focal necrosis in the turbin\u00e2tes, nasal epithelium, and tonsils", "PROBLEM", 15, 78], ["focal", "OBSERVATION_MODIFIER", 15, 20], ["necrosis", "OBSERVATION", 21, 29], ["turbin\u00e2tes", "ANATOMY_MODIFIER", 37, 47], ["nasal epithelium", "ANATOMY", 49, 65], ["tonsils", "ANATOMY", 71, 78]]], ["Viral inclusions and the antigen were detected in necrotizing bronchiolar epithelial cells and in turbinate and tonsillar cells .", [["necrotizing bronchiolar epithelial cells", "ANATOMY", 50, 90], ["turbinate", "ANATOMY", 98, 107], ["tonsillar cells", "ANATOMY", 112, 127], ["Viral", "ORGANISM", 0, 5], ["bronchiolar epithelial cells", "CELL", 62, 90], ["turbinate", "ORGAN", 98, 107], ["tonsillar cells", "CELL", 112, 127], ["necrotizing bronchiolar epithelial cells", "CELL_TYPE", 50, 90], ["turbinate and tonsillar cells", "CELL_TYPE", 98, 127], ["Viral inclusions", "PROBLEM", 0, 16], ["the antigen", "TEST", 21, 32], ["necrotizing bronchiolar epithelial cells and in turbinate and tonsillar cells", "PROBLEM", 50, 127], ["inclusions", "OBSERVATION", 6, 16], ["necrotizing", "OBSERVATION_MODIFIER", 50, 61], ["bronchiolar epithelial cells", "OBSERVATION", 62, 90], ["turbinate", "ANATOMY", 98, 107], ["tonsillar cells", "ANATOMY", 112, 127]]], ["(Carmichael, 1964; Curtis and Barnett, 1973; Carmichael et al., 1975) .Ocular Disease.", [["Ocular", "ANATOMY", 71, 77], ["Ocular Disease", "DISEASE", 71, 85], ["Ocular", "ORGAN", 71, 77], ["Ocular Disease", "PROBLEM", 71, 85], ["Disease", "OBSERVATION", 78, 85]]], ["Unilateral or bilateral corneal edema occurred in about 20% of animals recovering from Cl infection about 2-3 weeks PI.", [["corneal", "ANATOMY", 24, 31], ["corneal edema", "DISEASE", 24, 37], ["Cl", "CHEMICAL", 87, 89], ["infection", "DISEASE", 90, 99], ["Cl", "CHEMICAL", 87, 89], ["corneal edema", "PATHOLOGICAL_FORMATION", 24, 37], ["Unilateral or bilateral corneal edema", "PROBLEM", 0, 37], ["Cl infection", "PROBLEM", 87, 99], ["bilateral", "ANATOMY_MODIFIER", 14, 23], ["corneal", "ANATOMY", 24, 31], ["edema", "OBSERVATION", 32, 37], ["infection", "OBSERVATION", 90, 99]]], ["Usually transient, it became protracted, with permanent impairment of vision5.", [["impairment of vision5", "DISEASE", 56, 77], ["permanent impairment of vision5", "PROBLEM", 46, 77], ["protracted", "OBSERVATION_MODIFIER", 29, 39]]], ["Cl infection has also been associated with encephalopathy (Salyi and Knapp, 1958; Wright, 1967) and with focal interstitial nephri tis (Poppensiek and Baker, 1951; Hamilton et al., 1966) .", [["Cl", "CHEMICAL", 0, 2], ["infection", "DISEASE", 3, 12], ["encephalopathy", "DISEASE", 43, 57], ["interstitial nephri tis", "DISEASE", 111, 134], ["Cl", "CHEMICAL", 0, 2], ["Cl", "GENE_OR_GENE_PRODUCT", 0, 2], ["Cl infection", "PROBLEM", 0, 12], ["encephalopathy", "PROBLEM", 43, 57], ["focal interstitial nephri tis", "PROBLEM", 105, 134], ["infection", "OBSERVATION", 3, 12], ["encephalopathy", "OBSERVATION", 43, 57], ["focal", "OBSERVATION_MODIFIER", 105, 110], ["interstitial nephri", "ANATOMY", 111, 130]]], ["It has been suggested that Cl infection could be an important cause of chronic renal filure (Bush and Evans, 1972) , but other workers could not incriminate the virus .Ocular Disease.", [["renal", "ANATOMY", 79, 84], ["Ocular", "ANATOMY", 168, 174], ["Cl", "CHEMICAL", 27, 29], ["infection", "DISEASE", 30, 39], ["chronic renal filure", "DISEASE", 71, 91], ["Ocular Disease", "DISEASE", 168, 182], ["Cl", "CHEMICAL", 27, 29], ["Cl", "SIMPLE_CHEMICAL", 27, 29], ["renal", "ORGAN", 79, 84], ["Ocular", "ORGAN", 168, 174], ["Cl infection", "PROBLEM", 27, 39], ["chronic renal filure", "PROBLEM", 71, 91], ["the virus", "PROBLEM", 157, 166], ["Ocular Disease", "PROBLEM", 168, 182], ["Cl", "OBSERVATION_MODIFIER", 27, 29], ["infection", "OBSERVATION", 30, 39], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["renal", "ANATOMY", 79, 84], ["filure", "OBSERVATION", 85, 91], ["Disease", "OBSERVATION", 175, 182]]], ["Unilateral or bilateral corneal edema occurred in about 20% of animals recovering from Cl infection about 2-3 weeks PI.", [["corneal", "ANATOMY", 24, 31], ["corneal edema", "DISEASE", 24, 37], ["Cl", "CHEMICAL", 87, 89], ["infection", "DISEASE", 90, 99], ["Cl", "CHEMICAL", 87, 89], ["corneal edema", "PATHOLOGICAL_FORMATION", 24, 37], ["Unilateral or bilateral corneal edema", "PROBLEM", 0, 37], ["Cl infection", "PROBLEM", 87, 99], ["bilateral", "ANATOMY_MODIFIER", 14, 23], ["corneal", "ANATOMY", 24, 31], ["edema", "OBSERVATION", 32, 37], ["infection", "OBSERVATION", 90, 99]]], ["Usually transient, it became protracted, with permanent impairment of visionb.", [["impairment of visionb", "DISEASE", 56, 77], ["permanent impairment of visionb", "PROBLEM", 46, 77], ["transient", "OBSERVATION_MODIFIER", 8, 17], ["protracted", "OBSERVATION_MODIFIER", 29, 39]]], ["A26/61 Toronto Virus.", [["A26/61 Toronto Virus", "ORGANISM", 0, 20], ["Toronto Virus", "TREATMENT", 7, 20]]], ["This virus was isolated from dogs with pharyngotracheitis (Ditchfield et al., 1962) . .Other workers have also associated this virus with respiratory tract disease (Binn et al., 1967) , and experimental work has confirmed this.", [["respiratory tract", "ANATOMY", 138, 155], ["pharyngotracheitis", "DISEASE", 39, 57], ["respiratory tract disease", "DISEASE", 138, 163], ["dogs", "ORGANISM", 29, 33], ["tract", "ORGANISM_SUBDIVISION", 150, 155], ["dogs", "SPECIES", 29, 33], ["This virus", "PROBLEM", 0, 10], ["pharyngotracheitis", "PROBLEM", 39, 57], ["this virus", "PROBLEM", 122, 132], ["respiratory tract disease", "PROBLEM", 138, 163], ["respiratory tract", "ANATOMY", 138, 155]]], ["Thus, following a combined nasal-trach\u00e9al route of infec tion, signs and lesions were confined to the respiratory tract.", [["nasal", "ANATOMY", 27, 32], ["lesions", "ANATOMY", 73, 80], ["respiratory tract", "ANATOMY", 102, 119], ["infec", "ORGANISM", 51, 56], ["lesions", "PATHOLOGICAL_FORMATION", 73, 80], ["respiratory tract", "ORGANISM_SUBDIVISION", 102, 119], ["a combined nasal-trach\u00e9al route of infec tion", "TREATMENT", 16, 61], ["signs and lesions", "PROBLEM", 63, 80], ["lesions", "OBSERVATION", 73, 80], ["respiratory tract", "ANATOMY", 102, 119]]], ["There was a prolif erating necrotizing bronchitis and bronchiolitis, and large intranuclear inclusions were seen in the bronchial epithelial and alveolar septal cells (Swango et al., 1976) .DiagnosisThe canine adenoviruses are easily isolated in canine kidney cell cultures and in the MDCK cell line (Cabasso et al., 1954; Yamamoto, 1966; Danskin, 1973) .", [["bronchial epithelial", "ANATOMY", 120, 140], ["alveolar septal cells", "ANATOMY", 145, 166], ["kidney cell cultures", "ANATOMY", 253, 273], ["MDCK cell line", "ANATOMY", 285, 299], ["bronchitis", "DISEASE", 39, 49], ["bronchiolitis", "DISEASE", 54, 67], ["bronchial epithelial", "CELL", 120, 140], ["alveolar septal cells", "CELL", 145, 166], ["canine", "ORGANISM", 203, 209], ["adenoviruses", "ORGANISM", 210, 222], ["canine", "ORGANISM", 246, 252], ["kidney cell cultures", "CELL", 253, 273], ["MDCK cell line", "CELL", 285, 299], ["bronchial epithelial and alveolar septal cells", "CELL_TYPE", 120, 166], ["canine kidney cell cultures", "CELL_LINE", 246, 273], ["MDCK cell line", "CELL_LINE", 285, 299], ["canine", "SPECIES", 203, 209], ["canine", "SPECIES", 246, 252], ["canine", "SPECIES", 203, 209], ["canine", "SPECIES", 246, 252], ["a prolif erating necrotizing bronchitis", "PROBLEM", 10, 49], ["bronchiolitis", "PROBLEM", 54, 67], ["large intranuclear inclusions", "PROBLEM", 73, 102], ["The canine adenoviruses", "PROBLEM", 199, 222], ["canine kidney cell cultures", "TEST", 246, 273], ["the MDCK cell line", "TEST", 281, 299], ["necrotizing", "OBSERVATION_MODIFIER", 27, 38], ["bronchitis", "OBSERVATION", 39, 49], ["bronchiolitis", "OBSERVATION", 54, 67], ["large", "OBSERVATION_MODIFIER", 73, 78], ["intranuclear inclusions", "OBSERVATION", 79, 102], ["bronchial epithelial", "ANATOMY", 120, 140], ["alveolar", "ANATOMY_MODIFIER", 145, 153], ["septal cells", "ANATOMY", 154, 166], ["kidney", "ANATOMY", 253, 259], ["cell cultures", "OBSERVATION", 260, 273], ["MDCK cell line", "OBSERVATION", 285, 299]]], ["Cl virus will also replicate in pig, raccoon, and ferret kidney cells (Fieldsteel and Yoshihara, 1957; Bolin et al., 1958; Emery and York, 1958) .", [["kidney cells", "ANATOMY", 57, 69], ["Cl", "CHEMICAL", 0, 2], ["Cl virus", "ORGANISM", 0, 8], ["pig", "ORGANISM", 32, 35], ["ferret", "ORGANISM", 50, 56], ["kidney cells", "CELL", 57, 69], ["ferret kidney cells", "CELL_TYPE", 50, 69], ["pig", "SPECIES", 32, 35], ["ferret", "SPECIES", 50, 56], ["Cl virus", "SPECIES", 0, 8], ["pig", "SPECIES", 32, 35], ["ferret", "SPECIES", 50, 56], ["Cl virus", "PROBLEM", 0, 8], ["virus", "OBSERVATION", 3, 8], ["kidney", "ANATOMY", 57, 63]]], ["The virus, in common with other adenoviruses, affects the epithelial cells (Cabasso et al., 1954) .", [["epithelial cells", "ANATOMY", 58, 74], ["adenoviruses", "ORGANISM", 32, 44], ["epithelial cells", "CELL", 58, 74], ["epithelial cells", "CELL_TYPE", 58, 74], ["The virus", "PROBLEM", 0, 9], ["other adenoviruses", "PROBLEM", 26, 44], ["virus", "OBSERVATION", 4, 9], ["adenoviruses", "OBSERVATION", 32, 44], ["epithelial cells", "OBSERVATION", 58, 74]]], ["Hemagglutinin is produced in the cell fluid, and the isolate can be typed against appropriate serum.", [["cell fluid", "ANATOMY", 33, 43], ["serum", "ANATOMY", 94, 99], ["Hemagglutinin", "CHEMICAL", 0, 13], ["Hemagglutinin", "GENE_OR_GENE_PRODUCT", 0, 13], ["cell", "CELL", 33, 37], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["Hemagglutinin", "PROTEIN", 0, 13], ["Hemagglutinin", "TREATMENT", 0, 13], ["the cell fluid", "TEST", 29, 43], ["cell fluid", "OBSERVATION", 33, 43]]], ["Mouse ascitic fluid is often used as a source of antibody (Wright and Burns, 1966) .", [["ascitic fluid", "ANATOMY", 6, 19], ["Mouse", "ORGANISM", 0, 5], ["ascitic fluid", "ORGANISM_SUBSTANCE", 6, 19], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse ascitic fluid", "PROBLEM", 0, 19], ["ascitic", "ANATOMY", 6, 13], ["fluid", "OBSERVATION", 14, 19]]], ["Organ culture of dog trachea can also be used .", [["Organ", "ANATOMY", 0, 5], ["trachea", "ANATOMY", 21, 28], ["dog", "ORGANISM", 17, 20], ["trachea", "ORGAN", 21, 28], ["dog", "SPECIES", 17, 20], ["dog", "SPECIES", 17, 20], ["Organ culture", "TEST", 0, 13], ["dog trachea", "PROBLEM", 17, 28], ["trachea", "ANATOMY", 21, 28]]], ["Immunofluorescent staining of liver sections from cases of ICH has proved both quick and sensitive (Wright and Burns, 1966) .DiagnosisSerological investigations can be undertaken using the SN (Carmichael et al., 1963) or HI test.", [["liver sections", "ANATOMY", 30, 44], ["ICH", "DISEASE", 59, 62], ["liver sections", "MULTI-TISSUE_STRUCTURE", 30, 44], ["Immunofluorescent staining", "TEST", 0, 26], ["liver sections", "TEST", 30, 44], ["ICH", "PROBLEM", 59, 62], ["DiagnosisSerological investigations", "TEST", 125, 160], ["HI test", "TEST", 221, 228], ["liver", "ANATOMY", 30, 35], ["ICH", "OBSERVATION", 59, 62]]], ["Following thermal inactivation and kaolin treatment, the sera are tested for HI antibody using human cells (Espmark and Salenstedt, 1961; Marusyk and Yamamoto, 1971 )./ .", [["sera", "ANATOMY", 57, 61], ["cells", "ANATOMY", 101, 106], ["kaolin", "CHEMICAL", 35, 41], ["kaolin", "CHEMICAL", 35, 41], ["kaolin", "SIMPLE_CHEMICAL", 35, 41], ["sera", "ORGANISM_SUBSTANCE", 57, 61], ["HI antibody", "GENE_OR_GENE_PRODUCT", 77, 88], ["human", "ORGANISM", 95, 100], ["cells", "CELL", 101, 106], ["HI antibody", "PROTEIN", 77, 88], ["human cells", "CELL_TYPE", 95, 106], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["thermal inactivation", "TREATMENT", 10, 30], ["kaolin treatment", "TREATMENT", 35, 51], ["the sera", "TEST", 53, 61], ["HI antibody", "TEST", 77, 88]]], ["ClassificationViruses derived from rhesus (Macaca mulatta), patas (Erythrocebus patas), and vervet (Cercopithecus aethiops) monkeys fall into 16 species (Hull et al., 1956 (Hull et al., , 1958 Tyrrell et al., 1960; Malherbe and Harwin, 1963; Pereira et al., 1963 ; (Table V) .", [["rhesus", "ORGANISM", 35, 41], ["Macaca mulatta", "ORGANISM", 43, 57], ["patas", "ORGANISM", 60, 65], ["Erythrocebus patas", "ORGANISM", 67, 85], ["vervet", "ORGANISM", 92, 98], ["Cercopithecus aethiops", "ORGANISM", 100, 122], ["monkeys", "ORGANISM", 124, 131], ["rhesus", "SPECIES", 35, 41], ["Macaca mulatta", "SPECIES", 43, 57], ["Erythrocebus patas", "SPECIES", 67, 85], ["vervet", "SPECIES", 92, 98], ["Cercopithecus aethiops", "SPECIES", 100, 122], ["monkeys", "SPECIES", 124, 131], ["Macaca mulatta", "SPECIES", 43, 57], ["Erythrocebus patas", "SPECIES", 67, 85], ["vervet", "SPECIES", 92, 98], ["Cercopithecus aethiops", "SPECIES", 100, 122], ["ClassificationViruses", "TEST", 0, 21], ["rhesus (Macaca mulatta)", "TREATMENT", 35, 58], ["patas (Erythrocebus patas)", "TREATMENT", 60, 86], ["vervet (Cercopithecus aethiops", "TREATMENT", 92, 122]]], ["SV23 and SV39 could be distinguished using the HI test but are similar using the SN test and are classified as one species, S6.", [["SV23", "GENE_OR_GENE_PRODUCT", 0, 4], ["SV39", "GENE_OR_GENE_PRODUCT", 9, 13], ["SV23", "CELL_LINE", 0, 4], ["SV39", "DNA", 9, 13], ["S6", "PROTEIN", 124, 126], ["the HI test", "TEST", 43, 54], ["the SN test", "TEST", 77, 88]]], ["S10 and S14, although similar using the HI test, could be distinguished using the SN test and are therefore classified separately (Rapoza, 1967; Hull, 1968) .", [["S10", "GENE_OR_GENE_PRODUCT", 0, 3], ["S14", "GENE_OR_GENE_PRODUCT", 8, 11], ["S10", "PROTEIN", 0, 3], ["S14", "PROTEIN", 8, 11], ["the HI test", "TEST", 36, 47], ["the SN test", "TEST", 78, 89], ["S14", "ANATOMY", 8, 11]]], ["Viruses isolated from vervet monkeys were identified as either S3 or an unclassified type, V340 (Kim et al., 1967) , and isolates from baboons (Papio species) were either S16 or V340 (Eugster\u00e9tf\u00fbr/., 1969) ./ .", [["Viruses", "ORGANISM", 0, 7], ["vervet", "ORGANISM", 22, 28], ["monkeys", "ORGANISM", 29, 36], ["baboons", "ORGANISM", 135, 142], ["Papio species", "ORGANISM", 144, 157], ["vervet monkeys", "SPECIES", 22, 36], ["vervet monkeys", "SPECIES", 22, 36], ["Viruses", "PROBLEM", 0, 7], ["Papio species", "TEST", 144, 157]]], ["ClassificationThere was no crossing between SI-15 and 22 human adenoviruses, using both HI and SN tests, except that S2 and S7 neutralized H25 and H12, respec tively, at very low dilutions (Hull, 1968) ./ .", [["human", "ORGANISM", 57, 62], ["adenoviruses", "ORGANISM", 63, 75], ["S7", "GENE_OR_GENE_PRODUCT", 124, 126], ["H25", "GENE_OR_GENE_PRODUCT", 139, 142], ["H12", "PROTEIN", 147, 150], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["SI", "TEST", 44, 46], ["SN tests", "TEST", 95, 103], ["no", "UNCERTAINTY", 24, 26]]], ["ClassificationViruses have been isolated from chimpanzees (Pan troglodytes troglodytes) by a number of workers (Rowe et al., 1956; Hillis and Goodman, 1969; Basnight et al., 1971) .", [["chimpanzees", "ORGANISM", 46, 57], ["Pan troglodytes", "ORGANISM", 59, 74], ["troglodytes", "ORGANISM", 75, 86], ["Pan troglodytes", "SPECIES", 59, 74], ["troglodytes", "SPECIES", 75, 86], ["Pan troglodytes troglodytes", "SPECIES", 59, 86]]], ["The relationship of some of the chimpanzee and human adenoviruses has been discussed in Section II.DistributionNeutralizing antibody to SVI5 and V340 is widespread in primates, including man(Kinm a/., 1967).Epidemiology and Pathog\u00e8ne sisSome strains (SI, S2, S3, S4, S6, and S10) are more often isolated from the respiratory tract, while other strains are frequently isolated from feces (Hull, 1968) .Association with Diseasea.", [["respiratory tract", "ANATOMY", 313, 330], ["feces", "ANATOMY", 381, 386], ["chimpanzee", "ORGANISM", 32, 42], ["human", "ORGANISM", 47, 52], ["adenoviruses", "ORGANISM", 53, 65], ["SVI5", "GENE_OR_GENE_PRODUCT", 136, 140], ["V340", "GENE_OR_GENE_PRODUCT", 145, 149], ["primates", "ORGANISM", 167, 175], ["man", "ORGANISM", 187, 190], ["Pathog\u00e8ne sisSome strains", "ORGANISM", 224, 249], ["S3", "GENE_OR_GENE_PRODUCT", 259, 261], ["S4", "GENE_OR_GENE_PRODUCT", 263, 265], ["S6", "GENE_OR_GENE_PRODUCT", 267, 269], ["S10", "GENE_OR_GENE_PRODUCT", 275, 278], ["respiratory tract", "ORGANISM_SUBDIVISION", 313, 330], ["feces", "ORGANISM_SUBSTANCE", 381, 386], ["SVI5", "PROTEIN", 136, 140], ["V340", "PROTEIN", 145, 149], ["S6", "PROTEIN", 267, 269], ["S10", "PROTEIN", 275, 278], ["human", "SPECIES", 47, 52], ["man", "SPECIES", 187, 190], ["human", "SPECIES", 47, 52], ["the chimpanzee and human adenoviruses", "TREATMENT", 28, 65], ["Distribution", "TEST", 99, 111], ["Neutralizing antibody", "TEST", 111, 132], ["SVI5", "TEST", 136, 140], ["Pathog\u00e8ne sisSome strains (SI, S2, S3, S4, S6, and S10)", "PROBLEM", 224, 279], ["the respiratory tract", "PROBLEM", 309, 330], ["other strains", "PROBLEM", 338, 351], ["Diseasea", "PROBLEM", 418, 426], ["widespread", "OBSERVATION_MODIFIER", 153, 163], ["S2", "ANATOMY", 255, 257], ["S3", "ANATOMY", 259, 261], ["S4", "ANATOMY_MODIFIER", 263, 265], ["S6", "ANATOMY", 267, 269], ["S10", "ANATOMY", 275, 278], ["respiratory tract", "ANATOMY", 313, 330], ["Diseasea", "OBSERVATION", 418, 426]]], ["Adenoviruses have been isolated from normal animals or from latently infected cells (Malherbe and Harwin, 1963; Bullock, 1965; Hillis and Goodman, 1969; Basmight et al., 1971) . b.", [["cells", "ANATOMY", 78, 83], ["latently infected", "DISEASE", 60, 77], ["cells", "CELL", 78, 83], ["latently infected cells", "CELL_TYPE", 60, 83], ["Adenoviruses", "PROBLEM", 0, 12], ["latently infected cells", "PROBLEM", 60, 83], ["normal", "OBSERVATION_MODIFIER", 37, 43], ["animals", "OBSERVATION_MODIFIER", 44, 51], ["latently", "OBSERVATION_MODIFIER", 60, 68], ["infected cells", "OBSERVATION", 69, 83]]], ["Pneumoenteritis.", [["Pneumoenteritis", "DISEASE", 0, 15], ["Pneumoenteritis", "PROBLEM", 0, 15]]], ["Eugster et al. (1969) described outbreaks in young baboons 1-2 weeks postpartum from which V340 and three SA7 viruses were isolated.", [["three SA7 viruses", "PROBLEM", 100, 117]]], ["Kim et al. (1967) isolated V340 and S3 viruses from vervet monkeys with chronic interstitial type pneumonia and enteritis.", [["interstitial type pneumonia", "DISEASE", 80, 107], ["enteritis", "DISEASE", 112, 121], ["V340", "CELL", 27, 31], ["vervet", "ORGANISM", 52, 58], ["monkeys", "ORGANISM", 59, 66], ["vervet monkeys", "SPECIES", 52, 66], ["vervet monkeys", "SPECIES", 52, 66], ["S3 viruses", "PROBLEM", 36, 46], ["chronic interstitial type pneumonia", "PROBLEM", 72, 107], ["enteritis", "PROBLEM", 112, 121], ["S3", "ANATOMY", 36, 38], ["viruses", "OBSERVATION", 39, 46], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["interstitial", "OBSERVATION_MODIFIER", 80, 92], ["type", "OBSERVATION_MODIFIER", 93, 97], ["pneumonia", "OBSERVATION", 98, 107], ["enteritis", "OBSERVATION", 112, 121]]], ["S10 strains were isolated from a number of monkeys with pneumonia and diarrhea (Bullock, 1965 ).", [["pneumonia", "DISEASE", 56, 65], ["diarrhea", "DISEASE", 70, 78], ["monkeys", "ORGANISM", 43, 50], ["S10 strains", "PROBLEM", 0, 11], ["pneumonia", "PROBLEM", 56, 65], ["diarrhea", "PROBLEM", 70, 78], ["pneumonia", "OBSERVATION", 56, 65], ["diarrhea", "OBSERVATION", 70, 78]]], ["An S4 virus was isolated from patas monkeys suffering from an epidemic of conjuncti vitis and rhinorrhea (Tyrrell et al., 1960) .Association with Diseasec.", [["conjuncti vitis", "DISEASE", 74, 89], ["rhinorrhea", "DISEASE", 94, 104], ["S4 virus", "ORGANISM", 3, 11], ["patas monkeys", "ORGANISM", 30, 43], ["conjuncti", "ORGANISM", 74, 83], ["An S4 virus", "PROBLEM", 0, 11], ["conjuncti vitis", "PROBLEM", 74, 89], ["rhinorrhea", "PROBLEM", 94, 104], ["Diseasec", "PROBLEM", 146, 154], ["S4", "ANATOMY", 3, 5], ["virus", "OBSERVATION", 6, 11], ["epidemic", "OBSERVATION_MODIFIER", 62, 70], ["conjuncti vitis", "OBSERVATION", 74, 89]]], ["Enteritis.", [["Enteritis", "DISEASE", 0, 9], ["Enteritis", "PROBLEM", 0, 9]]], ["A number of workers have reported the isolation of adenoviruses from monkeys with diarrhea (Hoffert et al., 1958; Rapoza et al., 1961; Hull et al., 1968) .Association with Diseased.", [["diarrhea", "DISEASE", 82, 90], ["adenoviruses", "ORGANISM", 51, 63], ["monkeys", "ORGANISM", 69, 76], ["monkeys", "SPECIES", 69, 76], ["diarrhea", "PROBLEM", 82, 90], ["Diseased", "OBSERVATION", 172, 180]]], ["Chandler et al. (1974) have reported the association of adenovirus infection with necrotizing pancreatitis in a rhesus monkey.", [["adenovirus infection", "DISEASE", 56, 76], ["necrotizing pancreatitis", "DISEASE", 82, 106], ["adenovirus", "ORGANISM", 56, 66], ["rhesus", "ORGANISM", 112, 118], ["monkey", "ORGANISM", 119, 125], ["rhesus monkey", "SPECIES", 112, 125], ["rhesus monkey", "SPECIES", 112, 125], ["adenovirus infection", "PROBLEM", 56, 76], ["necrotizing pancreatitis", "PROBLEM", 82, 106], ["adenovirus", "ANATOMY", 56, 66], ["infection", "OBSERVATION", 67, 76], ["necrotizing", "OBSERVATION_MODIFIER", 82, 93], ["pancreatitis", "OBSERVATION", 94, 106]]], ["S3(SV15),S4(SV17), S6(SV23),S9(SV31), S10(SV32),S14(SV37) S1(SV1),S2(SV11), S5(SV20),S7(SV25), S8(SV30),S11(SV33), S12(SV34),S15(SV38) S16 ( (S6, S14) S1,S2, S5, S7,S8,S11 S12, S15 S16 (1978) .", [["S3", "GENE_OR_GENE_PRODUCT", 0, 2], ["SV15", "GENE_OR_GENE_PRODUCT", 3, 7], ["S4", "GENE_OR_GENE_PRODUCT", 9, 11], ["SV17", "GENE_OR_GENE_PRODUCT", 12, 16], ["S6", "GENE_OR_GENE_PRODUCT", 19, 21], ["SV23", "GENE_OR_GENE_PRODUCT", 22, 26], ["S9", "GENE_OR_GENE_PRODUCT", 28, 30], ["SV31", "GENE_OR_GENE_PRODUCT", 31, 35], ["S10", "GENE_OR_GENE_PRODUCT", 38, 41], ["SV32", "GENE_OR_GENE_PRODUCT", 42, 46], ["S14", "GENE_OR_GENE_PRODUCT", 48, 51], ["SV37) S1", "GENE_OR_GENE_PRODUCT", 52, 60], ["SV1", "GENE_OR_GENE_PRODUCT", 61, 64], ["S2", "GENE_OR_GENE_PRODUCT", 66, 68], ["SV11", "GENE_OR_GENE_PRODUCT", 69, 73], ["S5", "GENE_OR_GENE_PRODUCT", 76, 78], ["SV20", "GENE_OR_GENE_PRODUCT", 79, 83], ["S7", "GENE_OR_GENE_PRODUCT", 85, 87], ["SV25", "GENE_OR_GENE_PRODUCT", 88, 92], ["S8", "GENE_OR_GENE_PRODUCT", 95, 97], ["SV30", "GENE_OR_GENE_PRODUCT", 98, 102], ["S11", "GENE_OR_GENE_PRODUCT", 104, 107], ["SV33", "GENE_OR_GENE_PRODUCT", 108, 112], ["S12", "GENE_OR_GENE_PRODUCT", 115, 118], ["S15", "GENE_OR_GENE_PRODUCT", 125, 128], ["SV38) S16", "GENE_OR_GENE_PRODUCT", 129, 138], ["SV17", "PROTEIN", 12, 16], ["S6", "PROTEIN", 19, 21], ["SV23", "PROTEIN", 22, 26], ["S9", "PROTEIN", 28, 30], ["SV31", "PROTEIN", 31, 35], ["S10", "PROTEIN", 38, 41], ["SV32", "PROTEIN", 42, 46], ["S14", "PROTEIN", 48, 51], ["SV37", "PROTEIN", 52, 56], ["S1", "PROTEIN", 58, 60], ["SV1", "PROTEIN", 61, 64], ["S2", "PROTEIN", 66, 68], ["SV11", "PROTEIN", 69, 73], ["S5", "PROTEIN", 76, 78], ["SV20", "PROTEIN", 79, 83], ["S7", "PROTEIN", 85, 87], ["SV25", "PROTEIN", 88, 92], ["S8", "PROTEIN", 95, 97], ["SV30", "PROTEIN", 98, 102], ["S11", "PROTEIN", 104, 107], ["SV33", "PROTEIN", 108, 112], ["S12", "PROTEIN", 115, 118], ["SV34", "PROTEIN", 119, 123], ["S15", "PROTEIN", 125, 128], ["SV38", "PROTEIN", 129, 133], ["S16", "PROTEIN", 135, 138], ["S6", "PROTEIN", 142, 144], ["S14", "PROTEIN", 146, 149], ["S1", "PROTEIN", 151, 153], ["S2", "PROTEIN", 154, 156], ["S5", "PROTEIN", 158, 160], ["S7", "PROTEIN", 162, 164], ["S8", "PROTEIN", 165, 167], ["S11", "PROTEIN", 168, 171], ["S12", "PROTEIN", 172, 175], ["S15", "PROTEIN", 177, 180], ["1978", "PROTEIN", 186, 190], ["S4", "ANATOMY_MODIFIER", 9, 11], ["S1", "ANATOMY_MODIFIER", 58, 60], ["S2", "ANATOMY_MODIFIER", 66, 68], ["S5", "ANATOMY_MODIFIER", 76, 78], ["S1", "ANATOMY_MODIFIER", 151, 153], ["S2", "ANATOMY_MODIFIER", 154, 156], ["S5", "ANATOMY_MODIFIER", 158, 160], ["S7", "ANATOMY_MODIFIER", 162, 164], ["S8", "ANATOMY_MODIFIER", 165, 167], ["S11 S12", "ANATOMY", 168, 175]]], ["Burnett et al. (1972) found that S6 and S14 are not oncogenic. d Based on Goodheart (1971) .", [["S6", "GENE_OR_GENE_PRODUCT", 33, 35], ["S14", "GENE_OR_GENE_PRODUCT", 40, 43], ["S6", "PROTEIN", 33, 35], ["S14", "PROTEIN", 40, 43], ["S6 and S14", "PROBLEM", 33, 43], ["oncogenic", "PROBLEM", 52, 61], ["S14", "ANATOMY", 40, 43], ["not", "UNCERTAINTY", 48, 51], ["oncogenic", "OBSERVATION", 52, 61]]], ["Note that Burnett et al. (1972) obtained similar results, except that they found S12 had a density of 1.72 and S12 had a density of 1.71. e Based on Burnett et al. (1972) .", [["S12", "PROTEIN", 81, 84], ["a density", "TEST", 89, 98], ["density", "OBSERVATION", 91, 98], ["density", "OBSERVATION", 121, 128]]], ["Note that S5 and S8 have also been included in this group.", [["S5", "GENE_OR_GENE_PRODUCT", 10, 12], ["S8", "GENE_OR_GENE_PRODUCT", 17, 19], ["S5", "PROTEIN", 10, 12], ["S8", "PROTEIN", 17, 19], ["S5 and S8", "PROBLEM", 10, 19]]], ["They are not as closely related as members of other groups are to one another. / All gave 4-32 fold higher titers at 4\u00b0C than at 37\u00b0C, except S7 (SV25) and S8 and (SV30). * Serotypes S2 (SVI 1), S7 (SV25), S8 (SV30), and S16 (SA7) did not agglutinate these erythrocytes.DiagnosisThe monkey adenoviruses apparently grow only in cells of simian origin and probably best in primary homologous kidney cells.", [["erythrocytes", "ANATOMY", 257, 269], ["cells", "ANATOMY", 327, 332], ["kidney cells", "ANATOMY", 390, 402], ["Serotypes S2", "GENE_OR_GENE_PRODUCT", 173, 185], ["S7", "GENE_OR_GENE_PRODUCT", 195, 197], ["erythrocytes", "CELL", 257, 269], ["monkey", "ORGANISM", 283, 289], ["adenoviruses", "ORGANISM", 290, 302], ["cells", "CELL", 327, 332], ["simian", "ORGANISM", 336, 342], ["kidney cells", "CELL", 390, 402], ["SV25", "PROTEIN", 146, 150], ["S8", "PROTEIN", 156, 158], ["SV30", "PROTEIN", 164, 168], ["S7", "PROTEIN", 195, 197], ["S8", "PROTEIN", 206, 208], ["SV30", "PROTEIN", 210, 214], ["S16", "PROTEIN", 221, 224], ["SA7", "PROTEIN", 226, 229], ["erythrocytes", "CELL_TYPE", 257, 269], ["primary homologous kidney cells", "CELL_TYPE", 371, 402], ["Serotypes S2 (SVI", "TEST", 173, 190], ["agglutinate these erythrocytes", "PROBLEM", 239, 269], ["The monkey adenoviruses", "PROBLEM", 279, 302], ["primary homologous kidney cells", "PROBLEM", 371, 402], ["simian origin", "OBSERVATION", 336, 349], ["homologous kidney cells", "OBSERVATION", 379, 402]]], ["All grow in the monkey cell line LLC-MK2 except S13 (Hull, 1958) .", [["cell line", "ANATOMY", 23, 32], ["monkey", "ORGANISM", 16, 22], ["cell line LLC-MK2", "CELL", 23, 40], ["monkey cell line LLC", "CELL_LINE", 16, 36], ["MK2", "PROTEIN", 37, 40], ["grow", "OBSERVATION_MODIFIER", 4, 8], ["monkey cell line", "OBSERVATION", 16, 32], ["LLC", "ANATOMY", 33, 36]]], ["The isolates from chimpanzees also grow in human cells (Basnight et al., 1971 ) .DiagnosisThe HI test, using sensitive rat erythrocytes at 4\u00b0C, is suitable for all strains, except for S13 when rhesus cells must be used and S16 when the SN test is required./ .", [["cells", "ANATOMY", 49, 54], ["erythrocytes", "ANATOMY", 123, 135], ["cells", "ANATOMY", 200, 205], ["chimpanzees", "ORGANISM", 18, 29], ["human", "ORGANISM", 43, 48], ["cells", "CELL", 49, 54], ["rat", "ORGANISM", 119, 122], ["erythrocytes", "CELL", 123, 135], ["rhesus", "ORGANISM", 193, 199], ["cells", "CELL", 200, 205], ["human cells", "CELL_TYPE", 43, 54], ["rat erythrocytes", "CELL_TYPE", 119, 135], ["S13", "PROTEIN", 184, 187], ["rhesus cells", "CELL_TYPE", 193, 205], ["human", "SPECIES", 43, 48], ["rat", "SPECIES", 119, 122], ["human", "SPECIES", 43, 48], ["rat", "SPECIES", 119, 122], ["rhesus", "SPECIES", 193, 199], ["The isolates", "TEST", 0, 12], ["The HI test", "TEST", 90, 101], ["sensitive rat erythrocytes", "PROBLEM", 109, 135], ["all strains", "PROBLEM", 160, 171], ["S13 when rhesus cells", "TREATMENT", 184, 205], ["the SN test", "TEST", 232, 243], ["human cells", "OBSERVATION", 43, 54]]], ["ClassificationThere are two serotypes of mouse adenovirus (van der Veen and Mes, 1974) , represented by the FL strain (Hartley and Rowe, 1960) and the K87 strain (Hashimoto et al., 1966) .", [["mouse", "ORGANISM", 41, 46], ["adenovirus", "ORGANISM", 47, 57], ["FL strain", "ORGANISM", 108, 117], ["mouse", "SPECIES", 41, 46], ["mouse", "SPECIES", 41, 46], ["mouse adenovirus", "PROBLEM", 41, 57], ["serotypes", "OBSERVATION_MODIFIER", 28, 37], ["mouse adenovirus", "OBSERVATION", 41, 57]]], ["Wigand et al. (1977) disagreed and demonstrated a one-way cross, with antiserum to K87 neutralizing both antigens to the same titer but antiserum to FL only neutralizing itself./ .", [["FL", "CHEMICAL", 149, 151], ["antiserum", "ORGANISM_SUBSTANCE", 70, 79], ["K87", "GENE_OR_GENE_PRODUCT", 83, 86], ["antiserum", "ORGANISM_SUBSTANCE", 136, 145], ["FL", "GENE_OR_GENE_PRODUCT", 149, 151], ["K87", "PROTEIN", 83, 86], ["antigens", "PROTEIN", 105, 113], ["antiserum to K87 neutralizing", "TREATMENT", 70, 99]]], ["ClassificationThe isolate of Missal (1969) appears to be unclassified.DistributionTwo out of 11 mice colonies tested had CF antibody, and infection in these colonies ranged from 45 to 96% (Hartley and Rowe, 1960) .", [["colonies", "ANATOMY", 101, 109], ["colonies", "ANATOMY", 157, 165], ["infection", "DISEASE", 138, 147], ["mice", "ORGANISM", 96, 100], ["CF antibody", "PROTEIN", 121, 132], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["11 mice colonies", "TEST", 93, 109], ["CF antibody", "TEST", 121, 132], ["infection", "PROBLEM", 138, 147], ["these colonies", "TEST", 151, 165], ["isolate", "OBSERVATION_MODIFIER", 18, 25], ["appears to be", "UNCERTAINTY", 43, 56], ["unclassified", "OBSERVATION", 57, 69], ["infection", "OBSERVATION", 138, 147]]], ["Another survey found that 11% of mouse colonies tested were infected (Parker et al., 1966) .Epidemiology and Pathog\u00e8ne sisThe FL strain of virus was found in the urine and nasal tissue but not in the saliva or feces.", [["colonies", "ANATOMY", 39, 47], ["urine", "ANATOMY", 162, 167], ["nasal tissue", "ANATOMY", 172, 184], ["saliva", "ANATOMY", 200, 206], ["feces", "ANATOMY", 210, 215], ["mouse", "ORGANISM", 33, 38], ["FL strain", "ORGANISM", 126, 135], ["urine", "ORGANISM_SUBSTANCE", 162, 167], ["nasal tissue", "TISSUE", 172, 184], ["saliva", "ORGANISM_SUBSTANCE", 200, 206], ["feces", "ORGANISM_SUBSTANCE", 210, 215], ["mouse colonies", "CELL_LINE", 33, 47], ["mouse", "SPECIES", 33, 38], ["mouse", "SPECIES", 33, 38], ["Another survey", "TEST", 0, 14], ["mouse colonies", "PROBLEM", 33, 47], ["virus", "PROBLEM", 139, 144], ["the urine and nasal tissue", "PROBLEM", 158, 184], ["virus", "OBSERVATION", 139, 144], ["urine", "ANATOMY", 162, 167], ["nasal tissue", "ANATOMY", 172, 184], ["feces", "OBSERVATION", 210, 215]]], ["Infection is transmitted to in-contacts in the same cage but not in the same room.", [["Infection", "PROBLEM", 0, 9]]], ["Maternal antibody is protective (Hartley and Rowe, 1960) .", [["Maternal antibody", "PROTEIN", 0, 17]]], ["The FL strain given intraperitoneally to adult mice produced a persistent infection of the kidneys, shown by an extensive mononuclear cell infiltration of the cortex and medulla and tubular necrosis.", [["kidneys", "ANATOMY", 91, 98], ["mononuclear cell", "ANATOMY", 122, 138], ["cortex", "ANATOMY", 159, 165], ["medulla", "ANATOMY", 170, 177], ["tubular", "ANATOMY", 182, 189], ["FL", "CHEMICAL", 4, 6], ["infection of the kidneys", "DISEASE", 74, 98], ["necrosis", "DISEASE", 190, 198], ["FL strain", "ORGANISM", 4, 13], ["mice", "ORGANISM", 47, 51], ["kidneys", "ORGAN", 91, 98], ["mononuclear cell", "CELL", 122, 138], ["cortex", "CANCER", 159, 165], ["medulla", "TISSUE", 170, 177], ["tubular necrosis", "TISSUE", 182, 198], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["The FL strain", "TREATMENT", 0, 13], ["a persistent infection of the kidneys", "PROBLEM", 61, 98], ["an extensive mononuclear cell infiltration of the cortex", "PROBLEM", 109, 165], ["tubular necrosis", "PROBLEM", 182, 198], ["FL strain", "OBSERVATION", 4, 13], ["persistent", "OBSERVATION_MODIFIER", 63, 73], ["infection", "OBSERVATION", 74, 83], ["kidneys", "ANATOMY", 91, 98], ["extensive", "OBSERVATION_MODIFIER", 112, 121], ["mononuclear cell infiltration", "OBSERVATION", 122, 151], ["cortex", "ANATOMY_MODIFIER", 159, 165], ["medulla", "ANATOMY", 170, 177], ["tubular", "ANATOMY_MODIFIER", 182, 189], ["necrosis", "OBSERVATION", 190, 198]]], ["These changes predisposed to pyelonephritis (Ginder, 1965) .", [["pyelonephritis", "DISEASE", 29, 43], ["pyelonephritis", "PROBLEM", 29, 43], ["pyelonephritis", "OBSERVATION", 29, 43]]], ["Similar adenovirus effects have also been described in dogs (Ginder, 1974) .", [["adenovirus", "ORGANISM", 8, 18], ["dogs", "ORGANISM", 55, 59], ["dogs", "SPECIES", 55, 59], ["Similar adenovirus effects", "PROBLEM", 0, 26], ["adenovirus", "OBSERVATION", 8, 18]]], ["In adult mice with an inapparent infection, a viruria lasting for months or years was found (van der Veen and Mes, 1973) .Epidemiology and Pathog\u00e8ne sisThe K87 strain produced an intestinal infection, with peak fecal titers for 1-2 weeks after infection and virus continuing to be excreted for up to 4 weeks.", [["intestinal", "ANATOMY", 179, 189], ["fecal", "ANATOMY", 211, 216], ["inapparent infection", "DISEASE", 22, 42], ["viruria", "DISEASE", 46, 53], ["intestinal infection", "DISEASE", 179, 199], ["infection", "DISEASE", 244, 253], ["mice", "ORGANISM", 9, 13], ["K87 strain", "ORGANISM", 156, 166], ["intestinal", "ORGAN", 179, 189], ["fecal", "ORGANISM_SUBSTANCE", 211, 216], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["an inapparent infection", "PROBLEM", 19, 42], ["a viruria", "PROBLEM", 44, 53], ["an intestinal infection", "PROBLEM", 176, 199], ["peak fecal titers", "PROBLEM", 206, 223], ["infection", "PROBLEM", 244, 253], ["virus", "PROBLEM", 258, 263], ["inapparent", "OBSERVATION_MODIFIER", 22, 32], ["infection", "OBSERVATION", 33, 42], ["viruria", "OBSERVATION", 46, 53], ["intestinal", "ANATOMY", 179, 189], ["infection", "OBSERVATION", 190, 199], ["infection", "OBSERVATION", 244, 253]]], ["No excretion was detected in oronasal excretions or urine (Sugiyama^/ al., 1967) .Association with DiseaseThe FL strain was isolated from an apparently latently infected culture (Hartley and Rowe, 1960) and the K87 strain from the feces of apparently healthy mice (Hashimotoet al., 1966) .", [["oronasal", "ANATOMY", 29, 37], ["urine", "ANATOMY", 52, 57], ["feces", "ANATOMY", 231, 236], ["oronasal", "ORGANISM_SUBDIVISION", 29, 37], ["urine", "ORGANISM_SUBSTANCE", 52, 57], ["feces", "ORGANISM_SUBDIVISION", 231, 236], ["mice", "ORGANISM", 259, 263], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 259, 263], ["excretion", "PROBLEM", 3, 12], ["oronasal excretions or urine", "TEST", 29, 57], ["DiseaseThe FL strain", "PROBLEM", 99, 119], ["an apparently latently infected culture", "PROBLEM", 138, 177], ["excretion", "OBSERVATION", 3, 12], ["Disease", "OBSERVATION", 99, 106], ["FL strain", "OBSERVATION", 110, 119], ["latently", "OBSERVATION_MODIFIER", 152, 160], ["infected", "OBSERVATION", 161, 169]]], ["In newborn mice, lesions and intranuclear inclusions are seen in a number of organs, includ ing myocardium and brown fat.", [["lesions", "ANATOMY", 17, 24], ["intranuclear inclusions", "ANATOMY", 29, 52], ["organs", "ANATOMY", 77, 83], ["ing myocardium", "ANATOMY", 92, 106], ["brown fat", "ANATOMY", 111, 120], ["mice", "ORGANISM", 11, 15], ["lesions", "PATHOLOGICAL_FORMATION", 17, 24], ["organs", "ORGAN", 77, 83], ["ing myocardium", "TISSUE", 92, 106], ["brown fat", "TISSUE", 111, 120], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["lesions", "PROBLEM", 17, 24], ["intranuclear inclusions", "PROBLEM", 29, 52], ["lesions", "OBSERVATION", 17, 24], ["intranuclear inclusions", "OBSERVATION", 29, 52], ["organs", "ANATOMY", 77, 83], ["myocardium", "ANATOMY", 96, 106], ["brown fat", "OBSERVATION", 111, 120]]], ["The FL strain inoculated into mice with an Ehrlich's ascitic form of carcinoma produced a fatal illness.", [["carcinoma", "ANATOMY", 69, 78], ["FL", "CHEMICAL", 4, 6], ["carcinoma", "DISEASE", 69, 78], ["FL strain", "ORGANISM", 4, 13], ["mice", "ORGANISM", 30, 34], ["Ehrlich", "CANCER", 43, 50], ["carcinoma", "CANCER", 69, 78], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["The FL strain", "PROBLEM", 0, 13], ["carcinoma", "PROBLEM", 69, 78], ["a fatal illness", "PROBLEM", 88, 103], ["ascitic", "OBSERVATION", 53, 60], ["carcinoma", "OBSERVATION", 69, 78], ["fatal", "OBSERVATION_MODIFIER", 90, 95], ["illness", "OBSERVATION", 96, 103]]], ["The main areas of adenovirus replication were the lung and ascitic cells (Schmidt-Ruppin, 1968) .", [["lung", "ANATOMY", 50, 54], ["ascitic cells", "ANATOMY", 59, 72], ["adenovirus", "ORGANISM", 18, 28], ["lung", "ORGAN", 50, 54], ["ascitic cells", "CELL", 59, 72], ["lung and ascitic cells", "CELL_TYPE", 50, 72], ["adenovirus", "SPECIES", 18, 28], ["adenovirus replication", "TREATMENT", 18, 40], ["ascitic cells", "PROBLEM", 59, 72], ["main", "OBSERVATION_MODIFIER", 4, 8], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["adenovirus replication", "OBSERVATION", 18, 40], ["lung", "ANATOMY", 50, 54], ["ascitic cells", "OBSERVATION", 59, 72]]], ["No disease was produced by other strains in both suckling and weaned mice (Sugiyama^\u00f6/., 1967; Missal, 1969) .DiagnosisMouse kidney cells, and preferably young primary cultures, are the most sensitive.", [["kidney cells", "ANATOMY", 125, 137], ["primary cultures", "ANATOMY", 160, 176], ["mice", "ORGANISM", 69, 73], ["Mouse", "ORGANISM", 119, 124], ["kidney cells", "CELL", 125, 137], ["Mouse kidney cells", "CELL_TYPE", 119, 137], ["young primary cultures", "CELL_LINE", 154, 176], ["mice", "SPECIES", 69, 73], ["Mouse", "SPECIES", 119, 124], ["mice", "SPECIES", 69, 73], ["Sugiyama^\u00f6/., 1967; Missal, 1969)", "SPECIES", 75, 108], ["disease", "PROBLEM", 3, 10], ["Mouse kidney cells", "PROBLEM", 119, 137], ["primary cultures", "TEST", 160, 176], ["disease", "OBSERVATION", 3, 10], ["kidney", "ANATOMY", 125, 131], ["cells", "OBSERVATION", 132, 137]]], ["Some mouse cell lines are sensitive, while other mouse cell lines and cells from other species, including rat, are not (Hartley and Rowe, 1960; Larsen and Nathans., 1977; Wigand et al., 1977) .", [["cell lines", "ANATOMY", 11, 21], ["cell lines", "ANATOMY", 55, 65], ["cells", "ANATOMY", 70, 75], ["mouse", "ORGANISM", 5, 10], ["cell lines", "CELL", 11, 21], ["mouse", "ORGANISM", 49, 54], ["cell lines", "CELL", 55, 65], ["cells", "CELL", 70, 75], ["rat", "ORGANISM", 106, 109], ["mouse cell lines", "CELL_LINE", 5, 21], ["mouse cell lines", "CELL_LINE", 49, 65], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 49, 54], ["rat", "SPECIES", 106, 109], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 49, 54], ["rat", "SPECIES", 106, 109], ["Some mouse cell lines", "PROBLEM", 0, 21], ["mouse cell lines", "OBSERVATION", 5, 21], ["mouse cell lines", "OBSERVATION", 49, 65]]], ["There is one report of cytopathology in PK cells (Missal, 1969) .DiagnosisIsolation of some strains is difficult, requiring up to 56 days of incubation before a good CPE is produced (Hashimoto et al., 1966) ./ .", [["PK cells", "ANATOMY", 40, 48], ["PK cells", "CELL", 40, 48], ["PK cells", "CELL_LINE", 40, 48], ["cytopathology in PK cells", "PROBLEM", 23, 48], ["some strains", "PROBLEM", 87, 99], ["cytopathology", "OBSERVATION", 23, 36], ["PK cells", "OBSERVATION", 40, 48]]], ["ClassificationThe fowl adenoviruses have been classified by a number of workers (Clemmer, 1964; Khanna, 1966; Burke et al., 1968; McFerran et al., 1972; Calnek and Cowen, 1975; McFerran and Connor, 1977; Grimes and King, 1977a) .", [["fowl", "ORGANISM", 18, 22], ["adenoviruses", "ORGANISM", 23, 35], ["fowl adenoviruses", "SPECIES", 18, 35], ["Calnek", "TEST", 153, 159]]], ["Although the strains were initially found to be relatively clearly defined, prime strains were found (McFerran et al., 1972) .", [["the strains", "PROBLEM", 9, 20], ["prime strains", "PROBLEM", 76, 89]]], ["Strains of broad antigenicity were recognized when an isolate of Khanna (1966) was found to neutralize both 58 and 764 (McFerran et al., 1975) .", [["Strains of broad antigenicity", "PROBLEM", 0, 29], ["broad antigenicity", "OBSERVATION", 11, 29]]], ["The presence of prime strains and strains of broad antigenicity has been confirmed by others (Cowen et al., 1977; Grimes and King, 1977a) .DistributionThe fowl adenoviruses have a worldwide distribution.", [["fowl adenoviruses", "ORGANISM", 155, 172], ["fowl adenoviruses", "SPECIES", 155, 172], ["prime strains", "PROBLEM", 16, 29], ["strains of broad antigenicity", "PROBLEM", 34, 63], ["The fowl adenoviruses", "PROBLEM", 151, 172], ["prime strains", "OBSERVATION", 16, 29], ["adenoviruses", "OBSERVATION", 160, 172], ["worldwide", "OBSERVATION_MODIFIER", 180, 189], ["distribution", "OBSERVATION_MODIFIER", 190, 202]]], ["Serological investiga tions have shown that birds on a farm can be infected with many different serotypes.", [["birds", "ORGANISM", 44, 49], ["Serological investiga tions", "TEST", 0, 27], ["many different serotypes", "PROBLEM", 81, 105], ["infected", "OBSERVATION", 67, 75], ["different", "OBSERVATION_MODIFIER", 86, 95], ["serotypes", "OBSERVATION", 96, 105]]], ["Thus Grimes et al. (1977a) found, when testing 16 flocks for adenovi rus antibody, that titers to the eight serotypes used could be found in 8 flocks and to seven serotypes in 6 flocks.", [["adenovi rus antibody", "GENE_OR_GENE_PRODUCT", 61, 81], ["adenovi rus antibody", "PROTEIN", 61, 81], ["testing", "TEST", 39, 46], ["adenovi rus antibody", "PROBLEM", 61, 81]]], ["Antibody to F2, F5, F6, and F8 was found in all flocks and F2 and F8 also had the highest titers, while only Fl was found on 11 farms.", [["F5", "GENE_OR_GENE_PRODUCT", 16, 18], ["F6", "GENE_OR_GENE_PRODUCT", 20, 22], ["F8", "GENE_OR_GENE_PRODUCT", 28, 30], ["F2", "DNA", 12, 14], ["F5", "DNA", 16, 18], ["F6", "DNA", 20, 22], ["F8", "DNA", 28, 30], ["Antibody", "TEST", 0, 8]]], ["Although some of this antibody could be due to a heterotypic antibody response, virus isolation studies support the concept that adenovirus infection is widespread (Khanna, 1966; Yatesetal., 1976; Cowen et al., 1978b) . --380 a Based on the classification of b Based on the classifications of McFerran et al. (1972 McFerran et al. ( , 1975 and McFerran c Based on the classification of Calnek and Cowen (1975) . d Based on Adair (1978) . e See text.Erythrocytes Cytopathology^Original reference USA i-Erythrocytes Cytopathology^Yates and Fry (1957) Calnek and Cowen (1975) Calnek and Cowen (1975) McFerran and Connor (1977) Connor (1977).Epidemiology and PathogenesisVirus was excreted in the feces for up to 20 days after infection, with peak titers 4 to 7 days after infection (Kohn, 1962; Kawamura et al., 1963; Clemmer and Ichinose, 1968) .", [["feces", "ANATOMY", 693, 698], ["adenovirus infection", "DISEASE", 129, 149], ["PathogenesisVirus", "CHEMICAL", 655, 672], ["infection", "DISEASE", 723, 732], ["infection", "DISEASE", 769, 778], ["adenovirus", "ORGANISM", 129, 139], ["feces", "ORGANISM_SUBDIVISION", 693, 698], ["adenovirus", "SPECIES", 129, 139], ["this antibody", "PROBLEM", 17, 30], ["a heterotypic antibody response", "PROBLEM", 47, 78], ["virus isolation studies", "TEST", 80, 103], ["adenovirus infection", "PROBLEM", 129, 149], ["McFerran et al", "TREATMENT", 293, 307], ["Calnek", "TEST", 386, 392], ["Erythrocytes Cytopathology", "TEST", 449, 475], ["PathogenesisVirus", "TEST", 655, 672], ["infection", "PROBLEM", 723, 732], ["peak titers", "TEST", 739, 750], ["infection", "PROBLEM", 769, 778], ["infection", "OBSERVATION", 723, 732]]], ["Clemmer (1972) was able to distinguish between a juvenile and an adult pattern of virus excretion in the feces, depending on the age of infection.", [["feces", "ANATOMY", 105, 110], ["infection", "DISEASE", 136, 145], ["feces", "ORGANISM_SUBDIVISION", 105, 110], ["a juvenile", "PROBLEM", 47, 57], ["virus excretion in the feces", "PROBLEM", 82, 110], ["infection", "PROBLEM", 136, 145], ["virus", "OBSERVATION", 82, 87], ["feces", "ANATOMY", 105, 110], ["infection", "OBSERVATION", 136, 145]]], ["Day-old chicks excreted higher titers of virus for longer periods than did 21-day-old birds.", [["chicks", "ORGANISM", 8, 14], ["birds", "ORGANISM", 86, 91], ["chicks", "SPECIES", 8, 14], ["old chicks excreted higher titers of virus", "PROBLEM", 4, 46], ["higher titers", "OBSERVATION_MODIFIER", 24, 37]]], ["Little information is available on the oronasal secretions as a source of infection, but as virus is often present in the conjunctiva, nasal mucosa, pharynx, and trachea, it seems reasonable to assume that they have a role.", [["oronasal secretions", "ANATOMY", 39, 58], ["conjunctiva", "ANATOMY", 122, 133], ["nasal mucosa", "ANATOMY", 135, 147], ["pharynx", "ANATOMY", 149, 156], ["trachea", "ANATOMY", 162, 169], ["infection", "DISEASE", 74, 83], ["oronasal secretions", "ORGAN", 39, 58], ["conjunctiva", "ORGAN", 122, 133], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 135, 147], ["pharynx", "ORGAN", 149, 156], ["trachea", "ORGAN", 162, 169], ["the oronasal secretions", "PROBLEM", 35, 58], ["infection", "PROBLEM", 74, 83], ["virus", "PROBLEM", 92, 97], ["nasal mucosa, pharynx, and trachea", "PROBLEM", 135, 169], ["infection", "OBSERVATION", 74, 83], ["conjunctiva", "ANATOMY", 122, 133], ["nasal mucosa", "ANATOMY", 135, 147], ["pharynx", "ANATOMY", 149, 156], ["trachea", "ANATOMY", 162, 169]]], ["Egg transmission is important, and many workers have recorded the pres ence of adenovirus in uninoculated embryonated eggs or cell culture (Yates and Fry, 1957; Burke et al., 1965; Khanna, 1966; Cook, 1968) .Epidemiology and PathogenesisExperimental infection of birds with Fl and F2 viruses by natural routes resulted in widespread dissemination of virus, with maximum virus titers in the trachea and feces (Kohn, 1962; Kawamura \u00a3/al., 1963) .Epidemiology and PathogenesisIn a longitudinal survey of broiler flocks (McFerran et al., 1981) , birds were excreting adenovirus from 2-3 weeks of age, and at least two serotypes were found in each flock.", [["eggs", "ANATOMY", 118, 122], ["cell culture", "ANATOMY", 126, 138], ["trachea", "ANATOMY", 390, 397], ["feces", "ANATOMY", 402, 407], ["infection of birds", "DISEASE", 250, 268], ["adenovirus", "ORGANISM", 79, 89], ["cell culture", "CELL", 126, 138], ["birds", "ORGANISM", 263, 268], ["F2 viruses", "ORGANISM", 281, 291], ["trachea", "MULTI-TISSUE_STRUCTURE", 390, 397], ["feces", "ORGANISM_SUBSTANCE", 402, 407], ["birds", "ORGANISM", 542, 547], ["adenovirus", "ORGANISM", 563, 573], ["adenovirus", "PROBLEM", 79, 89], ["uninoculated embryonated eggs", "PROBLEM", 93, 122], ["cell culture", "TEST", 126, 138], ["Experimental infection of birds", "PROBLEM", 237, 268], ["Fl and F2 viruses", "PROBLEM", 274, 291], ["widespread dissemination of virus", "PROBLEM", 322, 355], ["maximum virus titers in the trachea and feces", "PROBLEM", 362, 407], ["broiler flocks", "TREATMENT", 501, 515], ["excreting adenovirus", "PROBLEM", 553, 573], ["Experimental", "OBSERVATION_MODIFIER", 237, 249], ["infection", "OBSERVATION", 250, 259], ["widespread", "OBSERVATION_MODIFIER", 322, 332], ["dissemination", "OBSERVATION", 333, 346], ["virus", "OBSERVATION", 350, 355], ["trachea", "ANATOMY", 390, 397], ["feces", "ANATOMY", 402, 407]]], ["The virus was confined to the intestine, bursa of the Fabricius, and upper respiratory tract, in contrast to the pattern seen in experi mental infection of antibody-free birds with massive doses of virus.", [["intestine", "ANATOMY", 30, 39], ["bursa", "ANATOMY", 41, 46], ["Fabricius", "ANATOMY", 54, 63], ["upper respiratory tract", "ANATOMY", 69, 92], ["infection", "DISEASE", 143, 152], ["intestine", "ORGAN", 30, 39], ["bursa", "ORGAN", 41, 46], ["Fabricius", "TISSUE", 54, 63], ["upper respiratory", "ORGANISM_SUBDIVISION", 69, 86], ["tract", "ORGANISM_SUBDIVISION", 87, 92], ["birds", "ORGANISM", 170, 175], ["The virus", "PROBLEM", 0, 9], ["experi mental infection of antibody", "PROBLEM", 129, 164], ["massive doses of virus", "TREATMENT", 181, 203], ["virus", "OBSERVATION", 4, 9], ["intestine", "ANATOMY", 30, 39], ["bursa", "ANATOMY", 41, 46], ["Fabricius", "ANATOMY", 54, 63], ["upper", "ANATOMY_MODIFIER", 69, 74], ["respiratory tract", "ANATOMY", 75, 92], ["infection", "OBSERVATION", 143, 152]]], ["In the type of husbandry practiced, with depletion of the flocks and with cleansing and disin fection of the houses between flocks, carryover of virus was not important.", [["the flocks", "PROBLEM", 54, 64], ["cleansing", "TREATMENT", 74, 83], ["carryover of virus", "PROBLEM", 132, 150]]], ["The viruses found in these flocks were antigenically similar to those present in the parent flocks of the same organization.", [["The viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11], ["flocks", "OBSERVATION", 27, 33]]], ["Presumably following vertical transmis sion, the virus becomes unmasked with the loss of maternal antibody at 2-4 weeks, and spreads slowly through the flock.", [["maternal antibody", "PROTEIN", 89, 106], ["vertical transmis sion", "PROBLEM", 21, 43], ["the virus", "PROBLEM", 45, 54], ["the loss of maternal antibody", "PROBLEM", 77, 106], ["virus", "OBSERVATION", 49, 54]]], ["Experimental work has shown that maternal antibody is lost within the first 4 weeks of life and that its presence does not prevent infection with some serotypes (Kohn, 1962) , but presumably it does prevent latent virus from becoming activated.", [["infection", "DISEASE", 131, 140], ["maternal antibody", "PROTEIN", 33, 50], ["maternal antibody", "PROBLEM", 33, 50], ["infection", "PROBLEM", 131, 140], ["some serotypes", "PROBLEM", 146, 160], ["latent virus", "PROBLEM", 207, 219], ["infection", "OBSERVATION", 131, 140], ["virus", "OBSERVATION", 214, 219]]], ["Because of the rather frequent isolation of more than one serotype from a bird, it is probable that there is little cross protection on the mucosal surface between species.Association with Disease a.", [["mucosal surface", "ANATOMY", 140, 155], ["mucosal surface", "MULTI-TISSUE_STRUCTURE", 140, 155], ["little cross protection on the mucosal surface between species", "PROBLEM", 109, 171], ["frequent", "OBSERVATION_MODIFIER", 22, 30], ["isolation", "OBSERVATION", 31, 40], ["is probable", "UNCERTAINTY", 83, 94], ["little", "OBSERVATION_MODIFIER", 109, 115], ["cross protection", "OBSERVATION", 116, 132], ["mucosal surface", "OBSERVATION_MODIFIER", 140, 155], ["Disease", "OBSERVATION", 189, 196]]], ["Inclusion Body Hepatitis (IBH).This disease was first recorded in the United States (Helmboldt and Frazier, 1963) .", [["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["Body Hepatitis", "ORGANISM", 10, 24], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["This disease", "PROBLEM", 31, 43], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24], ["disease", "OBSERVATION", 36, 43]]], ["The main sign was a sudden increase in mortality, with very few sick birds.", [["a sudden increase in mortality", "PROBLEM", 18, 48], ["main", "OBSERVATION_MODIFIER", 4, 8], ["sudden", "OBSERVATION_MODIFIER", 20, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35]]], ["Mortality reached 10% and usually peaked on the third and fourth days of onset, with deaths stopping after the fifth day but occasionally continuing for 2.5 weeks (Howell et al., 1970; Pettit and Carlson, 1972; Fadley and Winterfield, 1973; McFerran et al., 1976a) .", [["deaths", "DISEASE", 85, 91]]], ["The main lesions seen were pale, friable, swollen livers.", [["lesions", "ANATOMY", 9, 16], ["livers", "ANATOMY", 50, 56], ["lesions", "CANCER", 9, 16], ["livers", "ORGAN", 50, 56], ["The main lesions", "PROBLEM", 0, 16], ["pale", "PROBLEM", 27, 31], ["friable", "PROBLEM", 33, 40], ["swollen livers", "PROBLEM", 42, 56], ["main", "OBSERVATION_MODIFIER", 4, 8], ["lesions", "OBSERVATION", 9, 16], ["pale", "OBSERVATION_MODIFIER", 27, 31], ["friable", "OBSERVATION_MODIFIER", 33, 40], ["swollen", "OBSERVATION", 42, 49], ["livers", "ANATOMY", 50, 56]]], ["Petechial or ecchymotic hemorrhages may be present in the liver and skeletal muscles (Howell, 1974; Macpherson et al., 1974; McFerran et al., 1976a) .", [["Petechial", "ANATOMY", 0, 9], ["liver", "ANATOMY", 58, 63], ["skeletal muscles", "ANATOMY", 68, 84], ["hemorrhages", "DISEASE", 24, 35], ["liver", "ORGAN", 58, 63], ["skeletal muscles", "TISSUE", 68, 84], ["Petechial or ecchymotic hemorrhages", "PROBLEM", 0, 35], ["ecchymotic", "OBSERVATION_MODIFIER", 13, 23], ["hemorrhages", "OBSERVATION", 24, 35], ["may be", "UNCERTAINTY", 36, 42], ["liver", "ANATOMY", 58, 63], ["skeletal muscles", "ANATOMY", 68, 84]]], ["Some workers consid ered anemia the major sign (Stein, 1975) , and German workers suggested the disease be renamed \"hepatomyelopoietic disease\" (Hoffmann et al., 1975) .Association with Disease a.", [["anemia", "DISEASE", 25, 31], ["hepatomyelopoietic disease", "DISEASE", 116, 142], ["anemia", "PROBLEM", 25, 31], ["the disease", "PROBLEM", 92, 103], ["hepatomyelopoietic disease\"", "PROBLEM", 116, 143], ["Disease", "OBSERVATION", 186, 193]]], ["Inclusion Body Hepatitis (IBH).Eosinophilic inclusions were commonly seen in the hepatocytes of natural cases of IBH (Fig. 5) (Helmboldt and Frazier, 1963; Howell et al., 1970; Bickford et al., 1973; McFerran et al., 1976a) .", [["hepatocytes", "ANATOMY", 81, 92], ["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["IBH", "DISEASE", 113, 116], ["Body Hepatitis", "ORGANISM", 10, 24], ["hepatocytes", "CELL", 81, 92], ["hepatocytes", "CELL_TYPE", 81, 92], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["Eosinophilic inclusions", "PROBLEM", 31, 54], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24], ["inclusions", "OBSERVATION", 44, 54], ["hepatocytes", "ANATOMY", 81, 92]]], ["Basophilic inclusions were rarely seen in field cases of IBH.", [["IBH", "DISEASE", 57, 60], ["IBH", "CANCER", 57, 60], ["Basophilic inclusions", "PROBLEM", 0, 21], ["IBH", "PROBLEM", 57, 60], ["inclusions", "OBSERVATION", 11, 21]]], ["In a study of the livers of 20 naturally infected birds, eosinophilic inclusions were seen in all, but basophilic inclusions were seen only in 6 birds (Itakura et al., 1974 (Itakura et al., , 1977 .", [["livers", "ANATOMY", 18, 24], ["eosinophilic inclusions", "ANATOMY", 57, 80], ["basophilic inclusions", "ANATOMY", 103, 124], ["livers", "ORGAN", 18, 24], ["birds", "ORGANISM", 50, 55], ["a study", "TEST", 3, 10], ["eosinophilic inclusions", "PROBLEM", 57, 80], ["basophilic inclusions", "PROBLEM", 103, 124], ["livers", "ANATOMY", 18, 24], ["eosinophilic inclusions", "OBSERVATION", 57, 80], ["basophilic inclusions", "OBSERVATION", 103, 124]]], ["On electron microscopic examination of the livers in naturally occurring cases, these eosinophilic inclusions contained either very few or no adenovirus particles (Pettit and Carlson, 1972; Bickford et al., 1973; McCracken and McFerran, unpublished observations; (Fig. 5 ).", [["livers", "ANATOMY", 43, 49], ["eosinophilic inclusions", "ANATOMY", 86, 109], ["livers", "ORGAN", 43, 49], ["adenovirus", "ORGANISM", 142, 152], ["electron microscopic examination", "TEST", 3, 35], ["these eosinophilic inclusions", "PROBLEM", 80, 109], ["adenovirus particles", "PROBLEM", 142, 162], ["McCracken", "TREATMENT", 213, 222], ["McFerran", "TREATMENT", 227, 235], ["livers", "ANATOMY", 43, 49], ["eosinophilic inclusions", "OBSERVATION", 86, 109]]], ["Itakura et al. (1977) found that virus particles were detected only in the cells with basophilic inclusions and that the eosinophilic inclusions corresponded to those cells consisting of fibrillar granular material, without viral particles.", [["cells", "ANATOMY", 75, 80], ["basophilic inclusions", "ANATOMY", 86, 107], ["eosinophilic inclusions", "ANATOMY", 121, 144], ["cells", "ANATOMY", 167, 172], ["granular material", "ANATOMY", 197, 214], ["cells", "CELL", 75, 80], ["basophilic inclusions", "CELL", 86, 107], ["cells", "CELL", 167, 172], ["fibrillar granular material", "CELLULAR_COMPONENT", 187, 214], ["virus particles", "PROBLEM", 33, 48], ["basophilic inclusions", "PROBLEM", 86, 107], ["the eosinophilic inclusions", "PROBLEM", 117, 144], ["those cells", "PROBLEM", 161, 172], ["fibrillar granular material", "PROBLEM", 187, 214], ["viral particles", "PROBLEM", 224, 239], ["virus particles", "OBSERVATION", 33, 48], ["cells", "ANATOMY", 75, 80], ["basophilic inclusions", "OBSERVATION", 86, 107], ["eosinophilic inclusions", "OBSERVATION", 121, 144], ["those cells", "OBSERVATION", 161, 172], ["fibrillar granular material", "OBSERVATION", 187, 214], ["without", "UNCERTAINTY", 216, 223], ["viral particles", "OBSERVATION", 224, 239]]], ["The lack of virus particles in the eosinophilic inclusions should be compared to the large numbers of particles associated with the basophilic inclusions in the livers of birds with a hepatitis following experimental infection (Figs.", [["eosinophilic inclusions", "ANATOMY", 35, 58], ["basophilic inclusions", "ANATOMY", 132, 153], ["livers", "ANATOMY", 161, 167], ["hepatitis", "DISEASE", 184, 193], ["infection", "DISEASE", 217, 226], ["livers", "ORGAN", 161, 167], ["birds", "ORGANISM", 171, 176], ["virus particles", "PROBLEM", 12, 27], ["the eosinophilic inclusions", "PROBLEM", 31, 58], ["the basophilic inclusions", "PROBLEM", 128, 153], ["a hepatitis", "PROBLEM", 182, 193], ["experimental infection", "PROBLEM", 204, 226], ["virus particles", "OBSERVATION", 12, 27], ["eosinophilic inclusions", "OBSERVATION", 35, 58], ["large", "OBSERVATION_MODIFIER", 85, 90], ["numbers", "OBSERVATION_MODIFIER", 91, 98], ["particles", "OBSERVATION", 102, 111], ["basophilic inclusions", "OBSERVATION", 132, 153], ["livers", "ANATOMY", 161, 167], ["hepatitis", "OBSERVATION", 184, 193], ["infection", "OBSERVATION", 217, 226]]], ["5 and 6) (Bickford et al., 1973; McCracken and McFerran, unpublished observations) .Association with Disease a.", [["McFerran", "TREATMENT", 47, 55], ["Disease", "OBSERVATION", 101, 108]]], ["Inclusion Body Hepatitis (IBH).The naming of an isolate from IBH as the inclusion body hepatitis virus (Fadley and Winterfield, 1973) was premature because this virus was classified as a type 5 fowl adenovirus (McFerran et al., 1975) , and it is clear that if adenoviruses are associated with the etiology of IBH, then this affinity is not confined to one serotype.", [["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["IBH", "CHEMICAL", 61, 64], ["hepatitis", "DISEASE", 87, 96], ["IBH", "DISEASE", 309, 312], ["Body Hepatitis", "ORGANISM", 10, 24], ["IBH", "CANCER", 61, 64], ["body hepatitis virus", "ORGANISM", 82, 102], ["adenovirus", "ORGANISM", 199, 209], ["adenoviruses", "ORGANISM", 260, 272], ["IBH", "CANCER", 309, 312], ["hepatitis virus", "SPECIES", 87, 102], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["an isolate from IBH", "PROBLEM", 45, 64], ["the inclusion body hepatitis virus", "PROBLEM", 68, 102], ["this virus", "PROBLEM", 156, 166], ["a type 5 fowl adenovirus", "PROBLEM", 185, 209], ["adenoviruses", "PROBLEM", 260, 272], ["IBH", "PROBLEM", 309, 312], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24]]], ["Thus Fl (Winterfield et al., 1973), F2, F3, and F4 (McFerran et al., 1976a; Grimes and King, 1977a) , F5 (Fadly and Winterfield, 1973; McFerran et al., 1976a) , F8 (Macpherson et al., 1974; 1976a; Grimes et al., 1977b) , and F9 (Grimes et al., 1978) have all been isolated from clinical outbreaks of IBH.", [["IBH", "DISEASE", 300, 303], ["F9", "CELL", 225, 227], ["IBH", "CANCER", 300, 303], ["Grimes", "TEST", 197, 203], ["IBH", "PROBLEM", 300, 303]]], ["In addition, unclassified adenoviruses have been found (Di Francos//., 1974; Wells and Harrigan, 1974) .", [["adenoviruses", "ORGANISM", 26, 38], ["unclassified adenoviruses", "PROBLEM", 13, 38], ["adenoviruses", "OBSERVATION", 26, 38]]], ["It should be noted that reoviruses have also been isolated from some outbreaks (Hoffmann et al., 1975; McFerran et al., 1976a) .Association with Disease a.", [["reoviruses", "GENE_OR_GENE_PRODUCT", 24, 34], ["reoviruses", "PROBLEM", 24, 34], ["reoviruses", "OBSERVATION", 24, 34], ["Disease", "OBSERVATION", 145, 152]]], ["Inclusion Body Hepatitis (IBH).A number of workers have been able to reproduce the syndrome, but usually only by parenteral inoculation of very young chicks (Rosenberger et al., 1974; Grimes et al., 1977b) .", [["parenteral", "ANATOMY", 113, 123], ["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["Body Hepatitis", "ORGANISM", 10, 24], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["the syndrome", "PROBLEM", 79, 91], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24]]], ["One group has reproduced it both by natural routes of infection and in older birds (Fadly and Winterfield, 1973) .", [["infection", "DISEASE", 54, 63], ["infection", "PROBLEM", 54, 63], ["infection", "OBSERVATION", 54, 63]]], ["Other workers could not reproduce typical lesions even by unnatural routes (Sharpless and Jungherr, 1961; Kawamura and Horiuchi, 1964; McDougall and Peters, 1974; Macpherson et al., 1974) .", [["lesions", "ANATOMY", 42, 49], ["lesions", "PATHOLOGICAL_FORMATION", 42, 49], ["typical lesions", "PROBLEM", 34, 49], ["lesions", "OBSERVATION", 42, 49]]], ["McCracken et al. (1976) produced a hepatitis when type strains and strains isolated from birds with IBH were inoculated into 5-day-old chicks.", [["hepatitis", "DISEASE", 35, 44], ["IBH", "CHEMICAL", 100, 103], ["birds", "ORGANISM", 89, 94], ["chicks", "ORGANISM", 135, 141], ["chicks", "SPECIES", 135, 141], ["IBH", "SPECIES", 100, 103], ["a hepatitis", "PROBLEM", 33, 44], ["type strains", "PROBLEM", 50, 62], ["strains", "PROBLEM", 67, 74], ["IBH", "TREATMENT", 100, 103], ["hepatitis", "OBSERVATION", 35, 44]]], ["These changes occurred with seven fowl and two turkey adenovirus serotypes, but not with Fl strains.", [["turkey", "ORGANISM", 47, 53], ["adenovirus", "ORGANISM", 54, 64], ["turkey", "SPECIES", 47, 53], ["fowl", "SPECIES", 34, 38], ["turkey adenovirus", "SPECIES", 47, 64], ["These changes", "PROBLEM", 0, 13], ["seven fowl and two turkey adenovirus serotypes", "PROBLEM", 28, 74], ["Fl strains", "PROBLEM", 89, 99]]], ["It may be that some other agent is also required, a suggestion given substance by the development of a hemorrhagic-aplastic anemia syndrome in one trial which was not associated with adenoviruses (Grimes and King, 1977b) .", [["hemorrhagic", "DISEASE", 103, 114], ["aplastic anemia syndrome", "DISEASE", 115, 139], ["adenoviruses", "ORGANISM", 183, 195], ["a hemorrhagic-aplastic anemia syndrome", "PROBLEM", 101, 139], ["adenoviruses", "PROBLEM", 183, 195], ["hemorrhagic", "OBSERVATION_MODIFIER", 103, 114], ["aplastic anemia syndrome", "OBSERVATION", 115, 139], ["not associated with", "UNCERTAINTY", 163, 182]]], ["Some workers have claimed that prior infection with infectious bursal disease virus enhances the pathogenicity of the adenovirus in IBD (Rosenberger et al., 1975; Fadly et al., 1976) , and regression of the bursa of Fabricius in IBD has been described (Pettit and Carlson, 1972; Bickford et al., 1973) .", [["bursal", "ANATOMY", 63, 69], ["bursa", "ANATOMY", 207, 212], ["infection", "DISEASE", 37, 46], ["infectious bursal disease", "DISEASE", 52, 77], ["IBD", "DISEASE", 132, 135], ["IBD", "DISEASE", 229, 232], ["infectious bursal disease virus", "ORGANISM", 52, 83], ["adenovirus", "ORGANISM", 118, 128], ["bursa", "ORGAN", 207, 212], ["Fabricius", "TISSUE", 216, 225], ["infectious bursal disease virus", "SPECIES", 52, 83], ["prior infection", "PROBLEM", 31, 46], ["infectious bursal disease virus", "PROBLEM", 52, 83], ["infection", "OBSERVATION", 37, 46], ["infectious", "OBSERVATION_MODIFIER", 52, 62], ["adenovirus", "ANATOMY", 118, 128], ["bursa", "ANATOMY", 207, 212], ["Fabricius", "ANATOMY", 216, 225], ["IBD", "OBSERVATION", 229, 232]]], ["However, results from both natural cases (MacPherson et al., 1974) and experimental infection (Grimes et al., 1977b) suggest that IBD virus is not necessary to produce the IBH syn drome. b.", [["infection", "DISEASE", 84, 93], ["IBD virus", "SPECIES", 130, 139], ["experimental infection", "PROBLEM", 71, 93], ["IBD virus", "PROBLEM", 130, 139], ["infection", "OBSERVATION", 84, 93]]], ["Depressed Egg Production.", [["Egg", "PROTEIN", 10, 13], ["Depressed Egg Production", "PROBLEM", 0, 24], ["Egg Production", "OBSERVATION", 10, 24]]], ["Winterfield et al. (1973) recorded the isola tion of an Fl (Indiana C) virus from a flock with poor eggshell quality.", [["eggshell", "ANATOMY", 100, 108], ["Fl (Indiana C) virus", "ORGANISM", 56, 76], ["an Fl (Indiana C) virus", "PROBLEM", 53, 76], ["poor eggshell quality", "PROBLEM", 95, 116]]], ["Other workers have attributed a 10% decline in production to adenovirus infection (Berry, 1969; Cook, 1972) .", [["adenovirus infection", "DISEASE", 61, 81], ["adenovirus", "ORGANISM", 61, 71], ["a 10% decline", "PROBLEM", 30, 43], ["adenovirus infection", "PROBLEM", 61, 81]]], ["Adenoviruses were also associated, on the basis of the development of group antigen, with depressed egg production linked to soft-shelled and shell-less eggs in the Netherlands (Van Eck et al., 1976) .", [["egg", "ANATOMY", 100, 103], ["depressed", "DISEASE", 90, 99], ["group antigen", "PROTEIN", 70, 83], ["Adenoviruses", "PROBLEM", 0, 12], ["group antigen", "PROBLEM", 70, 83], ["depressed egg production", "PROBLEM", 90, 114], ["less eggs", "OBSERVATION_MODIFIER", 148, 157]]], ["McFerran et al. (1978a) , investigating the same syndrome, isolated adenoviruses be longing to serological groups from birds 26 to 40 weeks of age.", [["adenoviruses", "ORGANISM", 68, 80], ["birds", "ORGANISM", 119, 124], ["the same syndrome", "PROBLEM", 40, 57], ["isolated adenoviruses", "PROBLEM", 59, 80], ["adenoviruses", "OBSERVATION", 68, 80]]], ["However, they did not feel that these isolates were of major importance in the syndrome.", [["these isolates", "PROBLEM", 32, 46], ["the syndrome", "PROBLEM", 75, 87]]], ["Workers in the United States (Cowen et al., 1978b) experimentally infected birds with four isolates, including Fl (Indiana C).", [["birds", "ORGANISM", 75, 80], ["Indiana C", "ORGANISM", 115, 124]]], ["They had no effect on egg quality, and only one F5 (IBH-2) had a minimal effect on egg production.", [["egg", "ANATOMY", 22, 25], ["egg", "ANATOMY", 83, 86], ["egg", "ORGANISM_SUBDIVISION", 22, 25], ["egg", "ORGANISM_SUBSTANCE", 83, 86], ["effect on egg quality", "PROBLEM", 12, 33], ["IBH", "TEST", 52, 55], ["a minimal effect on egg production", "PROBLEM", 63, 97], ["minimal", "OBSERVATION_MODIFIER", 65, 72]]], ["Furthermore, it is quite common to isolate adenoviruses from uninoculated eggs or cell cultures derived from flocks with normal production (Cook, 1968; McFerran, unpublished observations) .Association with Disease a.", [["eggs", "ANATOMY", 74, 78], ["cell cultures", "ANATOMY", 82, 95], ["adenoviruses", "ORGANISM", 43, 55], ["cell cultures", "CELL", 82, 95], ["cell cultures", "CELL_LINE", 82, 95], ["uninoculated eggs", "PROBLEM", 61, 78], ["cell cultures", "TEST", 82, 95], ["Disease", "OBSERVATION", 206, 213]]], ["Inclusion Body Hepatitis (IBH).c.", [["Body Hepatitis", "DISEASE", 10, 24], ["Body Hepatitis", "ORGANISM", 10, 24], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24]]], ["Poor Food Conversion and Poor Growth.", [["Poor Growth", "PROBLEM", 25, 36], ["Food Conversion", "OBSERVATION", 5, 20], ["Poor", "OBSERVATION_MODIFIER", 25, 29], ["Growth", "OBSERVATION_MODIFIER", 30, 36]]], ["A growing complaint from meat chicken producers is poor food conversion or failure to achieve estimated weights for a given age.", [["chicken", "ORGANISM", 30, 37], ["chicken", "SPECIES", 30, 37], ["chicken", "SPECIES", 30, 37], ["failure", "PROBLEM", 75, 82], ["growing", "OBSERVATION_MODIFIER", 2, 9]]], ["Schwartz (1975) has reported increased food consump tion associated with adenovirus infection, while other workers (Cowen et al., 1978a) found that birds infected with F5 (IBH-2) had decreased food intake.", [["adenovirus infection", "DISEASE", 73, 93], ["birds infected", "DISEASE", 148, 162], ["adenovirus", "ORGANISM", 73, 83], ["birds", "ORGANISM", 148, 153], ["food", "ORGANISM_SUBDIVISION", 193, 197], ["adenovirus", "SPECIES", 73, 83], ["adenovirus infection", "PROBLEM", 73, 93], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["food consump", "OBSERVATION", 39, 51]]], ["Grimes and King (1977b) recorded that an F8 (AAG5 (2a)) virus given intraabdominally depressed body weight, and Cook (1974) , using the same route, found that F2 caused a 70% mortality and a significant depression of weight gain in the survivors.", [["body", "ANATOMY", 95, 99], ["depressed", "DISEASE", 85, 94], ["depression", "DISEASE", 203, 213], ["weight gain", "DISEASE", 217, 228], ["AAG5 (2a)", "GENE_OR_GENE_PRODUCT", 45, 54], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["an F8 (AAG5", "TEST", 38, 49], ["virus", "PROBLEM", 56, 61], ["intraabdominally depressed body weight", "PROBLEM", 68, 106], ["a 70% mortality", "PROBLEM", 169, 184], ["a significant depression of weight gain", "PROBLEM", 189, 228], ["significant", "OBSERVATION_MODIFIER", 191, 202], ["depression", "OBSERVATION", 203, 213]]], ["Surveys of normal and affected broiler flocks in Northern Ireland during the growing period yielded many isolates of adenovirus, but no differences in the types of serotypes or in the numbers isolated could be estab lished.Association with Disease a.", [["adenovirus", "ORGANISM", 117, 127], ["adenovirus", "SPECIES", 117, 127], ["adenovirus", "PROBLEM", 117, 127], ["serotypes", "PROBLEM", 164, 173], ["normal", "OBSERVATION", 11, 17], ["affected", "OBSERVATION_MODIFIER", 22, 30], ["broiler flocks", "OBSERVATION", 31, 45], ["many", "OBSERVATION_MODIFIER", 100, 104], ["isolates", "OBSERVATION_MODIFIER", 105, 113], ["adenovirus", "OBSERVATION", 117, 127], ["serotypes", "OBSERVATION", 164, 173], ["Disease", "OBSERVATION", 240, 247]]], ["Inclusion Body Hepatitis (IBH).d.", [["Body Hepatitis", "DISEASE", 10, 24], ["Body Hepatitis", "ORGANISM", 10, 24], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24]]], ["Tenosynovitis.", [["Tenosynovitis", "DISEASE", 0, 13], ["Tenosynovitis", "PROBLEM", 0, 13]]], ["This condition is usually associated with reovirus infec tion (Olsen and Weiss, 1972) .", [["reovirus", "ORGANISM", 42, 50]]], ["However, during routine isolations, both adenoviruses and reoviruses have been isolated from these affected joints, and many of these have been Fl, which is not a common isolate in Northern Ireland (McFerran, unpublished observations) .", [["joints", "ANATOMY", 108, 114], ["adenoviruses", "ORGANISM", 41, 53], ["reoviruses", "GENE_OR_GENE_PRODUCT", 58, 68], ["joints", "MULTI-TISSUE_STRUCTURE", 108, 114], ["Fl", "GENE_OR_GENE_PRODUCT", 144, 146], ["routine isolations", "TREATMENT", 16, 34], ["both adenoviruses", "PROBLEM", 36, 53], ["reoviruses", "PROBLEM", 58, 68], ["these affected joints", "PROBLEM", 93, 114], ["adenoviruses", "OBSERVATION", 41, 53], ["joints", "ANATOMY", 108, 114], ["Fl", "OBSERVATION", 144, 146]]], ["Grimes and King (1977a) also isolated an Fl from synovitis.", [["synovitis", "DISEASE", 49, 58], ["synovitis", "PROBLEM", 49, 58], ["synovitis", "OBSERVATION", 49, 58]]], ["Mackenzie and Bains (1976) isolated an adenovirus and Staphylococcus aureus from an outbreak of tenosynovitis, and Jones et al. (1978) studied 52 cases and isolated viruses from 20.", [["Staphylococcus aureus", "DISEASE", 54, 75], ["tenosynovitis", "DISEASE", 96, 109], ["adenovirus", "ORGANISM", 39, 49], ["Staphylococcus aureus", "ORGANISM", 54, 75], ["Staphylococcus aureus", "SPECIES", 54, 75], ["Staphylococcus aureus", "SPECIES", 54, 75], ["an adenovirus", "PROBLEM", 36, 49], ["Staphylococcus aureus", "PROBLEM", 54, 75], ["tenosynovitis", "PROBLEM", 96, 109], ["isolated viruses", "PROBLEM", 156, 172], ["Staphylococcus aureus", "OBSERVATION", 54, 75], ["tenosynovitis", "OBSERVATION", 96, 109], ["viruses", "OBSERVATION", 165, 172]]], ["Twelve of these isolates were reovirus, seven were adenovirus, and one was a mixture of both.Association with Disease a.", [["reovirus", "ORGANISM", 30, 38], ["adenovirus", "ORGANISM", 51, 61], ["adenovirus", "SPECIES", 51, 61], ["these isolates", "TEST", 10, 24], ["reovirus", "PROBLEM", 30, 38], ["adenovirus", "PROBLEM", 51, 61], ["Disease", "OBSERVATION", 110, 117]]], ["Inclusion Body Hepatitis (IBH).e.", [["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["Body Hepatitis", "ORGANISM", 10, 24], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24]]], ["Respiratory Tract Disease.", [["Respiratory Tract Disease", "DISEASE", 0, 25], ["Respiratory Tract Disease", "PROBLEM", 0, 25], ["Tract Disease", "OBSERVATION", 12, 25]]], ["A number of groups have recorded the isola tion of adenoviruses from birds with respiratory tract disease (Kawamura et al., 1963; Rinaldi et al., 1968; McDougall and Peters, 1974) .", [["respiratory tract", "ANATOMY", 80, 97], ["respiratory tract disease", "DISEASE", 80, 105], ["adenoviruses", "ORGANISM", 51, 63], ["birds", "ORGANISM", 69, 74], ["tract", "ORGANISM_SUBDIVISION", 92, 97], ["adenoviruses", "PROBLEM", 51, 63], ["respiratory tract disease", "PROBLEM", 80, 105], ["respiratory tract", "ANATOMY", 80, 97]]], ["In a study of 94 flocks with respiratory tract disease, adenoviruses were isolated from 44%, whereas 74 flocks without respiratory tract disease produced only a 15% recovery.", [["respiratory tract", "ANATOMY", 29, 46], ["respiratory tract", "ANATOMY", 119, 136], ["respiratory tract disease", "DISEASE", 29, 54], ["respiratory tract disease", "DISEASE", 119, 144], ["tract", "ORGANISM_SUBDIVISION", 41, 46], ["adenoviruses", "ORGANISM", 56, 68], ["tract", "ORGANISM_SUBDIVISION", 131, 136], ["a study", "TEST", 3, 10], ["respiratory tract disease", "PROBLEM", 29, 54], ["adenoviruses", "PROBLEM", 56, 68], ["respiratory tract disease", "PROBLEM", 119, 144], ["respiratory tract", "ANATOMY", 29, 46], ["without", "UNCERTAINTY", 111, 118], ["respiratory tract", "ANATOMY", 119, 136]]], ["Also, adenovirus was isolated from the lungs of the birds with respiratory tract disease (McFerran et al., 1971a) .", [["lungs", "ANATOMY", 39, 44], ["respiratory tract", "ANATOMY", 63, 80], ["respiratory tract disease", "DISEASE", 63, 88], ["adenovirus", "ORGANISM", 6, 16], ["lungs", "ORGAN", 39, 44], ["birds", "ORGANISM", 52, 57], ["tract", "ORGANISM_SUBDIVISION", 75, 80], ["adenovirus", "SPECIES", 6, 16], ["adenovirus", "PROBLEM", 6, 16], ["respiratory tract disease", "PROBLEM", 63, 88], ["adenovirus", "OBSERVATION", 6, 16], ["lungs", "ANATOMY", 39, 44], ["respiratory tract", "ANATOMY", 63, 80]]], ["Attempts at experimental reproduction of disease have given equivocal results.", [["disease", "PROBLEM", 41, 48]]], ["Some workers have produced respiratory tract disease or microscopic lesions only following natural routes of infection (Kawamura et al., 1963; Aghakhan and Pattison, 1974) .", [["respiratory tract", "ANATOMY", 27, 44], ["lesions", "ANATOMY", 68, 75], ["respiratory tract disease", "DISEASE", 27, 52], ["infection", "DISEASE", 109, 118], ["tract", "ORGANISM_SUBDIVISION", 39, 44], ["lesions", "PATHOLOGICAL_FORMATION", 68, 75], ["respiratory tract disease", "PROBLEM", 27, 52], ["microscopic lesions", "PROBLEM", 56, 75], ["infection", "PROBLEM", 109, 118], ["respiratory tract disease", "OBSERVATION", 27, 52], ["microscopic", "OBSERVATION_MODIFIER", 56, 67], ["lesions", "OBSERVATION", 68, 75], ["infection", "OBSERVATION", 109, 118]]], ["Other workers have been successful using only intratracheal inoculation (Lim et al., 1973; McDougall and Peters, 1974) or have not reproduced disease (Kawamura and Horiuchi, 1964) .Association with Disease a.", [["Disease", "OBSERVATION", 198, 205]]], ["Inclusion Body Hepatitis (IBH).Following the major outbreak of respiratory tract disease in Northern Ireland, a successful program of infectious bronchitis vaccination was introduced.", [["respiratory tract", "ANATOMY", 63, 80], ["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["respiratory tract disease", "DISEASE", 63, 88], ["infectious bronchitis", "DISEASE", 134, 155], ["Body Hepatitis", "ORGANISM", 10, 24], ["tract", "ORGANISM_SUBDIVISION", 75, 80], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["respiratory tract disease", "PROBLEM", 63, 88], ["infectious bronchitis vaccination", "TREATMENT", 134, 167], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24], ["respiratory tract", "ANATOMY", 63, 80], ["infectious", "OBSERVATION_MODIFIER", 134, 144], ["bronchitis", "OBSERVATION", 145, 155]]], ["The number of cases of respiratory tract disease has fallen dramatically, while adeno viruses are still widespread.", [["respiratory tract", "ANATOMY", 23, 40], ["respiratory tract disease", "DISEASE", 23, 48], ["respiratory tract", "ORGANISM_SUBDIVISION", 23, 40], ["adeno viruses", "ORGANISM", 80, 93], ["respiratory tract disease", "PROBLEM", 23, 48], ["adeno viruses", "PROBLEM", 80, 93], ["respiratory tract disease", "OBSERVATION", 23, 48], ["fallen", "OBSERVATION_MODIFIER", 53, 59], ["dramatically", "OBSERVATION_MODIFIER", 60, 72], ["widespread", "OBSERVATION_MODIFIER", 104, 114]]], ["However, examination of the autopsy and virus records suggests that where adenoviruses were isolated from trachea, lung, or air sacs, signs, lesions, and mortality were more severe (McFerran, unpublished observations) .Association with Disease a.", [["trachea", "ANATOMY", 106, 113], ["lung", "ANATOMY", 115, 119], ["air sacs", "ANATOMY", 124, 132], ["lesions", "ANATOMY", 141, 148], ["adenoviruses", "ORGANISM", 74, 86], ["trachea", "MULTI-TISSUE_STRUCTURE", 106, 113], ["lung", "ORGAN", 115, 119], ["air sacs", "MULTI-TISSUE_STRUCTURE", 124, 132], ["lesions", "PATHOLOGICAL_FORMATION", 141, 148], ["examination", "TEST", 9, 20], ["the autopsy", "TEST", 24, 35], ["virus records", "TEST", 40, 53], ["adenoviruses", "PROBLEM", 74, 86], ["trachea, lung, or air sacs", "PROBLEM", 106, 132], ["lesions", "PROBLEM", 141, 148], ["mortality", "PROBLEM", 154, 163], ["trachea", "ANATOMY", 106, 113], ["lung", "ANATOMY", 115, 119], ["air sacs", "OBSERVATION", 124, 132], ["lesions", "OBSERVATION", 141, 148], ["Disease", "OBSERVATION", 236, 243]]], ["Inclusion Body Hepatitis (IBH).f.", [["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["Body Hepatitis", "ORGANISM", 10, 24], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24]]], ["Disease Produced in Fowl by a Duck Adenovirus.", [["Duck Adenovirus", "ORGANISM", 30, 45], ["Duck Adenovirus", "SPECIES", 30, 45], ["Disease", "PROBLEM", 0, 7], ["a Duck Adenovirus", "PROBLEM", 28, 45]]], ["In 1976 a new condition affecting laying hens was described in the Netherlands.", [["hens", "ORGANISM", 41, 45], ["new", "OBSERVATION_MODIFIER", 10, 13]]], ["This was characterized by a fall in egg production and by the production of soft-shelled and shell-less eggs, and the albumin quality was affected.", [["egg", "ANATOMY", 36, 39], ["eggs", "ANATOMY", 104, 108], ["egg", "ORGANISM_SUBSTANCE", 36, 39], ["albumin", "GENE_OR_GENE_PRODUCT", 118, 125], ["a fall in egg production", "PROBLEM", 26, 50], ["the albumin quality", "TEST", 114, 133], ["fall", "OBSERVATION", 28, 32]]], ["Most cases were in birds around 30 weeks of age, and while the falls could be severe, they returned to normal production in 6-8 weeks (Van Eck?/al., 976) .Association with Disease a.", [["falls", "DISEASE", 63, 68], ["Disease", "OBSERVATION", 172, 179]]], ["Inclusion Body Hepatitis (IBH).A similar condition was described in Northern Ireland except that no effect was seen in the internal quality of the egg (McFerran et al., , 1978a .", [["egg", "ANATOMY", 147, 150], ["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["Body Hepatitis", "ORGANISM", 10, 24], ["egg", "ORGANISM_SUBSTANCE", 147, 150], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["A similar condition", "PROBLEM", 31, 50], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24], ["similar", "OBSERVATION_MODIFIER", 33, 40], ["condition", "OBSERVATION", 41, 50]]], ["As in the Dutch birds, no illness was evident and all cases occurred between 26 and 35 weeks, with most between 29 and 31 weeks.", [["illness", "DISEASE", 26, 33], ["illness", "PROBLEM", 26, 33], ["no", "UNCERTAINTY", 23, 25]]], ["Epidemiological evidence sugges ted that the virus was egg transmitted but otherwise had limited powers of lateral spread.", [["the virus", "PROBLEM", 41, 50], ["lateral spread", "PROBLEM", 107, 121], ["lateral", "OBSERVATION_MODIFIER", 107, 114], ["spread", "OBSERVATION", 115, 121]]], ["Viruses which agglutinated fowl erythrocytes and 17 fowl adenoviruses were isolated from affected flocks.", [["erythrocytes", "ANATOMY", 32, 44], ["fowl", "ORGANISM", 27, 31], ["erythrocytes", "CELL", 32, 44], ["fowl", "ORGANISM", 52, 56], ["adenoviruses", "ORGANISM", 57, 69], ["agglutinated fowl erythrocytes", "CELL_TYPE", 14, 44], ["fowl", "SPECIES", 27, 31], ["fowl", "SPECIES", 52, 56], ["fowl", "SPECIES", 27, 31], ["fowl", "SPECIES", 52, 56], ["Viruses", "PROBLEM", 0, 7], ["agglutinated fowl erythrocytes", "PROBLEM", 14, 44], ["17 fowl adenoviruses", "PROBLEM", 49, 69], ["affected flocks", "PROBLEM", 89, 104], ["agglutinated", "OBSERVATION_MODIFIER", 14, 26], ["fowl erythrocytes", "OBSERVATION", 27, 44], ["17 fowl", "OBSERVATION_MODIFIER", 49, 56], ["affected flocks", "OBSERVATION", 89, 104]]], ["One agent, 127, was selected for further study.", [["further study", "TEST", 33, 46]]], ["The hemagglutinating agents were classified as adenoviruses on the basis of their biochemical properties (Todd and McNulty, 1978) and their physical, chemical, and growth characteristics (Adair et al., 1979b) .Association with Disease a.", [["adenoviruses", "ORGANISM", 47, 59], ["The hemagglutinating agents", "TREATMENT", 0, 27], ["adenoviruses", "TREATMENT", 47, 59], ["Disease", "OBSERVATION", 227, 234]]], ["Inclusion Body Hepatitis (IBH).Although these viruses did not apparently share a group antigen with other avian adenoviruses using immunodiffusion techniques, the group antigen could be demonstrated by infecting birds previously infected with adenovirus with 127 virus and eliciting a recall of the group antigen (McFerran et al., 1978b) .", [["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["Body Hepatitis", "ORGANISM", 10, 24], ["avian adenoviruses", "ORGANISM", 106, 124], ["birds", "ORGANISM", 212, 217], ["adenovirus", "ORGANISM", 243, 253], ["group antigen", "PROTEIN", 299, 312], ["avian", "SPECIES", 106, 111], ["adenovirus", "SPECIES", 243, 253], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["these viruses", "PROBLEM", 40, 53], ["immunodiffusion techniques", "TEST", 131, 157], ["the group antigen", "TEST", 159, 176], ["adenovirus", "PROBLEM", 243, 253], ["127 virus", "PROBLEM", 259, 268], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24], ["viruses", "OBSERVATION", 46, 53]]], ["This would explain the Dutch findings, which on the basis of the DID test indicated that fowl adenoviruses were associated with this syndrome (Van Eck et al., 1976) .", [["fowl", "ORGANISM", 89, 93], ["adenoviruses", "ORGANISM", 94, 106], ["fowl", "SPECIES", 89, 93], ["the DID test", "TEST", 61, 73], ["fowl adenoviruses", "PROBLEM", 89, 106], ["this syndrome", "PROBLEM", 128, 141]]], ["A similar virus, BC14, was isolated in England (Baxendale, 1978) .", [["A similar virus", "PROBLEM", 0, 15], ["virus", "OBSERVATION", 10, 15]]], ["The disease can be experimentally reproduced using BC14 or 127 virus (Baxendale, 1978; McCracken and McFerran, 1978) .", [["127 virus", "ORGANISM", 59, 68], ["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["The first changes were seen 7 days after oral infection with 127 virus, when loss of shell pigment occurred.", [["oral", "ANATOMY", 41, 45], ["infection", "DISEASE", 46, 55], ["oral", "ORGANISM_SUBDIVISION", 41, 45], ["oral infection with 127 virus", "PROBLEM", 41, 70], ["loss of shell pigment", "PROBLEM", 77, 98], ["infection", "OBSERVATION", 46, 55], ["shell pigment", "OBSERVATION", 85, 98]]], ["This was followed by thinning of the eggshell and then on the ninth day by soft-shelled and shell-less eggs.", [["eggshell", "ANATOMY", 37, 45], ["eggs", "ANATOMY", 103, 107], ["eggshell", "ANATOMY", 37, 45]]], ["Eggshell quality was worst at 13-16 days after infection, and the majority of birds had returned to normal egg quality by day 24 (Fig. 7a) .Association with Disease a.", [["egg", "ANATOMY", 107, 110], ["infection", "DISEASE", 47, 56], ["birds", "ORGANISM", 78, 83], ["infection", "PROBLEM", 47, 56], ["infection", "OBSERVATION", 47, 56], ["Disease", "OBSERVATION", 157, 164]]], ["Inclusion Body Hepatitis (IBH).The origin of this virus is of interest.", [["Body Hepatitis", "DISEASE", 10, 24], ["IBH", "DISEASE", 26, 29], ["Body Hepatitis", "ORGANISM", 10, 24], ["Inclusion Body Hepatitis (IBH)", "PROBLEM", 0, 30], ["this virus", "PROBLEM", 45, 55], ["Body", "ANATOMY_MODIFIER", 10, 14], ["Hepatitis", "OBSERVATION", 15, 24], ["origin", "ANATOMY_MODIFIER", 35, 41], ["virus", "OBSERVATION", 50, 55]]], ["It grows better in cells of duck origin than in fowl cells, and it grows to very high titers in embryonated duck eggs but not in embryonated fowl eggs (Adair et al., 1979c) .", [["cells", "ANATOMY", 19, 24], ["cells", "ANATOMY", 53, 58], ["eggs", "ANATOMY", 113, 117], ["cells", "CELL", 19, 24], ["duck", "ORGANISM", 28, 32], ["fowl cells", "CELL", 48, 58], ["duck", "ORGANISM", 108, 112], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 113, 117], ["fowl", "ORGANISM", 141, 145], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 146, 150], ["fowl cells", "CELL_TYPE", 48, 58], ["duck", "SPECIES", 108, 112], ["fowl", "SPECIES", 141, 145], ["fowl", "SPECIES", 48, 52], ["duck", "SPECIES", 108, 112], ["fowl", "SPECIES", 141, 145], ["better", "OBSERVATION_MODIFIER", 9, 15], ["duck", "OBSERVATION_MODIFIER", 28, 32], ["origin", "OBSERVATION_MODIFIER", 33, 39], ["fowl cells", "OBSERVATION", 48, 58]]], ["Fowl sera prior to the importation of the infected birds did not have antibody to 127 virus .", [["sera", "ANATOMY", 5, 9], ["sera", "ORGANISM_SUBSTANCE", 5, 9], ["birds", "ORGANISM", 51, 56], ["127 virus", "ORGANISM", 82, 91], ["Fowl sera", "PROBLEM", 0, 9], ["the infected birds", "PROBLEM", 38, 56], ["antibody to 127 virus", "PROBLEM", 70, 91], ["infected", "OBSERVATION", 42, 50]]], ["Duck flocks in England have antibody, and this virus has been isolated from them (Baxendale, 1978) .", [["Duck flocks", "PROBLEM", 0, 11], ["antibody", "PROBLEM", 28, 36], ["this virus", "PROBLEM", 42, 52], ["flocks", "OBSERVATION", 5, 11]]], ["Duck flocks but not fowl flocks in the United States also have antibody to 127 virus, and there was evidence that infected ducks did not readily infect fowl (Calnek, 1978) .", [["ducks", "ORGANISM", 123, 128], ["fowl", "ORGANISM", 152, 156], ["fowl", "SPECIES", 20, 24], ["ducks", "SPECIES", 123, 128], ["fowl", "SPECIES", 20, 24], ["fowl", "SPECIES", 152, 156], ["Duck flocks", "PROBLEM", 0, 11], ["fowl flocks", "PROBLEM", 20, 31], ["antibody to 127 virus", "PROBLEM", 63, 84], ["infected ducks", "PROBLEM", 114, 128], ["flocks", "OBSERVATION", 5, 11], ["not", "UNCERTAINTY", 16, 19], ["fowl flocks", "OBSERVATION", 20, 31], ["infected", "OBSERVATION", 114, 122]]], ["It seems reasonable to postulate that these viruses are duck adenoviruses.", [["duck adenoviruses", "ORGANISM", 56, 73], ["duck", "SPECIES", 56, 60], ["these viruses", "PROBLEM", 38, 51], ["duck adenoviruses", "PROBLEM", 56, 73], ["viruses", "OBSERVATION", 44, 51]]], ["The problem of the widespread distribution of this virus in different breeds in Western Europe and its apparently poor ability to spread from flock to flock is best explained by contamination of a vaccine.", [["this virus", "PROBLEM", 46, 56], ["a vaccine", "TREATMENT", 195, 204], ["widespread", "OBSERVATION_MODIFIER", 19, 29], ["distribution", "OBSERVATION_MODIFIER", 30, 42], ["virus", "OBSERVATION", 51, 56]]], ["It is not related to the prototype fowl or turkey adenovirus.DiagnosisIt is preferable to use cell culture to isolate fowl adenoviruses.", [["cell", "ANATOMY", 94, 98], ["fowl", "ORGANISM", 35, 39], ["turkey adenovirus", "ORGANISM", 43, 60], ["cell", "CELL", 94, 98], ["fowl", "ORGANISM", 118, 122], ["adenoviruses", "ORGANISM", 123, 135], ["turkey", "SPECIES", 43, 49], ["fowl", "SPECIES", 118, 122], ["turkey adenovirus", "SPECIES", 43, 60], ["fowl adenoviruses", "SPECIES", 118, 135], ["the prototype fowl or turkey adenovirus", "PROBLEM", 21, 60], ["cell culture", "TEST", 94, 106], ["fowl adenoviruses", "PROBLEM", 118, 135], ["not related to", "UNCERTAINTY", 6, 20]]], ["Liver and kidney cells are equally sensitive, but chick embryo fibroblasts are much less sensitive.", [["Liver", "ANATOMY", 0, 5], ["kidney cells", "ANATOMY", 10, 22], ["embryo fibroblasts", "ANATOMY", 56, 74], ["Liver", "ORGAN", 0, 5], ["kidney cells", "CELL", 10, 22], ["chick", "ORGANISM", 50, 55], ["embryo fibroblasts", "CELL", 56, 74], ["Liver and kidney cells", "CELL_TYPE", 0, 22], ["chick embryo fibroblasts", "CELL_TYPE", 50, 74], ["Liver and kidney cells", "TEST", 0, 22], ["chick embryo fibroblasts", "PROBLEM", 50, 74], ["kidney", "ANATOMY", 10, 16], ["cells", "OBSERVATION", 17, 22], ["chick embryo fibroblasts", "OBSERVATION", 50, 74]]], ["Chick trach\u00e9al organ cultures are also not sensitive .", [["trach\u00e9al organ cultures", "ANATOMY", 6, 29], ["Chick", "ORGANISM", 0, 5], ["Chick trach\u00e9al organ cultures", "CELL_LINE", 0, 29], ["Chick", "SPECIES", 0, 5], ["Chick trach\u00e9al organ cultures", "TEST", 0, 29]]], ["In addition to examining the organ with lesions, it is advisable to test the pharynx and feces because virus persists in these specimens longer and to higher titers.", [["organ", "ANATOMY", 29, 34], ["lesions", "ANATOMY", 40, 47], ["pharynx", "ANATOMY", 77, 84], ["feces", "ANATOMY", 89, 94], ["specimens", "ANATOMY", 127, 136], ["organ", "ORGAN", 29, 34], ["lesions", "CANCER", 40, 47], ["pharynx", "ORGAN", 77, 84], ["feces", "ORGANISM_SUBSTANCE", 89, 94], ["lesions", "PROBLEM", 40, 47], ["virus", "PROBLEM", 103, 108], ["these specimens", "TEST", 121, 136], ["organ", "ANATOMY", 29, 34], ["lesions", "OBSERVATION", 40, 47], ["pharynx", "ANATOMY", 77, 84]]], ["Normally, two passages of 6 days each are sufficient for isolation, al though a third pass may be given (McFerran et al., 1971 a) .DiagnosisEmbryonated eggs, although widely used, cannot be recommended for adeno virus isolation.", [["eggs", "ANATOMY", 152, 156], ["adeno virus", "ORGANISM", 206, 217], ["adeno virus", "SPECIES", 206, 217], ["isolation", "TREATMENT", 57, 66], ["a third pass", "TREATMENT", 78, 90], ["DiagnosisEmbryonated eggs", "PROBLEM", 131, 156], ["adeno virus isolation", "TREATMENT", 206, 227]]], ["Thus Burke et al. (1959) The DID test has been used for diagnosis and monitoring of specific pathogenfree (SPF) flocks for infection.", [["infection", "DISEASE", 123, 132], ["monitoring", "TEST", 70, 80], ["infection", "PROBLEM", 123, 132], ["infection", "OBSERVATION", 123, 132]]], ["It has the advantage of being inexpensive and quick, and it detects group antibody.", [["group antibody", "PROTEIN", 68, 82]]], ["McFerran et al. (1975) drew attention to the failure of SPF birds experimentally infected by a natural route with one serotype always to develop detectable antibody.", [["SPF birds", "ORGANISM", 56, 65], ["the failure of SPF birds", "PROBLEM", 41, 65], ["detectable antibody", "PROBLEM", 145, 164], ["antibody", "OBSERVATION", 156, 164]]], ["Cowen et al. (1978b) found, when studying naturally infected flocks, that in spite of isolating many adeno viruses especially from the 8-14-week age group, the percentage of birds wtih detectable precipitin antibody rose steadily from 28% in 8-14-week-old birds to 97% in the 30-43-week age group.", [["adeno viruses", "ORGANISM", 101, 114], ["birds", "ORGANISM", 174, 179], ["birds", "ORGANISM", 256, 261], ["precipitin antibody", "PROTEIN", 196, 215], ["naturally infected flocks", "PROBLEM", 42, 67], ["isolating many adeno viruses", "PROBLEM", 86, 114], ["detectable precipitin antibody", "TEST", 185, 215], ["infected flocks", "OBSERVATION", 52, 67], ["adeno viruses", "OBSERVATION", 101, 114]]], ["Apart from the inherent lack of sensitivity of the test, it is probable that more sensitivity could be achieved by using more than one antigen.", [["the test", "TEST", 47, 55]]], ["Thus, although the fowl and turkey adenoviruses tested have a common immunoprecipitin antigen (McFerran et al., 1975) , it is clear from CF studies that this group antigen is not shared to the same extent by all strains (Kawamura^/o/., 1964) .DiagnosisThe most sensitive test in use is the SN test, and in its microtiter form (Grimes et al., 1977a) it is very useful.", [["fowl", "ORGANISM", 19, 23], ["turkey adenoviruses", "ORGANISM", 28, 47], ["immunoprecipitin antigen", "GENE_OR_GENE_PRODUCT", 69, 93], ["immunoprecipitin antigen", "PROTEIN", 69, 93], ["fowl", "SPECIES", 19, 23], ["turkey", "SPECIES", 28, 34], ["fowl", "SPECIES", 19, 23], ["turkey", "SPECIES", 28, 34], ["the fowl and turkey adenoviruses", "PROBLEM", 15, 47], ["CF studies", "TEST", 137, 147], ["this group antigen", "TEST", 153, 171], ["the SN test", "TEST", 286, 297]]], ["Other tests, such as the passive hemagglutination test (Trewick and Lang, 1971; Moreau, 1974) and ELISA (Todd and McFerran, unpublished observations) , have shown promise vut still need to be fully evaluat ed.", [["Other tests", "TEST", 0, 11], ["the passive hemagglutination test", "TEST", 21, 54]]], ["The radial immunodiffusion test (Pereira et al., 1972; McFerran et al., 1975) is useful for surveys but detects only group antibody.DiagnosisOne of the main requirements for a sensitive test is to monitor SPF flocks producing eggs for vaccines and research.", [["eggs", "ORGANISM_SUBDIVISION", 226, 230], ["group antibody", "PROTEIN", 117, 131], ["The radial immunodiffusion test", "TEST", 0, 31], ["a sensitive test", "TEST", 174, 190], ["SPF flocks", "TEST", 205, 215], ["vaccines", "TREATMENT", 235, 243], ["radial", "ANATOMY_MODIFIER", 4, 10], ["main", "OBSERVATION_MODIFIER", 152, 156]]], ["Often the first indication of infection is the degeneration of control cell cultures on first or second passage.", [["cell cultures", "ANATOMY", 71, 84], ["infection", "DISEASE", 30, 39], ["cell cultures", "CELL", 71, 84], ["control cell cultures", "CELL_LINE", 63, 84], ["infection", "PROBLEM", 30, 39], ["the degeneration of control cell cultures", "PROBLEM", 43, 84], ["infection", "OBSERVATION", 30, 39]]], ["In these circumstances, both cloacal swabbing of the flock and serological testing using the SN test have failed to detect the infected birds, but the use of the indirect immunofluorescence test has been successful (Adair and McFerran, unpublished observations) ./ .", [["cloacal", "ANATOMY", 29, 36], ["cloacal", "ORGANISM_SUBDIVISION", 29, 36], ["birds", "ORGANISM", 136, 141], ["the flock", "TEST", 49, 58], ["serological testing", "TEST", 63, 82], ["the SN test", "TEST", 89, 100], ["the infected birds", "PROBLEM", 123, 141], ["the indirect immunofluorescence test", "TEST", 158, 194], ["McFerran", "TREATMENT", 226, 234], ["both", "OBSERVATION_MODIFIER", 24, 28], ["cloacal", "OBSERVATION_MODIFIER", 29, 36], ["infected", "OBSERVATION", 127, 135]]], ["ClassificationThree classes of adenovirus infect turkeys.", [["adenovirus", "ORGANISM", 31, 41], ["turkeys", "ORGANISM", 49, 56], ["turkeys", "SPECIES", 49, 56], ["adenovirus infect turkeys", "PROBLEM", 31, 56], ["adenovirus infect", "OBSERVATION", 31, 48]]], ["These are fowl adenoviruses, tur key adenoviruses, and the virus of turkey hemorrhagic enteritis./ .", [["turkey hemorrhagic enteritis", "DISEASE", 68, 96], ["fowl adenoviruses", "ORGANISM", 10, 27], ["adenoviruses", "ORGANISM", 37, 49], ["turkey hemorrhagic enteritis", "ORGANISM", 68, 96], ["turkey hemorrhagic enteritis", "SPECIES", 68, 96], ["fowl adenoviruses", "SPECIES", 10, 27], ["fowl adenoviruses", "PROBLEM", 10, 27], ["tur key adenoviruses", "PROBLEM", 29, 49], ["the virus of turkey hemorrhagic enteritis", "PROBLEM", 55, 96], ["fowl", "OBSERVATION_MODIFIER", 10, 14], ["adenoviruses", "OBSERVATION", 15, 27], ["virus", "OBSERVATION_MODIFIER", 59, 64], ["turkey", "OBSERVATION_MODIFIER", 68, 74], ["hemorrhagic", "OBSERVATION_MODIFIER", 75, 86], ["enteritis", "OBSERVATION", 87, 96]]], ["Fowl Adenoviruses.", [["Fowl Adenoviruses", "PROBLEM", 0, 17], ["Adenoviruses", "OBSERVATION", 5, 17]]], ["Fowl adenoviruses type 1 have been isolated from turkeys.", [["Fowl adenoviruses type 1", "ORGANISM", 0, 24], ["turkeys", "ORGANISM", 49, 56], ["turkeys", "SPECIES", 49, 56], ["Fowl adenoviruses type 1", "PROBLEM", 0, 24]]], ["These viruses grow in embryonated egg and cell cultures of both fowl and turkey origin (Blalock et al., 1975; Cho, 1976; King, 1977 ).", [["egg", "ANATOMY", 34, 37], ["cell cultures", "ANATOMY", 42, 55], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 34, 37], ["cell cultures", "CELL", 42, 55], ["fowl", "ORGANISM", 64, 68], ["turkey", "ORGANISM", 73, 79], ["fowl", "SPECIES", 64, 68], ["turkey", "SPECIES", 73, 79], ["fowl", "SPECIES", 64, 68], ["turkey", "SPECIES", 73, 79], ["These viruses", "PROBLEM", 0, 13], ["embryonated egg", "TEST", 22, 37], ["cell cultures", "TEST", 42, 55], ["viruses", "OBSERVATION", 6, 13], ["embryonated egg", "OBSERVATION", 22, 37]]], ["An isolation made in Germany may also be Fl but was not fully characterized (Ahmed, 1971 ). b.", [["isolation", "OBSERVATION", 3, 12], ["may also be", "UNCERTAINTY", 29, 40], ["Fl", "OBSERVATION", 41, 43]]], ["A number of workers have reported the isolation of one or more serotypes, but unfortunately comparative studies have not been carried out.", [["comparative studies", "TEST", 92, 111]]], ["Thus two serotypes (TAV1 and TAV2) were described in Northern Ireland (Scott and McFerran, 1972; McFerran et al., 1975) .", [["TAV1", "GENE_OR_GENE_PRODUCT", 20, 24], ["TAV2", "GENE_OR_GENE_PRODUCT", 29, 33], ["two serotypes (TAV1 and TAV2", "TREATMENT", 5, 33], ["serotypes", "OBSERVATION_MODIFIER", 9, 18]]], ["Two serotypes (WTAV and AMK49) were described in the United States, and WTAV is similar to TAV1 (King and Hanson, 1975; King, 1977) .", [["AMK49", "GENE_OR_GENE_PRODUCT", 24, 29], ["WTAV", "GENE_OR_GENE_PRODUCT", 72, 76]]], ["The NC-120 isolate (Simmons et al., 1976) , and NC-J and NC-K isolates (Sutjipto et al., 1977) , and the MST virus isolated by Domermuth (Easton and Simmons, 1977) were compared (Sut jipto et al., 1977) .", [["NC-J", "CELL", 48, 52], ["NC-K isolates", "CELL", 57, 70], ["The NC", "TEST", 0, 6], ["NC", "TEST", 48, 50], ["NC", "TEST", 57, 59], ["the MST virus", "PROBLEM", 101, 114]]], ["Three serotypes were recognized.", [["Three serotypes", "PROBLEM", 0, 15], ["serotypes", "OBSERVATION", 6, 15]]], ["The NC-120 and MST viruses were identical and were different from the NC-J and NC-K viruses.", [["NC-120", "ORGANISM", 4, 10], ["NC-K viruses", "ORGANISM", 79, 91], ["The NC", "TEST", 0, 6], ["MST viruses", "PROBLEM", 15, 26], ["the NC", "TEST", 66, 72], ["NC", "TREATMENT", 79, 81]]], ["The turkey viruses studied share a group antigen with the fowl adenoviruses, are not neutralized by the prototype fowl antisera (McFerran et al., 1975) , and either do not grow or grow poorly in cells of fowl origin (Scott and McFerran, 1972; King, 1977) ./ .", [["cells", "ANATOMY", 195, 200], ["turkey viruses", "ORGANISM", 4, 18], ["fowl adenoviruses", "ORGANISM", 58, 75], ["cells", "CELL", 195, 200], ["turkey", "SPECIES", 4, 10], ["fowl", "SPECIES", 58, 62], ["fowl", "SPECIES", 114, 118], ["turkey viruses", "SPECIES", 4, 18], ["fowl adenoviruses", "SPECIES", 58, 75], ["fowl", "SPECIES", 114, 118], ["The turkey viruses", "PROBLEM", 0, 18], ["the fowl adenoviruses", "PROBLEM", 54, 75]]], ["Turkey Hemorrhagic Enteritis Virus (HEV).", [["Hemorrhagic Enteritis Virus", "DISEASE", 7, 34], ["Turkey Hemorrhagic Enteritis Virus", "ORGANISM", 0, 34], ["HEV", "ORGANISM", 36, 39], ["Hemorrhagic Enteritis Virus", "SPECIES", 7, 34], ["Turkey Hemorrhagic Enteritis Virus", "SPECIES", 0, 34], ["HEV", "SPECIES", 36, 39], ["Turkey Hemorrhagic Enteritis Virus", "PROBLEM", 0, 34], ["Hemorrhagic", "OBSERVATION_MODIFIER", 7, 18], ["Enteritis", "OBSERVATION", 19, 28]]], ["HEV has not yet been grown in embryonated eggs or cell culture; therefore, neutralization tests have not been carried out with other avian adenoviruses.", [["eggs", "ANATOMY", 42, 46], ["cell culture", "ANATOMY", 50, 62], ["HEV", "ORGANISM", 0, 3], ["eggs", "CELL", 42, 46], ["cell culture", "CELL", 50, 62], ["adenoviruses", "ORGANISM", 139, 151], ["HEV", "SPECIES", 0, 3], ["embryonated eggs", "PROBLEM", 30, 46], ["cell culture", "TEST", 50, 62], ["neutralization tests", "TEST", 75, 95]]], ["The HEV virus and the virus associated with marble spleen disease (MSV) of pheasants are very closely related.", [["spleen", "ANATOMY", 51, 57], ["spleen disease", "DISEASE", 51, 65], ["HEV virus", "ORGANISM", 4, 13], ["spleen", "ORGAN", 51, 57], ["MSV", "ORGANISM", 67, 70], ["pheasants", "ORGANISM", 75, 84], ["HEV virus", "SPECIES", 4, 13], ["HEV virus", "SPECIES", 4, 13], ["MSV", "SPECIES", 67, 70], ["pheasants", "SPECIES", 75, 84], ["The HEV virus", "PROBLEM", 0, 13], ["the virus", "PROBLEM", 18, 27], ["marble spleen disease", "PROBLEM", 44, 65], ["HEV virus", "OBSERVATION", 4, 13], ["virus", "OBSERVATION", 22, 27], ["marble", "OBSERVATION_MODIFIER", 44, 50], ["spleen", "ANATOMY", 51, 57], ["disease", "OBSERVATION", 58, 65]]], ["Marble spleen disease virus (MSDV) will infect pheasants and turkeys, producing lesions.", [["lesions", "ANATOMY", 80, 87], ["spleen disease", "DISEASE", 7, 21], ["Marble spleen disease virus", "ORGANISM", 0, 27], ["MSDV", "ORGANISM", 29, 33], ["pheasants", "ORGANISM", 47, 56], ["turkeys", "ORGANISM", 61, 68], ["lesions", "PATHOLOGICAL_FORMATION", 80, 87], ["pheasants", "SPECIES", 47, 56], ["turkeys", "SPECIES", 61, 68], ["Marble spleen disease virus", "SPECIES", 0, 27], ["MSDV", "SPECIES", 29, 33], ["turkeys", "SPECIES", 61, 68], ["Marble spleen disease virus", "PROBLEM", 0, 27], ["producing lesions", "PROBLEM", 70, 87], ["spleen", "ANATOMY", 7, 13], ["disease", "OBSERVATION", 14, 21], ["lesions", "OBSERVATION", 80, 87]]], ["These lesions could be prevented by the use of HEV antiserum (Domermuth et al., 1975; Iltis etal., 1975) ./ .", [["lesions", "ANATOMY", 6, 13], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["HEV", "ORGANISM", 47, 50], ["antiserum", "ORGANISM_SUBSTANCE", 51, 60], ["HEV", "SPECIES", 47, 50], ["These lesions", "PROBLEM", 0, 13], ["HEV antiserum", "TREATMENT", 47, 60], ["lesions", "OBSERVATION", 6, 13]]], ["ClassificationThese viruses can be classified as adenoviruses on the basis of their size of 70-90 nm and their morphology (Carlson et al., 1973; Fujiwara et al., 1975; Tolin and Domermuth, 1975; Iltis et al., 1977) .", [["adenoviruses", "ORGANISM", 49, 61], ["adenoviruses", "PROBLEM", 49, 61], ["viruses", "OBSERVATION", 20, 27], ["size", "OBSERVATION_MODIFIER", 84, 88]]], ["Also, they are resistant to chloroform (Domermuth et al., 1975) and have a density of 1.32-1.34 gm/ml in CsCl (Carlson et al., 1974; Iltis, 1975) .", [["chloroform", "CHEMICAL", 28, 38], ["CsCl", "CHEMICAL", 105, 109], ["chloroform", "CHEMICAL", 28, 38], ["CsCl", "CHEMICAL", 105, 109], ["chloroform", "SIMPLE_CHEMICAL", 28, 38], ["resistant", "OBSERVATION_MODIFIER", 15, 24]]], ["MSV contains DNA (Iltis, 1975) , and both HEV and MSDV replicate intranuclearly in the cells of the reticuloendothelial system, primarily in the spleen (Itakura and Carlson, 1975; Fujiwara et al., 1975) .", [["cells", "ANATOMY", 87, 92], ["reticuloendothelial system", "ANATOMY", 100, 126], ["spleen", "ANATOMY", 145, 151], ["MSV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["HEV", "ORGANISM", 42, 45], ["MSDV", "GENE_OR_GENE_PRODUCT", 50, 54], ["cells", "CELL", 87, 92], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 100, 126], ["spleen", "ORGAN", 145, 151], ["MSV", "SPECIES", 0, 3], ["HEV", "SPECIES", 42, 45], ["MSDV", "SPECIES", 50, 54], ["Iltis", "TEST", 18, 23], ["DNA", "OBSERVATION_MODIFIER", 13, 16], ["cells", "ANATOMY_MODIFIER", 87, 92], ["reticuloendothelial system", "ANATOMY", 100, 126], ["spleen", "ANATOMY", 145, 151]]], ["There are conflicting reports in the literature on whether they share a group antigen with avian and mammalian adenoviruses.", [["avian", "ORGANISM", 91, 96], ["mammalian adenoviruses", "ORGANISM", 101, 123], ["adenoviruses", "OBSERVATION", 111, 123]]], ["Iltis et al. (1977) claimed that MSDV shares an antigen with TA1 and TA2 turkey adenoviruses.", [["MSDV", "ORGANISM", 33, 37], ["TA1", "GENE_OR_GENE_PRODUCT", 61, 64], ["TA2 turkey adenoviruses", "ORGANISM", 69, 92], ["MSDV", "PROTEIN", 33, 37], ["turkey", "SPECIES", 73, 79], ["MSDV", "SPECIES", 33, 37], ["TA2 turkey adenoviruses", "SPECIES", 69, 92], ["an antigen", "TEST", 45, 55], ["TA1", "TEST", 61, 64], ["TA2 turkey adenoviruses", "PROBLEM", 69, 92]]], ["However, other workers have failed to show this relationship with fowl adenoviruses (Jakowski and Silim etal., 1978) .DistributionAntibody to turkey isolates is widespread in the United States (Simmons et al., 1976) , and in Northern Ireland 70% of 20-week-old birds had antibody to TAV1 (Scott, 1974) .DistributionHEV has been recorded in the United States, Canada, Japan, Australia, India, and Israel (Domermuth and Gross, 1978) , and antibody has been found in all flocks tested, although only half had signs of disease (Beasley and Wisdom, 1978) .", [["fowl adenoviruses", "ORGANISM", 66, 83], ["birds", "ORGANISM", 261, 266], ["turkey", "SPECIES", 142, 148], ["fowl adenoviruses", "SPECIES", 66, 83], ["turkey", "SPECIES", 142, 148], ["fowl adenoviruses", "PROBLEM", 66, 83], ["DistributionAntibody", "TEST", 118, 138], ["antibody", "TEST", 437, 445], ["disease", "PROBLEM", 515, 522], ["widespread", "OBSERVATION_MODIFIER", 161, 171], ["disease", "OBSERVATION", 515, 522]]], ["Scott (1974) infected turkeys by a combined oral-intranasal route.", [["oral", "ANATOMY", 44, 48], ["turkeys", "ORGANISM", 22, 29], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["turkeys", "SPECIES", 22, 29], ["turkeys", "SPECIES", 22, 29], ["a combined oral-intranasal route", "TREATMENT", 33, 65]]], ["Virus was reisolated from most organs on day 4, suggesting a viremia.", [["organs", "ANATOMY", 31, 37], ["viremia", "DISEASE", 61, 68], ["Virus", "ORGANISM", 0, 5], ["organs", "ORGAN", 31, 37], ["Virus", "PROBLEM", 0, 5], ["a viremia", "PROBLEM", 59, 68], ["viremia", "OBSERVATION", 61, 68]]], ["Virus persisted in the respiratory tract until the seventh day and in the alimentary tract and feces until the eleventh day after infection.", [["respiratory tract", "ANATOMY", 23, 40], ["alimentary tract", "ANATOMY", 74, 90], ["feces", "ANATOMY", 95, 100], ["infection", "DISEASE", 130, 139], ["Virus", "ORGANISM", 0, 5], ["respiratory tract", "ORGANISM_SUBDIVISION", 23, 40], ["alimentary tract", "ORGAN", 74, 90], ["feces", "ORGANISM_SUBSTANCE", 95, 100], ["Virus", "PROBLEM", 0, 5], ["infection", "PROBLEM", 130, 139], ["respiratory tract", "ANATOMY", 23, 40], ["alimentary tract", "ANATOMY", 74, 90], ["feces", "OBSERVATION", 95, 100], ["infection", "OBSERVATION", 130, 139]]], ["From experience gained in growing kidney cell cultures derived from embryos and young poults, obtained from commercial sources, it is clear that turkey adenoviruses can be transmitted in the embryo and can remain latent in kidney cells.Epidemiology and PathogenesisAlthough viruses were isolated from turkeys aged 10 days to 6 months (Scott and McFerran, 1972) , antibody studies indicate that birds 4 -6 weeks of age are frequently devoid of antibody.", [["kidney cell cultures", "ANATOMY", 34, 54], ["embryos", "ANATOMY", 68, 75], ["embryo", "ANATOMY", 191, 197], ["kidney cells", "ANATOMY", 223, 235], ["kidney cell cultures", "CELL", 34, 54], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 75], ["poults", "ORGANISM", 86, 92], ["turkey adenoviruses", "ORGANISM", 145, 164], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 191, 197], ["kidney cells", "CELL", 223, 235], ["turkeys", "ORGANISM", 301, 308], ["kidney cell cultures", "CELL_LINE", 34, 54], ["kidney cells", "CELL_TYPE", 223, 235], ["poults", "SPECIES", 86, 92], ["turkey", "SPECIES", 145, 151], ["turkeys", "SPECIES", 301, 308], ["turkey", "SPECIES", 145, 151], ["turkeys", "SPECIES", 301, 308], ["kidney cell cultures", "TEST", 34, 54], ["PathogenesisAlthough viruses", "PROBLEM", 253, 281], ["antibody studies", "TEST", 363, 379], ["antibody", "PROBLEM", 443, 451], ["kidney", "ANATOMY", 34, 40], ["cell", "OBSERVATION", 41, 45], ["latent", "OBSERVATION", 213, 219], ["kidney", "ANATOMY", 223, 229], ["viruses", "OBSERVATION", 274, 281]]], ["However, this was present in 10-week and older birds (Scott, 1974) .Epidemiology and PathogenesisHEV occurs in 6-12-week-old birds and is most common in 10-12-week-old birds (Domermuth and Gross, 1978) , but it has been seen in 2.5-week-old birds (Harris and Domermuth, 1977) .", [["birds", "ORGANISM", 125, 130], ["birds", "ORGANISM", 168, 173], ["birds", "ORGANISM", 241, 246]]], ["It appears that the resistance of young poults to infection is not due to maternal antibody (Beasley and Wisdom, 1978) .", [["infection", "DISEASE", 50, 59], ["poults", "ORGANISM", 40, 46], ["maternal antibody", "PROTEIN", 74, 91], ["poults", "SPECIES", 40, 46], ["young poults to infection", "PROBLEM", 34, 59], ["maternal antibody", "PROBLEM", 74, 91], ["resistance", "OBSERVATION_MODIFIER", 20, 30], ["infection", "OBSERVATION", 50, 59], ["not due to", "UNCERTAINTY", 63, 73]]], ["Turkeys are susceptible to oral infection with HEV (Gross and Moore, 1967) .", [["oral", "ANATOMY", 27, 31], ["infection", "DISEASE", 32, 41], ["oral", "ORGANISM_SUBDIVISION", 27, 31], ["HEV", "ORGANISM", 47, 50], ["HEV", "SPECIES", 47, 50], ["oral infection", "PROBLEM", 27, 41], ["infection", "OBSERVATION", 32, 41]]], ["Following infection there is a viremia, and the highest virus titers are found in the spleen (Domermuth et al., 1972) .", [["spleen", "ANATOMY", 86, 92], ["infection", "DISEASE", 10, 19], ["viremia", "DISEASE", 31, 38], ["spleen", "ORGAN", 86, 92], ["infection", "PROBLEM", 10, 19], ["a viremia", "PROBLEM", 29, 38], ["the highest virus titers", "TEST", 44, 68], ["infection", "OBSERVATION", 10, 19], ["viremia", "OBSERVATION", 31, 38], ["highest", "OBSERVATION_MODIFIER", 48, 55], ["virus titers", "OBSERVATION", 56, 68], ["spleen", "ANATOMY", 86, 92]]], ["The turkey is susceptible to oral infection (Gross and Moore, 1967) .", [["oral", "ANATOMY", 29, 33], ["oral infection", "DISEASE", 29, 43], ["turkey", "ORGANISM", 4, 10], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["turkey", "SPECIES", 4, 10], ["turkey", "SPECIES", 4, 10], ["oral infection", "PROBLEM", 29, 43], ["susceptible to", "UNCERTAINTY", 14, 28], ["infection", "OBSERVATION", 34, 43]]], ["There is no evidence of egg transmission or vectors, and it is considered that infection persists in the litter between crops of birds (Domermuth and Gross, 1978) .", [["egg", "ANATOMY", 24, 27], ["infection", "DISEASE", 79, 88], ["egg", "ORGANISM_SUBSTANCE", 24, 27], ["egg transmission or vectors", "PROBLEM", 24, 51], ["infection", "PROBLEM", 79, 88], ["no evidence of", "UNCERTAINTY", 9, 23], ["egg", "OBSERVATION", 24, 27], ["infection", "OBSERVATION", 79, 88]]], ["HEV will infect fowl if given intraperitoneally or orally, and fowl kept in contact with infected fowl also become infected.", [["intraperitoneally", "ANATOMY", 30, 47], ["HEV", "ORGANISM", 0, 3], ["fowl", "ORGANISM", 16, 20], ["fowl", "ORGANISM", 98, 102], ["fowl", "SPECIES", 16, 20], ["HEV", "SPECIES", 0, 3], ["fowl", "SPECIES", 16, 20], ["fowl", "SPECIES", 63, 67], ["fowl", "SPECIES", 98, 102], ["infected", "PROBLEM", 115, 123], ["infected", "OBSERVATION", 115, 123]]], ["Lesions compara ble to those seen in turkeys develop (Silim^r al., 1978) .Association with Diseasea.", [["turkeys", "ORGANISM", 37, 44], ["turkeys", "SPECIES", 37, 44], ["turkeys", "SPECIES", 37, 44], ["Lesions compara ble", "PROBLEM", 0, 19], ["Diseasea", "PROBLEM", 91, 99], ["Diseasea", "OBSERVATION", 91, 99]]], ["Conventional fowl and turkey adenoviruses have been isolated from clinically normal turkeys (Scott and McFerran, 1972; Cho, 1976) .", [["fowl", "ORGANISM", 13, 17], ["turkey adenoviruses", "ORGANISM", 22, 41], ["turkeys", "ORGANISM", 84, 91], ["turkey", "SPECIES", 22, 28], ["turkeys", "SPECIES", 84, 91], ["fowl", "SPECIES", 13, 17], ["turkey", "SPECIES", 22, 28], ["Conventional fowl and turkey adenoviruses", "PROBLEM", 0, 41]]], ["Using turkey strains to infect turkeys, no evidence of disease could be obtained (Scott, 1974; Simmons et al., 1976; Sutjipto et al., 1977) .", [["turkey", "ORGANISM", 6, 12], ["turkeys", "ORGANISM", 31, 38], ["turkey", "SPECIES", 6, 12], ["turkeys", "SPECIES", 31, 38], ["turkey", "SPECIES", 6, 12], ["turkeys", "SPECIES", 31, 38], ["disease", "PROBLEM", 55, 62], ["no evidence of", "UNCERTAINTY", 40, 54], ["disease", "OBSERVATION", 55, 62]]], ["Similar results were obtained with Fl virus (Yates and Fry, 1957) .Association with Diseaseb.", [["Fl virus", "ORGANISM", 35, 43], ["Diseaseb", "PROTEIN", 84, 92]]], ["Respiratory Disease.", [["Respiratory Disease", "DISEASE", 0, 19], ["Respiratory Disease", "PROBLEM", 0, 19], ["Disease", "OBSERVATION", 12, 19]]], ["Viruses have been isolated from the respiratory tract of turkeys with respiratory tract disease (Scott and McFerran, 1972; Blalock et al., 1975; Simmons et al., 1976; Sutjipto et al., 1977) .", [["respiratory tract", "ANATOMY", 36, 53], ["respiratory tract", "ANATOMY", 70, 87], ["respiratory tract disease", "DISEASE", 70, 95], ["respiratory tract", "ORGANISM_SUBDIVISION", 36, 53], ["turkeys", "ORGANISM", 57, 64], ["tract", "ORGANISM_SUBDIVISION", 82, 87], ["turkeys", "SPECIES", 57, 64], ["turkeys", "SPECIES", 57, 64], ["Viruses", "PROBLEM", 0, 7], ["respiratory tract disease", "PROBLEM", 70, 95], ["respiratory tract", "ANATOMY", 36, 53], ["respiratory tract", "ANATOMY", 70, 87]]], ["Blalock et al. (1975) elicited a respiratory response when their Fl isolate was inoculated into turkeys.", [["respiratory", "ANATOMY", 33, 44], ["turkeys", "ORGANISM", 96, 103], ["turkeys", "SPECIES", 96, 103], ["turkeys", "SPECIES", 96, 103], ["a respiratory response", "PROBLEM", 31, 53], ["their Fl isolate", "TEST", 59, 75], ["respiratory response", "OBSERVATION", 33, 53]]], ["Cho (1976) , using another Fl isolate, claimed to have produced hepatitis, respi ratory tract disease, bursal atrophy, and growth depression in both chicks and poults.", [["bursal", "ANATOMY", 103, 109], ["Cho", "CHEMICAL", 0, 3], ["hepatitis", "DISEASE", 64, 73], ["respi ratory tract disease", "DISEASE", 75, 101], ["bursal atrophy", "DISEASE", 103, 117], ["growth depression", "DISEASE", 123, 140], ["bursal", "ORGANISM_SUBDIVISION", 103, 109], ["chicks", "ORGANISM", 149, 155], ["poults", "ORGANISM", 160, 166], ["chicks", "SPECIES", 149, 155], ["poults", "SPECIES", 160, 166], ["another Fl isolate", "TREATMENT", 19, 37], ["hepatitis", "PROBLEM", 64, 73], ["respi ratory tract disease", "PROBLEM", 75, 101], ["bursal atrophy", "PROBLEM", 103, 117], ["growth depression in both chicks and poults", "PROBLEM", 123, 166], ["hepatitis", "OBSERVATION", 64, 73], ["tract disease", "OBSERVATION", 88, 101], ["bursal", "ANATOMY", 103, 109], ["atrophy", "OBSERVATION", 110, 117], ["growth", "OBSERVATION_MODIFIER", 123, 129], ["depression", "OBSERVATION", 130, 140]]], ["However the possibility of infectious bursal disease (IBD) virus infection was not eliminated since the affected organs were not examined by immunofluorescence or electron microscopy.", [["bursal", "ANATOMY", 38, 44], ["organs", "ANATOMY", 113, 119], ["infectious bursal disease", "DISEASE", 27, 52], ["IBD", "DISEASE", 54, 57], ["infection", "DISEASE", 65, 74], ["bursal", "ORGAN", 38, 44], ["organs", "ORGAN", 113, 119], ["infectious bursal disease", "PROBLEM", 27, 52], ["IBD) virus infection", "PROBLEM", 54, 74], ["the affected organs", "PROBLEM", 100, 119], ["immunofluorescence", "TEST", 141, 159], ["electron microscopy", "TEST", 163, 182], ["possibility of", "UNCERTAINTY", 12, 26], ["infectious", "OBSERVATION_MODIFIER", 27, 37], ["bursal disease", "OBSERVATION", 38, 52]]], ["Therefore the possibility exists that adenoviruses alone were not responsible for these lesions.", [["lesions", "ANATOMY", 88, 95], ["adenoviruses", "ORGANISM", 38, 50], ["lesions", "PATHOLOGICAL_FORMATION", 88, 95], ["adenoviruses", "PROBLEM", 38, 50], ["these lesions", "PROBLEM", 82, 95], ["adenoviruses", "OBSERVATION", 38, 50], ["not responsible for", "UNCERTAINTY", 62, 81], ["lesions", "OBSERVATION", 88, 95]]], ["Adenoviruses were isolated from a severe upper respiratory tract disease of young turkeys.", [["upper respiratory tract", "ANATOMY", 41, 64], ["upper respiratory tract disease", "DISEASE", 41, 72], ["upper", "ORGANISM_SUBDIVISION", 41, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 47, 64], ["turkeys", "ORGANISM", 82, 89], ["turkeys", "SPECIES", 82, 89], ["Adenoviruses", "PROBLEM", 0, 12], ["a severe upper respiratory tract disease", "PROBLEM", 32, 72], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["upper", "ANATOMY_MODIFIER", 41, 46], ["respiratory tract", "ANATOMY", 47, 64], ["young turkeys", "OBSERVATION", 76, 89]]], ["But attempts to repro-duce this condition have failed, although mild disease was produced with some strains (Simmons et al., 1976; Dillman and Simmons, 1977; Sutjipto et al., 1977) .", [["mild disease", "PROBLEM", 64, 76], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["disease", "OBSERVATION", 69, 76]]], ["Page et al. (1978) have shown that these birds had antibody to IBD virus, which had not previously been recognized in turkeys, and suggested that turkeys might be infected with IBD, which could interfere with the immune response.", [["IBD", "DISEASE", 177, 180], ["birds", "ORGANISM", 41, 46], ["turkeys", "ORGANISM", 118, 125], ["turkeys", "ORGANISM", 146, 153], ["turkeys", "SPECIES", 118, 125], ["turkeys", "SPECIES", 146, 153], ["IBD virus", "SPECIES", 63, 72], ["turkeys", "SPECIES", 118, 125], ["turkeys", "SPECIES", 146, 153], ["antibody", "PROBLEM", 51, 59], ["IBD virus", "PROBLEM", 63, 72], ["IBD", "PROBLEM", 177, 180]]], ["This suggestion was opportune, as IBD virus has now been isolated from turkeys (McNultyeftf/., 1979) .Association with Diseasec.", [["turkeys", "ORGANISM", 71, 78], ["turkeys", "SPECIES", 71, 78], ["IBD virus", "SPECIES", 34, 43], ["IBD virus", "PROBLEM", 34, 43], ["Diseasec", "PROBLEM", 119, 127]]], ["Isolates have been made from birds with diarrhea and depressed egg production, but their significance is unknown (Scott and McFerran, 1972; King, 1977) .Association with Diseased.", [["egg", "ANATOMY", 63, 66], ["diarrhea", "DISEASE", 40, 48], ["depressed", "DISEASE", 53, 62], ["birds", "ORGANISM", 29, 34], ["egg", "ORGANISM_SUBSTANCE", 63, 66], ["Isolates", "TREATMENT", 0, 8], ["diarrhea", "PROBLEM", 40, 48], ["depressed egg production", "PROBLEM", 53, 77], ["diarrhea", "OBSERVATION", 40, 48], ["depressed", "OBSERVATION_MODIFIER", 53, 62], ["egg production", "OBSERVATION", 63, 77], ["Diseased", "OBSERVATION", 170, 178]]], ["Hemorrhagic Enteritis.", [["Hemorrhagic Enteritis", "DISEASE", 0, 21], ["Hemorrhagic Enteritis", "PROBLEM", 0, 21], ["Enteritis", "OBSERVATION", 12, 21]]], ["This condition was first recognized in turkeys in Minnesota (Pomeroy and Fenstermacher, 1937) .", [["turkeys", "ORGANISM", 39, 46], ["turkeys", "SPECIES", 39, 46]]], ["Following a 5-6-day incuba tion period, there was sudden depression and thirst, and blood was seen in the feces.", [["blood", "ANATOMY", 84, 89], ["feces", "ANATOMY", 106, 111], ["depression", "DISEASE", 57, 67], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["feces", "ORGANISM_SUBDIVISION", 106, 111], ["sudden depression", "PROBLEM", 50, 67], ["thirst", "PROBLEM", 72, 78], ["blood", "PROBLEM", 84, 89], ["sudden", "OBSERVATION_MODIFIER", 50, 56], ["depression", "OBSERVATION", 57, 67], ["feces", "ANATOMY", 106, 111]]], ["Mortality varied from nil to 60% (Gross and Moore, 1967) .", [["Mortality", "TEST", 0, 9], ["nil", "OBSERVATION_MODIFIER", 22, 25]]], ["Experimental infection resulted in mortalities of 0-80%, depending on the virulence of the virus (Domermuth and Gross, 1978) .", [["infection", "DISEASE", 13, 22], ["Experimental infection", "PROBLEM", 0, 22], ["the virus", "PROBLEM", 87, 96], ["infection", "OBSERVATION", 13, 22]]], ["Death occurred in a few hours or the birds recovered.", [["Death", "DISEASE", 0, 5], ["birds", "ORGANISM", 37, 42], ["Death", "PROBLEM", 0, 5]]], ["The main lesions were splenomegaly, congestion of the small intestine, and hemorrhagic contents of the intestine.", [["lesions", "ANATOMY", 9, 16], ["splenomegaly", "ANATOMY", 22, 34], ["small intestine", "ANATOMY", 54, 69], ["intestine", "ANATOMY", 103, 112], ["splenomegaly", "DISEASE", 22, 34], ["hemorrhagic", "DISEASE", 75, 86], ["lesions", "CANCER", 9, 16], ["small intestine", "ORGAN", 54, 69], ["intestine", "ORGAN", 103, 112], ["The main lesions", "PROBLEM", 0, 16], ["splenomegaly", "PROBLEM", 22, 34], ["congestion of the small intestine", "PROBLEM", 36, 69], ["hemorrhagic contents of the intestine", "PROBLEM", 75, 112], ["main", "OBSERVATION_MODIFIER", 4, 8], ["lesions", "OBSERVATION", 9, 16], ["splenomegaly", "OBSERVATION", 22, 34], ["congestion", "OBSERVATION", 36, 46], ["small intestine", "ANATOMY", 54, 69], ["hemorrhagic", "OBSERVATION_MODIFIER", 75, 86], ["contents", "OBSERVATION", 87, 95], ["intestine", "ANATOMY", 103, 112]]], ["Microscopically, there was an acute hemorrhagic enteritis, degenera tive changes of the lymphoid tissue, and proliferation of reticuloendothelial cells in all areas.", [["lymphoid tissue", "ANATOMY", 88, 103], ["reticuloendothelial cells", "ANATOMY", 126, 151], ["enteritis", "DISEASE", 48, 57], ["lymphoid tissue", "TISSUE", 88, 103], ["reticuloendothelial cells", "CELL", 126, 151], ["reticuloendothelial cells", "CELL_TYPE", 126, 151], ["an acute hemorrhagic enteritis", "PROBLEM", 27, 57], ["degenera tive changes of the lymphoid tissue", "PROBLEM", 59, 103], ["proliferation of reticuloendothelial cells", "PROBLEM", 109, 151], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["hemorrhagic", "OBSERVATION_MODIFIER", 36, 47], ["enteritis", "OBSERVATION", 48, 57], ["degenera tive", "OBSERVATION", 59, 72], ["lymphoid tissue", "OBSERVATION", 88, 103], ["proliferation", "OBSERVATION_MODIFIER", 109, 122], ["reticuloendothelial cells", "OBSERVATION", 126, 151], ["all", "OBSERVATION_MODIFIER", 155, 158], ["areas", "OBSERVATION_MODIFIER", 159, 164]]], ["Intranuclear inclusions were seen in the large mononuclear cells in visceral organs and in reticular cells around sheathed arteries of the spleen.", [["mononuclear cells", "ANATOMY", 47, 64], ["visceral organs", "ANATOMY", 68, 83], ["reticular cells", "ANATOMY", 91, 106], ["arteries", "ANATOMY", 123, 131], ["spleen", "ANATOMY", 139, 145], ["mononuclear cells", "CELL", 47, 64], ["visceral organs", "TISSUE", 68, 83], ["reticular cells", "CELL", 91, 106], ["sheathed arteries", "MULTI-TISSUE_STRUCTURE", 114, 131], ["spleen", "ORGAN", 139, 145], ["large mononuclear cells", "CELL_TYPE", 41, 64], ["reticular cells", "CELL_TYPE", 91, 106], ["Intranuclear inclusions", "PROBLEM", 0, 23], ["inclusions", "OBSERVATION", 13, 23], ["large", "OBSERVATION_MODIFIER", 41, 46], ["mononuclear cells", "OBSERVATION", 47, 64], ["visceral organs", "ANATOMY", 68, 83], ["reticular cells", "OBSERVATION", 91, 106], ["sheathed", "ANATOMY_MODIFIER", 114, 122], ["arteries", "ANATOMY", 123, 131], ["spleen", "ANATOMY", 139, 145]]], ["Death was probably due to bleeding from damaged capiallaries in the tips of the villi.", [["capiallaries", "ANATOMY", 48, 60], ["villi", "ANATOMY", 80, 85], ["Death", "DISEASE", 0, 5], ["bleeding", "DISEASE", 26, 34], ["capiallaries", "PATHOLOGICAL_FORMATION", 48, 60], ["villi", "MULTI-TISSUE_STRUCTURE", 80, 85], ["Death", "PROBLEM", 0, 5], ["bleeding", "PROBLEM", 26, 34], ["damaged capiallaries", "PROBLEM", 40, 60], ["probably due to", "UNCERTAINTY", 10, 25], ["bleeding", "OBSERVATION", 26, 34], ["damaged", "OBSERVATION_MODIFIER", 40, 47], ["capiallaries", "OBSERVATION", 48, 60], ["tips", "ANATOMY_MODIFIER", 68, 72], ["villi", "ANATOMY", 80, 85]]], ["The HEV or a similar virus of chickens has been isolated from the enlarged spleens of birds condemned for Marek's disease (Domermuth, 1979) .DiagnosisTo isolate turkey adenoviruses, as opposed to fowl adenoviruses affecting turkeys, it is necessary to use turkey embryo kidney or liver cells or turkey kidney cells.", [["spleens", "ANATOMY", 75, 82], ["embryo kidney", "ANATOMY", 263, 276], ["liver cells", "ANATOMY", 280, 291], ["kidney cells", "ANATOMY", 302, 314], ["Marek's disease", "DISEASE", 106, 121], ["turkey adenoviruses", "DISEASE", 161, 180], ["HEV", "ORGANISM", 4, 7], ["chickens", "ORGANISM", 30, 38], ["spleens", "ORGAN", 75, 82], ["birds", "ORGANISM", 86, 91], ["turkey", "ORGANISM", 161, 167], ["adenoviruses", "ORGANISM", 168, 180], ["fowl adenoviruses", "ORGANISM", 196, 213], ["turkeys", "ORGANISM", 224, 231], ["turkey", "ORGANISM", 256, 262], ["embryo kidney", "CELL", 263, 276], ["liver cells", "CELL", 280, 291], ["turkey kidney cells", "CELL", 295, 314], ["turkey embryo kidney or liver cells", "CELL_TYPE", 256, 291], ["turkey kidney cells", "CELL_TYPE", 295, 314], ["chickens", "SPECIES", 30, 38], ["turkey", "SPECIES", 161, 167], ["fowl", "SPECIES", 196, 200], ["turkeys", "SPECIES", 224, 231], ["turkey", "SPECIES", 256, 262], ["turkey", "SPECIES", 295, 301], ["HEV", "SPECIES", 4, 7], ["chickens", "SPECIES", 30, 38], ["turkey", "SPECIES", 161, 167], ["fowl", "SPECIES", 196, 200], ["turkeys", "SPECIES", 224, 231], ["turkey", "SPECIES", 256, 262], ["turkey", "SPECIES", 295, 301], ["The HEV", "PROBLEM", 0, 7], ["a similar virus of chickens", "PROBLEM", 11, 38], ["Marek's disease", "PROBLEM", 106, 121], ["isolate turkey adenoviruses", "PROBLEM", 153, 180], ["liver cells", "PROBLEM", 280, 291], ["turkey kidney cells", "PROBLEM", 295, 314], ["HEV", "OBSERVATION", 4, 7], ["similar", "OBSERVATION_MODIFIER", 13, 20], ["virus", "OBSERVATION", 21, 26], ["enlarged", "OBSERVATION_MODIFIER", 66, 74], ["spleens", "OBSERVATION", 75, 82], ["kidney", "ANATOMY", 270, 276], ["liver", "ANATOMY", 280, 285], ["kidney", "ANATOMY", 302, 308]]], ["Turkey fibroblasts are not sensitive (McFerran, unpublished obser vations) .", [["fibroblasts", "ANATOMY", 7, 18], ["fibroblasts", "CELL", 7, 18], ["Turkey fibroblasts", "CELL_TYPE", 0, 18], ["Turkey fibroblasts", "PROBLEM", 0, 18], ["McFerran", "TREATMENT", 38, 46], ["not", "UNCERTAINTY", 23, 26], ["sensitive", "OBSERVATION_MODIFIER", 27, 36]]], ["Some turkey adenoviruses can be isolated on the first or second passage (Scott, 1974) .", [["turkey", "ORGANISM", 5, 11], ["adenoviruses", "ORGANISM", 12, 24], ["turkey", "SPECIES", 5, 11], ["turkey", "SPECIES", 5, 11], ["Some turkey adenoviruses", "PROBLEM", 0, 24], ["adenoviruses", "OBSERVATION", 12, 24]]], ["But other viruses required up to nine passages in cell culture before isolation (Simmons and Gray, 1976) .", [["cell", "ANATOMY", 50, 54], ["cell", "CELL", 50, 54], ["other viruses", "PROBLEM", 4, 17], ["cell culture", "TEST", 50, 62], ["viruses", "OBSERVATION", 10, 17]]], ["Although initial isolations were made in turkey kidney cells (Simmons et al., 1976) , in a comparative study, turkey embryo liver cells but not turkey kidney cells detected virus on initial isolation.", [["kidney cells", "ANATOMY", 48, 60], ["embryo liver cells", "ANATOMY", 117, 135], ["kidney cells", "ANATOMY", 151, 163], ["turkey", "ORGANISM", 41, 47], ["kidney cells", "CELL", 48, 60], ["turkey", "ORGANISM", 110, 116], ["embryo liver cells", "CELL", 117, 135], ["turkey", "ORGANISM", 144, 150], ["kidney cells", "CELL", 151, 163], ["turkey kidney cells", "CELL_TYPE", 41, 60], ["turkey embryo liver cells", "CELL_TYPE", 110, 135], ["turkey kidney cells", "CELL_TYPE", 144, 163], ["turkey", "SPECIES", 41, 47], ["turkey", "SPECIES", 110, 116], ["turkey", "SPECIES", 144, 150], ["turkey", "SPECIES", 41, 47], ["turkey", "SPECIES", 110, 116], ["turkey", "SPECIES", 144, 150], ["initial isolations", "PROBLEM", 9, 27], ["a comparative study", "TEST", 89, 108], ["turkey embryo liver cells", "PROBLEM", 110, 135], ["turkey kidney cells", "PROBLEM", 144, 163], ["virus", "PROBLEM", 173, 178], ["initial isolation", "TREATMENT", 182, 199], ["kidney", "ANATOMY", 48, 54], ["liver", "ANATOMY", 124, 129]]], ["Both cells were sensitive on subsequent passage (Simmons and Gray, 1976) .", [["cells", "ANATOMY", 5, 10], ["cells", "CELL", 5, 10]]], ["With these slow-growing adenoviruses, turkey adenoviruses had to be neutralized with antibody.", [["adenoviruses", "ORGANISM", 24, 36], ["turkey", "ORGANISM", 38, 44], ["adenoviruses", "ORGANISM", 45, 57], ["turkey", "SPECIES", 38, 44], ["turkey", "SPECIES", 38, 44], ["these slow-growing adenoviruses", "PROBLEM", 5, 36], ["turkey adenoviruses", "PROBLEM", 38, 57], ["antibody", "PROBLEM", 85, 93], ["slow", "OBSERVATION_MODIFIER", 11, 15], ["growing", "OBSERVATION_MODIFIER", 16, 23], ["adenoviruses", "OBSERVATION", 24, 36]]], ["Acridine orange was found to be helpful in detecting viral presence (Simmons and Gray, 1976) .", [["Acridine orange", "CHEMICAL", 0, 15], ["Acridine orange", "CHEMICAL", 0, 15], ["Acridine orange", "SIMPLE_CHEMICAL", 0, 15], ["Acridine orange", "TEST", 0, 15]]], ["As suggested for the bovine adeno viruses, FA staining might be of major help.DiagnosisHEV has not been grown in cell culture or embryonated eggs (Domermuth et al., 1972; Carlson et al., 1974) .", [["cell culture", "ANATOMY", 113, 125], ["eggs", "ANATOMY", 141, 145], ["bovine", "ORGANISM", 21, 27], ["adeno viruses", "ORGANISM", 28, 41], ["FA", "SIMPLE_CHEMICAL", 43, 45], ["cell culture", "CELL", 113, 125], ["bovine", "SPECIES", 21, 27], ["bovine adeno viruses", "SPECIES", 21, 41], ["the bovine adeno viruses", "PROBLEM", 17, 41], ["FA staining", "PROBLEM", 43, 54], ["cell culture", "TEST", 113, 125], ["embryonated eggs", "PROBLEM", 129, 145], ["grown", "OBSERVATION_MODIFIER", 104, 109]]], ["Therefore virus isolation involves inoculation of turkeys.", [["turkeys", "ORGANISM", 50, 57], ["turkeys", "SPECIES", 50, 57], ["turkeys", "SPECIES", 50, 57], ["virus isolation", "TREATMENT", 10, 25]]], ["Turkeys 6-10 weeks old are infected orally with feces or intravenously with spleen extract of affected birds.", [["orally", "ANATOMY", 36, 42], ["feces", "ANATOMY", 48, 53], ["intravenously", "ANATOMY", 57, 70], ["spleen extract", "ANATOMY", 76, 90], ["feces", "ORGANISM_SUBSTANCE", 48, 53], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["spleen", "ORGAN", 76, 82], ["birds", "ORGANISM", 103, 108], ["infected", "OBSERVATION", 27, 35], ["spleen", "ANATOMY", 76, 82]]], ["Deaths should occur 3 days after intrave nous or 5-6 days after oral infection.", [["oral", "ANATOMY", 64, 68], ["infection", "DISEASE", 69, 78], ["oral", "ORGANISM_SUBDIVISION", 64, 68], ["oral infection", "PROBLEM", 64, 78], ["infection", "OBSERVATION", 69, 78]]], ["Birds not dying should have enlarged spleens.", [["spleens", "ANATOMY", 37, 44], ["spleens", "ORGAN", 37, 44], ["enlarged spleens", "PROBLEM", 28, 44], ["enlarged", "OBSERVATION_MODIFIER", 28, 36], ["spleens", "OBSERVATION", 37, 44]]], ["These spleens or spleens from dying birds can be used as an antigen in a DID test (Domermuth et al., 1973) .", [["spleens", "ANATOMY", 6, 13], ["spleens", "ANATOMY", 17, 24], ["spleens", "ORGAN", 6, 13], ["spleens", "ORGAN", 17, 24], ["birds", "ORGANISM", 36, 41], ["spleens", "ANATOMY", 6, 13], ["spleens", "ANATOMY", 17, 24]]], ["Birds not dying will develop precipitating antibody after 2 weeks, and peak titers are reached around 4 weeks.ClassificationAn adenovirus has been isolated from pheasant chicks and identified as an adenovirus by the presence of group antigen (Cakala, 1966) .", [["adenovirus", "ORGANISM", 127, 137], ["pheasant", "ORGANISM", 161, 169], ["chicks", "ORGANISM_SUBDIVISION", 170, 176], ["adenovirus", "ORGANISM", 198, 208], ["group antigen", "PROTEIN", 228, 241], ["pheasant chicks", "SPECIES", 161, 176], ["adenovirus", "SPECIES", 127, 137], ["pheasant chicks", "SPECIES", 161, 176], ["precipitating antibody", "PROBLEM", 29, 51], ["peak titers", "TEST", 71, 82], ["ClassificationAn adenovirus", "PROBLEM", 110, 137], ["pheasant chicks", "PROBLEM", 161, 176], ["an adenovirus", "PROBLEM", 195, 208], ["pheasant chicks", "OBSERVATION_MODIFIER", 161, 176]]], ["The relationship of MSDV to the adenovirus group and to turkey hemorrhagic enteritis has already been considered.DistributionMSD has been recognized in Italy (Mandelli et al., 1966) , Canada (Carlson et al., 1973) , England (Bygrave and Pattison, 1973) , and the United States .Epidemiology and PautogenesisIn view of its close relationship to HEV, it is likely that MSD behaves in a similar fashion.", [["MSDV", "CHEMICAL", 20, 24], ["hemorrhagic enteritis", "DISEASE", 63, 84], ["MSDV", "GENE_OR_GENE_PRODUCT", 20, 24], ["adenovirus", "ORGANISM", 32, 42], ["HEV", "ORGANISM", 344, 347], ["turkey hemorrhagic enteritis", "SPECIES", 56, 84], ["MSDV", "SPECIES", 20, 24], ["turkey hemorrhagic enteritis", "SPECIES", 56, 84], ["HEV", "SPECIES", 344, 347], ["the adenovirus group", "TREATMENT", 28, 48], ["hemorrhagic enteritis", "PROBLEM", 63, 84], ["MSD", "PROBLEM", 367, 370], ["hemorrhagic", "OBSERVATION_MODIFIER", 63, 74], ["enteritis", "OBSERVATION", 75, 84]]], ["Pheasants 4 -8 months old are commonly affected, but MSD can occur in younger birds Bygrave and Pattison, 1973) .Association with DiseaseThe disease in pheasants produced by MSDV resembles the disease in turkeys produced by HEV, except that MSDV does not produce gut lesions in pheasants or turkeys and death appears to be due to pulmonary edema.", [["gut lesions", "ANATOMY", 263, 274], ["pulmonary", "ANATOMY", 330, 339], ["MSD", "DISEASE", 53, 56], ["MSDV", "CHEMICAL", 174, 178], ["MSDV", "CHEMICAL", 241, 245], ["gut lesions", "DISEASE", 263, 274], ["death", "DISEASE", 303, 308], ["pulmonary edema", "DISEASE", 330, 345], ["pheasants", "ORGANISM", 152, 161], ["turkeys", "ORGANISM", 204, 211], ["HEV", "ORGANISM", 224, 227], ["gut lesions", "PATHOLOGICAL_FORMATION", 263, 274], ["pheasants", "ORGANISM", 278, 287], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 330, 345], ["turkeys", "SPECIES", 204, 211], ["turkeys", "SPECIES", 291, 298], ["MSDV", "SPECIES", 174, 178], ["turkeys", "SPECIES", 204, 211], ["HEV", "SPECIES", 224, 227], ["MSDV", "SPECIES", 241, 245], ["turkeys", "SPECIES", 291, 298], ["Pheasants", "TREATMENT", 0, 9], ["DiseaseThe disease in pheasants", "PROBLEM", 130, 161], ["the disease", "PROBLEM", 189, 200], ["gut lesions in pheasants", "PROBLEM", 263, 287], ["death", "PROBLEM", 303, 308], ["pulmonary edema", "PROBLEM", 330, 345], ["Disease", "OBSERVATION", 130, 137], ["disease", "OBSERVATION", 141, 148], ["disease", "OBSERVATION", 193, 200], ["lesions", "OBSERVATION", 267, 274], ["appears to be due to", "UNCERTAINTY", 309, 329], ["pulmonary", "ANATOMY", 330, 339], ["edema", "OBSERVATION", 340, 345]]], ["Usually birds are found dead.", [["birds", "ORGANISM", 8, 13], ["dead", "PROBLEM", 24, 28]]], ["At autopsy, splenomegaly with varying confluent gray foci of necro sis (marble spleen) and intensely congested and edematous lungs were observed.", [["gray foci", "ANATOMY", 48, 57], ["necro sis", "ANATOMY", 61, 70], ["spleen", "ANATOMY", 79, 85], ["edematous lungs", "ANATOMY", 115, 130], ["splenomegaly", "DISEASE", 12, 24], ["necro sis", "CANCER", 61, 70], ["spleen", "ORGAN", 79, 85], ["lungs", "ORGAN", 125, 130], ["autopsy", "TEST", 3, 10], ["splenomegaly", "PROBLEM", 12, 24], ["varying confluent gray foci", "PROBLEM", 30, 57], ["necro sis (marble spleen)", "PROBLEM", 61, 86], ["intensely congested and edematous lungs", "PROBLEM", 91, 130], ["splenomegaly", "OBSERVATION", 12, 24], ["varying", "OBSERVATION_MODIFIER", 30, 37], ["confluent", "OBSERVATION_MODIFIER", 38, 47], ["gray", "OBSERVATION_MODIFIER", 48, 52], ["foci", "OBSERVATION", 53, 57], ["necro sis", "OBSERVATION", 61, 70], ["marble", "OBSERVATION_MODIFIER", 72, 78], ["spleen", "ANATOMY", 79, 85], ["intensely", "OBSERVATION_MODIFIER", 91, 100], ["congested", "OBSERVATION", 101, 110], ["edematous", "OBSERVATION", 115, 124], ["lungs", "ANATOMY", 125, 130]]], ["Focal necrosis around the tertiary bronchi of the lungs and of the germinal follicles of the spleen was observed.", [["bronchi", "ANATOMY", 35, 42], ["lungs", "ANATOMY", 50, 55], ["germinal follicles", "ANATOMY", 67, 85], ["spleen", "ANATOMY", 93, 99], ["necrosis", "DISEASE", 6, 14], ["bronchi", "MULTI-TISSUE_STRUCTURE", 35, 42], ["lungs", "ORGAN", 50, 55], ["germinal follicles", "MULTI-TISSUE_STRUCTURE", 67, 85], ["spleen", "ORGAN", 93, 99], ["Focal necrosis", "PROBLEM", 0, 14], ["necrosis", "OBSERVATION", 6, 14], ["tertiary", "ANATOMY_MODIFIER", 26, 34], ["bronchi", "ANATOMY", 35, 42], ["lungs", "ANATOMY", 50, 55], ["germinal", "ANATOMY_MODIFIER", 67, 75], ["follicles", "OBSERVATION", 76, 85], ["spleen", "ANATOMY", 93, 99]]], ["Masses of pale eosinophilic fibrinoid-type material, not amyloid, was seen around blood vessels and the areas of necrosis Bygrave and Pattison, 1973; Carlson et al., 1974) .", [["blood vessels", "ANATOMY", 82, 95], ["amyloid", "DISEASE", 57, 64], ["necrosis", "DISEASE", 113, 121], ["pale eosinophilic fibrinoid-type material", "TISSUE", 10, 51], ["amyloid", "GENE_OR_GENE_PRODUCT", 57, 64], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 82, 95], ["Masses of pale eosinophilic fibrinoid", "PROBLEM", 0, 37], ["type material", "PROBLEM", 38, 51], ["amyloid", "PROBLEM", 57, 64], ["necrosis", "PROBLEM", 113, 121], ["pale", "OBSERVATION_MODIFIER", 10, 14], ["eosinophilic fibrinoid", "OBSERVATION", 15, 37], ["type material", "OBSERVATION_MODIFIER", 38, 51], ["amyloid", "OBSERVATION", 57, 64], ["vessels", "ANATOMY", 88, 95], ["areas", "OBSERVATION_MODIFIER", 104, 109], ["necrosis", "OBSERVATION", 113, 121]]], ["Eosino philic and basophilic inclusions were seen in the lung and spleen and eosino philic inclusions in some liver cells.", [["basophilic inclusions", "ANATOMY", 18, 39], ["lung", "ANATOMY", 57, 61], ["spleen", "ANATOMY", 66, 72], ["liver cells", "ANATOMY", 110, 121], ["Eosino philic", "GENE_OR_GENE_PRODUCT", 0, 13], ["basophilic", "ORGANISM_SUBSTANCE", 18, 28], ["lung", "ORGAN", 57, 61], ["spleen", "ORGAN", 66, 72], ["liver cells", "CELL", 110, 121], ["liver cells", "CELL_TYPE", 110, 121], ["Eosino philic", "PROBLEM", 0, 13], ["basophilic inclusions", "PROBLEM", 18, 39], ["eosino philic inclusions in some liver cells", "PROBLEM", 77, 121], ["philic", "ANATOMY", 7, 13], ["basophilic inclusions", "OBSERVATION", 18, 39], ["lung", "ANATOMY", 57, 61], ["spleen", "ANATOMY", 66, 72], ["philic inclusions", "OBSERVATION", 84, 101], ["some", "ANATOMY_MODIFIER", 105, 109], ["liver", "ANATOMY", 110, 115], ["cells", "ANATOMY_MODIFIER", 116, 121]]], ["It is interesting that in experimental trans mission studies, neither death nor the full spectrum of MSD lesions was found.", [["lesions", "ANATOMY", 105, 112], ["death", "DISEASE", 70, 75], ["MSD", "DISEASE", 101, 104], ["MSD lesions", "CANCER", 101, 112], ["MSD lesions", "PROBLEM", 101, 112], ["MSD", "OBSERVATION_MODIFIER", 101, 104], ["lesions", "OBSERVATION", 105, 112]]], ["This led Iltis et al. (1975) to suggest that some synergistic factor must be required.DiagnosisThe history and pathological signs are usually sufficient.", [["some synergistic factor", "PROBLEM", 45, 68], ["pathological signs", "TEST", 111, 129]]], ["However, the tech niques suggested for HEV are suitable.L. Infection in Other Avian SpeciesQuail bronchitis was described in bobwhite quail (Colinies virginianus) by Olson (1950) .", [["SpeciesQuail bronchitis", "DISEASE", 84, 107], ["HEV", "ORGANISM", 39, 42], ["bobwhite quail", "ORGANISM", 125, 139], ["Colinies virginianus", "ORGANISM", 141, 161], ["Avian", "SPECIES", 78, 83], ["quail", "SPECIES", 134, 139], ["Colinies virginianus", "SPECIES", 141, 161], ["HEV", "SPECIES", 39, 42], ["Avian SpeciesQuail bronchitis", "SPECIES", 78, 107], ["bobwhite quail", "SPECIES", 125, 139], ["Colinies virginianus", "SPECIES", 141, 161], ["HEV", "PROBLEM", 39, 42], ["L. Infection", "PROBLEM", 56, 68], ["bronchitis", "PROBLEM", 97, 107], ["Infection", "OBSERVATION", 59, 68], ["bronchitis", "OBSERVATION", 97, 107]]], ["This condition has a short incubation period and sudden onset in young birds.", [["birds", "ORGANISM", 71, 76], ["short incubation", "OBSERVATION_MODIFIER", 21, 37]]], ["Mortality can reach 100%, and it is highly contagious.", [["highly", "OBSERVATION_MODIFIER", 36, 42], ["contagious", "OBSERVATION", 43, 53]]], ["The signs are rales, coughing, depression, nervous signs, and in some birds conjunctivitis (Olson, 1950; Dubose et al., 1958) .", [["nervous", "ANATOMY", 43, 50], ["coughing", "DISEASE", 21, 29], ["depression", "DISEASE", 31, 41], ["nervous signs", "DISEASE", 43, 56], ["conjunctivitis", "DISEASE", 76, 90], ["nervous", "ANATOMICAL_SYSTEM", 43, 50], ["rales", "PROBLEM", 14, 19], ["coughing", "PROBLEM", 21, 29], ["depression", "PROBLEM", 31, 41], ["nervous signs", "PROBLEM", 43, 56], ["some birds conjunctivitis", "PROBLEM", 65, 90], ["signs", "OBSERVATION_MODIFIER", 4, 9], ["rales", "OBSERVATION", 14, 19], ["nervous", "ANATOMY", 43, 50]]], ["The virus isolated from this condition has been shown to be identical to Fl (Yates and Fry, 1957; Dubose and Grumbles, 1959) .L. Infection in Other Avian SpeciesFl has also been isolated from guinea fowl with pancreatitis (Pascucci et al., 1973) .", [["SpeciesFl", "CHEMICAL", 154, 163], ["pancreatitis", "DISEASE", 209, 221], ["Avian", "ORGANISM", 148, 153], ["guinea fowl", "ORGANISM", 192, 203], ["guinea fowl", "SPECIES", 192, 203], ["guinea fowl", "SPECIES", 192, 203], ["The virus", "PROBLEM", 0, 9], ["Infection", "PROBLEM", 129, 138], ["pancreatitis", "PROBLEM", 209, 221], ["virus", "OBSERVATION", 4, 9], ["Infection", "OBSERVATION", 129, 138], ["pancreatitis", "OBSERVATION", 209, 221]]], ["F2 and F8 have been isolated from budgerigars, F5 from a mallard duck, and F8 from pigeons (McFerran et al., 1976b) .L. Infection in Other Avian SpeciesIt is interesting that fowl adenoviruses have been isolated from a number of avian species.", [["budgerigars", "ANATOMY", 34, 45], ["F8", "GENE_OR_GENE_PRODUCT", 7, 9], ["mallard duck", "ORGANISM", 57, 69], ["fowl adenoviruses", "ORGANISM", 175, 192], ["avian", "ORGANISM", 229, 234], ["F8", "DNA", 7, 9], ["mallard duck", "SPECIES", 57, 69], ["mallard duck", "SPECIES", 57, 69], ["fowl adenoviruses", "SPECIES", 175, 192], ["Infection", "PROBLEM", 120, 129], ["fowl adenoviruses", "PROBLEM", 175, 192], ["avian species", "PROBLEM", 229, 242], ["mallard duck", "ANATOMY", 57, 69], ["Infection", "OBSERVATION", 120, 129], ["avian species", "OBSERVATION", 229, 242]]], ["It is not clear if this means that they share one group of viruses or if the failure to detect other avian viruses simply reflects the failure to use homologous cell cultures.", [["cell cultures", "ANATOMY", 161, 174], ["cell cultures", "CELL", 161, 174], ["homologous cell cultures", "CELL_LINE", 150, 174], ["viruses", "PROBLEM", 59, 66], ["the failure", "PROBLEM", 73, 84], ["other avian viruses", "PROBLEM", 95, 114], ["the failure", "PROBLEM", 131, 142], ["homologous cell cultures", "TEST", 150, 174], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15]]], ["The second reason appears more feasible, because turkeys are infected with turkey adenoviruses in addition to fowl adenoviruses.", [["turkeys", "ORGANISM", 49, 56], ["turkey adenoviruses", "ORGANISM", 75, 94], ["fowl adenoviruses", "ORGANISM", 110, 127], ["turkeys", "SPECIES", 49, 56], ["turkey", "SPECIES", 75, 81], ["fowl", "SPECIES", 110, 114], ["turkeys", "SPECIES", 49, 56], ["turkey", "SPECIES", 75, 81], ["fowl", "SPECIES", 110, 114], ["turkey adenoviruses", "TREATMENT", 75, 94], ["fowl adenoviruses", "PROBLEM", 110, 127], ["infected", "OBSERVATION", 61, 69]]], ["The turkey viruses do not grow in fowl cells and are unrelated to fowl adenovirus serotypes.V. PROPHYLAXISVaccines are mainly used in canine and to a lesser degree in bovine and avian medicine.", [["cells", "ANATOMY", 39, 44], ["turkey viruses", "ORGANISM", 4, 18], ["fowl cells", "CELL", 34, 44], ["fowl adenovirus serotypes", "ORGANISM", 66, 91], ["canine", "ORGANISM", 134, 140], ["bovine", "ORGANISM", 167, 173], ["fowl cells", "CELL_TYPE", 34, 44], ["turkey", "SPECIES", 4, 10], ["fowl", "SPECIES", 66, 70], ["bovine", "SPECIES", 167, 173], ["turkey viruses", "SPECIES", 4, 18], ["fowl", "SPECIES", 34, 38], ["fowl adenovirus", "SPECIES", 66, 81], ["canine", "SPECIES", 134, 140], ["bovine", "SPECIES", 167, 173], ["The turkey viruses", "PROBLEM", 0, 18], ["fowl cells", "PROBLEM", 34, 44], ["fowl adenovirus serotypes", "PROBLEM", 66, 91], ["V. PROPHYLAXISVaccines", "TREATMENT", 92, 114], ["avian medicine", "TREATMENT", 178, 192], ["fowl cells", "OBSERVATION", 34, 44], ["unrelated to", "UNCERTAINTY", 53, 65], ["fowl adenovirus serotypes", "OBSERVATION", 66, 91], ["lesser degree", "OBSERVATION_MODIFIER", 150, 163]]], ["Both inactivated and attenuated vaccines are used for the control of ICH in dogs.", [["ICH", "DISEASE", 69, 72], ["dogs", "ORGANISM", 76, 80], ["dogs", "SPECIES", 76, 80], ["attenuated vaccines", "TREATMENT", 21, 40], ["ICH in dogs", "PROBLEM", 69, 80], ["ICH", "OBSERVATION", 69, 72]]], ["The attenuated vaccines have proved very effective.", [["The attenuated vaccines", "TREATMENT", 0, 23]]], ["However, not only is the vaccine virus excreted in the urine, but it may result in focal intersti tial nephritis (Appel et al., 1973) .", [["urine", "ANATOMY", 55, 60], ["nephritis", "DISEASE", 103, 112], ["urine", "ORGANISM_SUBSTANCE", 55, 60], ["the vaccine virus", "PROBLEM", 21, 38], ["focal intersti tial nephritis", "PROBLEM", 83, 112], ["focal", "OBSERVATION_MODIFIER", 83, 88], ["intersti tial nephritis", "OBSERVATION", 89, 112]]], ["In addition, it may cause corneal edema, which is usually transient, provided corticosteroids are not used.", [["corneal", "ANATOMY", 26, 33], ["corneal edema", "DISEASE", 26, 39], ["corticosteroids", "CHEMICAL", 78, 93], ["corneal edema", "PATHOLOGICAL_FORMATION", 26, 39], ["corticosteroids", "SIMPLE_CHEMICAL", 78, 93], ["corneal edema", "PROBLEM", 26, 39], ["corticosteroids", "TREATMENT", 78, 93], ["may cause", "UNCERTAINTY", 16, 25], ["corneal", "ANATOMY", 26, 33], ["edema", "OBSERVATION", 34, 39]]], ["One study suggests that over 0.4% of vaccinated dogs may have \"blue eye\" following vaccination (Curtis and Barnett, 1973) .", [["eye", "ANATOMY", 68, 71], ["dogs", "ORGANISM", 48, 52], ["eye", "ORGAN", 68, 71], ["dogs", "SPECIES", 48, 52], ["One study", "TEST", 0, 9], ["vaccinated dogs", "TREATMENT", 37, 52]]], ["The immunity following inactivated vaccine appears less effective, and this has led to some manufacturers to rec ommend repeated revaccination.", [["The immunity", "TREATMENT", 0, 12], ["inactivated vaccine", "TREATMENT", 23, 42], ["repeated revaccination", "TREATMENT", 120, 142]]], ["This procedure could lead to the development of circulating immune complexes and glomerulonephritis, as suggested by Mur ray and Wright (1974) , but there is no direct evidence for this.", [["glomerulonephritis", "DISEASE", 81, 99], ["This procedure", "TREATMENT", 0, 14], ["circulating immune complexes", "PROBLEM", 48, 76], ["glomerulonephritis", "PROBLEM", 81, 99], ["circulating immune complexes", "OBSERVATION", 48, 76], ["glomerulonephritis", "OBSERVATION", 81, 99], ["no direct evidence for", "UNCERTAINTY", 158, 180]]], ["Because A26/61 has been associated only with lesions of the respiratory tract, it has been sugges ted that an attenuated strain would be suitable for protection of dogs against both ICH and ILT (Appel et al., 1973) .", [["lesions", "ANATOMY", 45, 52], ["respiratory tract", "ANATOMY", 60, 77], ["A26/61", "CHEMICAL", 8, 14], ["lesions of the respiratory tract", "DISEASE", 45, 77], ["ICH", "DISEASE", 182, 185], ["A26/61", "GENE_OR_GENE_PRODUCT", 8, 14], ["lesions", "PATHOLOGICAL_FORMATION", 45, 52], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["dogs", "ORGANISM", 164, 168], ["A26/61", "PROTEIN", 8, 14], ["dogs", "SPECIES", 164, 168], ["lesions of the respiratory tract", "PROBLEM", 45, 77], ["an attenuated strain", "PROBLEM", 107, 127], ["dogs", "TREATMENT", 164, 168], ["both ICH", "PROBLEM", 177, 185], ["lesions", "OBSERVATION", 45, 52], ["respiratory tract", "ANATOMY", 60, 77], ["ICH", "OBSERVATION", 182, 185]]], ["A commercial A26/61 vaccine is now in use.", [["A26/61", "CHEMICAL", 13, 19], ["A commercial A26/61 vaccine", "TREATMENT", 0, 27]]], ["Some work has been carried out using both inactivated and attenuated vaccines in the control of adenovirus infection in cattle (Tribe et al., 1969; Burki, 1973; Bartha, 1974) .", [["adenovirus infection", "DISEASE", 96, 116], ["adenovirus", "ORGANISM", 96, 106], ["cattle", "ORGANISM", 120, 126], ["cattle", "SPECIES", 120, 126], ["adenovirus", "SPECIES", 96, 106], ["cattle", "SPECIES", 120, 126], ["attenuated vaccines", "TREATMENT", 58, 77], ["adenovirus infection", "PROBLEM", 96, 116]]], ["Bartha (1974) has suggested that immunization with Bl and B8 would provide protection against the other members of the subgroups, but this remains to be confirmed.", [["Bl", "CHEMICAL", 51, 53], ["Bl", "GENE_OR_GENE_PRODUCT", 51, 53], ["B8", "GENE_OR_GENE_PRODUCT", 58, 60], ["immunization", "TREATMENT", 33, 45], ["Bl and B8", "TREATMENT", 51, 60], ["protection", "TREATMENT", 75, 85]]], ["A temperature-sensitive mutant of B3 has also been produced (Zygraich et al., 1976 ).V. PROPHYLAXISAn inactivated vaccine prepared against the hemagglutinating adenovirus as sociated with falls in production has been prepared (Baxendale, 1978) , and it appears to be effective.VI. GENERAL CONSIDERATIONSAlthough not enough information is available to make valid judgments, it would appear that some of the adenoviruses discussed tend to grow in the upper respiratory tract and others to colonize the intestines.", [["upper respiratory tract", "ANATOMY", 449, 472], ["intestines", "ANATOMY", 500, 510], ["B3", "ORGANISM", 34, 36], ["adenovirus", "ORGANISM", 160, 170], ["adenoviruses", "ORGANISM", 406, 418], ["upper respiratory", "ORGANISM_SUBDIVISION", 449, 466], ["tract", "ORGANISM_SUBDIVISION", 467, 472], ["intestines", "ORGAN", 500, 510], ["B3", "PROTEIN", 34, 36], ["A temperature", "TEST", 0, 13], ["sensitive mutant of B3", "PROBLEM", 14, 36], ["PROPHYLAXISAn inactivated vaccine", "TREATMENT", 88, 121], ["the hemagglutinating adenovirus", "PROBLEM", 139, 170], ["the adenoviruses", "PROBLEM", 402, 418], ["upper", "ANATOMY_MODIFIER", 449, 454], ["respiratory tract", "ANATOMY", 455, 472], ["intestines", "ANATOMY", 500, 510]]], ["Norrby et al. (1976) sug gest that vertical transmission of adenoviruses does not occur.", [["adenoviruses", "ORGANISM", 60, 72], ["vertical transmission of adenoviruses", "PROBLEM", 35, 72], ["adenoviruses", "OBSERVATION", 60, 72]]], ["This may be true for human adenoviruses, but is not true for the animal viruses.", [["human", "ORGANISM", 21, 26], ["adenoviruses", "ORGANISM", 27, 39], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["human adenoviruses", "PROBLEM", 21, 39], ["the animal viruses", "PROBLEM", 61, 79], ["adenoviruses", "OBSERVATION", 27, 39], ["viruses", "OBSERVATION", 72, 79]]], ["In many species, and especially in the fowl, vertical transmission may be the main factor in the epidemiology.VI. GENERAL CONSIDERATIONSSome of the adenoviruses discussed are clearly associated with disease, but the majority appear to be normally not associated with disease and require the presence of some as yet undefined factor(s) before they cause recognizable signs and lesions.VI. GENERAL CONSIDERATIONSSurprisingly differences are found in the ease of isolating adenoviruses from different species.", [["lesions", "ANATOMY", 376, 383], ["adenoviruses", "ORGANISM", 148, 160], ["lesions", "PATHOLOGICAL_FORMATION", 376, 383], ["VI", "GENE_OR_GENE_PRODUCT", 384, 386], ["adenoviruses", "ORGANISM", 470, 482], ["fowl", "SPECIES", 39, 43], ["the adenoviruses", "PROBLEM", 144, 160], ["disease", "PROBLEM", 199, 206], ["disease", "PROBLEM", 267, 274], ["recognizable signs", "PROBLEM", 353, 371], ["lesions", "PROBLEM", 376, 383], ["isolating adenoviruses", "PROBLEM", 460, 482], ["different species", "PROBLEM", 488, 505], ["many", "OBSERVATION_MODIFIER", 3, 7], ["species", "OBSERVATION", 8, 15], ["main", "OBSERVATION_MODIFIER", 78, 82], ["adenoviruses", "OBSERVATION", 148, 160], ["lesions", "OBSERVATION", 376, 383], ["adenoviruses", "OBSERVATION", 470, 482], ["different species", "OBSERVATION", 488, 505]]], ["Thus it is easy to isolate fowl and canine adenoviruses and difficult to isolate bovine and porcine adenoviruses.", [["fowl", "ORGANISM", 27, 31], ["canine adenoviruses", "ORGANISM", 36, 55], ["bovine", "ORGANISM", 81, 87], ["porcine adenoviruses", "ORGANISM", 92, 112], ["canine", "SPECIES", 36, 42], ["bovine", "SPECIES", 81, 87], ["porcine", "SPECIES", 92, 99], ["fowl", "SPECIES", 27, 31], ["canine", "SPECIES", 36, 42], ["bovine", "SPECIES", 81, 87], ["porcine", "SPECIES", 92, 99], ["fowl and canine adenoviruses", "PROBLEM", 27, 55], ["porcine adenoviruses", "TREATMENT", 92, 112]]], ["Apart from inherent differ ences in the ability of adenoviruses to replicate in cell cultures, other factors may be important.", [["cell cultures", "ANATOMY", 80, 93], ["adenoviruses", "ORGANISM", 51, 63], ["cell cultures", "CELL", 80, 93], ["cell cultures", "CELL_LINE", 80, 93], ["inherent differ ences", "PROBLEM", 11, 32], ["adenoviruses", "PROBLEM", 51, 63], ["cell cultures", "TEST", 80, 93]]], ["It appears that they grow best in primary epithelial cells from the homologous species, and with some types (e.g., the group 2 bovines) these epithelial cells must be from certain organs.", [["primary epithelial cells", "ANATOMY", 34, 58], ["epithelial cells", "ANATOMY", 142, 158], ["organs", "ANATOMY", 180, 186], ["epithelial cells", "CELL", 42, 58], ["bovines", "ORGANISM", 127, 134], ["epithelial cells", "CELL", 142, 158], ["organs", "ORGAN", 180, 186], ["primary epithelial cells", "CELL_TYPE", 34, 58], ["epithelial cells", "CELL_TYPE", 142, 158], ["primary epithelial cells", "PROBLEM", 34, 58], ["the homologous species", "PROBLEM", 64, 86], ["the group 2 bovines", "TREATMENT", 115, 134], ["these epithelial cells", "PROBLEM", 136, 158], ["primary epithelial cells", "OBSERVATION", 34, 58], ["homologous species", "OBSERVATION", 68, 86], ["epithelial cells", "OBSERVATION", 142, 158]]], ["Some of the differences reported may be due to the percentage of epithelial cells in the cultures.", [["epithelial cells", "ANATOMY", 65, 81], ["cultures", "ANATOMY", 89, 97], ["epithelial cells", "CELL", 65, 81], ["epithelial cells", "CELL_TYPE", 65, 81], ["epithelial cells", "PROBLEM", 65, 81], ["the cultures", "TEST", 85, 97], ["may be due to", "UNCERTAINTY", 33, 46], ["epithelial cells", "OBSERVATION", 65, 81]]], ["Cells grown from bovine testes or embryo fowl liver can all too often end up as fibroblast cultures.", [["Cells", "ANATOMY", 0, 5], ["testes", "ANATOMY", 24, 30], ["embryo", "ANATOMY", 34, 40], ["liver", "ANATOMY", 46, 51], ["fibroblast cultures", "ANATOMY", 80, 99], ["Cells", "CELL", 0, 5], ["bovine", "ORGANISM", 17, 23], ["testes", "ORGAN", 24, 30], ["embryo fowl", "MULTI-TISSUE_STRUCTURE", 34, 45], ["liver", "ORGAN", 46, 51], ["fibroblast cultures", "CELL", 80, 99], ["fibroblast cultures", "CELL_LINE", 80, 99], ["bovine", "SPECIES", 17, 23], ["fowl", "SPECIES", 41, 45], ["bovine", "SPECIES", 17, 23], ["fowl", "SPECIES", 41, 45], ["Cells", "TEST", 0, 5], ["bovine testes", "PROBLEM", 17, 30], ["embryo fowl liver", "PROBLEM", 34, 51], ["fibroblast cultures", "TEST", 80, 99], ["bovine testes", "OBSERVATION", 17, 30], ["liver", "ANATOMY", 46, 51]]], ["Furthermore, the cells may contain latent adenovirus or, in the case of bovine cells, latent or noncytopathic bovine viral diarrhea (BVD) virus.", [["cells", "ANATOMY", 17, 22], ["cells", "ANATOMY", 79, 84], ["viral diarrhea (BVD) virus", "DISEASE", 117, 143], ["cells", "CELL", 17, 22], ["adenovirus", "ORGANISM", 42, 52], ["bovine", "ORGANISM", 72, 78], ["cells", "CELL", 79, 84], ["noncytopathic", "ORGANISM", 96, 109], ["bovine viral diarrhea (BVD) virus", "ORGANISM", 110, 143], ["bovine cells", "CELL_TYPE", 72, 84], ["bovine", "SPECIES", 72, 78], ["bovine", "SPECIES", 110, 116], ["bovine", "SPECIES", 72, 78], ["bovine viral diarrhea (BVD) virus", "SPECIES", 110, 143], ["the cells", "PROBLEM", 13, 22], ["latent adenovirus", "PROBLEM", 35, 52], ["bovine cells", "PROBLEM", 72, 84], ["latent or noncytopathic bovine viral diarrhea (BVD) virus", "PROBLEM", 86, 143], ["latent", "OBSERVATION_MODIFIER", 35, 41], ["adenovirus", "OBSERVATION", 42, 52], ["bovine cells", "OBSERVATION", 72, 84], ["noncytopathic", "OBSERVATION_MODIFIER", 96, 109]]], ["Furthermore, BVD virus may be introduced into other cell lines through the use of contami nated fetal calf serum.", [["cell lines", "ANATOMY", 52, 62], ["fetal calf serum", "ANATOMY", 96, 112], ["BVD virus", "ORGANISM", 13, 22], ["cell lines", "CELL", 52, 62], ["fetal calf serum", "ORGANISM_SUBSTANCE", 96, 112], ["cell lines", "CELL_LINE", 52, 62], ["calf", "SPECIES", 102, 106], ["BVD virus", "SPECIES", 13, 22], ["BVD virus", "PROBLEM", 13, 22], ["contami nated fetal calf serum", "PROBLEM", 82, 112], ["BVD virus", "OBSERVATION", 13, 22], ["cell lines", "OBSERVATION", 52, 62], ["calf", "ANATOMY", 102, 106]]], ["As a first step, all cultures should be tested for the presence of BVD virus by immunofluorescence.", [["BVD virus", "ORGANISM", 67, 76], ["BVD virus", "SPECIES", 67, 76], ["all cultures", "TEST", 17, 29], ["BVD virus", "PROBLEM", 67, 76]]], ["It may also be advisable, espe cially where low titers of stock pools are found, to treat them with chloroform to remove possible contaminants.", [["chloroform", "CHEMICAL", 100, 110], ["chloroform", "CHEMICAL", 100, 110], ["chloroform", "SIMPLE_CHEMICAL", 100, 110], ["low titers of stock pools", "PROBLEM", 44, 69], ["chloroform", "TREATMENT", 100, 110], ["contaminants", "PROBLEM", 130, 142], ["may also be", "UNCERTAINTY", 3, 14]]], ["Adeno-associated parvoviruses can also cause a major reduction in the titer of pools and, where possible, should be removed.VI. GENERAL CONSIDERATIONSOne of the problems with adenoviruses of certain species is the time required to identify the adenovirus effect on cell cultures, as for example, the five blind passages in calf-tested cells to isolate a B8 strain (Rondhuis, 1973) .", [["cell cultures", "ANATOMY", 265, 278], ["cells", "ANATOMY", 335, 340], ["Adeno-associated parvoviruses", "ORGANISM", 0, 29], ["adenoviruses", "ORGANISM", 175, 187], ["adenovirus", "ORGANISM", 244, 254], ["cell cultures", "CELL", 265, 278], ["calf", "ORGANISM", 323, 327], ["cells", "CELL", 335, 340], ["cell cultures", "CELL_LINE", 265, 278], ["calf", "SPECIES", 323, 327], ["Adeno-associated parvoviruses", "SPECIES", 0, 29], ["Adeno-associated parvoviruses", "PROBLEM", 0, 29], ["a major reduction", "PROBLEM", 45, 62], ["the problems", "PROBLEM", 157, 169], ["adenoviruses of certain species", "PROBLEM", 175, 206], ["the adenovirus effect", "PROBLEM", 240, 261], ["cell cultures", "TEST", 265, 278], ["parvoviruses", "OBSERVATION", 17, 29], ["major", "OBSERVATION_MODIFIER", 47, 52], ["reduction", "OBSERVATION_MODIFIER", 53, 62], ["calf", "ANATOMY", 323, 327]]], ["It is probable that the use of immunofluorescence would help to reduce the time.", [["immunofluorescence", "TREATMENT", 31, 49]]], ["Furthermore, in investigating major syndromes, convalescent serum can be used in the indirect immunofluorescence test to aid in viral detection.", [["serum", "ANATOMY", 60, 65], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["major syndromes", "PROBLEM", 30, 45], ["convalescent serum", "TEST", 47, 65], ["the indirect immunofluorescence test", "TEST", 81, 117], ["viral detection", "TEST", 128, 143]]], ["Convalescence or pooled serum collected from old animals can also be used most successfully for immunoelectron microscopy (McFerran and McNulta, 1978c [Fig. 8] ).", [["serum", "ANATOMY", 24, 29], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["pooled serum", "TEST", 17, 29], ["immunoelectron microscopy", "TEST", 96, 121]]], ["Possibly not enough attention has been paid to the metabolism of the cells, since for the growth of a number of strains, actively dividing cells are required.", [["cells", "ANATOMY", 69, 74], ["cells", "ANATOMY", 139, 144], ["cells", "CELL", 69, 74], ["cells", "CELL", 139, 144], ["actively dividing cells", "CELL_TYPE", 121, 144], ["strains", "PROBLEM", 112, 119]]]], "3fdbdfee260e2854a05f1f7fc5c6de4354c85632": [["Direct production of ethanol from raw corn starch via fermentation by use of a novel surface-engineered yeast strain codisplaying glucoamylase and \u03b1-amylase.", [["surface", "ANATOMY", 85, 92], ["ethanol", "CHEMICAL", 21, 28], ["corn starch", "CHEMICAL", 38, 49], ["ethanol", "CHEMICAL", 21, 28], ["ethanol", "SIMPLE_CHEMICAL", 21, 28], ["starch", "SIMPLE_CHEMICAL", 43, 49], ["glucoamylase", "GENE_OR_GENE_PRODUCT", 130, 142], ["\u03b1-amylase", "GENE_OR_GENE_PRODUCT", 147, 156], ["glucoamylase", "PROTEIN", 130, 142], ["\u03b1-amylase", "PROTEIN", 147, 156], ["corn", "SPECIES", 38, 42], ["yeast", "SPECIES", 104, 109], ["corn", "SPECIES", 38, 42], ["yeast", "SPECIES", 104, 109], ["a novel surface", "TEST", 77, 92], ["yeast strain", "OBSERVATION", 104, 116]]]], "9e9aaaacb26e95ceec9d7465ce65972e1fd84a7a": [["Understanding how contaminants continue to pose a significant threat to human health is highly emphasized.", [["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77]]], ["The airflow can carry hazardous air pollutants moving within a room or between rooms even buildings to influence the residents' health [1] .", [["airflow", "OBSERVATION", 4, 11], ["hazardous", "OBSERVATION_MODIFIER", 22, 31], ["air pollutants", "OBSERVATION", 32, 46]]], ["Such long-distance routes of transmission are called airborne transmission, which is reported to be one of the major respiratory syndrome transmission routes by numerous engineering and epidemiological studies [2] [3] [4] [5] .", [["respiratory syndrome", "DISEASE", 117, 137], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 210, 225], ["the major respiratory syndrome", "PROBLEM", 107, 137], ["epidemiological studies", "TEST", 186, 209], ["respiratory syndrome", "OBSERVATION", 117, 137]]], ["A lot of researches involving airflow patterns and aerosol-transmitted scenarios in multiscale area have been done by onsite full-scale measurements, reduced-scale wind/water tunnel experiments and computational fluid dynamics (CFD) techniques [6] [7] [8] [9] .", [["airflow patterns", "PROBLEM", 30, 46], ["aerosol", "TREATMENT", 51, 58], ["transmitted scenarios in multiscale area", "PROBLEM", 59, 99], ["reduced-scale wind/water tunnel experiments", "TREATMENT", 150, 193], ["computational fluid dynamics", "TEST", 198, 226]]], ["For urban scale, the airflow is complicated because of the interaction with the inhomogeneous underlying surfaces [8] .", [["urban scale", "TREATMENT", 4, 15], ["airflow", "OBSERVATION", 21, 28]]], ["For street scale or building arrays, the microclimate in the street canyon or a neighborhood area will influence the natural ventilation process of buildings.", [["building arrays", "TREATMENT", 20, 35], ["natural ventilation", "OBSERVATION", 117, 136]]], ["For indoor circumstance, studies about the travel of airborne infectious pathogens in hospitals, schools, offices, homes, aircraft cabins and other indoor environment have been performed to illustrate the pollutant behavior and help to guide the air distribution design [10] [11] [12] [13] .", [["infectious pathogens", "DISEASE", 62, 82], ["[10] [11] [12] [13]", "CHEMICAL", 270, 289], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 270, 289]]], ["Li et al. [14] reviewed over 40 multidisciplinary studies and demonstrated the evidence of interconnection between building ventilation and the transmission of airborne infections.IntroductionRegarding the isolated building environment, a special transmission mode called vertical cross-floor contamination has been detected, the cooking fume from lower floor to upper one is a very telling example for such physical phenomena.", [["airborne infections", "DISEASE", 160, 179], ["multidisciplinary studies", "TEST", 32, 57], ["building ventilation", "TREATMENT", 115, 135], ["airborne infections", "PROBLEM", 160, 179], ["vertical cross-floor contamination", "PROBLEM", 272, 306], ["such physical phenomena", "PROBLEM", 403, 426], ["airborne infections", "OBSERVATION", 160, 179]]], ["The airborne fine droplets can be carried upwards by buoyancy-forced air convection flow [15] .", [["The airborne fine droplets", "TREATMENT", 0, 26], ["forced air convection flow", "PROBLEM", 62, 88]]], ["Thus, the upward contaminant flow can take the potential health issues to the neighbor upstairs.", [["the upward contaminant flow", "PROBLEM", 6, 33]]], ["This inter-flat infection path is firstly identified and explored after the Severe Acute Respiratory Syndromes (SARS) clusters occurred in several high-rise residential buildings in Hong Kong, where the most affected occupants dwelled along the same vertical blocks on different storeys [16] [17] [18] .", [["infection", "DISEASE", 16, 25], ["Acute Respiratory Syndromes", "DISEASE", 83, 110], ["SARS", "DISEASE", 112, 116], ["This inter-flat infection path", "PROBLEM", 0, 30], ["the Severe Acute Respiratory Syndromes (SARS) clusters", "PROBLEM", 72, 126], ["infection", "OBSERVATION", 16, 25], ["Severe", "OBSERVATION_MODIFIER", 76, 82], ["Acute", "OBSERVATION_MODIFIER", 83, 88], ["Respiratory Syndromes", "OBSERVATION", 89, 110]]], ["Li et al. implemented a study for the largest SARS outbreak in Ward 8A at Prince of Wales Hospital [17] and in Block E of Amoy Garden [18] .", [["Li", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 46, 50], ["a study", "TEST", 22, 29], ["largest", "OBSERVATION_MODIFIER", 38, 45]]], ["They also verified the probability to reduce airborne infection by optimizing the ventilation performance in the hospital wards [19] .", [["infection", "DISEASE", 54, 63], ["airborne infection", "PROBLEM", 45, 63], ["airborne", "OBSERVATION_MODIFIER", 45, 53], ["infection", "OBSERVATION", 54, 63]]], ["Pressure control methods have been considered as an effective technology to control the transmission of infectious virus in hospital environment [20] .", [["Pressure control methods", "TREATMENT", 0, 24], ["an effective technology", "TREATMENT", 49, 72], ["infectious virus", "PROBLEM", 104, 120], ["infectious", "OBSERVATION", 104, 114]]], ["Nevertheless, such strategies are not feasible for those residential buildings without centralized ventilation systems.", [["centralized ventilation systems", "TREATMENT", 87, 118]]], ["Therefore, the process of pollutant interflat transmission in residential buildings is generally elaborated in the light of the mechanisms of natural ventilation.", [["pollutant interflat transmission", "TREATMENT", 26, 58], ["natural ventilation", "TREATMENT", 142, 161], ["natural ventilation", "OBSERVATION", 142, 161]]], ["As to the contaminants in residential buildings, the proliferation and accumulation of harmful components or odors such as second hand tobacco smoke and volatile organic compounds (VOCs) may also cause a health concern.", [["smoke", "CHEMICAL", 143, 148], ["volatile organic compounds", "CHEMICAL", 153, 179], ["VOCs", "CHEMICAL", 181, 185], ["tobacco", "ORGANISM", 135, 142], ["volatile organic compounds", "SIMPLE_CHEMICAL", 153, 179], ["tobacco", "SPECIES", 135, 142], ["tobacco", "SPECIES", 135, 142], ["the proliferation", "PROBLEM", 49, 66], ["harmful components", "PROBLEM", 87, 105], ["odors", "PROBLEM", 109, 114], ["harmful", "OBSERVATION_MODIFIER", 87, 94]]], ["Several studies revealed that the passive tracer gas method can be used for reflecting the movement and distribution of gaseous pollutants or fine particles [21, 22] .IntroductionBased on the above facts and work, Niu et al. [23] first proposed a possible airborne re-entry behavior of inter-flat cross-contamination driven by indoor/outdoor temperature difference under the condition of single-sided natural ventilation through open windows.", [["Several studies", "TEST", 0, 15], ["the passive tracer gas method", "TEST", 30, 59], ["gaseous pollutants", "PROBLEM", 120, 138], ["inter-flat cross-contamination", "PROBLEM", 286, 316], ["single-sided natural ventilation", "TREATMENT", 388, 420], ["open windows", "TREATMENT", 429, 441], ["gaseous pollutants", "OBSERVATION", 120, 138]]], ["Previous onsite tracer gas tests and numerical simulations on buoyancy-forced inter-flat dispersion well explained and quantified the vertically upward transport of gaseous pollutants [24, 25] .", [["Previous onsite tracer gas tests", "TEST", 0, 32], ["numerical simulations on buoyancy", "PROBLEM", 37, 70], ["forced inter-flat dispersion", "TREATMENT", 71, 99]]], ["Subsequently, a series of wind tunnel tests [26] [27] [28] [29] [30] and numerical calculations [31] [32] [33] were carefully carried out to explore the inter-flat transmission dominated by wind force.", [["[27] [28] [29] [30]", "SIMPLE_CHEMICAL", 49, 68], ["[31] [32] [33]", "SIMPLE_CHEMICAL", 96, 110], ["wind tunnel tests", "TEST", 26, 43], ["numerical calculations", "TEST", 73, 95]]], ["Mao et al. [34] reviewed the mechanisms and evaluation indexes for the airborne transmission and dispersion between flats by single-sided natural ventilation in high-rise residential buildings.", [["the mechanisms", "TEST", 25, 39], ["evaluation indexes", "TEST", 44, 62], ["the airborne transmission", "TREATMENT", 67, 92], ["single-sided natural ventilation", "TREATMENT", 125, 157], ["natural ventilation", "OBSERVATION", 138, 157]]], ["In general, it has been revealed from the previous studies that in the single-sided ventilation mode, the airflow exchange and migration of contaminants within the building are normally driven by wind effect, buoyancy effect, or combined wind and buoyancy effect.", [["the previous studies", "TEST", 38, 58], ["the airflow exchange", "TREATMENT", 102, 122], ["migration of contaminants", "TREATMENT", 127, 152], ["airflow exchange", "OBSERVATION", 106, 122], ["migration", "OBSERVATION_MODIFIER", 127, 136], ["buoyancy effect", "OBSERVATION", 247, 262]]], ["For the buoyancy effect, one inducement is the difference between indoor and outdoor temperature, the other one can be the thermal plume along the high-temperature walls heated by the solar radiation during the daytime, especially in windless or breezy sunny day [37] .", [["the solar radiation", "TREATMENT", 180, 199], ["buoyancy effect", "OBSERVATION", 8, 23]]], ["Fan et al. [38] measured boundary layer structure along the sunward surface of a sixteen-storey building in Guangzhou, and concluded that the maximum velocity in the boundary layer at a height of 50 m is about 1.0-1.5 m/s with absent wind and a wall/air temperature difference of 14-20 K. Such strong thermal flow should not be neglected since the most common wind speed in the urban environment is in the range of 1.0-2.0 m/s [39] .", [["sunward surface", "ANATOMY", 60, 75], ["measured boundary layer structure", "PROBLEM", 16, 49], ["the maximum velocity", "TEST", 138, 158], ["a wall/air temperature difference", "PROBLEM", 243, 276], ["maximum", "OBSERVATION_MODIFIER", 142, 149], ["velocity", "OBSERVATION_MODIFIER", 150, 158], ["boundary", "OBSERVATION_MODIFIER", 166, 174], ["layer", "OBSERVATION_MODIFIER", 175, 180], ["wall", "ANATOMY_MODIFIER", 245, 249], ["air temperature", "OBSERVATION", 250, 265]]], ["Hence the buoyancy forces basically generated by solar radiation will be a particular consideration in this paper.", [["the buoyancy forces", "TREATMENT", 6, 25], ["solar radiation", "TREATMENT", 49, 64]]], ["Over the past dozen years, several literature published about the combined wind and thermal flow patterns in urban region.", [["thermal", "OBSERVATION_MODIFIER", 84, 91], ["flow patterns", "OBSERVATION", 92, 105]]], ["Xie et al. [40] calculated a set of CFD simulation cases to investigate the impact of solar radiation on pollutant dispersion in different street layouts and estimated the relative strength of thermally/ mechanically induced flow using the ratio of Gr/Re 2 .", [["CFD simulation cases", "TEST", 36, 56], ["solar radiation", "TREATMENT", 86, 101], ["pollutant dispersion", "TREATMENT", 105, 125], ["solar radiation", "OBSERVATION", 86, 101]]], ["It was found that solar calefaction of a windward surface in a street canyon would give rise to an increase in pollutant concentration of the canyon.", [["windward surface", "ANATOMY", 41, 57], ["solar calefaction", "PROBLEM", 18, 35], ["solar calefaction", "OBSERVATION", 18, 35], ["increase", "OBSERVATION_MODIFIER", 99, 107], ["pollutant concentration", "OBSERVATION", 111, 134]]], ["Richards et al. [41] performed wind tunnel measurements to simulate the thermal effects within the vicinity of a onefold building with leeward facade heating with the same parameter Gr/Re 2 .", [["wind tunnel measurements", "TEST", 31, 55], ["the thermal effects", "PROBLEM", 68, 87], ["a onefold building", "TREATMENT", 111, 129], ["leeward facade heating", "TREATMENT", 135, 157]]], ["They concluded that compared with the isothermal condition, the leeward recirculation lengths were shorter for both cases of Gr/Re 2 = 0.9 and 1.6 (non-isothermal conditions).", [["the isothermal condition", "TEST", 34, 58], ["Gr/Re", "TEST", 125, 130]]], ["The velocity field and temperature distribution within the recirculation area were obviously different between two non-isothermal cases.", [["recirculation area", "ANATOMY", 59, 77], ["The velocity field", "TEST", 0, 18], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["field", "OBSERVATION_MODIFIER", 13, 18], ["temperature", "OBSERVATION_MODIFIER", 23, 34], ["distribution", "OBSERVATION_MODIFIER", 35, 47], ["recirculation", "OBSERVATION_MODIFIER", 59, 72], ["area", "OBSERVATION_MODIFIER", 73, 77], ["different", "OBSERVATION_MODIFIER", 93, 102]]], ["Larsen and Heiselberg [42] carried out a group of wind tunnel tests to create a scene of single-sided natural ventilation driven by wind pressure and temperature difference.", [["wind tunnel tests", "TEST", 50, 67], ["single-sided natural ventilation", "TREATMENT", 89, 121], ["temperature difference", "PROBLEM", 150, 172], ["natural ventilation", "OBSERVATION", 102, 121]]], ["They gave the velocity profiles and air-change rates in the openings, which greatly varied from wind force dominating to buoyant force governing.", [["the velocity profiles", "TEST", 10, 31], ["velocity", "OBSERVATION_MODIFIER", 14, 22], ["air", "OBSERVATION", 36, 39], ["openings", "OBSERVATION_MODIFIER", 60, 68], ["varied", "OBSERVATION_MODIFIER", 84, 90], ["wind force", "OBSERVATION", 96, 106], ["buoyant force", "OBSERVATION", 121, 134]]], ["Bangalee et al. [43] set four different open window modes to investigate the flow structures of fluid-driven natural cross-ventilation.", [["fluid", "ORGANISM_SUBSTANCE", 96, 101], ["different open window modes", "TREATMENT", 30, 57], ["fluid", "PROBLEM", 96, 101], ["fluid", "OBSERVATION", 96, 101]]], ["They found that a larger volumetric flow rate did not always ensure better replacement of the indoor air, and vice versa.", [["a larger volumetric flow rate", "TEST", 16, 45], ["larger", "OBSERVATION_MODIFIER", 18, 24]]], ["Dama and Angeli [44] designed three cases on the wind and buoyancy induced natural ventilation in double skin facades and compared two flow patterns derived from a simplified building simulation model and CFD.", [["skin", "ANATOMY", 105, 109], ["skin", "ORGAN", 105, 109], ["natural ventilation", "TREATMENT", 75, 94], ["double skin facades", "TREATMENT", 98, 117], ["natural ventilation", "OBSERVATION", 75, 94], ["skin", "ANATOMY", 105, 109]]], ["Their results showed that CFD analysis can provide a deeper insight on surface-level heat transfer.", [["surface", "ANATOMY", 71, 78], ["CFD analysis", "TEST", 26, 38], ["surface-level heat transfer", "TREATMENT", 71, 98]]], ["Most of the studies mainly paid attention to the heat and mass transfer around a single building block or building arrays, but there is a lack of research work on the cross-contamination mechanism through outer window flush driven by the combined buoyancy and wind effect.IntroductionAccording to the wind-driven airflow around a bluff body under normal wind direction [45] , there is a stagnation zone formed at the 2/ 3 height of the building on the windward side.", [["body", "ANATOMY", 336, 340], ["body", "ORGANISM_SUBDIVISION", 336, 340], ["the studies", "TEST", 8, 19], ["mass", "PROBLEM", 58, 62], ["a single building block", "TREATMENT", 79, 102], ["outer window flush", "TREATMENT", 205, 223], ["a stagnation zone", "PROBLEM", 385, 402], ["mass", "OBSERVATION", 58, 62], ["wind effect", "OBSERVATION", 260, 271], ["normal", "OBSERVATION", 347, 353], ["stagnation", "OBSERVATION_MODIFIER", 387, 397], ["zone", "OBSERVATION_MODIFIER", 398, 402]]], ["The airflow above the stagnation zone goes toward the building top, while the airflow below the stagnation zone goes downward to the ground.", [["The airflow above the stagnation zone", "PROBLEM", 0, 37], ["airflow", "OBSERVATION", 4, 11], ["stagnation", "OBSERVATION_MODIFIER", 22, 32], ["zone", "OBSERVATION_MODIFIER", 33, 37], ["top", "OBSERVATION_MODIFIER", 63, 66], ["airflow", "OBSERVATION", 78, 85], ["stagnation", "OBSERVATION_MODIFIER", 96, 106], ["zone", "OBSERVATION_MODIFIER", 107, 111], ["downward", "OBSERVATION_MODIFIER", 117, 125], ["ground", "ANATOMY_MODIFIER", 133, 139]]], ["The wall thermal plume can drive the gaseous pollutants released from lower unit to go to upper ones, especially in high-rise buildings.", [["wall", "ANATOMY", 4, 8], ["The wall thermal plume", "PROBLEM", 0, 22], ["the gaseous pollutants", "PROBLEM", 33, 55], ["wall", "ANATOMY_MODIFIER", 4, 8], ["thermal plume", "OBSERVATION", 9, 22], ["gaseous pollutants", "OBSERVATION", 37, 55], ["upper ones", "OBSERVATION_MODIFIER", 90, 100]]], ["When the heated wall is on the windward side, the near wall airflow direction will change with the variation of the relative force of buoyancy and wind, notably in the approaching wind downward flow region in front of the building (Fig. 1 ).", [["wall", "ANATOMY", 16, 20], ["wall", "ANATOMY", 55, 59], ["wall", "TISSUE", 16, 20], ["wall", "OBSERVATION_MODIFIER", 16, 20], ["wall", "ANATOMY_MODIFIER", 55, 59], ["airflow", "OBSERVATION", 60, 67], ["buoyancy", "OBSERVATION_MODIFIER", 134, 142], ["downward", "OBSERVATION_MODIFIER", 185, 193], ["flow", "OBSERVATION", 194, 198]]], ["If the buoyant force is stronger, the flow patterns at the window opening should be inflows at the lower part and outflows at the upper part.", [["lower part", "ANATOMY", 99, 109], ["upper", "ORGANISM_SUBDIVISION", 130, 135], ["the flow patterns", "TEST", 34, 51], ["inflows", "OBSERVATION", 84, 91], ["lower", "ANATOMY_MODIFIER", 99, 104], ["outflows", "ANATOMY_MODIFIER", 114, 122], ["upper part", "ANATOMY_MODIFIER", 130, 140]]], ["The purpose of the present work is to quantitatively explore the aforementioned phenomenon, namely the airflow field and pollutant transmission under effects of wind and thermal forces.", [["the aforementioned phenomenon", "PROBLEM", 61, 90], ["the airflow field", "PROBLEM", 99, 116]]], ["A hypothetical twenty-storey high-rise building with single-sided ventilation is modelled as the research object.", [["single-sided ventilation", "TREATMENT", 53, 77], ["sided", "ANATOMY_MODIFIER", 60, 65], ["ventilation", "OBSERVATION", 66, 77]]], ["To quantitatively clarify the effect of solar radiation on the exterior wall surface of the building, the intensity of solar radiation on a certain day is calculated.", [["wall surface", "ANATOMY", 72, 84], ["wall surface", "MULTI-TISSUE_STRUCTURE", 72, 84], ["solar radiation", "TREATMENT", 40, 55], ["solar radiation", "TREATMENT", 119, 134], ["solar radiation", "OBSERVATION", 40, 55], ["exterior", "ANATOMY_MODIFIER", 63, 71], ["wall", "ANATOMY_MODIFIER", 72, 76], ["surface", "OBSERVATION_MODIFIER", 77, 84], ["solar radiation", "OBSERVATION", 119, 134]]], ["Since the single-sided natural ventilation is usually used in transition season, we select a typical day from transition season as representative.", [["the single-sided natural ventilation", "TREATMENT", 6, 42], ["sided", "ANATOMY_MODIFIER", 17, 22], ["natural ventilation", "OBSERVATION", 23, 42]]], ["Then the temperature difference between the heated wall and the ambient air is calculated using a simplified energy balance model of the building envelop.", [["wall", "ANATOMY", 51, 55], ["wall", "TISSUE", 51, 55], ["the temperature difference", "PROBLEM", 5, 31], ["a simplified energy balance model", "TREATMENT", 96, 129], ["wall", "ANATOMY_MODIFIER", 51, 55], ["ambient air", "OBSERVATION", 64, 75]]], ["Finally, to analyse the influence of the wind and wall thermal plume flow on the pollutant transmission characteristics, the tracer gas method is employed in the numerical simulation.", [["wall", "ANATOMY", 50, 54], ["wall thermal plume flow", "TREATMENT", 50, 73], ["the tracer gas method", "TEST", 121, 142]]], ["The results of present work are helpful for a profound understanding of how solar radiation and near-wall flow affect the vertical inter-flat contaminant transmission routes, and the results also reveal the combined effect of wind force and buoyancy lift on the pollutant dispersion near the building.", [["wall", "ANATOMY", 101, 105], ["solar radiation", "TREATMENT", 76, 91], ["buoyancy lift", "TREATMENT", 241, 254], ["wall", "ANATOMY_MODIFIER", 101, 105], ["flow", "OBSERVATION", 106, 110], ["buoyancy lift", "OBSERVATION", 241, 254]]], ["To quantify the strength of the natural convection adjacent to the wall, the temperature difference between the building surface and the ambient air should be clarified.", [["wall", "ANATOMY", 67, 71], ["wall", "TISSUE", 67, 71], ["the temperature difference", "PROBLEM", 73, 99], ["wall", "ANATOMY_MODIFIER", 67, 71], ["temperature", "OBSERVATION_MODIFIER", 77, 88], ["difference", "OBSERVATION_MODIFIER", 89, 99], ["ambient air", "OBSERVATION", 137, 148]]], ["The solar radiation intensity has a strong influence on the wall heating process, which needs to be quantified first.", [["wall", "ANATOMY", 60, 64], ["wall", "TISSUE", 60, 64], ["The solar radiation intensity", "PROBLEM", 0, 29], ["the wall heating process", "TREATMENT", 56, 80], ["solar", "OBSERVATION_MODIFIER", 4, 9], ["radiation intensity", "OBSERVATION_MODIFIER", 10, 29], ["strong", "OBSERVATION_MODIFIER", 36, 42]]], ["The wall temperature can be obtained by the heat balance calculation afterwards.", [["wall", "ANATOMY", 4, 8], ["wall", "TISSUE", 4, 8], ["The wall temperature", "TEST", 0, 20], ["the heat balance calculation", "TEST", 40, 68]]], ["The parameters of meteorology and building envelope refer to those of Shanghai, a city of hot/humid climate zone in China.IntroductionBased on the method given by Yan and Zhao [46] , the solar radiation intensity (W/m 2 ) in the selected typical day on the horizontal plane and two vertical surfaces are calculated.", [["the method", "TREATMENT", 143, 153], ["the solar radiation intensity (W/m", "TREATMENT", 183, 217], ["vertical", "OBSERVATION_MODIFIER", 282, 290]]], ["The atmospheric transparency is set as 0.62 [47] [48] [49] .", [["The atmospheric transparency", "TEST", 0, 28], ["atmospheric transparency", "OBSERVATION", 4, 28]]], ["During 11:00 to 13:00, the solar radiation intensity on the sunward side is in a small range of 410-440 W/m 2 , while that of the opposite side is about 165 W/ m 2 .", [["the solar radiation intensity", "PROBLEM", 23, 52], ["radiation intensity", "OBSERVATION_MODIFIER", 33, 52], ["small", "OBSERVATION_MODIFIER", 81, 86]]], ["For both the sunward and shady side vertical walls at noon, the received solar radiation intensity changes in a very small range, which can be seen as a steady-state condition for the following calculation.IntroductionThe temperature of outer wall surface increases after receiving the solar radiation.", [["outer wall surface", "ANATOMY", 237, 255], ["solar radiation intensity changes", "TREATMENT", 73, 106], ["The temperature of outer wall surface", "TREATMENT", 218, 255], ["the solar radiation", "TREATMENT", 282, 301], ["radiation intensity", "OBSERVATION", 79, 98], ["very", "OBSERVATION_MODIFIER", 112, 116], ["small range", "OBSERVATION_MODIFIER", 117, 128], ["temperature", "OBSERVATION_MODIFIER", 222, 233], ["outer", "ANATOMY_MODIFIER", 237, 242], ["wall", "ANATOMY_MODIFIER", 243, 247], ["surface", "OBSERVATION_MODIFIER", 248, 255], ["increases", "OBSERVATION_MODIFIER", 256, 265], ["solar radiation", "OBSERVATION", 286, 301]]], ["There is heat conduction between outer and inner wall surfaces, heat convection and radiation heat exchange with the ambient environment (Fig. 2) .", [["inner wall surfaces", "ANATOMY", 43, 62], ["inner wall", "TISSUE", 43, 53], ["heat conduction", "PROBLEM", 9, 24], ["outer and inner wall surfaces", "TREATMENT", 33, 62], ["heat convection", "TREATMENT", 64, 79], ["radiation heat exchange", "TREATMENT", 84, 107], ["the ambient environment", "TREATMENT", 113, 136], ["heat conduction", "OBSERVATION", 9, 24], ["outer", "ANATOMY_MODIFIER", 33, 38], ["inner", "ANATOMY_MODIFIER", 43, 48], ["wall", "ANATOMY_MODIFIER", 49, 53], ["surfaces", "OBSERVATION_MODIFIER", 54, 62], ["heat convection", "OBSERVATION", 64, 79], ["radiation heat", "OBSERVATION", 84, 98]]], ["Because of the wall thermal inertia, the external wall will not reach the highest temperature when the solar radiation is the strongest, as well as the internal wall.", [["wall", "ANATOMY", 15, 19], ["external wall", "ANATOMY", 41, 54], ["internal wall", "ANATOMY", 152, 165], ["internal wall", "MULTI-TISSUE_STRUCTURE", 152, 165], ["the wall thermal inertia", "PROBLEM", 11, 35], ["the solar radiation", "TREATMENT", 99, 118], ["wall", "ANATOMY_MODIFIER", 15, 19], ["thermal inertia", "OBSERVATION", 20, 35], ["external wall", "ANATOMY", 41, 54], ["solar radiation", "OBSERVATION", 103, 118], ["internal wall", "ANATOMY", 152, 165]]], ["In the present study, the timeaverage states are concerned.", [["the present study", "TEST", 3, 20]]], ["So the thermal lag on the temperatures of wall surfaces and indoor air is neglected in the theoretical calculation.IntroductionFor an isolated building in a relatively open terrain, suppose the temperature distribution on the outer wall surface is uniform, which means no vertical and horizontal temperature difference.", [["wall surfaces", "ANATOMY", 42, 55], ["outer wall surface", "ANATOMY", 226, 244], ["wall surfaces", "MULTI-TISSUE_STRUCTURE", 42, 55], ["outer wall surface", "CELLULAR_COMPONENT", 226, 244], ["the thermal lag", "PROBLEM", 3, 18], ["indoor air", "PROBLEM", 60, 70], ["the theoretical calculation", "TEST", 87, 114], ["an isolated building", "TREATMENT", 131, 151], ["vertical and horizontal temperature difference", "PROBLEM", 272, 318], ["thermal", "OBSERVATION_MODIFIER", 7, 14], ["lag", "OBSERVATION_MODIFIER", 15, 18], ["wall", "ANATOMY_MODIFIER", 42, 46], ["surfaces", "OBSERVATION_MODIFIER", 47, 55], ["indoor air", "OBSERVATION", 60, 70], ["outer", "ANATOMY_MODIFIER", 226, 231], ["wall", "ANATOMY_MODIFIER", 232, 236], ["surface", "ANATOMY_MODIFIER", 237, 244], ["uniform", "OBSERVATION_MODIFIER", 248, 255], ["no", "UNCERTAINTY", 269, 271], ["vertical", "OBSERVATION_MODIFIER", 272, 280]]], ["(1),IntroductionQ solar represents the solar radiation absorbed by the outer wall surface, W/m 2 , the equation is as Eq.", [["outer wall surface", "ANATOMY", 71, 89], ["IntroductionQ solar", "TREATMENT", 4, 23], ["the solar radiation", "TREATMENT", 35, 54], ["solar radiation", "OBSERVATION", 39, 54], ["outer", "ANATOMY_MODIFIER", 71, 76], ["wall", "ANATOMY_MODIFIER", 77, 81], ["surface", "OBSERVATION_MODIFIER", 82, 89]]], ["(2),Introductionwhere \u03b1 w is the wall absorption.", [["wall", "ANATOMY", 33, 37], ["wall", "TISSUE", 33, 37], ["wall", "ANATOMY_MODIFIER", 33, 37]]], ["I SV is the received solar radiation by vertical outer wall, which includes the direction solar radiation, diffuse sky radiation and ground reflected solar radiation.", [["outer wall", "ANATOMY", 49, 59], ["outer wall", "TISSUE", 49, 59], ["solar radiation", "TREATMENT", 21, 36], ["the direction solar radiation", "TREATMENT", 76, 105], ["diffuse sky radiation", "TREATMENT", 107, 128], ["ground reflected solar radiation", "TREATMENT", 133, 165], ["solar radiation", "OBSERVATION", 21, 36], ["vertical", "ANATOMY_MODIFIER", 40, 48], ["outer", "ANATOMY_MODIFIER", 49, 54], ["wall", "ANATOMY_MODIFIER", 55, 59], ["diffuse", "OBSERVATION_MODIFIER", 107, 114], ["sky radiation", "OBSERVATION", 115, 128], ["solar radiation", "OBSERVATION", 150, 165]]], ["Q conduc represents the heat conduction from the outer wall surface to inner, W/m 2 , the equation is as Eq.", [["outer wall surface", "ANATOMY", 49, 67], ["the heat conduction", "PROBLEM", 20, 39], ["heat conduction", "OBSERVATION", 24, 39], ["outer", "ANATOMY_MODIFIER", 49, 54], ["wall", "ANATOMY_MODIFIER", 55, 59], ["surface", "OBSERVATION_MODIFIER", 60, 67], ["inner", "OBSERVATION_MODIFIER", 71, 76]]], ["(3),Introductionwhere T wout is the temperature of outer wall and T win means the temperature of inner wall. \u03b4 w represents the wall thickness and \u03bb is the thermal conductivity. \u03b4 w /\u03bb is the thermal-conduction resistance, set as 1.1 m 2 K/W [50] .IntroductionQ convec is the heat convection exchange between the outer wall surface and the ambience, W/m 2 , see Eq.", [["outer wall", "ANATOMY", 51, 61], ["inner wall", "ANATOMY", 97, 107], ["wall", "ANATOMY", 128, 132], ["outer wall surface", "ANATOMY", 313, 331], ["outer wall", "CELLULAR_COMPONENT", 51, 61], ["inner wall", "TISSUE", 97, 107], ["wall", "TISSUE", 128, 132], ["the thermal conductivity", "PROBLEM", 152, 176], ["the thermal-conduction resistance", "PROBLEM", 188, 221], ["IntroductionQ convec", "TREATMENT", 248, 268], ["the heat convection exchange", "TREATMENT", 272, 300], ["wall", "ANATOMY_MODIFIER", 57, 61], ["inner", "ANATOMY_MODIFIER", 97, 102], ["wall", "ANATOMY_MODIFIER", 103, 107], ["wall", "ANATOMY_MODIFIER", 128, 132], ["thickness", "OBSERVATION_MODIFIER", 133, 142], ["thermal conductivity", "OBSERVATION", 156, 176], ["conduction resistance", "OBSERVATION", 200, 221], ["heat convection", "OBSERVATION", 276, 291], ["outer", "ANATOMY_MODIFIER", 313, 318], ["wall", "ANATOMY_MODIFIER", 319, 323], ["surface", "OBSERVATION_MODIFIER", 324, 331]]], ["[50] [51] [52] , the value of h out can be calculated by Eq.", [["[50] [51] [52]", "SIMPLE_CHEMICAL", 0, 14]]], ["(5),IntroductionWhen the coming wind is below 2 m/s, the wind speed near the windward wall U w has a reference value of 0.5 m/s [53] , so h out = 12.2 W/(m 2 \u00b7K).IntroductionQ lw is the longwave radiation heat exchange between the outer wall surface and the surroundings, W/m 2 , here only the atmospheric longwave radiation to the sky is considered, see Eq.", [["outer wall surface", "ANATOMY", 231, 249], ["the longwave radiation heat exchange", "TREATMENT", 182, 218], ["the atmospheric longwave radiation", "TREATMENT", 290, 324], ["radiation heat", "OBSERVATION", 195, 209], ["outer", "ANATOMY_MODIFIER", 231, 236], ["wall", "ANATOMY_MODIFIER", 237, 241], ["surface", "OBSERVATION_MODIFIER", 242, 249]]], ["(6),Introductionwhere \u03c3 is the Stephen Boltzmann constant, 5.67 \u00d7 10 \u22128 W/(m 2 \u00b7K 4 ). \u025b w represents the system emissive of the outer wall surface longwave radiation, which is 0.9. x sky is the angle factor between the vertical wall and the sky, which is 0.5.", [["outer wall surface", "ANATOMY", 129, 147], ["vertical wall", "ANATOMY", 220, 233], ["vertical wall", "MULTI-TISSUE_STRUCTURE", 220, 233], ["outer", "ANATOMY_MODIFIER", 129, 134], ["wall", "ANATOMY_MODIFIER", 135, 139], ["surface", "OBSERVATION_MODIFIER", 140, 147], ["longwave", "OBSERVATION_MODIFIER", 148, 156], ["radiation", "OBSERVATION", 157, 166], ["angle", "OBSERVATION_MODIFIER", 195, 200], ["vertical", "ANATOMY_MODIFIER", 220, 228], ["wall", "ANATOMY_MODIFIER", 229, 233], ["sky", "ANATOMY_MODIFIER", 242, 245]]], ["T sky is the sky effective temperature, see Eq.IntroductionFor the inner wall surface, suppose the temperature difference between surfaces is small, then the radiation heat transfer can be neglected.", [["inner wall surface", "ANATOMY", 67, 85], ["the inner wall surface", "TREATMENT", 63, 85], ["the temperature difference", "PROBLEM", 95, 121], ["the radiation heat transfer", "TREATMENT", 154, 181], ["small", "OBSERVATION_MODIFIER", 142, 147]]], ["The heat balance equation is as following Eq.", [["The heat balance equation", "TEST", 0, 25], ["heat balance", "OBSERVATION", 4, 16]]], ["(8),IntroductionQ conducin represents the heat conduction received by the inner surface, W/m 2 , the value is equal to Q conduc .", [["inner surface", "ANATOMY", 74, 87], ["inner surface", "CELLULAR_COMPONENT", 74, 87], ["IntroductionQ conducin", "TREATMENT", 4, 26], ["the heat conduction", "TREATMENT", 38, 57], ["the value", "TEST", 97, 106]]], ["Q convecin is the heat convection exchange between the inner wall surface and the indoor air, W/m 2 .", [["inner wall surface", "ANATOMY", 55, 73], ["inner wall surface", "CELLULAR_COMPONENT", 55, 73], ["the heat convection exchange", "TREATMENT", 14, 42], ["the inner wall surface", "TREATMENT", 51, 73], ["heat convection", "OBSERVATION", 18, 33], ["inner", "ANATOMY_MODIFIER", 55, 60], ["wall", "ANATOMY_MODIFIER", 61, 65], ["surface", "ANATOMY_MODIFIER", 66, 73]]], ["The convective heat transfer coefficient h in is set as 5 W/(m 2 \u00b7K) [50] .", [["The convective heat transfer coefficient h", "TREATMENT", 0, 42]]], ["Since a change of 1 K for the indoor air temperature T ain only causes a 0.06 K variation of T wout , the value of T ain has a very small influence on the result of T wout .", [["K", "CHEMICAL", 20, 21], ["T ain", "CHEMICAL", 53, 58], ["T ain", "GENE_OR_GENE_PRODUCT", 115, 120], ["T wout", "GENE_OR_GENE_PRODUCT", 165, 171], ["T wout", "PROBLEM", 165, 171], ["very small", "OBSERVATION_MODIFIER", 127, 137]]], ["The given value of T ain is 3 K higher than T aout in the calculation.IntroductionBased on the above equations and variable values, the temperature values of vertical sunward and shady side outer wall surfaces at noon can be calculated.", [["outer wall", "ANATOMY", 190, 200], ["T ain", "TEST", 19, 24], ["the above equations", "TEST", 91, 110], ["the temperature values", "TEST", 132, 154], ["vertical sunward and shady side outer wall surfaces", "TREATMENT", 158, 209]]], ["The solar radiation intensity is an average value of 11:00-13:00.", [["solar", "OBSERVATION_MODIFIER", 4, 9], ["radiation intensity", "OBSERVATION_MODIFIER", 10, 29]]], ["It is observed that the temperature of the sunward outer surface is 10 K higher than the shady side, and 13 K higher than the outdoor air temperature.", [["outer surface", "ANATOMY", 51, 64], ["the temperature", "TEST", 20, 35], ["the sunward outer surface", "TEST", 39, 64], ["10 K higher", "OBSERVATION_MODIFIER", 68, 79]]], ["The calculation results are compared with the experimental data from Wang et al. [55] .", [["the experimental data", "TEST", 42, 63]]], ["Note: The atmospheric transparency is 0.62 [47] [48] [49] .", [["The atmospheric transparency", "TEST", 6, 34]]], ["During 11:00 to 13:00, the south face is sunward, while the north face is shady side.", [["shady", "OBSERVATION", 74, 79]]], ["They selected a 40 m height rectangular student dormitory as the target building and measured several parameters including external wall temperature, wind speed, solar intensity and air temperature in April 7th and 16th in 2010.", [["wall", "ANATOMY", 132, 136], ["a 40 m height rectangular student dormitory", "TREATMENT", 14, 57], ["external wall temperature", "TEST", 123, 148], ["external wall", "ANATOMY", 123, 136], ["air temperature", "OBSERVATION", 182, 197]]], ["During their test process, the solar radiation received by the south wall at 11:00-13:00 was in the range of 300-350 W/m 2 , the wind speed was below 4 m/s and the ambient temperature was 285-288 K. The temperature on the sunward surface varied with height.", [["sunward surface", "ANATOMY", 222, 237], ["the solar radiation", "TREATMENT", 27, 46], ["the ambient temperature", "TEST", 160, 183], ["The temperature", "TEST", 199, 214], ["temperature", "OBSERVATION_MODIFIER", 203, 214], ["surface", "OBSERVATION_MODIFIER", 230, 237], ["varied", "OBSERVATION_MODIFIER", 238, 244], ["height", "OBSERVATION_MODIFIER", 250, 256]]], ["The largest difference between bottom and top was 2.5 K. The measured average temperature difference between the external south wall and ambient at 11:00-13:00 was 12-18 K. The calculation result in the present work is relatively small compared with the aforementioned measurements.", [["south wall", "ANATOMY", 122, 132], ["the aforementioned measurements", "TEST", 250, 281], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["bottom", "OBSERVATION_MODIFIER", 31, 37], ["top", "OBSERVATION_MODIFIER", 42, 45], ["external", "ANATOMY_MODIFIER", 113, 121], ["south wall", "ANATOMY", 122, 132], ["relatively", "OBSERVATION_MODIFIER", 219, 229], ["small", "OBSERVATION_MODIFIER", 230, 235]]], ["In view of the other influence factors such as the wall thermal conductivity and radiation heat transfer, a 13 K temperature difference can be considered as a reasonable value.", [["wall", "ANATOMY", 51, 55], ["wall", "TISSUE", 51, 55], ["the other influence factors", "PROBLEM", 11, 38], ["the wall thermal conductivity", "TREATMENT", 47, 76], ["radiation heat transfer", "TREATMENT", 81, 104], ["a 13 K temperature difference", "PROBLEM", 106, 135]]], ["In the following numerical simulation, considering the computation accuracy for airflow on the windward side and the mesh quantity, the heated sunward and shady side walls are placed at the windward side in different cases separately.", [["sunward", "ANATOMY", 143, 150], ["the computation accuracy", "TEST", 51, 75], ["airflow on the windward side", "PROBLEM", 80, 108], ["the mesh quantity", "TREATMENT", 113, 130], ["the heated sunward and shady side walls", "TREATMENT", 132, 171], ["airflow", "OBSERVATION", 80, 87], ["mesh", "OBSERVATION", 117, 121]]], ["That is, in some cases the windward wall is sunward and in some cases it is shady side.Physical model and case configurationThe CFD method is adopted by using a commercial program, Fluent 17.0.", [["windward wall", "ANATOMY", 27, 40], ["windward wall", "TISSUE", 27, 40]]], ["Thus the building model is a slab one with the length-width ratio of 2.", [["the length-width ratio", "TEST", 43, 65]]], ["Six rooms in this building are focused on, which fall into three groups and each group contains two neighboring units, respectively the 2nd, 3rd, 10th, 11th, 18th and 19th floors along the middle column of the building windward facade, which are located at the lower, middle and upper positon of the building separately.", [["10th", "ANATOMY", 146, 150], ["middle", "ANATOMY_MODIFIER", 189, 195], ["column", "ANATOMY_MODIFIER", 196, 202], ["lower", "ANATOMY_MODIFIER", 261, 266], ["middle", "ANATOMY_MODIFIER", 268, 274], ["upper positon", "ANATOMY_MODIFIER", 279, 292]]], ["The dimensions of the concerned rooms are 2.9 m height(y), 3 m length(z), 3.6 m width(x).", [["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["2.9 m", "OBSERVATION_MODIFIER", 42, 47]]], ["The bottom of the window frame is 0.9 m above the room floor.", [["bottom", "OBSERVATION_MODIFIER", 4, 10]]], ["The dimensions of each room and window are in accordance with our previous wind tunnel tests [29, 30] .", [["our previous wind tunnel tests", "TEST", 62, 92], ["dimensions", "OBSERVATION_MODIFIER", 4, 14]]], ["The computational domain for the concerned cases is a rectangular zone surrounding the objective building.", [["rectangular", "OBSERVATION_MODIFIER", 54, 65], ["zone", "OBSERVATION_MODIFIER", 66, 70]]], ["The domain size is carefully designed, considering both efficiency and accuracy.", [["accuracy", "TEST", 71, 79], ["size", "OBSERVATION_MODIFIER", 11, 15], ["efficiency", "OBSERVATION_MODIFIER", 56, 66]]], ["According to Franke et al. [56] , the blockage ratio of the domain should be below 3%, which is about 1.8% in the present study.Physical model and case configurationAs for the boundary condition, the windward surface is set as a heated wall with constant temperature listed in Table 2 .", [["windward surface", "ANATOMY", 200, 216], ["wall", "ANATOMY", 236, 240], ["the blockage ratio", "TEST", 34, 52], ["the present study", "TEST", 110, 127], ["the boundary condition", "PROBLEM", 172, 194], ["the windward surface", "TREATMENT", 196, 216]]], ["The other walls of the building are assigned with adiabatic surfaces.", [["walls", "ANATOMY_MODIFIER", 10, 15], ["adiabatic surfaces", "OBSERVATION", 50, 68]]], ["Three different mesh systems of 3.5, 5.1, and 6.8 million grids are created and compared.", [["Three different mesh systems", "TEST", 0, 28], ["different", "OBSERVATION_MODIFIER", 6, 15], ["mesh", "OBSERVATION", 16, 20]]], ["The mesh refinement multiple is over 1.1 [57] .", [["The mesh refinement", "TREATMENT", 0, 19], ["mesh", "OBSERVATION", 4, 8], ["multiple", "OBSERVATION_MODIFIER", 20, 28]]], ["The medium one is selected because the latter two mesh systems generate similar values for air velocity and temperature at several specific locations in the computational domain.", [["air velocity", "TEST", 91, 103], ["medium one", "OBSERVATION_MODIFIER", 4, 14], ["mesh", "OBSERVATION", 50, 54], ["air velocity", "OBSERVATION", 91, 103]]], ["The near wall mesh on windward side is refined and y + < 5, as shown in Fig. 4 .", [["wall", "ANATOMY", 9, 13], ["wall mesh", "MULTI-TISSUE_STRUCTURE", 9, 18], ["The near wall mesh on windward side", "TREATMENT", 0, 35], ["wall", "ANATOMY_MODIFIER", 9, 13], ["mesh", "OBSERVATION", 14, 18]]], ["For the other surfaces, the value of y + is satisfied with 30 < y + < 300. .", [["the value", "TEST", 24, 33]]], ["The turbulence on the inlet boundary is characterized by turbulence intensity and length scale, which are 10% and 1 m [25, 59] , respectively.", [["turbulence intensity", "PROBLEM", 57, 77], ["length scale", "TEST", 82, 94], ["turbulence", "OBSERVATION", 4, 14], ["inlet boundary", "OBSERVATION_MODIFIER", 22, 36], ["turbulence", "OBSERVATION_MODIFIER", 57, 67], ["intensity", "OBSERVATION_MODIFIER", 68, 77], ["length", "OBSERVATION_MODIFIER", 82, 88]]], ["The turbulent effect is simulated by the renormalization group (RNG) k-\u025b model [60] with enhanced wall treatment.", [["wall", "ANATOMY", 98, 102], ["wall", "TISSUE", 98, 102], ["enhanced wall treatment", "TREATMENT", 89, 112], ["turbulent", "OBSERVATION_MODIFIER", 4, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20], ["wall treatment", "OBSERVATION", 98, 112]]], ["The pressure-velocity coupling algorithm is SIMPLE.", [["The pressure", "TEST", 0, 12], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["velocity", "OBSERVATION_MODIFIER", 13, 21], ["SIMPLE", "OBSERVATION_MODIFIER", 44, 50]]], ["The pressure interpolation method is a staggered scheme named PRESTO.", [["PRESTO", "PROTEIN", 62, 68], ["The pressure interpolation method", "TREATMENT", 0, 33], ["pressure", "OBSERVATION_MODIFIER", 4, 12]]], ["The discretization scheme used for the other variables except the pressure is second order upwind to ensure the computational precision.", [["The discretization scheme", "TREATMENT", 0, 25]]], ["As to the pollutant transmission, a 1 \u00d7 10 \u22126 m 3 tiny cube at the middle of the window is assigned as the source, located at the 2nd, 10th and 18th floor respectively in each case.", [["a 1 \u00d7 10 \u22126 m 3 tiny cube", "TREATMENT", 34, 59], ["middle", "ANATOMY_MODIFIER", 67, 73], ["window", "OBSERVATION", 81, 87]]], ["Propane (C 3 H 8 ) [26] [27] [28] , as a tracer gas of gaseous pollutants, is generated at a constant mass flow rate of 8 mg/ s [25, 31] .", [["Propane", "CHEMICAL", 0, 7], ["C 3 H 8 ) [26] [27] [28]", "CHEMICAL", 9, 33], ["Propane", "CHEMICAL", 0, 7], ["C 3 H 8 ) [26] [27] [28]", "CHEMICAL", 9, 33], ["Propane", "SIMPLE_CHEMICAL", 0, 7], ["C 3 H 8 ) [26] [27] [28]", "SIMPLE_CHEMICAL", 9, 33], ["Propane (C 3 H", "TREATMENT", 0, 14], ["a tracer gas", "TEST", 39, 51], ["gaseous pollutants", "PROBLEM", 55, 73], ["flow rate", "TEST", 107, 116], ["gaseous pollutants", "OBSERVATION", 55, 73]]], ["The calculations are terminated when the residuals do not show any further reduction and maintain at a reasonable level.", [["the residuals", "TEST", 37, 50], ["reduction", "OBSERVATION", 75, 84]]], ["The convergent values of residuals are as following: 10 \u22124 for continuity, 10 \u22125 for k, \u025b, x-, y-and z-velocity, 10 \u22126 for concentration and 10 \u22128 for energy.", [["continuity", "TEST", 63, 73], ["k", "TEST", 85, 86], ["\u025b", "TEST", 88, 89], ["convergent", "OBSERVATION_MODIFIER", 4, 14]]], ["The solutions, such as the air velocity, temperature and concentration at specific points, are stable or appear steady quasi-periodic variations with acceptable fluctuation amplitudes.", [["The solutions", "TREATMENT", 0, 13], ["the air velocity", "TEST", 23, 39], ["air velocity", "OBSERVATION", 27, 39], ["stable", "OBSERVATION_MODIFIER", 95, 101], ["fluctuation amplitudes", "OBSERVATION", 161, 183]]], ["The amplitudes of velocity and concentration values at specific points show significant ones in the buoyancy driven windless case, which are all below 8%.", [["concentration values", "TEST", 31, 51], ["amplitudes", "OBSERVATION_MODIFIER", 4, 14], ["velocity", "OBSERVATION_MODIFIER", 18, 26], ["concentration", "OBSERVATION_MODIFIER", 31, 44], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["buoyancy driven", "OBSERVATION", 100, 115]]], ["Table 3 shows 26 sets of configuration based on the airflow field without the influence of source, and these cases are divided into four groups according to the window condition and the temperature difference.", [["the temperature difference", "PROBLEM", 182, 208], ["airflow", "OBSERVATION", 52, 59]]], ["A 13 K temperature difference represents that the building windward wall faces the sun, while a 3.5 K temperature difference means that the windward wall is the shady side.Physical model and case configurationA dimensionless number, Richardson number, is adopted to represent the relative strength of buoyancy lift and wind.", [["windward wall", "ANATOMY", 59, 72], ["windward wall", "ANATOMY", 140, 153], ["K", "CHEMICAL", 5, 6], ["windward wall", "MULTI-TISSUE_STRUCTURE", 59, 72], ["windward wall", "MULTI-TISSUE_STRUCTURE", 140, 153], ["A 13 K temperature difference", "PROBLEM", 0, 29], ["a 3.5 K temperature difference", "PROBLEM", 94, 124], ["13 K temperature", "OBSERVATION_MODIFIER", 2, 18], ["wall", "ANATOMY_MODIFIER", 149, 153], ["buoyancy lift", "OBSERVATION", 301, 314]]], ["(10),Physical model and case configurationwhere \u03b2 is the thermal expansion coefficient, ((T aout + T wout )/2) \u22121 , K \u22121 , g is the gravity acceleration, 9.81 m/s 2 and \u03bd is the kinetic viscosity, 1.48 \u00d7 10 \u22125 m 2 /s.", [["the thermal expansion coefficient", "TEST", 53, 86], ["K", "TEST", 116, 117], ["the gravity acceleration", "TEST", 128, 152], ["the kinetic viscosity", "TEST", 174, 195], ["kinetic viscosity", "OBSERVATION", 178, 195]]], ["Gr is the Grashof number reflecting the intensity of natural convection and Re is the Reynolds number characterizing the forced convention flow patterns.", [["Gr", "GENE_OR_GENE_PRODUCT", 0, 2], ["intensity", "OBSERVATION_MODIFIER", 40, 49], ["natural convection", "OBSERVATION", 53, 71], ["flow patterns", "OBSERVATION", 139, 152]]], ["The building height is selected as the characteristic length since the flow direction along the windward heated wall is one of the biggest concerns.", [["windward heated wall", "ANATOMY", 96, 116], ["height", "OBSERVATION_MODIFIER", 13, 19], ["characteristic", "OBSERVATION_MODIFIER", 39, 53], ["length", "OBSERVATION_MODIFIER", 54, 60], ["flow", "OBSERVATION", 71, 75], ["wall", "OBSERVATION_MODIFIER", 112, 116], ["one", "OBSERVATION_MODIFIER", 120, 123], ["biggest", "OBSERVATION_MODIFIER", 131, 138]]], ["According to the parameters shown in Table 3 , these cases contain the processes from natural convection to forced convection.Model validationThe model involving pure wind driven inter-flat transmission has been validated in our previous paper [29] .", [["natural convection", "TREATMENT", 86, 104], ["forced convection", "TREATMENT", 108, 125], ["natural convection", "OBSERVATION", 86, 104], ["forced convection", "OBSERVATION", 108, 125]]], ["Since the formation of airflow field around the present objected building is contributed to the combined effect of approaching wind and buoyancy, the mechanism contains the natural convection and wind driven airflow around a bluff body.", [["body", "ANATOMY", 231, 235], ["body", "ORGANISM_SUBDIVISION", 231, 235], ["airflow", "OBSERVATION_MODIFIER", 23, 30], ["natural convection", "OBSERVATION", 173, 191]]], ["The following two correlative cases are done to validate the accuracy of the numerical configuration.Natural convection in a cavityBetts and Bokhar [61] carried out a series of experiments to investigate the natural convection of air in a tall cavity.", [["cavity", "ORGANISM_SUBDIVISION", 244, 250], ["air", "OBSERVATION", 230, 233]]], ["A portion of results are selected to certify the applicability of the numerical methods to predict the natural convection flow adjacent to the wall.", [["wall", "ANATOMY", 143, 147], ["wall", "TISSUE", 143, 147], ["convection flow", "OBSERVATION", 111, 126], ["wall", "ANATOMY_MODIFIER", 143, 147]]], ["The experimental cavity was 2.18 m height (y), 0.076 m width (x) and 0.52 m depth (z), with a cold wall of 15.1\u00b0C and a hot wall of 34.7\u00b0C (Fig. 5) .", [["a cold wall", "TEST", 92, 103], ["a hot wall", "TEST", 118, 128], ["cavity", "OBSERVATION_MODIFIER", 17, 23]]], ["Thus the temperature difference between these two vertical walls was 19.6\u00b0C, corresponding to a Rayleigh number of 8.6 \u00d7 10 5 .", [["the temperature difference", "PROBLEM", 5, 31], ["C", "TEST", 74, 75], ["a Rayleigh number", "TEST", 94, 111], ["vertical", "OBSERVATION_MODIFIER", 50, 58], ["walls", "OBSERVATION_MODIFIER", 59, 64]]], ["A K-type thermocouple was used for measuring the temperature distribution in the cavity and the accuracy was about 0.1\u00b0C. The velocity field was measured by a laser doppler anemometry (LDA) system.", [["cavity", "ORGANISM_SUBDIVISION", 81, 87], ["K-type thermocouple", "DNA", 2, 21], ["A K-type thermocouple", "TREATMENT", 0, 21], ["the accuracy", "TEST", 92, 104], ["The velocity field", "TEST", 122, 140], ["a laser doppler anemometry", "TEST", 157, 183], ["cavity", "ANATOMY", 81, 87], ["velocity", "OBSERVATION_MODIFIER", 126, 134]]], ["In the simulation configuration, the RNG k-\u025b model including low-Reynolds number effect is employed to solve the flow pattern.", [["the RNG k-\u025b model", "TEST", 33, 50], ["low-Reynolds", "OBSERVATION_MODIFIER", 61, 73], ["flow pattern", "OBSERVATION", 113, 125]]], ["The enhanced wall treatment combining a two-layer model is used for improving the prediction of the boundary layer flow and the heat transfer in the near wall area.", [["wall", "ANATOMY", 13, 17], ["wall area", "ANATOMY", 154, 163], ["The enhanced wall treatment", "TREATMENT", 0, 27], ["a two-layer model", "TREATMENT", 38, 55], ["the boundary layer flow", "TREATMENT", 96, 119], ["the heat transfer", "TREATMENT", 124, 141], ["wall", "OBSERVATION_MODIFIER", 13, 17], ["treatment", "OBSERVATION", 18, 27], ["boundary", "OBSERVATION_MODIFIER", 100, 108], ["layer flow", "OBSERVATION", 109, 119], ["wall", "ANATOMY_MODIFIER", 154, 158]]], ["As shown in Fig. 5 , the wall-adjacent grids are refined with y + below 5.Natural convection in a cavityThe profiles in Fig. 6 illustrate the comparisons of the temperature and velocity distribution results between the experiment and simulation at three different heights of the central x-y plane.", [["wall", "ANATOMY", 25, 29], ["wall", "MULTI-TISSUE_STRUCTURE", 25, 29], ["Natural convection in a cavity", "TREATMENT", 74, 104], ["the temperature", "TEST", 157, 172], ["wall", "ANATOMY_MODIFIER", 25, 29], ["convection", "OBSERVATION", 82, 92], ["cavity", "ANATOMY", 98, 104], ["velocity", "OBSERVATION_MODIFIER", 177, 185], ["distribution", "OBSERVATION_MODIFIER", 186, 198], ["central", "ANATOMY_MODIFIER", 279, 286]]], ["It can be seen that the temperature rises up from the cold wall to the hot wall.", [["hot wall", "ANATOMY", 71, 79], ["the temperature", "TEST", 20, 35], ["wall", "ANATOMY_MODIFIER", 59, 63], ["hot wall", "ANATOMY", 71, 79]]], ["The temperature profiles have two changes of gradient along the width direction, and the variation of temperature on each gradient is not exactly linear.", [["The temperature profiles", "TEST", 0, 24], ["two changes of gradient", "PROBLEM", 30, 53], ["two", "OBSERVATION_MODIFIER", 30, 33], ["changes", "OBSERVATION", 34, 41], ["gradient", "OBSERVATION_MODIFIER", 45, 53], ["width", "OBSERVATION_MODIFIER", 64, 69], ["direction", "OBSERVATION_MODIFIER", 70, 79], ["variation", "OBSERVATION_MODIFIER", 89, 98], ["temperature", "OBSERVATION_MODIFIER", 102, 113], ["not exactly", "UNCERTAINTY", 134, 145], ["linear", "OBSERVATION_MODIFIER", 146, 152]]], ["For the velocity profiles, the positive values mean the airflow direction is upward, while the negative ones mean downward.", [["the velocity profiles", "TEST", 4, 25], ["the positive values", "TEST", 27, 46], ["the airflow direction", "TEST", 52, 73], ["velocity", "OBSERVATION_MODIFIER", 8, 16], ["positive", "OBSERVATION_MODIFIER", 31, 39], ["values", "OBSERVATION_MODIFIER", 40, 46], ["airflow direction", "OBSERVATION", 56, 73], ["upward", "OBSERVATION_MODIFIER", 77, 83]]], ["Thus the airflow moves upward near the hot wall and downward near the cold wall.", [["hot wall", "ANATOMY", 39, 47], ["cold wall", "ANATOMY", 70, 79], ["the airflow", "PROBLEM", 5, 16], ["airflow", "OBSERVATION", 9, 16], ["upward", "OBSERVATION_MODIFIER", 23, 29], ["hot wall", "ANATOMY", 39, 47], ["downward", "OBSERVATION_MODIFIER", 52, 60], ["cold wall", "ANATOMY", 70, 79]]], ["The velocity magnitude near the walls is relatively larger than that at the central section of the cavity except the confined wall-adjacent regions where the airflow is adhered by the walls.", [["wall", "ANATOMY", 126, 130], ["wall", "TISSUE", 126, 130], ["The velocity magnitude", "TEST", 0, 22], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["magnitude", "OBSERVATION_MODIFIER", 13, 22], ["walls", "ANATOMY_MODIFIER", 32, 37], ["relatively", "OBSERVATION_MODIFIER", 41, 51], ["larger", "OBSERVATION", 52, 58], ["central", "ANATOMY_MODIFIER", 76, 83], ["cavity", "ANATOMY_MODIFIER", 99, 105], ["confined", "ANATOMY_MODIFIER", 117, 125], ["wall", "ANATOMY_MODIFIER", 126, 130], ["adjacent", "ANATOMY_MODIFIER", 131, 139], ["regions", "ANATOMY_MODIFIER", 140, 147], ["airflow", "OBSERVATION", 158, 165], ["adhered", "OBSERVATION", 169, 176], ["walls", "ANATOMY_MODIFIER", 184, 189]]], ["There are some tendencies in common between the corresponding temperature and velocity lines.Natural convection in a cavityThe first thing is that the gradient near walls is relatively higher than that at the central part.", [["velocity lines", "CELL_LINE", 78, 92], ["some tendencies", "PROBLEM", 10, 25], ["Natural convection in a cavity", "TREATMENT", 93, 123], ["some", "OBSERVATION_MODIFIER", 10, 14], ["tendencies", "OBSERVATION", 15, 25], ["common", "ANATOMY_MODIFIER", 29, 35], ["temperature", "OBSERVATION_MODIFIER", 62, 73], ["velocity lines", "OBSERVATION", 78, 92], ["convection", "OBSERVATION", 101, 111], ["cavity", "ANATOMY", 117, 123], ["gradient", "OBSERVATION_MODIFIER", 151, 159], ["walls", "OBSERVATION_MODIFIER", 165, 170], ["relatively", "OBSERVATION_MODIFIER", 174, 184], ["higher", "OBSERVATION_MODIFIER", 185, 191], ["central", "ANATOMY_MODIFIER", 209, 216]]], ["The next one is that at the upper height (y/ H = 0.9), the gradient near the hot wall is lower than that near the cold wall, and the simulation results at the middle part are slightly smaller than those at the near wall part.", [["hot wall", "ANATOMY", 77, 85], ["cold wall", "ANATOMY", 114, 123], ["wall part", "ANATOMY", 215, 224], ["upper", "ORGANISM_SUBDIVISION", 28, 33], ["wall part", "MULTI-TISSUE_STRUCTURE", 215, 224], ["the upper height (y/ H", "TEST", 24, 46], ["the gradient", "TEST", 55, 67], ["upper", "ANATOMY_MODIFIER", 28, 33], ["hot", "OBSERVATION_MODIFIER", 77, 80], ["wall", "ANATOMY_MODIFIER", 81, 85], ["lower", "OBSERVATION", 89, 94], ["cold wall", "ANATOMY", 114, 123], ["middle", "ANATOMY_MODIFIER", 159, 165], ["slightly", "OBSERVATION_MODIFIER", 175, 183], ["smaller", "OBSERVATION", 184, 191], ["wall", "ANATOMY_MODIFIER", 215, 219]]], ["Whereas at the lower height (y/ H = 0.1), the gradient near the hot wall is larger, and the simulation results at the middle part are mildly higher than at the near wall part.", [["hot wall", "ANATOMY", 64, 72], ["wall part", "ANATOMY", 165, 174], ["wall part", "MULTI-TISSUE_STRUCTURE", 165, 174], ["the lower height (y/ H", "TEST", 11, 33], ["the gradient", "TEST", 42, 54], ["mildly higher", "PROBLEM", 134, 147], ["lower", "ANATOMY_MODIFIER", 15, 20], ["hot", "OBSERVATION_MODIFIER", 64, 67], ["wall", "ANATOMY_MODIFIER", 68, 72], ["larger", "OBSERVATION_MODIFIER", 76, 82], ["middle", "ANATOMY_MODIFIER", 118, 124], ["mildly", "OBSERVATION_MODIFIER", 134, 140], ["higher", "OBSERVATION", 141, 147], ["wall", "ANATOMY_MODIFIER", 165, 169]]], ["Another one is that high quality of anti-symmetry shows in the midheight test line (y/H = 0.5) across the cavity.", [["cavity", "ORGAN", 106, 112], ["midheight test line", "CELL_LINE", 63, 82], ["high", "OBSERVATION_MODIFIER", 20, 24], ["cavity", "ANATOMY", 106, 112]]], ["In general, although there are deviations between simulation and experimental results, the coincidence rate is acceptable enough.Air flow around a bluff bodyJiang et al. [62] performed several sets of wind tunnel tests to measure the airflow patterns around a building-like cubic model with the dimensions of 250 mm height (y) \u00d7 250 mm length (x) \u00d7 250 mm width (z), and the wall thickness of 6 mm.", [["body", "ANATOMY", 153, 157], ["wall", "ANATOMY", 375, 379], ["wall", "TISSUE", 375, 379], ["deviations between simulation", "PROBLEM", 31, 60], ["Air flow", "PROBLEM", 129, 137], ["a bluff bodyJiang et al", "TREATMENT", 145, 168], ["wind tunnel tests", "TEST", 201, 218], ["the airflow patterns", "TEST", 230, 250], ["length", "TEST", 336, 342], ["mm width (z)", "TEST", 353, 365], ["the wall thickness", "TEST", 371, 389], ["flow", "OBSERVATION", 133, 137], ["airflow", "OBSERVATION", 234, 241], ["dimensions", "OBSERVATION_MODIFIER", 295, 305], ["250 mm", "OBSERVATION_MODIFIER", 309, 315], ["wall", "ANATOMY_MODIFIER", 375, 379], ["thickness", "OBSERVATION_MODIFIER", 380, 389], ["6 mm", "OBSERVATION_MODIFIER", 393, 397]]], ["The model had an opening on the windward side wall and the size was 125 mm (y) \u00d7 84 mm (z), resulting in wind-induced single-sided ventilation.", [["windward side wall", "ANATOMY", 32, 50], ["single-sided ventilation", "TREATMENT", 118, 142], ["opening", "OBSERVATION", 17, 24], ["wall", "ANATOMY_MODIFIER", 46, 50], ["size", "OBSERVATION_MODIFIER", 59, 63], ["125 mm", "OBSERVATION_MODIFIER", 68, 74], ["sided", "ANATOMY_MODIFIER", 125, 130], ["ventilation", "OBSERVATION", 131, 142]]], ["The mean and fluctuating velocity distributions along 10 vertical lines at the middle x-y plane, ranging from 25 to 500 mm in height, were measured by a onedimensional LDA with a resolution of \u00b1 0.05 m/s.", [["The mean", "TEST", 0, 8], ["fluctuating velocity distributions", "PROBLEM", 13, 47], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["fluctuating", "OBSERVATION_MODIFIER", 13, 24], ["velocity", "OBSERVATION_MODIFIER", 25, 33], ["distributions", "OBSERVATION_MODIFIER", 34, 47], ["vertical lines", "OBSERVATION", 57, 71], ["middle x-y", "ANATOMY_MODIFIER", 79, 89], ["ranging", "OBSERVATION_MODIFIER", 97, 104], ["25 to 500 mm", "OBSERVATION_MODIFIER", 110, 122]]], ["The mean velocity Fig. 7 .", [["The mean velocity Fig", "TEST", 0, 21], ["mean velocity", "OBSERVATION", 4, 17], ["Fig", "OBSERVATION_MODIFIER", 18, 21]]], ["The near wall meshes of the building model are locally densified with the minimum grid width of 0.1 mm.", [["wall", "ANATOMY", 9, 13], ["wall meshes", "MULTI-TISSUE_STRUCTURE", 9, 20], ["The near wall meshes", "TREATMENT", 0, 20], ["wall", "ANATOMY_MODIFIER", 9, 13], ["meshes", "OBSERVATION", 14, 20], ["locally", "OBSERVATION_MODIFIER", 47, 54], ["minimum", "OBSERVATION_MODIFIER", 74, 81], ["grid", "OBSERVATION_MODIFIER", 82, 86], ["width", "OBSERVATION_MODIFIER", 87, 92], ["0.1 mm", "OBSERVATION_MODIFIER", 96, 102]]], ["The RNG k-\u025b model combined with enhanced wall treatment is used again for reproducing the airflow field feature.", [["wall", "ANATOMY", 41, 45], ["The RNG k-\u025b model", "TEST", 0, 17], ["enhanced wall treatment", "TREATMENT", 32, 55], ["the airflow field feature", "PROBLEM", 86, 111], ["wall treatment", "OBSERVATION", 41, 55], ["airflow", "OBSERVATION", 90, 97]]], ["Fig. 8 shows the streamlines at the middle x-y section obtained by numerical simulation.", [["middle", "ANATOMY_MODIFIER", 36, 42]]], ["The comparisons of four velocity profiles at the middle x-y section between simulation and experiment are shown in Fig. 9 .", [["four velocity profiles", "TEST", 19, 41], ["velocity", "OBSERVATION_MODIFIER", 24, 32], ["middle", "ANATOMY_MODIFIER", 49, 55], ["Fig", "OBSERVATION_MODIFIER", 115, 118]]], ["The positive value of U/U ref means the airflow direction is the plus x direction, and the negative one means the airflow move to the minus x direction.", [["U/U", "GENE_OR_GENE_PRODUCT", 22, 25], ["U/U ref", "TEST", 22, 29], ["airflow", "OBSERVATION", 40, 47], ["airflow", "OBSERVATION", 114, 121]]], ["It can be seen that the backflow vortex at the bottom before the cubic model in Fig. 9 (a) (line -H/2) and Fig. 9 (b) (line -H/ 25), the reverse flow on the roof in Fig. 9 (c) (line H/2) and the recirculation zone in the downstream region in Fig. 9 (d) (line 1.5H) are captured by the present simulation.", [["the backflow vortex", "TREATMENT", 20, 39], ["Fig.", "TEST", 107, 111], ["the recirculation zone", "TREATMENT", 191, 213], ["backflow vortex", "OBSERVATION", 24, 39], ["bottom", "ANATOMY_MODIFIER", 47, 53], ["cubic model", "OBSERVATION", 65, 76], ["Fig", "OBSERVATION_MODIFIER", 80, 83], ["flow", "OBSERVATION", 145, 149], ["roof", "ANATOMY_MODIFIER", 157, 161], ["recirculation", "OBSERVATION", 195, 208], ["zone", "ANATOMY_MODIFIER", 209, 213], ["downstream", "ANATOMY_MODIFIER", 221, 231]]], ["The simulated velocity distributions are satisfactory compared with the measurement except along the line 1.5H behind the model.", [["the measurement", "TEST", 68, 83], ["simulated", "OBSERVATION_MODIFIER", 4, 13], ["velocity", "OBSERVATION_MODIFIER", 14, 22], ["distributions", "OBSERVATION_MODIFIER", 23, 36], ["satisfactory", "OBSERVATION_MODIFIER", 41, 53]]], ["The minus simulated velocities at the lower section of the line 1.5H mean that RNG k-\u025b model predicts a mildly larger separation region in the wake flow of a bluff body.", [["body", "ANATOMY", 164, 168], ["The minus simulated velocities", "TEST", 0, 30], ["a mildly larger separation region", "PROBLEM", 102, 135], ["minus", "OBSERVATION_MODIFIER", 4, 9], ["simulated", "OBSERVATION_MODIFIER", 10, 19], ["velocities", "OBSERVATION_MODIFIER", 20, 30], ["lower", "ANATOMY_MODIFIER", 38, 43], ["mildly", "OBSERVATION_MODIFIER", 104, 110], ["larger", "OBSERVATION_MODIFIER", 111, 117], ["separation", "OBSERVATION_MODIFIER", 118, 128], ["region", "OBSERVATION_MODIFIER", 129, 135], ["wake flow", "OBSERVATION", 143, 152], ["bluff body", "OBSERVATION", 158, 168]]], ["Despite the slight inaccuracy of RNG k-\u025b model in the prediction of the vortexshedding effects in the building wake, the calculations of the airflow field inside the cubic model and in the upstream areas near and beside to the windward fa\u00e7ade agree well with the experimental results.", [["slight", "OBSERVATION_MODIFIER", 12, 18], ["inaccuracy", "OBSERVATION_MODIFIER", 19, 29], ["airflow", "OBSERVATION", 141, 148], ["cubic model", "OBSERVATION", 166, 177]]], ["It is sufficient to justify the application of RNG k-\u025b model in the present main concern of inter-flat pollutant transmission on the windward side and the qualitative pollutant distribution behind the building.Results and discussionThe work in this section contains two parts.", [["RNG k-\u025b model", "TREATMENT", 47, 60], ["inter-flat pollutant transmission on the windward side", "PROBLEM", 92, 146], ["inter-flat", "OBSERVATION_MODIFIER", 92, 102], ["pollutant transmission", "OBSERVATION", 103, 125], ["pollutant distribution", "OBSERVATION", 167, 189]]], ["For the isolated building scale, concerning the comprehensive performance of combined wind and buoyancy effect, part 3.1 gives the airflow streamlines and tracer gas mass fraction distribution around the building in the close window mode.", [["combined wind and buoyancy effect", "PROBLEM", 77, 110], ["the airflow streamlines", "PROBLEM", 127, 150], ["tracer gas mass fraction distribution", "PROBLEM", 155, 192], ["tracer", "OBSERVATION", 155, 161], ["gas mass", "OBSERVATION", 162, 170], ["fraction", "OBSERVATION_MODIFIER", 171, 179], ["distribution", "OBSERVATION_MODIFIER", 180, 192]]], ["Since the heated wall is on the windward side, the thermal plume generated by natural ventilation is adjacent to the windward surface.", [["wall", "ANATOMY", 17, 21], ["windward surface", "ANATOMY", 117, 133], ["wall", "TISSUE", 17, 21], ["windward surface", "CELLULAR_COMPONENT", 117, 133], ["natural ventilation", "TREATMENT", 78, 97], ["wall", "ANATOMY_MODIFIER", 17, 21], ["thermal", "OBSERVATION_MODIFIER", 51, 58], ["plume", "OBSERVATION_MODIFIER", 59, 64], ["natural ventilation", "OBSERVATION", 78, 97], ["windward", "OBSERVATION_MODIFIER", 117, 125], ["surface", "OBSERVATION_MODIFIER", 126, 133]]], ["Part 3.2 firstly shows the concentration distribution along the windward wall in the open window mode.", [["windward wall", "ANATOMY", 64, 77], ["windward wall", "MULTI-TISSUE_STRUCTURE", 64, 77], ["concentration", "OBSERVATION_MODIFIER", 27, 40], ["distribution", "OBSERVATION_MODIFIER", 41, 53], ["windward", "ANATOMY_MODIFIER", 64, 72], ["wall", "ANATOMY_MODIFIER", 73, 77], ["open window", "OBSERVATION", 85, 96]]], ["Then for the room scale, part 3.2 illustrates the mean temperature and air exchange rate (ACH) of each room.", [["the room scale", "TEST", 9, 23], ["the mean temperature", "TEST", 46, 66], ["air exchange rate", "TEST", 71, 88]]], ["Furthermore, an evaluation index, reentry ratio, is introduced in to analyse the inter-flat transmission characteristics.", [["an evaluation index", "TEST", 13, 32]]], ["So this part mainly concerns the situations within the objective building.Airflow and tracer gas concentration distribution in close window modeTo compare the airflow patterns around the building in different cases, the velocity magnitude distribution on a portion of middle x-y plane for four representative close window mode cases are shown in Fig. 10 .", [["Airflow", "TEST", 74, 81], ["tracer gas concentration distribution", "TEST", 86, 123], ["tracer", "OBSERVATION", 86, 92], ["gas concentration", "OBSERVATION", 93, 110], ["airflow", "OBSERVATION", 159, 166], ["velocity", "OBSERVATION_MODIFIER", 220, 228], ["magnitude", "OBSERVATION_MODIFIER", 229, 238], ["distribution", "OBSERVATION_MODIFIER", 239, 251], ["middle", "ANATOMY_MODIFIER", 268, 274]]], ["In Fig. 10(I1) , Ri = 156.9, the buoyancy lift is dominant.", [["Ri", "TEST", 17, 19], ["buoyancy lift", "OBSERVATION", 33, 46], ["dominant", "OBSERVATION", 50, 58]]], ["The thermal plume along the windward surface can be observed distinctly and the flow over the building roof moves downstream toward the high sky.", [["windward surface", "ANATOMY", 28, 44], ["windward surface", "CELLULAR_COMPONENT", 28, 44], ["The thermal plume", "TREATMENT", 0, 17], ["thermal", "OBSERVATION_MODIFIER", 4, 11], ["plume", "OBSERVATION_MODIFIER", 12, 17], ["surface", "OBSERVATION_MODIFIER", 37, 44], ["flow", "OBSERVATION_MODIFIER", 80, 84], ["high sky", "OBSERVATION", 136, 144]]], ["The wall thermal flow velocity at the building height is up to 1.2 m/s.", [["wall", "ANATOMY", 4, 8], ["wall", "MULTI-TISSUE_STRUCTURE", 4, 8], ["The wall thermal flow velocity", "TEST", 0, 30], ["the building height", "TEST", 34, 53], ["wall", "ANATOMY_MODIFIER", 4, 8], ["thermal", "OBSERVATION_MODIFIER", 9, 16], ["flow velocity", "OBSERVATION", 17, 30]]], ["The airflow near the leeward surface is upward.", [["leeward surface", "ANATOMY", 21, 36], ["airflow", "OBSERVATION", 4, 11], ["leeward", "OBSERVATION_MODIFIER", 21, 28], ["surface", "OBSERVATION_MODIFIER", 29, 36], ["upward", "OBSERVATION_MODIFIER", 40, 46]]], ["Since the thermal air from upstream flows to the upper space of downstream, the air density and pressure of the upper zone are smaller than those of the lower zone.", [["upper zone", "ANATOMY", 112, 122], ["upper zone", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 122], ["the thermal air", "PROBLEM", 6, 21], ["the air density and pressure of the upper zone", "PROBLEM", 76, 122], ["thermal", "OBSERVATION_MODIFIER", 10, 17], ["air", "OBSERVATION", 18, 21], ["upstream", "OBSERVATION_MODIFIER", 27, 35], ["flows", "OBSERVATION_MODIFIER", 36, 41], ["upper space", "ANATOMY_MODIFIER", 49, 60], ["downstream", "OBSERVATION_MODIFIER", 64, 74], ["air density", "OBSERVATION", 80, 91], ["pressure", "OBSERVATION_MODIFIER", 96, 104], ["upper", "ANATOMY_MODIFIER", 112, 117], ["zone", "ANATOMY_MODIFIER", 118, 122], ["smaller", "OBSERVATION_MODIFIER", 127, 134], ["lower", "ANATOMY_MODIFIER", 153, 158], ["zone", "ANATOMY_MODIFIER", 159, 163]]], ["That should be one of the main reasons for the upgrade airflow on the leeward side.", [["the upgrade airflow on the leeward side", "PROBLEM", 43, 82], ["airflow", "OBSERVATION", 55, 62]]], ["In Fig. 10(I3) , the coming wind speed at the building height is 0.8 m/s, the corresponding Ri is 39.2.", [["the corresponding Ri", "TEST", 74, 94]]], ["It can be seen that the wall flow scope is weakened due to the suppression effect of the approaching wind.", [["wall", "ANATOMY", 24, 28], ["wall", "TISSUE", 24, 28], ["the wall flow scope", "TEST", 20, 39], ["wall", "OBSERVATION_MODIFIER", 24, 28], ["flow", "OBSERVATION", 29, 33]]], ["The airflow above the roof and behind the building is more likely to go to the downstream rather than to the higher altitude.", [["airflow", "OBSERVATION", 4, 11], ["roof", "ANATOMY_MODIFIER", 22, 26], ["more likely", "UNCERTAINTY", 54, 65], ["higher altitude", "OBSERVATION", 109, 124]]], ["A reverse vortex can be observed behind the building.", [["A reverse vortex", "TREATMENT", 0, 16], ["reverse vortex", "OBSERVATION", 2, 16]]], ["In Fig. 10(I4) , the corresponding Ri is 25.1.", [["Ri", "DNA", 35, 37], ["the corresponding Ri", "TEST", 17, 37]]], ["The airflow closely adhering to the windward wall still tends to go upward.", [["windward wall", "ANATOMY", 36, 49], ["windward wall", "MULTI-TISSUE_STRUCTURE", 36, 49], ["The airflow", "PROBLEM", 0, 11], ["airflow", "OBSERVATION", 4, 11], ["wall", "ANATOMY_MODIFIER", 45, 49]]], ["The velocity magnitude near the windward wall is below 0.5 m/s.", [["windward wall", "ANATOMY", 32, 45], ["windward wall", "MULTI-TISSUE_STRUCTURE", 32, 45], ["The velocity magnitude", "TEST", 0, 22], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["magnitude", "OBSERVATION_MODIFIER", 13, 22], ["windward", "ANATOMY_MODIFIER", 32, 40], ["wall", "ANATOMY_MODIFIER", 41, 45]]], ["A small backflow vortex forms at the windward bottom area.", [["windward bottom area", "ANATOMY", 37, 57], ["A small backflow vortex", "TREATMENT", 0, 23], ["small", "OBSERVATION_MODIFIER", 2, 7], ["backflow vortex", "OBSERVATION", 8, 23], ["bottom", "ANATOMY_MODIFIER", 46, 52]]], ["As the approaching wind speed goes up, and the temperature difference is constant, a stagnation zone shows between 16th and 17th floor on the windward side, as shown in Fig. 10(I7) .", [["the temperature difference", "PROBLEM", 43, 69], ["a stagnation zone", "TEST", 83, 100], ["constant", "OBSERVATION_MODIFIER", 73, 81]]], ["The downward flow below the stagnation zone has a velocity magnitude of about 1.0 m/s.", [["The downward flow", "TEST", 0, 17], ["a velocity magnitude", "TEST", 48, 68], ["downward", "OBSERVATION_MODIFIER", 4, 12], ["flow", "OBSERVATION", 13, 17], ["stagnation", "OBSERVATION_MODIFIER", 28, 38], ["zone", "OBSERVATION_MODIFIER", 39, 43], ["velocity", "OBSERVATION_MODIFIER", 50, 58], ["magnitude", "OBSERVATION_MODIFIER", 59, 68]]], ["The near wall upward thermal flow is severely restrained.", [["wall", "ANATOMY", 9, 13], ["wall", "MULTI-TISSUE_STRUCTURE", 9, 13], ["severely restrained", "PROBLEM", 37, 56], ["wall", "ANATOMY_MODIFIER", 9, 13], ["upward", "OBSERVATION_MODIFIER", 14, 20], ["thermal", "OBSERVATION_MODIFIER", 21, 28], ["flow", "OBSERVATION", 29, 33], ["severely", "OBSERVATION_MODIFIER", 37, 45], ["restrained", "OBSERVATION", 46, 56]]], ["The recirculation vortexes on the leeward side can be observed.", [["The recirculation vortexes", "TEST", 0, 26], ["recirculation vortexes", "OBSERVATION", 4, 26]]], ["Because of the relatively high wind speed, the airflow pattern in this case is almost the same with the pure wind driven airflow around a bluff body [45] .Airflow and tracer gas concentration distribution in close window modeAs to the pollutant dispersion characteristics, the tracer gas is released as a point source at a constant mass flow rate from one windward unit in each case.", [["body", "ANATOMY", 144, 148], ["the airflow pattern", "PROBLEM", 43, 62], ["Airflow", "TEST", 155, 162], ["tracer gas", "TEST", 167, 177], ["the tracer gas", "TEST", 273, 287], ["a constant mass flow rate", "PROBLEM", 321, 346], ["airflow", "OBSERVATION", 47, 54], ["tracer gas", "OBSERVATION", 167, 177], ["concentration", "OBSERVATION_MODIFIER", 178, 191], ["distribution", "OBSERVATION_MODIFIER", 192, 204], ["close window", "OBSERVATION_MODIFIER", 208, 220], ["tracer gas", "OBSERVATION", 277, 287], ["mass", "OBSERVATION", 332, 336]]], ["To observe the pollutant transmission routes and compare the concentration distributions, Fig. 11 gives the tracer gas In Case I3, the Ri number is reduced from 156.9 to 39.2, the infected area on the windward side reflects a peach-like shape around the source unit.", [["the tracer gas", "TEST", 104, 118], ["the Ri number", "TEST", 131, 144], ["reduced", "OBSERVATION_MODIFIER", 148, 155], ["infected", "OBSERVATION_MODIFIER", 180, 188], ["area", "OBSERVATION_MODIFIER", 189, 193]]], ["Both the vertical and horizontal transmissions are limited.", [["vertical", "OBSERVATION_MODIFIER", 9, 17], ["horizontal", "OBSERVATION_MODIFIER", 22, 32]]], ["Part of tracer gas can be taken to the front of building because of the backflow at the windward bottom region, and then spread to the lateral side.", [["tracer gas", "TEST", 8, 18], ["the backflow", "PROBLEM", 68, 80], ["tracer gas", "OBSERVATION", 8, 18], ["backflow", "OBSERVATION", 72, 80], ["bottom", "ANATOMY_MODIFIER", 97, 103], ["lateral", "ANATOMY_MODIFIER", 135, 142]]], ["In Case I4, the upward transmission on the windward side is totally suppressed by the downward coming wind, the tracer gas spread toward the ground and to the downstream with airflow, which means the buoyancy lift is weaker than the approaching wind at lower height.", [["the tracer gas", "TEST", 108, 122], ["upward", "OBSERVATION_MODIFIER", 16, 22], ["suppressed", "OBSERVATION", 68, 78], ["downward", "OBSERVATION_MODIFIER", 86, 94], ["tracer gas", "OBSERVATION", 112, 122], ["downstream", "ANATOMY_MODIFIER", 159, 169], ["airflow", "OBSERVATION", 175, 182], ["buoyancy", "OBSERVATION_MODIFIER", 200, 208], ["lift", "OBSERVATION_MODIFIER", 209, 213], ["weaker", "OBSERVATION_MODIFIER", 217, 223], ["lower", "ANATOMY_MODIFIER", 253, 258]]], ["In Case I7, the infected area is mainly restricted at the bottom in front of the building, which is influenced by the bottom airflow vortex when the approaching wind is ruling.", [["area", "ANATOMY", 25, 29], ["the infected area", "PROBLEM", 12, 29], ["infected", "OBSERVATION_MODIFIER", 16, 24], ["area", "OBSERVATION_MODIFIER", 25, 29], ["mainly", "OBSERVATION_MODIFIER", 33, 39], ["restricted", "OBSERVATION_MODIFIER", 40, 50], ["bottom", "ANATOMY_MODIFIER", 58, 64], ["bottom", "OBSERVATION_MODIFIER", 118, 124], ["airflow vortex", "OBSERVATION", 125, 139]]], ["For the region behind the building, the concentration magnitude is mostly below 10 \u22126 .", [["the concentration magnitude", "TEST", 36, 63], ["concentration", "OBSERVATION_MODIFIER", 40, 53], ["magnitude", "OBSERVATION_MODIFIER", 54, 63]]], ["In Case I1, although the thermal plume is dominant, the gentle wind still takes a part of tracer gas bypassing the lateral side to the leeward side during the upward transmission process along the windward surface.", [["windward surface", "ANATOMY", 197, 213], ["windward surface", "CELLULAR_COMPONENT", 197, 213], ["tracer gas", "TEST", 90, 100], ["dominant", "OBSERVATION", 42, 50], ["gentle", "OBSERVATION_MODIFIER", 56, 62], ["tracer gas", "OBSERVATION", 90, 100], ["lateral", "OBSERVATION_MODIFIER", 115, 122], ["upward", "OBSERVATION_MODIFIER", 159, 165], ["transmission", "OBSERVATION", 166, 178], ["windward", "OBSERVATION_MODIFIER", 197, 205], ["surface", "OBSERVATION_MODIFIER", 206, 213]]], ["In Case I3 and Case I4, where the Ri number is 69.7 and 39.2 respectively, the affected phenomenon is relatively more obvious due to the horizontal dispersion from the windward side and the upward near wall airflow on the leeward side.", [["windward", "ANATOMY", 168, 176], ["wall", "ANATOMY", 202, 206], ["the Ri number", "TEST", 30, 43], ["the affected phenomenon", "PROBLEM", 75, 98], ["the horizontal dispersion from the windward side", "PROBLEM", 133, 181], ["horizontal", "OBSERVATION_MODIFIER", 137, 147], ["dispersion", "OBSERVATION", 148, 158], ["upward", "OBSERVATION_MODIFIER", 190, 196], ["wall", "ANATOMY_MODIFIER", 202, 206], ["airflow", "OBSERVATION", 207, 214]]], ["When the Ri number decreases to a relatively low value of 2.5, in Case I7, the tracer gas mainly moves to the upstream with the bottom backflow and then to the lateral.", [["Ri", "DNA", 9, 11], ["the tracer gas", "TEST", 75, 89], ["bottom", "OBSERVATION_MODIFIER", 128, 134], ["backflow", "OBSERVATION", 135, 143], ["lateral", "ANATOMY_MODIFIER", 160, 167]]], ["When the source location is at the windward 10th floor, the vertical coverage area of 10 \u22126 -1 range along the windward wall is from the source floor to above the building top and still shows a symmetric shape in Case I1.", [["windward wall", "ANATOMY", 111, 124], ["windward wall", "MULTI-TISSUE_STRUCTURE", 111, 124], ["the vertical coverage area", "TEST", 56, 82], ["vertical", "OBSERVATION_MODIFIER", 60, 68], ["coverage", "OBSERVATION_MODIFIER", 69, 77], ["wall", "ANATOMY_MODIFIER", 120, 124], ["symmetric", "OBSERVATION_MODIFIER", 194, 203], ["shape", "OBSERVATION_MODIFIER", 204, 209]]], ["Since the thermal flow speed is faster at the upper height of the building, the windward tracer gas is brought to high altitude quickly, so the leeward space is barely affected.", [["upper", "ORGANISM_SUBDIVISION", 46, 51], ["the thermal flow speed", "TEST", 6, 28], ["the windward tracer gas", "PROBLEM", 76, 99], ["thermal", "OBSERVATION_MODIFIER", 10, 17], ["flow", "OBSERVATION", 18, 22], ["faster", "OBSERVATION_MODIFIER", 32, 38], ["upper height", "OBSERVATION_MODIFIER", 46, 58], ["tracer gas", "OBSERVATION", 89, 99], ["high altitude", "OBSERVATION_MODIFIER", 114, 127], ["barely", "OBSERVATION_MODIFIER", 161, 167], ["affected", "OBSERVATION", 168, 176]]], ["In Case I3, the wind speed is higher than in Case I1, the effect of the near wall thermal flow is weakened.", [["wall", "ANATOMY", 77, 81], ["higher", "OBSERVATION_MODIFIER", 30, 36], ["wall", "ANATOMY_MODIFIER", 77, 81], ["thermal flow", "OBSERVATION", 82, 94], ["weakened", "OBSERVATION", 98, 106]]], ["The tracer gas still goes up to the top of the building and the vertical coverage area is smaller than that in Case I1, while wider in horizontal direction.", [["Case I1", "CELL_LINE", 111, 118], ["The tracer gas", "TEST", 0, 14], ["tracer gas", "OBSERVATION", 4, 14], ["top", "OBSERVATION_MODIFIER", 36, 39], ["vertical", "OBSERVATION_MODIFIER", 64, 72], ["coverage", "OBSERVATION_MODIFIER", 73, 81], ["area", "OBSERVATION_MODIFIER", 82, 86], ["smaller", "OBSERVATION_MODIFIER", 90, 97], ["wider", "OBSERVATION_MODIFIER", 126, 131], ["horizontal", "OBSERVATION_MODIFIER", 135, 145]]], ["Part of tracer gas can cross the building roof moving to the downstream and the upper space on the leeward side is affected.", [["upper", "ORGANISM_SUBDIVISION", 80, 85], ["tracer gas", "TEST", 8, 18], ["tracer gas", "OBSERVATION", 8, 18], ["roof", "ANATOMY_MODIFIER", 42, 46], ["downstream", "ANATOMY_MODIFIER", 61, 71], ["upper space", "ANATOMY_MODIFIER", 80, 91], ["affected", "OBSERVATION", 115, 123]]], ["In Case I4, due to the low velocity along the windward wall, the tracer gas tends to spread in a small region around the source on the windward side.", [["windward wall", "ANATOMY", 46, 59], ["windward wall", "TISSUE", 46, 59], ["the low velocity along the windward wall", "PROBLEM", 19, 59], ["the tracer gas", "PROBLEM", 61, 75], ["low velocity", "OBSERVATION", 23, 35], ["wall", "ANATOMY_MODIFIER", 55, 59], ["tracer gas", "OBSERVATION", 65, 75], ["small", "OBSERVATION_MODIFIER", 97, 102], ["region", "OBSERVATION_MODIFIER", 103, 109], ["source", "OBSERVATION_MODIFIER", 121, 127]]], ["As the Ri number reduces to 2.5 in Case I7, the wind effect is dominant, the windward covered area seems like raindrop going downward because of the vertical downward airflow.", [["the vertical downward airflow", "PROBLEM", 145, 174], ["dominant", "OBSERVATION", 63, 71], ["raindrop", "OBSERVATION", 110, 118], ["vertical", "OBSERVATION_MODIFIER", 149, 157], ["downward", "OBSERVATION_MODIFIER", 158, 166], ["airflow", "OBSERVATION", 167, 174]]], ["The leeward space is affected, but slightly less than the former case.Airflow and tracer gas concentration distribution in close window modeWhen the source location is at the windward 18th floor, the tracer gas wouldn't disperse downward since the thermal plume and the airflow above the stagnation zone are both upward.", [["Airflow", "TEST", 70, 77], ["tracer gas concentration distribution", "TEST", 82, 119], ["the tracer gas", "TEST", 196, 210], ["the thermal plume", "TEST", 244, 261], ["leeward", "OBSERVATION_MODIFIER", 4, 11], ["space", "OBSERVATION", 12, 17], ["affected", "OBSERVATION_MODIFIER", 21, 29], ["slightly", "OBSERVATION_MODIFIER", 35, 43], ["less", "OBSERVATION_MODIFIER", 44, 48], ["tracer", "OBSERVATION", 82, 88], ["gas concentration", "OBSERVATION", 89, 106], ["thermal", "OBSERVATION_MODIFIER", 248, 255], ["plume", "OBSERVATION_MODIFIER", 256, 261], ["airflow", "OBSERVATION", 270, 277], ["stagnation", "OBSERVATION_MODIFIER", 288, 298], ["zone", "ANATOMY_MODIFIER", 299, 303], ["both", "OBSERVATION_MODIFIER", 308, 312], ["upward", "OBSERVATION_MODIFIER", 313, 319]]], ["The units on the leeward side are softly affected in Case I4.", [["softly affected", "PROBLEM", 34, 49], ["units", "OBSERVATION_MODIFIER", 4, 9], ["softly", "OBSERVATION", 34, 40]]], ["Overall, in the buoyancy lift governing cases (II-II3), the tracer gas mainly spreads from source unit to the upper ones on the windward side.", [["the tracer gas", "PROBLEM", 56, 70], ["upper", "ANATOMY_MODIFIER", 110, 115]]], ["In the two forces equivalent cases (II4), the tracer gas mainly disperses horizontally from windward side to leeward side.", [["the tracer gas", "TEST", 42, 56]]], ["In the wind force ruling cases (II5-II8), the tracer gas mainly moves from the source unit to the lower ones on the windward side.", [["the tracer gas", "TEST", 42, 56], ["lower", "ANATOMY_MODIFIER", 98, 103]]], ["Fig. 12 illustrates the tracer gas mass fraction distributions along the windward wall in each case of group II and group III.", [["windward wall", "ANATOMY", 73, 86], ["windward wall", "MULTI-TISSUE_STRUCTURE", 73, 86], ["the tracer gas mass fraction distributions", "PROBLEM", 20, 62], ["wall", "ANATOMY_MODIFIER", 82, 86]]], ["The overall tendency of group II is similar with that of group I, the close window mode.", [["overall", "OBSERVATION_MODIFIER", 4, 11], ["tendency", "OBSERVATION_MODIFIER", 12, 20], ["group II", "OBSERVATION_MODIFIER", 24, 32]]], ["In the windless case II1, the velocity of vertical upward flow adjacent to the wall increases with height.", [["wall", "ANATOMY", 79, 83], ["wall", "TISSUE", 79, 83], ["vertical upward flow", "PROBLEM", 42, 62], ["velocity", "OBSERVATION_MODIFIER", 30, 38], ["vertical", "OBSERVATION_MODIFIER", 42, 50], ["upward", "OBSERVATION_MODIFIER", 51, 57], ["flow", "OBSERVATION", 58, 62], ["wall", "ANATOMY_MODIFIER", 79, 83], ["increases", "OBSERVATION_MODIFIER", 84, 93], ["height", "OBSERVATION_MODIFIER", 99, 105]]], ["So compared with the source location at 2nd floor, the tracer gas releasing from the 10th floor moves upward faster and has a longer vertical coverage.", [["the tracer gas", "TEST", 51, 65], ["a longer vertical coverage", "TREATMENT", 124, 150]]], ["When the source is located at the 18th floor, the tracer gas covers a wider range at the horizontal direction in Case II7 where the wind force is ruling than that in II1 under buoyancy lift dominated condition.", [["the tracer gas", "TEST", 46, 60], ["buoyancy lift", "OBSERVATION", 176, 189]]], ["In group III, the temperature difference is 3.5 K. Under the same breeze condition, the vertical upward transmission in Case III1 is weaker than Case II1 due to the smaller thermal plume.", [["Case III1", "CELL_LINE", 120, 129], ["Case II1", "CELL_LINE", 145, 153], ["the temperature difference", "TEST", 14, 40], ["the smaller thermal plume", "PROBLEM", 161, 186], ["smaller", "OBSERVATION_MODIFIER", 165, 172], ["thermal", "OBSERVATION_MODIFIER", 173, 180], ["plume", "OBSERVATION", 181, 186]]], ["In Case III5 and III7, the Ri number is less than 7, the wind force is predominant.", [["Ri", "DNA", 27, 29], ["predominant", "OBSERVATION_MODIFIER", 71, 82]]], ["With the source releasing from the 10th floor, the shape of tracer gas coverage is like raindrop as mentioned above and the breadth of the raindrop decreases from Case III5 to III7, while the raindrop length increases.", [["raindrop", "DISEASE", 139, 147], ["tracer gas coverage", "TREATMENT", 60, 79], ["shape", "OBSERVATION_MODIFIER", 51, 56], ["tracer gas", "OBSERVATION", 60, 70], ["breadth", "OBSERVATION_MODIFIER", 124, 131], ["raindrop", "OBSERVATION_MODIFIER", 139, 147], ["decreases", "OBSERVATION_MODIFIER", 148, 157], ["length", "OBSERVATION_MODIFIER", 201, 207]]], ["The reason is the growing downward airflow speed below the stagnation zone.Tracer gas concentration distribution in open window modeFor each room in the objective building, open window mode means single-sided natural ventilation.", [["the growing downward airflow speed", "PROBLEM", 14, 48], ["Tracer gas", "TEST", 75, 85], ["open window mode", "TREATMENT", 116, 132], ["open window mode means", "TREATMENT", 173, 195], ["single-sided natural ventilation", "TREATMENT", 196, 228], ["growing", "OBSERVATION_MODIFIER", 18, 25], ["downward", "OBSERVATION_MODIFIER", 26, 34], ["airflow", "OBSERVATION", 35, 42], ["stagnation", "OBSERVATION_MODIFIER", 59, 69], ["zone", "OBSERVATION_MODIFIER", 70, 74], ["open window", "OBSERVATION", 116, 127], ["natural ventilation", "OBSERVATION", 209, 228]]], ["There's inside/outside heat transfer and air exchange through openings, resulting in inter-flat transmission.", [["air exchange", "TREATMENT", 41, 53], ["air exchange", "OBSERVATION", 41, 53]]], ["The mean indoor air temperature in each room of group II is shown in Fig. 13 .", [["The mean indoor air temperature", "TEST", 0, 31]]], ["Since the heat conduction from the building envelope is neglected in the simulation, the indoor air temperature can be slightly underestimated.", [["the heat conduction", "PROBLEM", 6, 25], ["the indoor air temperature", "TEST", 85, 111], ["slightly", "OBSERVATION_MODIFIER", 119, 127], ["underestimated", "OBSERVATION", 128, 142]]], ["One common thing can be observed from the profiles that for two neighbor flats, the mean indoor air temperature in the upper one is higher than that in the lower one.", [["the mean indoor air temperature", "TEST", 80, 111], ["upper", "ANATOMY_MODIFIER", 119, 124], ["higher", "OBSERVATION", 132, 138], ["lower", "ANATOMY_MODIFIER", 156, 161]]], ["Class one contains three cases under the condition when the approaching wind speed is in the range of 0.4 m/s -0.8 m/s and the buoyant lift dominates the near wall airflow.", [["wall", "ANATOMY", 159, 163], ["wall", "TISSUE", 159, 163], ["buoyant", "OBSERVATION_MODIFIER", 127, 134], ["lift", "OBSERVATION", 135, 139], ["wall", "ANATOMY_MODIFIER", 159, 163], ["airflow", "OBSERVATION", 164, 171]]], ["In this class, the mean indoor air temperature in the concerned room increases with height, which should contribute to a stronger thermal plume at a higher height.", [["the mean indoor air temperature", "TEST", 15, 46], ["a stronger thermal plume", "PROBLEM", 119, 143], ["stronger", "OBSERVATION_MODIFIER", 121, 129], ["thermal", "OBSERVATION_MODIFIER", 130, 137], ["plume", "OBSERVATION", 138, 143]]], ["For a certain flat, the temperature level increases with Ri number.", [["the temperature level", "TEST", 20, 41]]], ["The reason is that a higher approaching wind can take away more heat by convection, so less heat enters in the room, resulting in a relatively lower indoor temperature.", [["a relatively lower indoor temperature", "PROBLEM", 130, 167]]], ["The slope from 3rd to 10th floor is negative, while from 11th to 18th floor is positive.", [["The slope", "TEST", 0, 9], ["positive", "PROBLEM", 79, 87], ["negative", "OBSERVATION", 36, 44], ["positive", "OBSERVATION", 79, 87]]], ["The reason might be that the thermal flow is suppressed below the stagnation zone, whereas it still exists at the higher region.", [["the thermal flow", "PROBLEM", 25, 41], ["thermal", "OBSERVATION_MODIFIER", 29, 36], ["flow", "OBSERVATION", 37, 41], ["stagnation", "OBSERVATION_MODIFIER", 66, 76], ["zone", "OBSERVATION_MODIFIER", 77, 81], ["higher", "ANATOMY_MODIFIER", 114, 120], ["region", "ANATOMY_MODIFIER", 121, 127]]], ["The slopes of both 3rd \u2192 10th and 11th \u2192 18th are negative.", [["slopes", "OBSERVATION_MODIFIER", 4, 10], ["negative", "OBSERVATION", 50, 58]]], ["Since the downward airflow is strong at the lower half part of the building height, the wall heat also transfers downward.", [["wall", "ANATOMY", 88, 92], ["the downward airflow", "PROBLEM", 6, 26], ["the wall heat", "PROBLEM", 84, 97], ["downward", "OBSERVATION_MODIFIER", 10, 18], ["airflow", "OBSERVATION", 19, 26], ["strong", "OBSERVATION_MODIFIER", 30, 36], ["lower", "ANATOMY_MODIFIER", 44, 49], ["wall", "ANATOMY_MODIFIER", 88, 92], ["downward", "OBSERVATION_MODIFIER", 113, 121]]], ["In general, the indoor/ambient air temperature difference is in the range of 2 Ke6 K. The ACH (air exchange rate) is calculated by an integral method [62] , see Eq.", [["ACH", "CHEMICAL", 90, 93], ["the indoor/ambient air temperature difference", "PROBLEM", 12, 57], ["The ACH (air exchange rate", "TEST", 86, 112]]], ["(11),Tracer gas concentration distribution in open window modewhere the U x is the velocity normal to the window, m/s, A represents the window area, m 2 and Vol is the room volume, m 3 .", [["Tracer gas concentration distribution", "TEST", 5, 42], ["the velocity", "TEST", 79, 91], ["open window", "OBSERVATION", 46, 57], ["velocity", "OBSERVATION_MODIFIER", 83, 91], ["normal", "OBSERVATION", 92, 98]]], ["Since the airflow from outside is likely to form a small circuit at the opening window and the effective depth of fresh air is limited, the calculation result by this method is considered to be slightly higher than the tracer gas decay method, but the value is testified very close to the empirical models [25] .", [["a small circuit", "TREATMENT", 49, 64], ["the tracer gas", "TEST", 215, 229], ["the value", "TEST", 248, 257], ["airflow", "OBSERVATION", 10, 17], ["likely to", "UNCERTAINTY", 34, 43], ["small", "OBSERVATION_MODIFIER", 51, 56], ["circuit", "OBSERVATION", 57, 64], ["effective", "OBSERVATION_MODIFIER", 95, 104], ["depth", "OBSERVATION_MODIFIER", 105, 110], ["fresh air", "OBSERVATION", 114, 123], ["slightly", "OBSERVATION_MODIFIER", 194, 202], ["higher", "OBSERVATION_MODIFIER", 203, 209]]], ["The ACH values of six concerned units in different cases are listed in Fig. 14.", [["The ACH values", "TEST", 0, 14]]], ["In general, the ACH values change in a big range of 0.5-10.", [["the ACH values", "TEST", 12, 26]]], ["When the Ri numbers are approximate, the ACH values in group II are mostly higher than those in group III.", [["Ri", "DNA", 9, 11], ["the Ri numbers", "TEST", 5, 19], ["the ACH values", "TEST", 37, 51], ["mostly", "OBSERVATION_MODIFIER", 68, 74], ["higher", "OBSERVATION_MODIFIER", 75, 81]]], ["Take Case II4 (U ref = 1.0 m/s, \u0394T=13 K, Ri = 25.1) and III2 (U ref = 0.5 m/s, \u0394T=3.5 K, Ri = 27.5) as an example, the Ri numbers in these two cases are very close, while the ACH value in the former case is 1.5-2.0 times that of in the latter case for the same room.", [["\u0394T", "TEST", 32, 34], ["K", "TEST", 38, 39], ["Ri", "TEST", 41, 43], ["\u0394T", "TEST", 79, 81], ["K", "TEST", 86, 87], ["Ri", "TEST", 89, 91], ["the ACH value", "TEST", 171, 184]]], ["The temperature difference between the outer windward wall and the ambient in Case II4 is higher than in Case III2, so the thermal plume in Case II4 is stronger.", [["outer windward wall", "ANATOMY", 39, 58], ["windward wall", "MULTI-TISSUE_STRUCTURE", 45, 58], ["Case III2", "CELL_LINE", 105, 114], ["Case II4", "CELL_LINE", 140, 148], ["The temperature difference", "PROBLEM", 0, 26], ["temperature", "OBSERVATION_MODIFIER", 4, 15], ["difference", "OBSERVATION_MODIFIER", 16, 26], ["outer", "ANATOMY_MODIFIER", 39, 44], ["wall", "ANATOMY_MODIFIER", 54, 58], ["ambient", "OBSERVATION_MODIFIER", 67, 74], ["higher", "OBSERVATION_MODIFIER", 90, 96]]], ["These phenomena also appear in other corresponding conditions, such as Case II5 and Case III3, Case II6 and Case III4.", [["Case II5", "GENE_OR_GENE_PRODUCT", 71, 79], ["Case III3", "GENE_OR_GENE_PRODUCT", 84, 93], ["Case II6", "GENE_OR_GENE_PRODUCT", 95, 103], ["Case III4", "GENE_OR_GENE_PRODUCT", 108, 117], ["Case III3", "CELL_LINE", 84, 93], ["Case II6", "CELL_LINE", 95, 103], ["Case III4", "CELL_LINE", 108, 117], ["These phenomena", "PROBLEM", 0, 15], ["phenomena", "OBSERVATION", 6, 15]]], ["This might be concluded that under the coupling effect of wind force and buoyancy lift, the relative magnitude of wind and thermal plume is quite crucial for ACH value of the room.", [["wind force and buoyancy lift", "TREATMENT", 58, 86]]], ["Another thing can be found from Fig. 14 is that in the wind force predominant cases when Ri < 5 (II7, II8, III7, III8, Ref1, Ref2), the ACH values are lower than those in the buoyancy lift governing conditions or the two forces equivalent cases (II1-II4 and III1-III3), except for the 19th floor.Tracer gas concentration distribution in open window modeTo evaluate the potential inter-flat pollutant transmission, the quantifying method proposed by Niu and Tung [23] is used for analyzing the possibility of reentry.", [["Ref1", "DNA", 119, 123], ["Ref2", "DNA", 125, 129], ["Ri", "TEST", 89, 91], ["the ACH values", "TEST", 132, 146], ["Tracer gas", "TEST", 296, 306], ["open window mode", "TREATMENT", 337, 353], ["open window", "OBSERVATION", 337, 348], ["reentry", "OBSERVATION", 508, 515]]], ["The reentry ratio, R, is defined as the fraction of the exhaust air from a source unit i which reenters another unit j, which can be calculated by Eq.", [["The reentry ratio", "TEST", 0, 17], ["reentry", "OBSERVATION_MODIFIER", 4, 11], ["ratio", "OBSERVATION_MODIFIER", 12, 17], ["exhaust air", "OBSERVATION", 56, 67]]], ["(13):Tracer gas concentration distribution in open window modeM i-j represents the mass fraction of air that originates from the source room i and is present in another room j.", [["Tracer gas concentration distribution", "PROBLEM", 5, 42], ["the mass fraction of air", "PROBLEM", 79, 103], ["mass", "OBSERVATION", 83, 87], ["air", "OBSERVATION", 100, 103]]], ["In the present work, the pollutant concentration in a unit is represented by the mean II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7 II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7 II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7 concentration on the plane at the height of 1.6 m above the floor (human respiration plane), which is near the source height.", [["pollutant", "CHEMICAL", 25, 34], ["II1 II2", "CHEMICAL", 86, 93], ["II3 II4", "CHEMICAL", 94, 101], ["II5", "CHEMICAL", 102, 105], ["II6", "CHEMICAL", 106, 109], ["II7", "CHEMICAL", 110, 113], ["II8 III1 III2 III3 III4 III5 III6 III7 II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3", "CHEMICAL", 114, 199], ["III6 III7", "CHEMICAL", 277, 286], ["II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7 II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7 II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7", "CHEMICAL", 86, 286], ["II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7 II1 II2 II3 II4 II5 II6 II7 II8 III1 III2 III3 III4 III5 III6 III7 II1 II2 II3 II4", "SIMPLE_CHEMICAL", 86, 235], ["human", "ORGANISM", 354, 359], ["human", "SPECIES", 354, 359], ["human", "SPECIES", 354, 359], ["source height", "OBSERVATION", 398, 411]]], ["M i-j can be directly calculated from the predicted average concentration values of the tracer gas on the two corresponding planes, M i-j = C j /C i .", [["the tracer gas", "TEST", 84, 98], ["tracer gas", "OBSERVATION", 88, 98]]], ["The calculated reentry ratios are shown in Fig. 15 .", [["The calculated reentry ratios", "TEST", 0, 29], ["reentry ratios", "OBSERVATION", 15, 29]]], ["The six grid boxes along a column represent six concerned rooms in the objective building.", [["The six grid boxes", "TREATMENT", 0, 18]]], ["The color of the grid box indicates the magnitude of the reentry ratio in this room.", [["the grid box", "TEST", 13, 25], ["color", "OBSERVATION_MODIFIER", 4, 9], ["grid box", "OBSERVATION", 17, 25], ["magnitude", "OBSERVATION_MODIFIER", 40, 49], ["reentry ratio", "OBSERVATION", 57, 70]]], ["A high reentry ratio means a high cross contamination risk.", [["A high reentry ratio", "PROBLEM", 0, 20], ["a high cross contamination risk", "PROBLEM", 27, 58], ["high", "OBSERVATION_MODIFIER", 2, 6], ["reentry", "OBSERVATION_MODIFIER", 7, 14], ["high cross contamination", "OBSERVATION_MODIFIER", 29, 53]]], ["Only the infected units are discussed according to the figure.", [["the infected units", "TREATMENT", 5, 23], ["infected", "OBSERVATION", 9, 17]]], ["When the source is located at the windward 2nd floor, the 3rd floor is the most vulnerable.", [["3rd floor", "ANATOMY", 58, 67]]], ["The reentry ratios for the third floor are almost or above 20% when the buoyancy force is stronger (Case II1 -Case II3 and Case III1), and then reduces to near or below 10% when the two forces are approximately equal at lower height (Case II4, CaseIII2 and Case III3).", [["CaseIII2", "PROTEIN", 244, 252], ["Case III3", "PROTEIN", 257, 266], ["The reentry ratios", "TEST", 0, 18], ["reentry", "OBSERVATION_MODIFIER", 4, 11], ["ratios", "OBSERVATION_MODIFIER", 12, 18]]], ["In Case II1, Ri = 156.9, the reentry ratios for the middle units, the 10th and 11th floors, are around 1%, and the magnitude for the upper units are 0.1%.", [["Ri", "TEST", 13, 15], ["the reentry ratios", "TEST", 25, 43], ["middle", "ANATOMY_MODIFIER", 52, 58], ["upper", "ANATOMY_MODIFIER", 133, 138]]], ["When the Ri is 69.7, the reentry ratios for the middle units are in a range of 0.1%-0.2%, and for the upper units are at a magnitude of 0.01%.", [["the Ri", "TEST", 5, 11], ["the reentry ratios", "TEST", 21, 39], ["middle", "ANATOMY_MODIFIER", 48, 54], ["upper units", "OBSERVATION_MODIFIER", 102, 113]]], ["When the Ri decreases to 42.9, the reentry ratios for the middle units are below 0.1%.", [["Ri", "DNA", 9, 11], ["the Ri", "TEST", 5, 11], ["the reentry ratios", "TEST", 31, 49], ["middle", "ANATOMY_MODIFIER", 58, 64]]], ["In the isothermal cases, the tracer gas cannot go upward.Tracer gas concentration distribution in open window modeWhen the source is released from the 10th floor, the reentry ratios for the 11th floor are over 20% once the Ri numbers exceed 25.", [["the tracer gas", "TEST", 25, 39], ["Tracer gas concentration distribution", "PROBLEM", 57, 94], ["the Ri numbers", "TEST", 219, 233], ["concentration", "OBSERVATION_MODIFIER", 68, 81], ["distribution", "OBSERVATION_MODIFIER", 82, 94], ["open window", "OBSERVATION", 98, 109]]], ["As to the lower units, the affected risk exists when the Ri numbers are below 20, and the reentry ratios are generally below 0.5%.", [["the Ri numbers", "TEST", 53, 67], ["the reentry ratios", "TEST", 86, 104]]], ["In two isothermal cases, the values of R for the bottom two floors are close to ones in the wind effect dominated cases, II7, II8, III7 and III8.", [["the values", "TEST", 25, 35]]], ["For the upper two units, the reentry ratios are around 1% in Case II1 -Case II3 and Case III1 when Ri > 39, while it is around 0.2% in Case III2 when Ri = 27.5.Tracer gas concentration distribution in open window modeAnd the values are below 0.05% in Case II4 and Case III3.", [["Case III3", "GENE_OR_GENE_PRODUCT", 264, 273], ["the reentry ratios", "TEST", 25, 43], ["Ri", "TEST", 99, 101], ["Ri", "TEST", 150, 152], ["Tracer gas", "TEST", 160, 170], ["open window mode", "TREATMENT", 201, 217], ["the values", "TEST", 221, 231], ["open window", "OBSERVATION", 201, 212]]], ["Comparison work has been done between the present work and anterior study by Gao [25] .", [["anterior study", "TEST", 59, 73]]], ["In the previous numerical simulation of cascade effect, the indoor/outdoor temperature difference was 5 K, and the ACH values were both 10.08 in the two concerned rooms under windless condition.", [["the indoor/outdoor temperature difference", "TEST", 56, 97], ["K", "TEST", 104, 105], ["the ACH values", "TEST", 111, 125], ["cascade effect", "OBSERVATION", 40, 54]]], ["The pollutant was generated by a point source in the room with a constant mass flow rate of 8 mg/s.", [["a constant mass flow rate", "TREATMENT", 63, 88], ["mass", "OBSERVATION", 74, 78]]], ["It was found that in a windless day, around 7.5% of the exhaust air from lower unit can re-enter into the upper one, while it's around 25% in the present work.", [["exhaust air", "OBSERVATION", 56, 67], ["lower unit", "OBSERVATION_MODIFIER", 73, 83], ["upper one", "ANATOMY_MODIFIER", 106, 115]]], ["Different mechanisms can be one of the main reasons for the differences on reentry ratio values.", [["reentry ratio values", "TEST", 75, 95]]], ["In the indoor/outdoor temperature difference driven mode, cold flow enters from the lower part of the window and thermal flow exits from the upper part.", [["upper", "ORGANISM_SUBDIVISION", 141, 146], ["cold flow", "TEST", 58, 67], ["cold flow", "OBSERVATION", 58, 67], ["lower", "ANATOMY_MODIFIER", 84, 89], ["window", "OBSERVATION", 102, 108], ["thermal", "OBSERVATION_MODIFIER", 113, 120], ["flow", "OBSERVATION", 121, 125], ["upper part", "ANATOMY_MODIFIER", 141, 151]]], ["The outflow from indoor will not go upward exactly along the wall but have a certain distance with the wall.", [["wall", "ANATOMY", 61, 65], ["wall", "ANATOMY", 103, 107], ["wall", "TISSUE", 61, 65], ["wall", "TISSUE", 103, 107], ["outflow", "ANATOMY_MODIFIER", 4, 11], ["wall", "ANATOMY_MODIFIER", 61, 65], ["wall", "ANATOMY_MODIFIER", 103, 107]]], ["In the present study, the upward thermal plume is adhering to the wall, so the tracer gas moving with airflow is easier brought into the upper floor, causing a higher reentry ratio.", [["wall", "ANATOMY", 66, 70], ["wall", "TISSUE", 66, 70], ["upper floor", "ORGANISM_SUBDIVISION", 137, 148], ["the present study", "TEST", 3, 20], ["the upward thermal plume", "PROBLEM", 22, 46], ["the tracer gas", "TEST", 75, 89], ["a higher reentry ratio", "PROBLEM", 158, 180], ["upward", "OBSERVATION_MODIFIER", 26, 32], ["thermal", "OBSERVATION_MODIFIER", 33, 40], ["plume", "OBSERVATION", 41, 46], ["wall", "ANATOMY_MODIFIER", 66, 70], ["tracer gas", "OBSERVATION", 79, 89], ["upper floor", "ANATOMY", 137, 148], ["higher", "OBSERVATION_MODIFIER", 160, 166], ["reentry ratio", "OBSERVATION", 167, 180]]], ["Besides, the source locations and sampling methods of mean concentration may also have influences on the different values of reentry ratio.Tracer gas concentration distribution in open window modeWhen the source location is at the 18th unit, only the 19th floor among the concerned rooms is influenced.", [["mean concentration", "PROBLEM", 54, 72], ["reentry ratio", "TEST", 125, 138], ["Tracer gas concentration distribution", "PROBLEM", 139, 176], ["concentration", "OBSERVATION_MODIFIER", 150, 163], ["distribution", "OBSERVATION_MODIFIER", 164, 176], ["open window", "OBSERVATION", 180, 191]]], ["The reentry ratios are all over 20%, especially when Ri numbers are below 1, the R values can be up to 30% or even 40%.", [["The reentry ratios", "TEST", 0, 18], ["Ri numbers", "TEST", 53, 63], ["the R values", "TEST", 77, 89], ["reentry", "OBSERVATION_MODIFIER", 4, 11], ["ratios", "OBSERVATION_MODIFIER", 12, 18], ["all", "OBSERVATION_MODIFIER", 23, 26]]], ["One thing should be noticed that, for two isothermal cases, both of the reentry ratios exceed 50%, more than twice those of buoyancy lift ruling cases (II1-II3, III1-III2).", [["the reentry ratios", "TEST", 68, 86], ["II1", "TEST", 152, 155]]], ["Compared with the buoyancy force dominant cases, the ACH values in the isothermal cases are much smaller, which means the tracer gas is easier to stay in the source room rather than exhaust to another room.", [["the ACH values", "TEST", 49, 63], ["much", "OBSERVATION_MODIFIER", 92, 96], ["smaller", "OBSERVATION_MODIFIER", 97, 104]]], ["So the specific values M i-j are lower in the isothermal modes.", [["lower", "OBSERVATION_MODIFIER", 33, 38]]], ["(13), the reentry ratio is closely related to the concentration ratio and air exchange rate ratio of two units.", [["the reentry ratio", "TEST", 6, 23], ["the concentration ratio", "TEST", 46, 69], ["air exchange rate ratio", "TEST", 74, 97]]], ["In Case I1, the concentration ratio between 19th and 18th is about 1/5 while the ACH ratio is almost 1.", [["Case I1", "GENE_OR_GENE_PRODUCT", 3, 10], ["ACH", "SIMPLE_CHEMICAL", 81, 84], ["the concentration ratio", "TEST", 12, 35], ["the ACH ratio", "TEST", 77, 90]]], ["Thus the reentry ratio is close to 20%.", [["the reentry ratio", "TEST", 5, 22], ["reentry", "OBSERVATION_MODIFIER", 9, 16], ["ratio", "OBSERVATION_MODIFIER", 17, 22]]], ["In Case Ref1, the concentration ratio between 19th and 18th is about 1/8 while the ACH ratio is approximate 4.", [["ACH", "SIMPLE_CHEMICAL", 83, 86], ["the concentration ratio", "TEST", 14, 37], ["the ACH ratio", "TEST", 79, 92]]], ["So the reentry ratio is up to 50%.", [["the reentry ratio", "TEST", 3, 20], ["reentry", "OBSERVATION_MODIFIER", 7, 14], ["ratio", "OBSERVATION_MODIFIER", 15, 20]]], ["Similarity rules can be found between isothermal cases and combined wind and buoyancy effects forces cases.", [["buoyancy effects forces cases", "PROBLEM", 77, 106]]], ["In general, the upstairs residents should pay more attention to the intervention measures on the control of contamination risk.ConclusionsConcerning the inter-flat pollutant transmission phenomenon, the impact of solar radiation has not been taken into account before.", [["the intervention measures", "TREATMENT", 64, 89], ["the inter-flat pollutant transmission phenomenon", "PROBLEM", 149, 197], ["solar radiation", "TREATMENT", 213, 228], ["pollutant", "OBSERVATION_MODIFIER", 164, 173], ["transmission phenomenon", "OBSERVATION", 174, 197]]], ["The present work pays attention to this factor, and also the coupling effect of approaching wind and near wall thermal plume originating from solar radiation.", [["near wall thermal plume", "TREATMENT", 101, 124], ["solar radiation", "TREATMENT", 142, 157], ["wall", "ANATOMY_MODIFIER", 106, 110], ["thermal", "OBSERVATION_MODIFIER", 111, 118], ["plume", "OBSERVATION_MODIFIER", 119, 124], ["solar radiation", "OBSERVATION", 142, 157]]], ["The different influences between the sunward surface and shady side surface are compared.", [["sunward surface", "ANATOMY", 37, 52], ["side surface", "ANATOMY", 63, 75], ["different", "OBSERVATION_MODIFIER", 4, 13], ["sunward", "OBSERVATION_MODIFIER", 37, 44], ["surface", "OBSERVATION_MODIFIER", 45, 52], ["shady", "OBSERVATION_MODIFIER", 57, 62], ["side", "OBSERVATION_MODIFIER", 63, 67], ["surface", "OBSERVATION_MODIFIER", 68, 75]]], ["Richardson number is adopted to represent the combined effect of buoyancy lift and wind.", [["buoyancy lift", "OBSERVATION", 65, 78]]], ["The pollutant dispersion routes on the windward side under different Ri number cases are analysed.", [["The pollutant dispersion", "TREATMENT", 0, 24], ["pollutant", "OBSERVATION_MODIFIER", 4, 13], ["dispersion", "OBSERVATION_MODIFIER", 14, 24]]], ["For a 58 m high building at noon of a typical day of transition season in Shanghai, the near wall thermal plume speed at the building height is up to 1.2 m/s.", [["wall", "ANATOMY_MODIFIER", 93, 97], ["plume", "OBSERVATION_MODIFIER", 106, 111]]], ["The following conclusions can be obtained:Conclusions(1) In a gentle breezy day, the tracer gas can spread vertically upward driven by thermal flow, from bottom to top in a high-rise building.", [["the tracer gas", "TEST", 81, 95]]], ["The reentry ratio of the flat immediately above the source is around 25%.", [["The reentry ratio", "TEST", 0, 17], ["reentry", "OBSERVATION_MODIFIER", 4, 11], ["ratio", "OBSERVATION_MODIFIER", 12, 17], ["flat", "OBSERVATION_MODIFIER", 25, 29]]], ["However, for the isothermal condition, the vertically upward transmission is only possible above the stagnation zone, and the reentry ratio can be up to more than 50%.", [["the isothermal condition", "PROBLEM", 13, 37], ["the reentry ratio", "TEST", 122, 139], ["only possible", "UNCERTAINTY", 77, 90], ["stagnation", "OBSERVATION_MODIFIER", 101, 111], ["zone", "OBSERVATION_MODIFIER", 112, 116], ["reentry", "OBSERVATION_MODIFIER", 126, 133]]], ["For source location below the stagnation zone conditions, the pollutants disperse from the middle of the building to bottom with the downward flow in the isothermal cases.", [["the pollutants", "TREATMENT", 58, 72], ["middle", "ANATOMY_MODIFIER", 91, 97], ["downward", "OBSERVATION_MODIFIER", 133, 141], ["flow", "OBSERVATION", 142, 146]]], ["(2) As to the comparisons between the sunward and shady side, both of two surfaces are placed at the windward side.", [["the sunward and shady side", "TREATMENT", 34, 60], ["surfaces", "OBSERVATION_MODIFIER", 74, 82]]], ["Take the gentle breeze cases as contrast objects, the results show that when the source is released from the bottom flat of the building, the vertical upward coverage length of tracer gas on the shady side surface is nearly half of that on the sunward surface.", [["side surface", "ANATOMY", 201, 213], ["sunward surface", "ANATOMY", 244, 259], ["sunward surface", "CELLULAR_COMPONENT", 244, 259], ["the gentle breeze cases", "TREATMENT", 5, 28], ["tracer gas", "TEST", 177, 187], ["vertical", "OBSERVATION_MODIFIER", 142, 150], ["upward", "OBSERVATION_MODIFIER", 151, 157], ["coverage", "OBSERVATION_MODIFIER", 158, 166], ["length", "OBSERVATION_MODIFIER", 167, 173], ["tracer gas", "OBSERVATION", 177, 187], ["nearly", "OBSERVATION_MODIFIER", 217, 223], ["half", "OBSERVATION_MODIFIER", 224, 228]]], ["Both of the reentry ratio values of the flat immediately above the source are almost 20%.", [["the reentry ratio values", "TEST", 8, 32], ["reentry", "OBSERVATION_MODIFIER", 12, 19], ["ratio", "OBSERVATION_MODIFIER", 20, 25], ["values", "OBSERVATION_MODIFIER", 26, 32], ["flat", "OBSERVATION_MODIFIER", 40, 44]]], ["(3) In terms of the combined effect of wind and buoyancy forces, multiple cases are set for relevant analysis and investigation.", [["wind and buoyancy forces", "TREATMENT", 39, 63], ["relevant analysis", "TEST", 92, 109], ["investigation", "TEST", 114, 127], ["buoyancy forces", "OBSERVATION", 48, 63]]], ["When the source location is above the stagnation zone, the pollutant always goes up with the rising airflow.", [["the rising airflow", "PROBLEM", 89, 107], ["stagnation", "OBSERVATION", 38, 48], ["pollutant", "OBSERVATION_MODIFIER", 59, 68], ["rising", "OBSERVATION_MODIFIER", 93, 99], ["airflow", "OBSERVATION", 100, 107]]], ["Under the conditions of the source location below the stagnation zone, as the Ri number decreases, the effect of force convection strengthens, so the pollutant spread from lower floor to upper ones is weakened.", [["lower floor", "ORGANISM_SUBDIVISION", 172, 183], ["force convection strengthens", "TREATMENT", 113, 141], ["the pollutant spread", "PROBLEM", 146, 166], ["stagnation", "OBSERVATION_MODIFIER", 54, 64], ["zone", "OBSERVATION_MODIFIER", 65, 69], ["Ri", "OBSERVATION_MODIFIER", 78, 80], ["number", "OBSERVATION_MODIFIER", 81, 87], ["decreases", "OBSERVATION_MODIFIER", 88, 97], ["upper", "ANATOMY_MODIFIER", 187, 192], ["weakened", "OBSERVATION", 201, 209]]], ["As the source located at the 2nd floor, the vertical upgrade transmission is suppressed once Ri is lower than 40.", [["Ri", "DNA", 93, 95], ["vertical", "OBSERVATION_MODIFIER", 44, 52]]], ["When the source is released from the 10th floor, the vertical upward transmission is restrained once Ri is smaller than 20.ConclusionsOverall, the vertical upward transmission driven by wall thermal plume and the affected risks of leeward units from a windward source should not be overlooked in a high-rise building.", [["wall", "ANATOMY", 186, 190], ["Ri", "DNA", 101, 103], ["the vertical upward transmission", "TREATMENT", 49, 81], ["the vertical upward transmission", "PROBLEM", 143, 175], ["wall thermal plume", "PROBLEM", 186, 204], ["leeward units", "TREATMENT", 231, 244], ["a windward source", "PROBLEM", 250, 267], ["smaller", "OBSERVATION_MODIFIER", 107, 114], ["vertical", "OBSERVATION_MODIFIER", 147, 155], ["upward", "OBSERVATION_MODIFIER", 156, 162], ["wall", "OBSERVATION_MODIFIER", 186, 190], ["thermal plume", "OBSERVATION", 191, 204]]], ["There are still many limitations in the present study.", [["the present study", "TEST", 36, 53]]], ["The airflow patterns around an isolated building under different meteorological conditions are diverse.", [["The airflow patterns", "PROBLEM", 0, 20], ["airflow", "OBSERVATION", 4, 11], ["isolated", "OBSERVATION_MODIFIER", 31, 39], ["different", "OBSERVATION_MODIFIER", 55, 64], ["meteorological conditions", "OBSERVATION", 65, 90], ["diverse", "OBSERVATION_MODIFIER", 95, 102]]], ["The direction of approaching wind has been proved as one of the main influencing factors, which is not considered in this paper.", [["not considered", "UNCERTAINTY", 99, 113]]], ["Besides, the near wall flow features are distinct in daylight and night, also in different seasons.", [["wall", "ANATOMY", 18, 22], ["wall", "ANATOMY_MODIFIER", 18, 22], ["flow", "OBSERVATION", 23, 27], ["distinct", "OBSERVATION_MODIFIER", 41, 49]]], ["In addition, the calculations in this paper are based on steady-state simulations without considering the effect of time-dependent dynamics on heat and mass transfer.", [["heat and mass transfer", "TREATMENT", 143, 165], ["mass", "OBSERVATION", 152, 156]]], ["The selection of more applicable dimensionless numbers can be another issue, since a global Ri number has limitations to reflect a local pollutant dispersion phenomenon for a large scale problem, such as in the high-rise building.", [["a local pollutant dispersion phenomenon", "TREATMENT", 129, 168], ["a large scale problem", "PROBLEM", 173, 194], ["pollutant dispersion", "OBSERVATION", 137, 157], ["large", "OBSERVATION_MODIFIER", 175, 180], ["scale", "OBSERVATION_MODIFIER", 181, 186]]], ["Further investigations are worthy to be done on the above matters.", [["Further investigations", "TEST", 0, 22]]]], "c96f4ad600e103612c06f384622d847d8bc6e8ac": [["The agenda identified 17 Sustainable Development Goals (SDGs) and 169 targets intended to catalyse \"peace and prosperity for people and the planet\".", [["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131]]], ["Substantial effort has been made to quantify the progress towards meeting the targets set in SDG3.", [["SDG3", "GENE_OR_GENE_PRODUCT", 93, 97], ["SDG3", "PROTEIN", 93, 97]]], ["1,2 Examples include WHO's Thirteenth General Programme of Work, which provides a framework for tracking progress towards the health-related SDGs and research done by the Global Burden of Diseases, Injuries, and Risk Factors study (GBD) Collaborator Network, while less research has focused on tracking spending on SDG priority areas, especially how they relate to specific SDG3 indicators.", [["Injuries", "DISEASE", 198, 206], ["SDG3", "GENE_OR_GENE_PRODUCT", 374, 378], ["SDG3", "PROTEIN", 374, 378], ["Injuries", "PROBLEM", 198, 206], ["Diseases", "OBSERVATION", 188, 196]]], ["3 Tracking financial resources for SDG3 priority areas is crucial for two distinct reasons.", [["SDG3 priority areas", "TREATMENT", 35, 54]]], ["First, any For SDG3 specifically, the Third Edition of the Disease Control Priorities in Developing Countries assessed financial needs for universal health coverage, while researchers at the Institute of Health Metrics and Evaluation have estimated funding gaps to achieve universal health coverage.", [["the Disease Control Priorities", "PROBLEM", 55, 85], ["universal health coverage", "TREATMENT", 139, 164], ["Evaluation", "TEST", 223, 233], ["estimated funding gaps", "PROBLEM", 239, 261], ["universal health coverage", "TREATMENT", 273, 298]]], ["The Department of Health Systems Governance and Financing at WHO has also projected resource needs to finance transformative health systems towards achievement of SDG3.", [["SDG3", "GENE_OR_GENE_PRODUCT", 163, 167], ["SDG3", "PROTEIN", 163, 167], ["SDG3", "PROBLEM", 163, 167]]], ["Beyond estimated financing targets, needs, and gaps, only four of 27 SDG3 indicators have estimates of past or current total spending.", [["gaps", "TEST", 47, 51]]], ["These financial estimates are not directly comparable due to differences in study designs, scopes, and completeness.Added value of this studyThis study is the first to our knowledge, that assesses spending on and explores the association with health gains for key SDG3 targets related to HIV/AIDS (3.3.1), tuberculosis (3.3 .2), malaria (3.3.3) , universal health coverage (3.8.1), financial risk protection (3.8 .2), and development assistance for health (DAH; 3.b.2).", [["HIV/AIDS", "DISEASE", 288, 296], ["tuberculosis", "DISEASE", 306, 318], ["malaria", "DISEASE", 329, 336], ["SDG3", "GENE_OR_GENE_PRODUCT", 264, 268], ["HIV", "ORGANISM", 288, 291], ["HIV", "SPECIES", 288, 291], ["HIV", "SPECIES", 288, 291], ["scopes", "TEST", 91, 97], ["this study", "TEST", 131, 141], ["This study", "TEST", 141, 151], ["key SDG3 targets", "PROBLEM", 260, 276], ["HIV/AIDS", "PROBLEM", 288, 296], ["tuberculosis", "PROBLEM", 306, 318], ["malaria", "PROBLEM", 329, 336], ["universal health coverage", "TREATMENT", 347, 372], ["financial risk protection", "TREATMENT", 382, 407]]], ["We focused on quantifying total health spending on HIV/AIDS, malaria, and tuberculosis and DAH contributions.", [["HIV/AIDS", "DISEASE", 51, 59], ["malaria", "DISEASE", 61, 68], ["tuberculosis", "DISEASE", 74, 86], ["DAH", "DISEASE", 91, 94], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 51, 54], ["HIV/AIDS", "TREATMENT", 51, 59], ["malaria", "PROBLEM", 61, 68], ["tuberculosis", "PROBLEM", 74, 86], ["DAH contributions", "PROBLEM", 91, 108], ["malaria", "OBSERVATION", 61, 68], ["tuberculosis", "OBSERVATION", 74, 86]]], ["This work adds value to existing literature by using similar methods as previous studies to quantify progress in financing SDG3 priority by estimating domestic spending by source spending on four SDG3 indicators and DAH funding on eight SDG3 indicators.Implications of all available evidenceTracking progress towards the financing of health systems and specific targets associated with SDG3 draws attention to the need for sufficient resources to achieve health gains without placing financial hardship on households.", [["SDG3", "PROTEIN", 386, 390], ["previous studies", "TEST", 72, 88], ["DAH funding", "PROBLEM", 216, 227], ["SDG3 draws attention", "TREATMENT", 386, 406]]], ["This study also highlights the need to estimate the financing available for the other SDG3 priority areas.", [["This study", "TEST", 0, 10]]], ["This complexity highlights that, although more resources are probably needed to achieve SDG3, other constraints such as inefficient resource allocation, weak governance systems, inadequate health workforce, and drug shortages will likely need to be addressed to achieve the SDG3 targets. efficiency of health systems), knowing precisely how much is being spent and for what purpose is essential for tracking effectiveness and ensuring an equitable distribution of resources.", [["SDG3", "GENE_OR_GENE_PRODUCT", 88, 92], ["SDG3", "GENE_OR_GENE_PRODUCT", 274, 278], ["SDG3", "PROTEIN", 88, 92], ["SDG3", "PROTEIN", 274, 278], ["weak governance systems", "PROBLEM", 153, 176], ["drug shortages", "TREATMENT", 211, 225], ["tracking effectiveness", "PROBLEM", 399, 421]]], ["Second, SDG3 target 3.8 identifies financial risk protection and access to essential services as key targets.", [["SDG3", "PROTEIN", 8, 12], ["financial risk protection", "TREATMENT", 35, 60]]], ["Achieving SDG3 target 3.8 not only requries enough resources are available to provide the services and interventions needed to prevent and treat ill health, but also that an awareness of the source of those funds is key.", [["ill", "DISEASE", 145, 148], ["SDG3", "PROTEIN", 10, 14], ["the services", "TREATMENT", 86, 98], ["interventions", "TREATMENT", 103, 116]]], ["6 The alternative to prepaid and pooled resources for health is reliance on out-of-pocket spending, which forces households without sufficient resources to choose between receiving health care or medical impoverishment.Implications of all available evidenceThis study builds on past work and aims to make progress towards filling the current gap in knowledge on the financing of SDG3 priority areas.", [["This study", "TEST", 257, 267]]], ["[7] [8] [9] Little evidence exists on how much is being spent towards the SDG3 targets and how this spending relates to changes in health outcomes of interest.", [["SDG3", "GENE_OR_GENE_PRODUCT", 74, 78]]], ["The objectives of this study are to measure spending on SDG3 priority areas where estimates are relatively complete and comparable, examine the association between outcomes and financings levels, and identify where resource shortages are most apparent for four SDG3 indicators.", [["this study", "TEST", 18, 28], ["financings levels", "TEST", 177, 194]]], ["We quantified health spending for universal health coverage; domestic and DAH spending on HIV/AIDS, tuberculosis, malaria; and DAH spending for reproductive, maternal, newborn, and child health, tobacco control, non-communicable diseases, vaccines, and human resources.", [["HIV/AIDS", "DISEASE", 90, 98], ["tuberculosis", "DISEASE", 100, 112], ["malaria", "DISEASE", 114, 121], ["non-communicable diseases", "DISEASE", 212, 237], ["human", "ORGANISM", 253, 258], ["HIV", "SPECIES", 90, 93], ["human", "SPECIES", 253, 258], ["HIV", "SPECIES", 90, 93], ["tobacco", "SPECIES", 195, 202], ["human", "SPECIES", 253, 258], ["universal health coverage", "TREATMENT", 34, 59], ["DAH", "PROBLEM", 74, 77], ["HIV/AIDS", "TREATMENT", 90, 98], ["tuberculosis", "PROBLEM", 100, 112], ["malaria", "PROBLEM", 114, 121], ["DAH", "PROBLEM", 127, 130], ["non-communicable diseases", "PROBLEM", 212, 237], ["vaccines", "TREATMENT", 239, 247], ["tuberculosis", "OBSERVATION", 100, 112], ["malaria", "OBSERVATION", 114, 121]]], ["We also evaluated spending against key SDG3 indicators for HIV/AIDS, tuberculosis, malaria, universal health coverage, and pandemic preparedness.", [["HIV/AIDS", "DISEASE", 59, 67], ["tuberculosis", "DISEASE", 69, 81], ["malaria", "DISEASE", 83, 90], ["HIV", "SPECIES", 59, 62], ["HIV", "SPECIES", 59, 62], ["HIV", "PROBLEM", 59, 62], ["AIDS", "PROBLEM", 63, 67], ["tuberculosis", "PROBLEM", 69, 81], ["malaria", "PROBLEM", 83, 90], ["universal health coverage", "TREATMENT", 92, 117], ["pandemic preparedness", "TREATMENT", 123, 144], ["tuberculosis", "OBSERVATION", 69, 81]]], ["Additionally, this research estimates future spending on health up to 2030 and 2050 to highlight the expected resource availability and, in particular, provides information that can be used to identify where more prepaid and pooled resources are needed.OverviewWe measured health sector spending by source; domestic spending on HIV/AIDS, tuberculosis, and malaria; and development assistance for health (DAH; ie, from donors) for as many years as possible with the availability of input data.", [["HIV/AIDS", "DISEASE", 328, 336], ["tuberculosis", "DISEASE", 338, 350], ["malaria", "DISEASE", 356, 363], ["DAH", "DISEASE", 404, 407], ["HIV", "SPECIES", 328, 331], ["HIV", "SPECIES", 328, 331], ["HIV/AIDS", "PROBLEM", 328, 336], ["tuberculosis", "PROBLEM", 338, 350], ["malaria", "PROBLEM", 356, 363], ["tuberculosis", "OBSERVATION", 338, 350], ["malaria", "OBSERVATION", 356, 363]]], ["For total health sector spending and domestic health spending, we generated estimates for 1995-2017 for 195 countries and territories; for domestic spending on HIV, tuber culosis, and malaria, we generated estimates for 2000-17 for 135 low-income and middle-income countries (although for malaria, 28 low-income and middle-income countries without endemic malaria were excluded); and for DAH, we generated estimates for 1990-2019 and all low-income and middle-income countries.", [["HIV, tuber culosis", "DISEASE", 160, 178], ["malaria", "DISEASE", 184, 191], ["malaria", "DISEASE", 289, 296], ["malaria", "DISEASE", 356, 363], ["HIV", "ORGANISM", 160, 163], ["HIV", "SPECIES", 160, 163], ["HIV", "SPECIES", 160, 163], ["tuber culosis", "SPECIES", 165, 178], ["HIV, tuber culosis", "PROBLEM", 160, 178], ["malaria", "PROBLEM", 184, 191], ["malaria", "PROBLEM", 289, 296], ["endemic malaria", "PROBLEM", 348, 363], ["DAH", "PROBLEM", 388, 391]]], ["7 The sum of spending from these three domestic sources, plus DAH, equate to total spending on health, meaning these four sources are mutually exclusive and collectively exhaustive.", [["DAH", "DISEASE", 62, 65], ["DAH", "PROBLEM", 62, 65]]], ["Out-of-pocket health spending captures health-care spending by an individual patient or their household, excluding insurance premiums paid before needing care.", [["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84]]], ["10 We downloaded the data in current national currency units, adjusted for inflation, and then converted to 2019 $US, completed our analysis, and then also converted our estimates into 2019 purchasing-power parity-adjusted ).", [["inflation", "TREATMENT", 75, 84], ["our analysis", "TEST", 128, 140]]], ["The input data for our disease-specific spending esti mates came from multiple sources.", [["The input data", "TEST", 0, 14], ["our disease", "PROBLEM", 19, 30]]], ["For HIV/AIDS, we extracted spending data for 135 lowincome and middle-income countries from the National AIDS Spending Assessments, 13 the Global Fund (including concept notes, proposals, and funding landscape documents), National Health Accounts and subaccounts, UNAIDS Global AIDS response progress reports, and three online public databases provided by UNAIDS: the AIDSinfo database, the HIV financing dashboard, and the Asia-Pacific region AIDS Data Hub.", [["HIV/AIDS", "DISEASE", 4, 12], ["AIDS", "DISEASE", 105, 109], ["AIDS", "DISEASE", 278, 282], ["AIDS", "DISEASE", 444, 448], ["HIV", "SPECIES", 4, 7], ["HIV", "SPECIES", 4, 7], ["HIV/AIDS", "PROBLEM", 4, 12]]], ["Additional details on the data sources we used are in the appendix (pp 113-16).Domestic spending on HIV/AIDS, tuberculosis, and malaria 2000-17For tuberculosis, we extracted spending data for 135 lowincome and middle-income countries from the WHO Global Tuberculosis database, Global Fund (proposals, concept notes, and funding landscaping documents), National Health Accounts and sub-accounts, WHO Global Health Expenditure database, 10 National Tuberculosis Reports, Ministry of Health Reports, GBD data, and unit cost data from WHO-Choosing Interven tions that are Cost Effective (CHOICE), and Moses et al. 14 Additional details on the data sources we used are in the appendix (pp [13] [14] [15] [16] [17] [18] [19] [20] [21] .Domestic spending on HIV/AIDS, tuberculosis, and malaria 2000-17For malaria, we extracted spending data for 106 malariaendemic low-income and middle-income countries from the World Malaria Report, the Global Fund (including concept notes, proposals, and funding landscape documents), National Health Accounts and sub-accounts, the Global Fund Price Quality Reporting, WHO Global Price Reporting Mechanism, Management Sciences for Health reference prices, Global Affordable Medicine Facility, Health Action International database, treatment data provided by the Malaria Atlas Project, Demographic and Health Surveys, malaria out-of-pocket cost literature, malaria inpatient and outpatient cost literature, and inpatient and outpatient unit costs from Moses et al. 14 Further details on the data sources we used are in the appendix (pp 89-90).Domestic spending on HIV/AIDS, tuberculosis, and malaria 2000-17Second, we used a spatiotemporal Gaussian process model to generate a complete time series of estimates by disease from 2000 to 2017 for each country included.", [["HIV/AIDS", "DISEASE", 100, 108], ["tuberculosis", "DISEASE", 110, 122], ["malaria", "DISEASE", 128, 135], ["tuberculosis", "DISEASE", 147, 159], ["Tuberculosis", "DISEASE", 254, 266], ["Tuberculosis", "DISEASE", 447, 459], ["pp [13] [14] [15] [16] [17] [18] [19] [20", "CHEMICAL", 681, 722], ["HIV/AIDS", "DISEASE", 751, 759], ["tuberculosis", "DISEASE", 761, 773], ["malaria", "DISEASE", 779, 786], ["malaria", "DISEASE", 798, 805], ["Malaria", "DISEASE", 911, 918], ["malaria", "DISEASE", 1346, 1353], ["malaria", "DISEASE", 1385, 1392], ["HIV/AIDS", "DISEASE", 1592, 1600], ["tuberculosis", "DISEASE", 1602, 1614], ["malaria", "DISEASE", 1620, 1627], ["appendix", "ORGAN", 58, 66], ["pp [13] [14] [15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 681, 728], ["appendix", "ORGAN", 1551, 1559], ["HIV", "SPECIES", 100, 103], ["HIV", "SPECIES", 751, 754], ["HIV", "SPECIES", 1592, 1595], ["HIV", "SPECIES", 100, 103], ["HIV", "SPECIES", 751, 754], ["HIV", "SPECIES", 1592, 1595], ["pp", "TEST", 68, 70], ["HIV/AIDS", "PROBLEM", 100, 108], ["tuberculosis", "PROBLEM", 110, 122], ["malaria", "PROBLEM", 128, 135], ["tuberculosis", "PROBLEM", 147, 159], ["Global Tuberculosis database", "PROBLEM", 247, 275], ["HIV/AIDS", "PROBLEM", 751, 759], ["tuberculosis", "PROBLEM", 761, 773], ["malaria", "PROBLEM", 779, 786], ["malaria", "PROBLEM", 798, 805], ["malaria", "PROBLEM", 1346, 1353], ["malaria", "PROBLEM", 1385, 1392], ["pp", "TEST", 1561, 1563], ["HIV/AIDS", "PROBLEM", 1592, 1600], ["tuberculosis", "PROBLEM", 1602, 1614], ["malaria", "PROBLEM", 1620, 1627], ["appendix", "ANATOMY", 58, 66], ["tuberculosis", "OBSERVATION", 110, 122], ["Tuberculosis", "OBSERVATION", 254, 266], ["appendix", "ANATOMY", 671, 679], ["tuberculosis", "OBSERVATION", 761, 773], ["appendix", "ANATOMY", 1551, 1559], ["tuberculosis", "OBSERVATION", 1602, 1614]]], ["For our HIV/AIDS spending estimates, tabulated data of annual spending of all components-government, out-of-pocket, and prepaid private spending-were available, so we used those to generate our estimates.", [["HIV/AIDS", "DISEASE", 8, 16], ["HIV", "SPECIES", 8, 11]]], ["For malaria and tuberculosis, little tabulated data and estimates on out-of-pocket spending were available, so we developed out-of-pocket spending estimates by taking the product of coverage (ie, volume) and unit costs for key services for which users pay out of pocket.Universal health coverage, 2000-17We extracted the universal health coverage service index from the GBD 2017 SDG Collaborators.", [["malaria", "DISEASE", 4, 11], ["tuberculosis", "DISEASE", 16, 28], ["malaria", "PROBLEM", 4, 11], ["tuberculosis", "PROBLEM", 16, 28], ["little tabulated data", "PROBLEM", 30, 51], ["Universal health coverage", "TREATMENT", 270, 295], ["malaria", "OBSERVATION", 4, 11], ["tuberculosis", "OBSERVATION", 16, 28]]], ["1 The index aggregates across a diverse set of intermediate coverage estimates, such as vaccine coverage, and measured of health system performance.", [["The index aggregates", "PROBLEM", 2, 22], ["intermediate coverage estimates", "TREATMENT", 47, 78], ["vaccine coverage", "TREATMENT", 88, 104], ["intermediate coverage", "OBSERVATION", 47, 68]]], ["We extracted data on 195 countries from 2000 to 2017 used these data in this analysis.Universal health coverage, 2000-17No commonly agreed on system exists to differentiate between which health spending is intended to help countries achieve universal health coverage.", [["this analysis", "TEST", 72, 85], ["universal health coverage", "TREATMENT", 241, 266]]], ["Pooled spending is health-care spending collected in advance and spread across a large set of individuals, and includes government and prepaid private spending and DAH.Estimating DAH, 1990-2019We defined DAH as the financial and in-kind resources transferred through international development agencies to low-income and middle-income countries for the primary purpose of maintaining and improving health.", [["DAH", "DISEASE", 164, 167], ["DAH", "DISEASE", 179, 182], ["DAH", "DISEASE", 204, 207], ["DAH", "PROBLEM", 164, 167], ["Estimating DAH", "PROBLEM", 168, 182]]], ["We extracted project disbursement data from online databases, annual reports, and financial statements of the major inter national development agencies and philanthropic insti tutions including the World Bank, the Organisation for Economic Co-operation and Development's (OECD's) Creditor Reporting System, and the Bill & Melinda Gates Foundation; details on the agencies and institutions included are in the appendix (pp [28] [29] [30] [31] [32] [33] .", [["appendix", "ORGAN", 409, 417], ["pp [28] [29] [30] [31] [32] [33]", "SIMPLE_CHEMICAL", 419, 451], ["Economic Co-operation", "TREATMENT", 231, 252], ["appendix", "ANATOMY", 409, 417]]], ["The estimates of DAH include the expenses incurred to administer the grants and loans.Estimating DAH, 1990-2019We classified estimates of how DAH funds were disbursed into ten mutually exclusive and collectively exhaustive health focus areas and 52 programme areas on the basis of project descriptions, project titles, including pandemic preparedness, and budget documents.", [["DAH", "DISEASE", 17, 20], ["DAH", "PROBLEM", 17, 20], ["Estimating DAH", "PROBLEM", 86, 100], ["pandemic preparedness", "TREATMENT", 329, 350], ["DAH", "OBSERVATION", 17, 20]]], ["Disbursement of DAH funds to single countries were identified as such, while global initiatives and administrative costs were classified separately.", [["DAH", "DISEASE", 16, 19], ["DAH funds", "PROBLEM", 16, 25], ["DAH", "OBSERVATION", 16, 19]]], ["Administrative costs capture the operational cost of running projects-eg, staff salaries.", [["running projects", "TREATMENT", 53, 69]]], ["The DAH contributions towards human resources we captured here include indirect funding for human resources activities, such as per diems, and direct funding for human resources for health projects that invest in human resources activities, such as training, education, and policy development.", [["human", "ORGANISM", 30, 35], ["human", "ORGANISM", 92, 97], ["human", "ORGANISM", 162, 167], ["human", "ORGANISM", 213, 218], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 213, 218]]], ["The health focus areas included in this study are HIV/AIDS; tuberculosis; malaria; reproductive, maternal, newborn, and child health; other infectious disease; non-communicable diseases; sectorwide approaches; and health system strengthening.", [["HIV/AIDS", "DISEASE", 50, 58], ["tuberculosis", "DISEASE", 60, 72], ["malaria", "DISEASE", 74, 81], ["infectious disease", "DISEASE", 140, 158], ["non-communicable diseases", "DISEASE", 160, 185], ["HIV", "SPECIES", 50, 53], ["HIV", "SPECIES", 50, 53], ["this study", "TEST", 35, 45], ["HIV/AIDS", "PROBLEM", 50, 58], ["tuberculosis", "PROBLEM", 60, 72], ["malaria", "PROBLEM", 74, 81], ["other infectious disease", "PROBLEM", 134, 158], ["non-communicable diseases", "PROBLEM", 160, 185], ["sectorwide approaches", "TREATMENT", 187, 208], ["tuberculosis", "OBSERVATION", 60, 72], ["malaria", "OBSERVATION", 74, 81], ["infectious", "OBSERVATION", 140, 150]]], ["Detailed descriptions of the methods we used to isolate the disbursements of DAH funds for relevant health focus areas and preliminary estimates are in the appendix (pp 34-45) and elsewhere.", [["DAH", "DISEASE", 77, 80], ["appendix", "ORGAN", 156, 164], ["the methods", "TREATMENT", 25, 36], ["DAH funds", "TREATMENT", 77, 86], ["pp", "TEST", 166, 168], ["appendix", "ANATOMY", 156, 164]]], ["7, 15 The estimates presented here of DAH incorporated improvements in our methods compared with previous years, such as using additional project-level descriptions [34] [35] [36] [37] [38] [39] [40] [41] [42] .", [["DAH", "DISEASE", 38, 41], ["[34] [35] [36] [37] [38] [39] [40] [41]", "CHEMICAL", 165, 204], ["[34] [35] [36] [37] [38] [39] [40] [41] [42]", "SIMPLE_CHEMICAL", 165, 209], ["DAH", "PROBLEM", 38, 41]]], ["The Millennium Development Goals (MDGs) were eight development goals adopted by the UN in 2000.", [["Millennium", "OBSERVATION_MODIFIER", 4, 14]]], ["The goals, to be achieved by 2015, included the eradication of extreme poverty and hunger; achievement of universal primary enrolment; promotion of gender equality and empowerment of women; reduction in child mortality, HIV/AIDS, malaria, and other diseases; and improvement in maternal health.", [["poverty", "DISEASE", 71, 78], ["hunger", "DISEASE", 83, 89], ["HIV/AIDS", "DISEASE", 220, 228], ["malaria", "DISEASE", 230, 237], ["women", "ORGANISM", 183, 188], ["women", "SPECIES", 183, 188], ["HIV", "SPECIES", 220, 223], ["HIV", "SPECIES", 220, 223], ["hunger", "PROBLEM", 83, 89], ["universal primary enrolment", "TREATMENT", 106, 133], ["HIV", "PROBLEM", 220, 223], ["AIDS", "PROBLEM", 224, 228], ["malaria", "PROBLEM", 230, 237], ["other diseases", "PROBLEM", 243, 257], ["malaria", "OBSERVATION", 230, 237], ["improvement", "OBSERVATION_MODIFIER", 263, 274]]], ["In our analyses, we examine spending over the duration of the MDGs, starting in 2000 up to 2015.Estimating DAH, 1990-2019DAH data for 2018 and 2019 are preliminary estimates based on budget data and estimation.", [["Estimating DAH", "PROBLEM", 96, 110], ["budget data", "TEST", 183, 194], ["estimation", "TEST", 199, 209]]], ["Detailed information on the sources of the budget data and the estimation approaches we used are provided in the appendix (pp 29-33).Financial risk protectionWe extracted incidence data on catastrophic health spending estimates from World Bank World Development Indicators database for all years and countries for which data were available.", [["appendix", "ORGAN", 113, 121], ["the budget data", "TEST", 39, 54], ["the estimation approaches", "TREATMENT", 59, 84], ["pp", "TEST", 123, 125], ["appendix", "ANATOMY", 113, 121]]], ["The methods used for these projections draw heavily from our previous research, 7, 18, 19 with the key updates being the improvement of the retro spective estimates on which these projections are based.Health spending in the future: 2018 to 2030 and 2050We generated each projection using ensemble modelling techniques, such that the estimates are the mean of 1000 estimated time series from a broad set of models.", [["ensemble modelling techniques", "TREATMENT", 289, 318]]], ["For example, government health spending was modelled as a fraction of general government spending, which was modelled as a fraction of GDP.", [["GDP", "CHEMICAL", 135, 138], ["GDP", "CHEMICAL", 135, 138], ["GDP", "SIMPLE_CHEMICAL", 135, 138]]], ["On the basis of model performance, we modelled GDP as a proportion of the population who were of working age, which for this study was determined to be aged 20-65 years.Health spending in the future: 2018 to 2030 and 2050We modelled DAH as a fraction of the donor country's general government spending, or, for private donors, on the basis of autoregressive integrated moving average (ARIMA) modelling techniques.", [["DAH", "DISEASE", 233, 236], ["GDP", "CHEMICAL", 47, 50], ["GDP", "SIMPLE_CHEMICAL", 47, 50], ["this study", "TEST", 120, 130]]], ["20 We aggregated total DAH across sources.", [["DAH", "DISEASE", 23, 26], ["total", "OBSERVATION_MODIFIER", 17, 22], ["DAH", "OBSERVATION", 23, 26]]], ["We constructed a separate model that projected the fraction of total DAH that each recipient was expected to receive.", [["DAH", "DISEASE", 69, 72], ["total DAH", "PROBLEM", 63, 72], ["total", "OBSERVATION_MODIFIER", 63, 68], ["DAH", "OBSERVATION", 69, 72]]], ["As a country's own GDP percapita increases, the fraction of total DAH received by the country is expected to go down.", [["GDP", "CHEMICAL", 19, 22], ["DAH", "DISEASE", 66, 69], ["GDP", "CHEMICAL", 19, 22], ["GDP", "SIMPLE_CHEMICAL", 19, 22], ["total DAH", "PROBLEM", 60, 69], ["total", "OBSERVATION_MODIFIER", 60, 65], ["DAH", "OBSERVATION", 66, 69]]], ["We also modelled when countries transi tioned to being high-income and are no longer eligible to receive DAH.Health spending in the future: 2018 to 2030 and 2050All projections incorporated several types of uncertainty.", [["DAH", "DISEASE", 105, 108], ["DAH", "PROBLEM", 105, 108], ["no longer", "UNCERTAINTY", 75, 84], ["DAH", "OBSERVATION", 105, 108]]], ["We used ensemble modelling techniques to propagate model uncertainty.", [["ensemble modelling techniques", "TREATMENT", 8, 37]]], ["21 We took draws of the variancecovariance matrix of each estimate's model to propagate parameter uncertainty.", [["the variancecovariance matrix", "TREATMENT", 20, 49]]], ["We generated 95% uncertainty intervals (UIs) by taking the 2\u00b75th and 97\u00b75th percentile of the 1000 estimated random draws.Health spending in the future: 2018 to 2030 and 2050More details are in the appendix (pp 121-41).Statistical analysisWe report all spending estimates in inflation-adjusted 2019 US$, although some data are also presented in 2019 purchasing-power parity-adjusted $ and proportion of GDP.", [["GDP", "CHEMICAL", 403, 406], ["GDP", "CHEMICAL", 403, 406], ["appendix", "ORGAN", 198, 206], ["GDP", "SIMPLE_CHEMICAL", 403, 406], ["pp", "TEST", 208, 210], ["GDP", "PROBLEM", 403, 406], ["appendix", "ANATOMY", 198, 206]]], ["We report spending estimates for Venezuela in 2014 US$ because necessary exchange rates for more recent years were not reliable.", [["exchange rates", "TREATMENT", 73, 87]]], ["We evaluated health spending against key indicators relative to SDG3.", [["SDG3", "GENE_OR_GENE_PRODUCT", 64, 68], ["SDG3", "PROTEIN", 64, 68]]], ["In particular, we extracted estimates of incidence of HIV/AIDS, tuberculosis, and malaria from GBD 2017, 22 and the universal health coverage service coverage index.", [["HIV/AIDS", "DISEASE", 54, 62], ["tuberculosis", "DISEASE", 64, 76], ["malaria", "DISEASE", 82, 89], ["HIV", "ORGANISM", 54, 57], ["HIV", "SPECIES", 54, 57], ["HIV", "SPECIES", 54, 57], ["HIV/AIDS", "PROBLEM", 54, 62], ["tuberculosis", "PROBLEM", 64, 76], ["malaria", "PROBLEM", 82, 89], ["tuberculosis", "OBSERVATION", 64, 76]]], ["1, 23 We used different measures to report findings from our spending and outcomes analyses.", [["outcomes analyses", "TEST", 74, 91]]], ["For HIV/AIDS, we report spending per prevalent case, because a lot of HIV/AIDS spending is determined by the number of people undergoing treatment.", [["HIV/AIDS", "DISEASE", 4, 12], ["HIV/", "DISEASE", 70, 74], ["AIDS", "DISEASE", 74, 78], ["HIV", "ORGANISM", 70, 73], ["people", "ORGANISM", 119, 125], ["HIV", "SPECIES", 4, 7], ["people", "SPECIES", 119, 125], ["HIV", "SPECIES", 4, 7], ["HIV", "SPECIES", 70, 73], ["HIV/AIDS", "PROBLEM", 4, 12], ["HIV/AIDS", "PROBLEM", 70, 78], ["treatment", "TREATMENT", 137, 146]]], ["For malaria, we report spending per capita, because as countries move towards elimination a lot of malaria spending is on surveillance.", [["malaria", "DISEASE", 4, 11], ["malaria", "DISEASE", 99, 106], ["malaria", "PROBLEM", 4, 11], ["malaria", "PROBLEM", 99, 106], ["surveillance", "TEST", 122, 134], ["malaria", "OBSERVATION", 4, 11], ["malaria", "OBSERVATION", 99, 106]]], ["For tuberculosis, we report spending per incident case, because a lot of tuberculosis spending is determined by detection of incident cases.", [["tuberculosis", "DISEASE", 4, 16], ["tuberculosis", "DISEASE", 73, 85], ["tuberculosis", "PROBLEM", 4, 16], ["tuberculosis", "PROBLEM", 73, 85], ["tuberculosis", "OBSERVATION", 4, 16], ["tuberculosis", "OBSERVATION", 73, 85]]], ["Population estimates, both retrospective and prospective were also extracted from the GBD 2017 study.", [["the GBD 2017 study", "TEST", 82, 100]]], ["We divided the extracted estimates by total domestic spending on health and then regressed on national income using loess regression methods.", [["loess regression methods", "TREATMENT", 116, 140]]], ["25, 26 We report estimates of DAH from 1990 up to 2019 for low-income and middle-income countries.", [["DAH", "DISEASE", 30, 33], ["DAH", "PROBLEM", 30, 33]]], ["The data for 2018 and 2019 are preliminary estimates based on budget data and estimation.", [["budget data", "TEST", 62, 73], ["estimation", "TEST", 78, 88]]], ["We also analysed DAH by Argentina is the only country in the World Bank category of lowincome and middle-income countries to fall in the GBD high-income super-region; hence, in the present study we do not include Argentina, and its GBD super-region, in figures that disaggregate by GBD super-region.", [["DAH", "DISEASE", 17, 20], ["GBD super-region", "PROTEIN", 232, 248], ["GBD super-region", "PROTEIN", 282, 298]]], ["We did all analyses using R (version 3.6.0) and Stata (version 15).", [["all analyses", "TEST", 7, 19], ["R (version", "TREATMENT", 26, 36], ["Stata (version", "TEST", 48, 62]]], ["All spending estimates used in this analysis are publicly available on the Global Health Data Exchange website.Role of the funding sourceThe funder of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.", [["this study", "TEST", 151, 161], ["data collection", "TEST", 191, 206], ["data analysis", "TEST", 208, 221], ["data interpretation", "TEST", 223, 242]]], ["All authors had full access to all the data in the study, and AEM and JLD had final responsibility for the decision to submit for publication.", [["the study", "TEST", 47, 56]]], ["Table 1 lists the SDG3 targets and the associated indicators for monitoring these targets, and reports existing estimates of financing needed for attaining these targets and our spending estimates.", [["SDG3", "GENE_OR_GENE_PRODUCT", 18, 22], ["SDG3 targets", "DNA", 18, 30]]], ["Our estimates of disease-specific spending focus on domestic and DAH spending among 135 low-income and middle-income countries while spending on universal health coverage is measured for 195 countries and territories including high-income countries.ResultsGlobally, total health spending has increased since the start of the SDGs in 2015, reaching $7\u00b79 trillion (95% UI 7\u00b78-8\u00b70) in 2017, and is expected to increase to $11\u00b70 trillion (10\u00b77-11\u00b72) by 2030, and $16\u00b77 trillion (16\u00b70-17\u00b74) in 2050, although with substantial disparity across countries.", [["DAH", "DISEASE", 65, 68], ["disease", "PROBLEM", 17, 24], ["DAH", "PROBLEM", 65, 68], ["universal health coverage", "TREATMENT", 145, 170], ["UI", "TEST", 367, 369], ["disease", "OBSERVATION", 17, 24]]], ["In 2017, in low-income and middleincome countries, $20\u00b72 billion (17\u00b70-25\u00b70) was spent on HIV/AIDS, $10\u00b79 billion (10\u00b73-11\u00b78) was spent on tuberculosis, and in 106 malaria-endemic countries, $5\u00b71 billion (4\u00b79-5\u00b74) was spent on malaria.", [["HIV/AIDS", "DISEASE", 90, 98], ["tuberculosis", "DISEASE", 139, 151], ["malaria", "DISEASE", 164, 171], ["malaria", "DISEASE", 227, 234], ["HIV", "SPECIES", 90, 93], ["HIV", "SPECIES", 90, 93], ["tuberculosis", "PROBLEM", 139, 151], ["malaria", "PROBLEM", 227, 234], ["tuberculosis", "OBSERVATION", 139, 151], ["malaria", "OBSERVATION", 227, 234]]], ["DAH was estimated to be $40\u00b76 billion in 2019, the most recent year for which data are available.", [["DAH", "DISEASE", 0, 3], ["DAH", "PROBLEM", 0, 3]]], ["Estimates of DAH in 2019were also available for the following SDG3 health areas: maternal health ($1\u00b75 billion), neonatal and child health ($8\u00b75 billion), HIV/AIDS ($9\u00b75 billion), tuberculosis ($1\u00b77 billion), malaria ($2\u00b73 billion), non-communicable diseases ($735\u00b70 mil lion), family planning ($1\u00b72 billion), tobacco control ($66\u00b72 million), vaccine ($3\u00b71 billion), and human resources ($4\u00b70 billion).", [["DAH", "DISEASE", 13, 16], ["HIV/AIDS", "DISEASE", 155, 163], ["tuberculosis", "DISEASE", 180, 192], ["malaria", "DISEASE", 209, 216], ["non-communicable diseases", "DISEASE", 233, 258], ["human", "ORGANISM", 371, 376], ["HIV", "SPECIES", 155, 158], ["human", "SPECIES", 371, 376], ["HIV", "SPECIES", 155, 158], ["tobacco", "SPECIES", 310, 317], ["human", "SPECIES", 371, 376], ["DAH", "PROBLEM", 13, 16], ["HIV/AIDS", "PROBLEM", 155, 163], ["tuberculosis", "PROBLEM", 180, 192], ["malaria", "PROBLEM", 209, 216], ["non-communicable diseases", "PROBLEM", 233, 258], ["DAH", "OBSERVATION", 13, 16], ["tuberculosis", "OBSERVATION", 180, 192], ["malaria", "OBSERVATION", 209, 216]]], ["Spending for several SDG3 indicators, including hepatitis B incidence (3.3.4), substance abuse (3.5.1-5.2), road injuries (3.6.1), adoles cent birth rate (3.7.2), and chemical and environmental pollution (3.9.1-9.3) do not have a large, comparable set of spending estimates for either development assistance or domestic spending and so are not included in these analyses.ResultsIn 2019, DAH for pandemic preparedness was estimated to be $374 million (<1% of total DAH). $2\u00b74 billion (6%) of all DAH was for infectious diseases (other than HIV/AIDS, tuberculosis, and malaria) in 2019, but these funds were generally spent on treatment or disease focused efforts rather than pandemic preparedness more broadly.", [["hepatitis B", "DISEASE", 48, 59], ["substance abuse", "DISEASE", 79, 94], ["injuries", "DISEASE", 113, 121], ["pandemic", "DISEASE", 395, 403], ["DAH", "DISEASE", 464, 467], ["DAH", "DISEASE", 495, 498], ["infectious diseases", "DISEASE", 507, 526], ["HIV/AIDS", "DISEASE", 539, 547], ["tuberculosis", "DISEASE", 549, 561], ["malaria", "DISEASE", 567, 574], ["hepatitis B", "ORGANISM", 48, 59], ["HIV", "SPECIES", 539, 542], ["HIV", "SPECIES", 539, 542], ["hepatitis B incidence", "PROBLEM", 48, 69], ["road injuries", "PROBLEM", 108, 121], ["adoles cent birth rate", "TEST", 131, 153], ["environmental pollution", "TEST", 180, 203], ["DAH", "PROBLEM", 387, 390], ["total DAH", "PROBLEM", 458, 467], ["billion", "TREATMENT", 475, 482], ["infectious diseases", "PROBLEM", 507, 526], ["HIV/AIDS", "PROBLEM", 539, 547], ["tuberculosis", "PROBLEM", 549, 561], ["malaria", "PROBLEM", 567, 574], ["treatment", "TREATMENT", 625, 634], ["disease", "PROBLEM", 638, 645], ["pandemic preparedness", "TREATMENT", 674, 695], ["large", "OBSERVATION_MODIFIER", 230, 235], ["infectious", "OBSERVATION", 507, 517], ["tuberculosis", "OBSERVATION", 549, 561]]], ["Despite DAH for pandemic preparedness being such a small fraction of total DAH, DAH for pandemic preparedness has grown faster than total DAH over the past 10 years.", [["DAH", "DISEASE", 8, 11], ["pandemic", "DISEASE", 16, 24], ["DAH", "DISEASE", 75, 78], ["DAH", "DISEASE", 80, 83], ["pandemic", "DISEASE", 88, 96], ["DAH", "DISEASE", 138, 141], ["DAH", "PROBLEM", 8, 11], ["pandemic preparedness", "TREATMENT", 16, 37], ["total DAH", "PROBLEM", 69, 78], ["DAH", "PROBLEM", 80, 83], ["pandemic preparedness", "PROBLEM", 88, 109], ["total DAH", "PROBLEM", 132, 141], ["small", "OBSERVATION_MODIFIER", 51, 56], ["total", "OBSERVATION_MODIFIER", 69, 74], ["DAH", "OBSERVATION", 75, 78]]], ["Since 2010, DAH for pandemic preparedness has more than doubled (increasing 8\u00b71% annually from $185\u00b78 million in 2010), while total DAH has increased by only 1\u00b79% annually.", [["DAH", "DISEASE", 12, 15], ["pandemic", "DISEASE", 20, 28], ["DAH", "DISEASE", 132, 135], ["DAH", "PROBLEM", 12, 15], ["total DAH", "PROBLEM", 126, 135], ["increased", "OBSERVATION_MODIFIER", 140, 149]]], ["The develop ment agency that provided the most DAH for pandemic preparedness in 2019 was the WHO.ResultsIn 2017, global health spending per capita was $1048 (95% UI 1034-1062).", [["DAH", "DISEASE", 47, 50], ["pandemic", "DISEASE", 55, 63], ["UI", "TEST", 162, 164]]], ["Of this amount, 81\u00b73% (80\u00b77-81\u00b78) was financed by domestic government and prepaid private health spending (table 2) .", [["amount", "OBSERVATION_MODIFIER", 8, 14]]], ["Of $37 (36-39) spent per capita in low-income countries in 2017, 30\u00b79% (28\u00b75-33\u00b76) was government and prepaid health spending.ResultsTotal HIV/AIDS spending disaggregated by financing source in 135 low-income and middle-income countries for 2000-17 is shown in figure 1A .", [["HIV/AIDS", "DISEASE", 139, 147], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 139, 142]]], ["For these countries, which included 93\u00b79% (95% UI 91\u00b72-96\u00b73) of the global HIV incidence and 98\u00b73% ( USA 10 243 (10 087-10 390) Since 2015, spending in low-income and middleincome countries to prevent and treat HIV/AIDS has increased from $10\u00b76 billion (95% UI 8\u00b73-13\u00b79) to $12\u00b70 billion (9\u00b71-16\u00b72) in 2017, primarily due to increases in government spending.", [["HIV/AIDS", "DISEASE", 211, 219], ["HIV", "SPECIES", 211, 214], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 211, 214], ["UI", "TEST", 47, 49], ["the global HIV incidence", "PROBLEM", 64, 88], ["HIV/AIDS", "PROBLEM", 211, 219], ["increases", "OBSERVATION_MODIFIER", 325, 334]]], ["Despite this growth, increases in spending levels have not been even across countries.", [["this growth", "PROBLEM", 8, 19], ["increases in spending levels", "PROBLEM", 21, 49], ["growth", "OBSERVATION_MODIFIER", 13, 19], ["increases", "OBSERVATION_MODIFIER", 21, 30]]], ["39 countries (including Zimbabwe and Kenya) spent less on HIV/AIDS in 2017 than in 2015, primarily because of reductions in DAH; a full list of country estimates is on the Global Health Data Exchange website.ResultsThe amount of HIV/AIDS spending per prevalent case for each region in 2017, and the fraction that is from each financing source is shown in figure 1B .", [["HIV/AIDS", "DISEASE", 58, 66], ["DAH", "DISEASE", 124, 127], ["HIV/AIDS", "DISEASE", 229, 237], ["HIV", "ORGANISM", 229, 232], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 229, 232], ["DAH", "PROBLEM", 124, 127], ["HIV/AIDS", "PROBLEM", 229, 237], ["DAH", "OBSERVATION", 124, 127]]], ["SDG indicator 3.3.1 is to eliminate HIV/AIDS incidence.", [["HIV/AIDS", "DISEASE", 36, 44], ["SDG", "CHEMICAL", 0, 3], ["SDG", "SIMPLE_CHEMICAL", 0, 3], ["HIV", "SPECIES", 36, 39], ["HIV/AIDS incidence", "PROBLEM", 36, 54]]], ["Change in HIV/AIDS incidence and HIV/AIDS spending per capita for each low-income and middle-income country for 2000-17 is shown in figure 1C .", [["HIV/AIDS", "DISEASE", 10, 18], ["HIV/AIDS", "DISEASE", 33, 41], ["HIV", "ORGANISM", 10, 13], ["HIV", "SPECIES", 10, 13], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 10, 13], ["HIV", "SPECIES", 33, 36], ["Change in HIV/AIDS incidence", "PROBLEM", 0, 28], ["HIV/AIDS", "PROBLEM", 33, 41]]], ["For all but one (Venezuela) of 135 countries, HIV/AIDS spending per capita has increased since 2000.", [["HIV/AIDS", "DISEASE", 46, 54], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 46, 49], ["increased", "OBSERVATION_MODIFIER", 79, 88]]], ["73 countries had reductions in HIV/AIDS incidence, while 62 had increases in incidence.", [["HIV/AIDS", "DISEASE", 31, 39], ["HIV", "SPECIES", 31, 34]]], ["While sub-Saharan Africa has had major decreases in HIV incidence and increases in spending per capita, other super-regions have had increases in HIV incidence since 2015.ResultsTotal tuberculosis spending disaggregated by source in 135 low-income and middle-income countries for 2000-17 is shown in figure 2A .", [["tuberculosis", "DISEASE", 184, 196], ["HIV", "SPECIES", 52, 55], ["HIV", "SPECIES", 146, 149], ["HIV incidence", "PROBLEM", 52, 65], ["Total tuberculosis", "PROBLEM", 178, 196], ["major", "OBSERVATION_MODIFIER", 33, 38], ["decreases", "OBSERVATION_MODIFIER", 39, 48], ["HIV", "OBSERVATION", 52, 55], ["increases", "OBSERVATION_MODIFIER", 70, 79], ["increases", "OBSERVATION_MODIFIER", 133, 142], ["HIV incidence", "OBSERVATION", 146, 159], ["tuberculosis", "OBSERVATION", 184, 196], ["middle", "ANATOMY_MODIFIER", 252, 258]]], ["These countries comprise 98\u00b74% (95% UI 98\u00b73-98\u00b74) global tuberculosis incidence in 2017 and 98\u00b77% (98\u00b77-98\u00b78) of tuberculosis deaths for the same year.", [["tuberculosis", "DISEASE", 57, 69], ["tuberculosis", "DISEASE", 113, 125], ["deaths", "DISEASE", 126, 132], ["These countries", "TEST", 0, 15], ["UI", "TEST", 36, 38], ["global tuberculosis incidence", "PROBLEM", 50, 79], ["tuberculosis deaths", "PROBLEM", 113, 132], ["tuberculosis", "OBSERVATION", 57, 69], ["tuberculosis", "OBSERVATION", 113, 125]]], ["23, 38 For these countries, spending on tuberculosis increased at an annualised rate of 3\u00b787% (3\u00b704-4\u00b764), from $5\u00b77 billion (5\u00b72-6\u00b75) in 2000 to $10\u00b79 billion (10\u00b73-11\u00b78) in 2017.", [["tuberculosis", "DISEASE", 40, 52], ["tuberculosis", "PROBLEM", 40, 52], ["tuberculosis", "OBSERVATION", 40, 52]]], ["Government spending amounted to $6\u00b79 billion (6\u00b75-7\u00b75) or 63\u00b75% (59\u00b72-66\u00b78) of all tuberculosis spending in 2017 and increased annually by 5\u00b706% (4\u00b743 to 5\u00b772) since 2000.", [["tuberculosis", "DISEASE", 83, 95], ["all tuberculosis", "PROBLEM", 79, 95], ["tuberculosis", "OBSERVATION", 83, 95]]], ["Although DAH for tuberculosis increased at an even faster rate (15\u00b791%), the amount in 2017 was $1\u00b77 billion, of which 33\u00b75% was spent on administrative costs and global initiatives.", [["DAH", "DISEASE", 9, 12], ["tuberculosis", "DISEASE", 17, 29], ["DAH", "PROBLEM", 9, 12], ["tuberculosis", "PROBLEM", 17, 29], ["administrative costs", "TREATMENT", 138, 158], ["global initiatives", "TREATMENT", 163, 181], ["tuberculosis", "OBSERVATION", 17, 29]]], ["The amount of tuberculosis spending that was out-of-pocket has decreased steadily since 2000, as more tuberculosis cases have been treated in the public system.", [["tuberculosis", "DISEASE", 14, 26], ["tuberculosis", "DISEASE", 102, 114], ["tuberculosis", "PROBLEM", 14, 26], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["tuberculosis", "OBSERVATION", 14, 26], ["decreased", "OBSERVATION_MODIFIER", 63, 72], ["steadily", "OBSERVATION_MODIFIER", 73, 81], ["tuberculosis", "OBSERVATION", 102, 114], ["public system", "ANATOMY", 146, 159]]], ["In 2000, an estimated $2\u00b74 billion (1\u00b79-3\u00b71) was spent out-of-pocket on tuberculosis, while in 2017, $2\u00b71 billion (1\u00b76-2\u00b77) was spent.", [["tuberculosis", "DISEASE", 72, 84], ["tuberculosis", "PROBLEM", 72, 84], ["tuberculosis", "OBSERVATION", 72, 84]]], ["Spending on tuberculosis from prepaid private sources was $246\u00b79 million (171\u00b79-368\u00b77) in 2000 and $225\u00b70 million (184\u00b71-280\u00b77) in 2017.", [["tuberculosis", "DISEASE", 12, 24], ["tuberculosis", "OBSERVATION", 12, 24]]], ["Since the start of the SDGs in 2015, 87 of 135 low-income and middle-income countries we analysed increased their spending on tuberculosis (for more details see the WHO Global Health Data Exchange).ResultsThe amount of tuberculosis spending per incident case for each GBD super-region in 2017 (excluding the high-income region), and the fraction that is from each financing source are shown in figure 2B .", [["tuberculosis", "DISEASE", 126, 138], ["tuberculosis", "DISEASE", 219, 231], ["tuberculosis", "PROBLEM", 219, 231], ["amount", "OBSERVATION_MODIFIER", 209, 215], ["tuberculosis", "OBSERVATION", 219, 231]]], ["Total spending was greatest in the central Europe, eastern Europe, and central Asia (appendix p 10), which also had the largest spending per incident case ($13 955 [95% UI SDG indicator 3.3.2 is to eliminate tuberculosis incidence.", [["tuberculosis", "DISEASE", 208, 220], ["UI SDG indicator", "TEST", 169, 185], ["tuberculosis incidence", "PROBLEM", 208, 230], ["greatest", "OBSERVATION_MODIFIER", 19, 27], ["central", "ANATOMY_MODIFIER", 35, 42], ["central", "ANATOMY_MODIFIER", 71, 78], ["tuberculosis", "OBSERVATION", 208, 220]]], ["Change in tuberculosis incidence and tuberculosis spending per capita for each low-income and middleincome country for 2000-17 is shown in figure 2C .", [["tuberculosis", "DISEASE", 10, 22], ["tuberculosis", "DISEASE", 37, 49], ["Change in tuberculosis incidence", "PROBLEM", 0, 32], ["tuberculosis", "PROBLEM", 37, 49], ["tuberculosis", "OBSERVATION", 10, 22], ["tuberculosis", "OBSERVATION", 37, 49]]], ["122 (90%) of 135 low-income and middle-income countries saw decreases in tuberculosis incidence between 2000 and 2017, with the few exceptions being primarily in sub-Saharan Africa and southeast Asia, east Asia, and Oceania.", [["tuberculosis", "DISEASE", 73, 85], ["middle", "ANATOMY_MODIFIER", 32, 38], ["decreases", "OBSERVATION_MODIFIER", 60, 69], ["tuberculosis", "OBSERVATION", 73, 85]]], ["We saw substantial variation in spending patterns over time, with 113 (84%) of 135 countries increasing spending and 22 (16%) countries decreasing tuberculosis spending per capita.", [["tuberculosis", "DISEASE", 147, 159], ["substantial", "OBSERVATION_MODIFIER", 7, 18], ["variation", "OBSERVATION_MODIFIER", 19, 28], ["tuberculosis", "OBSERVATION", 147, 159]]], ["For tuberculosis, in eSwatini, Lesotho, and Nicaragua, we observed a more than 12% annualised rate of change in per capita spending with varying annualised rates of change in incidence (0\u00b789% decrease for eSwatini, 0\u00b704% increase for Lesotho, 2\u00b714% decrease for Nicaragua; figure 2C ).ResultsTotal malaria spending disaggregated by financing source in 106 countries with local malaria transmission since 2000 is shown in figure 3A .", [["tuberculosis", "DISEASE", 4, 16], ["eSwatini", "DISEASE", 205, 213], ["malaria", "DISEASE", 298, 305], ["malaria", "DISEASE", 377, 384], ["tuberculosis", "PROBLEM", 4, 16], ["eSwatini", "TEST", 205, 213], ["Lesotho", "TEST", 234, 241], ["Total malaria", "PROBLEM", 292, 305], ["local malaria transmission", "PROBLEM", 371, 397], ["tuberculosis", "OBSERVATION", 4, 16]]], ["102 (96%) of 106 countries are low-income or middle-income countries, and 99\u00b798% (95% UI 99\u00b797-99\u00b798) of malaria deaths in 2017 were in these 106 countries.", [["malaria", "DISEASE", 105, 112], ["deaths", "DISEASE", 113, 119], ["UI", "TEST", 86, 88], ["malaria deaths", "PROBLEM", 105, 119]]], ["38 Spending on malaria increased annually by 7\u00b796% (95% UI 8\u00b720-7\u00b774) from $1\u00b74 billion (1\u00b73-1\u00b75) in 2000 to $5\u00b71 billion (4\u00b79-5\u00b74) in 2017.", [["malaria", "DISEASE", 15, 22], ["malaria", "PROBLEM", 15, 22], ["UI", "TEST", 56, 58]]], ["Domestic govern ments have been a relatively stable source of funding for malaria, with spending changing from $0\u00b78 billion (0\u00b77-0\u00b79) in 2000 to $1\u00b76 billion (1\u00b75-1\u00b78) in 2017.", [["malaria", "DISEASE", 74, 81], ["malaria", "PROBLEM", 74, 81]]], ["Meanwhile, spending from DAH and out-of-pocket spending have substantially increased, comprising 48\u00b77% (46\u00b73-50\u00b78) and 16\u00b71% (13\u00b74-19\u00b78) of total spending in 2017.", [["DAH", "DISEASE", 25, 28], ["DAH", "PROBLEM", 25, 28], ["substantially increased", "PROBLEM", 61, 84], ["substantially", "OBSERVATION_MODIFIER", 61, 74], ["increased", "OBSERVATION_MODIFIER", 75, 84]]], ["DAH contributed $2\u00b75 billion in 2017, while $0\u00b78 billion (0\u00b77-1\u00b70) was contributed by out-ofpocket spending.ResultsSince 2015, spending on malaria increased from $4\u00b78 bil lion (95% UI 4\u00b76-5\u00b71) to $5\u00b71 billion (4\u00b79-5\u00b74) in 2017, and spending in 63 (59%) of 106 countries increased (figure 3).", [["DAH", "DISEASE", 0, 3], ["malaria", "DISEASE", 139, 146], ["DAH", "PROBLEM", 0, 3], ["malaria", "PROBLEM", 139, 146], ["bil lion", "TEST", 167, 175], ["UI", "TEST", 181, 183]]], ["Increases in prepaid-private spending, out-ofpocket spending, and DAH all contributed to these increases.ResultsThe amount of malaria spending per capita for each region in 2017 and the fraction that is from each financing source are shown in figure 3B .", [["DAH", "DISEASE", 66, 69], ["malaria", "DISEASE", 126, 133], ["DAH", "PROBLEM", 66, 69], ["malaria", "PROBLEM", 126, 133], ["amount", "OBSERVATION_MODIFIER", 116, 122], ["malaria", "OBSERVATION", 126, 133]]], ["The spending per capita in sub-Saharan Africa was $3\u00b721 (95% UI 3\u00b701-3\u00b744), which was much larger than in the other malaria endemic GBD super-regions.", [["malaria", "DISEASE", 116, 123], ["UI", "TEST", 61, 63], ["larger", "OBSERVATION_MODIFIER", 91, 97], ["malaria", "OBSERVATION", 116, 123], ["regions", "ANATOMY_MODIFIER", 142, 149]]], ["The least spending per capita was in central Europe, eastern Europe, and central Asia ($0\u00b710 [0\u00b708-0\u00b713]).", [["central", "ANATOMY_MODIFIER", 37, 44]]], ["Govern ment spending constitutes the most spending on malaria in the superregions of central Europe, eastern Europe, and central Asia; Latin America and Caribbean; north Africa and the Middle East; and southeast Asia, east Asia, and Oceania.", [["malaria", "DISEASE", 54, 61], ["malaria", "PROBLEM", 54, 61], ["malaria", "OBSERVATION", 54, 61], ["central", "ANATOMY_MODIFIER", 85, 92], ["Middle", "ANATOMY_MODIFIER", 185, 191]]], ["DAH made up a larger share of the spending on malaria for sub-Saharan Africa than the other communicable diseases tracked in this study.", [["DAH", "DISEASE", 0, 3], ["malaria", "DISEASE", 46, 53], ["communicable diseases", "DISEASE", 92, 113], ["DAH", "PROBLEM", 0, 3], ["malaria", "PROBLEM", 46, 53], ["the other communicable diseases", "PROBLEM", 82, 113], ["this study", "TEST", 125, 135], ["larger", "OBSERVATION_MODIFIER", 14, 20], ["diseases", "OBSERVATION", 105, 113]]], ["SDG indicator 3\u00b73.3 is to eliminate malaria incidence.", [["malaria", "DISEASE", 36, 43], ["SDG", "CHEMICAL", 0, 3], ["malaria incidence", "PROBLEM", 36, 53], ["malaria", "OBSERVATION", 36, 43]]], ["Change in malaria incidence and malaria spending per capita for each of 102 malaria endemic low-income and middle-income country for 2000-17 are shown in figure 3C .", [["malaria", "DISEASE", 10, 17], ["malaria", "DISEASE", 32, 39], ["malaria", "DISEASE", 76, 83], ["Change in malaria incidence", "PROBLEM", 0, 27], ["malaria", "PROBLEM", 32, 39], ["malaria endemic", "PROBLEM", 76, 91], ["malaria", "OBSERVATION", 10, 17], ["malaria", "OBSERVATION", 32, 39]]], ["This figure highlights the 13 of 102 countries that have eliminated malaria since 2000 and relatively constant malaria spending per capita.", [["malaria", "DISEASE", 68, 75], ["malaria", "DISEASE", 111, 118], ["malaria", "PROBLEM", 68, 75], ["malaria", "OBSERVATION", 68, 75], ["constant", "OBSERVATION_MODIFIER", 102, 110], ["malaria", "OBSERVATION", 111, 118]]], ["Additionally, all but three of the remaining 93 remaining malaria endemic low-income and middle-income countries-Djibouti, Niger, and Venezuela-have seen reductions in malaria incidence.", [["malaria", "DISEASE", 58, 65], ["malaria", "DISEASE", 168, 175], ["malaria incidence", "PROBLEM", 168, 185], ["malaria", "OBSERVATION_MODIFIER", 58, 65], ["endemic", "OBSERVATION_MODIFIER", 66, 73], ["low", "OBSERVATION_MODIFIER", 74, 77], ["middle", "ANATOMY_MODIFIER", 89, 95], ["malaria", "OBSERVATION", 168, 175]]], ["Meanwhile, malaria spending per capita has increased in 78 of 106 malaria endemic lowincome and middle-income countries with the largest spending increases in sub-Saharan Africa.", [["malaria", "DISEASE", 11, 18], ["malaria", "DISEASE", 66, 73], ["malaria", "PROBLEM", 11, 18], ["malaria endemic lowincome", "PROBLEM", 66, 91], ["malaria", "OBSERVATION", 11, 18], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["middle", "ANATOMY_MODIFIER", 96, 102], ["largest", "OBSERVATION_MODIFIER", 129, 136], ["sub", "OBSERVATION_MODIFIER", 159, 162]]], ["We observed that in Myanmar and eSwatini, per capita spending increased at an annualised rate of more than 15% from 2000 to 2017, and annualised incidence rate of the disease decreased by more than 10% (figure 3C).ResultsChange in universal health coverage service coverage index and pooled health spending per capita for 2000-17 across all 195 countries and territories is shown in figure 4 .", [["the disease", "PROBLEM", 163, 174], ["disease", "OBSERVATION", 167, 174], ["decreased", "OBSERVATION_MODIFIER", 175, 184]]], ["We saw a strong association between increases in pooled health spending per capita and progress towards universal health coverage, with countries in the GBD super-regions of sub-Saharan Africa, south Asia, and southeast Asia, east Asia and Oceania making large gains in universal health coverage as pooled spending per capita increased.", [["universal health coverage", "TREATMENT", 104, 129], ["universal health coverage", "TREATMENT", 270, 295], ["strong", "OBSERVATION_MODIFIER", 9, 15], ["increases", "OBSERVATION_MODIFIER", 36, 45], ["large", "OBSERVATION_MODIFIER", 255, 260]]], ["For any one level of GDP per capita, a sizeable range of the fraction of domestic health spending is financed by out-of-pocket spending, suggesting that economic development does not solely determine the transition away from household financing.", [["GDP", "CHEMICAL", 21, 24], ["GDP", "CHEMICAL", 21, 24], ["GDP", "SIMPLE_CHEMICAL", 21, 24]]], ["Additionally, large variation exists across countries in the association between rate of change in the fraction of domestic health spending that is out-of-pocket and the rate of change in the proportion of households with catastrophic health expenditure (figure 5B).", [["large variation", "PROBLEM", 14, 29], ["catastrophic health expenditure", "PROBLEM", 222, 253], ["large", "OBSERVATION_MODIFIER", 14, 19], ["variation", "OBSERVATION_MODIFIER", 20, 29]]], ["A reliance on domestic government, prepaid, and pooled health financing is a means towards achieving universal health coverage and financial risk protection.", [["universal health coverage", "TREATMENT", 101, 126], ["financial risk protection", "TREATMENT", 131, 156]]], ["Globally, this fraction contributing to universal health coverage ranges from 6\u00b77% (95% UI 4\u00b75-9\u00b71) in Afghanistan to 100% (100-100) in Greenland (for more details see the WHO Global Health Data Exchange).ResultsIn 2019, $40\u00b76 billion of DAH was disbursed and increased at an annualised rate of 1\u00b774% since 2015 ( figure 6A) .", [["DAH", "DISEASE", 238, 241], ["this fraction", "PROBLEM", 10, 23], ["UI", "TEST", 88, 90], ["DAH", "PROBLEM", 238, 241], ["an annualised rate", "TEST", 273, 291], ["increased", "OBSERVATION_MODIFIER", 260, 269]]], ["However, since in 2004, DAH for HIV/AIDS has received the highest contributions of all health focus areas, peaking at $12\u00b70 billion in 2012.ResultsThe annualised rate of change across the health focus areas for the time periods associated with the Millennium Development Goals (MDGs) and the SDGs are shown in figure 6B .", [["DAH", "DISEASE", 24, 27], ["HIV/AIDS", "DISEASE", 32, 40], ["HIV", "SPECIES", 32, 35], ["DAH", "PROBLEM", 24, 27], ["HIV/AIDS", "PROBLEM", 32, 40]]], ["Between 2000 and 2015, DAH increased by 7\u00b775%, with disburse ments for malaria increasing by 18\u00b732%, for tuberculosis by 16\u00b718%, and for HIV/AIDS by 13\u00b702% .", [["DAH", "DISEASE", 23, 26], ["malaria", "DISEASE", 71, 78], ["tuberculosis", "DISEASE", 105, 117], ["HIV/AIDS", "DISEASE", 137, 145], ["HIV", "SPECIES", 137, 140], ["DAH", "PROBLEM", 23, 26], ["malaria", "PROBLEM", 71, 78], ["tuberculosis", "PROBLEM", 105, 117], ["HIV/AIDS", "TREATMENT", 137, 145]]], ["For the period 2015-19, the annu alised growth rate for tuberculosis spending is 5\u00b775%, for HIV/AIDS is 2\u00b718%, and for malaria is 1\u00b743%.", [["tuberculosis", "DISEASE", 56, 68], ["HIV/AIDS", "DISEASE", 92, 100], ["malaria", "DISEASE", 119, 126], ["HIV", "SPECIES", 92, 95], ["tuberculosis", "PROBLEM", 56, 68], ["HIV/AIDS", "PROBLEM", 92, 100], ["malaria", "PROBLEM", 119, 126]]], ["Other key health focus areas that are funding progress on specific SDG indi cators have had annual rates of change for 2015-19 of 4\u00b725% for non-communicable diseases, 2\u00b753% for reproductive and maternal health, and 0\u00b766% for newborn and child health.", [["non-communicable diseases", "DISEASE", 140, 165], ["non-communicable diseases", "PROBLEM", 140, 165]]], ["The annu alised growth rate of DAH for other infectious diseases has decreased for the period 2015-19, which is driven by the increased contributions that went towards the Ebola outbreak in 2014-15 and the subsequent re-alignment of resources after the Ebola crisis.ResultsBased on past trends and associations, we estimate that an additional $238 (95% UI 209-267) per capita will be available for health globally in 2030 compared with 2017, with persistent disparities in spending between countries and across income groups (table 2).", [["DAH", "DISEASE", 31, 34], ["infectious diseases", "DISEASE", 45, 64], ["Ebola", "DISEASE", 172, 177], ["Ebola", "DISEASE", 253, 258], ["Ebola", "ORGANISM", 253, 258], ["DAH", "PROBLEM", 31, 34], ["other infectious diseases", "PROBLEM", 39, 64], ["the Ebola crisis", "PROBLEM", 249, 265], ["UI", "TEST", 353, 355], ["infectious", "OBSERVATION", 45, 55], ["decreased", "OBSERVATION_MODIFIER", 69, 78], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["Ebola crisis", "OBSERVATION", 253, 265]]], ["The proportion of health spending from pooled sources is expected to increase from 81\u00b76% (81\u00b76-81\u00b77) in 2015 to 83\u00b71% (82\u00b78-83\u00b73) in 2030.", [["increase", "OBSERVATION_MODIFIER", 69, 77]]], ["In high-income countries, health spending is expected to continue to increase, with expected annualised growth rates of 1\u00b793% (1\u00b777-2\u00b710), reaching $6596 (6482-6708) per capita in 2030.", [["growth rates", "TEST", 104, 116], ["high", "OBSERVATION_MODIFIER", 3, 7]]], ["Health spending growth is expected to be fastest in lower-middle-income countries, where the annual growth rate is expected to be 4\u00b738% (4\u00b713-4\u00b766) between 2018 and 2030, with per-capita spending reaching $127 (114-141).", [["the annual growth rate", "TEST", 89, 111], ["middle", "ANATOMY_MODIFIER", 58, 64]]], ["For countries currently considered to be low income by The World Bank, resources for health are expected to grow annually by 4\u00b713% (3\u00b775-4\u00b755) between 2018 and 2030, although in per capita terms, annualised health spending growth is expected to be only 1\u00b752% (1\u00b715-1\u00b793), reaching $45 (42) (43) (44) (45) (46) (47) (48) per capita in 2030.DiscussionDisease-specific spending studies are valuable because they can provide policy makers and planners with insights into the financial burden created by specific diseases.", [["spending studies", "TEST", 366, 382]]], ["This knowledge can subsequently be used in prioritisation, planning, budgeting, and evaluation of programmes; programme and policy interventions and development; and ultimately in better management of health systems.", [["evaluation", "TEST", 84, 94], ["policy interventions", "TREATMENT", 124, 144]]], ["Our analysis quantified health sector spending and health spending on HIV/AIDS, tuberculosis, and malaria relative to outcomes, which are all priorities under SDG3.", [["HIV/AIDS", "DISEASE", 70, 78], ["tuberculosis", "DISEASE", 80, 92], ["malaria", "DISEASE", 98, 105], ["HIV", "SPECIES", 70, 73], ["HIV", "SPECIES", 70, 73], ["HIV/AIDS", "TREATMENT", 70, 78], ["tuberculosis", "PROBLEM", 80, 92], ["malaria", "PROBLEM", 98, 105], ["tuberculosis", "OBSERVATION", 80, 92]]], ["Our results highlight that, globally, total health spending has increased since the state of the SDGs in 2015, reaching $7\u00b79 trillion (7\u00b78-8\u00b70) in 2017, and is expected to increase to $11\u00b70 trillion (10\u00b77-11\u00b72) by 2030, although with substan tial disparity across countries.", [["increased", "OBSERVATION_MODIFIER", 64, 73]]], ["In 2017, in lowincome and middle-income countries, an estimated $20\u00b72 billion was spent on HIV/AIDS, $10\u00b79 billion was spent on tuberculosis, and $5\u00b71 billion was spent on malaria in endemic countries.", [["HIV/AIDS", "DISEASE", 91, 99], ["tuberculosis", "DISEASE", 128, 140], ["malaria", "DISEASE", 172, 179], ["HIV", "SPECIES", 91, 94], ["tuberculosis", "PROBLEM", 128, 140], ["malaria", "PROBLEM", 172, 179], ["tuberculosis", "OBSERVATION", 128, 140], ["malaria", "OBSERVATION", 172, 179]]], ["Although both domestic government and DAH spending, has increased across these three diseases, the accom panied changes in outcomes have varied.", [["DAH", "PROBLEM", 38, 41], ["increased across these three diseases", "PROBLEM", 56, 93], ["both", "OBSERVATION_MODIFIER", 9, 13], ["domestic government", "OBSERVATION", 14, 33], ["DAH", "OBSERVATION_MODIFIER", 38, 41], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["three diseases", "OBSERVATION", 79, 93]]], ["We found that malaria had the most consistent decreases in outcomes across countries as spending has increased.DiscussionThese health spending estimates enable further examination of the existing publicly available estimates of the financing required to achieve the SDG3 targets.", [["malaria", "DISEASE", 14, 21], ["SDG3", "GENE_OR_GENE_PRODUCT", 266, 270], ["SDG3", "PROTEIN", 266, 270], ["malaria", "PROBLEM", 14, 21], ["further examination", "TEST", 160, 179], ["the financing", "TREATMENT", 228, 241], ["malaria", "OBSERVATION", 14, 21], ["most consistent", "OBSERVATION_MODIFIER", 30, 45], ["decreases", "OBSERVATION_MODIFIER", 46, 55], ["increased", "OBSERVATION_MODIFIER", 101, 110]]], ["ExistingWorld Bank income groupHigh-income countries Upper-middle-income countries Lower-middle-income countries Low-income countries estimates suggest that the additional annual financing required to achieve SDG3 in 67 low-income and middleincome countries is $274 billion (progress scenario in which the attainment of goals is limited by countries' health systems existing absorptive capacity), and to reach health system targets for SDG3 including scale-up of health workforce and infrastructure is $371 billion.", [["SDG3", "CHEMICAL", 209, 213], ["SDG3", "TEST", 209, 213], ["SDG3", "PROBLEM", 436, 440]]], ["28 Stenberg and colleagues estimated that to achieve SDG3 in 67 low-income and middle-income countries, the corresponding per capita spending would need to increase to $249 per year (progress scenario) or $271 per year (ambitious scenario) by 2030.", [["SDG3", "TEST", 53, 57]]], ["28 Another study by the Sustainable Development Solutions Network that included 59 low-income countries estimated that to achieve SDG3 would cost, approximately $225 billion between 2019 and 2030, with a per capita cost of $86 for low-income countries and $134 for lower-middle-income countries as the minimum needed to provide care consistent with basic human rights.", [["human", "ORGANISM", 355, 360], ["human", "SPECIES", 355, 360], ["human", "SPECIES", 355, 360], ["Another study", "TEST", 3, 16], ["lower-middle-income countries", "TREATMENT", 265, 294], ["basic human rights", "TREATMENT", 349, 367]]], ["39 A few other studies have also generated estimates of the resources needed using different methods.", [["A few other studies", "TEST", 3, 22], ["different methods", "TREATMENT", 83, 100]]], ["Although these financing goals can be benchmarks to encourage more spending and increased health system efficiency, they do not ensure that SDG3 will be achieved.", [["SDG3", "SIMPLE_CHEMICAL", 140, 144], ["SDG3", "PROTEIN", 140, 144]]], ["Ultimately, costing estimates like these need to be continuously improved to make them locally relevant and price appropriate, with realistic assumptions about health system inefficiency and the distribution of spending in a country, and to incorporate any challenges associated with preventing and treating disease in difficult to reach contexts.World Bank income groupFor all three diseases for which a complete and comparable series of spending estimates exist in low-income and middle-income countries-HIV/AIDS, tuber culosis, and malaria-comparing the relative con tributions from the different financing sources high lights interesting patterns.", [["AIDS", "DISEASE", 510, 514], ["tuber culosis", "DISEASE", 516, 529], ["malaria", "DISEASE", 535, 542], ["HIV", "ORGANISM", 506, 509], ["HIV", "SPECIES", 506, 509], ["tuber culosis", "SPECIES", 516, 529], ["treating disease", "PROBLEM", 299, 315], ["all three diseases", "PROBLEM", 374, 392], ["spending estimates", "TEST", 439, 457], ["HIV/AIDS", "PROBLEM", 506, 514], ["tuber culosis", "PROBLEM", 516, 529], ["malaria", "PROBLEM", 535, 542], ["diseases", "OBSERVATION", 384, 392], ["tuber culosis", "OBSERVATION", 516, 529], ["malaria", "OBSERVATION", 535, 542]]], ["Governments contribute substantially across all three diseases.", [["three diseases", "OBSERVATION", 48, 62]]], ["4 While DAH contributions to malaria and HIV/AIDS are substantial, contributions to tuberculosis are smaller.", [["DAH", "DISEASE", 8, 11], ["malaria", "DISEASE", 29, 36], ["HIV/AIDS", "DISEASE", 41, 49], ["tuberculosis", "DISEASE", 84, 96], ["HIV", "SPECIES", 41, 44], ["HIV", "SPECIES", 41, 44], ["malaria", "PROBLEM", 29, 36], ["HIV", "PROBLEM", 41, 44], ["AIDS", "PROBLEM", 45, 49], ["tuberculosis", "PROBLEM", 84, 96], ["malaria", "OBSERVATION", 29, 36], ["substantial", "OBSERVATION_MODIFIER", 54, 65], ["tuberculosis", "OBSERVATION", 84, 96], ["smaller", "OBSERVATION_MODIFIER", 101, 108]]], ["This pattern brings into light longstanding concerns and debate regarding the allocation of DAH especially across health focus areas.", [["DAH", "DISEASE", 92, 95], ["DAH", "PROBLEM", 92, 95], ["DAH", "OBSERVATION", 92, 95]]], ["[41] [42] [43] These concerns and debate include whether the current criteria that rely mainly on a country's level of development are the most appro priate to use for allocation, donor preference for implementing vertical programmes with short-term measurable effects, and prioritisation of such diseases to broader health system challenges.", [["such diseases", "PROBLEM", 292, 305]]], ["Also, the relative dependence on household out-of-pocket spending across the three diseases is notable, with the proportion of out-of-pocket spending for tuberculosis and malaria being much larger than the proportion for HIV/AIDS.", [["tuberculosis", "DISEASE", 154, 166], ["malaria", "DISEASE", 171, 178], ["HIV/AIDS", "DISEASE", 221, 229], ["HIV", "SPECIES", 221, 224], ["HIV", "SPECIES", 221, 224], ["the three diseases", "PROBLEM", 73, 91], ["tuberculosis", "PROBLEM", 154, 166], ["malaria", "PROBLEM", 171, 178], ["HIV/AIDS", "PROBLEM", 221, 229], ["dependence", "OBSERVATION_MODIFIER", 19, 29], ["three", "OBSERVATION_MODIFIER", 77, 82], ["diseases", "OBSERVATION", 83, 91], ["tuberculosis", "OBSERVATION", 154, 166], ["malaria", "OBSERVATION", 171, 178], ["larger", "OBSERVATION_MODIFIER", 190, 196]]], ["Changes in policy, such as making HIV treatment available and free to all, has transformed management of care for HIV/AIDS and its by-source funding distribution.", [["HIV/AIDS", "DISEASE", 114, 122], ["HIV", "SPECIES", 34, 37], ["HIV", "SPECIES", 114, 117], ["HIV treatment", "TREATMENT", 34, 47], ["HIV/AIDS", "PROBLEM", 114, 122]]], ["Previous studies have shown that high out-of-pocket spending promotes health impoverishment.", [["Previous studies", "TEST", 0, 16], ["high", "OBSERVATION_MODIFIER", 33, 37]]], ["The distribution of health spending by source across different regions also highlights heterogeneous health financing patterns for the three diseases globally.", [["the three diseases globally", "PROBLEM", 131, 158], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["heterogeneous", "OBSERVATION_MODIFIER", 87, 100]]], ["For some geographical regions (eg, Central Europe, eastern Europe, and central Asia, and sub-Saharan Africa), governments carry the primary burden of providing resources for these diseases, while in other regions (eg, southeast Asia, east Asia, and Oceania, and south Asia) the pattern of financing changes with the type of disease.", [["these diseases", "PROBLEM", 174, 188], ["financing changes", "PROBLEM", 289, 306], ["disease", "PROBLEM", 324, 331], ["Central", "ANATOMY_MODIFIER", 35, 42], ["diseases", "OBSERVATION", 180, 188], ["disease", "OBSERVATION", 324, 331]]], ["Similarly, health spending globally has distinct patterns.", [["distinct patterns", "OBSERVATION", 40, 57]]], ["In the high-income GBD super-region, spending by governments dominates, while in other super-regions, such as south Asia and sub-Saharan Africa, DAH and out-of-pocket spending are prominent.", [["DAH", "DISEASE", 145, 148], ["DAH", "PROBLEM", 145, 148], ["high", "OBSERVATION_MODIFIER", 7, 11], ["prominent", "OBSERVATION_MODIFIER", 180, 189]]], ["Preferably, resources for financing health care should be pooled to restrict the risk of health impoverishment for the population and delays in accessing needed care.", [["financing health care", "TREATMENT", 26, 47]]], ["Resources for financing health care could be pooled through government facilitation of the development of viable prepaid mandatory insurance programmes.World Bank income groupThe association between spending on health and health outcomes is of interest to many audiences, especially because of the increases in spending on health that have been observed in the past two decades with the adoption of the MDGs and now the SDGs.", [["financing health care", "TREATMENT", 14, 35], ["increases", "OBSERVATION_MODIFIER", 298, 307]]], ["Our results highlight a nuanced and complex picture regarding the link between health spending and its associated effect on outcomeshere, disease-specific outcomes.", [["disease", "PROBLEM", 138, 145]]], ["Although substantial reductions in the inci dence of some diseases were observed as spending increased in some countries, in others decreases in the inci dence of other disease were minimal or even increases in incidence were seen.", [["substantial reductions", "PROBLEM", 9, 31], ["some diseases", "PROBLEM", 53, 66], ["other disease", "PROBLEM", 163, 176], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["reductions", "OBSERVATION_MODIFIER", 21, 31], ["some", "OBSERVATION_MODIFIER", 53, 57], ["diseases", "OBSERVATION", 58, 66], ["some", "OBSERVATION_MODIFIER", 106, 110], ["countries", "OBSERVATION_MODIFIER", 111, 120], ["decreases", "OBSERVATION_MODIFIER", 132, 141], ["disease", "OBSERVATION", 169, 176], ["minimal", "OBSERVATION_MODIFIER", 182, 189], ["increases", "OBSERVATION_MODIFIER", 198, 207]]], ["For example, for malaria, we observed that in Myanmar and eSwatini, per-capita spending increased at an annualised rate of more than 15% from 2000 to 2017, and the annualised incidence rate decreased by more than 10%, while for tuberculosis, in eSwatini, Lesotho, and Nicaragua, we observed a more than 12% annualised rate of growth in per-capita spending with varying annualised rates of change in incidence (0\u00b789% decrease for eSwatini, 0\u00b704% increase for Lesotho, 2\u00b714% decrease for Nicaragua).", [["malaria", "DISEASE", 17, 24], ["tuberculosis", "DISEASE", 228, 240], ["eSwatini", "DISEASE", 429, 437], ["malaria", "PROBLEM", 17, 24], ["tuberculosis", "PROBLEM", 228, 240], ["eSwatini", "TEST", 429, 437], ["Lesotho", "TREATMENT", 458, 465], ["malaria", "OBSERVATION", 17, 24], ["tuberculosis", "OBSERVATION", 228, 240]]], ["Because these findings are not causal, interest in understanding this link between spending on health and health outcomes is strong and more efforts would be needed to understand the drivers of success.World Bank income groupOverall, these results highlight the continued importance of domestic resource mobilisation in securing the financing required for the SDGs and the health-related SDGs in particular.", [["domestic resource mobilisation", "TREATMENT", 286, 316], ["the SDGs", "PROBLEM", 356, 364]]], ["For most middle-income countries, the aspiration is that national economic growth will also bolster what resources are allocated to the health sector by the government.", [["the aspiration", "PROBLEM", 34, 48], ["aspiration", "OBSERVATION", 38, 48]]], ["Further more, although DAH will continue to be needed in some low-income countries, a continued need for and value in DAH provision to cover so-called global public goods or common goods for health exists (such as pandemic preparedness or research and development for neglected tropical diseases).", [["DAH", "DISEASE", 23, 26], ["DAH", "PROBLEM", 23, 26], ["pandemic preparedness", "TREATMENT", 214, 235], ["neglected tropical diseases", "PROBLEM", 268, 295]]], ["35, [46] [47] [48] [49] [50] [51] [52] This continued need is because the multisectoral nature of the SDGs and the increasingly interconnected world we live in present shared global challenges that need to be addressed beyond the individual country support framework that DAH has typically addressed.World Bank income groupIn addition to the need to generate more resources to finance the health-related SDGs, the need to efficiently use existing resources should be highlighted.", [["DAH", "DISEASE", 272, 275], ["[46] [47] [48] [49] [50] [51] [52]", "SIMPLE_CHEMICAL", 4, 38], ["DAH", "PROBLEM", 272, 275], ["existing resources", "TREATMENT", 438, 456]]], ["The comparison of the annualised rates of change of pooled health spending per capita and universal health cov erage index highlighted some of the best performers at each level of development.", [["universal health cov erage index", "TEST", 90, 122]]], ["For example, Myanmar and Georgia show annualised growth in per-capita-pooled spending of more than 13%, which was associated with 2\u00b714% annualised growth in universal health coverage index in Myanmar and 0\u00b705% in Georgia.", [["annualised growth", "PROBLEM", 38, 55], ["growth", "OBSERVATION_MODIFIER", 49, 55], ["growth", "OBSERVATION_MODIFIER", 147, 153]]], ["The second annual Universal Health Coverage Financing Forum organised by the World Bank high lighted strategies such as strategic purchasing, improve ment in data management systems, and organisational management that can be adopted to promote better efficiency for health.", [["strategic purchasing", "TREATMENT", 120, 140], ["organisational management", "TREATMENT", 187, 212]]], ["This complexity highlights that, although more resources are likely to be needed to achieve SDG3, other constraints such as inefficient resource allocation, weak governance systems, drug shortages, and inadequate health workforce and management systems for health information in the broader health system that constrain improvements in health outcomes will need to be addressed to achieve the SDG3 targets.World Bank income groupFinally, this study has also shown the gaps in current resource tracking efforts as they relate to the health-related SDGs.", [["SDG3", "GENE_OR_GENE_PRODUCT", 92, 96], ["SDG3", "GENE_OR_GENE_PRODUCT", 393, 397], ["SDG3", "PROTEIN", 92, 96], ["SDG3", "PROTEIN", 393, 397], ["weak governance systems", "PROBLEM", 157, 180], ["management systems", "TREATMENT", 234, 252], ["this study", "TEST", 438, 448]]], ["Most comparative data are available for the three diseases we studied but little comparable data on financing for most of the remaining indicators are available.", [["the three diseases", "PROBLEM", 40, 58]]], ["This pattern might reflect funding priorities spurred by the MDGs.", [["might reflect", "UNCERTAINTY", 13, 26], ["funding", "OBSERVATION", 27, 34]]], ["Given the broader orientation of the goals under the SDGs, a need exists for increased understanding on the financing for the other SDG3 targets.World Bank income groupFuture research areas might include efforts targeted at financing health-related SDGs, such as hepatitis B, neglected tropical diseases, and non-communicable diseases, including substance abuse, alcohol use, road injury, adolescent birth, hazardous chemicals, and air, water, and soil pollution.", [["SDGs", "DISEASE", 249, 253], ["hepatitis B", "DISEASE", 263, 274], ["tropical diseases", "DISEASE", 286, 303], ["non-communicable diseases", "DISEASE", 309, 334], ["substance abuse", "DISEASE", 346, 361], ["alcohol", "CHEMICAL", 363, 370], ["road injury", "DISEASE", 376, 387], ["alcohol", "CHEMICAL", 363, 370], ["SDG3", "GENE_OR_GENE_PRODUCT", 132, 136], ["hepatitis B", "ORGANISM", 263, 274], ["SDG3 targets", "DNA", 132, 144], ["hepatitis B", "SPECIES", 263, 274], ["related SDGs", "PROBLEM", 241, 253], ["hepatitis B", "PROBLEM", 263, 274], ["neglected tropical diseases", "PROBLEM", 276, 303], ["non-communicable diseases", "PROBLEM", 309, 334], ["road injury", "PROBLEM", 376, 387], ["tropical diseases", "OBSERVATION", 286, 303], ["non-communicable diseases", "OBSERVATION", 309, 334], ["air", "ANATOMY", 432, 435]]], ["Additionally, studies that aim to determine the types of spending that promote improvements in outcomes are needed to guide resource investments.World Bank income groupThis study has several limitations.", [["studies", "TEST", 14, 21], ["resource investments", "TREATMENT", 124, 144], ["This study", "TEST", 168, 178]]], ["First, the data we used reported using different research units for each SDG3 indicator.", [["SDG3", "PROTEIN", 73, 77]]], ["HIV/AIDS, tuberculosis, and malaria spending estimates were available for a subset of total countries.", [["HIV/AIDS", "DISEASE", 0, 8], ["tuberculosis", "DISEASE", 10, 22], ["malaria", "DISEASE", 28, 35], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3], ["AIDS", "PROBLEM", 4, 8], ["tuberculosis", "PROBLEM", 10, 22], ["malaria", "PROBLEM", 28, 35], ["tuberculosis", "OBSERVATION", 10, 22]]], ["Also, multiple competing cost estimates exist, and so the existing financing targets that we found for comparison with our spending estimates often differed in geographical scope, methods, and currency.", [["multiple", "OBSERVATION_MODIFIER", 6, 14]]], ["We used modelling methods to enable incorporation of these data but we acknowledge that challenges exist in terms of the quality of the available global health spending data.", [["modelling methods", "TREATMENT", 8, 25], ["these data", "TEST", 53, 63]]], ["Third, while the use of keywords to isolate relevant health focus and pro gramme areas for our DAH analysis is the best existing strategy for a comprehensive effort, it relies heavily on the project description provided in the databases and in some instances might not accurately reflect what the funds actually contributed to.", [["our DAH analysis", "TEST", 91, 107]]], ["We plan to provide estimates that include these levels of disaggregation in the near future.", [["disaggregation", "PROBLEM", 58, 72]]], ["Notably, our analysis of spending and outcomes was not designed to detect causality, but was primarily a descriptive analysis of the associations between these two metrics.", [["our analysis", "TEST", 9, 21], ["a descriptive analysis", "TEST", 103, 125]]], ["Current estimates do not directly account for mass migration due to conflict and are only able to be incorporated on the basis of these events being reflected in the underlying covariates.World Bank income groupFurthermore, due to data availability, our analyses mainly covered four SDG priority areas.", [["mass migration", "PROBLEM", 46, 60], ["our analyses", "TEST", 250, 262], ["do not directly account for", "UNCERTAINTY", 18, 45], ["mass", "OBSERVATION", 46, 50]]], ["Spending on several SDG3 targets, including hepatitis B incidence, substance abuse, chemical and environmental pollution do not yet have a comparable set of spending estimates, which would prohibit analyses.", [["hepatitis B", "DISEASE", 44, 55], ["substance abuse", "DISEASE", 67, 82], ["SDG3", "GENE_OR_GENE_PRODUCT", 20, 24], ["hepatitis B", "ORGANISM", 44, 55]]], ["Ideally, estimates on DAH and domestic spending on all the priority areas under SDG3 will provide a more comprehensive picture.", [["DAH", "DISEASE", 22, 25], ["DAH", "PROBLEM", 22, 25], ["DAH", "OBSERVATION", 22, 25]]], ["Nonetheless, we believe that the data and estimates we have provided are an adequate first step in monitoring the spending for these key SDG3 areas.World Bank income groupFinally, while each set of spending estimates is consistent and comparable on its own, the input data vary enough between diseases that the spending estimates between diseases are not perfectly comparable.", [["the data", "TEST", 29, 37], ["diseases", "PROBLEM", 338, 346]]], ["For example, the HIV/AIDS and malaria government spending estimates are modelled on the basis of tabulated data, generally reporting total spending or budgets, while government spending estimates for tuberculosis and for out-of-pocket malaria and tuberculosis spending were based on taking the product of unit cost and service coverage estimates.", [["HIV/AIDS", "DISEASE", 17, 25], ["malaria", "DISEASE", 30, 37], ["tuberculosis", "DISEASE", 200, 212], ["malaria", "DISEASE", 235, 242], ["tuberculosis", "DISEASE", 247, 259], ["HIV", "SPECIES", 17, 20], ["HIV", "SPECIES", 17, 20], ["the HIV/AIDS", "PROBLEM", 13, 25], ["malaria", "PROBLEM", 30, 37], ["tuberculosis", "PROBLEM", 200, 212], ["pocket malaria", "PROBLEM", 228, 242], ["tuberculosis", "PROBLEM", 247, 259], ["tuberculosis", "OBSERVATION", 247, 259]]], ["These distinct estimation strategies will drive some differences, with unit cost and service coverage estimates not compre hensively including inefficient spending that does not yield increases in service coverage.World Bank income groupAs of publication of this Article, health systems throughout the world are stretched thin addressing the effects of coronavirus disease 2019 (COVID-19).", [["coronavirus disease", "DISEASE", 353, 372], ["coronavirus", "ORGANISM", 353, 364], ["coronavirus disease", "PROBLEM", 353, 372], ["COVID", "TEST", 379, 384]]], ["Over the past 5 months it has become increasingly clear that, although not yet fully realised, both the health and economic losses caused by this novel coronavirus will be immense.", [["coronavirus", "DISEASE", 152, 163], ["coronavirus", "ORGANISM", 152, 163], ["economic losses", "PROBLEM", 115, 130], ["this novel coronavirus", "PROBLEM", 141, 163], ["increasingly", "OBSERVATION_MODIFIER", 37, 49], ["clear", "OBSERVATION", 50, 55]]], ["Because these costs are not yet known in full and because the pandemic is ongoing, the effects of COVID-19 have not been considered in the financing projections reported in this Article.", [["COVID-19", "CHEMICAL", 98, 106], ["COVID", "TEST", 98, 103]]], ["If these costs lead to reductions in health spending as nations focus inward on economic woes or if these costs can be a catalyst for investment in robust public health systems and in shared vision of global health security remains to be seen.World Bank income groupThe link between spending and changes in outcomes remains complex, and realistic country-specific spending targets for most SDG3 indicators do not exist.", [["a catalyst", "TREATMENT", 119, 129], ["reductions", "OBSERVATION_MODIFIER", 23, 33]]], ["Using the resources available more efficiently and addressing broader health system constraints to service delivery, such as inadequate health information manage ment systems, weak governance systems, short ages in health workforce and pharmaceuticals, are crucial if substantial progress is to be made towards achieving the health-related SDGs.World Bank income groupA key tenet under lying the SDG era is that \"no one is left behind\".", [["delivery", "TREATMENT", 107, 115], ["weak governance systems", "PROBLEM", 176, 199], ["left", "ANATOMY_MODIFIER", 423, 427]]]], "184897d7318443ef85e9f72d731f406749847d8c": [["IntroductionAn essential aspect for achieving product success in the software-intensive business is that all stakeholders, i.e., all internal and external people who are involved in the product development and related activities (such as engineering, user experience, marketing, sales, suppliers etc.) are aligned and committed around a common product plan.", [["people", "ORGANISM", 155, 161], ["people", "SPECIES", 155, 161]]], ["Consequently, the main purpose of a product roadmap is to provide a high-level view of the direction of the product planning incorporating all key perspectives that supports the strategic dialogue about the future product portfolio.", [["main", "OBSERVATION_MODIFIER", 18, 22]]], ["New ways of working such as DevOps, continuous delivery and the increasing use of customer data require to have much more flexible product roadmap formats.", [["continuous delivery", "TREATMENT", 36, 55]]], ["Alignment means a concerted effort to help people understand the issues and what their respective roles are.", [["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49]]], ["Therefore, the product roadmaps will not fulfill its purpose without alignment and buy-in of the key stakeholders.", [["the product roadmaps", "TREATMENT", 11, 31]]], ["Moreover, stakeholders often do not have consistent and department-specific representations of a common high-level product roadmap that reflects their information needs (e.g., the department product management requires different information on the product roadmap than the department engineering) [3] .", [["the department product management", "TREATMENT", 176, 209]]], ["One consequence of this situation is that often each department identifies and pursues its own goals and creates its own roadmap independently of the larger goals of the company.", [["larger", "OBSERVATION_MODIFIER", 150, 156]]], ["As a result, not every product activity contributes to achieving the company's vision and goals, thus wasting important organizational resources [2, 4] .IntroductionThe current scientific literature provides only little knowledge on how alignment can be achieved around a product roadmap [5] .", [["wasting", "DISEASE", 102, 109]]], ["In order to close this gap, the aim of this paper is to identify measures, methods and techniques that help companies to achieve alignment based on the analysis of the so-called \"grey literature\" (i.e., white papers, articles, blogs, business bocks etc.).", [["the analysis", "TEST", 148, 160]]], ["Khurum and Gorschek [6] describe a method to evaluate the degree of alignment between successcritical stakeholders with respect to the understanding and interpretation of a product strategy.", [["a method", "TEST", 33, 41], ["a product strategy", "TREATMENT", 171, 189]]], ["The method also covers misalignments and enables the identification of leading causes.", [["leading causes", "PROBLEM", 71, 85]]], ["Furthermore, Luftman [7] presents a \"strategic alignment maturity assessment tool\" which consists of 38 alignment practices grouped into six categories.", [["a \"strategic alignment maturity", "PROBLEM", 34, 65]]], ["The authors point out that the most valuable part of the assessment is not the assessment itself but understanding its impact on the entire organization and what needs to be done to improve alignment.", [["the assessment", "TEST", 53, 67], ["the assessment", "TEST", 75, 89]]], ["Barney et al. [8] present a case study in order to understand different levels of alignment between key stakeholders with respect to software quality attributes.", [["a case study", "TEST", 26, 38]]], ["As the main reason for the low alignment between different stakeholders, the authors identified among other things insufficiently defined quality requirements and a culture that does not question management decisions.", [["the low alignment", "PROBLEM", 23, 40], ["a culture", "TEST", 163, 172], ["main", "OBSERVATION_MODIFIER", 7, 11]]], ["The authors indicate that if just one person or one function is responsible for the roadmapping process, the other stakeholders may not see the benefits from their viewpoints and therefore feel unmotivated.", [["person", "SPECIES", 38, 44]]], ["Finally, Suomalainen et al. [10] point out that typically 1-5 person should participate in the roadmapping process and identified the following as the most important stakeholders of the product roadmapping process: 1) product management, 2) marketing, 3) customer and partner representatives and 4) development including manufacturing and engineering.Research ApproachIn order to conduct the study in a systematic and repeatable manner, the study at hand follows the guidelines according to Garousi et al. [11] .", [["person", "SPECIES", 62, 68], ["the study", "TEST", 388, 397], ["the study", "TEST", 437, 446]]], ["The individual phases are described below.Planning the ReviewIdentification of the Need of a Grey Literature Review (GLR): First, we assessed whether a GLR is the appropriate method for our study.", [["our study", "TEST", 186, 195]]], ["For this purpose, we used the checklist developed by Garousi et al. [11] .", [["the checklist", "TEST", 26, 39]]], ["In order to obtain more insights, the conduction of a grey literature review is an appropriate approach and contributes to the transfer of practical knowledge in the scientific community.Planning the ReviewFormulation of the Research Question: Based on the study goals we have defined the following research question:Planning the Review\u2022 RQ1: Which measures, methods and techniques are reported in the grey literature in order to achieve alignment around the product roadmap?Planning the ReviewIdentification of the Search String: Our search term was developed in a brainstorming session that aimed at identifying grey literature about product roadmapping in general.", [["Review\u2022 RQ1", "PROTEIN", 330, 341], ["the study", "TEST", 253, 262]]], ["After the application of the selection process (1) Quality Assessment: The criterion for the quality assessment was that the reviewers were able to comprehend the suggested approach based on their practical experience.", [["the selection process", "TREATMENT", 25, 46], ["the quality assessment", "TEST", 89, 111]]], ["In addition, all steps of the selection procedure were carried out individually by two reviewers.", [["the selection procedure", "TREATMENT", 26, 49]]], ["In the case that the individual reviews led to different results, the process was carried out by a third reviewer to make a final inclusion/exclusion decision.Threats of ValidityWe use the framework based on Wohlin et al. [15] as the basis for the discussion of the validity of our study.", [["our study", "TEST", 278, 287]]], ["Internal validity: In order to mitigate this thread, the quality assessment was conducted by two reviewers independently to limit confirmation bias and interpretation bias.", [["the quality assessment", "TEST", 53, 75], ["validity", "OBSERVATION", 9, 17]]], ["In this context no major ambiguities or inconsistencies were found [15, 16] .ResultsIn order to answer our research question, we analyzed the relevant articles and identified the following measures, methods and techniques that can be used to gain alignment around the product roadmap.ResultsFoster Alignment with Shared Vision and Goals (OKRs).", [["methods and techniques", "TREATMENT", 199, 221]]], ["Khanna [17] presents an approach to reach vertical and horizontal alignment.", [["an approach", "TREATMENT", 21, 32], ["horizontal alignment", "OBSERVATION", 55, 75]]], ["In contrast, horizontal alignment represents the collaboration between product teams with other stakeholder such as design, engineering, operation and marketing.", [["operation", "TREATMENT", 137, 146]]], ["In this context, Harke [18] recommends using a mixture of a top-down and bottom-up approach.", [["a top", "TREATMENT", 58, 63]]], ["Besides the definition of a clear vision, Khanna [17] suggests utilizing the following activities: 1) the conduction of weekly progress updates between the management and the product teams in order to ensure that the product activities are focused towards institutional objectives, while fostering transparency across the different levels of the company, 2) the performance of regular cross-functional meetings on the operative level to discuss the future product strategy and eliminate ambiguities regarding the direction of the future product portfolio, and 3) the publication and communication of a product roadmap that lets product teams and stakeholders know which direction the company will take in the future and which topics can be expected.", [["the future product strategy", "TREATMENT", 445, 472]]], ["The presentation of recommendations at a meeting or the conduction of co-creation workshops can support alignment under certain conditions (e.g., if a culture exists that encourages constructive disagreement).", [["the conduction of co-creation workshops", "TREATMENT", 52, 91], ["a culture", "TEST", 149, 158]]], ["Therefore, Lombardo et al. recommend using software applications such as \"Roadmunk\", \"Aha!\" or \"ProductPlan\".", [["software applications", "TREATMENT", 43, 64]]], ["The combination of such tools with other communications and tracking tools (such as \"JIRA\"; \"Slack\", \"GoogleDocs\", \"Asana\" or \"Trello\") can help to create alignment by allowing the teams to agree on topics.", [["such tools", "PROBLEM", 19, 29]]], ["The tools also help to raise, manage and track issues and prioritize/reprioritize as necessary.ResultsMission Briefing.", [["prioritize/reprioritize", "TREATMENT", 58, 81]]], ["Within the section \"key implied tasks\" the forthcoming challenges as well as the persons who act as a contact person for the respective challenges are identified.", [["persons", "ORGANISM", 81, 88], ["persons", "SPECIES", 81, 88], ["person", "SPECIES", 110, 116]]], ["Finally, the overall scope for the other sections is described in the section \"boundaries\".ResultsBehavioural Change Stairway Model.", [["sections", "ANATOMY", 41, 49], ["the other sections", "TEST", 31, 49]]], ["Therefore, the author suggests using the socalled \"Behavioural Change Stairway Model\" that intends to take the negotiator from listening to influencing the behaviour of other persons.", [["persons", "ORGANISM", 175, 182], ["persons", "SPECIES", 175, 182]]], ["The model consists of the following five stages: 1) active listening (i.e., make an effort to empathically listen to other person while suspending judgement), 2) empathy (i.e., understand the perspective, needs and interests of each individual), 3) rapport (i.e., build rapport and establish trust) 4) influence (i.e., help other persons let go of their position and look for a solution that at least partially addresses the needs of each individual involved), 5) behavioural change (i.e., agree on an acceptable solution).SummaryAlignment with a product roadmap is extremely important to ensure that all product development activities contribute to the achievement of corporate goals.", [["person", "SPECIES", 123, 129], ["persons", "SPECIES", 330, 337], ["behavioural change", "PROBLEM", 464, 482]]], ["The aim is that every involved person identifies with this vision and directs his or her activities towards achieving this vision.", [["person", "SPECIES", 31, 37]]], ["Before applying any of these methods, it should be ensured that the expected results and the purpose of applying the method are clearly defined and communicated to the participants and that the way to achieve the results is well structured.", [["participants", "SPECIES", 168, 180], ["these methods", "TREATMENT", 23, 36], ["the method", "TREATMENT", 113, 123]]]], "7e232c192b439ef6a844be6a2f40bbbae64469fb": [["ResultsTargeting antigen to DCs induces humoral immunity.", [["DCs", "ANATOMY", 28, 31], ["DCs", "CELL", 28, 31], ["DCs", "CELL_TYPE", 28, 31]]], ["We first compared the OVA-specific humoral immune response after immunization with either \u03b1 DEC-205/OVA adjuvanted with Poly(I:C) and CpG (\u03b1 DEC-205/OVA + Poly(I:C)/CpG; for simplification termed \u03b1 DEC-205/OVA), BPPcysOVAMPEG or, in addition to the two DC targeting approaches, BPPcysMPEG co-administered together with soluble OVA (OVA + BPPcysMPEG).", [["DC", "ANATOMY", 253, 255], ["\u03b1 DEC-205", "CHEMICAL", 90, 99], ["Poly(I:C", "CHEMICAL", 120, 128], ["CpG", "CHEMICAL", 134, 137], ["\u03b1 DEC-205", "CHEMICAL", 139, 148], ["CpG", "CHEMICAL", 165, 168], ["\u03b1 DEC-205", "CHEMICAL", 196, 205], ["BPPcysOVAMPEG", "CHEMICAL", 212, 225], ["BPPcysMPEG", "CHEMICAL", 278, 288], ["Poly(I:C)", "CHEMICAL", 120, 129], ["CpG", "CHEMICAL", 134, 137], ["Poly(I:C)", "CHEMICAL", 155, 164], ["CpG", "CHEMICAL", 165, 168], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 90, 99], ["OVA", "SIMPLE_CHEMICAL", 100, 103], ["Poly(I:C", "SIMPLE_CHEMICAL", 120, 128], ["CpG", "SIMPLE_CHEMICAL", 134, 137], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 139, 148], ["Poly(I:C", "SIMPLE_CHEMICAL", 155, 163], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 196, 205], ["OVA", "SIMPLE_CHEMICAL", 206, 209], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 212, 225], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 278, 288], ["OVA", "SIMPLE_CHEMICAL", 327, 330], ["OVA + BPPcysMPEG", "SIMPLE_CHEMICAL", 332, 348], ["DC", "CELL_TYPE", 253, 255], ["immunization", "TREATMENT", 65, 77], ["Poly(I:C)", "TREATMENT", 120, 129], ["OVA + Poly(I:C)/CpG", "TREATMENT", 149, 168], ["BPPcysOVAMPEG", "TREATMENT", 212, 225], ["the two DC targeting approaches", "TREATMENT", 245, 276], ["BPPcysMPEG co-administered", "TREATMENT", 278, 304], ["soluble OVA (OVA + BPPcysMPEG)", "TREATMENT", 319, 349]]], ["As controls we included \u03b1 DEC-205 and OVA alone, both adjuvanted with Poly(I:C) and CpG as well as BPPcysMPEG alone, OVA peptides alone, and OVA peptides adjuvanted with BPPcysMPEG.ResultsAlready after two vaccinations with \u03b1 DEC-205/OVA, we observed a strong OVA-specific IgG response ( Fig. 1A ) that was significantly increased in comparison to both the OVA + BPPcysMPEG and the OVA + Poly(I:C)/CpG groups at this time (Fig. 1B ).", [["\u03b1 DEC-205", "CHEMICAL", 24, 33], ["OVA", "CHEMICAL", 38, 41], ["Poly", "CHEMICAL", 70, 74], ["CpG", "CHEMICAL", 84, 87], ["BPPcysMPEG", "CHEMICAL", 99, 109], ["BPPcysMPEG", "CHEMICAL", 170, 180], ["\u03b1 DEC-205", "CHEMICAL", 224, 233], ["BPPcysMPEG", "CHEMICAL", 363, 373], ["Poly", "CHEMICAL", 388, 392], ["CpG", "CHEMICAL", 398, 401], ["CpG", "CHEMICAL", 84, 87], ["BPPcysMPEG", "CHEMICAL", 99, 109], ["Poly(I:C", "CHEMICAL", 388, 396], ["CpG", "CHEMICAL", 398, 401], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 24, 33], ["OVA", "SIMPLE_CHEMICAL", 38, 41], ["Poly(I:C", "SIMPLE_CHEMICAL", 70, 78], ["CpG", "SIMPLE_CHEMICAL", 84, 87], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 99, 109], ["OVA peptides", "SIMPLE_CHEMICAL", 117, 129], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 170, 180], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 224, 233], ["OVA", "SIMPLE_CHEMICAL", 234, 237], ["OVA", "SIMPLE_CHEMICAL", 260, 263], ["IgG", "GENE_OR_GENE_PRODUCT", 273, 276], ["Poly(I:C", "SIMPLE_CHEMICAL", 388, 396], ["IgG", "PROTEIN", 273, 276], ["Poly(I:C)", "TREATMENT", 70, 79], ["CpG", "TREATMENT", 84, 87], ["BPPcysMPEG alone", "TREATMENT", 99, 115], ["OVA peptides", "TREATMENT", 117, 129], ["OVA peptides", "TREATMENT", 141, 153], ["BPPcysMPEG", "TREATMENT", 170, 180], ["the OVA", "TEST", 353, 360], ["the OVA + Poly(I:C)/CpG groups", "TREATMENT", 378, 408]]], ["Mice vaccinated with the novel antigen targeting system BPPcysOVAMPEG initially exhibited a weaker IgG response, which was however strongly enhanced following the third boost ( Fig. 1A,C) .ResultsWe next compared OVA-specific IgG 1 and IgG 2c titres which represent the main IgG isotypes stimulated by Th2 and Th1 cells, respectively 26 .", [["Th1 cells", "ANATOMY", 310, 319], ["Mice", "ORGANISM", 0, 4], ["IgG", "GENE_OR_GENE_PRODUCT", 99, 102], ["OVA", "SIMPLE_CHEMICAL", 213, 216], ["IgG 1", "GENE_OR_GENE_PRODUCT", 226, 231], ["IgG 2c", "GENE_OR_GENE_PRODUCT", 236, 242], ["Th2", "CELL", 302, 305], ["Th1 cells", "CELL", 310, 319], ["BPPcysOVAMPEG", "PROTEIN", 56, 69], ["IgG", "PROTEIN", 99, 102], ["IgG 1", "PROTEIN", 226, 231], ["IgG 2c", "PROTEIN", 236, 242], ["IgG isotypes", "PROTEIN", 275, 287], ["Th2 and Th1 cells", "CELL_TYPE", 302, 319], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["Mice vaccinated", "TREATMENT", 0, 15], ["a weaker IgG response", "PROBLEM", 90, 111], ["OVA", "TEST", 213, 216], ["IgG", "TEST", 226, 229], ["IgG 2c titres", "TEST", 236, 249], ["the main IgG isotypes", "TEST", 266, 287], ["weaker", "OBSERVATION_MODIFIER", 92, 98], ["IgG response", "OBSERVATION", 99, 111], ["main", "OBSERVATION_MODIFIER", 270, 274], ["IgG isotypes", "OBSERVATION", 275, 287]]], ["Vaccination with either \u03b1 DEC-205/OVA, OVA + Poly(I:C)/CpG or BPPcysOVAMPEG induced a rather balanced IgG 1 /IgG 2c ratio, whereas OVA + BPPcysMPEG induced substantially higher IgG 1 than IgG 2c titres, pointing towards a more Th2-dominated immune response (Fig. 1D ).", [["\u03b1 DEC-205", "CHEMICAL", 24, 33], ["OVA", "CHEMICAL", 39, 42], ["Poly", "CHEMICAL", 45, 49], ["CpG", "CHEMICAL", 55, 58], ["BPPcysOVAMPEG", "CHEMICAL", 62, 75], ["OVA", "CHEMICAL", 131, 134], ["BPPcysMPEG", "CHEMICAL", 137, 147], ["CpG", "CHEMICAL", 55, 58], ["BPPcysOVAMPEG", "CHEMICAL", 62, 75], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 24, 33], ["OVA", "SIMPLE_CHEMICAL", 34, 37], ["OVA", "SIMPLE_CHEMICAL", 39, 42], ["Poly(I:C", "SIMPLE_CHEMICAL", 45, 53], ["CpG", "SIMPLE_CHEMICAL", 55, 58], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 62, 75], ["IgG 1", "GENE_OR_GENE_PRODUCT", 102, 107], ["IgG 2c", "GENE_OR_GENE_PRODUCT", 109, 115], ["OVA + BPPcysMPEG", "SIMPLE_CHEMICAL", 131, 147], ["IgG 1", "GENE_OR_GENE_PRODUCT", 177, 182], ["IgG 2c", "GENE_OR_GENE_PRODUCT", 188, 194], ["IgG 1", "PROTEIN", 102, 107], ["IgG 2c", "PROTEIN", 109, 115], ["IgG 1", "PROTEIN", 177, 182], ["IgG 2c", "PROTEIN", 188, 194], ["Vaccination", "TREATMENT", 0, 11], ["CpG", "PROBLEM", 55, 58], ["BPPcysOVAMPEG", "TREATMENT", 62, 75], ["a rather balanced IgG", "TEST", 84, 105], ["IgG 2c ratio", "TEST", 109, 121], ["OVA", "TEST", 131, 134], ["BPPcysMPEG", "TEST", 137, 147], ["substantially higher IgG", "PROBLEM", 156, 180], ["IgG 2c titres", "TEST", 188, 201]]], ["As expected, neither the injection of the adjuvant BPPcysMPEG alone, nor the vaccination with the immunodominant CD4 + and CD8 + OVA peptides without adjuvant did induce humoral immunity.", [["BPPcysMPEG", "CHEMICAL", 51, 61], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 51, 61], ["CD4", "GENE_OR_GENE_PRODUCT", 113, 116], ["CD8", "GENE_OR_GENE_PRODUCT", 123, 126], ["CD4", "PROTEIN", 113, 116], ["CD8", "PROTEIN", 123, 126], ["the adjuvant BPPcysMPEG", "TREATMENT", 38, 61], ["the immunodominant CD4", "TEST", 94, 116], ["CD8 + OVA peptides", "TREATMENT", 123, 141], ["adjuvant", "TREATMENT", 150, 158]]], ["Moreover, peptide targeting to DCs by means of vaccination with BPPcysOVAMPEG was superior in inducing antibody responses than vaccination with soluble peptides adjuvanted with BPPcysMPEG ( Supplementary Fig. S1A -C).ResultsInduction of CTLs following \u03b1DEC-205/OVA and BPPcysOVAMPEG immunization.", [["DCs", "ANATOMY", 31, 34], ["BPPcysOVAMPEG", "CHEMICAL", 64, 77], ["BPPcysMPEG", "CHEMICAL", 177, 187], ["\u03b1DEC-205", "CHEMICAL", 252, 260], ["OVA", "CHEMICAL", 261, 264], ["BPPcysOVAMPEG", "CHEMICAL", 269, 282], ["DCs", "CELL", 31, 34], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 64, 77], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 177, 187], ["S1A -C", "GENE_OR_GENE_PRODUCT", 209, 215], ["CTLs", "CELL", 237, 241], ["\u03b1DEC-205", "SIMPLE_CHEMICAL", 252, 260], ["OVA", "SIMPLE_CHEMICAL", 261, 264], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 269, 282], ["DCs", "CELL_TYPE", 31, 34], ["S1A", "PROTEIN", 209, 212], ["CTLs", "CELL_TYPE", 237, 241], ["vaccination", "TREATMENT", 47, 58], ["BPPcysOVAMPEG", "TREATMENT", 64, 77], ["vaccination with soluble peptides", "TREATMENT", 127, 160], ["BPPcysMPEG ( Supplementary Fig", "TREATMENT", 177, 207], ["CTLs", "TEST", 237, 241], ["BPPcysOVAMPEG immunization", "TREATMENT", 269, 295]]], ["To further characterize the type of T cell response induced with the different vaccine formulations, OVA-specific IL-4-and IFN\u03b3 -secreting T cells were evaluated by ex vivo stimulation of splenocytes from immunized mice with the dominant OVA MHC-I and -II peptides.", [["T cell", "ANATOMY", 36, 42], ["T cells", "ANATOMY", 139, 146], ["splenocytes", "ANATOMY", 188, 199], ["T cell", "CELL", 36, 42], ["OVA", "SIMPLE_CHEMICAL", 101, 104], ["IL-4", "GENE_OR_GENE_PRODUCT", 114, 118], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 123, 127], ["T cells", "CELL", 139, 146], ["splenocytes", "CELL", 188, 199], ["mice", "ORGANISM", 215, 219], ["MHC-I", "GENE_OR_GENE_PRODUCT", 242, 247], ["-II peptides", "GENE_OR_GENE_PRODUCT", 252, 264], ["IL-4", "PROTEIN", 114, 118], ["IFN\u03b3", "PROTEIN", 123, 127], ["secreting T cells", "CELL_TYPE", 129, 146], ["splenocytes", "CELL_TYPE", 188, 199], ["MHC", "PROTEIN", 242, 245], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 215, 219], ["T cell response", "PROBLEM", 36, 51], ["the different vaccine formulations", "TREATMENT", 65, 99], ["OVA", "PROBLEM", 101, 104], ["specific IL", "TEST", 105, 116], ["IFN", "TREATMENT", 123, 126], ["secreting T cells", "PROBLEM", 129, 146], ["splenocytes", "PROBLEM", 188, 199], ["immunized mice", "TREATMENT", 205, 219], ["splenocytes", "ANATOMY", 188, 199]]], ["As expected, due to the exclusive selection towards these epitopes when immunizing with BPPcysOVAMPEG, the highest number of cytokine producing T cells was observed in this group ( Fig. 2A-C) .", [["T cells", "ANATOMY", 144, 151], ["2A-C", "CHEMICAL", 186, 190], ["2A-C", "CHEMICAL", 186, 190], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 88, 101], ["T cells", "CELL", 144, 151], ["2A-C", "SIMPLE_CHEMICAL", 186, 190], ["epitopes", "PROTEIN", 58, 66], ["BPPcysOVAMPEG", "PROTEIN", 88, 101], ["cytokine producing T cells", "CELL_TYPE", 125, 151], ["these epitopes", "TREATMENT", 52, 66], ["BPPcysOVAMPEG", "TREATMENT", 88, 101], ["cytokine producing T cells", "PROBLEM", 125, 151]]], ["BPPcysOVAMPEG vaccination induced increased numbers of IL-4-producing Th2 cells compared to the \u03b1 DEC-205/OVA and OVA + Poly(I:C)/CpG immunized groups ( Fig. 2A) .", [["Th2 cells", "ANATOMY", 70, 79], ["BPPcysOVAMPEG", "CHEMICAL", 0, 13], ["\u03b1 DEC-205", "CHEMICAL", 96, 105], ["CpG", "CHEMICAL", 130, 133], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 0, 13], ["IL-4", "GENE_OR_GENE_PRODUCT", 55, 59], ["Th2 cells", "CELL", 70, 79], ["OVA", "ORGANISM", 106, 109], ["OVA", "ORGANISM", 114, 117], ["Poly(I:C", "SIMPLE_CHEMICAL", 120, 128], ["IL-4", "PROTEIN", 55, 59], ["Th2 cells", "CELL_TYPE", 70, 79], ["BPPcysOVAMPEG vaccination", "TREATMENT", 0, 25], ["IL", "TEST", 55, 57], ["Th2 cells", "PROBLEM", 70, 79], ["OVA + Poly(I:C)/CpG immunized groups", "TREATMENT", 114, 150], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["numbers", "OBSERVATION_MODIFIER", 44, 51]]], ["Compared to the vaccine formulations lacking direct antigen targeting to DCs, BPPcysOVAMPEG, and to a lesser extent \u03b1 DEC-205/OVA immunization, at the same time showed the strongest potential to induce IFN\u03b3 -producing T cells (Fig. 2B,C) .", [["DCs", "ANATOMY", 73, 76], ["T cells", "ANATOMY", 218, 225], ["BPPcysOVAMPEG", "CHEMICAL", 78, 91], ["\u03b1", "CHEMICAL", 116, 117], ["DEC-205", "CHEMICAL", 118, 125], ["DCs", "CELL", 73, 76], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 78, 91], ["OVA", "SIMPLE_CHEMICAL", 126, 129], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 202, 206], ["T cells", "CELL", 218, 225], ["Fig. 2B,C", "CELL", 227, 236], ["DCs", "CELL_TYPE", 73, 76], ["IFN\u03b3", "PROTEIN", 202, 206], ["T cells", "CELL_TYPE", 218, 225], ["the vaccine formulations", "TREATMENT", 12, 36], ["OVA immunization", "TREATMENT", 126, 142], ["IFN", "TEST", 202, 205]]], ["Of note, the adjuvant BPPcysMPEG alone or vaccination with non-adjuvanted immunodominant OVA peptides did not induce IFN\u03b3 -producing T cells.", [["T cells", "ANATOMY", 133, 140], ["BPPcysMPEG", "CHEMICAL", 22, 32], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 22, 32], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 117, 121], ["T cells", "CELL", 133, 140], ["IFN\u03b3", "PROTEIN", 117, 121], ["T cells", "CELL_TYPE", 133, 140], ["the adjuvant BPPcysMPEG alone", "TREATMENT", 9, 38], ["vaccination", "TREATMENT", 42, 53], ["non-adjuvanted immunodominant OVA peptides", "PROBLEM", 59, 101], ["IFN", "TEST", 117, 120]]], ["Furthermore, peptide targeting to DCs using the BPPcyOVAMPEG formulation induced significantly more IFN\u03b3 -producing T cells than vaccination of mice using peptides adjuvanted with BPPcysMPEG ( Supplementary Fig. S1D -G).ResultsSince IFN\u03b3 -producing CTLs are important for virus clearance from the liver 27 , we evaluated OVA-specific CTL activity in vaccinated mice.", [["DCs", "ANATOMY", 34, 37], ["T cells", "ANATOMY", 116, 123], ["CTLs", "ANATOMY", 249, 253], ["liver", "ANATOMY", 297, 302], ["BPPcyOVAMPEG", "CHEMICAL", 48, 60], ["BPPcysMPEG", "CHEMICAL", 180, 190], ["DCs", "CELL", 34, 37], ["BPPcyOVAMPEG", "SIMPLE_CHEMICAL", 48, 60], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 100, 104], ["T cells", "CELL", 116, 123], ["mice", "ORGANISM", 144, 148], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 180, 190], ["S1D -G", "GENE_OR_GENE_PRODUCT", 212, 218], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 233, 237], ["CTLs", "CELL", 249, 253], ["liver", "ORGAN", 297, 302], ["OVA", "SIMPLE_CHEMICAL", 321, 324], ["CTL", "GENE_OR_GENE_PRODUCT", 334, 337], ["mice", "ORGANISM", 361, 365], ["DCs", "CELL_TYPE", 34, 37], ["IFN\u03b3", "PROTEIN", 100, 104], ["T cells", "CELL_TYPE", 116, 123], ["S1D", "PROTEIN", 212, 215], ["IFN\u03b3", "PROTEIN", 233, 237], ["CTLs", "CELL_TYPE", 249, 253], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 361, 365], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 361, 365], ["the BPPcyOVAMPEG formulation", "TREATMENT", 44, 72], ["vaccination of mice using peptides", "TREATMENT", 129, 163], ["BPPcysMPEG ( Supplementary Fig", "TREATMENT", 180, 210], ["IFN", "TEST", 233, 236], ["CTLs", "PROBLEM", 249, 253], ["virus clearance", "TEST", 272, 287], ["OVA", "PROBLEM", 321, 324], ["liver", "ANATOMY", 297, 302]]], ["Immunization with \u03b1 DEC-205/OVA or BPPcysOVAMPEG induced a robust Scientific RepoRts | 7:43985 | DOI: 10.1038/srep43985 OVA-specific CTL response already after the first immunization (Fig. 2D) .", [["\u03b1 DEC-205", "CHEMICAL", 18, 27], ["OVA", "CHEMICAL", 28, 31], ["BPPcysOVAMPEG", "CHEMICAL", 35, 48], ["DOI", "CHEMICAL", 97, 100], ["DOI", "CHEMICAL", 97, 100], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 18, 27], ["OVA", "SIMPLE_CHEMICAL", 28, 31], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 35, 48], ["Immunization", "TREATMENT", 0, 12], ["OVA", "PROBLEM", 120, 123], ["the first immunization", "TREATMENT", 160, 182]]], ["Despite the fact that IFN\u03b3 -producing CD8 + T cells were also induced in OVA + BPPcysMPEG immunized mice (Fig. 2C ) no lysis of target cells was detectable in this group (Fig. 2D) .", [["CD8 + T cells", "ANATOMY", 38, 51], ["cells", "ANATOMY", 135, 140], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 22, 26], ["CD8", "GENE_OR_GENE_PRODUCT", 38, 41], ["OVA + BPPcysMPEG", "ORGANISM", 73, 89], ["mice", "ORGANISM", 100, 104], ["cells", "CELL", 135, 140], ["IFN\u03b3", "PROTEIN", 22, 26], ["CD8 + T cells", "CELL_TYPE", 38, 51], ["target cells", "CELL_TYPE", 128, 140], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 100, 104], ["IFN", "TEST", 22, 25], ["T cells", "PROBLEM", 44, 51], ["lysis of target cells", "PROBLEM", 119, 140]]], ["Thus, while antigen delivery to DCs by targeting DEC-205 resulted in a rather weak and balanced Th1 (IFN\u03b3 ) and Th2 (IL-4) cell response, it was highly effective in generating antigen-specific CTLs.", [["DCs", "ANATOMY", 32, 35], ["-4) cell", "ANATOMY", 119, 127], ["CTLs", "ANATOMY", 193, 197], ["DEC-205", "CHEMICAL", 49, 56], ["antigen", "GENE_OR_GENE_PRODUCT", 12, 19], ["DCs", "CELL", 32, 35], ["DEC-205", "GENE_OR_GENE_PRODUCT", 49, 56], ["Th1", "GENE_OR_GENE_PRODUCT", 96, 99], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 101, 105], ["IL-4", "GENE_OR_GENE_PRODUCT", 117, 121], ["CTLs", "CELL", 193, 197], ["DCs", "CELL_TYPE", 32, 35], ["CTLs", "CELL_TYPE", 193, 197], ["a rather weak", "PROBLEM", 69, 82], ["Th2", "TEST", 112, 115], ["IL", "TEST", 117, 119], ["cell response", "TEST", 123, 136]]], ["Similarly, BPPcysOVAMPEG-mediated antigen targeting to TLR2/6 induced balanced Th1/Th2 T helper and robust OVA-specific CTL responses.ResultsTargeted antigen delivery to DCs induces IFN\u03b3-producing memory CD8 + T cells in the liver.", [["DCs", "ANATOMY", 170, 173], ["memory CD8 + T cells", "ANATOMY", 197, 217], ["liver", "ANATOMY", 225, 230], ["BPPcysOVAMPEG", "CHEMICAL", 11, 24], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 11, 24], ["TLR2", "GENE_OR_GENE_PRODUCT", 55, 59], ["6", "GENE_OR_GENE_PRODUCT", 60, 61], ["Th1", "GENE_OR_GENE_PRODUCT", 79, 82], ["CTL", "CELL", 120, 123], ["DCs", "CELL", 170, 173], ["IFN\u03b3-", "GENE_OR_GENE_PRODUCT", 182, 187], ["CD8", "GENE_OR_GENE_PRODUCT", 204, 207], ["liver", "ORGAN", 225, 230], ["BPPcysOVAMPEG", "PROTEIN", 11, 24], ["TLR2/6", "PROTEIN", 55, 61], ["DCs", "CELL_TYPE", 170, 173], ["IFN\u03b3-producing memory CD8 + T cells", "CELL_TYPE", 182, 217], ["BPPcysOVAMPEG", "TEST", 11, 24], ["TLR2", "TEST", 55, 59], ["IFN", "PROBLEM", 182, 185], ["T cells in the liver", "PROBLEM", 210, 230], ["liver", "ANATOMY", 225, 230]]], ["To test whether CTLs induced by antigen delivery to DCs can effectively recognize and eliminate virus infected hepatocytes, a hepatotropic adenovirus challenge model was utilized (Fig. 3A) .", [["DCs", "ANATOMY", 52, 55], ["hepatocytes", "ANATOMY", 111, 122], ["CTLs", "CELL", 16, 20], ["antigen", "GENE_OR_GENE_PRODUCT", 32, 39], ["DCs", "CELL", 52, 55], ["hepatocytes", "CELL", 111, 122], ["adenovirus", "ORGANISM", 139, 149], ["CTLs", "CELL_TYPE", 16, 20], ["DCs", "CELL_TYPE", 52, 55], ["virus infected hepatocytes", "CELL_TYPE", 96, 122], ["adenovirus", "SPECIES", 139, 149], ["CTLs", "PROBLEM", 16, 20], ["antigen delivery", "TREATMENT", 32, 48], ["virus infected hepatocytes", "PROBLEM", 96, 122], ["a hepatotropic adenovirus challenge model", "TREATMENT", 124, 165]]], ["Immunized mice were infected with a recombinant adenovirus (AdOVA-GFP-luc) leading to the MHC-I presentation of the OVA CD8 257-264 peptide on infected hepatocytes.", [["hepatocytes", "ANATOMY", 152, 163], ["257-264", "CHEMICAL", 124, 131], ["mice", "ORGANISM", 10, 14], ["adenovirus", "ORGANISM", 48, 58], ["AdOVA-GFP", "GENE_OR_GENE_PRODUCT", 60, 69], ["luc", "GENE_OR_GENE_PRODUCT", 70, 73], ["MHC-I", "GENE_OR_GENE_PRODUCT", 90, 95], ["CD8", "GENE_OR_GENE_PRODUCT", 120, 123], ["hepatocytes", "CELL", 152, 163], ["recombinant adenovirus (AdOVA-GFP-luc", "DNA", 36, 73], ["MHC", "PROTEIN", 90, 93], ["infected hepatocytes", "CELL_TYPE", 143, 163], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["adenovirus", "SPECIES", 48, 58], ["a recombinant adenovirus", "TREATMENT", 34, 58], ["the OVA CD8", "TEST", 112, 123], ["infected hepatocytes", "PROBLEM", 143, 163], ["hepatocytes", "ANATOMY", 152, 163]]], ["Furthermore, AdOVA-GFP-luc infected cells express EGFP (enhanced green fluorescent protein) and luciferase, allowing the quantification of the infection (Fig. 3A) 28 .", [["cells", "ANATOMY", 36, 41], ["infection", "DISEASE", 143, 152], ["AdOVA-GFP", "GENE_OR_GENE_PRODUCT", 13, 22], ["cells", "CELL", 36, 41], ["EGFP", "GENE_OR_GENE_PRODUCT", 50, 54], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 65, 90], ["luciferase", "GENE_OR_GENE_PRODUCT", 96, 106], ["AdOVA", "PROTEIN", 13, 18], ["GFP", "PROTEIN", 19, 22], ["EGFP", "PROTEIN", 50, 54], ["enhanced green fluorescent protein", "PROTEIN", 56, 90], ["luciferase", "PROTEIN", 96, 106], ["Furthermore", "TEST", 0, 11], ["AdOVA", "TEST", 13, 18], ["GFP", "TEST", 19, 22], ["luc infected cells", "PROBLEM", 23, 41], ["luciferase", "TEST", 96, 106], ["the infection", "PROBLEM", 139, 152], ["infection", "OBSERVATION", 143, 152]]], ["While infection of one-way Anova (mean \u00b1 SD) (p < 0.0001).", [["infection", "DISEASE", 6, 15], ["infection", "PROBLEM", 6, 15], ["infection", "OBSERVATION", 6, 15]]], ["Bars represent the mean \u00b1 SEM (n = 5, triplicates from pooled animals) of three independent experiments (p < 0.05, *p \u2264 0.0007). \u03b1 DEC-205 mock-immunized mice with AdOVA-GFP-luc did not lead to an accumulation of CD44 high CD8 + T cells in the liver, an accumulation of intrahepatic CD44 high CD8 + T cells was detectable in all other experimental groups following AdOVA-GFP-luc infection (Fig. 3B) .ResultsThe release of IFN\u03b3 by CTLs has been shown to mediate non-cytolytic clearance of infected hepatocytes and IFN\u03b3 per se directly inhibits viral replication in the liver 29, 30 .", [["CD44 high CD8 + T cells", "ANATOMY", 213, 236], ["liver", "ANATOMY", 244, 249], ["intrahepatic CD44 high CD8 + T cells", "ANATOMY", 270, 306], ["hepatocytes", "ANATOMY", 497, 508], ["liver", "ANATOMY", 568, 573], ["\u03b1 DEC-205", "CHEMICAL", 129, 138], ["AdOVA", "CHEMICAL", 365, 370], ["infection", "DISEASE", 379, 388], ["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 154, 158], ["AdOVA", "GENE_OR_GENE_PRODUCT", 164, 169], ["GFP", "GENE_OR_GENE_PRODUCT", 170, 173], ["luc", "GENE_OR_GENE_PRODUCT", 174, 177], ["CD44", "GENE_OR_GENE_PRODUCT", 213, 217], ["CD8", "GENE_OR_GENE_PRODUCT", 223, 226], ["liver", "ORGAN", 244, 249], ["CD44", "GENE_OR_GENE_PRODUCT", 283, 287], ["CD8", "GENE_OR_GENE_PRODUCT", 293, 296], ["GFP", "GENE_OR_GENE_PRODUCT", 371, 374], ["luc", "ORGANISM", 375, 378], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 422, 426], ["CTLs", "CELL", 430, 434], ["hepatocytes", "CELL", 497, 508], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 513, 517], ["liver", "ORGAN", 568, 573], ["AdOVA-GFP-luc", "DNA", 164, 177], ["CD44", "PROTEIN", 213, 217], ["CD8", "PROTEIN", 223, 226], ["T cells", "CELL_TYPE", 229, 236], ["intrahepatic CD44 high CD8 + T cells", "CELL_TYPE", 270, 306], ["IFN\u03b3", "PROTEIN", 422, 426], ["CTLs", "CELL_TYPE", 430, 434], ["infected hepatocytes", "CELL_TYPE", 488, 508], ["IFN\u03b3", "PROTEIN", 513, 517], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 154, 158], ["the mean \u00b1 SEM", "TEST", 15, 29], ["CD44", "TEST", 213, 217], ["T cells in the liver", "PROBLEM", 229, 249], ["intrahepatic CD44", "TEST", 270, 287], ["T cells", "PROBLEM", 299, 306], ["AdOVA", "TEST", 365, 370], ["GFP", "TEST", 371, 374], ["luc infection", "PROBLEM", 375, 388], ["IFN\u03b3", "TREATMENT", 422, 426], ["infected hepatocytes", "PROBLEM", 488, 508], ["IFN", "TREATMENT", 513, 516], ["viral replication in the liver", "PROBLEM", 543, 573], ["T cells", "OBSERVATION", 229, 236], ["liver", "ANATOMY", 244, 249], ["accumulation", "OBSERVATION_MODIFIER", 254, 266], ["intrahepatic", "ANATOMY", 270, 282], ["luc infection", "OBSERVATION", 375, 388], ["infected", "OBSERVATION", 488, 496], ["hepatocytes", "ANATOMY", 497, 508], ["viral replication", "OBSERVATION", 543, 560], ["liver", "ANATOMY", 568, 573]]], ["While hardly any IFN\u03b3 production was detectable in the hepatic CD44 -CD8 + T cells (Fig. 3C) , the AdOVA-GFP-luc challenge resulted in a nearly two-fold increase of the proportion of IFN\u03b3 -producing CD44 high CD8 + T cells in the OVA + BPPcysMPEG (11.3%) and Presence of IFN\u03b3 + CD44 high CD8 + effector T cells in the liver correlates with hepatitis development following AdOVA-GFP-luc challenge.", [["hepatic CD44 -CD8 + T cells", "ANATOMY", 55, 82], ["CD44 high CD8 + T cells", "ANATOMY", 199, 222], ["+ CD44 high CD8 + effector T cells", "ANATOMY", 276, 310], ["liver", "ANATOMY", 318, 323], ["hepatitis", "DISEASE", 340, 349], ["AdOVA-GFP", "CHEMICAL", 372, 381], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 17, 21], ["CD44", "GENE_OR_GENE_PRODUCT", 63, 67], ["CD8", "GENE_OR_GENE_PRODUCT", 69, 72], ["AdOVA", "GENE_OR_GENE_PRODUCT", 99, 104], ["GFP", "GENE_OR_GENE_PRODUCT", 105, 108], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 183, 187], ["CD44", "GENE_OR_GENE_PRODUCT", 199, 203], ["CD8", "GENE_OR_GENE_PRODUCT", 209, 212], ["CD44", "GENE_OR_GENE_PRODUCT", 278, 282], ["CD8", "GENE_OR_GENE_PRODUCT", 288, 291], ["liver", "ORGAN", 318, 323], ["AdOVA", "SIMPLE_CHEMICAL", 372, 377], ["GFP", "GENE_OR_GENE_PRODUCT", 378, 381], ["luc", "ORGANISM", 382, 385], ["IFN\u03b3", "PROTEIN", 17, 21], ["hepatic CD44 -CD8 + T cells", "CELL_TYPE", 55, 82], ["AdOVA", "PROTEIN", 99, 104], ["GFP", "PROTEIN", 105, 108], ["IFN\u03b3", "PROTEIN", 183, 187], ["CD44 high CD8 + T cells", "CELL_TYPE", 199, 222], ["IFN", "PROTEIN", 271, 274], ["CD44", "PROTEIN", 278, 282], ["CD8 + effector T cells", "CELL_TYPE", 288, 310], ["the hepatic CD44", "TEST", 51, 67], ["the AdOVA", "TEST", 95, 104], ["luc challenge", "TEST", 109, 122], ["IFN\u03b3", "TEST", 183, 187], ["T cells", "PROBLEM", 215, 222], ["the OVA", "TEST", 226, 233], ["BPPcysMPEG", "TEST", 236, 246], ["IFN", "PROBLEM", 271, 274], ["CD44", "TEST", 278, 282], ["hepatitis development", "PROBLEM", 340, 361], ["AdOVA", "TEST", 372, 377], ["hepatic", "ANATOMY", 55, 62], ["CD44", "OBSERVATION_MODIFIER", 278, 282], ["high CD8 +", "OBSERVATION", 283, 293], ["effector T cells", "OBSERVATION", 294, 310], ["liver", "ANATOMY", 318, 323], ["hepatitis", "OBSERVATION", 340, 349]]], ["We next asked whether the IFN\u03b3 -producing effector memory CD8 + T cells in the liver would respond to virus-expressed antigen on hepatocytes.", [["effector memory CD8 + T cells", "ANATOMY", 42, 71], ["liver", "ANATOMY", 79, 84], ["hepatocytes", "ANATOMY", 129, 140], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 26, 30], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["liver", "ORGAN", 79, 84], ["hepatocytes", "CELL", 129, 140], ["IFN\u03b3", "PROTEIN", 26, 30], ["effector memory CD8 + T cells", "CELL_TYPE", 42, 71], ["hepatocytes", "CELL_TYPE", 129, 140], ["the IFN\u03b3", "TEST", 22, 30], ["T cells in the liver", "PROBLEM", 64, 84], ["virus", "PROBLEM", 102, 107], ["liver", "ANATOMY", 79, 84], ["hepatocytes", "ANATOMY", 129, 140]]], ["While Ad-GFP-luc control infection induced only marginal hepatocellular cell death or cellular infiltrations (Fig. 4A) , infection of all OVA-immunized groups with AdOVA-GFP-luc led to drastic histological lesions in the liver, hepatocellular cell death and marked infiltration of lymphocytes and macrophages into the tissue (Fig. 4A -C).", [["hepatocellular cell", "ANATOMY", 57, 76], ["cellular", "ANATOMY", 86, 94], ["lesions", "ANATOMY", 206, 213], ["liver", "ANATOMY", 221, 226], ["hepatocellular cell", "ANATOMY", 228, 247], ["lymphocytes", "ANATOMY", 281, 292], ["macrophages", "ANATOMY", 297, 308], ["tissue", "ANATOMY", 318, 324], ["infection", "DISEASE", 25, 34], ["infection", "DISEASE", 121, 130], ["AdOVA", "CHEMICAL", 164, 169], ["4A -C", "CHEMICAL", 331, 336], ["Ad", "ORGANISM", 6, 8], ["GFP", "GENE_OR_GENE_PRODUCT", 9, 12], ["hepatocellular cell", "CELL", 57, 76], ["cellular", "CELL", 86, 94], ["AdOVA", "SIMPLE_CHEMICAL", 164, 169], ["GFP", "GENE_OR_GENE_PRODUCT", 170, 173], ["luc", "GENE_OR_GENE_PRODUCT", 174, 177], ["histological lesions", "PATHOLOGICAL_FORMATION", 193, 213], ["liver", "ORGAN", 221, 226], ["hepatocellular cell", "CELL", 228, 247], ["lymphocytes", "CELL", 281, 292], ["macrophages", "CELL", 297, 308], ["tissue", "TISSUE", 318, 324], ["4A -C", "SIMPLE_CHEMICAL", 331, 336], ["GFP", "PROTEIN", 9, 12], ["AdOVA-GFP-luc", "DNA", 164, 177], ["lymphocytes", "CELL_TYPE", 281, 292], ["macrophages", "CELL_TYPE", 297, 308], ["luc control infection", "PROBLEM", 13, 34], ["marginal hepatocellular cell death", "PROBLEM", 48, 82], ["cellular infiltrations", "PROBLEM", 86, 108], ["infection", "PROBLEM", 121, 130], ["all OVA", "PROBLEM", 134, 141], ["AdOVA", "TEST", 164, 169], ["drastic histological lesions in the liver", "PROBLEM", 185, 226], ["hepatocellular cell death", "PROBLEM", 228, 253], ["marked infiltration of lymphocytes", "PROBLEM", 258, 292], ["marginal", "OBSERVATION_MODIFIER", 48, 56], ["hepatocellular cell death", "OBSERVATION", 57, 82], ["cellular infiltrations", "OBSERVATION", 86, 108], ["drastic", "OBSERVATION_MODIFIER", 185, 192], ["histological", "OBSERVATION_MODIFIER", 193, 205], ["lesions", "OBSERVATION", 206, 213], ["liver", "ANATOMY", 221, 226], ["hepatocellular", "ANATOMY", 228, 242], ["cell death", "OBSERVATION", 243, 253], ["marked", "OBSERVATION_MODIFIER", 258, 264], ["infiltration", "OBSERVATION", 265, 277], ["lymphocytes", "OBSERVATION", 281, 292], ["tissue", "ANATOMY", 318, 324], ["Fig", "OBSERVATION_MODIFIER", 326, 329]]], ["Since histological scoring revealed a trend towards an enhanced immunopathology in the liver of \u03b1 DEC-205/OVA immunized and AdOVA-GFP-luc infected mice compared to the BPPcysOVAMPEG group, we further elucidated whether \u03b1 DEC-205/OVA and BPPcysOVAMPEG vaccination would result in distinct immune cell recruitment following viral infection.", [["liver", "ANATOMY", 87, 92], ["immune cell", "ANATOMY", 288, 299], ["\u03b1 DEC-205", "CHEMICAL", 96, 105], ["\u03b1 DEC-205", "CHEMICAL", 219, 228], ["OVA", "CHEMICAL", 229, 232], ["BPPcysOVAMPEG", "CHEMICAL", 237, 250], ["viral infection", "DISEASE", 322, 337], ["liver", "ORGAN", 87, 92], ["OVA immunized", "ORGANISM", 106, 119], ["AdOVA", "GENE_OR_GENE_PRODUCT", 124, 129], ["GFP", "GENE_OR_GENE_PRODUCT", 130, 133], ["luc", "GENE_OR_GENE_PRODUCT", 134, 137], ["mice", "ORGANISM", 147, 151], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 168, 181], ["\u03b1", "SIMPLE_CHEMICAL", 219, 220], ["DEC-205", "GENE_OR_GENE_PRODUCT", 221, 228], ["OVA", "SIMPLE_CHEMICAL", 229, 232], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 237, 250], ["immune cell", "CELL", 288, 299], ["GFP", "PROTEIN", 130, 133], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["histological scoring", "TEST", 6, 26], ["an enhanced immunopathology", "PROBLEM", 52, 79], ["DEC", "TEST", 98, 101], ["OVA", "PROBLEM", 106, 109], ["AdOVA", "TEST", 124, 129], ["luc infected mice", "PROBLEM", 134, 151], ["DEC", "TEST", 221, 224], ["OVA", "PROBLEM", 229, 232], ["BPPcysOVAMPEG vaccination", "TREATMENT", 237, 262], ["distinct immune cell recruitment", "TREATMENT", 279, 311], ["viral infection", "PROBLEM", 322, 337], ["immunopathology", "OBSERVATION", 64, 79], ["liver", "ANATOMY", 87, 92], ["distinct", "OBSERVATION_MODIFIER", 279, 287], ["immune cell recruitment", "OBSERVATION", 288, 311], ["viral infection", "OBSERVATION", 322, 337]]], ["However, automated multidimensional fluorescent microscopy (MELC) on liver sections revealed no significant differences in the hepatic composition of leukocytes, macrophages, neutrophils, NK cells, B cells and T cell subsets among the groups (Fig. 5A ,B and Supplementary Fig. S2 ).", [["liver sections", "ANATOMY", 69, 83], ["hepatic", "ANATOMY", 127, 134], ["leukocytes", "ANATOMY", 150, 160], ["macrophages", "ANATOMY", 162, 173], ["neutrophils", "ANATOMY", 175, 186], ["NK cells", "ANATOMY", 188, 196], ["B cells", "ANATOMY", 198, 205], ["T cell", "ANATOMY", 210, 216], ["liver sections", "MULTI-TISSUE_STRUCTURE", 69, 83], ["hepatic", "ORGAN", 127, 134], ["leukocytes", "CELL", 150, 160], ["macrophages", "CELL", 162, 173], ["neutrophils", "CELL", 175, 186], ["NK cells", "CELL", 188, 196], ["B cells", "CELL", 198, 205], ["T cell subsets", "CELL", 210, 224], ["B", "CELL", 252, 253], ["leukocytes", "CELL_TYPE", 150, 160], ["macrophages", "CELL_TYPE", 162, 173], ["neutrophils", "CELL_TYPE", 175, 186], ["NK cells", "CELL_TYPE", 188, 196], ["B cells", "CELL_TYPE", 198, 205], ["T cell subsets", "CELL_TYPE", 210, 224], ["S2", "PROTEIN", 277, 279], ["automated multidimensional fluorescent microscopy", "TEST", 9, 58], ["liver sections", "TEST", 69, 83], ["significant differences", "PROBLEM", 96, 119], ["macrophages", "TEST", 162, 173], ["neutrophils", "TEST", 175, 186], ["NK cells", "TEST", 188, 196], ["B cells", "PROBLEM", 198, 205], ["T cell subsets", "PROBLEM", 210, 224], ["Supplementary Fig", "TREATMENT", 258, 275], ["liver", "ANATOMY", 69, 74], ["no", "UNCERTAINTY", 93, 95], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["differences", "OBSERVATION", 108, 119], ["hepatic", "ANATOMY", 127, 134], ["leukocytes", "ANATOMY", 150, 160], ["macrophages", "ANATOMY", 162, 173], ["neutrophils", "ANATOMY", 175, 186], ["NK cells", "OBSERVATION", 188, 196], ["cell subsets", "OBSERVATION", 212, 224]]], ["Altogether, the observed type of immunopathology in \u03b1 DEC-205/OVA and BPPcysOVAMPEG immunized mice was indicative for acute hepatitis as a consequence of the immune-mediated clearance of virus infected hepatocytes suggesting that antigen-specific CTLs present in the liver following vaccination accounted for the hepatocyte damage.ResultsVaccination with \u03b1DEC-205/OVA and BPPcysOVAMPEG results in effective antigen-specific virus clearance in the liver.", [["hepatocytes", "ANATOMY", 202, 213], ["liver", "ANATOMY", 267, 272], ["hepatocyte", "ANATOMY", 313, 323], ["liver", "ANATOMY", 447, 452], ["immunopathology", "DISEASE", 33, 48], ["\u03b1 DEC-205", "CHEMICAL", 52, 61], ["hepatitis", "DISEASE", 124, 133], ["\u03b1DEC-205", "CHEMICAL", 355, 363], ["OVA", "CHEMICAL", 364, 367], ["BPPcysOVAMPEG", "CHEMICAL", 372, 385], ["\u03b1 DEC-205", "CELL", 52, 61], ["OVA", "ORGANISM", 62, 65], ["BPPcysOVAMPEG immunized", "ORGANISM", 70, 93], ["mice", "ORGANISM", 94, 98], ["hepatocytes", "CELL", 202, 213], ["antigen", "GENE_OR_GENE_PRODUCT", 230, 237], ["CTLs", "CELL", 247, 251], ["liver", "ORGAN", 267, 272], ["hepatocyte", "CELL", 313, 323], ["\u03b1DEC-205", "SIMPLE_CHEMICAL", 355, 363], ["OVA", "SIMPLE_CHEMICAL", 364, 367], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 372, 385], ["antigen", "GENE_OR_GENE_PRODUCT", 407, 414], ["liver", "ORGAN", 447, 452], ["virus infected hepatocytes", "CELL_TYPE", 187, 213], ["CTLs", "CELL_TYPE", 247, 251], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["immunopathology", "PROBLEM", 33, 48], ["OVA", "PROBLEM", 62, 65], ["BPPcysOVAMPEG immunized mice", "TREATMENT", 70, 98], ["acute hepatitis", "PROBLEM", 118, 133], ["virus infected hepatocytes", "PROBLEM", 187, 213], ["antigen", "TEST", 230, 237], ["specific CTLs", "TEST", 238, 251], ["vaccination", "TREATMENT", 283, 294], ["the hepatocyte damage", "PROBLEM", 309, 330], ["BPPcysOVAMPEG", "TREATMENT", 372, 385], ["effective antigen", "TEST", 397, 414], ["specific virus clearance in the liver", "PROBLEM", 415, 452], ["immunopathology", "OBSERVATION", 33, 48], ["indicative for", "UNCERTAINTY", 103, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["hepatitis", "OBSERVATION", 124, 133], ["liver", "ANATOMY", 267, 272], ["hepatocyte", "ANATOMY", 313, 323], ["damage", "OBSERVATION", 324, 330], ["liver", "ANATOMY", 447, 452]]], ["To further substantiate the cytolytic function of CTLs, serum concentrations of alanine transaminase (ALT) were determined in vaccinated and adenovirus-challenged animals.", [["CTLs", "ANATOMY", 50, 54], ["serum", "ANATOMY", 56, 61], ["alanine", "CHEMICAL", 80, 87], ["alanine", "CHEMICAL", 80, 87], ["CTLs", "CELL", 50, 54], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["alanine transaminase", "GENE_OR_GENE_PRODUCT", 80, 100], ["ALT", "SIMPLE_CHEMICAL", 102, 105], ["adenovirus", "ORGANISM", 141, 151], ["animals", "ORGANISM", 163, 170], ["CTLs", "CELL_TYPE", 50, 54], ["alanine transaminase", "PROTEIN", 80, 100], ["ALT", "PROTEIN", 102, 105], ["adenovirus", "SPECIES", 141, 151], ["CTLs", "TEST", 50, 54], ["serum concentrations", "TEST", 56, 76], ["alanine transaminase", "TEST", 80, 100], ["ALT", "TEST", 102, 105], ["adenovirus", "PROBLEM", 141, 151]]], ["As expected, infection with the Ad-GFP-luc control virus did not affect serum ALT levels in any of the experimental groups (Fig. 6A) .", [["serum", "ANATOMY", 72, 77], ["infection", "DISEASE", 13, 22], ["Ad", "ORGANISM", 32, 34], ["GFP", "GENE_OR_GENE_PRODUCT", 35, 38], ["luc", "GENE_OR_GENE_PRODUCT", 39, 42], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["ALT", "SIMPLE_CHEMICAL", 78, 81], ["GFP", "PROTEIN", 35, 38], ["ALT", "PROTEIN", 78, 81], ["infection", "PROBLEM", 13, 22], ["the Ad-GFP", "TEST", 28, 38], ["luc control virus", "PROBLEM", 39, 56], ["serum ALT levels", "TEST", 72, 88], ["infection", "OBSERVATION", 13, 22]]], ["Strikingly, in \u03b1 DEC-205/OVA as well as in BPPcysOVAMPEG immunized mice we observed a dramatic and comparably high increase of the serum ALT level (~950 U/l and ~770 U/I, respectively) indicating massive CTL-mediated killing of AdOVA-GFP-luc infected hepatocytes (Fig. 6A ).", [["serum", "ANATOMY", 131, 136], ["hepatocytes", "ANATOMY", 251, 262], ["\u03b1 DEC-205", "CHEMICAL", 15, 24], ["BPPcysOVAMPEG immunized", "ORGANISM", 43, 66], ["mice", "ORGANISM", 67, 71], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["ALT", "SIMPLE_CHEMICAL", 137, 140], ["CTL", "GENE_OR_GENE_PRODUCT", 204, 207], ["AdOVA", "GENE_OR_GENE_PRODUCT", 228, 233], ["GFP", "GENE_OR_GENE_PRODUCT", 234, 237], ["luc", "GENE_OR_GENE_PRODUCT", 238, 241], ["hepatocytes", "CELL", 251, 262], ["ALT", "PROTEIN", 137, 140], ["AdOVA", "PROTEIN", 228, 233], ["GFP", "PROTEIN", 234, 237], ["luc infected hepatocytes", "CELL_TYPE", 238, 262], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["OVA", "PROBLEM", 25, 28], ["the serum ALT level", "TEST", 127, 146], ["U/l", "TEST", 153, 156], ["U/I", "TEST", 166, 169], ["massive CTL-mediated killing of AdOVA", "PROBLEM", 196, 233], ["GFP", "TEST", 234, 237], ["luc infected hepatocytes", "PROBLEM", 238, 262], ["massive", "OBSERVATION_MODIFIER", 196, 203], ["CTL", "OBSERVATION", 204, 207], ["hepatocytes", "ANATOMY", 251, 262]]], ["Significantly lower ALT concentrations (~330 U/l) were measured in OVA + BPPcysMPEG immunized mice which is in line with lower abundance of IFN\u03b3 -producing memory CD8 + T cells (Fig. 3) .ResultsTo further confirm specific killing of AdOVA-GFP-luc infected hepatocytes, virus clearance was examined by assessing luciferase expression in liver tissue.", [["memory CD8 + T cells", "ANATOMY", 156, 176], ["hepatocytes", "ANATOMY", 256, 267], ["liver tissue", "ANATOMY", 336, 348], ["ALT", "SIMPLE_CHEMICAL", 20, 23], ["OVA + BPPcysMPEG", "SIMPLE_CHEMICAL", 67, 83], ["mice", "ORGANISM", 94, 98], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 140, 144], ["CD8", "GENE_OR_GENE_PRODUCT", 163, 166], ["AdOVA", "GENE_OR_GENE_PRODUCT", 233, 238], ["GFP", "GENE_OR_GENE_PRODUCT", 239, 242], ["luc", "GENE_OR_GENE_PRODUCT", 243, 246], ["hepatocytes", "CELL", 256, 267], ["luciferase", "GENE_OR_GENE_PRODUCT", 311, 321], ["liver tissue", "TISSUE", 336, 348], ["ALT", "PROTEIN", 20, 23], ["IFN\u03b3", "PROTEIN", 140, 144], ["memory CD8 + T cells", "CELL_TYPE", 156, 176], ["AdOVA", "PROTEIN", 233, 238], ["GFP", "PROTEIN", 239, 242], ["luc infected hepatocytes", "CELL_TYPE", 243, 267], ["luciferase", "PROTEIN", 311, 321], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["Significantly lower ALT concentrations", "PROBLEM", 0, 38], ["IFN", "TEST", 140, 143], ["AdOVA", "TEST", 233, 238], ["GFP", "TEST", 239, 242], ["luc infected hepatocytes", "PROBLEM", 243, 267], ["virus clearance", "TEST", 269, 284], ["luciferase expression in liver tissue", "PROBLEM", 311, 348], ["hepatocytes", "ANATOMY", 256, 267], ["liver", "ANATOMY", 336, 341]]], ["As expected, strong luciferase activity was detectable in the liver of all mice infected with the control Ad-GFP-luc virus (Fig. 6B ).", [["liver", "ANATOMY", 62, 67], ["luciferase", "GENE_OR_GENE_PRODUCT", 20, 30], ["liver", "ORGAN", 62, 67], ["mice", "ORGANISM", 75, 79], ["Ad-GFP-luc virus", "ORGANISM", 106, 122], ["Fig. 6B", "ORGANISM", 124, 131], ["luciferase", "PROTEIN", 20, 30], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["Ad-GFP-luc virus", "SPECIES", 106, 122], ["strong luciferase activity", "PROBLEM", 13, 39], ["strong", "OBSERVATION_MODIFIER", 13, 19], ["luciferase activity", "OBSERVATION", 20, 39], ["liver", "ANATOMY", 62, 67], ["infected", "OBSERVATION", 80, 88]]], ["In contrast, luciferase activity in the livers of immunized and AdOVA-GFP-luc infected mice was significantly reduced in \u03b1 DEC-205/OVA and BPPcysOVAMPEG vaccinated mice in comparison to both OVA + BPPcysMPEG and \u03b1 DEC-205 + Poly(I:C)/CpG mock-immunized animals (Fig. 6B ).", [["livers", "ANATOMY", 40, 46], ["\u03b1 DEC-205", "CHEMICAL", 121, 130], ["BPPcysOVAMPEG", "CHEMICAL", 139, 152], ["BPPcysMPEG", "CHEMICAL", 197, 207], ["\u03b1 DEC-205", "CHEMICAL", 212, 221], ["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["livers", "ORGAN", 40, 46], ["AdOVA", "GENE_OR_GENE_PRODUCT", 64, 69], ["GFP", "GENE_OR_GENE_PRODUCT", 70, 73], ["luc", "GENE_OR_GENE_PRODUCT", 74, 77], ["mice", "ORGANISM", 87, 91], ["\u03b1 DEC-205", "CELL", 121, 130], ["OVA", "ORGANISM", 131, 134], ["BPPcysOVAMPEG vaccinated", "ORGANISM", 139, 163], ["mice", "ORGANISM", 164, 168], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 197, 207], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 212, 221], ["Poly(I:C", "SIMPLE_CHEMICAL", 224, 232], ["CpG mock", "SIMPLE_CHEMICAL", 234, 242], ["luciferase", "PROTEIN", 13, 23], ["GFP", "PROTEIN", 70, 73], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 164, 168], ["AdOVA", "TEST", 64, 69], ["BPPcysOVAMPEG vaccinated mice", "TREATMENT", 139, 168], ["OVA", "TEST", 191, 194], ["BPPcysMPEG", "TEST", 197, 207], ["DEC", "TEST", 214, 217], ["CpG mock", "TEST", 234, 242], ["livers", "ANATOMY", 40, 46]]], ["Taken together, our results clearly demonstrated that antigen targeting to cross-presenting DCs by either \u03b1 DEC-205/OVA or BPPcysOVAMPEG is highly effective at inducing effector T cells capable of recognizing and eliminating virus infected hepatocytes.Vaccination with \u03b1DEC-205/OVA and BPPcysOVAMPEG induces distinct patterns of CD8 + T cell interaction with virus infected and apoptotic hepatocytes.In order to gain first indication regarding the underlying mechanisms for the elimination of infected hepatocytes we analysed liver sections of \u03b1 DEC-205/ OVA and BPPcysOVAMPEG immunized and AdOVA-GFP-luc infected mice for potential differences in the distance of CD8 + T cells to virus infected hepatocytes.", [["DCs", "ANATOMY", 92, 95], ["effector T cells", "ANATOMY", 169, 185], ["hepatocytes", "ANATOMY", 240, 251], ["CD8 + T cell", "ANATOMY", 329, 341], ["hepatocytes", "ANATOMY", 388, 399], ["hepatocytes", "ANATOMY", 502, 513], ["liver sections", "ANATOMY", 526, 540], ["CD8 + T cells", "ANATOMY", 664, 677], ["hepatocytes", "ANATOMY", 696, 707], ["\u03b1 DEC-205", "CHEMICAL", 106, 115], ["OVA", "CHEMICAL", 116, 119], ["BPPcysOVAMPEG", "CHEMICAL", 123, 136], ["\u03b1DEC-205", "CHEMICAL", 269, 277], ["OVA", "CHEMICAL", 278, 281], ["BPPcysOVAMPEG", "CHEMICAL", 286, 299], ["\u03b1 DEC-205", "CHEMICAL", 544, 553], ["DCs", "CELL", 92, 95], ["OVA", "SIMPLE_CHEMICAL", 116, 119], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 123, 136], ["effector T cells", "CELL", 169, 185], ["hepatocytes", "CELL", 240, 251], ["\u03b1DEC-205", "SIMPLE_CHEMICAL", 269, 277], ["OVA", "SIMPLE_CHEMICAL", 278, 281], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 286, 299], ["CD8", "GENE_OR_GENE_PRODUCT", 329, 332], ["hepatocytes", "CELL", 388, 399], ["hepatocytes", "CELL", 502, 513], ["liver sections", "MULTI-TISSUE_STRUCTURE", 526, 540], ["OVA", "ORGANISM", 555, 558], ["BPPcysOVAMPEG immunized", "ORGANISM", 563, 586], ["AdOVA", "GENE_OR_GENE_PRODUCT", 591, 596], ["GFP", "GENE_OR_GENE_PRODUCT", 597, 600], ["luc", "GENE_OR_GENE_PRODUCT", 601, 604], ["mice", "ORGANISM", 614, 618], ["CD8", "GENE_OR_GENE_PRODUCT", 664, 667], ["hepatocytes", "CELL", 696, 707], ["cross-presenting DCs", "CELL_TYPE", 75, 95], ["effector T cells", "CELL_TYPE", 169, 185], ["virus infected hepatocytes", "CELL_TYPE", 225, 251], ["CD8", "PROTEIN", 329, 332], ["apoptotic hepatocytes", "CELL_TYPE", 378, 399], ["infected hepatocytes", "CELL_TYPE", 493, 513], ["GFP", "PROTEIN", 597, 600], ["CD8 + T cells", "CELL_TYPE", 664, 677], ["virus infected hepatocytes", "CELL_TYPE", 681, 707], ["mice", "SPECIES", 614, 618], ["mice", "SPECIES", 614, 618], ["OVA", "PROBLEM", 116, 119], ["BPPcysOVAMPEG", "TREATMENT", 123, 136], ["virus infected hepatocytes", "PROBLEM", 225, 251], ["BPPcysOVAMPEG", "TREATMENT", 286, 299], ["CD8", "PROBLEM", 329, 332], ["T cell interaction", "PROBLEM", 335, 353], ["virus infected and apoptotic hepatocytes", "PROBLEM", 359, 399], ["infected hepatocytes", "PROBLEM", 493, 513], ["liver sections", "TEST", 526, 540], ["DEC", "TEST", 546, 549], ["OVA", "PROBLEM", 555, 558], ["BPPcysOVAMPEG", "TREATMENT", 563, 576], ["AdOVA", "TEST", 591, 596], ["T cells", "PROBLEM", 670, 677], ["virus infected hepatocytes", "PROBLEM", 681, 707], ["T cell", "OBSERVATION", 335, 341], ["apoptotic hepatocytes", "OBSERVATION", 378, 399], ["infected", "OBSERVATION", 493, 501], ["liver", "ANATOMY", 526, 531], ["hepatocytes", "ANATOMY", 696, 707]]], ["While we did neither observe significant differences in the number of virus infected hepatocytes, nor in the number of hepatocytes staining positive for active caspase-3 (Fig. 5C,D) or in the frequency of CD8 + T cells being in loose contact with infected hepatocytes (> 22 \u03bc m distance, Fig. 5E ), we indeed observed significantly fewer CD8 + T cells being in direct contact (< 9 \u03bc m) to AdOVA-GFP-luc infected hepatocytes in \u03b1 DEC-205/OVA immunized mice compared to the BPPcysOVAMPEG immunized group (Fig. 5E ).", [["hepatocytes", "ANATOMY", 85, 96], ["hepatocytes", "ANATOMY", 119, 130], ["CD8 + T cells", "ANATOMY", 205, 218], ["hepatocytes", "ANATOMY", 256, 267], ["CD8 + T cells", "ANATOMY", 338, 351], ["hepatocytes", "ANATOMY", 412, 423], ["\u03b1 DEC-205", "CHEMICAL", 427, 436], ["hepatocytes", "CELL", 85, 96], ["hepatocytes", "CELL", 119, 130], ["caspase-3", "GENE_OR_GENE_PRODUCT", 160, 169], ["Fig. 5C", "GENE_OR_GENE_PRODUCT", 171, 178], ["D", "GENE_OR_GENE_PRODUCT", 179, 180], ["CD8", "GENE_OR_GENE_PRODUCT", 205, 208], ["hepatocytes", "CELL", 256, 267], ["CD8", "GENE_OR_GENE_PRODUCT", 338, 341], ["AdOVA-GFP", "GENE_OR_GENE_PRODUCT", 389, 398], ["luc", "GENE_OR_GENE_PRODUCT", 399, 402], ["hepatocytes", "CELL", 412, 423], ["\u03b1 DEC-205", "ORGANISM", 427, 436], ["OVA", "ORGANISM", 437, 440], ["mice", "ORGANISM", 451, 455], ["virus infected hepatocytes", "CELL_TYPE", 70, 96], ["hepatocytes", "CELL_TYPE", 119, 130], ["caspase-3", "PROTEIN", 160, 169], ["CD8 + T cells", "CELL_TYPE", 205, 218], ["infected hepatocytes", "CELL_TYPE", 247, 267], ["CD8 + T cells", "CELL_TYPE", 338, 351], ["GFP", "PROTEIN", 395, 398], ["mice", "SPECIES", 451, 455], ["mice", "SPECIES", 451, 455], ["virus infected hepatocytes", "PROBLEM", 70, 96], ["hepatocytes staining", "TEST", 119, 139], ["active caspase", "TEST", 153, 167], ["T cells", "PROBLEM", 211, 218], ["infected hepatocytes", "PROBLEM", 247, 267], ["T cells", "PROBLEM", 344, 351], ["AdOVA", "TEST", 389, 394], ["GFP", "TEST", 395, 398], ["luc infected hepatocytes", "PROBLEM", 399, 423], ["the BPPcysOVAMPEG immunized group", "TREATMENT", 468, 501], ["hepatocytes", "ANATOMY", 119, 130], ["loose", "OBSERVATION_MODIFIER", 228, 233], ["hepatocytes", "ANATOMY", 256, 267], ["hepatocytes", "ANATOMY", 412, 423]]], ["Strikingly, despite lower abundance of CD8 + T cells being in intimate contact with virus infected cells, substantially more of them were found to be closely associated with active caspase-3 and thus apoptotic cells in the liver of \u03b1 DEC-205/OVA immunized mice (Fig. 5E ).", [["CD8 + T cells", "ANATOMY", 39, 52], ["cells", "ANATOMY", 99, 104], ["cells", "ANATOMY", 210, 215], ["liver", "ANATOMY", 223, 228], ["\u03b1 DEC-205", "CHEMICAL", 232, 241], ["CD8", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 99, 104], ["caspase-3", "GENE_OR_GENE_PRODUCT", 181, 190], ["cells", "CELL", 210, 215], ["liver", "ORGAN", 223, 228], ["\u03b1 DEC-205/OVA immunized", "ORGANISM", 232, 255], ["mice", "ORGANISM", 256, 260], ["CD8", "PROTEIN", 39, 42], ["T cells", "CELL_TYPE", 45, 52], ["virus infected cells", "CELL_TYPE", 84, 104], ["caspase-3", "PROTEIN", 181, 190], ["apoptotic cells", "CELL_TYPE", 200, 215], ["mice", "SPECIES", 256, 260], ["mice", "SPECIES", 256, 260], ["T cells", "PROBLEM", 45, 52], ["virus infected cells", "PROBLEM", 84, 104], ["active caspase", "TEST", 174, 188], ["apoptotic cells", "PROBLEM", 200, 215], ["apoptotic cells", "OBSERVATION", 200, 215], ["liver", "ANATOMY", 223, 228]]], ["Together with the observation that compared to BPPcysOVAMPEG vaccination \u03b1 DEC-205/OVA immunization resulted in the accumulation of significantly higher frequency of IFN\u03b3 + CD44 high CD8 + effector T cells in virus infected livers (Fig. 3C ) these data may indicate that the two different DC-targeting formulations may indeed stimulate distinct types of effector functions being active during virus elimination from the liver.DiscussionWe show here that in vivo antigen delivery to CD8\u03b1 + cross-presenting DCs is highly effective in inducing antiviral immunity in the liver.", [["CD8 + effector T cells", "ANATOMY", 183, 205], ["livers", "ANATOMY", 224, 230], ["DC", "ANATOMY", 289, 291], ["liver", "ANATOMY", 420, 425], ["CD8\u03b1 + cross-presenting DCs", "ANATOMY", 482, 509], ["liver", "ANATOMY", 568, 573], ["BPPcysOVAMPEG", "CHEMICAL", 47, 60], ["\u03b1", "CHEMICAL", 73, 74], ["DEC-205", "CHEMICAL", 75, 82], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 47, 60], ["OVA", "ORGANISM", 83, 86], ["CD44", "GENE_OR_GENE_PRODUCT", 173, 177], ["CD8", "GENE_OR_GENE_PRODUCT", 183, 186], ["livers", "ORGAN", 224, 230], ["DC", "CELL", 289, 291], ["liver", "ORGAN", 420, 425], ["CD8\u03b1", "GENE_OR_GENE_PRODUCT", 482, 486], ["liver", "ORGAN", 568, 573], ["IFN", "PROTEIN", 166, 169], ["CD44", "PROTEIN", 173, 177], ["CD8 + effector T cells", "CELL_TYPE", 183, 205], ["DC", "CELL_TYPE", 289, 291], ["CD8\u03b1 + cross-presenting DCs", "CELL_TYPE", 482, 509], ["the observation", "TEST", 14, 29], ["BPPcysOVAMPEG vaccination", "TREATMENT", 47, 72], ["DEC", "TEST", 75, 78], ["OVA immunization", "TREATMENT", 83, 99], ["CD44", "PROBLEM", 173, 177], ["effector T cells in virus infected livers", "PROBLEM", 189, 230], ["these data", "TEST", 242, 252], ["the two different DC-targeting formulations", "TREATMENT", 271, 314], ["effector functions", "PROBLEM", 354, 372], ["DCs", "PROBLEM", 506, 509], ["high CD8", "OBSERVATION", 178, 186], ["effector T cells", "OBSERVATION", 189, 205], ["livers", "ANATOMY", 224, 230], ["liver", "ANATOMY", 420, 425], ["antiviral immunity", "OBSERVATION", 542, 560], ["liver", "ANATOMY", 568, 573]]], ["BPPcysOVAMPEG vaccination, which was included as a novel antigen targeting system, exhibited outstanding properties in inducing high antibody titres (Fig. 1 ), Th1 and Th2 cells, as well as CTLs (Fig. 2 ) that effectively cleared virus infected hepatocytes (Fig. 6 ).", [["Th2 cells", "ANATOMY", 168, 177], ["hepatocytes", "ANATOMY", 245, 256], ["BPPcysOVAMPEG", "CHEMICAL", 0, 13], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 0, 13], ["Th1", "CELL", 160, 163], ["Th2 cells", "CELL", 168, 177], ["CTLs", "CELL", 190, 194], ["hepatocytes", "CELL", 245, 256], ["Th1 and Th2 cells", "CELL_TYPE", 160, 177], ["CTLs", "CELL_TYPE", 190, 194], ["virus infected hepatocytes", "CELL_TYPE", 230, 256], ["BPPcysOVAMPEG vaccination", "TREATMENT", 0, 25], ["a novel antigen targeting system", "PROBLEM", 49, 81], ["high antibody titres", "PROBLEM", 128, 148], ["Th1 and Th2 cells", "PROBLEM", 160, 177], ["CTLs", "TEST", 190, 194], ["virus infected hepatocytes", "PROBLEM", 230, 256], ["Th1", "ANATOMY", 160, 163], ["Th2 cells", "OBSERVATION", 168, 177], ["hepatocytes", "ANATOMY", 245, 256]]], ["Although not reaching statistical significance compared to \u03b1 DEC-205/OVA vaccination, this approach tended to promote a more robust viral clearance, as well as slightly less pronounced hepatocellular cell death and pro-inflammatory effect.", [["hepatocellular cell", "ANATOMY", 185, 204], ["\u03b1", "CHEMICAL", 59, 60], ["DEC-205", "CHEMICAL", 61, 68], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 59, 68], ["OVA", "SIMPLE_CHEMICAL", 69, 72], ["hepatocellular cell", "CELL", 185, 204], ["DEC", "TEST", 61, 64], ["OVA vaccination", "TREATMENT", 69, 84], ["slightly less pronounced hepatocellular cell death", "PROBLEM", 160, 210], ["pro-inflammatory effect", "PROBLEM", 215, 238], ["less pronounced", "OBSERVATION_MODIFIER", 169, 184], ["hepatocellular cell death", "OBSERVATION", 185, 210], ["pro-inflammatory effect", "OBSERVATION", 215, 238]]], ["The value of TLR agonist-antigen conjugates for inducing Th1 and CD8 + T cell responses are clearly underscored by our new data and previous studies 31, 32 .", [["CD8 + T cell", "ANATOMY", 65, 77], ["TLR", "GENE_OR_GENE_PRODUCT", 13, 16], ["Th1", "CELL", 57, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["TLR", "PROTEIN", 13, 16], ["CD8", "PROTEIN", 65, 68], ["The value", "TEST", 0, 9], ["TLR agonist", "TEST", 13, 24], ["antigen conjugates", "TEST", 25, 43], ["Th1", "PROBLEM", 57, 60], ["previous studies", "TEST", 132, 148]]], ["However, for clinical application such conjugates will need to be tailored to match different HLA alleles and rapidly mutating viruses (e.g. HCV) 33 .", [["HLA", "GENE_OR_GENE_PRODUCT", 94, 97], ["HLA alleles", "DNA", 94, 105], ["HCV", "SPECIES", 141, 144], ["clinical application such conjugates", "TREATMENT", 13, 49], ["different HLA alleles", "PROBLEM", 84, 105], ["rapidly mutating viruses", "PROBLEM", 110, 134]]], ["It could be possible to exploit chemical groups of BPPcysMPEG to generate conjugates with more complex antigens or to engineer universal docking systems enabling non-covalent binding, such as those used in the past for antibodies 34 .DiscussionPrajeeth et al. have shown that BPPcysMPEG-mediated activation of CD8 + DCs led to effective cross-priming against co-administered antigen resulting in CTL responses in the spleen 12 .", [["CD8 + DCs", "ANATOMY", 310, 319], ["spleen", "ANATOMY", 417, 423], ["BPPcysMPEG", "CHEMICAL", 51, 61], ["BPPcysMPEG", "CHEMICAL", 276, 286], ["BPPcysMPEG", "CHEMICAL", 51, 61], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 51, 61], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 276, 286], ["CD8", "GENE_OR_GENE_PRODUCT", 310, 313], ["CTL", "CELL", 396, 399], ["spleen", "ORGAN", 417, 423], ["complex antigens", "PROTEIN", 95, 111], ["antibodies 34", "PROTEIN", 219, 232], ["BPPcysMPEG", "PROTEIN", 276, 286], ["CD8", "PROTEIN", 310, 313], ["DCs", "CELL_TYPE", 316, 319], ["BPPcysMPEG", "TREATMENT", 51, 61], ["more complex antigens", "PROBLEM", 90, 111], ["non-covalent binding", "PROBLEM", 162, 182], ["antibodies", "PROBLEM", 219, 229], ["BPPcysMPEG", "TEST", 276, 286], ["CD8", "PROBLEM", 310, 313], ["DCs", "PROBLEM", 316, 319], ["effective cross-priming", "TREATMENT", 327, 350], ["co-administered antigen", "PROBLEM", 359, 382], ["could be possible", "UNCERTAINTY", 3, 20], ["spleen", "ANATOMY", 417, 423]]], ["While we detected small numbers of CD44 + CD8 + memory T cells in the liver of OVA + BPPcysMPEG immunized mice following AdOVA-GFP-luc infection (Fig. 3) , these cells did not exert effector functions (Figs 2 and 6 ).", [["CD44 + CD8 + memory T cells", "ANATOMY", 35, 62], ["liver", "ANATOMY", 70, 75], ["cells", "ANATOMY", 162, 167], ["AdOVA", "CHEMICAL", 121, 126], ["infection", "DISEASE", 135, 144], ["CD44", "GENE_OR_GENE_PRODUCT", 35, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 42, 45], ["liver", "ORGAN", 70, 75], ["OVA + BPPcysMPEG", "ORGANISM", 79, 95], ["mice", "ORGANISM", 106, 110], ["AdOVA", "GENE_OR_GENE_PRODUCT", 121, 126], ["GFP", "GENE_OR_GENE_PRODUCT", 127, 130], ["cells", "CELL", 162, 167], ["CD44", "PROTEIN", 35, 39], ["CD8 + memory T cells", "CELL_TYPE", 42, 62], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["CD44", "TEST", 35, 39], ["CD8", "TEST", 42, 45], ["memory T cells", "PROBLEM", 48, 62], ["OVA", "PROBLEM", 79, 82], ["AdOVA", "TEST", 121, 126], ["GFP", "TEST", 127, 130], ["luc infection", "PROBLEM", 131, 144], ["these cells", "PROBLEM", 156, 167], ["Figs", "TEST", 202, 206], ["small", "OBSERVATION_MODIFIER", 18, 23], ["numbers", "OBSERVATION_MODIFIER", 24, 31], ["liver", "ANATOMY", 70, 75]]], ["These discrepancies may be due to differences in the antigen concentration used (3 mg vs. 7 \u03bc g) 12 .", [["the antigen concentration", "TREATMENT", 49, 74], ["may be due to", "UNCERTAINTY", 20, 33]]], ["However, we have no explanation yet why the memory T cells present in the liver of OVA + BPPcysMPEG immunized mice did not exhibit cytotoxic function.", [["memory T cells", "ANATOMY", 44, 58], ["liver", "ANATOMY", 74, 79], ["memory T cells", "CELL", 44, 58], ["liver", "ORGAN", 74, 79], ["OVA + BPPcysMPEG", "ORGANISM", 83, 99], ["mice", "ORGANISM", 110, 114], ["memory T cells", "CELL_TYPE", 44, 58], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["OVA", "PROBLEM", 83, 86], ["cytotoxic function", "PROBLEM", 131, 149], ["no explanation", "UNCERTAINTY", 17, 31], ["liver", "ANATOMY", 74, 79], ["cytotoxic function", "OBSERVATION", 131, 149]]], ["Strikingly, despite the lack of viral eradication in the OVA + BPPcysMPEG vaccinated group, these mice displayed marked immunopathology and elevated ALT levels following AdOVA-GFP-luc infection.", [["BPPcysMPEG", "CHEMICAL", 63, 73], ["AdOVA", "CHEMICAL", 170, 175], ["infection", "DISEASE", 184, 193], ["OVA + BPPcysMPEG", "ORGANISM", 57, 73], ["mice", "ORGANISM", 98, 102], ["ALT", "SIMPLE_CHEMICAL", 149, 152], ["AdOVA", "GENE_OR_GENE_PRODUCT", 170, 175], ["GFP", "GENE_OR_GENE_PRODUCT", 176, 179], ["luc", "GENE_OR_GENE_PRODUCT", 180, 183], ["ALT", "PROTEIN", 149, 152], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["viral eradication", "TREATMENT", 32, 49], ["marked immunopathology", "PROBLEM", 113, 135], ["elevated ALT levels", "PROBLEM", 140, 159], ["AdOVA", "TEST", 170, 175], ["GFP", "PROBLEM", 176, 179], ["luc infection", "PROBLEM", 180, 193], ["marked", "OBSERVATION_MODIFIER", 113, 119], ["immunopathology", "OBSERVATION", 120, 135], ["luc infection", "OBSERVATION", 180, 193]]], ["We may speculate that, although being functionally impaired in terms of cytotoxicity, antigen-specific recognition of the virus by IFN\u03b3 + CD44 + CD8 + T cells results in cytokine release followed by innate immune activation and immune cell recruitment that finally result in hepatic cell death and inflammation independent of CTL mediated killing.DiscussionImmunization with \u03b1 DEC-205/OVA induced a robust CTL response (Fig. 2) , which resulted in effective viral clearance in the liver (Fig. 6) .", [["+ CD44 + CD8 + T cells", "ANATOMY", 136, 158], ["immune cell", "ANATOMY", 228, 239], ["hepatic cell", "ANATOMY", 275, 287], ["liver", "ANATOMY", 481, 486], ["death", "DISEASE", 288, 293], ["inflammation", "DISEASE", 298, 310], ["\u03b1 DEC-205", "CHEMICAL", 375, 384], ["CD44", "GENE_OR_GENE_PRODUCT", 138, 142], ["CD8", "GENE_OR_GENE_PRODUCT", 145, 148], ["immune cell", "CELL", 228, 239], ["hepatic cell", "CELL", 275, 287], ["CTL", "GENE_OR_GENE_PRODUCT", 326, 329], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 375, 384], ["OVA", "SIMPLE_CHEMICAL", 385, 388], ["liver", "ORGAN", 481, 486], ["IFN", "PROTEIN", 131, 134], ["CD44", "PROTEIN", 138, 142], ["CD8", "PROTEIN", 145, 148], ["T cells", "CELL_TYPE", 151, 158], ["cytokine", "PROTEIN", 170, 178], ["cytotoxicity", "PROBLEM", 72, 84], ["antigen", "TEST", 86, 93], ["the virus", "PROBLEM", 118, 127], ["CD44", "TEST", 138, 142], ["T cells", "PROBLEM", 151, 158], ["cytokine release", "TREATMENT", 170, 186], ["innate immune activation", "TREATMENT", 199, 223], ["immune cell recruitment", "TREATMENT", 228, 251], ["hepatic cell death", "PROBLEM", 275, 293], ["inflammation", "PROBLEM", 298, 310], ["CTL mediated killing", "PROBLEM", 326, 346], ["effective viral clearance in the liver", "PROBLEM", 448, 486], ["impaired", "OBSERVATION", 51, 59], ["CD44", "OBSERVATION", 138, 142], ["CD8 + T cells", "OBSERVATION", 145, 158], ["immune cell recruitment", "OBSERVATION", 228, 251], ["hepatic", "ANATOMY", 275, 282], ["cell death", "OBSERVATION", 283, 293], ["viral clearance", "OBSERVATION", 458, 473], ["liver", "ANATOMY", 481, 486]]], ["Our data are well in line with a previous study demonstrating that vaccination with \u03b1 DEC-205/OVA induces CD8 + T cells capable to protect against tumour or virus challenge 14 .", [["CD8 + T cells", "ANATOMY", 106, 119], ["tumour", "ANATOMY", 147, 153], ["\u03b1 DEC-205", "CHEMICAL", 84, 93], ["tumour", "DISEASE", 147, 153], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 84, 93], ["OVA", "SIMPLE_CHEMICAL", 94, 97], ["CD8", "GENE_OR_GENE_PRODUCT", 106, 109], ["tumour", "CANCER", 147, 153], ["CD8 + T cells", "CELL_TYPE", 106, 119], ["a previous study", "TEST", 31, 47], ["DEC", "TEST", 86, 89], ["CD8 + T cells", "TREATMENT", 106, 119]]], ["Similar results were obtained by targeting tumour 24, 25 or viral antigens 21, 35 to DEC-205 + DCs.", [["tumour", "ANATOMY", 43, 49], ["DEC-205 + DCs", "ANATOMY", 85, 98], ["tumour", "DISEASE", 43, 49], ["DEC-205", "CHEMICAL", 85, 92], ["tumour", "CANCER", 43, 49], ["DEC-205", "SIMPLE_CHEMICAL", 85, 92], ["DCs", "CELL", 95, 98], ["tumour 24, 25 or viral antigens 21, 35 to DEC-205", "PROTEIN", 43, 92], ["DCs", "CELL_TYPE", 95, 98], ["viral antigens", "TEST", 60, 74], ["DEC", "TEST", 85, 88], ["DCs", "PROBLEM", 95, 98]]], ["Next to the CTL response induced in \u03b1 DEC-205/OVA immunized mice, we detected antigen-specific CD4 + T cells.", [["CD4 + T cells", "ANATOMY", 95, 108], ["\u03b1 DEC-205", "CHEMICAL", 36, 45], ["CTL", "CELL", 12, 15], ["\u03b1 DEC-205", "CELL", 36, 45], ["OVA", "ORGANISM", 46, 49], ["mice", "ORGANISM", 60, 64], ["antigen", "GENE_OR_GENE_PRODUCT", 78, 85], ["CD4", "GENE_OR_GENE_PRODUCT", 95, 98], ["CD4", "PROTEIN", 95, 98], ["T cells", "CELL_TYPE", 101, 108], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["antigen", "TEST", 78, 85]]], ["While previous studies described a preferential induction of Th1 responses by \u03b1 DEC-205/antigen immunization 16,23 , we observed similar levels of Th1 (IFN\u03b3 + ) and Th2 (IL-4 + ) CD4 + T cells ( Fig. 2A and B) , consistent with minor differences in the IgG subclasses (Fig. 1C) .", [["Th2 (IL-4 + ) CD4 + T cells", "ANATOMY", 165, 192], ["\u03b1 DEC-205", "CHEMICAL", 78, 87], ["Th1", "GENE_OR_GENE_PRODUCT", 61, 64], ["\u03b1 DEC-205", "GENE_OR_GENE_PRODUCT", 78, 87], ["Th1", "GENE_OR_GENE_PRODUCT", 147, 150], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 152, 156], ["Th2", "GENE_OR_GENE_PRODUCT", 165, 168], ["IL-4", "GENE_OR_GENE_PRODUCT", 170, 174], ["B", "GENE_OR_GENE_PRODUCT", 207, 208], ["IFN\u03b3", "PROTEIN", 152, 156], ["CD4", "PROTEIN", 179, 182], ["T cells", "CELL_TYPE", 185, 192], ["IgG subclasses", "PROTEIN", 253, 267], ["previous studies", "TEST", 6, 22], ["DEC", "TEST", 80, 83], ["antigen immunization", "TEST", 88, 108], ["Th1", "TEST", 147, 150], ["IFN", "TEST", 152, 155], ["Th2", "TEST", 165, 168], ["IL", "TEST", 170, 172], ["CD4", "TEST", 179, 182], ["T cells", "TEST", 185, 192], ["the IgG subclasses", "TEST", 249, 267], ["consistent with", "UNCERTAINTY", 212, 227]]], ["Irrespectively of the antibody subclasses, we demonstrate that in comparison to the other formulations the two DC targeting approaches were most effective at inducing a rapid and robust humoral immune response (Fig. 1) .DiscussionWhile in our hands both DC targeting approaches next to CTL responses induced a rather balanced Th1/Th2 profile, immunization with OVA + BPPcysMPEG that does not involve DC targeting failed to induce CTLs and resulted in a Th2 dominated cytokine profile (Figs 1C and 2) .", [["DC", "ANATOMY", 111, 113], ["DC", "ANATOMY", 254, 256], ["DC", "ANATOMY", 400, 402], ["CTLs", "ANATOMY", 430, 434], ["OVA", "CHEMICAL", 361, 364], ["BPPcysMPEG", "CHEMICAL", 367, 377], ["CTL", "CELL", 286, 289], ["OVA + BPPcysMPEG", "SIMPLE_CHEMICAL", 361, 377], ["DC", "CELL", 400, 402], ["CTLs", "CELL", 430, 434], ["antibody subclasses", "PROTEIN", 22, 41], ["DC", "CELL_TYPE", 111, 113], ["DC", "CELL_TYPE", 254, 256], ["DC", "CELL_TYPE", 400, 402], ["CTLs", "CELL_TYPE", 430, 434], ["cytokine", "PROTEIN", 467, 475], ["the antibody subclasses", "TEST", 18, 41], ["two DC targeting approaches", "TREATMENT", 107, 134], ["immunization", "TREATMENT", 343, 355], ["CTLs", "TEST", 430, 434], ["a Th2 dominated cytokine profile", "PROBLEM", 451, 483]]], ["Interestingly, BPPcysMPEG has been shown to induce Th1-type immune responses in the context of allergens and parasite antigens [36] [37] [38] .", [["BPPcysMPEG", "CHEMICAL", 15, 25], ["BPPcysMPEG", "CHEMICAL", 15, 25], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 15, 25], ["BPPcysMPEG", "PROTEIN", 15, 25], ["allergens", "PROBLEM", 95, 104], ["parasite antigens", "TEST", 109, 126]]], ["However, intramuscular immunization with hepatitis B surface antigen virus-like particles co-administered with BPPcysMPEG resulted in a Th2 dominated response 39 .", [["intramuscular", "ANATOMY", 9, 22], ["hepatitis B surface antigen", "CHEMICAL", 41, 68], ["BPPcysMPEG", "CHEMICAL", 111, 121], ["BPPcysMPEG", "CHEMICAL", 111, 121], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 9, 22], ["hepatitis B surface antigen virus-like particles", "ORGANISM", 41, 89], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 111, 121], ["hepatitis B", "SPECIES", 41, 52], ["intramuscular immunization", "TREATMENT", 9, 35], ["hepatitis B surface antigen virus", "TREATMENT", 41, 74], ["BPPcysMPEG", "TREATMENT", 111, 121]]], ["Therefore, the adjuvant dose, the route of administration and the intrinsic features of the antigen may account for the observed differences in the T helper cell phenotype.", [["T helper cell", "ANATOMY", 148, 161], ["T helper cell", "CELL", 148, 161], ["T helper cell phenotype", "CELL_TYPE", 148, 171], ["the adjuvant dose", "TREATMENT", 11, 28], ["administration", "TREATMENT", 43, 57], ["may account for", "UNCERTAINTY", 100, 115], ["helper cell phenotype", "OBSERVATION", 150, 171]]], ["While Schulze and colleagues proved BPPcysMPEG to be a potent mucosal adjuvant for vaccination against severe acute respiratory syndrome coronavirus, the authors focused on the cellular and humoral immune responses, but did not test for antiviral activity 40 .", [["mucosal", "ANATOMY", 62, 69], ["cellular", "ANATOMY", 177, 185], ["BPPcysMPEG", "CHEMICAL", 36, 46], ["acute respiratory syndrome coronavirus", "DISEASE", 110, 148], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 36, 46], ["mucosal", "ORGAN", 62, 69], ["cellular", "CELL", 177, 185], ["severe acute respiratory syndrome coronavirus", "SPECIES", 103, 148], ["a potent mucosal adjuvant", "TREATMENT", 53, 78], ["vaccination", "TREATMENT", 83, 94], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 103, 148], ["antiviral activity", "TEST", 237, 255], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["respiratory syndrome coronavirus", "OBSERVATION", 116, 148]]], ["Thus, BPPcysMPEG has not been investigated before regarding its potency to induce antiviral immunity.", [["BPPcysMPEG", "CHEMICAL", 6, 16], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 6, 16], ["BPPcysMPEG", "PROTEIN", 6, 16], ["antiviral immunity", "TREATMENT", 82, 100]]], ["In the absence of DC targeting, i.e. by using the OVA + BPPcysMPEG formulation, we clearly show the induction of a Th2-biased CD4 + T cell phenotype, the lack of CTLs and in consequence no antigen-specific clearance of virus infected hepatocytes.", [["DC", "ANATOMY", 18, 20], ["CD4 + T cell", "ANATOMY", 126, 138], ["CTLs", "ANATOMY", 162, 166], ["hepatocytes", "ANATOMY", 234, 245], ["DC", "CELL", 18, 20], ["OVA", "SIMPLE_CHEMICAL", 50, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 126, 129], ["CTLs", "CELL", 162, 166], ["hepatocytes", "CELL", 234, 245], ["DC", "CELL_TYPE", 18, 20], ["CD4", "PROTEIN", 126, 129], ["CTLs", "CELL_TYPE", 162, 166], ["virus infected hepatocytes", "CELL_TYPE", 219, 245], ["the OVA + BPPcysMPEG formulation", "TREATMENT", 46, 78], ["T cell phenotype", "PROBLEM", 132, 148], ["CTLs", "PROBLEM", 162, 166], ["antigen", "PROBLEM", 189, 196], ["virus infected hepatocytes", "PROBLEM", 219, 245], ["cell phenotype", "OBSERVATION", 134, 148]]], ["While previous studies have demonstrated the exceptional potential of DEC-205-mediated antigen targeting to elicit adaptive immunity [14] [15] [16] [17] [18] 24 to our knowledge this is the first study showing the induction of liver-specific immune reactions.", [["liver", "ANATOMY", 227, 232], ["DEC-205", "CHEMICAL", 70, 77], ["DEC-205", "CHEMICAL", 70, 77], ["DEC-205", "SIMPLE_CHEMICAL", 70, 77], ["[14] [15] [16] [17] [18] 24", "SIMPLE_CHEMICAL", 133, 160], ["liver", "ORGAN", 227, 232], ["previous studies", "TEST", 6, 22], ["DEC", "TEST", 70, 73], ["the first study", "TEST", 186, 201], ["specific immune reactions", "PROBLEM", 233, 258], ["liver", "ANATOMY", 227, 232]]], ["We demonstrate that targeting DEC-205 + DCs resulted in a high frequency of local IFN\u03b3 + CD44 + CD8 + memory T cells (Fig. 3C) , which correlate with protection against adenovirus challenge in the liver (Fig. 6) .", [["DEC-205 + DCs", "ANATOMY", 30, 43], ["+ CD44 + CD8 + memory T cells", "ANATOMY", 87, 116], ["liver", "ANATOMY", 197, 202], ["DEC-205", "CHEMICAL", 30, 37], ["DEC-205", "GENE_OR_GENE_PRODUCT", 30, 37], ["CD44", "GENE_OR_GENE_PRODUCT", 89, 93], ["CD8", "GENE_OR_GENE_PRODUCT", 96, 99], ["adenovirus", "ORGANISM", 169, 179], ["liver", "ORGAN", 197, 202], ["DEC-205", "CELL_LINE", 30, 37], ["DCs", "CELL_TYPE", 40, 43], ["IFN", "PROTEIN", 82, 85], ["CD44", "PROTEIN", 89, 93], ["CD8", "PROTEIN", 96, 99], ["memory T cells", "CELL_TYPE", 102, 116], ["adenovirus", "SPECIES", 169, 179], ["DEC", "TEST", 30, 33], ["CD44", "TEST", 89, 93], ["adenovirus challenge in the liver", "PROBLEM", 169, 202], ["CD44", "OBSERVATION", 89, 93], ["CD8 + memory T cells", "OBSERVATION", 96, 116], ["liver", "ANATOMY", 197, 202]]], ["One critical point in fighting viral infections is to keep the balance between protective immunity and immunopathology, which are both mainly driven by CTLs and often decisive for the fate of the infected host 41, 42 .", [["viral infections", "DISEASE", 31, 47], ["immunopathology", "DISEASE", 103, 118], ["CTLs", "CELL_TYPE", 152, 156], ["fighting viral infections", "PROBLEM", 22, 47], ["immunopathology", "PROBLEM", 103, 118], ["fighting", "OBSERVATION_MODIFIER", 22, 30], ["viral infections", "OBSERVATION", 31, 47]]], ["For hepatotropic viruses such as HCV, which is not believed to be directly cytopathic, liver damage is attributed to T cell-mediated immunity 29 and immunopathology is inevitable for sterilizing immunity.", [["liver", "ANATOMY", 87, 92], ["T cell", "ANATOMY", 117, 123], ["liver damage", "DISEASE", 87, 99], ["immunopathology", "DISEASE", 149, 164], ["HCV", "ORGANISM", 33, 36], ["liver", "ORGAN", 87, 92], ["T cell", "CELL", 117, 123], ["HCV", "SPECIES", 33, 36], ["hepatotropic viruses", "PROBLEM", 4, 24], ["HCV", "PROBLEM", 33, 36], ["cytopathic", "PROBLEM", 75, 85], ["liver damage", "PROBLEM", 87, 99], ["T cell", "TEST", 117, 123], ["immunopathology", "PROBLEM", 149, 164], ["sterilizing immunity", "TREATMENT", 183, 203], ["viruses", "OBSERVATION", 17, 24], ["HCV", "OBSERVATION", 33, 36], ["not believed to be", "UNCERTAINTY", 47, 65], ["cytopathic", "OBSERVATION", 75, 85], ["liver", "ANATOMY", 87, 92], ["damage", "OBSERVATION", 93, 99]]], ["On the other hand, a less vigorous CTL response allows for viral persistence, ultimately leading to progressive tissue injury 43 .", [["tissue", "ANATOMY", 112, 118], ["tissue", "TISSUE", 112, 118], ["viral persistence", "PROBLEM", 59, 76], ["progressive tissue injury", "PROBLEM", 100, 125], ["progressive", "OBSERVATION_MODIFIER", 100, 111], ["tissue", "OBSERVATION_MODIFIER", 112, 118], ["injury", "OBSERVATION", 119, 125]]], ["Only in the \u03b1 DEC-205/OVA and BPPcysOVAMPEG group could immunopathology be correlated with antigen-specific viral clearance in the liver (Fig. 6) .", [["liver", "ANATOMY", 131, 136], ["\u03b1 DEC-205", "CHEMICAL", 12, 21], ["BPPcysOVAMPEG", "CHEMICAL", 30, 43], ["OVA", "SIMPLE_CHEMICAL", 22, 25], ["BPPcysOVAMPEG", "SIMPLE_CHEMICAL", 30, 43], ["antigen", "GENE_OR_GENE_PRODUCT", 91, 98], ["liver", "ORGAN", 131, 136], ["OVA", "PROBLEM", 22, 25], ["antigen", "TEST", 91, 98], ["viral clearance", "OBSERVATION", 108, 123], ["liver", "ANATOMY", 131, 136]]], ["Regarding the severity of hepatitis that occurs as a side effect of pathogen elimination, it is highly conceivable that \u03b1 DEC-205/OVA and BPPcysOVAMPEG immunized mice would have recovered from liver damage.", [["liver", "ANATOMY", 193, 198], ["hepatitis", "DISEASE", 26, 35], ["\u03b1 DEC-205", "CHEMICAL", 120, 129], ["BPPcysOVAMPEG", "CHEMICAL", 138, 151], ["liver damage", "DISEASE", 193, 205], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 120, 129], ["OVA", "SIMPLE_CHEMICAL", 130, 133], ["BPPcysOVAMPEG immunized", "ORGANISM", 138, 161], ["mice", "ORGANISM", 162, 166], ["liver", "ORGAN", 193, 198], ["mice", "SPECIES", 162, 166], ["mice", "SPECIES", 162, 166], ["hepatitis", "PROBLEM", 26, 35], ["pathogen elimination", "PROBLEM", 68, 88], ["OVA", "PROBLEM", 130, 133], ["BPPcysOVAMPEG immunized mice", "TREATMENT", 138, 166], ["liver damage", "PROBLEM", 193, 205], ["hepatitis", "OBSERVATION", 26, 35], ["liver", "ANATOMY", 193, 198], ["damage", "OBSERVATION", 199, 205]]], ["In a published model of fulminant hepatic failure, ALT levels peaked at day 4-5 post infection, which was the end-point of the experiments in our study, and had almost normalized by day 6 post infection 44 .", [["hepatic", "ANATOMY", 34, 41], ["fulminant hepatic failure", "DISEASE", 24, 49], ["infection", "DISEASE", 85, 94], ["infection", "DISEASE", 193, 202], ["hepatic", "ORGAN", 34, 41], ["ALT", "SIMPLE_CHEMICAL", 51, 54], ["ALT", "PROTEIN", 51, 54], ["fulminant hepatic failure", "PROBLEM", 24, 49], ["ALT levels", "TEST", 51, 61], ["infection", "PROBLEM", 85, 94], ["our study", "TEST", 142, 151], ["infection", "PROBLEM", 193, 202], ["fulminant", "OBSERVATION_MODIFIER", 24, 33], ["hepatic", "ANATOMY", 34, 41], ["failure", "OBSERVATION", 42, 49], ["infection", "OBSERVATION", 85, 94], ["infection", "OBSERVATION", 193, 202]]], ["However, further studies are needed to evaluate the consequences of immune-mediated hepatitis.DiscussionIn terms of clinical application the use of well tolerated adjuvants is of foremost importance.", [["hepatitis", "DISEASE", 84, 93], ["further studies", "TEST", 9, 24], ["immune-mediated hepatitis", "PROBLEM", 68, 93], ["adjuvants", "TREATMENT", 163, 172], ["hepatitis", "OBSERVATION", 84, 93]]], ["While a number of clinical trials indicated that CpG is sufficiently well tolerated, Poly(I:C) was shown to exhibit severe side effects in humans 45 .", [["CpG", "CHEMICAL", 49, 52], ["Poly(I:C", "CHEMICAL", 85, 93], ["CpG", "CHEMICAL", 49, 52], ["Poly(I:C", "CHEMICAL", 85, 93], ["CpG", "SIMPLE_CHEMICAL", 49, 52], ["Poly(I:C", "SIMPLE_CHEMICAL", 85, 93], ["humans", "ORGANISM", 139, 145], ["humans", "SPECIES", 139, 145], ["humans", "SPECIES", 139, 145], ["severe side effects in humans", "PROBLEM", 116, 145]]], ["Of note, its synthetic derivative, PolyICLC, which has already been successfully used in DEC-205 targeting trials 46-48 exhibits a better resistance to hydrolysis as well as a greater potency to induce IFN\u03b3 -secreting T cells 49 than Poly(I:C) and, most importantly, was proven a safe adjuvant in healthy human volunteers 50 and in cancer patients 51, 52 .", [["T cells", "ANATOMY", 218, 225], ["cancer", "ANATOMY", 332, 338], ["PolyICLC", "CHEMICAL", 35, 43], ["DEC-205", "CHEMICAL", 89, 96], ["cancer", "DISEASE", 332, 338], ["PolyICLC", "CHEMICAL", 35, 43], ["DEC-205", "CHEMICAL", 89, 96], ["PolyICLC", "SIMPLE_CHEMICAL", 35, 43], ["DEC-205", "SIMPLE_CHEMICAL", 89, 96], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 202, 206], ["T cells", "CELL", 218, 225], ["Poly(I:C", "SIMPLE_CHEMICAL", 234, 242], ["human", "ORGANISM", 305, 310], ["volunteers", "ORGANISM", 311, 321], ["cancer", "CANCER", 332, 338], ["patients", "ORGANISM", 339, 347], ["IFN\u03b3", "PROTEIN", 202, 206], ["human", "SPECIES", 305, 310], ["patients", "SPECIES", 339, 347], ["human", "SPECIES", 305, 310], ["IFN", "TEST", 202, 205], ["secreting T cells", "TEST", 208, 225]]], ["Additional studies are needed to clarify whether \u03b1 DEC-205/OVA vaccination using PolyICLC/CpG as an adjuvant will be as efficient as (or even more efficient than) \u03b1 DEC-205/OVA + Poly(I:C)/ CpG vaccination in inducing antiviral immunity in the liver.", [["liver", "ANATOMY", 244, 249], ["\u03b1", "CHEMICAL", 49, 50], ["DEC-205", "CHEMICAL", 51, 58], ["PolyICLC", "CHEMICAL", 81, 89], ["CpG", "CHEMICAL", 90, 93], ["DEC-205", "CHEMICAL", 165, 172], ["Poly(I:C", "CHEMICAL", 179, 187], ["CpG", "CHEMICAL", 190, 193], ["CpG", "CHEMICAL", 90, 93], ["Poly(I:C", "CHEMICAL", 179, 187], ["CpG", "CHEMICAL", 190, 193], ["\u03b1", "SIMPLE_CHEMICAL", 49, 50], ["DEC-205", "SIMPLE_CHEMICAL", 51, 58], ["OVA", "SIMPLE_CHEMICAL", 59, 62], ["PolyICLC", "SIMPLE_CHEMICAL", 81, 89], ["CpG", "SIMPLE_CHEMICAL", 90, 93], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 163, 172], ["OVA", "SIMPLE_CHEMICAL", 173, 176], ["Poly(I:C", "SIMPLE_CHEMICAL", 179, 187], ["CpG", "SIMPLE_CHEMICAL", 190, 193], ["liver", "ORGAN", 244, 249], ["Additional studies", "TEST", 0, 18], ["OVA vaccination", "TREATMENT", 59, 74], ["PolyICLC/CpG", "TREATMENT", 81, 93], ["an adjuvant", "TREATMENT", 97, 108], ["Poly(I:C)/ CpG vaccination", "TREATMENT", 179, 205], ["antiviral immunity", "OBSERVATION", 218, 236], ["liver", "ANATOMY", 244, 249]]], ["Regarding the TLR2/6 agonist BPPcysMPEG which is known to activate cross-priming CD8\u03b1 + DCs in mice, so far no published data are available for clinical applications.", [["CD8\u03b1 + DCs", "ANATOMY", 81, 91], ["BPPcysMPEG", "CHEMICAL", 29, 39], ["TLR2", "GENE_OR_GENE_PRODUCT", 14, 18], ["6", "GENE_OR_GENE_PRODUCT", 19, 20], ["BPPcysMPEG", "SIMPLE_CHEMICAL", 29, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 81, 84], ["mice", "ORGANISM", 95, 99], ["TLR2", "PROTEIN", 14, 18], ["BPPcysMPEG", "PROTEIN", 29, 39], ["CD8\u03b1", "PROTEIN", 81, 85], ["DCs", "CELL_TYPE", 88, 91], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["the TLR2/6 agonist BPPcysMPEG", "TREATMENT", 10, 39], ["DCs", "PROBLEM", 88, 91]]], ["It has recently been shown that human CD141 + DCs which are thought to represent the functional equivalent of mouse CD8\u03b1 + DCs do express TLR2 and 6 53 .", [["CD141 + DCs", "ANATOMY", 38, 49], ["CD8\u03b1", "ANATOMY", 116, 120], ["DCs", "ANATOMY", 123, 126], ["human", "ORGANISM", 32, 37], ["CD141 + DCs", "CELL", 38, 49], ["mouse", "ORGANISM", 110, 115], ["CD8", "GENE_OR_GENE_PRODUCT", 116, 119], ["TLR2", "GENE_OR_GENE_PRODUCT", 138, 142], ["CD141", "PROTEIN", 38, 43], ["DCs", "CELL_TYPE", 46, 49], ["CD8", "PROTEIN", 116, 119], ["DCs", "CELL_TYPE", 123, 126], ["TLR2", "PROTEIN", 138, 142], ["6 53", "PROTEIN", 147, 151], ["human", "SPECIES", 32, 37], ["mouse", "SPECIES", 110, 115], ["human", "SPECIES", 32, 37], ["mouse", "SPECIES", 110, 115], ["DCs", "PROBLEM", 46, 49], ["TLR2", "TEST", 138, 142], ["thought to represent", "UNCERTAINTY", 60, 80], ["mouse CD8", "OBSERVATION", 110, 119]]], ["Thus, an interaction of BPPcysOVAMPEG with DCs via the TLR2/6 receptors is likely to take place also in humans.", [["DCs", "ANATOMY", 43, 46], ["BPPcysOVAMPEG", "GENE_OR_GENE_PRODUCT", 24, 37], ["DCs", "CELL", 43, 46], ["TLR2/6 receptors", "GENE_OR_GENE_PRODUCT", 55, 71], ["humans", "ORGANISM", 104, 110], ["BPPcysOVAMPEG", "PROTEIN", 24, 37], ["DCs", "CELL_TYPE", 43, 46], ["TLR2/6 receptors", "PROTEIN", 55, 71], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 104, 110], ["BPPcysOVAMPEG", "TREATMENT", 24, 37], ["DCs via the TLR2/6 receptors", "TREATMENT", 43, 71]]], ["Nevertheless, future in vitro studies are needed to clarify this issue in more detail.DiscussionWe observed distinct patterns of CD8 + T cell interaction with virus infected and apoptotic hepatocytes, dependent on the vaccine formulation we used (Fig. 5C-E) .", [["CD8 + T cell", "ANATOMY", 129, 141], ["hepatocytes", "ANATOMY", 188, 199], ["CD8", "GENE_OR_GENE_PRODUCT", 129, 132], ["hepatocytes", "CELL", 188, 199], ["CD8", "PROTEIN", 129, 132], ["apoptotic hepatocytes", "CELL_TYPE", 178, 199], ["vitro studies", "TEST", 24, 37], ["CD8", "PROBLEM", 129, 132], ["T cell interaction", "PROBLEM", 135, 153], ["virus infected and apoptotic hepatocytes", "PROBLEM", 159, 199], ["the vaccine formulation", "TREATMENT", 214, 237], ["cell", "OBSERVATION", 137, 141], ["apoptotic hepatocytes", "OBSERVATION", 178, 199]]], ["While significantly fewer CD8 + T cells were in intimate contact with virus infected hepatocytes in the \u03b1 DEC-205/OVA-immunized group, these CD8 + T cells appear to be more effective in inducing apoptosis which is in line with the higher expression of IFN\u03b3 as a marker for their cytotoxic potential.", [["CD8 + T cells", "ANATOMY", 26, 39], ["hepatocytes", "ANATOMY", 85, 96], ["CD8 + T cells", "ANATOMY", 141, 154], ["\u03b1 DEC-205", "CHEMICAL", 104, 113], ["CD8", "GENE_OR_GENE_PRODUCT", 26, 29], ["hepatocytes", "CELL", 85, 96], ["\u03b1 DEC-205", "ORGANISM", 104, 113], ["OVA-immunized", "ORGANISM", 114, 127], ["CD8", "GENE_OR_GENE_PRODUCT", 141, 144], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 252, 256], ["CD8 + T cells", "CELL_TYPE", 26, 39], ["virus infected hepatocytes", "CELL_TYPE", 70, 96], ["CD8 + T cells", "CELL_TYPE", 141, 154], ["IFN\u03b3", "PROTEIN", 252, 256], ["T cells", "PROBLEM", 32, 39], ["virus infected hepatocytes", "PROBLEM", 70, 96], ["the \u03b1 DEC", "TEST", 100, 109], ["OVA", "PROBLEM", 114, 117], ["these CD8", "TEST", 135, 144], ["T cells", "PROBLEM", 147, 154], ["inducing apoptosis", "PROBLEM", 186, 204], ["apoptosis", "OBSERVATION", 195, 204]]], ["It is well established that CTLs eliminate infected hepatocytes after direct antigen recognition on target cells via perforin/granzyme or Fas-mediated killing.", [["CTLs", "ANATOMY", 28, 32], ["hepatocytes", "ANATOMY", 52, 63], ["cells", "ANATOMY", 107, 112], ["CTLs", "CELL", 28, 32], ["hepatocytes", "CELL", 52, 63], ["cells", "CELL", 107, 112], ["perforin", "GENE_OR_GENE_PRODUCT", 117, 125], ["granzyme", "GENE_OR_GENE_PRODUCT", 126, 134], ["CTLs", "CELL_TYPE", 28, 32], ["infected hepatocytes", "CELL_TYPE", 43, 63], ["target cells", "CELL_TYPE", 100, 112], ["perforin", "PROTEIN", 117, 125], ["granzyme", "PROTEIN", 126, 134], ["infected hepatocytes", "PROBLEM", 43, 63], ["direct antigen recognition", "TEST", 70, 96], ["perforin/granzyme", "TREATMENT", 117, 134], ["Fas-mediated killing", "PROBLEM", 138, 158]]], ["However, cytotoxicity in virus infected hepatocytes can also be exerted via the non-canonical CTL effector function where CTLs are stimulated by cross-presenting liver sinusoidal endothelial cells and secrete TNF after stimulation 54 .", [["hepatocytes", "ANATOMY", 40, 51], ["CTLs", "ANATOMY", 122, 126], ["liver sinusoidal endothelial cells", "ANATOMY", 162, 196], ["hepatocytes", "CELL", 40, 51], ["CTLs", "GENE_OR_GENE_PRODUCT", 122, 126], ["liver sinusoidal endothelial cells", "CELL", 162, 196], ["TNF", "GENE_OR_GENE_PRODUCT", 209, 212], ["virus infected hepatocytes", "CELL_TYPE", 25, 51], ["CTLs", "CELL_TYPE", 122, 126], ["cross-presenting liver sinusoidal endothelial cells", "CELL_TYPE", 145, 196], ["TNF", "PROTEIN", 209, 212], ["cytotoxicity in virus infected hepatocytes", "PROBLEM", 9, 51], ["secrete TNF", "TEST", 201, 212], ["stimulation", "TEST", 219, 230], ["liver", "ANATOMY", 162, 167], ["sinusoidal endothelial cells", "OBSERVATION", 168, 196]]], ["TNF induces cell death specifically in infected hepatocytes involving caspase-3 activation following TNFR stimulation.", [["cell", "ANATOMY", 12, 16], ["hepatocytes", "ANATOMY", 48, 59], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 12, 16], ["hepatocytes", "CELL", 48, 59], ["caspase-3", "GENE_OR_GENE_PRODUCT", 70, 79], ["TNFR", "GENE_OR_GENE_PRODUCT", 101, 105], ["TNF", "PROTEIN", 0, 3], ["infected hepatocytes", "CELL_TYPE", 39, 59], ["caspase-3", "PROTEIN", 70, 79], ["TNFR", "PROTEIN", 101, 105], ["TNF", "PROBLEM", 0, 3], ["cell death", "PROBLEM", 12, 22], ["infected hepatocytes", "PROBLEM", 39, 59], ["caspase", "TREATMENT", 70, 77], ["TNFR stimulation", "TREATMENT", 101, 117], ["cell death", "OBSERVATION", 12, 22], ["infected", "OBSERVATION_MODIFIER", 39, 47], ["hepatocytes", "ANATOMY", 48, 59]]], ["Of note, well in line with the observed elevated frequencies of IFN\u03b3 + CD44 + CD8 + CTL in AdOVA-GFP-luc infected livers of \u03b1 DEC-205/OVA compared to BPPcysOVAMPEG immunized mice, the overall IFN\u03b3 and as well TNF expression levels were by far higher in the \u03b1 DEC-205/OVA treated group (Supplementary Fig. S3 ).", [["+ CD44 + CD8 + CTL", "ANATOMY", 69, 87], ["livers", "ANATOMY", 114, 120], ["\u03b1 DEC-205", "CHEMICAL", 124, 133], ["\u03b1 DEC-205", "CHEMICAL", 257, 266], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 64, 68], ["CD44", "GENE_OR_GENE_PRODUCT", 71, 75], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["AdOVA", "GENE_OR_GENE_PRODUCT", 91, 96], ["GFP", "GENE_OR_GENE_PRODUCT", 97, 100], ["livers", "ORGAN", 114, 120], ["OVA", "ORGANISM", 134, 137], ["BPPcysOVAMPEG immunized", "ORGANISM", 150, 173], ["mice", "ORGANISM", 174, 178], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 192, 196], ["TNF", "GENE_OR_GENE_PRODUCT", 209, 212], ["IFN", "PROTEIN", 64, 67], ["CD44", "PROTEIN", 71, 75], ["CD8", "PROTEIN", 78, 81], ["GFP", "PROTEIN", 97, 100], ["IFN\u03b3", "PROTEIN", 192, 196], ["TNF", "PROTEIN", 209, 212], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 174, 178], ["CD44", "TEST", 71, 75], ["CD8", "TEST", 78, 81], ["CTL", "TEST", 84, 87], ["AdOVA", "TEST", 91, 96], ["GFP", "TEST", 97, 100], ["OVA", "PROBLEM", 134, 137], ["BPPcysOVAMPEG immunized mice", "TREATMENT", 150, 178], ["TNF expression levels", "TEST", 209, 230], ["livers", "ANATOMY", 114, 120]]], ["IFN\u03b3 secreted by highly abundant IFN\u03b3 + CD44 + CD8 + CTL may account for elevated TNF expression in hepatic macrophages in AdOVA-GFP-luc infected \u03b1 DEC-205/OVA immunized mice.", [["+ CD44 + CD8 + CTL", "ANATOMY", 38, 56], ["hepatic macrophages", "ANATOMY", 100, 119], ["\u03b1 DEC-205", "CHEMICAL", 146, 155], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD44", "GENE_OR_GENE_PRODUCT", 40, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 47, 50], ["TNF", "GENE_OR_GENE_PRODUCT", 82, 85], ["hepatic macrophages", "CELL", 100, 119], ["AdOVA", "GENE_OR_GENE_PRODUCT", 123, 128], ["GFP", "GENE_OR_GENE_PRODUCT", 129, 132], ["luc", "GENE_OR_GENE_PRODUCT", 133, 136], ["\u03b1 DEC-205/OVA", "ORGANISM", 146, 159], ["mice", "ORGANISM", 170, 174], ["IFN\u03b3", "PROTEIN", 0, 4], ["IFN", "PROTEIN", 33, 36], ["CD44", "PROTEIN", 40, 44], ["CD8", "PROTEIN", 47, 50], ["CTL", "CELL_TYPE", 53, 56], ["TNF", "PROTEIN", 82, 85], ["hepatic macrophages", "CELL_TYPE", 100, 119], ["GFP", "PROTEIN", 129, 132], ["mice", "SPECIES", 170, 174], ["mice", "SPECIES", 170, 174], ["CD44", "TEST", 40, 44], ["CTL", "PROBLEM", 53, 56], ["elevated TNF expression", "PROBLEM", 73, 96], ["AdOVA", "TEST", 123, 128], ["hepatic", "ANATOMY", 100, 107], ["macrophages", "OBSERVATION", 108, 119]]], ["Alternatively, as shown before by Wohlleber et al. 54 , virus-specific CTLs induced during \u03b1 DEC-205/OVA may be the source of TNF.", [["CTLs", "ANATOMY", 71, 75], ["\u03b1 DEC-205", "CHEMICAL", 91, 100], ["CTLs", "CELL", 71, 75], ["OVA", "SIMPLE_CHEMICAL", 101, 104], ["TNF", "GENE_OR_GENE_PRODUCT", 126, 129], ["CTLs", "CELL_TYPE", 71, 75], ["TNF", "PROTEIN", 126, 129], ["virus", "PROBLEM", 56, 61], ["OVA", "PROBLEM", 101, 104], ["TNF", "PROBLEM", 126, 129]]], ["While further investigation is needed to decipher the specific mechanisms underlying the elimination of virus infected hepatocytes in \u03b1 DEC-205/OVA and BPPcysOVAMPEG vaccinated mice, we may speculate that immune surveillance in \u03b1 DEC-205/ OVA immunized mice in addition to cell-contact dependent CTL-mediated killing to a higher degree involves cytokine-mediated effector functions.", [["hepatocytes", "ANATOMY", 119, 130], ["cell", "ANATOMY", 273, 277], ["\u03b1 DEC-205", "CHEMICAL", 134, 143], ["\u03b1 DEC-205", "CHEMICAL", 228, 237], ["hepatocytes", "CELL", 119, 130], ["\u03b1 DEC-205/OVA", "ORGANISM", 134, 147], ["BPPcysOVAMPEG vaccinated mice", "ORGANISM", 152, 181], ["\u03b1 DEC-205/", "ORGANISM", 228, 238], ["OVA immunized mice", "ORGANISM", 239, 257], ["cell", "CELL", 273, 277], ["CTL", "CELL", 296, 299], ["virus infected hepatocytes", "CELL_TYPE", 104, 130], ["cytokine", "PROTEIN", 345, 353], ["mice", "SPECIES", 177, 181], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 177, 181], ["mice", "SPECIES", 253, 257], ["further investigation", "TEST", 6, 27], ["virus infected hepatocytes", "PROBLEM", 104, 130], ["OVA", "PROBLEM", 144, 147], ["BPPcysOVAMPEG vaccinated mice", "TREATMENT", 152, 181], ["immune surveillance", "TEST", 205, 224], ["cell-contact dependent CTL-mediated killing", "TREATMENT", 273, 316]]], ["At first line TNF may be the most important cytokine involved in elimination of virus infected hepatocytes as it can induce apoptosis in adenovirus infected hepatocytes.", [["hepatocytes", "ANATOMY", 95, 106], ["hepatocytes", "ANATOMY", 157, 168], ["TNF", "GENE_OR_GENE_PRODUCT", 14, 17], ["hepatocytes", "CELL", 95, 106], ["adenovirus", "ORGANISM", 137, 147], ["hepatocytes", "CELL", 157, 168], ["TNF", "PROTEIN", 14, 17], ["cytokine", "PROTEIN", 44, 52], ["virus infected hepatocytes", "CELL_TYPE", 80, 106], ["adenovirus infected hepatocytes", "CELL_TYPE", 137, 168], ["adenovirus", "SPECIES", 137, 147], ["first line TNF", "TREATMENT", 3, 17], ["virus infected hepatocytes", "PROBLEM", 80, 106], ["apoptosis", "PROBLEM", 124, 133], ["adenovirus infected hepatocytes", "PROBLEM", 137, 168]]], ["Although IFN\u03b3 has been shown to exert non-cytolytic antiviral effector function in HBV infected hepatocytes 55 , previous reports have shown that IFN\u03b3 ko mice behave exactly the same as wildtype mice with regards to antiviral immune response against adenovirus infected hepatocytes and following liver damage 28, 54 .", [["hepatocytes", "ANATOMY", 96, 107], ["hepatocytes", "ANATOMY", 270, 281], ["liver", "ANATOMY", 296, 301], ["adenovirus infected", "DISEASE", 250, 269], ["liver damage", "DISEASE", 296, 308], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 9, 13], ["HBV", "ORGANISM", 83, 86], ["hepatocytes 55", "CELL", 96, 110], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 146, 150], ["mice", "ORGANISM", 154, 158], ["mice", "ORGANISM", 195, 199], ["adenovirus", "ORGANISM", 250, 260], ["hepatocytes", "CELL", 270, 281], ["liver", "ORGAN", 296, 301], ["IFN\u03b3", "PROTEIN", 9, 13], ["IFN\u03b3", "PROTEIN", 146, 150], ["adenovirus infected hepatocytes", "CELL_TYPE", 250, 281], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 195, 199], ["HBV", "SPECIES", 83, 86], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 195, 199], ["adenovirus", "SPECIES", 250, 260], ["IFN", "PROBLEM", 9, 12], ["non-cytolytic antiviral effector function", "PROBLEM", 38, 79], ["HBV infected hepatocytes", "PROBLEM", 83, 107], ["antiviral immune response", "TREATMENT", 216, 241], ["adenovirus infected hepatocytes", "PROBLEM", 250, 281], ["liver damage", "TEST", 296, 308], ["liver", "ANATOMY", 296, 301]]], ["This does not exclude that high levels of IFN\u03b3 may enhance secondary antiviral effects for example by the upregulation of antigen-presentation by hepatocytes enhancing recognition of infected cells by CTLs.DiscussionThe induction of antiviral immunity in the liver is per se a challenging issue.", [["hepatocytes", "ANATOMY", 146, 157], ["cells", "ANATOMY", 192, 197], ["CTLs", "ANATOMY", 201, 205], ["liver", "ANATOMY", 259, 264], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 42, 46], ["antigen", "GENE_OR_GENE_PRODUCT", 122, 129], ["hepatocytes", "CELL", 146, 157], ["cells", "CELL", 192, 197], ["CTLs", "CELL", 201, 205], ["liver", "ORGAN", 259, 264], ["IFN\u03b3", "PROTEIN", 42, 46], ["hepatocytes", "CELL_TYPE", 146, 157], ["infected cells", "CELL_TYPE", 183, 197], ["CTLs", "CELL_TYPE", 201, 205], ["high levels of IFN", "PROBLEM", 27, 45], ["antiviral effects", "PROBLEM", 69, 86], ["infected cells", "PROBLEM", 183, 197], ["antiviral immunity", "TREATMENT", 233, 251], ["hepatocytes", "ANATOMY", 146, 157], ["infected cells", "OBSERVATION", 183, 197], ["liver", "ANATOMY", 259, 264]]], ["A hallmark of e.g. HCV persistence is the appearance of functionally impaired and exhausted T cells that are unable to secrete antiviral effector molecules, show impaired proliferation 29, 56, 57 and dysregulate expression of activating/inhibitory receptors [58] [59] [60] .", [["T cells", "ANATOMY", 92, 99], ["HCV", "ORGANISM", 19, 22], ["T cells", "CELL", 92, 99], ["T cells", "CELL_TYPE", 92, 99], ["antiviral effector molecules", "PROTEIN", 127, 155], ["inhibitory receptors", "PROTEIN", 237, 257], ["HCV", "SPECIES", 19, 22], ["A hallmark of e.g. HCV persistence", "PROBLEM", 0, 34], ["functionally impaired and exhausted T cells", "PROBLEM", 56, 99], ["impaired proliferation", "PROBLEM", 162, 184], ["activating/inhibitory receptors", "TEST", 226, 257], ["hallmark", "OBSERVATION_MODIFIER", 2, 10], ["HCV", "OBSERVATION", 19, 22], ["functionally", "OBSERVATION_MODIFIER", 56, 68], ["impaired", "OBSERVATION", 69, 77], ["impaired", "OBSERVATION_MODIFIER", 162, 170], ["proliferation", "OBSERVATION_MODIFIER", 171, 184]]], ["Next to this, in patients chronically infected with HCV the higher frequency of suppressive CD4 + CD25 + T regulatory cells 61 most likely contribute to T cell dysfunction.", [["CD4 + CD25 + T regulatory cells", "ANATOMY", 92, 123], ["T cell", "ANATOMY", 153, 159], ["patients", "ORGANISM", 17, 25], ["HCV", "ORGANISM", 52, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD25", "GENE_OR_GENE_PRODUCT", 98, 102], ["T cell", "CELL", 153, 159], ["CD4", "PROTEIN", 92, 95], ["CD25", "PROTEIN", 98, 102], ["patients", "SPECIES", 17, 25], ["HCV", "SPECIES", 52, 55], ["HCV", "TREATMENT", 52, 55], ["T regulatory cells", "PROBLEM", 105, 123], ["T cell dysfunction", "PROBLEM", 153, 171], ["infected", "OBSERVATION", 38, 46], ["cell dysfunction", "OBSERVATION", 155, 171]]], ["Since blocking of PD-1, CTLA-4 and Tim-3 hold some therapeutic promise for the functional recovery of exhausted T cells 59,60,62 , a combined strategy encompassing both antibody-mediated blocking of immunosuppressive pathways together with boosting antiviral immunity by means of DEC-205-or TLR-mediated antigen delivery to cross-presenting DCs could represent a promising scenario for future developments.", [["T cells", "ANATOMY", 112, 119], ["DCs", "ANATOMY", 341, 344], ["DEC-205", "CHEMICAL", 280, 287], ["PD-1", "GENE_OR_GENE_PRODUCT", 18, 22], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 24, 30], ["Tim-3", "GENE_OR_GENE_PRODUCT", 35, 40], ["T cells", "CELL", 112, 119], ["DEC-205", "SIMPLE_CHEMICAL", 280, 287], ["TLR", "GENE_OR_GENE_PRODUCT", 291, 294], ["DCs", "CELL", 341, 344], ["CTLA-4", "PROTEIN", 24, 30], ["Tim", "PROTEIN", 35, 38], ["exhausted T cells", "CELL_TYPE", 102, 119], ["TLR", "PROTEIN", 291, 294], ["cross-presenting DCs", "CELL_TYPE", 324, 344], ["PD", "TEST", 18, 20], ["CTLA", "TEST", 24, 28], ["exhausted T cells", "PROBLEM", 102, 119], ["a combined strategy", "TREATMENT", 131, 150], ["both antibody", "TREATMENT", 164, 177], ["immunosuppressive pathways", "TREATMENT", 199, 225], ["boosting antiviral immunity", "TREATMENT", 240, 267], ["TLR-mediated antigen delivery", "TREATMENT", 291, 320]]], ["This may also imply the use of DC targeting as a therapeutic vaccine, which has been shown to be clearly effective in several other studies 14, 21, 25 , and might also contribute to the treatment of patients with hepatic virus infection after liver transplantation to avoid reinfection.MethodsMice.", [["DC", "ANATOMY", 31, 33], ["liver", "ANATOMY", 243, 248], ["hepatic virus infection", "DISEASE", 213, 236], ["patients", "ORGANISM", 199, 207], ["hepatic virus", "ORGANISM", 213, 226], ["liver", "ORGAN", 243, 248], ["DC", "CELL_TYPE", 31, 33], ["patients", "SPECIES", 199, 207], ["a therapeutic vaccine", "TREATMENT", 47, 68], ["several other studies", "TEST", 118, 139], ["hepatic virus infection", "PROBLEM", 213, 236], ["liver transplantation", "TREATMENT", 243, 264], ["reinfection", "PROBLEM", 274, 285], ["hepatic", "ANATOMY", 213, 220], ["virus", "OBSERVATION", 221, 226], ["liver", "ANATOMY", 243, 248], ["transplantation", "OBSERVATION", 249, 264], ["reinfection", "OBSERVATION", 274, 285]]], ["Female C57BL/6 mice were obtained from Harlan Winkelmann (Borchen, Germany) and housed under specific pathogen-free conditions according to the national and institutional guidelines.", [["C57BL/6 mice", "ORGANISM", 7, 19], ["Harlan Winkelmann", "ORGANISM", 39, 56], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19]]], ["All experiments were approved by the local government agency (Nieders\u00e4chsisches Landesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit; file number 33.12-42502-04-10/0108) and have been performed in accordance to these guidelines.MethodsAntibodies, antigens and cell lines.", [["cell lines", "ANATOMY", 266, 276], ["cell lines", "CELL", 266, 276], ["antigens", "PROTEIN", 253, 261], ["cell lines", "CELL_LINE", 266, 276], ["Nieders\u00e4chsisches Landesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit; file number 33.12-42502-04-10/0108", "SPECIES", 62, 174], ["MethodsAntibodies", "TREATMENT", 234, 251], ["cell lines", "TREATMENT", 266, 276], ["cell lines", "OBSERVATION", 266, 276]]], ["EndoGrade Conjugation of OVA to \u03b1DEC-205.", [["\u03b1DEC-205", "CHEMICAL", 32, 40]]], ["Chemical conjugation of purified \u03b1 DEC-205 to OVA was performed as previously published 64 with minor modifications.", [["\u03b1 DEC-205", "CHEMICAL", 33, 42], ["OVA", "SIMPLE_CHEMICAL", 46, 49]]], ["In brief, \u03b1 DEC-205 was first activated by sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate) (Thermo Fisher Scientific, USA), according to the manufacturer's protocol, and in parallel the sulfhydryl-groups of the OVA protein were exposed by using 30 mM tris(2-carboxyethyl) phosphine hydrochloride (TCEP-HCl) (Thermo Fisher Scientific, USA) (1.5 hours at room temperature).", [["\u03b1 DEC-205", "CHEMICAL", 10, 19], ["sulfo-SMCC", "CHEMICAL", 43, 53], ["sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate", "CHEMICAL", 55, 120], ["sulfhydryl", "CHEMICAL", 217, 227], ["tris(2-carboxyethyl) phosphine hydrochloride", "CHEMICAL", 282, 326], ["TCEP-HCl", "CHEMICAL", 328, 336], ["DEC-205", "CHEMICAL", 12, 19], ["sulfo-SMCC", "CHEMICAL", 43, 53], ["sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate", "CHEMICAL", 55, 120], ["sulfhydryl", "CHEMICAL", 217, 227], ["tris(2-carboxyethyl) phosphine hydrochloride", "CHEMICAL", 282, 326], ["TCEP", "CHEMICAL", 328, 332], ["HCl", "CHEMICAL", 333, 336], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 10, 19], ["sulfo-SMCC", "SIMPLE_CHEMICAL", 43, 53], ["sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate", "SIMPLE_CHEMICAL", 55, 120], ["sulfhydryl", "SIMPLE_CHEMICAL", 217, 227], ["tris(2-carboxyethyl) phosphine hydrochloride", "SIMPLE_CHEMICAL", 282, 326], ["TCEP-HCl", "SIMPLE_CHEMICAL", 328, 336], ["OVA protein", "PROTEIN", 242, 253], ["sulfo-SMCC (sulfosuccinimidyl", "TREATMENT", 43, 72], ["N-maleimidomethyl] cyclohexane", "TREATMENT", 76, 106], ["the manufacturer's protocol", "TREATMENT", 168, 195], ["the OVA protein", "TREATMENT", 238, 253], ["30 mM tris(2-carboxyethyl) phosphine hydrochloride", "TREATMENT", 276, 326]]], ["Excess of TCEP and sulfo-SMCC in the respective samples was removed using Zeba Desalt Spin Columns, according to the manufacturer's recommendations (Thermo Fisher Scientific, USA).", [["samples", "ANATOMY", 48, 55], ["TCEP", "CHEMICAL", 10, 14], ["sulfo-SMCC", "CHEMICAL", 19, 29], ["TCEP", "CHEMICAL", 10, 14], ["sulfo-SMCC", "CHEMICAL", 19, 29], ["TCEP", "SIMPLE_CHEMICAL", 10, 14], ["sulfo-SMCC", "SIMPLE_CHEMICAL", 19, 29], ["TCEP", "TREATMENT", 10, 14], ["sulfo", "TREATMENT", 19, 24], ["TCEP", "OBSERVATION_MODIFIER", 10, 14], ["SMCC", "OBSERVATION", 25, 29]]], ["The reduced OVA was immediately mixed with the activated antibody and incubated overnight at 4 \u00b0C. The resulting \u03b1 DEC-205/OVA conjugate was concentrated and separated from unbound OVA using 150 K MWCO Pierce \u00ae concentrators (Thermo Fisher Scientific, USA).", [["\u03b1 DEC-205", "CHEMICAL", 113, 122], ["\u03b1 DEC-205", "SIMPLE_CHEMICAL", 113, 122], ["OVA conjugate", "SIMPLE_CHEMICAL", 123, 136], ["OVA", "SIMPLE_CHEMICAL", 181, 184], ["activated antibody", "PROTEIN", 47, 65], ["The reduced OVA", "PROBLEM", 0, 15], ["the activated antibody", "TREATMENT", 43, 65], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["OVA", "OBSERVATION", 12, 15]]], ["Quantification of the OVA content within the \u03b1 DEC-205/OVA conjugate was achieved by comparison of OVA signal intensities on Western blot with graded quantities of OVA on the same blot ( Supplementary Fig. S4) 14 Immunization.", [["\u03b1 DEC-205", "CHEMICAL", 45, 54], ["OVA", "SIMPLE_CHEMICAL", 22, 25], ["DEC-205", "SIMPLE_CHEMICAL", 47, 54], ["OVA", "SIMPLE_CHEMICAL", 55, 58], ["the OVA content", "PROBLEM", 18, 33], ["OVA conjugate", "TREATMENT", 55, 68], ["OVA signal intensities", "PROBLEM", 99, 121], ["Western blot", "TEST", 125, 137], ["OVA", "PROBLEM", 164, 167], ["Immunization", "TREATMENT", 213, 225], ["OVA content", "OBSERVATION", 22, 33], ["OVA", "OBSERVATION", 164, 167]]], ["Mice were subcutaneously immunized on days 0, 14 and 28 with either 30 \u03bc g \u03b1 DEC-205/ OVA, 30 \u03bc g \u03b1 DEC-205, 10 \u03bc g BPPcysOVAMPEG 12 or 7 \u03bc g OVA co-administered either with 50 \u03bc g Poly(I:C) and 50 \u03bc g CpG, as previously published 15, 16, 24, 25 or 5-10 \u03bc g BPPcysMPEG 39 in a total volume of 50 \u03bc l PBS per animal.MethodsDetermination of serum ALT.", [["serum", "ANATOMY", 339, 344], ["\u03b1 DEC-205", "CHEMICAL", 75, 84], ["\u03b1 DEC-205", "CHEMICAL", 98, 107], ["BPPcysOVAMPEG", "CHEMICAL", 116, 129], ["BPPcysMPEG", "CHEMICAL", 258, 268], ["BPPcysOVAMPEG", "CHEMICAL", 116, 129], ["Poly(I:C)", "CHEMICAL", 181, 190], ["CpG", "CHEMICAL", 202, 205], ["Mice", "ORGANISM", 0, 4], ["OVA", "SIMPLE_CHEMICAL", 86, 89], ["serum", "ORGANISM_SUBSTANCE", 339, 344], ["ALT", "SIMPLE_CHEMICAL", 345, 348], ["serum ALT", "PROTEIN", 339, 348], ["Mice", "SPECIES", 0, 4], ["BPPcysOVAMPEG", "TEST", 116, 129], ["CpG", "TEST", 202, 205], ["BPPcysMPEG", "TEST", 258, 268], ["a total volume", "TEST", 275, 289], ["serum ALT", "TEST", 339, 348]]], ["For ALT quantification, 75 \u03bc l peripheral blood were mixed with 25 \u03bc l 1% heparin (Ratiopharm, Germany), centrifuged (10,600\u00d7 g, 10 minutes, room temperature) and 32 \u03bc l of the supernatant were used for detecting ALT activity using the scil Reflovet \u00ae Plus reflection-photometer (scil animal care, Germany).MethodsAnalysis of liver lymphocytes.", [["peripheral blood", "ANATOMY", 31, 47], ["supernatant", "ANATOMY", 177, 188], ["liver lymphocytes", "ANATOMY", 326, 343], ["heparin", "CHEMICAL", 74, 81], ["ALT", "SIMPLE_CHEMICAL", 4, 7], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["heparin", "SIMPLE_CHEMICAL", 74, 81], ["ALT", "SIMPLE_CHEMICAL", 213, 216], ["liver lymphocytes", "CELL", 326, 343], ["ALT", "PROTEIN", 213, 216], ["liver lymphocytes", "CELL_TYPE", 326, 343], ["ALT quantification", "TEST", 4, 22], ["heparin", "TREATMENT", 74, 81], ["the supernatant", "TREATMENT", 173, 188], ["ALT activity", "PROBLEM", 213, 225], ["the scil Reflovet", "TREATMENT", 232, 249], ["photometer (scil animal care", "TREATMENT", 268, 296], ["MethodsAnalysis", "TEST", 307, 322], ["liver", "ANATOMY", 326, 331]]], ["Livers were perfused with ice-cold PBS and minced on ice followed by enzymatic digestion in IMDM (Gibco, Germany) containing 0.2 mg/ml collagenase D (Roche, Germany), 10 \u03bc g/ml DNase (Sigma, Germany) and 5% FCS for 30 minutes at 37 \u00b0C. After addition of EDTA (5 mM final concentration), cells were pelleted by centrifugation (15 minutes at 300\u00d7 g) and liver lymphocytes were enriched by Percoll density gradient centrifugation.", [["Livers", "ANATOMY", 0, 6], ["cells", "ANATOMY", 287, 292], ["liver lymphocytes", "ANATOMY", 352, 369], ["EDTA", "CHEMICAL", 254, 258], ["EDTA", "CHEMICAL", 254, 258], ["Livers", "ORGAN", 0, 6], ["collagenase D", "SIMPLE_CHEMICAL", 135, 148], ["EDTA", "SIMPLE_CHEMICAL", 254, 258], ["cells", "CELL", 287, 292], ["liver lymphocytes", "CELL", 352, 369], ["DNase", "PROTEIN", 177, 182], ["liver lymphocytes", "CELL_TYPE", 352, 369], ["ice-cold PBS", "TREATMENT", 26, 38], ["ice", "TREATMENT", 53, 56], ["enzymatic digestion", "PROBLEM", 69, 88], ["5% FCS", "TREATMENT", 204, 210], ["EDTA (5 mM final concentration)", "TREATMENT", 254, 285], ["Percoll density gradient centrifugation", "TREATMENT", 387, 426], ["perfused", "OBSERVATION_MODIFIER", 12, 20], ["liver", "ANATOMY", 352, 357], ["lymphocytes", "ANATOMY", 358, 369], ["Percoll density", "OBSERVATION", 387, 402], ["gradient centrifugation", "OBSERVATION", 403, 426]]], ["The cells were stimulated with a mixture of OVA protein and the OVA peptides CD4 323-339 and CD8 257-264 (20 \u03bc g/ml final concentration for all) for 24 hours at 37 \u00b0C. The cells were then stimulated by incubation with 0.01 \u03bc g/ml PMA (Sigma, Germany) and 1 \u03bc g/ml ionomycin (Sigma, Germany) for a total of 4 hours, 10 \u03bc g/ml Brefeldin A (Sigma, Germany) were added after 2 hours.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 172, 177], ["CD8 257-264", "CHEMICAL", 93, 104], ["ionomycin", "CHEMICAL", 264, 273], ["Brefeldin A", "CHEMICAL", 325, 336], ["PMA", "CHEMICAL", 230, 233], ["ionomycin", "CHEMICAL", 264, 273], ["Brefeldin A", "CHEMICAL", 325, 336], ["cells", "CELL", 4, 9], ["cells", "CELL", 172, 177], ["PMA", "SIMPLE_CHEMICAL", 230, 233], ["ionomycin", "SIMPLE_CHEMICAL", 264, 273], ["Brefeldin A", "SIMPLE_CHEMICAL", 325, 336], ["OVA protein", "PROTEIN", 44, 55], ["OVA protein", "TREATMENT", 44, 55], ["the OVA peptides CD4", "TEST", 60, 80], ["CD8", "TEST", 93, 96], ["ionomycin", "TREATMENT", 264, 273], ["Brefeldin A (Sigma, Germany)", "TREATMENT", 325, 353]]], ["For flow cytometric analysis, Fc-block was performed through incubation with anti-mouse CD16/CD36 antibody (2.4G2) followed by surface staining for mouse CD8 (53-6.7) and CD44 (IM7) (BD Biosciences, eBioscience).", [["surface", "ANATOMY", 127, 134], ["Fc", "GENE_OR_GENE_PRODUCT", 30, 32], ["CD16", "GENE_OR_GENE_PRODUCT", 88, 92], ["CD36", "GENE_OR_GENE_PRODUCT", 93, 97], ["mouse", "ORGANISM", 148, 153], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["CD44", "GENE_OR_GENE_PRODUCT", 171, 175], ["Fc", "PROTEIN", 30, 32], ["anti-mouse CD16", "PROTEIN", 77, 92], ["CD36 antibody", "PROTEIN", 93, 106], ["CD8", "PROTEIN", 154, 157], ["CD44", "PROTEIN", 171, 175], ["IM7", "PROTEIN", 177, 180], ["BD Biosciences", "PROTEIN", 183, 197], ["eBioscience", "PROTEIN", 199, 210], ["mouse", "SPECIES", 148, 153], ["mouse", "SPECIES", 148, 153], ["flow cytometric analysis", "TEST", 4, 28], ["Fc-block", "TREATMENT", 30, 38], ["anti-mouse CD16", "TEST", 77, 92], ["CD36 antibody", "TEST", 93, 106], ["surface staining", "TEST", 127, 143], ["mouse CD8", "TEST", 148, 157], ["CD44", "TEST", 171, 175], ["BD Biosciences", "TEST", 183, 197]]], ["After fixation (2% paraformaldehyde/PBS v/v), cells were permeabilized using 0.1% Igepal \u00ae CA-630/PBS (Sigma, Germany) and stained for intracellular IFN\u03b3 (XMG1.2).", [["cells", "ANATOMY", 46, 51], ["intracellular", "ANATOMY", 135, 148], ["Igepal \u00ae CA-630", "CHEMICAL", 82, 97], ["paraformaldehyde", "CHEMICAL", 19, 35], ["paraformaldehyde", "SIMPLE_CHEMICAL", 19, 35], ["cells", "CELL", 46, 51], ["CA-630", "SIMPLE_CHEMICAL", 91, 97], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 148], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 149, 153], ["XMG1.2", "GENE_OR_GENE_PRODUCT", 155, 161], ["IFN\u03b3", "PROTEIN", 149, 153], ["XMG1.2", "PROTEIN", 155, 161], ["fixation (2% paraformaldehyde/PBS v/v)", "TREATMENT", 6, 44], ["CA", "TEST", 91, 93]]], ["Data were acquired on an LSR Fortessa instrument (BD Biosciences) and further analysed using the FlowJo software (Tree Star, USA).Detection of antigen-specific serum IgG.To monitor the humoral immune response, 75 \u03bc l of blood were collected from the retro-orbital sinus and serum was obtained through incubation of the samples for 45 minutes at 37 \u00b0C, followed by 45 minutes incubation at 4 \u00b0C and subsequent centrifugation (10 minutes at 420\u00d7 g).", [["serum", "ANATOMY", 160, 165], ["blood", "ANATOMY", 220, 225], ["retro-orbital sinus", "ANATOMY", 250, 269], ["serum", "ANATOMY", 274, 279], ["samples", "ANATOMY", 319, 326], ["antigen", "GENE_OR_GENE_PRODUCT", 143, 150], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["IgG", "GENE_OR_GENE_PRODUCT", 166, 169], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["retro-orbital sinus", "MULTI-TISSUE_STRUCTURE", 250, 269], ["serum", "ORGANISM_SUBSTANCE", 274, 279], ["serum IgG", "PROTEIN", 160, 169], ["antigen", "TEST", 143, 150], ["specific serum IgG", "TEST", 151, 169], ["retro-orbital sinus", "ANATOMY", 250, 269]]], ["Sera were assayed for the presence of antigen-specific IgG and IgG subclasses (IgG 1 , IgG 2c ) by enzyme-linked immunosorbent assay (ELISA) using 96-well Nunc-Immuno MaxiSorp plates (Nunc, Germany) coated with 2 \u03bc g/ml OVA protein in 0.05 M carbonate buffer (pH 9.6).", [["Sera", "ANATOMY", 0, 4], ["carbonate", "CHEMICAL", 242, 251], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["antigen", "GENE_OR_GENE_PRODUCT", 38, 45], ["IgG", "GENE_OR_GENE_PRODUCT", 55, 58], ["IgG", "GENE_OR_GENE_PRODUCT", 63, 66], ["IgG 1", "GENE_OR_GENE_PRODUCT", 79, 84], ["IgG 2c", "GENE_OR_GENE_PRODUCT", 87, 93], ["carbonate", "SIMPLE_CHEMICAL", 242, 251], ["IgG", "PROTEIN", 55, 58], ["IgG subclasses", "PROTEIN", 63, 77], ["IgG 1", "PROTEIN", 79, 84], ["IgG 2c", "PROTEIN", 87, 93], ["OVA protein", "PROTEIN", 220, 231], ["Sera", "TEST", 0, 4], ["antigen", "TEST", 38, 45], ["specific IgG", "TEST", 46, 58], ["IgG subclasses", "TEST", 63, 77], ["IgG", "TEST", 79, 82], ["IgG", "TEST", 87, 90], ["enzyme", "TEST", 99, 105], ["immunosorbent assay", "TEST", 113, 132], ["ELISA", "TEST", 134, 139], ["Nunc-Immuno MaxiSorp plates", "TREATMENT", 155, 182], ["2 \u03bc g/ml OVA protein", "TREATMENT", 211, 231], ["0.05 M carbonate buffer", "TREATMENT", 235, 258], ["pH", "TEST", 260, 262]]], ["After overnight incubation at 4 \u00b0C, the plates were washed with PBS supplemented with 0.1% Tween 20 and blocked with 3% BSA in PBS for 1 hour at 37 \u00b0C. Serial 2-fold dilutions of sera in 3% BSA/PBS were added and plates were further incubated for 2 hours at 37 \u00b0C. After washing, antibody binding was detected using biotin-conjugated goat \u03b1 -mouse IgG (Sigma, Germany), goat \u03b1 -mouse IgG 1 (Southern Biotech, USA) and goat \u03b1 -mouse IgG 2c (Southern Biotech, USA) antibodies (1 hour, 37 \u00b0C), respectively, and streptavidin-HRPO (BD Biosciences, Germany) (30 minutes, 37 \u00b0C).", [["sera", "ANATOMY", 179, 183], ["BSA", "CHEMICAL", 120, 123], ["BSA", "CHEMICAL", 190, 193], ["biotin", "CHEMICAL", 316, 322], ["streptavidin-HRPO", "CHEMICAL", 509, 526], ["Tween 20", "CHEMICAL", 91, 99], ["biotin", "CHEMICAL", 316, 322], ["BSA", "SIMPLE_CHEMICAL", 120, 123], ["sera", "ORGANISM_SUBSTANCE", 179, 183], ["BSA", "SIMPLE_CHEMICAL", 190, 193], ["PBS", "SIMPLE_CHEMICAL", 194, 197], ["biotin", "SIMPLE_CHEMICAL", 316, 322], ["mouse", "ORGANISM", 342, 347], ["goat", "ORGANISM", 370, 374], ["mouse", "ORGANISM", 378, 383], ["goat", "ORGANISM", 418, 422], ["mouse", "ORGANISM", 426, 431], ["streptavidin-HRPO", "SIMPLE_CHEMICAL", 509, 526], ["biotin-conjugated goat \u03b1", "PROTEIN", 316, 340], ["mouse IgG", "PROTEIN", 342, 351], ["Sigma, Germany), goat \u03b1", "PROTEIN", 353, 376], ["mouse IgG 1", "PROTEIN", 378, 389], ["Southern Biotech", "PROTEIN", 391, 407], ["goat \u03b1", "PROTEIN", 418, 424], ["mouse IgG 2c", "PROTEIN", 426, 438], ["Southern Biotech, USA) antibodies", "PROTEIN", 440, 473], ["goat", "SPECIES", 334, 338], ["mouse", "SPECIES", 342, 347], ["goat", "SPECIES", 370, 374], ["mouse", "SPECIES", 378, 383], ["goat", "SPECIES", 418, 422], ["mouse", "SPECIES", 426, 431], ["mouse", "SPECIES", 342, 347], ["goat", "SPECIES", 370, 374], ["mouse", "SPECIES", 378, 383], ["goat", "SPECIES", 418, 422], ["mouse", "SPECIES", 426, 431], ["the plates", "TREATMENT", 36, 46], ["PBS", "TREATMENT", 64, 67], ["3% BSA in PBS", "TREATMENT", 117, 130], ["Serial 2-fold dilutions", "TREATMENT", 152, 175], ["sera", "TEST", 179, 183], ["BSA/PBS", "TEST", 190, 197], ["plates", "TEST", 213, 219], ["antibody binding", "TEST", 280, 296], ["biotin", "TEST", 316, 322], ["antibodies", "TEST", 463, 473], ["streptavidin", "TEST", 509, 521]]], ["ABTS in 0.1 M citrate-phosphate buffer (pH 4.35) containing 0.03% H 2 O 2 was added to each well and the absorbance at 405 nm was recorded after 30 minutes of incubation.", [["ABTS", "CHEMICAL", 0, 4], ["citrate-phosphate", "CHEMICAL", 14, 31], ["H 2 O", "CHEMICAL", 66, 71], ["ABTS", "CHEMICAL", 0, 4], ["citrate", "CHEMICAL", 14, 21], ["phosphate", "CHEMICAL", 22, 31], ["H 2 O 2", "CHEMICAL", 66, 73], ["ABTS", "SIMPLE_CHEMICAL", 0, 4], ["citrate-phosphate buffer", "SIMPLE_CHEMICAL", 14, 38], ["H 2 O 2", "SIMPLE_CHEMICAL", 66, 73], ["ABTS", "TEST", 0, 4], ["citrate-phosphate buffer (pH", "TREATMENT", 14, 42]]], ["Endpoint titres were expressed as the reciprocal value of the last serum dilution which yielded an absorbance two times above the values of negative controls.Enzyme-linked immunosorbent spot (ELIsPOT) assay.", [["serum", "ANATOMY", 67, 72], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["Endpoint titres", "TEST", 0, 15], ["the last serum dilution", "TEST", 58, 81], ["an absorbance", "PROBLEM", 96, 109], ["Enzyme", "TEST", 158, 164], ["immunosorbent spot (ELIsPOT) assay", "TEST", 172, 206], ["negative controls", "OBSERVATION", 140, 157], ["immunosorbent spot", "OBSERVATION", 172, 190]]], ["ELISPOT kits for the detection of murineIFN\u03b3 (eBioscience, Germany) and IL-4 (BD Biosciences, Germany) were used according to the manufacturer's instructions.", [["murineIFN\u03b3", "GENE_OR_GENE_PRODUCT", 34, 44], ["IL-4", "GENE_OR_GENE_PRODUCT", 72, 76], ["murineIFN\u03b3", "PROTEIN", 34, 44], ["eBioscience", "PROTEIN", 46, 57], ["IL", "PROTEIN", 72, 74], ["ELISPOT kits", "TEST", 0, 12], ["murineIFN", "PROBLEM", 34, 43]]], ["The results are presented as spot forming units per 10 6 cells.Enzyme-linked immunosorbent spot (ELIsPOT) assay.", [["cells", "ANATOMY", 57, 62], ["cells", "CELL", 57, 62], ["Enzyme", "TEST", 63, 69], ["immunosorbent spot (ELIsPOT) assay", "TEST", 77, 111], ["immunosorbent spot", "OBSERVATION", 77, 95]]], ["ELISPOT kits for the detection of murineIn vivo cytotoxicity assay.", [["ELISPOT kits", "TEST", 0, 12], ["the detection", "TEST", 17, 30], ["murineIn vivo cytotoxicity assay", "TEST", 34, 66]]], ["Splenocytes were isolated from naive syngeneic donor mice and equal cell numbers were pulsed with 1 \u03bc g/ml SIINFEKL (OVA 257-264 ) peptide for 30 minutes at room temperature or left untreated followed by labelling with 2.5 \u03bc M (CFSE high ) or 0.25 \u03bc M (CFSE low ) CFSE, respectively, and mixing in a one to one ratio.", [["Splenocytes", "ANATOMY", 0, 11], ["cell", "ANATOMY", 68, 72], ["OVA 257-264", "CHEMICAL", 117, 128], ["CFSE", "CHEMICAL", 228, 232], ["CFSE", "CHEMICAL", 253, 257], ["CFSE", "CHEMICAL", 264, 268], ["Splenocytes", "CELL", 0, 11], ["mice", "ORGANISM", 53, 57], ["cell", "CELL", 68, 72], ["CFSE", "SIMPLE_CHEMICAL", 264, 268], ["Splenocytes", "CELL_TYPE", 0, 11], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["naive syngeneic donor mice", "TREATMENT", 31, 57], ["OVA", "TEST", 117, 120], ["naive syngeneic", "OBSERVATION", 31, 46], ["cell numbers", "OBSERVATION", 68, 80], ["left", "ANATOMY_MODIFIER", 177, 181]]], ["A total of 2 \u00d7 10 7 target cells was intravenously (i.v.) injected into recipient mice.", [["cells", "ANATOMY", 27, 32], ["intravenously", "ANATOMY", 37, 50], ["cells", "CELL", 27, 32], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["mice", "ORGANISM", 82, 86], ["target cells", "CELL_TYPE", 20, 32], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["A total of 2 \u00d7 10 7 target cells", "TREATMENT", 0, 32]]], ["After one day, splenocytes were re-isolated and the ratio of CFSE high to CFSE low labelled cells was determined by flow cytometry using a FACS Canto instrument (BD Biosciences, Germany).", [["splenocytes", "ANATOMY", 15, 26], ["cells", "ANATOMY", 92, 97], ["CFSE", "CHEMICAL", 61, 65], ["CFSE", "CHEMICAL", 74, 78], ["CFSE", "CHEMICAL", 61, 65], ["CFSE", "CHEMICAL", 74, 78], ["splenocytes", "CELL", 15, 26], ["CFSE", "SIMPLE_CHEMICAL", 61, 65], ["CFSE", "SIMPLE_CHEMICAL", 74, 78], ["cells", "CELL", 92, 97], ["splenocytes", "CELL_TYPE", 15, 26], ["CFSE low labelled cells", "CELL_LINE", 74, 97], ["the ratio", "TEST", 48, 57], ["CFSE", "TEST", 61, 65], ["CFSE low labelled cells", "PROBLEM", 74, 97], ["flow cytometry", "TEST", 116, 130], ["splenocytes", "ANATOMY", 15, 26], ["flow cytometry", "OBSERVATION", 116, 130]]], ["Adenovirus challenge assay.", [["Adenovirus", "ORGANISM", 0, 10], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus challenge assay", "TEST", 0, 26]]], ["On day 42 after the first immunization, mice were infected intravenously with 2 \u00d7 10 8 plaque forming units (PFU) of a recombinant adenovirus expressing fusion proteins either of GFP and luciferase (Ad-GFP-luc) or GFP, luciferase and the OVA aa257-264 SIINFEKL (AdOVA-GFP-luc).", [["intravenously", "ANATOMY", 59, 72], ["mice", "ORGANISM", 40, 44], ["adenovirus", "ORGANISM", 131, 141], ["GFP", "GENE_OR_GENE_PRODUCT", 179, 182], ["luciferase", "GENE_OR_GENE_PRODUCT", 187, 197], ["Ad-GFP-luc)", "GENE_OR_GENE_PRODUCT", 199, 210], ["GFP", "GENE_OR_GENE_PRODUCT", 214, 217], ["luciferase", "GENE_OR_GENE_PRODUCT", 219, 229], ["AdOVA-GFP-luc", "GENE_OR_GENE_PRODUCT", 262, 275], ["recombinant adenovirus expressing fusion proteins", "PROTEIN", 119, 168], ["GFP", "PROTEIN", 179, 182], ["luciferase", "PROTEIN", 187, 197], ["GFP", "PROTEIN", 202, 205], ["luc", "PROTEIN", 206, 209], ["GFP", "PROTEIN", 214, 217], ["luciferase", "PROTEIN", 219, 229], ["OVA aa257", "PROTEIN", 238, 247], ["AdOVA", "PROTEIN", 262, 267], ["GFP", "PROTEIN", 268, 271], ["luc", "PROTEIN", 272, 275], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["adenovirus", "SPECIES", 131, 141], ["the first immunization", "TREATMENT", 16, 38], ["a recombinant adenovirus", "TREATMENT", 117, 141], ["GFP", "TEST", 179, 182], ["luciferase", "TEST", 187, 197], ["GFP", "TEST", 214, 217], ["luciferase", "TEST", 219, 229], ["the OVA aa257", "TEST", 234, 247], ["SIINFEKL", "TEST", 252, 260], ["AdOVA", "TEST", 262, 267]]], ["Control animals received PBS and were either mock-infected (PBS) or infected with AdOVA-GFP-luc 28 .", [["GFP", "GENE_OR_GENE_PRODUCT", 88, 91], ["AdOVA-GFP-luc 28", "DNA", 82, 98], ["PBS", "TREATMENT", 25, 28], ["AdOVA", "TEST", 82, 87], ["GFP", "TEST", 88, 91]]], ["For luciferase activity assays, the lower liver lobe was separated into two parts, weighed and tissue fragments were homogenized in proportional volumes of reporter lysis buffer (Promega, Germany) using Lysing Matrix D (MP Biomedicals, Germany) and a FastPrep-24 instrument (3 \u00d7 10 sec, 5.5 m/sec).", [["lower liver lobe", "ANATOMY", 36, 52], ["tissue fragments", "ANATOMY", 95, 111], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["liver lobe", "MULTI-TISSUE_STRUCTURE", 42, 52], ["tissue", "TISSUE", 95, 101], ["luciferase", "PROTEIN", 4, 14], ["luciferase activity assays", "TEST", 4, 30], ["reporter lysis buffer", "TREATMENT", 156, 177], ["Lysing Matrix D (MP Biomedicals", "TREATMENT", 203, 234], ["a FastPrep", "TEST", 249, 259], ["lower", "ANATOMY_MODIFIER", 36, 41], ["liver", "ANATOMY", 42, 47], ["lobe", "ANATOMY_MODIFIER", 48, 52], ["two", "OBSERVATION_MODIFIER", 72, 75], ["parts", "OBSERVATION_MODIFIER", 76, 81], ["tissue", "OBSERVATION_MODIFIER", 95, 101], ["fragments", "OBSERVATION_MODIFIER", 102, 111]]], ["After centrifugation (3 minutes, 10,000\u00d7 g, 4 \u00b0C), lysates were mixed with Luciferase Assay Reagent II (Promega, Germany) and measured in a luminometer (Berthold Technologies, Germany).MELC analyses.Liver tissues of \u03b1 DEC-205/OVA + Poly(I:C)/CpG and BPPcysOVAMPEG immunized mice were snap frozen and embedded into O.C.T. (Sakura Finetek).", [["lysates", "ANATOMY", 51, 58], ["Liver tissues", "ANATOMY", 199, 212], ["\u03b1 DEC-205", "CHEMICAL", 216, 225], ["CpG", "CHEMICAL", 242, 245], ["lysates", "ORGANISM_SUBSTANCE", 51, 58], ["Liver tissues", "TISSUE", 199, 212], ["OVA", "ORGANISM", 226, 229], ["Poly(I:C", "SIMPLE_CHEMICAL", 232, 240], ["CpG", "SIMPLE_CHEMICAL", 242, 245], ["BPPcysOVAMPEG", "ORGANISM", 250, 263], ["mice", "ORGANISM", 274, 278], ["mice", "SPECIES", 274, 278], ["mice", "SPECIES", 274, 278], ["lysates", "TREATMENT", 51, 58], ["MELC analyses", "TEST", 185, 198], ["Liver tissues", "TEST", 199, 212], ["DEC", "TEST", 218, 221], ["CpG", "TREATMENT", 242, 245], ["BPPcysOVAMPEG immunized mice", "TREATMENT", 250, 278]]], ["Liver samples from \u03b1 DEC-205/OVA and BPPcysOVAMPEG mice displaying comparable ALT levels were in each case analysed by the MELC robot in parallel.", [["Liver samples", "ANATOMY", 0, 13], ["\u03b1 DEC-205", "CHEMICAL", 19, 28], ["Liver samples", "CANCER", 0, 13], ["\u03b1 DEC-205", "CELL", 19, 28], ["OVA", "ORGANISM", 29, 32], ["BPPcysOVAMPEG", "ORGANISM", 37, 50], ["mice", "ORGANISM", 51, 55], ["ALT", "GENE_OR_GENE_PRODUCT", 78, 81], ["ALT", "PROTEIN", 78, 81], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["Liver samples", "TEST", 0, 13], ["DEC", "TEST", 21, 24], ["OVA", "PROBLEM", 29, 32], ["comparable ALT levels", "TEST", 67, 88]]], ["Cryosections of 10 \u03bc m thickness, which adhere to silan-coated cover slides, were prepared on Leica Cryostat CM3050, fixed with 2% paraformaldehyde (Santa Cruz) and permeabilized with 0.2% Triton-X-100 before blocking with 1% BSA/PBS (Sigma) for 1 h.", [["Cryosections", "ANATOMY", 0, 12], ["CM3050", "CHEMICAL", 109, 115], ["Triton-X-100", "CHEMICAL", 189, 201], ["BSA", "CHEMICAL", 226, 229], ["paraformaldehyde", "CHEMICAL", 131, 147], ["paraformaldehyde", "SIMPLE_CHEMICAL", 131, 147], ["Triton-X-100", "SIMPLE_CHEMICAL", 189, 201], ["BSA", "SIMPLE_CHEMICAL", 226, 229], ["PBS", "SIMPLE_CHEMICAL", 230, 233], ["Leica Cryostat CM3050", "SPECIES", 94, 115], ["Cryosections", "TEST", 0, 12], ["silan-coated cover slides", "TREATMENT", 50, 75], ["10 \u03bc m thickness", "OBSERVATION_MODIFIER", 16, 32]]], ["Detailed information on image acquisition and analysis are described in the Supplementary material.", [["image acquisition", "TEST", 24, 41], ["analysis", "TEST", 46, 54]]], ["Optimal antibody dilutions, incubation times, and positions within the MELC experiment for all antibodies used (see Supplementary Table S1 ) were validated systematically using conditions suitable to MELC 65 (see Supplementary Figure S5 ).Histological analyses.The left upper liver lobe was fixed in 4% formaldehyde solution, followed by paraffin embedding, preparation of 2-4 \u03bc m sections and staining with haematoxylin and eosin (H&E).", [["left upper liver lobe", "ANATOMY", 265, 286], ["sections", "ANATOMY", 381, 389], ["formaldehyde", "CHEMICAL", 303, 315], ["formaldehyde", "CHEMICAL", 303, 315], ["paraffin", "CHEMICAL", 338, 346], ["haematoxylin", "CHEMICAL", 408, 420], ["eosin", "CHEMICAL", 425, 430], ["upper liver lobe", "MULTI-TISSUE_STRUCTURE", 270, 286], ["formaldehyde", "SIMPLE_CHEMICAL", 303, 315], ["haematoxylin", "SIMPLE_CHEMICAL", 408, 420], ["eosin", "SIMPLE_CHEMICAL", 425, 430], ["antibodies", "PROTEIN", 95, 105], ["Optimal antibody dilutions", "TREATMENT", 0, 26], ["the MELC experiment", "TEST", 67, 86], ["all antibodies", "PROBLEM", 91, 105], ["Histological analyses", "TEST", 239, 260], ["4% formaldehyde solution", "TREATMENT", 300, 324], ["haematoxylin", "TREATMENT", 408, 420], ["left", "ANATOMY_MODIFIER", 265, 269], ["upper", "ANATOMY_MODIFIER", 270, 275], ["liver", "ANATOMY", 276, 281], ["lobe", "ANATOMY_MODIFIER", 282, 286], ["fixed", "OBSERVATION_MODIFIER", 291, 296]]], ["Histological evaluation was performed by an animal pathologist certified by the American College of Veterinary Pathologists in a blinded fashion.Histological analyses.Statistical analyses.", [["Histological evaluation", "TEST", 0, 23], ["Histological analyses", "TEST", 145, 166], ["Statistical analyses", "TEST", 167, 187]]], ["Results were statistically analysed by one-way Anova followed by the Dunnett's test, two-way RM Anova, non-parametric Mann Whitney test or the paired, two-tailed t-test using the Graph Pad Prism 5 software (Graph Pad software, La Jolla).", [["the Dunnett's test", "TEST", 65, 83], ["the Graph Pad Prism", "TEST", 175, 194], ["Graph Pad software", "TEST", 207, 225]]], ["Data are presented as mean \u00b1 SEM or mean \u00b1 SD and a p-value below 0.05 was considered significant.", [["a p-value", "TEST", 50, 59], ["significant", "OBSERVATION_MODIFIER", 86, 97]]]], "bd6297382658997708a7adfb67e2b4981f0d388c": [["www.nature.com/scientificreports/ investigated metabolic changes by determining the serum levels of metabolites, insulin sensitivity in the liver, glucose availability, and hepatic gene expressions in the early stages of symptom onset as well as the lethal phase of influenza in a mouse model.", [["serum", "ANATOMY", 84, 89], ["liver", "ANATOMY", 140, 145], ["hepatic", "ANATOMY", 173, 180], ["glucose", "CHEMICAL", 147, 154], ["influenza", "DISEASE", 266, 275], ["glucose", "CHEMICAL", 147, 154], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["insulin", "GENE_OR_GENE_PRODUCT", 113, 120], ["liver", "ORGAN", 140, 145], ["glucose", "SIMPLE_CHEMICAL", 147, 154], ["hepatic", "MULTI-TISSUE_STRUCTURE", 173, 180], ["mouse", "ORGANISM", 281, 286], ["mouse", "SPECIES", 281, 286], ["mouse", "SPECIES", 281, 286], ["metabolic changes", "PROBLEM", 47, 64], ["the serum levels", "TEST", 80, 96], ["insulin sensitivity", "TEST", 113, 132], ["glucose availability", "TEST", 147, 167], ["hepatic gene expressions", "PROBLEM", 173, 197], ["symptom onset", "PROBLEM", 221, 234], ["influenza", "PROBLEM", 266, 275], ["liver", "ANATOMY", 140, 145], ["hepatic", "ANATOMY", 173, 180], ["influenza", "OBSERVATION", 266, 275]]], ["The results of this study indicate that influenza virus infection dysregulates glucose and fatty acid metabolism and decreases tricarboxylic acid (TCA) cycle activity, leading to enhanced degradation of adenosine triphosphate (ATP) and guanosine triphosphate (GTP).", [["influenza virus infection", "DISEASE", 40, 65], ["glucose", "CHEMICAL", 79, 86], ["fatty acid", "CHEMICAL", 91, 101], ["tricarboxylic acid", "CHEMICAL", 127, 145], ["TCA", "CHEMICAL", 147, 150], ["adenosine triphosphate", "CHEMICAL", 203, 225], ["ATP", "CHEMICAL", 227, 230], ["guanosine triphosphate", "CHEMICAL", 236, 258], ["GTP", "CHEMICAL", 260, 263], ["glucose", "CHEMICAL", 79, 86], ["fatty acid", "CHEMICAL", 91, 101], ["tricarboxylic acid", "CHEMICAL", 127, 145], ["TCA", "CHEMICAL", 147, 150], ["adenosine triphosphate", "CHEMICAL", 203, 225], ["ATP", "CHEMICAL", 227, 230], ["guanosine triphosphate", "CHEMICAL", 236, 258], ["GTP", "CHEMICAL", 260, 263], ["influenza virus", "ORGANISM", 40, 55], ["glucose", "SIMPLE_CHEMICAL", 79, 86], ["fatty acid", "SIMPLE_CHEMICAL", 91, 101], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 127, 145], ["TCA", "SIMPLE_CHEMICAL", 147, 150], ["adenosine triphosphate", "SIMPLE_CHEMICAL", 203, 225], ["ATP", "SIMPLE_CHEMICAL", 227, 230], ["guanosine triphosphate", "SIMPLE_CHEMICAL", 236, 258], ["GTP", "SIMPLE_CHEMICAL", 260, 263], ["influenza virus", "SPECIES", 40, 55], ["influenza virus", "SPECIES", 40, 55], ["this study", "TEST", 15, 25], ["influenza virus infection", "PROBLEM", 40, 65], ["glucose", "TEST", 79, 86], ["fatty acid metabolism", "PROBLEM", 91, 112], ["decreases tricarboxylic acid (TCA) cycle activity", "PROBLEM", 117, 166], ["adenosine triphosphate (ATP", "TREATMENT", 203, 230], ["guanosine triphosphate (GTP", "TREATMENT", 236, 263], ["influenza virus", "OBSERVATION", 40, 55]]], ["We believe that this research provides novel insights into the pathogenesis of influenza and contributes to the development of novel influenza drugs.ResultsMetabolome analysis indicated reduced TCA cycle activity and enhanced purine degradation in mice with severe influenza.", [["influenza", "DISEASE", 79, 88], ["purine", "CHEMICAL", 226, 232], ["influenza", "DISEASE", 265, 274], ["TCA", "CHEMICAL", 194, 197], ["purine", "CHEMICAL", 226, 232], ["TCA", "SIMPLE_CHEMICAL", 194, 197], ["purine", "SIMPLE_CHEMICAL", 226, 232], ["mice", "ORGANISM", 248, 252], ["mice", "SPECIES", 248, 252], ["mice", "SPECIES", 248, 252], ["influenza", "PROBLEM", 79, 88], ["novel influenza drugs", "TREATMENT", 127, 148], ["Metabolome analysis", "TEST", 156, 175], ["reduced TCA cycle activity", "PROBLEM", 186, 212], ["enhanced purine degradation", "PROBLEM", 217, 244], ["severe influenza", "PROBLEM", 258, 274], ["influenza", "OBSERVATION", 79, 88], ["purine degradation", "OBSERVATION", 226, 244], ["severe", "OBSERVATION_MODIFIER", 258, 264], ["influenza", "OBSERVATION", 265, 274]]], ["Upon infection of 500 plaque-forming units of PR8 virus, the mice showed significant body weight loss starting at 3 day post infection (1 dpi, 98.3% \u00b1 2.1% in control mice, 99.5% \u00b1 0.9% in PR8 virus-infected mice; 3 dpi, 100.2% \u00b1 2.2% in control, 85.9% \u00b1 0.7% in PR8 virus-infected mice; 6 dpi, 100.2% \u00b1 2.4% in control mice, 75.5% \u00b1 2.2% in PR8 virus-infected mice).", [["plaque", "ANATOMY", 22, 28], ["body", "ANATOMY", 85, 89], ["infection", "DISEASE", 5, 14], ["weight loss", "DISEASE", 90, 101], ["infection", "DISEASE", 125, 134], ["PR8 virus", "ORGANISM", 46, 55], ["mice", "ORGANISM", 61, 65], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["mice", "ORGANISM", 167, 171], ["PR8 virus", "ORGANISM", 189, 198], ["mice", "ORGANISM", 208, 212], ["PR8 virus", "ORGANISM", 263, 272], ["mice", "ORGANISM", 282, 286], ["mice", "ORGANISM", 320, 324], ["PR8 virus", "ORGANISM", 342, 351], ["mice", "ORGANISM", 361, 365], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 208, 212], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 320, 324], ["mice", "SPECIES", 361, 365], ["PR8 virus", "SPECIES", 46, 55], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 167, 171], ["PR8 virus", "SPECIES", 189, 198], ["mice", "SPECIES", 208, 212], ["PR8 virus", "SPECIES", 263, 272], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 320, 324], ["PR8 virus", "SPECIES", 342, 351], ["mice", "SPECIES", 361, 365], ["infection", "PROBLEM", 5, 14], ["500 plaque", "PROBLEM", 18, 28], ["PR8 virus", "TREATMENT", 46, 55], ["significant body weight loss", "PROBLEM", 73, 101], ["infection", "PROBLEM", 125, 134], ["dpi", "TEST", 138, 141], ["PR8 virus", "TEST", 189, 198], ["dpi", "TEST", 216, 219], ["control", "TEST", 238, 245], ["PR8 virus", "TEST", 263, 272], ["dpi", "TEST", 290, 293], ["PR8 virus", "TEST", 342, 351], ["infection", "OBSERVATION", 5, 14], ["500 plaque", "OBSERVATION_MODIFIER", 18, 28], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["body", "OBSERVATION_MODIFIER", 85, 89], ["weight loss", "OBSERVATION", 90, 101], ["infection", "OBSERVATION", 125, 134]]], ["Mice were sacrificed when weight loss reached a humane endpoint (25% at 6 dpi).", [["weight loss", "DISEASE", 26, 37], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["weight loss", "PROBLEM", 26, 37]]], ["To investigate the systemic effect of influenza virus infection on the host metabolic system, metabolome analyses were performed with serum samples collected at 1, 3, and 6 dpi for samples at very early-stage, onset of symptoms, and lethal phase during influenza, respectively.", [["serum samples", "ANATOMY", 134, 147], ["samples", "ANATOMY", 181, 188], ["influenza virus infection", "DISEASE", 38, 63], ["influenza", "DISEASE", 253, 262], ["influenza virus", "ORGANISM", 38, 53], ["serum samples", "ORGANISM_SUBSTANCE", 134, 147], ["influenza virus", "SPECIES", 38, 53], ["influenza virus infection", "PROBLEM", 38, 63], ["metabolome analyses", "TEST", 94, 113], ["serum samples", "TEST", 134, 147], ["samples", "TEST", 181, 188], ["symptoms", "PROBLEM", 219, 227], ["lethal phase", "PROBLEM", 233, 245], ["influenza", "PROBLEM", 253, 262], ["influenza virus", "OBSERVATION", 38, 53]]], ["Metabolome analyses identified 74 metabolites in the serum samples of the control and PR8 virus-infected mice at all time points.", [["serum samples", "ANATOMY", 53, 66], ["serum samples", "ORGANISM_SUBSTANCE", 53, 66], ["PR8 virus", "ORGANISM", 86, 95], ["mice", "ORGANISM", 105, 109], ["PR8 virus", "SPECIES", 86, 95], ["mice", "SPECIES", 105, 109], ["PR8 virus", "SPECIES", 86, 95], ["mice", "SPECIES", 105, 109], ["Metabolome analyses", "TEST", 0, 19], ["the serum samples", "TEST", 49, 66], ["PR8 virus", "PROBLEM", 86, 95]]], ["Peak areas and relative ratios of all metabolites are provided in Supplemental Tables S1 and S2.", [["S2", "PROTEIN", 93, 95], ["Peak areas", "TEST", 0, 10], ["relative", "OBSERVATION_MODIFIER", 15, 23], ["ratios", "OBSERVATION_MODIFIER", 24, 30], ["S2", "ANATOMY", 93, 95]]], ["Samples collected at 6 dpi showed the greatest effect of PR8 virus infection on serum metabolomes, as indicated by principle component analyses with high contribution rates of principle component 1 (PC1; 51.4%; Supplemental Fig. S1 ).", [["Samples", "ANATOMY", 0, 7], ["serum", "ANATOMY", 80, 85], ["infection", "DISEASE", 67, 76], ["PR8 virus", "ORGANISM", 57, 66], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["S1", "GENE_OR_GENE_PRODUCT", 229, 231], ["S1", "PROTEIN", 229, 231], ["PR8 virus", "SPECIES", 57, 66], ["Samples", "TEST", 0, 7], ["PR8 virus infection", "PROBLEM", 57, 76], ["serum metabolomes", "TEST", 80, 97], ["PC1", "TEST", 199, 202], ["Supplemental Fig", "TREATMENT", 211, 227], ["greatest effect", "OBSERVATION_MODIFIER", 38, 53], ["PR8 virus infection", "OBSERVATION", 57, 76]]], ["Moreover, PC1 scores for the control and PR8 virus-infected mice were negative and positive, respectively, suggesting that the PC1 score was positively related to the effects of PR8 virus infection.", [["infection", "DISEASE", 188, 197], ["PC1", "GENE_OR_GENE_PRODUCT", 10, 13], ["PR8 virus", "ORGANISM", 41, 50], ["mice", "ORGANISM", 60, 64], ["PC1", "GENE_OR_GENE_PRODUCT", 127, 130], ["PR8 virus", "ORGANISM", 178, 187], ["PC1", "PROTEIN", 10, 13], ["PC1", "PROTEIN", 127, 130], ["PR8 virus", "SPECIES", 41, 50], ["mice", "SPECIES", 60, 64], ["PR8 virus", "SPECIES", 41, 50], ["mice", "SPECIES", 60, 64], ["PR8 virus", "SPECIES", 178, 187], ["PC1 scores", "TEST", 10, 20], ["PR8 virus", "TEST", 41, 50], ["the PC1 score", "TEST", 123, 136], ["PR8 virus infection", "PROBLEM", 178, 197]]], ["Accordingly, metabolites with high positive and negative factor loading in PC1 tended to increase and decrease with PR8 virus infection, respectively (Table 1) .", [["infection", "DISEASE", 126, 135], ["PC1", "GENE_OR_GENE_PRODUCT", 75, 78], ["PR8 virus", "ORGANISM", 116, 125], ["PR8 virus", "SPECIES", 116, 125], ["metabolites", "TEST", 13, 24], ["high positive", "PROBLEM", 30, 43], ["negative factor loading in PC1", "PROBLEM", 48, 78], ["PR8 virus infection", "PROBLEM", 116, 135], ["decrease", "OBSERVATION_MODIFIER", 102, 110]]], ["Relative increases in the serum levels of hypoxanthine, xanthine, and inosine were 4.56-, 2.90-, and 2.68-fold, respectively, in the PR8 virus-infected mice.", [["serum", "ANATOMY", 26, 31], ["hypoxanthine", "CHEMICAL", 42, 54], ["xanthine", "CHEMICAL", 56, 64], ["inosine", "CHEMICAL", 70, 77], ["hypoxanthine", "CHEMICAL", 42, 54], ["xanthine", "CHEMICAL", 56, 64], ["inosine", "CHEMICAL", 70, 77], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["hypoxanthine", "SIMPLE_CHEMICAL", 42, 54], ["xanthine", "SIMPLE_CHEMICAL", 56, 64], ["inosine", "SIMPLE_CHEMICAL", 70, 77], ["PR8 virus", "ORGANISM", 133, 142], ["mice", "ORGANISM", 152, 156], ["mice", "SPECIES", 152, 156], ["PR8 virus", "SPECIES", 133, 142], ["mice", "SPECIES", 152, 156], ["Relative increases", "PROBLEM", 0, 18], ["the serum levels", "TEST", 22, 38], ["hypoxanthine", "TREATMENT", 42, 54], ["xanthine", "TREATMENT", 56, 64], ["inosine", "TREATMENT", 70, 77], ["the PR8 virus", "PROBLEM", 129, 142], ["increases", "OBSERVATION_MODIFIER", 9, 18], ["infected mice", "OBSERVATION", 143, 156]]], ["These molecules are intermediates of purine degradation, and their increased serum levels are considered indicative of enhanced adenosine triphosphate (ATP) and guanosine triphosphate (GTP) catabolism.", [["serum", "ANATOMY", 77, 82], ["purine", "CHEMICAL", 37, 43], ["adenosine triphosphate", "CHEMICAL", 128, 150], ["ATP", "CHEMICAL", 152, 155], ["guanosine triphosphate", "CHEMICAL", 161, 183], ["GTP", "CHEMICAL", 185, 188], ["purine", "CHEMICAL", 37, 43], ["adenosine triphosphate", "CHEMICAL", 128, 150], ["ATP", "CHEMICAL", 152, 155], ["guanosine triphosphate", "CHEMICAL", 161, 183], ["GTP", "CHEMICAL", 185, 188], ["purine", "SIMPLE_CHEMICAL", 37, 43], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["adenosine triphosphate", "SIMPLE_CHEMICAL", 128, 150], ["ATP", "SIMPLE_CHEMICAL", 152, 155], ["guanosine triphosphate", "SIMPLE_CHEMICAL", 161, 183], ["GTP", "SIMPLE_CHEMICAL", 185, 188], ["purine degradation", "PROBLEM", 37, 55], ["their increased serum levels", "TEST", 61, 89], ["enhanced adenosine triphosphate", "TREATMENT", 119, 150], ["ATP", "TEST", 152, 155], ["guanosine triphosphate (GTP) catabolism", "TREATMENT", 161, 200], ["purine degradation", "OBSERVATION", 37, 55], ["considered indicative of", "UNCERTAINTY", 94, 118], ["enhanced adenosine triphosphate", "OBSERVATION", 119, 150]]], ["In agreement, the relative serum levels of the upstream purine metabolites adenosine monophosphate (AMP), adenosine, guanosine monophosphate (GMP), and guanosine, were decreased by 0.033-, 0.010-, 0.0075-, and 0.25-fold, respectively, at 6 dpi.", [["serum", "ANATOMY", 27, 32], ["purine", "CHEMICAL", 56, 62], ["adenosine", "CHEMICAL", 75, 84], ["monophosphate", "CHEMICAL", 85, 98], ["AMP", "CHEMICAL", 100, 103], ["adenosine", "CHEMICAL", 106, 115], ["guanosine monophosphate", "CHEMICAL", 117, 140], ["GMP", "CHEMICAL", 142, 145], ["guanosine", "CHEMICAL", 152, 161], ["purine", "CHEMICAL", 56, 62], ["adenosine monophosphate", "CHEMICAL", 75, 98], ["AMP", "CHEMICAL", 100, 103], ["adenosine", "CHEMICAL", 106, 115], ["guanosine monophosphate", "CHEMICAL", 117, 140], ["GMP", "CHEMICAL", 142, 145], ["guanosine", "CHEMICAL", 152, 161], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["purine", "SIMPLE_CHEMICAL", 56, 62], ["adenosine monophosphate", "SIMPLE_CHEMICAL", 75, 98], ["AMP", "SIMPLE_CHEMICAL", 100, 103], ["adenosine", "SIMPLE_CHEMICAL", 106, 115], ["guanosine monophosphate", "SIMPLE_CHEMICAL", 117, 140], ["GMP", "SIMPLE_CHEMICAL", 142, 145], ["guanosine", "SIMPLE_CHEMICAL", 152, 161], ["the relative serum levels", "TEST", 14, 39], ["the upstream purine metabolites adenosine monophosphate (AMP)", "TREATMENT", 43, 104], ["adenosine", "TREATMENT", 106, 115], ["guanosine monophosphate (GMP)", "TREATMENT", 117, 146], ["guanosine", "TREATMENT", 152, 161]]], ["Among them, the serum levels of AMP and adenosine did not differ significantly between the control and infected groups at any time point owing to large individual differences in the control groups (Fig. 1) .", [["serum", "ANATOMY", 16, 21], ["AMP", "CHEMICAL", 32, 35], ["adenosine", "CHEMICAL", 40, 49], ["AMP", "CHEMICAL", 32, 35], ["adenosine", "CHEMICAL", 40, 49], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["AMP", "SIMPLE_CHEMICAL", 32, 35], ["adenosine", "SIMPLE_CHEMICAL", 40, 49], ["the serum levels", "TEST", 12, 28], ["AMP", "TEST", 32, 35], ["adenosine", "TREATMENT", 40, 49], ["large individual differences", "PROBLEM", 146, 174], ["infected", "OBSERVATION", 103, 111], ["large", "OBSERVATION_MODIFIER", 146, 151], ["individual", "OBSERVATION_MODIFIER", 152, 162], ["differences", "OBSERVATION_MODIFIER", 163, 174]]], ["Thus, the lethal phase of influenza is considered to be characterized by increased degradation of ATP and GTP.ResultsMetabolites that were present at reduced levels in the sera of PR8 virus-infected mice were mainly related to the TCA cycle, urea cycle, and amino acid metabolism, as indicated by the serum levels of metabolite in these pathways at 1, 3, and 6 dpi (Fig. 2) .", [["sera", "ANATOMY", 172, 176], ["serum", "ANATOMY", 301, 306], ["influenza", "DISEASE", 26, 35], ["ATP", "CHEMICAL", 98, 101], ["GTP", "CHEMICAL", 106, 109], ["urea", "CHEMICAL", 242, 246], ["amino acid", "CHEMICAL", 258, 268], ["ATP", "CHEMICAL", 98, 101], ["GTP", "CHEMICAL", 106, 109], ["TCA", "CHEMICAL", 231, 234], ["urea", "CHEMICAL", 242, 246], ["amino acid", "CHEMICAL", 258, 268], ["ATP", "SIMPLE_CHEMICAL", 98, 101], ["GTP", "SIMPLE_CHEMICAL", 106, 109], ["sera", "ORGANISM_SUBSTANCE", 172, 176], ["PR8 virus", "ORGANISM", 180, 189], ["mice", "ORGANISM", 199, 203], ["TCA", "SIMPLE_CHEMICAL", 231, 234], ["urea", "SIMPLE_CHEMICAL", 242, 246], ["amino acid", "AMINO_ACID", 258, 268], ["serum", "ORGANISM_SUBSTANCE", 301, 306], ["PR8 virus", "SPECIES", 180, 189], ["mice", "SPECIES", 199, 203], ["PR8 virus", "SPECIES", 180, 189], ["mice", "SPECIES", 199, 203], ["influenza", "PROBLEM", 26, 35], ["increased degradation of ATP", "PROBLEM", 73, 101], ["GTP", "PROBLEM", 106, 109], ["reduced levels", "PROBLEM", 150, 164], ["the sera", "TEST", 168, 176], ["PR8 virus", "PROBLEM", 180, 189], ["infected mice", "PROBLEM", 190, 203], ["the TCA cycle", "TEST", 227, 240], ["urea cycle", "TEST", 242, 252], ["amino acid metabolism", "TEST", 258, 279], ["the serum levels", "TEST", 297, 313]]], ["The effects of 6-day PR8 virus infections on the serum levels of metabolite are summarized in Fig. 3 .", [["serum", "ANATOMY", 49, 54], ["infections", "DISEASE", 31, 41], ["PR8 virus", "ORGANISM", 21, 30], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["6-day PR8 virus infections", "PROBLEM", 15, 41], ["the serum levels", "TEST", 45, 61]]], ["The levels of TCA cycle metabolites pyruvic acid, 2-ketoglutaric acid, fumaric acid, and malic acid were significantly reduced in PR8 virus-infected mice at 6 dpi (0.60-, 0.54-, 0.24-, and 0.27-fold, respectively).", [["TCA", "CHEMICAL", 14, 17], ["pyruvic acid", "CHEMICAL", 36, 48], ["2-ketoglutaric acid", "CHEMICAL", 50, 69], ["fumaric acid", "CHEMICAL", 71, 83], ["malic acid", "CHEMICAL", 89, 99], ["TCA", "CHEMICAL", 14, 17], ["pyruvic acid", "CHEMICAL", 36, 48], ["2-ketoglutaric acid", "CHEMICAL", 50, 69], ["fumaric acid", "CHEMICAL", 71, 83], ["malic acid", "CHEMICAL", 89, 99], ["TCA", "SIMPLE_CHEMICAL", 14, 17], ["pyruvic acid", "SIMPLE_CHEMICAL", 36, 48], ["2-ketoglutaric acid", "SIMPLE_CHEMICAL", 50, 69], ["fumaric acid", "SIMPLE_CHEMICAL", 71, 83], ["malic acid", "SIMPLE_CHEMICAL", 89, 99], ["PR8 virus", "ORGANISM", 130, 139], ["mice", "ORGANISM", 149, 153], ["mice", "SPECIES", 149, 153], ["PR8 virus", "SPECIES", 130, 139], ["mice", "SPECIES", 149, 153], ["The levels", "TEST", 0, 10], ["TCA cycle metabolites", "TEST", 14, 35], ["pyruvic acid", "TEST", 36, 48], ["ketoglutaric acid", "TEST", 52, 69], ["fumaric acid", "TEST", 71, 83], ["malic acid", "TEST", 89, 99], ["PR8 virus", "PROBLEM", 130, 139]]], ["Succinic acid levels were significantly increased by 1.62-fold at 1 dpi but decreased by 0.26-fold at 6 dpi in PR8 virus-infected mice.", [["Succinic acid", "CHEMICAL", 0, 13], ["Succinic acid", "CHEMICAL", 0, 13], ["Succinic acid", "SIMPLE_CHEMICAL", 0, 13], ["PR8 virus", "ORGANISM", 111, 120], ["mice", "ORGANISM", 130, 134], ["mice", "SPECIES", 130, 134], ["PR8 virus", "SPECIES", 111, 120], ["mice", "SPECIES", 130, 134], ["Succinic acid levels", "TEST", 0, 20], ["infected mice", "OBSERVATION", 121, 134]]], ["In addition, 4-aminobutyric acid, which is synthesized from glutamic acid and converted to succinic acid, was present at reduced in PR8 virus-infected mice at 3 and 6 dpi (0.61-and 0.55-fold, respectively).", [["4-aminobutyric acid", "CHEMICAL", 13, 32], ["glutamic acid", "CHEMICAL", 60, 73], ["succinic acid", "CHEMICAL", 91, 104], ["4-aminobutyric acid", "CHEMICAL", 13, 32], ["glutamic acid", "CHEMICAL", 60, 73], ["succinic acid", "CHEMICAL", 91, 104], ["4-aminobutyric acid", "SIMPLE_CHEMICAL", 13, 32], ["glutamic acid", "SIMPLE_CHEMICAL", 60, 73], ["succinic acid", "SIMPLE_CHEMICAL", 91, 104], ["PR8 virus", "ORGANISM", 132, 141], ["mice", "ORGANISM", 151, 155], ["mice", "SPECIES", 151, 155], ["PR8 virus", "SPECIES", 132, 141], ["mice", "SPECIES", 151, 155], ["aminobutyric acid", "TREATMENT", 15, 32], ["glutamic acid", "TREATMENT", 60, 73], ["succinic acid", "TREATMENT", 91, 104]]], ["The levels of urea cycle metabolites argininosuccinic acid, ornithine, and citrulline were decreased by 0.35-, 0.57-, and 0.61-fold, respectively, in PR8 virus-infected mice at 6 dpi, whereas the level of arginine was not altered significantly at any time point.", [["urea", "CHEMICAL", 14, 18], ["argininosuccinic acid", "CHEMICAL", 37, 58], ["ornithine", "CHEMICAL", 60, 69], ["citrulline", "CHEMICAL", 75, 85], ["arginine", "CHEMICAL", 205, 213], ["urea", "CHEMICAL", 14, 18], ["argininosuccinic acid", "CHEMICAL", 37, 58], ["ornithine", "CHEMICAL", 60, 69], ["citrulline", "CHEMICAL", 75, 85], ["arginine", "CHEMICAL", 205, 213], ["urea", "SIMPLE_CHEMICAL", 14, 18], ["argininosuccinic acid", "SIMPLE_CHEMICAL", 37, 58], ["ornithine", "SIMPLE_CHEMICAL", 60, 69], ["citrulline", "SIMPLE_CHEMICAL", 75, 85], ["PR8 virus", "ORGANISM", 150, 159], ["mice", "ORGANISM", 169, 173], ["arginine", "SIMPLE_CHEMICAL", 205, 213], ["mice", "SPECIES", 169, 173], ["PR8 virus", "SPECIES", 150, 159], ["mice", "SPECIES", 169, 173], ["The levels", "TEST", 0, 10], ["urea cycle metabolites argininosuccinic acid", "TEST", 14, 58], ["ornithine", "TEST", 60, 69], ["citrulline", "TEST", 75, 85]]], ["Given that the levels of most metabolites were significantly reduced in the TCA cycle and related pathways, we suggest that PR8 virus infection reduces flux through these pathways, particularly through the TCA cycle.ResultsAs for amino acids, while the serum levels of ketogenic amino acids did not show any apparent decreases, those of glucogenic amino acids were significantly reduced in PR8 virus-infected mice at 6 dpi.", [["serum", "ANATOMY", 253, 258], ["TCA", "CHEMICAL", 76, 79], ["infection", "DISEASE", 134, 143], ["amino acids", "CHEMICAL", 230, 241], ["amino acids", "CHEMICAL", 279, 290], ["amino acids", "CHEMICAL", 348, 359], ["TCA", "CHEMICAL", 76, 79], ["TCA", "CHEMICAL", 206, 209], ["amino acids", "CHEMICAL", 230, 241], ["amino acids", "CHEMICAL", 279, 290], ["amino acids", "CHEMICAL", 348, 359], ["TCA", "SIMPLE_CHEMICAL", 76, 79], ["PR8 virus", "ORGANISM", 124, 133], ["TCA", "SIMPLE_CHEMICAL", 206, 209], ["amino acids", "AMINO_ACID", 230, 241], ["serum", "ORGANISM_SUBSTANCE", 253, 258], ["amino acids", "AMINO_ACID", 279, 290], ["glucogenic", "SIMPLE_CHEMICAL", 337, 347], ["amino acids", "AMINO_ACID", 348, 359], ["PR8 virus", "ORGANISM", 390, 399], ["mice", "ORGANISM", 409, 413], ["mice", "SPECIES", 409, 413], ["PR8 virus", "SPECIES", 124, 133], ["PR8 virus", "SPECIES", 390, 399], ["mice", "SPECIES", 409, 413], ["the levels", "TEST", 11, 21], ["PR8 virus infection", "PROBLEM", 124, 143], ["amino acids", "TEST", 230, 241], ["the serum levels", "TEST", 249, 265], ["ketogenic amino acids", "TEST", 269, 290], ["any apparent decreases", "PROBLEM", 304, 326], ["glucogenic amino acids", "TEST", 337, 359], ["PR8 virus", "PROBLEM", 390, 399], ["decreases", "OBSERVATION_MODIFIER", 317, 326]]], ["Specifically, the serum levels of asparagine, glycine, proline, serine, and tyrosine were significantly decreased by 0.49-, 0.50-, 0.62-, 0.52-, and 0.58-fold, respectively.", [["serum", "ANATOMY", 18, 23], ["asparagine", "CHEMICAL", 34, 44], ["glycine", "CHEMICAL", 46, 53], ["proline", "CHEMICAL", 55, 62], ["serine", "CHEMICAL", 64, 70], ["tyrosine", "CHEMICAL", 76, 84], ["asparagine", "CHEMICAL", 34, 44], ["glycine", "CHEMICAL", 46, 53], ["proline", "CHEMICAL", 55, 62], ["serine", "CHEMICAL", 64, 70], ["tyrosine", "CHEMICAL", 76, 84], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["asparagine", "AMINO_ACID", 34, 44], ["glycine", "SIMPLE_CHEMICAL", 46, 53], ["proline", "AMINO_ACID", 55, 62], ["serine", "AMINO_ACID", 64, 70], ["tyrosine", "AMINO_ACID", 76, 84], ["the serum levels", "TEST", 14, 30], ["asparagine", "TEST", 34, 44], ["glycine, proline", "TREATMENT", 46, 62], ["tyrosine", "TEST", 76, 84]]], ["Furthermore, to estimate the effect of PR8 virus infection on glutaminolysis in which glutamine is converted to 2-ketoglutaric acid via glutamic acid and enters the TCA cycle, we compared the ratio of the peak areas of glutamic acid to those of glutamine and the ratio of the peak areas of ketoglutaric acid to those of glutamic acid.", [["infection", "DISEASE", 49, 58], ["glutamine", "CHEMICAL", 86, 95], ["2-ketoglutaric acid", "CHEMICAL", 112, 131], ["glutamic acid", "CHEMICAL", 136, 149], ["glutamic acid", "CHEMICAL", 219, 232], ["glutamine", "CHEMICAL", 245, 254], ["ketoglutaric acid", "CHEMICAL", 290, 307], ["glutamic acid", "CHEMICAL", 320, 333], ["glutamine", "CHEMICAL", 86, 95], ["2-ketoglutaric acid", "CHEMICAL", 112, 131], ["glutamic acid", "CHEMICAL", 136, 149], ["TCA", "CHEMICAL", 165, 168], ["glutamic acid", "CHEMICAL", 219, 232], ["glutamine", "CHEMICAL", 245, 254], ["ketoglutaric acid", "CHEMICAL", 290, 307], ["glutamic acid", "CHEMICAL", 320, 333], ["PR8 virus", "ORGANISM", 39, 48], ["glutamine", "AMINO_ACID", 86, 95], ["2-ketoglutaric acid", "SIMPLE_CHEMICAL", 112, 131], ["glutamic acid", "SIMPLE_CHEMICAL", 136, 149], ["TCA", "SIMPLE_CHEMICAL", 165, 168], ["glutamic acid", "AMINO_ACID", 219, 232], ["glutamine", "AMINO_ACID", 245, 254], ["ketoglutaric acid", "SIMPLE_CHEMICAL", 290, 307], ["glutamic acid", "SIMPLE_CHEMICAL", 320, 333], ["PR8 virus", "SPECIES", 39, 48], ["PR8 virus infection", "PROBLEM", 39, 58], ["glutaminolysis", "TREATMENT", 62, 76], ["glutamine", "TREATMENT", 86, 95], ["ketoglutaric acid via glutamic acid", "TREATMENT", 114, 149], ["glutamic acid", "TREATMENT", 219, 232], ["glutamine", "TREATMENT", 245, 254], ["ketoglutaric acid", "TREATMENT", 290, 307], ["glutamic acid", "TREATMENT", 320, 333]]], ["While the ratio of glutamic acid to glutamine was not changed by the infection, the ratio of 2-ketoglutaric acid to glutamic acid was significantly decreased by 0.48-and 0.65-fold, respectively, at 3 and 6 dpi (Supplemental Table S3 ).", [["glutamic acid", "CHEMICAL", 19, 32], ["glutamine", "CHEMICAL", 36, 45], ["infection", "DISEASE", 69, 78], ["2-ketoglutaric acid", "CHEMICAL", 93, 112], ["glutamic acid", "CHEMICAL", 116, 129], ["glutamic acid", "CHEMICAL", 19, 32], ["glutamine", "CHEMICAL", 36, 45], ["2-ketoglutaric acid", "CHEMICAL", 93, 112], ["glutamic acid", "CHEMICAL", 116, 129], ["glutamic acid", "AMINO_ACID", 19, 32], ["glutamine", "AMINO_ACID", 36, 45], ["2-ketoglutaric acid", "SIMPLE_CHEMICAL", 93, 112], ["glutamic acid", "SIMPLE_CHEMICAL", 116, 129], ["glutamic acid to glutamine", "TREATMENT", 19, 45], ["the infection", "PROBLEM", 65, 78], ["the ratio", "TEST", 80, 89], ["ketoglutaric acid", "TEST", 95, 112], ["glutamic acid", "TEST", 116, 129], ["infection", "OBSERVATION", 69, 78]]], ["Therefore, it was indicated that glutaminolysis contribution to the TCA cycle was attenuated by influenza virus infection.ResultsPathway analysis using MetaboAnalyst further confirmed that the TCA cycle and related pathways were significantly affected by PR8 virus infection at 6 dpi.", [["TCA", "CHEMICAL", 68, 71], ["influenza virus infection", "DISEASE", 96, 121], ["infection", "DISEASE", 265, 274], ["TCA", "CHEMICAL", 68, 71], ["TCA", "CHEMICAL", 193, 196], ["TCA", "SIMPLE_CHEMICAL", 68, 71], ["influenza virus", "ORGANISM", 96, 111], ["TCA", "SIMPLE_CHEMICAL", 193, 196], ["PR8 virus", "ORGANISM", 255, 264], ["influenza virus", "SPECIES", 96, 111], ["PR8 virus", "SPECIES", 255, 264], ["glutaminolysis contribution", "PROBLEM", 33, 60], ["the TCA cycle", "PROBLEM", 64, 77], ["influenza virus infection", "PROBLEM", 96, 121], ["the TCA cycle", "TEST", 189, 202], ["PR8 virus infection", "PROBLEM", 255, 274]]], ["Given that the TCA cycle generates GTP and contributes electrons to mitochondrial oxidative phosphorylation to generate a substantial amount of ATP, suppression of the TCA cycle in PR8 virus-infected mice is considered to cause imbalanced synthesis and degradation of ATP and GTP.", [["mitochondrial", "ANATOMY", 68, 81], ["GTP", "CHEMICAL", 35, 38], ["ATP", "CHEMICAL", 144, 147], ["TCA", "CHEMICAL", 168, 171], ["ATP", "CHEMICAL", 268, 271], ["GTP", "CHEMICAL", 276, 279], ["TCA", "CHEMICAL", 15, 18], ["GTP", "CHEMICAL", 35, 38], ["ATP", "CHEMICAL", 144, 147], ["TCA", "CHEMICAL", 168, 171], ["ATP", "CHEMICAL", 268, 271], ["GTP", "CHEMICAL", 276, 279], ["TCA", "SIMPLE_CHEMICAL", 15, 18], ["GTP", "SIMPLE_CHEMICAL", 35, 38], ["mitochondrial", "CELLULAR_COMPONENT", 68, 81], ["ATP", "SIMPLE_CHEMICAL", 144, 147], ["TCA", "SIMPLE_CHEMICAL", 168, 171], ["PR8 virus", "ORGANISM", 181, 190], ["mice", "ORGANISM", 200, 204], ["ATP", "SIMPLE_CHEMICAL", 268, 271], ["GTP", "SIMPLE_CHEMICAL", 276, 279], ["mice", "SPECIES", 200, 204], ["PR8 virus", "SPECIES", 181, 190], ["mice", "SPECIES", 200, 204], ["the TCA cycle generates GTP", "PROBLEM", 11, 38], ["mitochondrial oxidative phosphorylation", "TREATMENT", 68, 107], ["ATP", "PROBLEM", 144, 147], ["the TCA cycle", "PROBLEM", 164, 177], ["PR8 virus", "TREATMENT", 181, 190], ["imbalanced synthesis", "PROBLEM", 228, 248], ["ATP and GTP", "TREATMENT", 268, 279]]], ["Moreover, these data suggest that suppression of the TCA cycle was due to reduced substrate supply to the pathway due to PR8 virus infection, rather than inhibition of specific metabolic reactions.", [["TCA", "CHEMICAL", 53, 56], ["infection", "DISEASE", 131, 140], ["TCA", "CHEMICAL", 53, 56], ["TCA", "SIMPLE_CHEMICAL", 53, 56], ["PR8 virus", "ORGANISM", 121, 130], ["PR8 virus", "SPECIES", 121, 130], ["the TCA cycle", "PROBLEM", 49, 62], ["reduced substrate supply", "PROBLEM", 74, 98], ["PR8 virus infection", "PROBLEM", 121, 140], ["specific metabolic reactions", "PROBLEM", 168, 196]]], ["TCA cycle flux is associated with glucose and fatty acid metabolism because both these energy sources are eventually converted to acetyl-CoA, which enters the TCA cycle.", [["TCA", "CHEMICAL", 0, 3], ["glucose", "CHEMICAL", 34, 41], ["fatty acid", "CHEMICAL", 46, 56], ["acetyl-CoA", "CHEMICAL", 130, 140], ["TCA", "CHEMICAL", 0, 3], ["glucose", "CHEMICAL", 34, 41], ["fatty acid", "CHEMICAL", 46, 56], ["acetyl-CoA", "CHEMICAL", 130, 140], ["TCA", "CHEMICAL", 159, 162], ["TCA", "SIMPLE_CHEMICAL", 0, 3], ["glucose", "SIMPLE_CHEMICAL", 34, 41], ["fatty acid", "SIMPLE_CHEMICAL", 46, 56], ["acetyl-CoA", "SIMPLE_CHEMICAL", 130, 140], ["TCA", "SIMPLE_CHEMICAL", 159, 162], ["TCA cycle flux", "TEST", 0, 14], ["glucose", "TEST", 34, 41], ["fatty acid metabolism", "PROBLEM", 46, 67], ["acetyl-CoA", "TREATMENT", 130, 140]]], ["Because the liver plays a predominant role in whole-body energy metabolism, we further investigated the effect of PR8 virus infection on liver function in terms of glucose and fatty acid metabolism. www.nature.com/scientificreports/Influenza virus infection impairs insulin sensitivity in the liver.Insulin regulates cellular glucose uptake from the blood and intracellular glycolysis 9,10 , which supplies substrates to the TCA cycle.", [["liver", "ANATOMY", 12, 17], ["body", "ANATOMY", 52, 56], ["liver", "ANATOMY", 137, 142], ["liver", "ANATOMY", 293, 298], ["cellular", "ANATOMY", 317, 325], ["blood", "ANATOMY", 350, 355], ["intracellular", "ANATOMY", 360, 373], ["infection", "DISEASE", 124, 133], ["glucose", "CHEMICAL", 164, 171], ["fatty acid", "CHEMICAL", 176, 186], ["infection", "DISEASE", 248, 257], ["Insulin", "CHEMICAL", 299, 306], ["glucose", "CHEMICAL", 326, 333], ["glucose", "CHEMICAL", 164, 171], ["fatty acid", "CHEMICAL", 176, 186], ["glucose", "CHEMICAL", 326, 333], ["TCA", "CHEMICAL", 425, 428], ["liver", "ORGAN", 12, 17], ["body", "ORGANISM_SUBDIVISION", 52, 56], ["PR8 virus", "ORGANISM", 114, 123], ["liver", "ORGAN", 137, 142], ["glucose", "SIMPLE_CHEMICAL", 164, 171], ["fatty acid", "SIMPLE_CHEMICAL", 176, 186], ["www.nature.com/scientificreports/Influenza virus", "ORGANISM", 199, 247], ["insulin", "GENE_OR_GENE_PRODUCT", 266, 273], ["liver", "ORGAN", 293, 298], ["Insulin", "GENE_OR_GENE_PRODUCT", 299, 306], ["cellular", "CELL", 317, 325], ["glucose", "SIMPLE_CHEMICAL", 326, 333], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 360, 373], ["TCA", "SIMPLE_CHEMICAL", 425, 428], ["PR8 virus", "SPECIES", 114, 123], ["www.nature.com/scientificreports/Influenza virus", "SPECIES", 199, 247], ["PR8 virus infection", "PROBLEM", 114, 133], ["liver function", "TEST", 137, 151], ["glucose", "TEST", 164, 171], ["fatty acid metabolism", "PROBLEM", 176, 197], ["/scientificreports/Influenza virus infection", "PROBLEM", 213, 257], ["insulin sensitivity", "TEST", 266, 285], ["Insulin", "TREATMENT", 299, 306], ["cellular glucose uptake", "TEST", 317, 340], ["the blood", "TEST", 346, 355], ["intracellular glycolysis", "TEST", 360, 384], ["liver", "ANATOMY", 12, 17], ["predominant", "OBSERVATION_MODIFIER", 26, 37], ["liver", "ANATOMY", 137, 142], ["fatty acid metabolism", "OBSERVATION", 176, 197], ["liver", "ANATOMY", 293, 298], ["glucose uptake", "OBSERVATION", 326, 340]]], ["Upon insulin binding to the insulin receptor on the cell surface, the signal is transduced to downstream molecules and phosphorylates Akt.", [["cell surface", "ANATOMY", 52, 64], ["insulin", "GENE_OR_GENE_PRODUCT", 5, 12], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 28, 44], ["cell surface", "CELLULAR_COMPONENT", 52, 64], ["Akt.", "GENE_OR_GENE_PRODUCT", 134, 138], ["insulin", "PROTEIN", 5, 12], ["insulin receptor", "PROTEIN", 28, 44], ["insulin binding", "TREATMENT", 5, 20], ["the insulin receptor", "TREATMENT", 24, 44], ["phosphorylates Akt.", "TEST", 119, 138]]], ["Phosphorylated Akt activates glucose transporters to increase glucose uptake.", [["glucose", "CHEMICAL", 29, 36], ["glucose", "CHEMICAL", 62, 69], ["glucose", "CHEMICAL", 29, 36], ["glucose", "CHEMICAL", 62, 69], ["Akt", "GENE_OR_GENE_PRODUCT", 15, 18], ["glucose", "SIMPLE_CHEMICAL", 29, 36], ["glucose", "SIMPLE_CHEMICAL", 62, 69], ["Akt", "PROTEIN", 15, 18], ["glucose transporters", "PROTEIN", 29, 49], ["Phosphorylated Akt", "TEST", 0, 18], ["glucose transporters", "TEST", 29, 49], ["glucose uptake", "TEST", 62, 76]]], ["Therefore, phosphorylation of Akt is a good indicator of activation of insulin signaling.", [["Akt", "GENE_OR_GENE_PRODUCT", 30, 33], ["insulin", "GENE_OR_GENE_PRODUCT", 71, 78], ["Akt", "PROTEIN", 30, 33], ["insulin signaling", "TREATMENT", 71, 88]]], ["Here we examined the effect of influenza virus infection on insulin sensitivity in the livers according to ratios of insulin-induced phosphoryla- Table 1 .", [["livers", "ANATOMY", 87, 93], ["influenza virus infection", "DISEASE", 31, 56], ["phosphoryla-", "CHEMICAL", 133, 145], ["influenza virus", "ORGANISM", 31, 46], ["insulin", "GENE_OR_GENE_PRODUCT", 60, 67], ["livers", "ORGAN", 87, 93], ["insulin", "GENE_OR_GENE_PRODUCT", 117, 124], ["phosphoryla", "SIMPLE_CHEMICAL", 133, 144], ["insulin", "PROTEIN", 117, 124], ["influenza virus", "SPECIES", 31, 46], ["influenza virus", "SPECIES", 31, 46], ["influenza virus infection", "PROBLEM", 31, 56], ["insulin sensitivity", "TEST", 60, 79], ["insulin", "TEST", 117, 124], ["livers", "ANATOMY", 87, 93]]], ["Increased or decreased serum levels of metabolites in PR8 virus-infected mice at 6 dpi.", [["serum", "ANATOMY", 23, 28], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["PR8 virus", "ORGANISM", 54, 63], ["mice", "ORGANISM", 73, 77], ["mice", "SPECIES", 73, 77], ["PR8 virus", "SPECIES", 54, 63], ["mice", "SPECIES", 73, 77], ["Increased or decreased serum levels of metabolites", "PROBLEM", 0, 50], ["PR8 virus", "PROBLEM", 54, 63], ["decreased", "OBSERVATION_MODIFIER", 13, 22], ["serum levels", "OBSERVATION_MODIFIER", 23, 35]]], ["Metabolites with high factor loading (> 0.7) and significant differences (p < 0.05, t-test) were selected as significant metabolites and are listed here.", [["Metabolites", "TEST", 0, 11], ["high factor loading", "PROBLEM", 17, 36], ["t-test", "TEST", 84, 90], ["high", "OBSERVATION_MODIFIER", 17, 21], ["significant", "OBSERVATION_MODIFIER", 49, 60]]], ["The relative serum levels of each metabolite from PR8 virus-infected mice are presented as fold changes relative to those from control mice.", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["PR8 virus", "ORGANISM", 50, 59], ["mice", "ORGANISM", 69, 73], ["mice", "ORGANISM", 135, 139], ["PR8 virus", "SPECIES", 50, 59], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 135, 139], ["PR8 virus", "SPECIES", 50, 59], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 135, 139], ["The relative serum levels", "TEST", 0, 25], ["each metabolite", "TEST", 29, 44], ["PR8 virus", "PROBLEM", 50, 59], ["fold changes", "PROBLEM", 91, 103]]], ["Factor loading was defined for each metabolite as correlation coefficients between PC1 scores and metabolite levels that were normalized by autoscaling in each sample. www.nature.com/scientificreports/ tion of Akt.", [["Factor", "GENE_OR_GENE_PRODUCT", 0, 6], ["Akt", "GENE_OR_GENE_PRODUCT", 210, 213], ["PC1", "PROTEIN", 83, 86], ["Akt", "PROTEIN", 210, 213], ["Factor loading", "PROBLEM", 0, 14], ["PC1 scores", "TEST", 83, 93], ["metabolite levels", "TEST", 98, 115], ["Akt", "PROBLEM", 210, 213]]], ["Western blotting analyses ( Fig. 4a ) of phosphorylated and total Akt in whole liver lysates of control and PR8 virus-infected mice at 6 dpi revealed that the ratios of phosphorylated Akt to total Akt were increased by 13.0-fold after insulin treatments in control mice, but this ratio was increased by only 4.6-fold in PR8 virusinfected mice (Fig. 4b) .", [["liver lysates", "ANATOMY", 79, 92], ["Akt", "GENE_OR_GENE_PRODUCT", 66, 69], ["liver lysates", "ORGANISM_SUBSTANCE", 79, 92], ["PR8 virus", "ORGANISM", 108, 117], ["mice", "ORGANISM", 127, 131], ["Akt", "GENE_OR_GENE_PRODUCT", 184, 187], ["Akt", "GENE_OR_GENE_PRODUCT", 197, 200], ["insulin", "GENE_OR_GENE_PRODUCT", 235, 242], ["mice", "ORGANISM", 265, 269], ["PR8", "ORGANISM", 320, 323], ["mice", "ORGANISM", 338, 342], ["Akt", "PROTEIN", 66, 69], ["phosphorylated Akt", "PROTEIN", 169, 187], ["Akt", "PROTEIN", 197, 200], ["PR8 virus", "SPECIES", 108, 117], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 338, 342], ["PR8 virus", "SPECIES", 108, 117], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 338, 342], ["blotting analyses", "TEST", 8, 25], ["phosphorylated", "TREATMENT", 41, 55], ["Akt", "TEST", 66, 69], ["whole liver lysates of control", "TREATMENT", 73, 103], ["PR8 virus", "PROBLEM", 108, 117], ["the ratios", "TEST", 155, 165], ["phosphorylated Akt", "TEST", 169, 187], ["total Akt", "TEST", 191, 200], ["insulin treatments", "TREATMENT", 235, 253], ["this ratio", "TEST", 275, 285], ["liver", "ANATOMY", 79, 84]]], ["Similar experiments were performed with the livers collected at other time points.", [["livers", "ANATOMY", 44, 50], ["livers", "ORGAN", 44, 50], ["livers", "ANATOMY", 44, 50]]], ["At 3 dpi, Akt phosphorylation was clearly inhibited by PR8 virus infection, but no clear differences were observed in samples collected at 1 dpi (Supplemental Fig. S2 ).", [["samples", "ANATOMY", 118, 125], ["infection", "DISEASE", 65, 74], ["Akt", "GENE_OR_GENE_PRODUCT", 10, 13], ["PR8 virus", "ORGANISM", 55, 64], ["Akt", "PROTEIN", 10, 13], ["S2", "PROTEIN", 164, 166], ["PR8 virus", "SPECIES", 55, 64], ["Akt phosphorylation", "TEST", 10, 29], ["PR8 virus infection", "PROBLEM", 55, 74], ["Supplemental Fig", "TREATMENT", 146, 162]]], ["Taken together, these results demonstrated that influenza virus infection impairs insulin actions in the liver.", [["liver", "ANATOMY", 105, 110], ["influenza virus infection", "DISEASE", 48, 73], ["influenza virus", "ORGANISM", 48, 63], ["insulin", "GENE_OR_GENE_PRODUCT", 82, 89], ["liver", "ORGAN", 105, 110], ["influenza virus", "SPECIES", 48, 63], ["influenza virus", "SPECIES", 48, 63], ["influenza virus infection", "PROBLEM", 48, 73], ["influenza virus", "OBSERVATION", 48, 63], ["liver", "ANATOMY", 105, 110]]], ["We also performed glucose tolerance tests (GTT) in control and PR8 virus-infected mice at 6 dpi to investigate whether PR8 virus infection affected glucose uptake in response to high doses of glucose (Fig. 4c) .", [["glucose", "CHEMICAL", 18, 25], ["infection", "DISEASE", 129, 138], ["glucose", "CHEMICAL", 148, 155], ["glucose", "CHEMICAL", 192, 199], ["glucose", "CHEMICAL", 18, 25], ["glucose", "CHEMICAL", 148, 155], ["glucose", "CHEMICAL", 192, 199], ["glucose", "SIMPLE_CHEMICAL", 18, 25], ["PR8 virus", "ORGANISM", 63, 72], ["mice", "ORGANISM", 82, 86], ["PR8 virus", "ORGANISM", 119, 128], ["glucose", "SIMPLE_CHEMICAL", 148, 155], ["glucose", "SIMPLE_CHEMICAL", 192, 199], ["mice", "SPECIES", 82, 86], ["PR8 virus", "SPECIES", 63, 72], ["mice", "SPECIES", 82, 86], ["PR8 virus", "SPECIES", 119, 128], ["glucose tolerance tests", "TEST", 18, 41], ["GTT)", "TREATMENT", 43, 47], ["PR8 virus", "TREATMENT", 63, 72], ["PR8 virus infection affected glucose uptake", "PROBLEM", 119, 162], ["glucose (Fig.", "TREATMENT", 192, 205]]], ["We found no significant differences in fasting blood glucose levels between the groups.", [["blood", "ANATOMY", 47, 52], ["glucose", "CHEMICAL", 53, 60], ["glucose", "CHEMICAL", 53, 60], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["glucose", "SIMPLE_CHEMICAL", 53, 60], ["fasting blood glucose levels", "TEST", 39, 67], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["differences", "OBSERVATION_MODIFIER", 24, 35]]], ["Moreover, at 30 min after glucose injections, the control and PR8 virus-infected mice showed similar blood glucose levels (394.4 \u00b1 18.2 mg/dL vs. 363.2 \u00b1 29.7 mg/dL).", [["blood", "ANATOMY", 101, 106], ["glucose", "CHEMICAL", 26, 33], ["glucose", "CHEMICAL", 107, 114], ["glucose", "CHEMICAL", 26, 33], ["glucose", "CHEMICAL", 107, 114], ["glucose", "SIMPLE_CHEMICAL", 26, 33], ["PR8 virus", "ORGANISM", 62, 71], ["mice", "ORGANISM", 81, 85], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["glucose", "SIMPLE_CHEMICAL", 107, 114], ["mice", "SPECIES", 81, 85], ["PR8 virus", "SPECIES", 62, 71], ["mice", "SPECIES", 81, 85], ["glucose injections", "TREATMENT", 26, 44], ["the control", "TREATMENT", 46, 57], ["PR8 virus", "TEST", 62, 71], ["blood glucose levels", "TEST", 101, 121], ["dL", "TEST", 139, 141]]], ["Subsequently, blood glucose levels were rapidly decreased in control mice (60 min, 274.2 \u00b1 13.7 mg/dL; 90 min, 193.4 \u00b1 8.5 mg/dL; 120 min, 165.4 \u00b1 9.0 mg/dL).", [["blood", "ANATOMY", 14, 19], ["glucose", "CHEMICAL", 20, 27], ["glucose", "CHEMICAL", 20, 27], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["glucose", "SIMPLE_CHEMICAL", 20, 27], ["mice", "ORGANISM", 69, 73], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 69, 73], ["blood glucose levels", "TEST", 14, 34], ["decreased", "OBSERVATION_MODIFIER", 48, 57]]], ["Conversely, decreases in blood glucose levels were delayed and higher blood glucose levels were observed in PR8 virus-infected mice, compared with the control mice, at all time points (60 min, 387.0 \u00b1 35.4 mg/dL; 90 min, 258.6 \u00b1 11.1 mg/dL; 120 min, 184.2 \u00b1 4.4 mg/dL).", [["blood", "ANATOMY", 25, 30], ["blood", "ANATOMY", 70, 75], ["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 76, 83], ["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 76, 83], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["glucose", "SIMPLE_CHEMICAL", 31, 38], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["glucose", "SIMPLE_CHEMICAL", 76, 83], ["PR8 virus", "ORGANISM", 108, 117], ["mice", "ORGANISM", 127, 131], ["mice", "ORGANISM", 159, 163], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 159, 163], ["PR8 virus", "SPECIES", 108, 117], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 159, 163], ["blood glucose levels", "TEST", 25, 45], ["higher blood glucose levels", "TEST", 63, 90], ["PR8 virus", "PROBLEM", 108, 117], ["decreases", "OBSERVATION_MODIFIER", 12, 21]]], ["Significant differences in blood glucose levels were identified at 60 and 90 min between the groups (p < 0.05, two-way ANOVA).", [["blood", "ANATOMY", 27, 32], ["glucose", "CHEMICAL", 33, 40], ["glucose", "CHEMICAL", 33, 40], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["glucose", "SIMPLE_CHEMICAL", 33, 40], ["blood glucose levels", "TEST", 27, 47]]], ["These results indicate that PR8 virus infection impairs insulin signaling in the liver and induces a tendency toward glucose intolerance, potentially reflecting reduced glucose uptake.Influenza virus infection impairs insulin sensitivity in the liver.Fatty acid accumulation in the liver of infected mice was suggested by gene expression assays.", [["liver", "ANATOMY", 81, 86], ["liver", "ANATOMY", 245, 250], ["liver", "ANATOMY", 282, 287], ["infection", "DISEASE", 38, 47], ["glucose intolerance", "DISEASE", 117, 136], ["glucose", "CHEMICAL", 169, 176], ["Influenza virus infection", "DISEASE", 184, 209], ["Fatty acid", "CHEMICAL", 251, 261], ["glucose", "CHEMICAL", 117, 124], ["glucose", "CHEMICAL", 169, 176], ["Fatty acid", "CHEMICAL", 251, 261], ["PR8 virus", "ORGANISM", 28, 37], ["insulin", "GENE_OR_GENE_PRODUCT", 56, 63], ["liver", "ORGAN", 81, 86], ["glucose", "SIMPLE_CHEMICAL", 117, 124], ["glucose", "SIMPLE_CHEMICAL", 169, 176], ["Influenza virus", "ORGANISM", 184, 199], ["insulin", "GENE_OR_GENE_PRODUCT", 218, 225], ["liver", "ORGAN", 245, 250], ["Fatty acid", "SIMPLE_CHEMICAL", 251, 261], ["liver", "ORGAN", 282, 287], ["mice", "ORGANISM", 300, 304], ["Influenza virus", "SPECIES", 184, 199], ["mice", "SPECIES", 300, 304], ["PR8 virus", "SPECIES", 28, 37], ["Influenza virus", "SPECIES", 184, 199], ["mice", "SPECIES", 300, 304], ["PR8 virus infection", "PROBLEM", 28, 47], ["insulin signaling in the liver", "PROBLEM", 56, 86], ["a tendency toward glucose intolerance", "PROBLEM", 99, 136], ["reduced glucose uptake", "PROBLEM", 161, 183], ["Influenza virus infection", "PROBLEM", 184, 209], ["insulin sensitivity", "TEST", 218, 237], ["Fatty acid accumulation in the liver of infected mice", "PROBLEM", 251, 304], ["liver", "ANATOMY", 81, 86], ["glucose intolerance", "OBSERVATION", 117, 136], ["reduced", "OBSERVATION_MODIFIER", 161, 168], ["glucose uptake", "OBSERVATION", 169, 183], ["virus", "OBSERVATION", 194, 199], ["liver", "ANATOMY", 245, 250], ["acid accumulation", "OBSERVATION", 257, 274], ["liver", "ANATOMY", 282, 287], ["infected", "OBSERVATION", 291, 299]]], ["We also investigated the effects of PR8 virus infection on the hepatic expressions of genes that are transcriptionally regulated by insulin signaling (Fig. 5) .", [["hepatic", "ANATOMY", 63, 70], ["infection", "DISEASE", 46, 55], ["PR8 virus", "ORGANISM", 36, 45], ["hepatic", "ORGAN", 63, 70], ["insulin", "GENE_OR_GENE_PRODUCT", 132, 139], ["insulin", "PROTEIN", 132, 139], ["PR8 virus", "SPECIES", 36, 45], ["PR8 virus infection", "PROBLEM", 36, 55], ["PR8 virus infection", "OBSERVATION", 36, 55], ["hepatic", "ANATOMY", 63, 70]]], ["Pck2, which encodes a gluconeogenic enzyme, was expressed dpi.", [["Pck2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Pck2", "PROTEIN", 0, 4], ["gluconeogenic enzyme", "PROTEIN", 22, 42], ["a gluconeogenic enzyme", "TEST", 20, 42]]], ["Mice were intranasally inoculated with PBS alone or PBS comprising PR8 virus, and serum samples were collected for metabolome analysis at 1, 3, and 6 dpi.", [["serum samples", "ANATOMY", 82, 95], ["Mice", "ORGANISM", 0, 4], ["PR8 virus", "ORGANISM", 67, 76], ["serum samples", "ORGANISM_SUBSTANCE", 82, 95], ["Mice", "SPECIES", 0, 4], ["PR8 virus", "SPECIES", 67, 76], ["PBS", "TREATMENT", 39, 42], ["PBS comprising PR8 virus", "PROBLEM", 52, 76], ["serum samples", "TEST", 82, 95], ["metabolome analysis", "TEST", 115, 134]]], ["The serum levels of purine metabolites in PR8 virusinfected mice were expressed relative to those in control mice at each time point.", [["serum", "ANATOMY", 4, 9], ["purine", "CHEMICAL", 20, 26], ["purine", "CHEMICAL", 20, 26], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["purine", "SIMPLE_CHEMICAL", 20, 26], ["PR8 virusinfected mice", "ORGANISM", 42, 64], ["mice", "ORGANISM", 109, 113], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 109, 113], ["The serum levels", "TEST", 0, 16], ["purine metabolites", "TEST", 20, 38]]], ["Bars represent mean \u00b1 SEM of 3 or 4 animals.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mean \u00b1 SEM", "TEST", 15, 25], ["mean", "OBSERVATION_MODIFIER", 15, 19], ["\u00b1 SEM", "OBSERVATION_MODIFIER", 20, 25]]], ["In each panel, white, gray, and black bars indicate data from PR8 virus-infecetd mice at 1, 3, and 6 dpi, respectively; p < 0.05, unpaired t test using the Holm-Sidak correction method with an alpha value of 0.05, control vs. PR8 virus-infected mice at each time point. www.nature.com/scientificreports/ Cd36 and Pnpla2 as well as of Pck2 suggested the attenuation of insulin signaling in the liver of PR8 virus-infected mice.", [["liver", "ANATOMY", 393, 398], ["PR8 virus", "ORGANISM", 62, 71], ["mice", "ORGANISM", 81, 85], ["PR8 virus", "ORGANISM", 226, 235], ["mice", "ORGANISM", 245, 249], ["Cd36", "GENE_OR_GENE_PRODUCT", 304, 308], ["Pnpla2", "GENE_OR_GENE_PRODUCT", 313, 319], ["Pck2", "GENE_OR_GENE_PRODUCT", 334, 338], ["insulin", "GENE_OR_GENE_PRODUCT", 368, 375], ["liver", "ORGAN", 393, 398], ["PR8 virus", "ORGANISM", 402, 411], ["mice", "ORGANISM", 421, 425], ["www.nature.com", "PROTEIN", 270, 284], ["scientificreports", "PROTEIN", 285, 302], ["Cd36", "PROTEIN", 304, 308], ["Pnpla2", "PROTEIN", 313, 319], ["Pck2", "PROTEIN", 334, 338], ["insulin", "PROTEIN", 368, 375], ["mice", "SPECIES", 81, 85], ["PR8 virus", "SPECIES", 226, 235], ["mice", "SPECIES", 245, 249], ["mice", "SPECIES", 421, 425], ["PR8 virus", "SPECIES", 62, 71], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 245, 249], ["PR8 virus", "SPECIES", 402, 411], ["mice", "SPECIES", 421, 425], ["each panel", "TEST", 3, 13], ["white, gray", "TEST", 15, 26], ["PR8 virus", "TEST", 62, 71], ["unpaired t test", "TEST", 130, 145], ["the Holm", "TREATMENT", 152, 160], ["Sidak correction method", "TREATMENT", 161, 184], ["an alpha value", "TEST", 190, 204], ["PR8 virus", "TREATMENT", 226, 235], ["Pnpla2", "TREATMENT", 313, 319], ["Pck2", "TREATMENT", 334, 338], ["insulin signaling", "TREATMENT", 368, 385], ["infected mice", "OBSERVATION", 236, 249], ["liver", "ANATOMY", 393, 398], ["infected mice", "OBSERVATION", 412, 425]]], ["Conversely, we observed no changes in the expressions of Acox1 and Cpt1\u03b2, which encode key enzymes of fatty acid \u03b2-oxidation.", [["fatty acid", "CHEMICAL", 102, 112], ["fatty acid", "CHEMICAL", 102, 112], ["Acox1", "GENE_OR_GENE_PRODUCT", 57, 62], ["Cpt1\u03b2", "GENE_OR_GENE_PRODUCT", 67, 72], ["fatty acid", "SIMPLE_CHEMICAL", 102, 112], ["Acox1", "PROTEIN", 57, 62], ["Cpt1\u03b2", "PROTEIN", 67, 72], ["Acox1", "TREATMENT", 57, 62], ["Cpt1\u03b2", "TREATMENT", 67, 72], ["fatty acid \u03b2-oxidation", "PROBLEM", 102, 124], ["fatty acid", "OBSERVATION", 102, 112]]], ["In addition, the serum levels of carnitine were significantly decreased by 0.52-fold at 6 dpi (Fig. 2) .", [["serum", "ANATOMY", 17, 22], ["carnitine", "CHEMICAL", 33, 42], ["carnitine", "CHEMICAL", 33, 42], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["carnitine", "SIMPLE_CHEMICAL", 33, 42], ["the serum levels", "TEST", 13, 29], ["carnitine", "TEST", 33, 42]]], ["Because carnitine is involved in fatty acid transport into mitochondria, the observed decrease would possibly reduce fatty acid \u03b2-oxidation in mitochondria.", [["mitochondria", "ANATOMY", 59, 71], ["mitochondria", "ANATOMY", 143, 155], ["carnitine", "CHEMICAL", 8, 17], ["fatty acid", "CHEMICAL", 33, 43], ["fatty acid", "CHEMICAL", 117, 127], ["carnitine", "CHEMICAL", 8, 17], ["fatty acid", "CHEMICAL", 33, 43], ["fatty acid", "CHEMICAL", 117, 127], ["carnitine", "SIMPLE_CHEMICAL", 8, 17], ["fatty acid", "SIMPLE_CHEMICAL", 33, 43], ["mitochondria", "CELLULAR_COMPONENT", 59, 71], ["fatty acid", "SIMPLE_CHEMICAL", 117, 127], ["mitochondria", "CELLULAR_COMPONENT", 143, 155], ["fatty acid \u03b2-oxidation in mitochondria", "PROBLEM", 117, 155], ["fatty acid \u03b2-oxidation", "OBSERVATION", 117, 139]]], ["These changes suggest fatty acid accumulation in the liver cells of PR8 virus-infected mice, although further analyses on protein expressions and enzymatic activities are warranted in the future.DiscussionIn the present study, metabolome analyses demonstrated that PR8 virus infection decreases the serum levels of most TCA cycle intermediates and metabolites in the related metabolic pathways, suggesting reduced flux through the TCA cycle.", [["liver cells", "ANATOMY", 53, 64], ["serum", "ANATOMY", 299, 304], ["fatty acid", "CHEMICAL", 22, 32], ["infection", "DISEASE", 275, 284], ["fatty acid", "CHEMICAL", 22, 32], ["TCA", "CHEMICAL", 320, 323], ["TCA", "CHEMICAL", 431, 434], ["fatty acid", "SIMPLE_CHEMICAL", 22, 32], ["liver cells", "CELL", 53, 64], ["PR8 virus", "ORGANISM", 68, 77], ["mice", "ORGANISM", 87, 91], ["PR8 virus", "ORGANISM", 265, 274], ["serum", "ORGANISM_SUBSTANCE", 299, 304], ["TCA", "SIMPLE_CHEMICAL", 320, 323], ["TCA", "SIMPLE_CHEMICAL", 431, 434], ["liver cells", "CELL_TYPE", 53, 64], ["mice", "SPECIES", 87, 91], ["PR8 virus", "SPECIES", 68, 77], ["mice", "SPECIES", 87, 91], ["PR8 virus", "SPECIES", 265, 274], ["fatty acid accumulation in the liver cells", "PROBLEM", 22, 64], ["PR8 virus", "PROBLEM", 68, 77], ["further analyses", "TEST", 102, 118], ["protein expressions", "TEST", 122, 141], ["enzymatic activities", "TEST", 146, 166], ["the present study", "TEST", 208, 225], ["metabolome analyses", "TEST", 227, 246], ["PR8 virus infection", "PROBLEM", 265, 284], ["the serum levels", "TEST", 295, 311], ["reduced flux through the TCA cycle", "PROBLEM", 406, 440], ["fatty acid accumulation", "OBSERVATION", 22, 45], ["liver", "ANATOMY", 53, 58], ["PR8 virus", "OBSERVATION", 68, 77], ["infected", "OBSERVATION_MODIFIER", 78, 86], ["metabolic pathways", "OBSERVATION", 375, 393], ["reduced flux", "OBSERVATION", 406, 418]]], ["Because the TCA cycle greatly contributes electrons for mitochondrial oxidative phosphorylation, suppression of the TCA cycle leads to reduced ATP synthesis.", [["mitochondrial", "ANATOMY", 56, 69], ["TCA", "CHEMICAL", 12, 15], ["ATP", "CHEMICAL", 143, 146], ["TCA", "CHEMICAL", 12, 15], ["TCA", "CHEMICAL", 116, 119], ["ATP", "CHEMICAL", 143, 146], ["TCA", "SIMPLE_CHEMICAL", 12, 15], ["mitochondrial", "CELLULAR_COMPONENT", 56, 69], ["TCA", "SIMPLE_CHEMICAL", 116, 119], ["ATP", "SIMPLE_CHEMICAL", 143, 146], ["the TCA cycle", "PROBLEM", 8, 21], ["mitochondrial oxidative phosphorylation", "TREATMENT", 56, 95], ["the TCA cycle", "TREATMENT", 112, 125], ["reduced ATP synthesis", "PROBLEM", 135, 156], ["oxidative phosphorylation", "OBSERVATION", 70, 95], ["ATP synthesis", "OBSERVATION", 143, 156]]], ["Hence, the rates of ATP and GTP degradation were possibly greater than the respective rates of their synthesis in PR8 virus-infected mice, leading to significant increases in the serum levels of metabolites, such as xanthine, hypoxanthine, and inosine.", [["serum", "ANATOMY", 179, 184], ["ATP", "CHEMICAL", 20, 23], ["GTP", "CHEMICAL", 28, 31], ["xanthine", "CHEMICAL", 216, 224], ["hypoxanthine", "CHEMICAL", 226, 238], ["inosine", "CHEMICAL", 244, 251], ["ATP", "CHEMICAL", 20, 23], ["GTP", "CHEMICAL", 28, 31], ["xanthine", "CHEMICAL", 216, 224], ["hypoxanthine", "CHEMICAL", 226, 238], ["inosine", "CHEMICAL", 244, 251], ["ATP", "SIMPLE_CHEMICAL", 20, 23], ["GTP", "SIMPLE_CHEMICAL", 28, 31], ["PR8 virus", "ORGANISM", 114, 123], ["mice", "ORGANISM", 133, 137], ["serum", "ORGANISM_SUBSTANCE", 179, 184], ["xanthine", "SIMPLE_CHEMICAL", 216, 224], ["hypoxanthine", "SIMPLE_CHEMICAL", 226, 238], ["inosine", "SIMPLE_CHEMICAL", 244, 251], ["mice", "SPECIES", 133, 137], ["PR8 virus", "SPECIES", 114, 123], ["mice", "SPECIES", 133, 137], ["ATP", "PROBLEM", 20, 23], ["GTP degradation", "PROBLEM", 28, 43], ["their synthesis in PR8 virus", "PROBLEM", 95, 123], ["significant increases in the serum levels of metabolites", "PROBLEM", 150, 206], ["xanthine", "TREATMENT", 216, 224], ["hypoxanthine", "TREATMENT", 226, 238], ["inosine", "TREATMENT", 244, 251], ["significant", "OBSERVATION_MODIFIER", 150, 161], ["increases", "OBSERVATION_MODIFIER", 162, 171]]], ["Energy depletion indicated by the reduced levels of ATP and GTP has been described in several studies on infectious diseases and endotoxemia [16] [17] [18] .", [["ATP", "CHEMICAL", 52, 55], ["GTP", "CHEMICAL", 60, 63], ["infectious diseases", "DISEASE", 105, 124], ["endotoxemia", "DISEASE", 129, 140], ["ATP", "CHEMICAL", 52, 55], ["GTP", "CHEMICAL", 60, 63], ["ATP", "SIMPLE_CHEMICAL", 52, 55], ["GTP", "SIMPLE_CHEMICAL", 60, 63], ["endotoxemia [16] [17] [18]", "SIMPLE_CHEMICAL", 129, 155], ["Energy depletion", "PROBLEM", 0, 16], ["the reduced levels of ATP and GTP", "PROBLEM", 30, 63], ["endotoxemia", "PROBLEM", 129, 140], ["depletion", "OBSERVATION", 7, 16]]], ["Reduced ATP levels in blood and various organs, including the liver, have been previously associated with influenza virus infection in a mouse model 16 .", [["blood", "ANATOMY", 22, 27], ["organs", "ANATOMY", 40, 46], ["liver", "ANATOMY", 62, 67], ["ATP", "CHEMICAL", 8, 11], ["influenza virus infection", "DISEASE", 106, 131], ["ATP", "CHEMICAL", 8, 11], ["ATP", "SIMPLE_CHEMICAL", 8, 11], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["organs", "ORGAN", 40, 46], ["liver", "ORGAN", 62, 67], ["influenza virus", "ORGANISM", 106, 121], ["mouse", "ORGANISM", 137, 142], ["influenza virus", "SPECIES", 106, 121], ["mouse", "SPECIES", 137, 142], ["influenza virus", "SPECIES", 106, 121], ["mouse", "SPECIES", 137, 142], ["Reduced ATP levels in blood and various organs", "PROBLEM", 0, 46], ["influenza virus infection", "PROBLEM", 106, 131], ["ATP levels", "OBSERVATION", 8, 18], ["various", "ANATOMY_MODIFIER", 32, 39], ["organs", "ANATOMY", 40, 46], ["liver", "ANATOMY", 62, 67], ["associated with", "UNCERTAINTY", 90, 105], ["influenza virus infection", "OBSERVATION", 106, 131]]], ["Decreased GTP levels have been shown www.nature.com/scientificreports/ in the lung tissues of rabbits treated with bacterial endotoxin lipopolysaccharide 17 .", [["lung tissues", "ANATOMY", 78, 90], ["GTP", "CHEMICAL", 10, 13], ["lipopolysaccharide", "CHEMICAL", 135, 153], ["GTP", "CHEMICAL", 10, 13], ["GTP", "SIMPLE_CHEMICAL", 10, 13], ["lung tissues", "TISSUE", 78, 90], ["rabbits", "ORGANISM", 94, 101], ["rabbits", "SPECIES", 94, 101], ["rabbits", "SPECIES", 94, 101], ["Decreased GTP levels", "PROBLEM", 0, 20], ["bacterial endotoxin lipopolysaccharide", "TREATMENT", 115, 153], ["GTP levels", "OBSERVATION", 10, 20], ["lung", "ANATOMY", 78, 82]]], ["Increases in the serum levels of hypoxanthine and inosine have also been reported in patients with primary dengue virus infection at the febrile stage, suggesting an imbalance of ATP and/or GTP synthesis and degradation during the acute stage of the dengue fever 18 .", [["serum", "ANATOMY", 17, 22], ["hypoxanthine", "CHEMICAL", 33, 45], ["inosine", "CHEMICAL", 50, 57], ["primary dengue virus infection", "DISEASE", 99, 129], ["febrile", "DISEASE", 137, 144], ["ATP", "CHEMICAL", 179, 182], ["GTP", "CHEMICAL", 190, 193], ["dengue fever", "DISEASE", 250, 262], ["hypoxanthine", "CHEMICAL", 33, 45], ["inosine", "CHEMICAL", 50, 57], ["ATP", "CHEMICAL", 179, 182], ["GTP", "CHEMICAL", 190, 193], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["hypoxanthine", "SIMPLE_CHEMICAL", 33, 45], ["inosine", "SIMPLE_CHEMICAL", 50, 57], ["patients", "ORGANISM", 85, 93], ["dengue virus", "ORGANISM", 107, 119], ["ATP", "SIMPLE_CHEMICAL", 179, 182], ["GTP", "SIMPLE_CHEMICAL", 190, 193], ["patients", "SPECIES", 85, 93], ["dengue virus", "SPECIES", 107, 119], ["the serum levels", "TEST", 13, 29], ["hypoxanthine", "TREATMENT", 33, 45], ["inosine", "TREATMENT", 50, 57], ["primary dengue virus infection", "PROBLEM", 99, 129], ["the febrile stage", "PROBLEM", 133, 150], ["ATP", "PROBLEM", 179, 182], ["GTP synthesis", "PROBLEM", 190, 203], ["the dengue fever", "PROBLEM", 246, 262], ["imbalance", "OBSERVATION", 166, 175]]], ["These studies and ours indicate that regulatory energy depletion is a common symptom of infectious diseases.", [["infectious diseases", "DISEASE", 88, 107], ["These studies", "TEST", 0, 13], ["regulatory energy depletion", "PROBLEM", 37, 64], ["infectious diseases", "PROBLEM", 88, 107], ["energy depletion", "OBSERVATION", 48, 64], ["infectious", "OBSERVATION", 88, 98]]], ["TCA cycle flux is associated with glucose and fatty acid metabolism because these energy sources are eventually converted to acetyl-CoA for entry into the TCA cycle.", [["TCA", "CHEMICAL", 0, 3], ["glucose", "CHEMICAL", 34, 41], ["fatty acid", "CHEMICAL", 46, 56], ["acetyl-CoA", "CHEMICAL", 125, 135], ["TCA", "CHEMICAL", 0, 3], ["glucose", "CHEMICAL", 34, 41], ["fatty acid", "CHEMICAL", 46, 56], ["acetyl-CoA", "CHEMICAL", 125, 135], ["TCA", "CHEMICAL", 155, 158], ["TCA", "SIMPLE_CHEMICAL", 0, 3], ["glucose", "SIMPLE_CHEMICAL", 34, 41], ["fatty acid", "SIMPLE_CHEMICAL", 46, 56], ["acetyl-CoA", "SIMPLE_CHEMICAL", 125, 135], ["TCA", "SIMPLE_CHEMICAL", 155, 158], ["TCA cycle flux", "TEST", 0, 14], ["glucose", "TEST", 34, 41], ["fatty acid metabolism", "PROBLEM", 46, 67], ["acetyl-CoA", "TREATMENT", 125, 135]]], ["If either pathway is inhibited, the other pathway becomes activated to compensate for the reduced substrate supply to the TCA cycle.", [["TCA", "CHEMICAL", 122, 125], ["TCA", "SIMPLE_CHEMICAL", 122, 125], ["the reduced substrate supply", "PROBLEM", 86, 114]]], ["In the case of HFD-induced obese mice with insulin resistance, fatty acid oxidation is increased in a leptin-dependent manner, and TCA cycle activity is enhanced 19, 20 .", [["fatty acid", "CHEMICAL", 63, 73], ["TCA", "CHEMICAL", 131, 134], ["fatty acid", "CHEMICAL", 63, 73], ["TCA", "CHEMICAL", 131, 134], ["HFD", "SIMPLE_CHEMICAL", 15, 18], ["mice", "ORGANISM", 33, 37], ["insulin", "GENE_OR_GENE_PRODUCT", 43, 50], ["fatty acid", "SIMPLE_CHEMICAL", 63, 73], ["leptin", "GENE_OR_GENE_PRODUCT", 102, 108], ["TCA", "SIMPLE_CHEMICAL", 131, 134], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["HFD", "TEST", 15, 18], ["insulin resistance", "TREATMENT", 43, 61], ["fatty acid oxidation", "TEST", 63, 83], ["TCA cycle activity", "TEST", 131, 149], ["insulin resistance", "OBSERVATION", 43, 61], ["increased", "OBSERVATION_MODIFIER", 87, 96]]], ["Conversely, db/db mice, a well-known mouse model of type 2 diabetes, reportedly developed insulin resistance without activation of fatty acid oxidation due to lack of leptin receptor and showed reduced serum levels of the TCA cycle intermediates citric acid, 2-ketoglutaric acid, malic acid, and fumaric acid with disease progression 21 .", [["serum", "ANATOMY", 202, 207], ["type 2 diabetes", "DISEASE", 52, 67], ["fatty acid", "CHEMICAL", 131, 141], ["citric acid", "CHEMICAL", 246, 257], ["2-ketoglutaric acid", "CHEMICAL", 259, 278], ["malic acid", "CHEMICAL", 280, 290], ["fumaric acid", "CHEMICAL", 296, 308], ["fatty acid", "CHEMICAL", 131, 141], ["TCA", "CHEMICAL", 222, 225], ["citric acid", "CHEMICAL", 246, 257], ["2-ketoglutaric acid", "CHEMICAL", 259, 278], ["malic acid", "CHEMICAL", 280, 290], ["fumaric acid", "CHEMICAL", 296, 308], ["db/db mice", "ORGANISM", 12, 22], ["mouse", "ORGANISM", 37, 42], ["insulin", "GENE_OR_GENE_PRODUCT", 90, 97], ["fatty acid", "SIMPLE_CHEMICAL", 131, 141], ["leptin receptor", "GENE_OR_GENE_PRODUCT", 167, 182], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["TCA", "SIMPLE_CHEMICAL", 222, 225], ["citric acid", "SIMPLE_CHEMICAL", 246, 257], ["2-ketoglutaric acid", "SIMPLE_CHEMICAL", 259, 278], ["malic acid", "SIMPLE_CHEMICAL", 280, 290], ["fumaric acid", "SIMPLE_CHEMICAL", 296, 308], ["leptin receptor", "PROTEIN", 167, 182], ["mice", "SPECIES", 18, 22], ["mouse", "SPECIES", 37, 42], ["mouse", "SPECIES", 37, 42], ["type 2 diabetes", "PROBLEM", 52, 67], ["insulin resistance", "PROBLEM", 90, 108], ["fatty acid oxidation", "PROBLEM", 131, 151], ["leptin receptor", "TEST", 167, 182], ["reduced serum levels", "PROBLEM", 194, 214], ["citric acid", "TEST", 246, 257], ["ketoglutaric acid", "TEST", 261, 278], ["malic acid", "TEST", 280, 290], ["fumaric acid", "TEST", 296, 308], ["disease progression", "PROBLEM", 314, 333], ["diabetes", "OBSERVATION", 59, 67], ["insulin resistance", "OBSERVATION", 90, 108]]], ["In the present study, no changes in the expression of Cpt1 or Acox1 in the liver suggest that fatty acid oxidation was not enhanced in PR8 virus-infected mice despite insulin resistance.", [["liver", "ANATOMY", 75, 80], ["fatty acid", "CHEMICAL", 94, 104], ["fatty acid", "CHEMICAL", 94, 104], ["Cpt1", "GENE_OR_GENE_PRODUCT", 54, 58], ["Acox1", "GENE_OR_GENE_PRODUCT", 62, 67], ["liver", "ORGAN", 75, 80], ["fatty acid", "SIMPLE_CHEMICAL", 94, 104], ["PR8 virus", "ORGANISM", 135, 144], ["mice", "ORGANISM", 154, 158], ["insulin", "GENE_OR_GENE_PRODUCT", 167, 174], ["Cpt1", "PROTEIN", 54, 58], ["Acox1", "PROTEIN", 62, 67], ["mice", "SPECIES", 154, 158], ["PR8 virus", "SPECIES", 135, 144], ["mice", "SPECIES", 154, 158], ["the present study", "TEST", 3, 20], ["Cpt1", "PROBLEM", 54, 58], ["Acox1 in the liver", "TEST", 62, 80], ["fatty acid oxidation", "PROBLEM", 94, 114], ["PR8 virus", "PROBLEM", 135, 144], ["insulin resistance", "TREATMENT", 167, 185], ["no", "UNCERTAINTY", 22, 24], ["liver", "ANATOMY", 75, 80], ["fatty acid", "OBSERVATION", 94, 104], ["insulin resistance", "OBSERVATION", 167, 185]]], ["Although the effect of PR8 virus infection on fatty acid oxidation was not evaluated in the present study, reduced fatty acid oxidation during influenza has been demonstrated previously 12, 13 .", [["infection", "DISEASE", 33, 42], ["fatty acid", "CHEMICAL", 46, 56], ["fatty acid", "CHEMICAL", 115, 125], ["influenza", "DISEASE", 143, 152], ["fatty acid", "CHEMICAL", 46, 56], ["fatty acid", "CHEMICAL", 115, 125], ["PR8 virus", "ORGANISM", 23, 32], ["fatty acid", "SIMPLE_CHEMICAL", 46, 56], ["fatty acid", "SIMPLE_CHEMICAL", 115, 125], ["PR8 virus", "SPECIES", 23, 32], ["PR8 virus infection", "PROBLEM", 23, 42], ["fatty acid oxidation", "TEST", 46, 66], ["the present study", "TEST", 88, 105], ["reduced fatty acid oxidation", "PROBLEM", 107, 135], ["influenza", "PROBLEM", 143, 152], ["fatty acid oxidation", "OBSERVATION", 115, 135]]], ["If both insulin signaling and fatty acid oxidation are inhibited during influenza, it might result in suppression of the TCA cycle due to reduced substrate supply.", [["fatty acid", "CHEMICAL", 30, 40], ["influenza", "DISEASE", 72, 81], ["fatty acid", "CHEMICAL", 30, 40], ["TCA", "CHEMICAL", 121, 124], ["insulin", "GENE_OR_GENE_PRODUCT", 8, 15], ["fatty acid", "SIMPLE_CHEMICAL", 30, 40], ["TCA", "SIMPLE_CHEMICAL", 121, 124], ["both insulin signaling", "TREATMENT", 3, 25], ["fatty acid oxidation", "PROBLEM", 30, 50], ["influenza", "PROBLEM", 72, 81], ["the TCA cycle", "TREATMENT", 117, 130], ["reduced substrate supply", "PROBLEM", 138, 162]]], ["Given significant body weight loss in PR8 virus-infected mice, however, decrease in food intake during influenza could affect the serum levels of the TCA cycle and related pathways.", [["body", "ANATOMY", 18, 22], ["serum", "ANATOMY", 130, 135], ["weight loss", "DISEASE", 23, 34], ["influenza", "DISEASE", 103, 112], ["TCA", "CHEMICAL", 150, 153], ["body", "ORGANISM_SUBDIVISION", 18, 22], ["PR8 virus", "ORGANISM", 38, 47], ["mice", "ORGANISM", 57, 61], ["food", "ORGANISM_SUBDIVISION", 84, 88], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["TCA", "SIMPLE_CHEMICAL", 150, 153], ["mice", "SPECIES", 57, 61], ["PR8 virus", "SPECIES", 38, 47], ["mice", "SPECIES", 57, 61], ["significant body weight loss", "PROBLEM", 6, 34], ["PR8 virus", "PROBLEM", 38, 47], ["influenza", "PROBLEM", 103, 112], ["the serum levels", "TEST", 126, 142], ["significant", "OBSERVATION_MODIFIER", 6, 17], ["body", "OBSERVATION_MODIFIER", 18, 22], ["weight loss", "OBSERVATION", 23, 34], ["decrease", "OBSERVATION_MODIFIER", 72, 80]]], ["Further investigations, such as studies with pair-fed control and lower titer of virus, will provide helpful information to confirm the underlying association.DiscussionHere we demonstrated for the first time that influenza virus infection impairs insulin signaling in liver tissues, which critically regulates glucose metabolism 9,10 , and induces a tendency toward glucose intolerance.", [["liver tissues", "ANATOMY", 269, 282], ["influenza virus infection", "DISEASE", 214, 239], ["glucose", "CHEMICAL", 311, 318], ["glucose intolerance", "DISEASE", 367, 386], ["glucose", "CHEMICAL", 311, 318], ["glucose", "CHEMICAL", 367, 374], ["influenza virus", "ORGANISM", 214, 229], ["insulin", "GENE_OR_GENE_PRODUCT", 248, 255], ["liver tissues", "TISSUE", 269, 282], ["glucose", "SIMPLE_CHEMICAL", 311, 318], ["glucose", "SIMPLE_CHEMICAL", 367, 374], ["influenza virus", "SPECIES", 214, 229], ["influenza virus", "SPECIES", 214, 229], ["Further investigations", "TEST", 0, 22], ["studies", "TEST", 32, 39], ["pair-fed control", "TREATMENT", 45, 61], ["lower titer of virus", "PROBLEM", 66, 86], ["influenza virus infection", "PROBLEM", 214, 239], ["insulin signaling in liver tissues", "PROBLEM", 248, 282], ["glucose metabolism", "TEST", 311, 329], ["a tendency toward glucose intolerance", "PROBLEM", 349, 386], ["liver", "ANATOMY", 269, 274], ["glucose intolerance", "OBSERVATION", 367, 386]]], ["Importantly, Nagao et al., reported a high blood glucose level (over 150 mg/dL) as one of the worst prognostic factors in pediatric patients with influenza-associated encephalopathy 22 .", [["blood", "ANATOMY", 43, 48], ["glucose", "CHEMICAL", 49, 56], ["influenza", "DISEASE", 146, 155], ["encephalopathy", "DISEASE", 167, 181], ["glucose", "CHEMICAL", 49, 56], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["glucose", "SIMPLE_CHEMICAL", 49, 56], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["a high blood glucose level", "PROBLEM", 36, 62], ["influenza", "PROBLEM", 146, 155], ["associated encephalopathy", "PROBLEM", 156, 181], ["encephalopathy", "OBSERVATION", 167, 181]]], ["In addition to the elevated glucocorticoid levels, as speculated by Nagao et al., our study suggests the impairment of insulin signaling as a mechanism of elevated blood glucose levels in children with severe influenza.", [["blood", "ANATOMY", 164, 169], ["glucose", "CHEMICAL", 170, 177], ["influenza", "DISEASE", 209, 218], ["glucose", "CHEMICAL", 170, 177], ["glucocorticoid", "SIMPLE_CHEMICAL", 28, 42], ["insulin", "GENE_OR_GENE_PRODUCT", 119, 126], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["glucose", "SIMPLE_CHEMICAL", 170, 177], ["children", "ORGANISM", 188, 196], ["children", "SPECIES", 188, 196], ["the elevated glucocorticoid levels", "PROBLEM", 15, 49], ["our study", "TEST", 82, 91], ["insulin signaling", "PROBLEM", 119, 136], ["elevated blood glucose levels", "PROBLEM", 155, 184], ["severe influenza", "PROBLEM", 202, 218], ["elevated", "OBSERVATION_MODIFIER", 19, 27], ["glucocorticoid levels", "OBSERVATION", 28, 49], ["severe", "OBSERVATION_MODIFIER", 202, 208], ["influenza", "OBSERVATION", 209, 218]]], ["Conversely, another study reported that glucose uptake was activated in the lungs of patients with respiratory viral infections, including influenza virus infection 23 .", [["lungs", "ANATOMY", 76, 81], ["glucose", "CHEMICAL", 40, 47], ["respiratory viral infections", "DISEASE", 99, 127], ["influenza virus infection", "DISEASE", 139, 164], ["glucose", "CHEMICAL", 40, 47], ["glucose", "SIMPLE_CHEMICAL", 40, 47], ["lungs", "ORGAN", 76, 81], ["patients", "ORGANISM", 85, 93], ["influenza virus", "ORGANISM", 139, 154], ["patients", "SPECIES", 85, 93], ["influenza virus", "SPECIES", 139, 154], ["another study", "TEST", 12, 25], ["glucose uptake", "PROBLEM", 40, 54], ["respiratory viral infections", "PROBLEM", 99, 127], ["influenza virus infection", "PROBLEM", 139, 164], ["lungs", "ANATOMY", 76, 81], ["respiratory", "ANATOMY", 99, 110], ["viral infections", "OBSERVATION", 111, 127], ["influenza virus", "OBSERVATION", 139, 154]]], ["This discrepancy may be associated with tissue-specific metabolic changes in response to influenza virus infection.", [["tissue", "ANATOMY", 40, 46], ["influenza virus infection", "DISEASE", 89, 114], ["tissue", "TISSUE", 40, 46], ["influenza virus", "ORGANISM", 89, 104], ["influenza virus", "SPECIES", 89, 104], ["tissue-specific metabolic changes", "PROBLEM", 40, 73], ["influenza virus infection", "PROBLEM", 89, 114], ["may be associated with", "UNCERTAINTY", 17, 39], ["influenza virus infection", "OBSERVATION", 89, 114]]], ["However, given the direct activating effect of influenza virus proliferation on glucose metabolism in cultured Mice were intranasally inoculated with PBS alone or PBS comprising PR8 virus.", [["glucose", "CHEMICAL", 80, 87], ["glucose", "CHEMICAL", 80, 87], ["influenza virus", "ORGANISM", 47, 62], ["glucose", "SIMPLE_CHEMICAL", 80, 87], ["Mice", "ORGANISM", 111, 115], ["PR8 virus", "ORGANISM", 178, 187], ["Mice", "SPECIES", 111, 115], ["PR8 virus", "SPECIES", 178, 187], ["influenza virus proliferation", "PROBLEM", 47, 76], ["glucose metabolism", "TREATMENT", 80, 98], ["PBS", "TREATMENT", 150, 153], ["PBS comprising PR8 virus", "PROBLEM", 163, 187], ["influenza virus proliferation", "OBSERVATION", 47, 76], ["PR8 virus", "OBSERVATION", 178, 187]]], ["At 6 dpi, the mice were intraperitoneally injected with PBS or insulin after overnight fasting, and liver samples were collected after 15 min for whole lysate preparation.", [["liver samples", "ANATOMY", 100, 113], ["lysate", "ANATOMY", 152, 158], ["mice", "ORGANISM", 14, 18], ["insulin", "GENE_OR_GENE_PRODUCT", 63, 70], ["liver samples", "CANCER", 100, 113], ["insulin", "PROTEIN", 63, 70], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["PBS", "TREATMENT", 56, 59], ["insulin", "TREATMENT", 63, 70], ["overnight fasting", "TEST", 77, 94], ["liver samples", "TEST", 100, 113], ["whole lysate preparation", "TREATMENT", 146, 170], ["liver", "ANATOMY", 100, 105]]], ["Western blotting was performed to quantitate phosphorylated and total Akt protein levels in lysates. (a) A representative Western blotting analysis shows total Akt and Akt phosphorylated at Ser473 on the same membrane that was sequentially immunoblotted with corresponding antibodies. (b) Relative Akt phosphorylation levels were calculated from band densities and expressed relative to data from PBS-treated control mice.", [["lysates", "ANATOMY", 92, 99], ["membrane", "ANATOMY", 209, 217], ["Akt", "GENE_OR_GENE_PRODUCT", 70, 73], ["lysates", "ORGANISM_SUBSTANCE", 92, 99], ["Akt", "GENE_OR_GENE_PRODUCT", 160, 163], ["Akt", "GENE_OR_GENE_PRODUCT", 168, 171], ["Ser473", "AMINO_ACID", 190, 196], ["membrane", "CELLULAR_COMPONENT", 209, 217], ["Akt", "GENE_OR_GENE_PRODUCT", 298, 301], ["PBS", "SIMPLE_CHEMICAL", 397, 400], ["mice", "ORGANISM", 417, 421], ["Akt", "PROTEIN", 70, 73], ["Akt", "PROTEIN", 160, 163], ["Akt", "PROTEIN", 168, 171], ["Ser473", "PROTEIN", 190, 196], ["antibodies", "PROTEIN", 273, 283], ["Akt", "PROTEIN", 298, 301], ["mice", "SPECIES", 417, 421], ["mice", "SPECIES", 417, 421], ["Western blotting", "TEST", 0, 16], ["phosphorylated", "TEST", 45, 59], ["total Akt protein levels", "TEST", 64, 88], ["lysates", "TEST", 92, 99], ["A representative Western blotting analysis", "TEST", 105, 147], ["total Akt", "TEST", 154, 163], ["Akt phosphorylated", "TEST", 168, 186], ["Relative Akt phosphorylation levels", "TEST", 289, 324], ["band densities", "PROBLEM", 346, 360], ["PBS", "TEST", 397, 400]]], ["Bars represent mean \u00b1 SEM of 3 animals.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["mean", "OBSERVATION_MODIFIER", 15, 19], ["\u00b1 SEM", "OBSERVATION_MODIFIER", 20, 25]]], ["White and black bars indicate data from PBS-and insulin-treated mice, respectively; p < 0.05, two-way ANOVA, PBS vs. insulin (p < 0.05, unpaired t test using the Holm-Sidak correction method with an alpha value of 0.05, control vs. PR8 virus-infected mice at each time point. www.nature.com/scientificreports/ Madin-Darby Canine Kidney cells 24 , the hepatic insulin resistance demonstrated here could have been induced by host factors and not the virus itself.", [["Kidney cells", "ANATOMY", 329, 341], ["hepatic", "ANATOMY", 351, 358], ["insulin", "CHEMICAL", 48, 55], ["insulin", "GENE_OR_GENE_PRODUCT", 48, 55], ["mice", "ORGANISM", 64, 68], ["insulin", "GENE_OR_GENE_PRODUCT", 117, 124], ["PR8 virus", "ORGANISM", 232, 241], ["mice", "ORGANISM", 251, 255], ["hepatic", "ORGAN", 351, 358], ["insulin", "GENE_OR_GENE_PRODUCT", 359, 366], ["insulin", "PROTEIN", 48, 55], ["insulin", "PROTEIN", 117, 124], ["Madin-Darby Canine Kidney cells 24", "CELL_LINE", 310, 344], ["host factors", "PROTEIN", 423, 435], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 251, 255], ["mice", "SPECIES", 64, 68], ["PR8 virus", "SPECIES", 232, 241], ["mice", "SPECIES", 251, 255], ["PBS", "TEST", 40, 43], ["insulin", "TREATMENT", 48, 55], ["insulin", "TREATMENT", 117, 124], ["unpaired t test", "TEST", 136, 151], ["the Holm", "TREATMENT", 158, 166], ["Sidak correction method", "TREATMENT", 167, 190], ["an alpha value", "TEST", 196, 210], ["PR8 virus", "PROBLEM", 232, 241], ["Madin", "TREATMENT", 310, 315], ["Darby Canine Kidney cells", "TEST", 316, 341], ["the hepatic insulin resistance", "TEST", 347, 377], ["the virus itself", "PROBLEM", 444, 460], ["Kidney", "ANATOMY", 329, 335], ["hepatic", "ANATOMY", 351, 358], ["insulin resistance", "OBSERVATION", 359, 377]]], ["Upon intranasal infection of PR8 virus, proliferation of the virus occurs mainly in the lung and not in the liver of mice 25 .", [["lung", "ANATOMY", 88, 92], ["liver", "ANATOMY", 108, 113], ["infection", "DISEASE", 16, 25], ["intranasal", "IMMATERIAL_ANATOMICAL_ENTITY", 5, 15], ["PR8 virus", "ORGANISM", 29, 38], ["lung", "ORGAN", 88, 92], ["liver", "ORGAN", 108, 113], ["mice", "ORGANISM", 117, 121], ["mice", "SPECIES", 117, 121], ["PR8 virus", "SPECIES", 29, 38], ["mice", "SPECIES", 117, 121], ["intranasal infection", "PROBLEM", 5, 25], ["PR8 virus", "PROBLEM", 29, 38], ["the virus", "PROBLEM", 57, 66], ["infection", "OBSERVATION", 16, 25], ["PR8 virus", "OBSERVATION", 29, 38], ["virus", "OBSERVATION", 61, 66], ["lung", "ANATOMY", 88, 92], ["liver", "ANATOMY", 108, 113]]], ["Hence, the hepatic insulin resistance observed herein is possibly induced by host factors, such as systemically secreted cytokines.", [["hepatic", "ANATOMY", 11, 18], ["hepatic", "ORGAN", 11, 18], ["insulin", "GENE_OR_GENE_PRODUCT", 19, 26], ["host factors", "PROTEIN", 77, 89], ["systemically secreted cytokines", "PROTEIN", 99, 130], ["the hepatic insulin resistance", "TREATMENT", 7, 37], ["systemically secreted cytokines", "PROBLEM", 99, 130], ["hepatic", "ANATOMY", 11, 18], ["insulin resistance", "OBSERVATION", 19, 37], ["possibly", "UNCERTAINTY", 57, 65]]], ["The direct roles of cytokines on insulin signaling have been demonstrated in a study showing that the proinflammatory cytokine interleukin-6 (IL-6) inhibited insulin-dependent phosphorylation of Akt in HepG2 cells and human primary hepatocytes 26 .", [["HepG2 cells", "ANATOMY", 202, 213], ["primary hepatocytes", "ANATOMY", 224, 243], ["insulin", "GENE_OR_GENE_PRODUCT", 33, 40], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 127, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 142, 146], ["insulin", "GENE_OR_GENE_PRODUCT", 158, 165], ["Akt", "GENE_OR_GENE_PRODUCT", 195, 198], ["HepG2 cells", "CELL", 202, 213], ["human", "ORGANISM", 218, 223], ["hepatocytes", "CELL", 232, 243], ["cytokines", "PROTEIN", 20, 29], ["proinflammatory cytokine interleukin-6", "PROTEIN", 102, 140], ["insulin", "PROTEIN", 158, 165], ["Akt", "PROTEIN", 195, 198], ["HepG2 cells", "CELL_LINE", 202, 213], ["human primary hepatocytes 26", "CELL_LINE", 218, 246], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 218, 223], ["insulin signaling", "TREATMENT", 33, 50], ["a study", "TEST", 77, 84], ["the proinflammatory cytokine interleukin", "TEST", 98, 138], ["IL", "TEST", 142, 144], ["insulin", "TREATMENT", 158, 165], ["Akt in HepG2 cells", "TEST", 195, 213], ["human primary hepatocytes", "TEST", 218, 243]]], ["Furthermore, IL-6 treatments reportedly impaired insulin signaling and inhibited insulin-induced decreases in blood glucose levels in mice 27 ; in this previous experiment, the serum levels of IL-6 reached approximately 125 pg/mL, which was comparable to that observed herein in PR8 virus-infected mice at 3 and 6 dpi when reduced insulin-induced phosphorylation of Akt was observed (Supplemental Fig. S3, 109.3 and 137.1 pg/mL at 3 and 6 dpi, respectively).", [["blood", "ANATOMY", 110, 115], ["serum", "ANATOMY", 177, 182], ["glucose", "CHEMICAL", 116, 123], ["glucose", "CHEMICAL", 116, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 13, 17], ["insulin", "GENE_OR_GENE_PRODUCT", 49, 56], ["insulin", "GENE_OR_GENE_PRODUCT", 81, 88], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["glucose", "SIMPLE_CHEMICAL", 116, 123], ["mice", "ORGANISM", 134, 138], ["serum", "ORGANISM_SUBSTANCE", 177, 182], ["IL-6", "GENE_OR_GENE_PRODUCT", 193, 197], ["PR8 virus", "ORGANISM", 279, 288], ["mice", "ORGANISM", 298, 302], ["insulin", "GENE_OR_GENE_PRODUCT", 331, 338], ["Akt", "GENE_OR_GENE_PRODUCT", 366, 369], ["IL-6", "PROTEIN", 193, 197], ["insulin", "PROTEIN", 331, 338], ["Akt", "PROTEIN", 366, 369], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 298, 302], ["mice", "SPECIES", 134, 138], ["PR8 virus", "SPECIES", 279, 288], ["mice", "SPECIES", 298, 302], ["IL-6 treatments", "TREATMENT", 13, 28], ["impaired insulin signaling", "PROBLEM", 40, 66], ["insulin", "TREATMENT", 81, 88], ["blood glucose levels", "TEST", 110, 130], ["the serum levels", "TEST", 173, 189], ["IL", "TEST", 193, 195], ["reduced insulin", "TREATMENT", 323, 338], ["Akt", "PROBLEM", 366, 369], ["Supplemental Fig", "TREATMENT", 384, 400], ["decreases", "OBSERVATION_MODIFIER", 97, 106]]], ["Thus, we suggest that this cytokine is one of host factor candidates that affect insulin resistance, particularly in the liver.", [["liver", "ANATOMY", 121, 126], ["insulin", "GENE_OR_GENE_PRODUCT", 81, 88], ["liver", "ORGAN", 121, 126], ["cytokine", "PROTEIN", 27, 35], ["host factor candidates", "TREATMENT", 46, 68], ["insulin resistance", "PROBLEM", 81, 99], ["insulin resistance", "OBSERVATION", 81, 99], ["liver", "ANATOMY", 121, 126]]], ["In addition to IL-6, interferon-gamma (IFN-\u03b3) was reportedly induced by murine cytomegalovirus infections and was recently shown to induce insulin resistance in skeletal muscle 28 .", [["skeletal muscle", "ANATOMY", 161, 176], ["cytomegalovirus infections", "DISEASE", 79, 105], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 21, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 39, 42], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 42, 44], ["murine", "ORGANISM", 72, 78], ["cytomegalovirus", "ORGANISM", 79, 94], ["insulin", "GENE_OR_GENE_PRODUCT", 139, 146], ["skeletal muscle", "ORGAN", 161, 176], ["IL-6", "PROTEIN", 15, 19], ["interferon-gamma", "PROTEIN", 21, 37], ["IFN", "PROTEIN", 39, 42], ["murine", "SPECIES", 72, 78], ["murine cytomegalovirus", "SPECIES", 72, 94], ["IL", "TEST", 15, 17], ["interferon", "TREATMENT", 21, 31], ["murine cytomegalovirus infections", "PROBLEM", 72, 105], ["insulin resistance in skeletal muscle", "PROBLEM", 139, 176], ["gamma", "ANATOMY", 32, 37], ["cytomegalovirus infections", "OBSERVATION", 79, 105], ["insulin resistance", "OBSERVATION", 139, 157], ["skeletal muscle", "ANATOMY", 161, 176]]], ["Besides IL-6, the serum levels of IFN-\u03b3 were elevated in PR8 virus-infected mice at 6 dpi but were very low at 3 dpi in our study (Supplemental Fig. S3; 1 .391 and 313.4 pg/mL at 3 and 6 dpi, respectively).", [["serum", "ANATOMY", 18, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 8, 12], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 34, 39], ["PR8 virus", "ORGANISM", 57, 66], ["mice", "ORGANISM", 76, 80], ["IL-6", "PROTEIN", 8, 12], ["IFN-\u03b3", "PROTEIN", 34, 39], ["mice", "SPECIES", 76, 80], ["PR8 virus", "SPECIES", 57, 66], ["mice", "SPECIES", 76, 80], ["IL", "TEST", 8, 10], ["the serum levels", "TEST", 14, 30], ["IFN", "TEST", 34, 37], ["elevated", "PROBLEM", 45, 53], ["PR8 virus", "PROBLEM", 57, 66], ["our study", "TEST", 120, 129], ["Supplemental Fig", "TREATMENT", 131, 147]]], ["Therefore, we propose that influenza virus infection induces hepatic insulin resistance through systemic cytokine secretion.", [["hepatic", "ANATOMY", 61, 68], ["influenza virus infection", "DISEASE", 27, 52], ["influenza virus", "ORGANISM", 27, 42], ["hepatic", "ORGAN", 61, 68], ["insulin", "GENE_OR_GENE_PRODUCT", 69, 76], ["cytokine", "PROTEIN", 105, 113], ["influenza virus", "SPECIES", 27, 42], ["influenza virus", "SPECIES", 27, 42], ["influenza virus infection", "PROBLEM", 27, 52], ["hepatic insulin resistance", "TREATMENT", 61, 87], ["systemic cytokine secretion", "PROBLEM", 96, 123], ["hepatic", "ANATOMY", 61, 68], ["insulin resistance", "OBSERVATION", 69, 87], ["cytokine secretion", "OBSERVATION", 105, 123]]], ["As stated above, in addition to glucose, fatty acids are important sources of the TCA cycle substrate acetyl-CoA.", [["glucose", "CHEMICAL", 32, 39], ["fatty acids", "CHEMICAL", 41, 52], ["acetyl-CoA", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 32, 39], ["fatty acids", "CHEMICAL", 41, 52], ["TCA", "CHEMICAL", 82, 85], ["acetyl-CoA", "CHEMICAL", 102, 112], ["glucose", "SIMPLE_CHEMICAL", 32, 39], ["fatty acids", "SIMPLE_CHEMICAL", 41, 52], ["TCA", "SIMPLE_CHEMICAL", 82, 85], ["acetyl-CoA", "SIMPLE_CHEMICAL", 102, 112], ["glucose", "TEST", 32, 39], ["fatty acids", "PROBLEM", 41, 52]]], ["Reduced fatty acid metabolism during influenza has been reported in previous reports showing mitochondrial abnormalities, decreases in the expressions of relevant enzymes, and hepatic steatosis in mice 12, 13 .", [["mitochondrial", "ANATOMY", 93, 106], ["hepatic", "ANATOMY", 176, 183], ["fatty acid", "CHEMICAL", 8, 18], ["influenza", "DISEASE", 37, 46], ["mitochondrial abnormalities", "DISEASE", 93, 120], ["hepatic steatosis", "DISEASE", 176, 193], ["fatty acid", "CHEMICAL", 8, 18], ["fatty acid", "SIMPLE_CHEMICAL", 8, 18], ["mitochondrial", "CELLULAR_COMPONENT", 93, 106], ["hepatic", "PATHOLOGICAL_FORMATION", 176, 183], ["mice", "ORGANISM", 197, 201], ["enzymes", "PROTEIN", 163, 170], ["mice", "SPECIES", 197, 201], ["mice", "SPECIES", 197, 201], ["Reduced fatty acid metabolism", "PROBLEM", 0, 29], ["influenza", "PROBLEM", 37, 46], ["mitochondrial abnormalities", "PROBLEM", 93, 120], ["relevant enzymes", "TEST", 154, 170], ["hepatic steatosis", "PROBLEM", 176, 193], ["fatty acid metabolism", "OBSERVATION", 8, 29], ["abnormalities", "OBSERVATION", 107, 120], ["decreases", "OBSERVATION_MODIFIER", 122, 131], ["hepatic", "ANATOMY", 176, 183], ["steatosis", "OBSERVATION", 184, 193]]], ["Consistently, our gene expression data indicate altered fatty acid metabolism in the livers of PR8 virus-infected mice.", [["livers", "ANATOMY", 85, 91], ["fatty acid", "CHEMICAL", 56, 66], ["fatty acid", "CHEMICAL", 56, 66], ["fatty acid", "SIMPLE_CHEMICAL", 56, 66], ["livers", "ORGAN", 85, 91], ["PR8 virus", "ORGANISM", 95, 104], ["mice", "ORGANISM", 114, 118], ["mice", "SPECIES", 114, 118], ["PR8 virus", "SPECIES", 95, 104], ["mice", "SPECIES", 114, 118], ["our gene expression data", "TEST", 14, 38], ["altered fatty acid metabolism", "PROBLEM", 48, 77], ["PR8 virus", "PROBLEM", 95, 104], ["fatty acid metabolism", "OBSERVATION", 56, 77], ["livers", "ANATOMY", 85, 91], ["PR8 virus", "OBSERVATION", 95, 104]]], ["In particular, the transcription levels of the fatty acid transporter Cd36 and the lipolytic enzyme Pnpla2 were upregulated at 3 and 6 dpi, possibly elevating extracellular fatty acid delivery and stored triglyceride lysis in liver cells.", [["extracellular", "ANATOMY", 159, 172], ["liver cells", "ANATOMY", 226, 237], ["fatty acid", "CHEMICAL", 47, 57], ["fatty acid", "CHEMICAL", 173, 183], ["triglyceride", "CHEMICAL", 204, 216], ["fatty acid", "CHEMICAL", 47, 57], ["fatty acid", "CHEMICAL", 173, 183], ["triglyceride", "CHEMICAL", 204, 216], ["fatty acid transporter Cd36", "GENE_OR_GENE_PRODUCT", 47, 74], ["Pnpla2", "GENE_OR_GENE_PRODUCT", 100, 106], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 172], ["fatty acid", "SIMPLE_CHEMICAL", 173, 183], ["triglyceride", "SIMPLE_CHEMICAL", 204, 216], ["liver cells", "CELL", 226, 237], ["fatty acid transporter", "PROTEIN", 47, 69], ["Cd36", "PROTEIN", 70, 74], ["lipolytic enzyme", "PROTEIN", 83, 99], ["Pnpla2", "PROTEIN", 100, 106], ["liver cells", "CELL_TYPE", 226, 237], ["the transcription levels", "TEST", 15, 39], ["the fatty acid transporter Cd36", "TEST", 43, 74], ["the lipolytic enzyme Pnpla2", "TEST", 79, 106], ["extracellular fatty acid delivery", "TREATMENT", 159, 192], ["triglyceride lysis in liver cells", "TREATMENT", 204, 237], ["possibly", "UNCERTAINTY", 140, 148], ["fatty acid", "OBSERVATION", 173, 183], ["triglyceride lysis", "OBSERVATION", 204, 222], ["liver", "ANATOMY", 226, 231]]], ["However, no changes were observed in the mRNA expressions of Acox1 and Cpt1b.", [["Acox1", "GENE_OR_GENE_PRODUCT", 61, 66], ["Cpt1b", "GENE_OR_GENE_PRODUCT", 71, 76], ["Acox1", "PROTEIN", 61, 66], ["Cpt1b", "PROTEIN", 71, 76], ["Acox1", "TEST", 61, 66], ["Cpt1b", "TEST", 71, 76], ["no", "UNCERTAINTY", 9, 11]]], ["These encoded enzymes are rate limiting factors for fatty acid \u03b2-oxidation in peroxisomes and mitochondria, respectively.", [["peroxisomes", "ANATOMY", 78, 89], ["mitochondria", "ANATOMY", 94, 106], ["fatty acid", "CHEMICAL", 52, 62], ["fatty acid", "CHEMICAL", 52, 62], ["fatty acid", "SIMPLE_CHEMICAL", 52, 62], ["peroxisomes", "CELLULAR_COMPONENT", 78, 89], ["mitochondria", "CELLULAR_COMPONENT", 94, 106], ["These encoded enzymes", "TEST", 0, 21], ["fatty acid \u03b2-oxidation", "PROBLEM", 52, 74]]], ["Taken together, our data suggest that fatty acids are accumulated in the cytoplasm of liver cells in influenza virus-infected mice.", [["cytoplasm", "ANATOMY", 73, 82], ["liver cells", "ANATOMY", 86, 97], ["fatty acids", "CHEMICAL", 38, 49], ["influenza virus-infected", "DISEASE", 101, 125], ["fatty acids", "CHEMICAL", 38, 49], ["fatty acids", "SIMPLE_CHEMICAL", 38, 49], ["cytoplasm", "ORGANISM_SUBSTANCE", 73, 82], ["liver cells", "CELL", 86, 97], ["influenza virus", "ORGANISM", 101, 116], ["mice", "ORGANISM", 126, 130], ["liver cells", "CELL_TYPE", 86, 97], ["influenza virus", "SPECIES", 101, 116], ["mice", "SPECIES", 126, 130], ["influenza virus", "SPECIES", 101, 116], ["mice", "SPECIES", 126, 130], ["our data", "TEST", 16, 24], ["fatty acids", "PROBLEM", 38, 49], ["liver cells", "PROBLEM", 86, 97], ["influenza virus", "PROBLEM", 101, 116], ["fatty acids", "OBSERVATION", 38, 49], ["liver", "ANATOMY", 86, 91], ["influenza virus", "OBSERVATION", 101, 116]]], ["Although anorexia due to influenza virus infection may induce similar alterations in gene expressions and subsequent hepatic steatosis, the findings of pair-fed studies on influenza eliminated the possibility that starvation www.nature.com/scientificreports/ is solely responsible for these changes 12, 13 .", [["hepatic", "ANATOMY", 117, 124], ["anorexia", "DISEASE", 9, 17], ["influenza virus infection", "DISEASE", 25, 50], ["hepatic steatosis", "DISEASE", 117, 134], ["influenza", "DISEASE", 172, 181], ["influenza virus", "ORGANISM", 25, 40], ["hepatic", "PATHOLOGICAL_FORMATION", 117, 124], ["influenza virus", "SPECIES", 25, 40], ["influenza virus", "SPECIES", 25, 40], ["anorexia", "PROBLEM", 9, 17], ["influenza virus infection", "PROBLEM", 25, 50], ["similar alterations in gene expressions", "PROBLEM", 62, 101], ["subsequent hepatic steatosis", "PROBLEM", 106, 134], ["influenza", "PROBLEM", 172, 181], ["anorexia", "OBSERVATION", 9, 17], ["due to", "UNCERTAINTY", 18, 24], ["influenza virus", "OBSERVATION", 25, 40], ["hepatic", "ANATOMY", 117, 124], ["steatosis", "OBSERVATION", 125, 134]]], ["Moreover, fasting generally increases the mRNA expressions of Acox1 and Cpt1b, thereby discriminating the effects of influenza virus infection on fatty acid metabolism from those of starvation 29, 30 .", [["influenza virus infection", "DISEASE", 117, 142], ["fatty acid", "CHEMICAL", 146, 156], ["fatty acid", "CHEMICAL", 146, 156], ["Acox1", "GENE_OR_GENE_PRODUCT", 62, 67], ["Cpt1b", "GENE_OR_GENE_PRODUCT", 72, 77], ["influenza virus", "ORGANISM", 117, 132], ["fatty acid", "SIMPLE_CHEMICAL", 146, 156], ["Acox1", "PROTEIN", 62, 67], ["Cpt1b", "PROTEIN", 72, 77], ["influenza virus", "SPECIES", 117, 132], ["influenza virus", "SPECIES", 117, 132], ["Acox1", "TREATMENT", 62, 67], ["Cpt1b", "TREATMENT", 72, 77], ["influenza virus infection", "PROBLEM", 117, 142], ["fatty acid metabolism", "PROBLEM", 146, 167], ["influenza virus", "OBSERVATION", 117, 132]]], ["Fatty acid accumulation can induce mitochondrial dysfunction, as reported previously in cultured hepatocytes 31 .", [["mitochondrial", "ANATOMY", 35, 48], ["hepatocytes", "ANATOMY", 97, 108], ["Fatty acid", "CHEMICAL", 0, 10], ["mitochondrial dysfunction", "DISEASE", 35, 60], ["Fatty acid", "CHEMICAL", 0, 10], ["Fatty acid", "SIMPLE_CHEMICAL", 0, 10], ["mitochondrial", "CELLULAR_COMPONENT", 35, 48], ["hepatocytes", "CELL", 97, 108], ["cultured hepatocytes 31", "CELL_LINE", 88, 111], ["Fatty acid accumulation", "PROBLEM", 0, 23], ["mitochondrial dysfunction", "PROBLEM", 35, 60], ["cultured hepatocytes", "TEST", 88, 108], ["acid accumulation", "OBSERVATION", 6, 23], ["mitochondrial dysfunction", "OBSERVATION", 35, 60]]], ["Mitochondrial dysfunction increases oxidative stress via reactive oxygen species production.", [["Mitochondrial", "ANATOMY", 0, 13], ["oxygen", "CHEMICAL", 66, 72], ["oxygen", "CHEMICAL", 66, 72], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["reactive oxygen species", "SIMPLE_CHEMICAL", 57, 80], ["Mitochondrial dysfunction", "PROBLEM", 0, 25], ["oxidative stress", "PROBLEM", 36, 52], ["reactive oxygen species production", "PROBLEM", 57, 91], ["dysfunction", "OBSERVATION", 14, 25], ["increases", "OBSERVATION_MODIFIER", 26, 35], ["oxidative stress", "OBSERVATION", 36, 52], ["reactive", "OBSERVATION_MODIFIER", 57, 65], ["oxygen species", "OBSERVATION", 66, 80]]], ["Reactive oxygen species and diacylglycerol, converted from triacylglycerol by adipose triglyceride lipase (encoded by Pnpla2), inhibit insulin signaling 32 .", [["oxygen", "CHEMICAL", 9, 15], ["diacylglycerol", "CHEMICAL", 28, 42], ["triacylglycerol", "CHEMICAL", 59, 74], ["oxygen", "CHEMICAL", 9, 15], ["diacylglycerol", "CHEMICAL", 28, 42], ["triacylglycerol", "CHEMICAL", 59, 74], ["triglyceride", "CHEMICAL", 86, 98], ["Reactive oxygen species", "SIMPLE_CHEMICAL", 0, 23], ["diacylglycerol", "SIMPLE_CHEMICAL", 28, 42], ["triacylglycerol", "SIMPLE_CHEMICAL", 59, 74], ["adipose triglyceride lipase", "GENE_OR_GENE_PRODUCT", 78, 105], ["Pnpla2", "GENE_OR_GENE_PRODUCT", 118, 124], ["insulin", "GENE_OR_GENE_PRODUCT", 135, 142], ["adipose triglyceride lipase", "PROTEIN", 78, 105], ["Pnpla2", "PROTEIN", 118, 124], ["insulin signaling 32", "PROTEIN", 135, 155], ["Reactive oxygen species", "TREATMENT", 0, 23], ["diacylglycerol", "TREATMENT", 28, 42], ["triacylglycerol", "TREATMENT", 59, 74], ["adipose triglyceride lipase", "TEST", 78, 105], ["inhibit insulin signaling", "TREATMENT", 127, 152], ["oxygen species", "OBSERVATION", 9, 23]]], ["It is suggested that accumulation of intracellular fatty acids triggers and complicates insulin resistance in the liver of infected mice.", [["intracellular", "ANATOMY", 37, 50], ["liver", "ANATOMY", 114, 119], ["fatty acids", "CHEMICAL", 51, 62], ["fatty acids", "CHEMICAL", 51, 62], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["fatty acids", "SIMPLE_CHEMICAL", 51, 62], ["insulin", "GENE_OR_GENE_PRODUCT", 88, 95], ["liver", "ORGAN", 114, 119], ["mice", "ORGANISM", 132, 136], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 132, 136], ["intracellular fatty acids triggers", "PROBLEM", 37, 71], ["insulin resistance", "PROBLEM", 88, 106], ["accumulation", "OBSERVATION_MODIFIER", 21, 33], ["intracellular", "OBSERVATION_MODIFIER", 37, 50], ["fatty acids", "OBSERVATION", 51, 62], ["insulin resistance", "OBSERVATION", 88, 106], ["liver", "ANATOMY", 114, 119], ["infected mice", "OBSERVATION", 123, 136]]], ["Given the higher influenza-associated mortality and morbidity rates in patients and mice with energy metabolism disorders 2-6 , energy metabolism dysregulation induced by influenza virus infection is possibly associated with pathogenicity.", [["influenza virus infection", "DISEASE", 171, 196], ["patients", "ORGANISM", 71, 79], ["mice", "ORGANISM", 84, 88], ["influenza virus", "ORGANISM", 171, 186], ["patients", "SPECIES", 71, 79], ["mice", "SPECIES", 84, 88], ["influenza virus", "SPECIES", 171, 186], ["mice", "SPECIES", 84, 88], ["influenza virus", "SPECIES", 171, 186], ["the higher influenza-associated mortality", "PROBLEM", 6, 47], ["morbidity rates", "PROBLEM", 52, 67], ["energy metabolism disorders", "PROBLEM", 94, 121], ["energy metabolism dysregulation", "PROBLEM", 128, 159], ["influenza virus infection", "PROBLEM", 171, 196], ["pathogenicity", "PROBLEM", 225, 238], ["metabolism dysregulation", "OBSERVATION", 135, 159], ["influenza virus infection", "OBSERVATION", 171, 196], ["possibly associated with", "UNCERTAINTY", 200, 224], ["pathogenicity", "OBSERVATION", 225, 238]]], ["Increased mortality rates with influenza have been reported in diet-induced obese mice which probably had insulin resistance as well as in long-chain acyl-CoA dehydrogenase-knockout mice, which had reduced mitochondrial fatty acid oxidation 2,5 .", [["mitochondrial", "ANATOMY", 206, 219], ["influenza", "DISEASE", 31, 40], ["fatty acid", "CHEMICAL", 220, 230], ["acyl-CoA", "CHEMICAL", 150, 158], ["fatty acid", "CHEMICAL", 220, 230], ["mice", "ORGANISM", 82, 86], ["insulin", "GENE_OR_GENE_PRODUCT", 106, 113], ["long-chain acyl-CoA dehydrogenase", "GENE_OR_GENE_PRODUCT", 139, 172], ["mice", "ORGANISM", 182, 186], ["mitochondrial", "CELLULAR_COMPONENT", 206, 219], ["fatty acid", "SIMPLE_CHEMICAL", 220, 230], ["long-chain acyl-CoA dehydrogenase", "PROTEIN", 139, 172], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 182, 186], ["Increased mortality rates", "PROBLEM", 0, 25], ["influenza", "PROBLEM", 31, 40], ["insulin resistance", "PROBLEM", 106, 124], ["reduced mitochondrial fatty acid oxidation", "PROBLEM", 198, 240], ["insulin resistance", "OBSERVATION", 106, 124], ["fatty acid oxidation", "OBSERVATION", 220, 240]]], ["Interestingly, both these mouse models presented with subdued immune responses to virus infection and similar or lower lung virus titers compared with the control mice.", [["lung", "ANATOMY", 119, 123], ["infection", "DISEASE", 88, 97], ["mouse", "ORGANISM", 26, 31], ["lung", "ORGAN", 119, 123], ["mice", "ORGANISM", 163, 167], ["mouse", "SPECIES", 26, 31], ["mice", "SPECIES", 163, 167], ["mouse", "SPECIES", 26, 31], ["mice", "SPECIES", 163, 167], ["subdued immune responses", "PROBLEM", 54, 78], ["virus infection", "PROBLEM", 82, 97], ["lower lung virus titers", "PROBLEM", 113, 136], ["lower", "ANATOMY_MODIFIER", 113, 118], ["lung", "ANATOMY", 119, 123], ["virus titers", "OBSERVATION", 124, 136]]], ["Hence, increased influenza severity in animals and patients with energy metabolism disorders can be explained neither by the increased levels of inflammatory cytokines nor by the reduced clearance of pathogens 2,5 .", [["influenza", "DISEASE", 17, 26], ["patients", "ORGANISM", 51, 59], ["inflammatory cytokines", "PROTEIN", 145, 167], ["patients", "SPECIES", 51, 59], ["increased influenza severity in animals", "PROBLEM", 7, 46], ["energy metabolism disorders", "PROBLEM", 65, 92], ["inflammatory cytokines", "PROBLEM", 145, 167], ["the reduced clearance of pathogens", "PROBLEM", 175, 209], ["increased", "OBSERVATION_MODIFIER", 7, 16], ["influenza", "OBSERVATION", 17, 26], ["inflammatory", "OBSERVATION_MODIFIER", 145, 157]]], ["As described above, dysregulation of energy metabolism appears to be a downstream response to cytokine and inflammatory signaling and thus could be more directly associated with the pathogenesis and severity of influenza.", [["influenza", "DISEASE", 211, 220], ["cytokine", "PROTEIN", 94, 102], ["dysregulation of energy metabolism", "PROBLEM", 20, 54], ["cytokine and inflammatory signaling", "PROBLEM", 94, 129], ["the pathogenesis", "PROBLEM", 178, 194], ["influenza", "PROBLEM", 211, 220], ["energy metabolism", "OBSERVATION", 37, 54], ["appears to be", "UNCERTAINTY", 55, 68], ["inflammatory", "OBSERVATION_MODIFIER", 107, 119], ["influenza", "OBSERVATION", 211, 220]]], ["Previous cohort studies have demonstrated that antiinflammatory corticosteroids have no beneficial effects and that these corticosteroids can exacerbate outcomes in patients with severe influenza 33 .", [["corticosteroids", "CHEMICAL", 122, 137], ["influenza", "DISEASE", 186, 195], ["corticosteroids", "CHEMICAL", 64, 79], ["corticosteroids", "CHEMICAL", 122, 137], ["corticosteroids", "SIMPLE_CHEMICAL", 122, 137], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["Previous cohort studies", "TEST", 0, 23], ["antiinflammatory corticosteroids", "TREATMENT", 47, 79], ["these corticosteroids", "TREATMENT", 116, 137], ["severe influenza", "PROBLEM", 179, 195], ["antiinflammatory", "OBSERVATION_MODIFIER", 47, 63]]], ["Given that glucocorticoids inhibit insulin signaling as well as cytokine-dependent pathogen clearance 34, 35 , corticosteroid treatments could confound pathogenicity.", [["glucocorticoids", "CHEMICAL", 11, 26], ["glucocorticoids", "SIMPLE_CHEMICAL", 11, 26], ["insulin", "GENE_OR_GENE_PRODUCT", 35, 42], ["cytokine", "PROTEIN", 64, 72], ["glucocorticoids inhibit insulin signaling", "TREATMENT", 11, 52], ["cytokine-dependent pathogen clearance", "TEST", 64, 101], ["corticosteroid treatments", "TREATMENT", 111, 136], ["pathogenicity", "PROBLEM", 152, 165]]], ["Thus, improvements in host energy metabolism would be a novel therapeutic target for severe influenza rather than immune suppression.", [["influenza", "DISEASE", 92, 101], ["host energy metabolism", "PROBLEM", 22, 44], ["severe influenza", "PROBLEM", 85, 101], ["immune suppression", "PROBLEM", 114, 132], ["influenza", "OBSERVATION", 92, 101]]], ["Moreover, this concept could be expanded to other infectious diseases because energy metabolism dysregulation is possibly induced by host factors, such as proinflammatory cytokines, and not by the viruses themselves.", [["infectious diseases", "DISEASE", 50, 69], ["host factors", "PROTEIN", 133, 145], ["proinflammatory cytokines", "PROTEIN", 155, 180], ["other infectious diseases", "PROBLEM", 44, 69], ["energy metabolism dysregulation", "PROBLEM", 78, 109], ["proinflammatory cytokines", "PROBLEM", 155, 180], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["metabolism dysregulation", "OBSERVATION", 85, 109]]], ["Given the recent emerging infectious diseases such as the pandemic influenza in 2009 and severe pneumonia by the novel corona virus in 2019, the importance of developing novel therapeutic drugs that target host factors against common symptoms of various diseases is important.DiscussionInfants and children younger than 5 years of age are generally at high risks of mortality and morbidity due to influenza compared with middle-aged adults 36 .", [["infectious diseases", "DISEASE", 26, 45], ["influenza", "DISEASE", 67, 76], ["pneumonia", "DISEASE", 96, 105], ["influenza", "DISEASE", 397, 406], ["corona virus", "ORGANISM", 119, 131], ["children", "ORGANISM", 298, 306], ["children", "SPECIES", 298, 306], ["the recent emerging infectious diseases", "PROBLEM", 6, 45], ["the pandemic influenza", "PROBLEM", 54, 76], ["severe pneumonia", "PROBLEM", 89, 105], ["the novel corona virus", "PROBLEM", 109, 131], ["novel therapeutic drugs", "TREATMENT", 170, 193], ["common symptoms", "PROBLEM", 227, 242], ["various diseases", "PROBLEM", 246, 262], ["morbidity", "PROBLEM", 380, 389], ["influenza", "PROBLEM", 397, 406], ["infectious", "OBSERVATION", 26, 36], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["pneumonia", "OBSERVATION", 96, 105], ["various", "OBSERVATION_MODIFIER", 246, 253], ["diseases", "OBSERVATION", 254, 262]]], ["Previously, a negative correlation of nasal lavage and plasma inflammatory cytokine levels with age has been reported and thought to be a reason for the high mortality and severe illness caused by influenza virus infection in young children 37, 38 .", [["nasal lavage", "ANATOMY", 38, 50], ["plasma", "ANATOMY", 55, 61], ["illness", "DISEASE", 179, 186], ["influenza virus infection", "DISEASE", 197, 222], ["nasal lavage", "ORGANISM_SUBSTANCE", 38, 50], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["influenza virus", "ORGANISM", 197, 212], ["children", "ORGANISM", 232, 240], ["cytokine", "PROTEIN", 75, 83], ["influenza virus", "SPECIES", 197, 212], ["children", "SPECIES", 232, 240], ["influenza virus", "SPECIES", 197, 212], ["nasal lavage", "TEST", 38, 50], ["plasma inflammatory cytokine levels", "TEST", 55, 90], ["the high mortality", "PROBLEM", 149, 167], ["severe illness", "PROBLEM", 172, 186], ["influenza virus infection", "PROBLEM", 197, 222], ["nasal", "ANATOMY", 38, 43], ["lavage", "OBSERVATION", 44, 50], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["illness", "OBSERVATION", 179, 186], ["influenza virus", "OBSERVATION", 197, 212]]], ["In addition to cytokine responses, age-specific features of energy metabolism could provide insights into the pathogenesis of influenza at different ages.", [["influenza", "DISEASE", 126, 135], ["cytokine", "PROTEIN", 15, 23], ["cytokine responses", "TEST", 15, 33], ["energy metabolism", "PROBLEM", 60, 77], ["influenza", "PROBLEM", 126, 135], ["influenza", "OBSERVATION", 126, 135]]], ["In pediatric patients with type I diabetes, the youngest population (0-5 years of age) reportedly showed the highest prevalence of diabetic ketoacidosis, which has an impact on morbidity and mortality 39 , indicating that attenuation of insulin signaling by virus infection could result in more severe symptoms in such populations.DiscussionThe present study provides novel insights into host responses during influenza.", [["type I diabetes", "DISEASE", 27, 42], ["diabetic ketoacidosis", "DISEASE", 131, 152], ["infection", "DISEASE", 264, 273], ["influenza", "DISEASE", 410, 419], ["patients", "ORGANISM", 13, 21], ["insulin", "GENE_OR_GENE_PRODUCT", 237, 244], ["patients", "SPECIES", 13, 21], ["type I diabetes", "PROBLEM", 27, 42], ["diabetic ketoacidosis", "PROBLEM", 131, 152], ["insulin signaling", "PROBLEM", 237, 254], ["virus infection", "PROBLEM", 258, 273], ["more severe symptoms in such populations", "PROBLEM", 290, 330], ["The present study", "TEST", 341, 358], ["influenza", "PROBLEM", 410, 419], ["diabetes", "OBSERVATION", 34, 42], ["diabetic", "OBSERVATION_MODIFIER", 131, 139], ["ketoacidosis", "OBSERVATION", 140, 152], ["severe", "OBSERVATION_MODIFIER", 295, 301]]], ["Based on the findings of the present and previous studies, we conclude that influenza virus infection induces dysregulation of both insulinregulating glucose metabolism and fatty acid oxidation, leading to decreased TCA activity.", [["influenza virus infection", "DISEASE", 76, 101], ["glucose", "CHEMICAL", 150, 157], ["fatty acid", "CHEMICAL", 173, 183], ["TCA", "CHEMICAL", 216, 219], ["glucose", "CHEMICAL", 150, 157], ["fatty acid", "CHEMICAL", 173, 183], ["TCA", "CHEMICAL", 216, 219], ["influenza virus", "ORGANISM", 76, 91], ["glucose", "SIMPLE_CHEMICAL", 150, 157], ["fatty acid", "SIMPLE_CHEMICAL", 173, 183], ["TCA", "SIMPLE_CHEMICAL", 216, 219], ["influenza virus", "SPECIES", 76, 91], ["influenza virus", "SPECIES", 76, 91], ["previous studies", "TEST", 41, 57], ["influenza virus infection", "PROBLEM", 76, 101], ["dysregulation of both insulinregulating glucose metabolism", "PROBLEM", 110, 168], ["fatty acid oxidation", "PROBLEM", 173, 193], ["decreased TCA activity", "PROBLEM", 206, 228], ["fatty acid oxidation", "OBSERVATION", 173, 193], ["decreased", "OBSERVATION_MODIFIER", 206, 215], ["TCA activity", "OBSERVATION", 216, 228]]], ["In future studies, we aim to investigate the effect of influenza virus infection at lethal and sublethal doses of various virus strains for further understanding of influenza pathogenesis and examine the therapeutic effects of interventions that improve host energy metabolism.Materials and methodsMaterials.", [["influenza virus infection", "DISEASE", 55, 80], ["influenza", "DISEASE", 165, 174], ["influenza virus", "ORGANISM", 55, 70], ["influenza virus", "SPECIES", 55, 70], ["influenza virus", "SPECIES", 55, 70], ["future studies", "TEST", 3, 17], ["influenza virus infection", "PROBLEM", 55, 80], ["various virus strains", "TREATMENT", 114, 135], ["influenza pathogenesis", "PROBLEM", 165, 187], ["interventions", "TREATMENT", 227, 240]]], ["Phosphate-buffered saline (PBS) was purchased from Gibco/Life technologies (Carlsbad, CA).Materials and methodsTris-buffered saline (TBS) tablets were purchased from Takara Bio (Otsu, Japan).", [["Phosphate", "CHEMICAL", 0, 9], ["Phosphate", "CHEMICAL", 0, 9], ["Tris", "CHEMICAL", 111, 115], ["Phosphate-buffered saline", "SIMPLE_CHEMICAL", 0, 25], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 111, 131], ["Phosphate", "TEST", 0, 9], ["buffered saline (PBS", "TREATMENT", 10, 30], ["methodsTris-buffered saline (TBS) tablets", "TREATMENT", 104, 145]]], ["Urea, Tween 20, and glucose were purchased from Sigma-Aldrich (St Louis, MO).", [["Urea", "CHEMICAL", 0, 4], ["Tween 20", "CHEMICAL", 6, 14], ["glucose", "CHEMICAL", 20, 27], ["Urea", "CHEMICAL", 0, 4], ["Tween 20", "CHEMICAL", 6, 14], ["glucose", "CHEMICAL", 20, 27], ["Urea", "SIMPLE_CHEMICAL", 0, 4], ["Tween 20", "SIMPLE_CHEMICAL", 6, 14], ["glucose", "SIMPLE_CHEMICAL", 20, 27], ["Sigma-Aldrich", "ORGANISM", 48, 61], ["St Louis, MO", "ORGANISM", 63, 75], ["Urea", "TEST", 0, 4], ["Tween", "TEST", 6, 11], ["glucose", "TEST", 20, 27]]], ["Sodium dodecyl sulfate (SDS) was purchased from WAKO (Tokyo, Japan).", [["Sodium dodecyl sulfate", "CHEMICAL", 0, 22], ["Sodium dodecyl sulfate", "CHEMICAL", 0, 22], ["SDS", "CHEMICAL", 24, 27], ["Sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 0, 22], ["Sodium dodecyl sulfate", "TREATMENT", 0, 22]]], ["Mouse.", [["Mouse", "ORGANISM", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5]]], ["Male C57BL/6 mice were purchased from Hokudo (Sapporo, Japan) and were kept at a BSL-2 laboratory at the Research Center for Zoonosis Control, Hokkaido University, under standard laboratory conditions (room temperature 22 \u00b0C \u00b1 2 \u00b0C, relative humidity 50% \u00b1 10%) and a 12/12-h light/dark cycle.", [["Male C57BL/6 mice", "ORGANISM", 0, 17], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["temperature", "TEST", 207, 218], ["relative humidity", "TREATMENT", 233, 250]]], ["The mice were administered a standard CE-2 chow diet purchased from CLEA Japan (Sapporo, Japan) with water ad libtum.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["a standard CE-2 chow diet", "TREATMENT", 27, 52], ["water ad libtum", "TREATMENT", 101, 116]]], ["Experiments were performed on 9-14 week-old mice.Virus.", [["mice", "ORGANISM", 44, 48], ["Virus", "ORGANISM", 49, 54], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["Virus", "PROBLEM", 49, 54]]], ["Influenza virusVirus infection and sample collection.", [["sample", "ANATOMY", 35, 41], ["Influenza virusVirus infection", "DISEASE", 0, 30], ["Influenza", "SPECIES", 0, 9], ["Influenza virusVirus infection", "PROBLEM", 0, 30], ["sample collection", "TEST", 35, 52], ["infection", "OBSERVATION", 21, 30]]], ["PR8 virus particles at 500 plaque-forming units in 50 \u00b5L of PBS or PBS only (control) were intranasally inoculated into the mice under inhalation anesthesia with isoflurane.", [["plaque", "ANATOMY", 27, 33], ["isoflurane", "CHEMICAL", 162, 172], ["isoflurane", "CHEMICAL", 162, 172], ["PR8 virus", "ORGANISM", 0, 9], ["mice", "ORGANISM", 124, 128], ["isoflurane", "SIMPLE_CHEMICAL", 162, 172], ["PR8 virus", "SPECIES", 0, 9], ["mice", "SPECIES", 124, 128], ["PR8 virus", "SPECIES", 0, 9], ["mice", "SPECIES", 124, 128], ["PR8 virus particles", "TREATMENT", 0, 19], ["PBS", "TREATMENT", 60, 63], ["PBS", "TREATMENT", 67, 70], ["inhalation anesthesia", "TREATMENT", 135, 156], ["isoflurane", "TREATMENT", 162, 172]]], ["At 1, 3, or 6 dpi, the mice were euthanized, and their liver and blood samples were collected.", [["liver", "ANATOMY", 55, 60], ["blood samples", "ANATOMY", 65, 78], ["mice", "ORGANISM", 23, 27], ["liver", "ORGAN", 55, 60], ["blood samples", "ORGANISM_SUBSTANCE", 65, 78], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["blood samples", "TEST", 65, 78], ["liver", "ANATOMY", 55, 60], ["blood", "ANATOMY", 65, 70]]], ["Blood samples were incubated at room temperature for 1 h to clot and were then centrifuged at 1,000g for 20 min.", [["Blood samples", "ANATOMY", 0, 13], ["clot", "ANATOMY", 60, 64], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["clot", "ORGANISM_SUBSTANCE", 60, 64], ["Blood samples", "TEST", 0, 13], ["clot", "PROBLEM", 60, 64], ["clot", "OBSERVATION", 60, 64]]], ["Supernatants were collected as serum and were stored at \u2212 20 \u00b0C until further analysis.", [["Supernatants", "ANATOMY", 0, 12], ["serum", "ANATOMY", 31, 36], ["Supernatants", "CELL", 0, 12], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["Supernatants", "TEST", 0, 12], ["serum", "TEST", 31, 36], ["further analysis", "TEST", 70, 86]]], ["Tissue samples were stored at \u2212 80 \u00b0C until further analysis.", [["Tissue samples", "ANATOMY", 0, 14], ["Tissue samples", "CANCER", 0, 14], ["Tissue samples", "TEST", 0, 14], ["further analysis", "TEST", 44, 60]]], ["To evaluate insulin sensitivity, the mice were administered insulin (Humulin R, Eli Lilly, Indianapolis, IN) at 2 U/kg body weight intraperitoneally at 6 dpi after overnight fasting.", [["body", "ANATOMY", 119, 123], ["insulin", "CHEMICAL", 60, 67], ["Humulin R, Eli Lilly", "CHEMICAL", 69, 89], ["insulin", "GENE_OR_GENE_PRODUCT", 12, 19], ["mice", "ORGANISM", 37, 41], ["insulin", "GENE_OR_GENE_PRODUCT", 60, 67], ["Humulin R", "SIMPLE_CHEMICAL", 69, 78], ["Lilly", "SIMPLE_CHEMICAL", 84, 89], ["Indianapolis", "SIMPLE_CHEMICAL", 91, 103], ["IN", "ORGANISM", 105, 107], ["body", "ORGANISM_SUBDIVISION", 119, 123], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["insulin sensitivity", "TEST", 12, 31], ["insulin (Humulin R", "TREATMENT", 60, 78]]], ["After 15 min, the mice were euthanized, and their liver samples were collected and frozen immediately in liquid nitrogen.", [["liver samples", "ANATOMY", 50, 63], ["nitrogen", "CHEMICAL", 112, 120], ["mice", "ORGANISM", 18, 22], ["liver samples", "CANCER", 50, 63], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["their liver samples", "TEST", 44, 63], ["liquid nitrogen", "TREATMENT", 105, 120], ["liver", "ANATOMY", 50, 55]]], ["Liver samples were stored at \u2212 80 \u00b0C until further analysis.", [["Liver samples", "ANATOMY", 0, 13], ["Liver samples", "CANCER", 0, 13], ["Liver samples", "TEST", 0, 13], ["further analysis", "TEST", 43, 59]]], ["Research (Kyoto, Japan) using liquid chromatography-tandem mass spectrometry (LC-MS/MS).", [["liquid chromatography", "TEST", 30, 51], ["tandem mass spectrometry", "TEST", 52, 76]]], ["Briefly, after the addition of an internal standard (2-isopropylmalic acid) to the serum samples, sample preparation was conducted using a series of hydrochloride and acetonitrile extractions.", [["serum samples", "ANATOMY", 83, 96], ["sample", "ANATOMY", 98, 104], ["2-isopropylmalic acid", "CHEMICAL", 53, 74], ["hydrochloride", "CHEMICAL", 149, 162], ["acetonitrile", "CHEMICAL", 167, 179], ["2-isopropylmalic acid", "CHEMICAL", 53, 74], ["hydrochloride", "CHEMICAL", 149, 162], ["acetonitrile", "CHEMICAL", 167, 179], ["2-isopropylmalic acid", "SIMPLE_CHEMICAL", 53, 74], ["serum samples", "ORGANISM_SUBSTANCE", 83, 96], ["hydrochloride", "SIMPLE_CHEMICAL", 149, 162], ["acetonitrile", "SIMPLE_CHEMICAL", 167, 179], ["an internal standard (2-isopropylmalic acid)", "TREATMENT", 31, 75], ["the serum samples", "TEST", 79, 96], ["hydrochloride", "TREATMENT", 149, 162], ["acetonitrile extractions", "TREATMENT", 167, 191]]], ["After centrifugation at 10,000 rpm for 5 min at room temperature, the supernatants were divided into two tubes: one was used for analyses of AMP, GMP, aconitic acid, citric acid, and fumaric acid, whereas in the other one, the supernatant was mixed with hydrochloride and used for analysis of other compounds.", [["supernatants", "ANATOMY", 70, 82], ["supernatant", "ANATOMY", 227, 238], ["AMP", "CHEMICAL", 141, 144], ["GMP", "CHEMICAL", 146, 149], ["aconitic acid", "CHEMICAL", 151, 164], ["citric acid", "CHEMICAL", 166, 177], ["fumaric acid", "CHEMICAL", 183, 195], ["hydrochloride", "CHEMICAL", 254, 267], ["AMP", "CHEMICAL", 141, 144], ["GMP", "CHEMICAL", 146, 149], ["aconitic acid", "CHEMICAL", 151, 164], ["citric acid", "CHEMICAL", 166, 177], ["fumaric acid", "CHEMICAL", 183, 195], ["hydrochloride", "CHEMICAL", 254, 267], ["AMP", "SIMPLE_CHEMICAL", 141, 144], ["GMP", "SIMPLE_CHEMICAL", 146, 149], ["aconitic acid", "SIMPLE_CHEMICAL", 151, 164], ["citric acid", "SIMPLE_CHEMICAL", 166, 177], ["fumaric acid", "SIMPLE_CHEMICAL", 183, 195], ["hydrochloride", "SIMPLE_CHEMICAL", 254, 267], ["centrifugation", "TREATMENT", 6, 20], ["the supernatants", "TREATMENT", 66, 82], ["AMP", "TEST", 141, 144], ["GMP", "TEST", 146, 149], ["aconitic acid", "TREATMENT", 151, 164], ["citric acid", "TREATMENT", 166, 177], ["fumaric acid", "TEST", 183, 195], ["hydrochloride", "TREATMENT", 254, 267], ["other compounds", "PROBLEM", 293, 308], ["tubes", "OBSERVATION", 105, 110]]], ["Chromatographic separations were performed on a 2 Discovery HS F5-3 column (2.1 mm \u00d7 150 mm, 3 \u03bcm, Sigma-Aldrich).", [["Chromatographic separations", "TEST", 0, 27], ["column", "TEST", 68, 74]]], ["The oven temperature for the column was maintained at 40 \u00b0C. Mobile phases A and B were 0.1% formic acid-water solution and 0.1% formic acid-acetonitrile, respectively.", [["formic acid-acetonitrile", "CHEMICAL", 129, 153], ["formic acid-", "CHEMICAL", 93, 105], ["formic acid-acetonitrile", "CHEMICAL", 129, 153], ["formic acid-water", "SIMPLE_CHEMICAL", 93, 110], ["formic acid-acetonitrile", "SIMPLE_CHEMICAL", 129, 153], ["The oven temperature", "TEST", 0, 20], ["the column", "TREATMENT", 25, 35], ["formic acid-water solution", "TREATMENT", 93, 119]]], ["Separation was performed using gradient elution at a flow rate of 0.25 mL/min with a Nexera UHPLC system (Shimadzu).", [["gradient elution", "TREATMENT", 31, 47], ["a flow rate", "TEST", 51, 62], ["a Nexera UHPLC system", "TREATMENT", 83, 104]]], ["Compounds were detected using an LCMS-8050 (Shimadzu) instrument with electrospray ionization.", [["an LCMS", "TEST", 30, 37], ["electrospray ionization", "TREATMENT", 70, 93]]], ["The peak areas of each compound were measured using Labsolutions (Shimadzu) and were normalized to that of an internal standard.", [["peak", "OBSERVATION_MODIFIER", 4, 8], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["each", "OBSERVATION_MODIFIER", 18, 22], ["compound", "OBSERVATION_MODIFIER", 23, 31]]], ["The metabolome analyses identified 74 molecules in our sample sets.", [["The metabolome analyses", "TEST", 0, 23]]], ["Among them, cysteine, cytosine, and methionine sulfoxide were not detected in some samples from PR8 virus-infected mice at 3 and 6 dpi (Supplemental Table S1 ).", [["samples", "ANATOMY", 83, 90], ["cysteine", "CHEMICAL", 12, 20], ["cytosine", "CHEMICAL", 22, 30], ["methionine sulfoxide", "CHEMICAL", 36, 56], ["cysteine", "CHEMICAL", 12, 20], ["cytosine", "CHEMICAL", 22, 30], ["methionine sulfoxide", "CHEMICAL", 36, 56], ["cysteine", "AMINO_ACID", 12, 20], ["cytosine", "SIMPLE_CHEMICAL", 22, 30], ["methionine sulfoxide", "SIMPLE_CHEMICAL", 36, 56], ["PR8 virus", "ORGANISM", 96, 105], ["mice", "ORGANISM", 115, 119], ["mice", "SPECIES", 115, 119], ["PR8 virus", "SPECIES", 96, 105], ["mice", "SPECIES", 115, 119], ["cysteine", "TREATMENT", 12, 20], ["cytosine", "TREATMENT", 22, 30], ["methionine sulfoxide", "TREATMENT", 36, 56], ["PR8 virus", "PROBLEM", 96, 105]]], ["To examine the effects of PR8 virus infection on the serum levels of various compounds, the relative peak areas for PR8 virus-infected mice were expressed as fold changes relative to the average peak areas for the control mice at corresponding time points.", [["serum", "ANATOMY", 53, 58], ["infection", "DISEASE", 36, 45], ["PR8 virus", "ORGANISM", 26, 35], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["PR8 virus", "ORGANISM", 116, 125], ["mice", "ORGANISM", 135, 139], ["mice", "ORGANISM", 222, 226], ["PR8 virus", "SPECIES", 116, 125], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 222, 226], ["PR8 virus", "SPECIES", 26, 35], ["PR8 virus", "SPECIES", 116, 125], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 222, 226], ["PR8 virus infection", "PROBLEM", 26, 45], ["the serum levels", "TEST", 49, 65], ["various compounds", "PROBLEM", 69, 86], ["PR8 virus", "PROBLEM", 116, 125], ["infected mice", "PROBLEM", 126, 139], ["fold changes", "PROBLEM", 158, 170], ["peak", "OBSERVATION_MODIFIER", 101, 105]]], ["The peak areas and relative ratios are provided in Supplemental Table S1 and S2.Virus.", [["Virus", "ORGANISM", 80, 85], ["S2", "PROTEIN", 77, 79], ["The peak areas", "TEST", 0, 14], ["relative ratios", "TEST", 19, 34], ["Virus", "PROBLEM", 80, 85], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["ratios", "OBSERVATION_MODIFIER", 28, 34], ["S2", "ANATOMY", 77, 79]]], ["Influenza virusSerum metabolome data analysis using MetaboAnalyst.", [["Influenza", "SPECIES", 0, 9], ["Influenza virusSerum metabolome data analysis", "TEST", 0, 45], ["MetaboAnalyst", "TEST", 52, 65]]], ["Utilizing peak areas of 74 molecules, principal component analysis and pathway analysis were performed with MetaboAnalyst (https ://www.metab oanal yst.ca).", [["peak areas", "TEST", 10, 20], ["principal component analysis", "TEST", 38, 66], ["pathway analysis", "TEST", 71, 87], ["MetaboAnalyst", "TEST", 108, 121]]], ["The values were normalized by autoscaling function.", [["The values", "TEST", 0, 10]]], ["Missing values in cysteine, cytosine, and methionine sulfoxide were replaced by small values (a half of the minimum positive values in the original data).", [["cysteine", "CHEMICAL", 18, 26], ["cytosine", "CHEMICAL", 28, 36], ["methionine sulfoxide", "CHEMICAL", 42, 62], ["cysteine", "CHEMICAL", 18, 26], ["cytosine", "CHEMICAL", 28, 36], ["methionine sulfoxide", "CHEMICAL", 42, 62], ["cysteine", "AMINO_ACID", 18, 26], ["cytosine", "SIMPLE_CHEMICAL", 28, 36], ["methionine sulfoxide", "SIMPLE_CHEMICAL", 42, 62], ["Missing values in cysteine", "PROBLEM", 0, 26], ["cytosine", "TREATMENT", 28, 36], ["methionine sulfoxide", "TREATMENT", 42, 62]]], ["Factor loading was defined for each metabolite as the correlation coefficient between the PC1 score and the level of the metabolite after normalizing by autoscaling for each sample.", [["Factor", "GENE_OR_GENE_PRODUCT", 0, 6], ["PC1", "PROTEIN", 90, 93], ["Factor loading", "PROBLEM", 0, 14], ["the PC1 score", "TEST", 86, 99], ["each sample", "TEST", 169, 180]]], ["Metabolites with high factor loading (> 0.7) and significant differences (p < 0.05, t-test) were selected as significant metabolites and are listed in Table 1 .", [["Metabolites", "TEST", 0, 11], ["high factor loading", "PROBLEM", 17, 36], ["t-test", "TEST", 84, 90], ["high", "OBSERVATION_MODIFIER", 17, 21], ["significant", "OBSERVATION_MODIFIER", 49, 60]]], ["Pathway analyses were performed based on the Kyoto Encyclopedia of Genes and Genomes (https ://www.genom e.jp/ kegg/), and the most significantly altered metabolic pathways in PR8 virus-infected mice were identified.", [["PR8 virus", "ORGANISM", 176, 185], ["mice", "ORGANISM", 195, 199], ["kegg", "DNA", 111, 115], ["PR8 virus", "SPECIES", 176, 185], ["mice", "SPECIES", 195, 199], ["PR8 virus", "SPECIES", 176, 185], ["mice", "SPECIES", 195, 199], ["Pathway analyses", "TEST", 0, 16], ["altered metabolic pathways", "PROBLEM", 146, 172], ["PR8 virus", "PROBLEM", 176, 185], ["infected mice", "PROBLEM", 186, 199]]], ["The top 10 pathways identified are listed in Table 2 .Virus.", [["Virus", "ORGANISM", 54, 59], ["Virus", "PROBLEM", 54, 59]]], ["Influenza virusEvaluation of phosphorylated Akt by Western blotting.", [["Akt", "GENE_OR_GENE_PRODUCT", 44, 47], ["phosphorylated Akt", "PROTEIN", 29, 47], ["Influenza", "PROBLEM", 0, 9], ["phosphorylated Akt", "TREATMENT", 29, 47]]], ["Liver samples were homogenized in TBS comprising 8 M urea and 1% SDS using an ultrasonic homogenizer (Q125 sonicator, Qsonica, Newtown, CT) and centrifuged at 15,000g for 10 min at 10 \u00b0C to obtain supernatants as whole liver lysates.", [["Liver samples", "ANATOMY", 0, 13], ["supernatants", "ANATOMY", 197, 209], ["liver lysates", "ANATOMY", 219, 232], ["urea", "CHEMICAL", 53, 57], ["urea", "CHEMICAL", 53, 57], ["Liver samples", "CANCER", 0, 13], ["urea", "SIMPLE_CHEMICAL", 53, 57], ["liver lysates", "ORGANISM_SUBSTANCE", 219, 232], ["Liver samples", "TEST", 0, 13], ["TBS", "TEST", 34, 37], ["urea", "TEST", 53, 57], ["1% SDS", "TREATMENT", 62, 68], ["an ultrasonic homogenizer", "TREATMENT", 75, 100], ["CT", "TEST", 136, 138], ["whole liver lysates", "TREATMENT", 213, 232], ["liver", "ANATOMY", 219, 224]]], ["Protein levels were measured using Pierce BCA protein assay kits (Thermo Fisher Scientific, Waltham, MA).", [["Protein levels", "TEST", 0, 14]]], ["Samples for Western blotting were prepared by mixing whole liver lysates with the NuPAGE LDS Sample buffer (Thermo Fisher Scientific) and heating at 70 \u00b0C for 10 min.", [["Samples", "ANATOMY", 0, 7], ["liver lysates", "ANATOMY", 59, 72], ["NuPAGE", "CHEMICAL", 82, 88], ["liver", "ORGAN", 59, 64], ["lysates", "ORGANISM_SUBSTANCE", 65, 72], ["Samples", "TEST", 0, 7], ["Western blotting", "TREATMENT", 12, 28], ["liver", "ANATOMY", 59, 64]]], ["Subsequently, 10 \u03bcg aliquots of total protein were separated using 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to polyvinylidene difluoride membranes.", [["SDS-polyacrylamide", "CHEMICAL", 71, 89], ["SDS", "CHEMICAL", 71, 74], ["polyacrylamide", "CHEMICAL", 75, 89], ["polyvinylidene", "CHEMICAL", 145, 159], ["difluoride", "CHEMICAL", 160, 170], ["membranes", "CELLULAR_COMPONENT", 171, 180], ["total protein", "TREATMENT", 32, 45], ["10% SDS", "TREATMENT", 67, 74], ["polyacrylamide gel electrophoresis", "TREATMENT", 75, 109], ["polyvinylidene difluoride membranes", "TREATMENT", 145, 180]]], ["After blocking with 5% nonfat dry milk in TBS buffer comprising 0.1% Tween 20 (TBST), the membranes were probed with an anti-Akt phosphorylated at Ser473 antibody (1:1,000, #9271, Cell Signaling Technology, Beverly, MA) or an anti-Akt antibody (1:1,000, Cell Signaling Technology) in TBST buffer comprising 5% bovine serum albumin overnight at 4 \u00b0C. The membranes were then treated with secondary horseradish peroxidase-conjugated antirabbit antibody (1:5,000, sc-2357, Santa Cruz) for 1 h at room temperature.", [["milk", "ANATOMY", 34, 38], ["membranes", "ANATOMY", 90, 99], ["Cell", "ANATOMY", 180, 184], ["Cell", "ANATOMY", 254, 258], ["serum", "ANATOMY", 317, 322], ["membranes", "ANATOMY", 354, 363], ["Tween 20", "CHEMICAL", 69, 77], ["milk", "ORGANISM_SUBSTANCE", 34, 38], ["Tween 20", "SIMPLE_CHEMICAL", 69, 77], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Akt", "GENE_OR_GENE_PRODUCT", 125, 128], ["Ser473", "GENE_OR_GENE_PRODUCT", 147, 153], ["Akt", "GENE_OR_GENE_PRODUCT", 231, 234], ["Cell", "CELL", 254, 258], ["bovine", "ORGANISM", 310, 316], ["serum", "ORGANISM_SUBSTANCE", 317, 322], ["albumin", "GENE_OR_GENE_PRODUCT", 323, 330], ["membranes", "CELLULAR_COMPONENT", 354, 363], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 397, 419], ["sc-2357", "SIMPLE_CHEMICAL", 461, 468], ["Akt", "PROTEIN", 125, 128], ["Ser473 antibody", "PROTEIN", 147, 162], ["anti-Akt antibody", "PROTEIN", 226, 243], ["horseradish peroxidase", "PROTEIN", 397, 419], ["antirabbit antibody", "PROTEIN", 431, 450], ["Santa Cruz", "PROTEIN", 470, 480], ["bovine", "SPECIES", 310, 316], ["horseradish", "SPECIES", 397, 408], ["bovine", "SPECIES", 310, 316], ["5% nonfat dry milk in TBS buffer", "TREATMENT", 20, 52], ["the membranes", "TREATMENT", 86, 99], ["Ser473 antibody", "TEST", 147, 162], ["Beverly", "TEST", 207, 214], ["an anti-Akt antibody", "TEST", 223, 243], ["TBST buffer", "TREATMENT", 284, 295], ["bovine serum albumin", "TEST", 310, 330], ["secondary horseradish peroxidase", "TEST", 387, 419], ["conjugated antirabbit antibody", "TEST", 420, 450]]], ["Protein bands on membranes were detected using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) and an ImageQuant LAS4000 system (GE, Buckinghamshire, UK).", [["membranes", "ANATOMY", 17, 26], ["membranes", "CELLULAR_COMPONENT", 17, 26], ["Protein bands on membranes", "PROBLEM", 0, 26]]], ["The bands were quantified using the ImageQuant TL analysis system (GE).", [["The bands", "TREATMENT", 0, 9]]], ["Full-length images are provided in Supplemental Fig. S4 .GTT .", [["S4", "GENE_OR_GENE_PRODUCT", 53, 55], ["GTT", "TREATMENT", 57, 60]]], ["The control and PR8 virus-infected mice received intraperitoneal injections of 20% glucose solution inPBS at 2 g/kg body weight after overnight fasting.", [["intraperitoneal", "ANATOMY", 49, 64], ["body", "ANATOMY", 116, 120], ["glucose", "CHEMICAL", 83, 90], ["inPBS", "CHEMICAL", 100, 105], ["glucose", "CHEMICAL", 83, 90], ["PR8 virus", "ORGANISM", 16, 25], ["mice", "ORGANISM", 35, 39], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 64], ["glucose", "SIMPLE_CHEMICAL", 83, 90], ["inPBS", "SIMPLE_CHEMICAL", 100, 105], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["mice", "SPECIES", 35, 39], ["PR8 virus", "SPECIES", 16, 25], ["mice", "SPECIES", 35, 39], ["The control", "TREATMENT", 0, 11], ["PR8 virus", "TREATMENT", 16, 25], ["intraperitoneal injections", "TREATMENT", 49, 75], ["20% glucose solution inPBS", "TREATMENT", 79, 105], ["body weight", "TEST", 116, 127], ["overnight fasting", "TEST", 134, 151]]], ["Blood was collected from tail veins at 0, 30, 60, and 90 min after injections, and plasma glucose concentrations were measured using an Accu-chek glucose meter (Roche Diagnostic, Mannheim, Germany). www.nature.com/scientificreports/ amount of assay buffer for serum samples or serum matrix for standards and controls.", [["Blood", "ANATOMY", 0, 5], ["tail veins", "ANATOMY", 25, 35], ["plasma", "ANATOMY", 83, 89], ["serum samples", "ANATOMY", 260, 273], ["serum matrix", "ANATOMY", 277, 289], ["glucose", "CHEMICAL", 90, 97], ["glucose", "CHEMICAL", 90, 97], ["glucose", "CHEMICAL", 146, 153], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["tail veins", "MULTI-TISSUE_STRUCTURE", 25, 35], ["plasma", "ORGANISM_SUBSTANCE", 83, 89], ["glucose", "SIMPLE_CHEMICAL", 90, 97], ["glucose", "SIMPLE_CHEMICAL", 146, 153], ["serum samples", "ORGANISM_SUBSTANCE", 260, 273], ["serum", "ORGANISM_SUBSTANCE", 277, 282], ["matrix", "CELLULAR_COMPONENT", 283, 289], ["Blood", "TEST", 0, 5], ["tail veins", "TEST", 25, 35], ["injections", "TREATMENT", 67, 77], ["plasma glucose concentrations", "TEST", 83, 112], ["assay buffer", "TREATMENT", 243, 255], ["serum samples", "TEST", 260, 273], ["serum matrix", "TEST", 277, 289], ["tail veins", "ANATOMY", 25, 35]]], ["Magnetic beads coated with antibodies against the target cytokines were added to each well, and the plates were incubated on a plate shaker overnight at 4 \u00b0C. After washing with washing buffer in the kit, the samples were reacted with biotinylated detection antibodies for 1 h and then with streptavidin-phycoerythrin for 30 min.", [["samples", "ANATOMY", 209, 216], ["streptavidin-phycoerythrin", "CHEMICAL", 291, 317], ["streptavidin-phycoerythrin", "SIMPLE_CHEMICAL", 291, 317], ["antibodies", "PROTEIN", 27, 37], ["cytokines", "PROTEIN", 57, 66], ["biotinylated detection antibodies", "PROTEIN", 235, 268], ["phycoerythrin", "PROTEIN", 304, 317], ["Magnetic beads", "TREATMENT", 0, 14], ["antibodies", "TREATMENT", 27, 37], ["the target cytokines", "TREATMENT", 46, 66], ["a plate shaker", "TREATMENT", 125, 139], ["washing buffer", "TREATMENT", 178, 192], ["the samples", "TEST", 205, 216], ["biotinylated detection antibodies", "TEST", 235, 268], ["streptavidin-phycoerythrin", "TREATMENT", 291, 317]]], ["After washing and addition of loading buffer from the kit, the samples were analyzed by the MAGPIX system (Luminex, Austin, TX, USA).", [["samples", "ANATOMY", 63, 70], ["washing", "TREATMENT", 6, 13], ["loading buffer", "TREATMENT", 30, 44], ["the samples", "TEST", 59, 70]]], ["The results are presented in Supplemental Fig. S3 .Measurement of selected gene expressionsStatistical analysis.", [["S3", "GENE_OR_GENE_PRODUCT", 47, 49], ["Statistical analysis", "TEST", 91, 111]]], ["Statistical analyses were performed using Prism 7 (GraphPad Software, San Diego, CA, USA).", [["Statistical analyses", "TEST", 0, 20], ["Prism", "TEST", 42, 47]]], ["Differences were identified using unpaired t-tests or two-way ANOVA and were considered significant when p < 0.05.", [["unpaired t-tests", "TEST", 34, 50]]], ["All mouse experiments were performed with approval from the Animal Care and Use Committee of Hokkaido University following the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology in Japan.", [["mouse", "ORGANISM", 4, 9], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9]]], ["Body weight losses were monitored daily after infection, and mice were humanely euthanized when weight loss reached 25%.Data availabilityAll data generated or analyzed during this study are included in this published article and its Supplementary Information Files.Data availabilityReceived: 28 December 2019; Accepted: 8 June 2020", [["Body", "ANATOMY", 0, 4], ["infection", "DISEASE", 46, 55], ["weight loss", "DISEASE", 96, 107], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["mice", "ORGANISM", 61, 65], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["Body weight losses", "TEST", 0, 18], ["infection", "PROBLEM", 46, 55], ["weight loss", "PROBLEM", 96, 107], ["All data", "TEST", 137, 145], ["this study", "TEST", 175, 185]]]]}